Abstracts  by unknown
 AMP AbstractsGENETICS 
 
G01. Detection of HLA-A*3101 by Real-Time PCR Assay 
R. Avula, J.L. Black 
Mayo Clinic, Rochester, MN. 
Introduction: Carbamazepine is one of the most commonly prescribed drugs for the 
treatment of epilepsy, as well as trigeminal neuralgia and bipolar disorder. A minority 
of treated persons have hypersensitivity reactions that vary in prevalence and 
severity. The HLA-B*1502 allele has been shown to be strongly correlated with 
carbamazepine-induced Stevens–Johnson syndrome and toxic epidermal necrolysis 
(SJS–TEN) in the Han Chinese and other Asian populations. The presence of the 
HLA-A*3101 allele was associated with carbamazepine-induced hypersensitivity 
reactions among subjects of Northern European ancestry. The presence of the allele 
increased the risk from 5.0% to 26.0%, whereas its absence reduced the risk from 
5.0% to 3.8%. We developed a real-time SYBR green melting curve assay that 
specifically detects HLA-A*3101. Methods: The real-time detection system consists 
of primers for amplifying human growth hormone (HGH) as control gene and the 
HLA-A*3101 allele. As the DNA amplifies, SYBR green intercalates into the double 
stranded DNA structure and the fluorescence increases greatly. During a 
dissociation step, the amplicon is incrementally increased in temperature until it 
reaches its melting temperature where the double-stranded DNA dissociates causing 
the fluorescence to decrease. The fluorescence is observed only if the primers bind 
and create the product thereby determining if the allele is present or absent. The 
control primer amplifies and gives a fluorescent signal for each sample to ensure 
DNA quality. To increase the specificity of the sequence specific primers, locked 
nucleic acid (LNA) primers were used. Results: We tested a total of 75 samples 
consisting of Coriell DNA and patient DNA. The sample set included HLA-A*2902, 
HLA-A*30.02, HLA-A*33.03 and HLA-A*2402 that are closely related alleles to HLA-
A*3101. The primers were able to distinguish the closely related alleles from HLA-
A*3101. Both the melting curves and Ct values are taken into account in making the 
allele calls. We found 5 HLA-A*3101 positive samples among the 75 samples tested 
mostly of European descent. To confirm the results, the HLA-A gene was amplified 
and exon 2 region sequenced; the sequencing results were concordant with the 
SYBR green real-time assay. Conclusions: Detection of HLA-A*3101 helps in 
predicting likelihood of hypersensitivity reactions to Carbamazepine and assisting 
physicians in customizing carbamazepine therapy. We developed a simple, rapid, 
and cost effective method for detecting HLA-A*3101. In real-time SYBR green 
melting curve assay the analysis and detection is done simultaneously that 
eliminates post PCR handling. This method has better specificity than serological 
methods and cost effective compared to sequencing. 
 
G02. Development and Validation of a Diagnostic Test for Five Distinct 
Genetic Disorders with Heterogeneous Genetic Etiology Using Next-
Generation Sequencing  
Z. Yu1, T. Tischler1, M. Sarmady1, A. Sasson1, J. Perin1, J. Pennington1, P.S. White1, 
B. Ruth1, M. Italia1, B. McLarney1, B. Brown-Kipphut1, L. Conlin1, P. Warren1, J. 
Zook2, C. Stolle 1, A. Santani1 
1Children's Hospital of Philadelphia, Philadelphia, PA; 2The National Institute of 
Standards and Technology, Gaithersburg, MD. 
Introduction: Genetic testing of clinically heterogeneous group of disorders with a 
complex genetic etiology using Sanger sequencing can pose major challenges for 
molecular diagnosis. Next-generation sequencing (NGS) allows rapid and cost-
effective detection of mutations in genes associated with multigenic disorders. In 
contrast to whole exome sequencing, where coverage is not complete, targeted NGS 
sequencing panels allow for comprehensive high quality coverage of genes of 
interest. Methods: For this study, five distinct genetic disorders were selected based 
on send out reports & client feedback. The CHOP_5D panel was designed to 
resequence the coding exons of 154 genes associated with five disorders (early 
infantile epileptic encephalopathy, craniosynostosis, noonan spectrum of disorders, 
hearing loss and paraganglioma-pheochromocytoma syndrome). The capture library 
(SureSelect) was optimized by rebalancing baits to improve coverage uniformity after 
examining the initial design. Enriched libraries were sequenced on the MiSeq. 
Sequence data were analyzed using a custom bioinformatics pipeline. Validation 
was performed on two HapMap samples and 33 previously characterized blinded 
clinical samples, of which 15 specimens were patients with disease causing 
mutations. Exons with coverage below 30x were Sanger sequenced for high 
analytical sensitivity. Data quality was evaluated based on average coverage, base 
quality scores and percentage of bases with 30x coverage. Inter-run and intra-run 
reproducibility was assessed using a standard set of alignment and variant metrics. 
Analytical sensitivity and specificity were evaluated by comparing genotyping results The Journal of Molecular Diagnostics ■ jmd.amjpathol.org(obtained by Sanger sequencing or SNP array) to NGS results. Results: Re-
balancing capture baits improved coverage uniformity dramatically. Percentage of 
exons with minimum per-base coverage below 30x dropped from 14.4% (>105 
exons) to 4.6% (<40 exons) after bait redesign. On average, greater than 99% of 
bases within the region of interest had at least 30x coverage (mean coverage:600x). 
Consistent alignment and variant calling metrics were obtained with multiple 
triplicates demonstrating high reproducibility of this assay. Validation testing correctly 
identified all point mutations and indels in the 15 positive control samples; no false 
positives were identified in the negative control samples. The results demonstrate 
that both the analytical sensitivity and specificity of the assay are >99%. 
Conclusions: We have validated a comprehensive NGS assay that, in contrast to 
whole-exome sequencing, will offer complete coverage and cost effective analysis of 
154 genes associated with five distinct genetic disorders. This panel can provide 
treatment options and diagnostic advantage in cases with atypical clinical 
presentation and in cases where previous analyses have failed to identify a genetic 
defect. 
 
G03. Mosaic DNA Methylation in Atypical Angelman Syndrome: A Case 
Report and the Development of a Molecular Technique to Improve Detection of 
Mosaic DNA Methylation in Prader-Willi and Angelman Syndromes 
R. Gagnon1, K. Sheets1, M. Procter2, R. Mao2, M. McDonald1, M. Datto1, S. 
Sebastian1 
1Duke University Health System, Durham, NC; 2ARUP Laboratories, Salt Lake City, 
UT. 
Introduction: Here we report a 3-year-old boy conceived by in vitro fertilization (IVF) 
who presented with global developmental delay, absent speech, and an unsteady 
gait in the absence of other cardinal features but suspicious of Angelman syndrome 
(AS). Multiple independent Methylation Specific PCR (MS-PCR) tests using the 
patient’s peripheral blood and buccal swab genomic DNA showed a normal paternal, 
but faint band for maternal SRNPN gene allele. Additional tests employing 
Methylation-specific Multiple Ligation Probe Assay and pyrosequencing showed 
complete absence of maternal allele, a result consistent with classical AS. The 
chromosome 15 UPD studies indicated biparental inheritance of chromosome 15. 
Imprinting Center deletion analysis did not reveal a deletion of the imprinting center 
region. We have developed and validated a sensitive semi-quantitative MS-PCR to 
improve the detection of mosaicism and/or incomplete imprinting defects of SRNPN 
gene, and to obtain a meaningful genotype-phenotype correlation on atypical/mild 
AS or Prader-Willi Syndrome (PWS) cases. Methods: This assay uses MS-PCR to 
determine the maternal or paternal origin of SNRPN gene within the PWS/AS critical 
region. Genomic DNA is treated with sodium bisulfate to convert unmethylated 
cytosines to uracil. To quantify the PCR band intensity, a multiplex PCR amplification 
reaction using fluorescently (FAM) tagged primers that amplify either the uracil-
containing SRNPN locus (unmethylated, paternal DNA producing a 101bp 
amplification product) or the methylated cytosine-containing SRNPN locus 
(methylated maternal DNA producing a 177bp product). Amplification products are 
analyzed on an ABI 3130xl system for the presence of maternal and paternal 
SNRPN alleles. By analyzing and quantifying the amplicon band intensities on 
normal and mixed samples, a ratio was established to determine normal and 
mosaicism. Test validation studies showed reliable detection of 5% to 40% of 
somatic mosiacisim with this methodology. 
Results: Here, we report the development and validation of a simple semi-
quantitative, Fluorescent-MS-PCR-capillary gel electrophoresis based assay to 
reliably detect somatic mosaic and/or incomplete imprinting defect in a patient with 
exceptionally mild AS. Conclusions: Reliable detection of somatic mosaicism for 
imprinting defects both helped to explain the exceptionally mild clinical AS features 
observed in our patient, and resulted in better patient management and genetic 
counseling. This case highlight the inability of widely used tests employing regular 
MS-PCR, MS-MLPA and pyrosequencing to detect somatic/methylation mosaics for 
the SNRPN gene alleles and risk for molecular misdiagnosis. In addition, this case 
revealed another example of increased risk of imprinting defects observed in children 
born with assisted reproductive technology. 
 
G04. The Creation and Implementation of a Clinical Exome and Exome 
Confirmation Pipeline 
D. Rhodenizer, A. Tanner, d. Cristina, K. Huang, S. Neil, M. Hegde 
Emory University, Decatur, GA. 
Introduction: Whole exome sequencing (WES) has rapidly moved from the 
research laboratory to the clinical laboratory and is increasing in both use and utility 
for clinical testing. The benefits of WES remains the same for clinical diagnostics as 843
8AMP Abstractsit does for the research setting, specifically sequencing large numbers of genes in a 
short time frame allowing for rapid evaluation of homogenous, ambiguous, or mild 
disorders and phenotypes. However, issues such as missing coverage and the high 
rate of false positives and false negatives associated with WES are amplified in the 
clinical setting. WES sequencing routinely identifies over 10,000 variants and 
typically 15% to 20% of the targeted exome is not covered well, with known disease 
causing genes at a higher rate of 30% to 40%. Exons with no or low coverage could 
be harboring a causative mutation and clinical labs must be able to verify that the 
mutations reported are a true positive. Many methodologies have been implemented 
including using simultaneous WES of parental samples and family members, but the 
Sanger sequencing is still the gold standard. Methods: To facilitate better detection 
of variants in the 5000 genes associated with disease in the Human Gene Mutation 
Database (HGMD), we have created a Clinical Exome that includes higher coverage 
of these genes and created an Exome Confirmation pipeline to rapidly confirm 
chosen variants through Sanger Sequencing. The addition of probes in the genes of 
interest allows for greater interrogation of disease related genes and the Sanger 
pipeline allows for efficient confirmation of variants. The Exome Confirmation 
pipeline combines PrimerFinder, an automated primer design script; GLOBE, an 
internally developed LIMS system; robotics; and Bioneer Pyrostart lypholized Master 
Mix plates to rapidly and reliably amplify and sequence variants selected for 
confirmations. Here we show the comparison data between the Clinical Exome and 
commercially available exomes as well as the detection and failure rates of the 
Exome Confirmation pipeline developed and currently in use at Emory Genetics 
Laboratory.  
Results: The average coverage of HGMD listed genes was decreased from 36% to 
11% in the Clinical Exome compared to commercially available products. The Exome 
Confirmation Pipeline boasts a 4% failure rate on the first PCR pass, with only 1% of 
the total needing manual redesign. Conclusions: The combination of the Clinical 
Exome and the Exome Confirmation pipeline allows for increased diagnostic utility of 
the test along with rapid validation of selected variants. 
 
G05. SNP Microarray Analysis Reveals Whole Gene Deletion of the 
Mineralocorticoid Receptor in a Patient with Features of 
Pseudohypoaldosteronism Type 1 
L. Dyer 
Cincinnati Children's Hospital, Cincinnati, OH. 
Introduction: Pseudohypoaldosteronism type 1 (PHA1) is a rare disorder of 
mineralocorticoid resistance presenting in infancy with dehydration, hyponatremia, 
hyperkalemia, and failure to thrive. Renal unresponsiveness to aldosterone leads to 
salt-wasting despite increased plasma renin and aldosterone concentrations. 
Autosomal dominant PHA1 is caused by inactivating mutations of the 
mineralocorticoid receptor (MR) gene, NR3C2, located on chromosome 4q31.23. 
Many PHA1 patients with sporadic or inherited mutations of NR3C2 have been 
reported, but gross deletions that include NR3C2 have yet to be documented as a 
cause of PHA1. We report a large heterozygous deletion on chromosome 4, 
including the NR3C2 gene, in a male who presented with hyponatremia (Na+ 125 
mmol/l) and hyperkalemia (K+ >10 mmol/l) at 10 days of life. Normal 17-
hydroxyprogesterone (26 ng/ml) excluded classic congenital adrenal hyperplasia. A 
mineralocorticoid pathway defect was suspected, and confirmed subsequently by 
determination of increased aldosterone (3,475 ng/dl) and plasma renin activity (PRA, 
560 mg/ml/hr), after the first aldosterone measured low (2 ng/ml). Renal ultrasound 
showed mild left pelvocaliectasis without hydroureter. SNP microarray analysis was 
obtained because the patient also had partial anomalous pulmonary venous return. 
Methods: SNP microarray analysis was done using the Infinium Assay with the 
Illumina HumanOmniExpressExome Beadchip platform. B-allele frequency and 
log2R ratio were analyzed with Illumina Genome Studio V2009.2 software. DNA 
copy-number changes were prioritized using cnvPartition Plug-in v2.3.4. Results: 
SNP microarray analysis detected a clinically significant interstitial deletion of 4.2Mb 
of DNA from the long arm of chromosome 4 (4q31.22-4q31.3). This deletion includes 
NR3C2, which encodes for the MR. Parental chromosome studies to determine the 
mode of inheritance are currently pending. Conclusions: SNP microarray analysis 
identified a 4.2Mb deletion from chromosome 4q31.22-4q31.3 that includes NR3C2 
in an infant with hyponatremia and hyperkalemia, indicative of a diagnosis of PHA1. 
Genetic testing has been helpful in determining the diagnosis for this patient 
because initial laboratory values yielded a high PRA with low aldosterone. Molecular 
diagnostic confirmation will be done via Quantitative Multiplex Polymerase Chain 
Reaction of Short Fluorescent (QMPSF). Our patient is the first with a documented 
whole gene deletion of NR3C2 as a cause for autosomal dominant PHA1. This 
report illustrates the clinical utility of SNP microarray as an initial genetic test in the 
evaluation of rare disorders, for which complex biochemical testing does not directly 
yield a clear diagnosis. 44G06. Beyond the Standard Exome: A Roadmap to Comprehensive Clinical 
Sequencing of Disease Genes with High Homology 
D. Mandelker1, E. Duffy2, B. Harrison2, M. Hedge3, A. Santani4, T. Pugh2, S. Amr2, H. 
Rehm2, B. Funke2 
1Brigham and Women's Hospital, Boston, MA; 2Partners Healthcare Center for 
Personalized Genetic Medicine, Cambridge, MA; 3Emory University School of 
Medicine, Atlanta, GA; 4The Children's Hospital of Philadelphia, Philadelphia, PA. 
Introduction: Exome sequencing is being implemented in clinical laboratories to 
enable comprehensive testing and accelerate diagnosis of genetic disease. 
However, limitations include inadequate coverage of many loci as well as difficulty 
interrogating genes with complex sequence contexts such as pseudogenes, genetic 
rearrangements, and high GC content. Complementary laboratory assays will need 
to be developed for the portion of the exome that is inaccessible through current 
NGS technologies. We report our work on one of these inaccessible genes, STRC, 
which is homozygously deleted in approximately 2% to 5% of individuals with 
autosomal recessive hearing loss, and whose analysis is complicated by a nearly 
identical pseudogene. Compound heterozygous cases with a deletion as well as 
small sequence variants have been reported in STRC. Therefore, comprehensive 
medical testing of this gene must include copy number assessment as well as non-
standard sequencing assays. Methods: By parsing and compiling databases 
containing gene-disease associations, we have developed a comprehensive list of 
medically relevant genes (n = 4631). This list was cross referenced with a database 
of known pseudogenes, and one gene (STRC) was selected for developing a 
framework for analyzing these genes. Copy number assessment was performed on 
NGS data using VisCap, a novel tool tailored to targeted gene panels. Because NGS 
cannot correctly interpret the highly repetitive STRC coding region, we developed a 
long-range PCR assay that discriminates between gene and pseudogene and used 
this product as a template for standard Sanger sequencing. STRC copy number 
analysis and sequencing were performed on samples from patients without 
established genetic cause for their hearing loss despite prior NGS gene panel 
testing. Results: Of our list of medically relevant genes, 22% (1039/4631) have 
homology to other genomic loci. One such gene, STRC, is part of a tandem 
duplication on chromosome 15, which also contains a pseudogene, that is 99.6% 
identical across coding and intronic sequence. CNV analysis detected 11 STRC 
heterozygous deletions in our patient cohort. Of those, 6 (55%) were found to have a 
pathogenic substitution or small indel on the remaining allele. Biallelic STRC 
alterations were therefore established as the genetic cause of hearing loss in these 
patients. Conclusions: Exome wide genetic analysis is feasible but does currently 
not cover many medically relevant genes due to difficult sequence contexts. Our 
STRC results show that the development of ancillary assays to analyze these loci is 
critical for maximizing the clinical sensitivity of genetic testing. 
 
G07. Replication of Panel of GWAS Candidate Genes/Loci for Myocardial 
Infarction in the Genetic Isolated Newfoundland Population 
Y. Xie1, J. Cui 1, E. Randell 1, A. Pope2, S. Li 1, G. Sun 1, W. Gulliver 1, F. Han 1 
1Memorial Uiniversity, St. John's, Newfoundland, Canada; 2Newfound Genomics, St. 
John's, Newfoundland, Canada. 
Introduction: Genome-wide association studies (GWAS), have provided some 
promising achievements for a number of multifactor diseases including coronary 
artery disease (CAD). However, many of these GWAS candidate genes failed to 
been replicated in studies using different ethnic populations that indicates the variety 
of genetic modifiers among different ethnic populations. Additionally, the genetic 
heterogeneity in the studied population can reduce the sensitivity in detection of 
weak genetic effects and leads to false negative results in replication studies. The 
population of Newfoundland and Labrador (NL) is a well known genetic isolated 
population, and this population has a high prevalence of CAD in Canada.  
Methods: As a part of our ongoing study, a panel of 15 genetic variants from 12 
selected prior GWAS candidate genes/loci has been used to genotype 500 patients 
with myocardial infarction (MI) and 500 age- and sex-matched controls from the NL 
population by using the Sequenom’s MassARRAY system. The further genotyping of 
selected SNPs from 9p21 locus in expanded population was conducted using Taq 
Man SNP genotyping technology on real-time PCR (ABI Prism 7000 Sequence 
Detection System). Odds ratios (OR) were calculated as a measure of the relative 
risk for MI and were given with 95% CIs. P < 0.05 (two-tailed) was considered 
statistically significant. Statistical power was calculated using QUANTO V1.2.3 
software. Results: Among the 12 studied genes/loci, only the 9p21 locus (rs133049, 
rs10757274, rs238306, and rs238307) was successfully associated to the patients 
(P < 0.000 in all SNPs). This association was further confirmed in another study with 
enlarged sample size (1,000 MI patients and 1,000 controls) from the same 
population (P<0.000 in all SNPs). Conclusions: We, therefore, conclude that the 
9p21 locus is a genetic susceptibility for CAD in the NL population. The failure of jmd.amjpathol.org ■ The Journal of Molecular Diagnostics
 AMP Abstractsreplicating other GWAS candidate genes for CAD in NL patients strongly suggests 
the diversity of genetic modifiers for CAD in Newfoundland population. 
 
G08. Performance Characteristics of Collaborative, Multiple-Director Sign-
Out for Next-Generation Sequencing Tests 
B.H. Shirts, T. Walsh, A. Jacobson, S.J. Salipante, M. King, J.F. Tait, C.C. Pritchard 
University of Washington, Seattle, WA. 
Introduction: Clinical next-generation sequencing tests are more complex to 
analyze than traditional sequencing tests due to the technical complexity of the 
bioinformatics pipelines, the large number of genes tested requiring broader genetics 
knowledge, the lower specific pretest probability of any specific mutation, and the 
dramatically increased probability of incidental findings. Methods: We evaluated the 
performance of a team model for signout of next-generation sequencing panels for 
familial cancer. Panels included were a 13 gene panel for familial polyposis and 
colon cancer (ColoSeq) and a 40 gene pan-familial cancer panel (BROCA). Two to 
four MD or PhD level genetics or laboratory faculty independently reviewed primary 
calls for multiple classes of variants (SNPs, indels, copy number variants, inversions 
and tranlsocations) generated through multiple variant detection software programs 
for 141 consecutive patients. In initial review there was a low threshold for bringing 
potential deleterious mutation to a group signout meeting. Individual reviewers had 
discretion to determine their own specific criteria for variant selection using the same 
general principles. At consensus signout sessions three to four reviewers discussed 
all variants flagged by individual reviewers and reached a consensus about how to 
classify variants for clinical signout. Although clinical reports contained detailed 
gradations of evidence for each reported variant, for this study variants were 
classified as pathogenic, variant of uncertain significance (VUS), or 
benign/polymorphism. Results: In 141 patients, 208 variants were brought to 
consensus signout meetings. No variants were flagged for 27 patients (19%).  Of 
variants brought to consensus signout for discussion, 157 (75%) were eventually 
classified as benign, 18 were classified VUS (9%), and 33 were classified as 
pathogenic (16%). For the 51 variants eventually classified as pathogenic or VUS, 7 
(14%) were brought to consensus signout by only one independent reviewer and 24 
(47%) were brought to consensus meetings by all independent reviewers. 
Pathogenic variants had the highest concordance between reviewers. Conversely, of 
the 157 variants eventually classified as benign, 98 (62%) were flagged by only one 
reviewer and 16 (10%) were highlighted by all reviewers for discussion. 
Conclusions: There is a clear need for expert geneticists and molecular genetic 
pathologists to have an active role clinical next-generation sequencing testing due to 
inherent limitations in current annotation tools and criteria for variant classification. 
Nevertheless, experts have limitations as well. Our study illustrates the advantages 
of having multiple experts working as a team on each clinical case.  
 
G09. Reduced Interval of the 9p21 Locus Is Associated with Ischemic Stroke 
in Chinese Northern Han Population  
F. Han1, S. Li1, E. Randell 1, J. Cui 1, Y. Xu2, H. Zheng4, H. Wang2, G. Sun 1, G. Zai1, 
M. Godlewski3, Y. Xie1 
1Memorial University, St. John's, Newfoundland, Canada; 2First Affiliated Hospital, 
Zhengzhou University, Zhengzhou, Henan, China; 3Saint John Regional Hospital, 
Saint John, New Brunswick, Canada. 
Introduction: Common variants within the 9p21 locus have been strongly 
associated with coronary arterial disease by a number of parallel genome-wide 
association studies in Caucasians, and this result was later successfully replicated in 
several other populations. Subsequently, the 9p21 locus has also being reported to 
be associated with other cardiovascular diseases including ischemic stroke (IS). 
However, the association between 9p21 locus and IS in Chinese Han population is 
still debatable because of the ambiguous results from the previous replication 
studies. Possible genetic heterogeneity between Southern and Northern Chinese 
Han populations could be the reasons for indefinite conclusion. Therefore, continued 
efforts targeting of each sub Han population are necessary. Methods: Four SNPs 
(rs1333049, rs2383207, rs10757274, and rs10116277) selected from the three 
conjunctional LD blocks within the 44 kb candidate region on 9p21 were genotyping 
analyzed in 1429 IS patients and 1191 controls from the Northern Chinese Han 
population. Genotyping was performed by using the TaqMan SNP genotyping 
technology on a real-time PCR platform. Association analysis was performed at both 
genotype and haplotype levels. Results: Among the four studied variants, only the G 
allele of rs2383207 was showed to be associated with IS. This association was 
observed in both heterozygous (OR=1.382, P=0.010) and homozygous GG 
(OR=1.417, P=0.003) statuses, and confirmed by analysis of the prevalence of 
genotypes AG+GG, (OR=1.417, P= 0.003) and G allelic frequency (OR=1.162, 
P=0.01).Conclusions: The chromosome 9p21 locus is confirmed to be the 
susceptibility locus for IS in the Northern Chinese Han population. The previous The Journal of Molecular Diagnostics ■ jmd.amjpathol.orgreported 40 kb candidate region could be further narrowed down to an interval with 
size less than 28kb.  
 
G10. Newborn Screening by Next-Generation Sequencing (NGS): 
Comparison of NGS Results from Haloplex Custom Panel, SureSelect XTv4, 
and Nextera Exome Enrichment on DNA from Dried Blood Spots and Whole 
Blood 
A. McDonald, D. Gavrilov, S. Baheti, Middha, B. Eckloff, Y. Lee, R. Majumdar, A. 
Fadlalla, J. Kocher, D. Oglesbee 
Mayo Clinic, Rochester, MN. 
Introduction: For 40 years, newborn screening (NBS) programs in the United States 
and worldwide have successfully identified disease in pre-symptomatic babies using 
blood samples collected on filter paper (dried blood spots, DBS) shortly after birth. In 
recent years, next-generation sequencing (NGS) technology has greatly reduced the 
cost and effort needed to obtain accurate DNA sequence data from exomes, and 
even the whole human genome, in one massively parallel process. This technology 
is capable of quickly allowing the assembly of a single multi-gene panel relevant to 
newborn screening. Here, we provide empirical evidence that dried blood spots as a 
source of genomic DNA will yield quality results with NGS methods, thus, opening 
the possibility to use this technology for newborn screening in the future. Methods: 
Nine anonymous DBS and whole blood samples were processed for DNA extraction 
using our clinical methods. NGS-compatible libraries were prepared from whole 
blood using the Agilent Sure Select v4 Human All Exome Capture kit, from dried 
blood spots using the Illumina Nextera Exome Enrichment kit and from dried blood 
spots on a custom panel of 375 genes related to inborn errors of metabolism and 
disorders presenting during the newborn period using Agilent HaloPlex capture kit. 
The DNA libraries were NGS on the Illumina HiSeq. Bioinformatic analysis of NGS 
data was completed using an in-house, custom suite of NGS tools. Results: On 
average, the HaloPlex custom panel yielded 30x or greater coverage from DBS DNA 
on ~97% of our genomic region of interest, whereas SureSelect and Nextera yielded 
approximately 80% and 57% respectively across identical genomic coordinates at 
that read-depth. The average to-target-region reads from the total NGS reads 
obtained were 76.6%, 79.6%, and 34.7% for HaloPlex, SureSelect, and Nextera, 
respectively. In addition, identical variant calls over lapped by 78.0% between all 
three chemistries. Conclusions: We have demonstrated that NGS for a large panel 
of NBS genes from DBS is feasible and will yield results with quality that is 
equivalent to a current exome-capture method for whole blood DNA. In ongoing 
work, we are developing efficient methods to accurately obtain variant calls in 
regions of interest with high homology to pseudogenes or multiple genomic loci. 
 
G11. Development of a Genomic DNA Reference Material Panel for Rett 
Syndrome Genetic Testing 
L. Kalman1, J. Tarleton2, A. Percy3, S. Aradhya4, S. Bale4, P. Bayrak-Toydemir5, C. 
Bridges2, A. Buller-Burckle6, S. Das7, R. Iyer8, T. Vo9, V. Zvereff10, L. Toji11 
1Centers for Disease Control and Prevention, Atlanta, GA; 2Mission Health System, 
Fullerton Genetics Center, Asheville, NC; 3University of Alabama, Birmingham, 
Birmingham, AL; 4GeneDx, Gaithersburg, MD; 5ARUP Laboratories, Salt Lake City, 
UT; 6Quest Diagnostics, San Juan Capistrano, CA; 7University of Chicago, Chicago, 
IL; 8University of Michigan, Ann Arbor, MI; 9Ambry Genetics, Aliso Viejo, CA; 
10LabCorp, Research Triangle Park, NC; 11Coriell Cell Repositories, Camden, NJ. 
Introduction: Rett syndrome, a dominant X-linked disorder caused by point 
mutations (~80%) and deletions (~8%) in the MECP2 gene, is usually lethal in 
males. The prevalence in females is approximately 1:10,000.  Patients with Rett 
syndrome have severe neurological and behavioral problems. Diagnosis of Rett 
syndrome is performed by examination of patient DNA using both DNA sequence 
and deletion/duplication analysis. Clinical genetic testing laboratories commonly use 
characterized genomic DNA reference materials for assay development, assay 
validation, quality control and proficiency testing to assure the quality of the testing 
process. There are no commercially available reference materials for Rett syndrome 
genetic testing. Methods: To address the need for characterized genomic DNA 
reference materials for Rett syndrome testing, the United States Centers for Disease 
Control and Prevention’s (CDC) Genetic Testing Reference Material Coordination 
Program (GeT-RM), in collaboration with members of the genetic testing community 
and the National Institute of General Medical Sciences (NIGMS) Repository at the 
Coriell Cell Repositories, have characterized the MECP2 mutations in 35 publicly 
available human cell lines derived from patients with Rett syndrome, primarily 
created as part of this project. Peripheral blood was collected from consented Rett 
syndrome patients who carried MECP2 genetic variants not previously represented 
in Coriell cell lines. Results: DNA samples from 8 existing Coriell Rett cell lines and 
27 newly created Rett lines were tested by 8 separate clinical genetic testing 
laboratories using DNA sequence analysis and methods to assess copy number 845
8AMP Abstracts(MLPA, semi-quantitative PCR or array-based comparative genomic hybridization). 
All of the common point mutations known to cause approximately 60% of Rett 
syndrome cases were identified (p.R106W, p.R168X, p.R255X, p.T158M, p.R306C, 
p.R294X, p.R270X and p.R133C) plus other MECP2 variants including deletions, 
duplications, frame shifts and splice site mutations. Two of the samples tested were 
from males with duplications in the MECP2 gene. The results were concordant 
among laboratories and across multiple assay platforms. Conclusions: We have 
characterized a panel of 35 publicly available genomic DNA samples with variations 
including point mutations and deletions important for MECP2 clinical diagnostic 
genetic testing. Use of these reference materials will help to ensure the quality of 
Rett syndrome testing. These and other characterized genomic DNA samples are 
publicly available from the NIGMS Repository at the Coriell Cell Repositories 
(http://ccr.coriell.org).   
 
G12. Development and Clinical Validation of a PCR-Based Test for the 
Hexanucleotide Expansion in C9orf72, the Most Common Genetic Cause of 
Amyotrophic Lateral Sclerosis and Frontotemporal Dementia 
B. Krock1, C. Gentile2, E. Suh2, V.M. Van Deerlin2 
1ARUP Laboratories, Salt Lake City, UT; 2University of Pennsylvania, Philadelphia, 
PA. 
Introduction: A GGGGCC repeat expansion in the C9orf72 gene is the most 
common genetic cause of both sporadic and familial amyotrophic lateral sclerosis 
(ALS) and frontotemporal dementia (FTD). Normal individuals have between 2 and 
20 GGGGCC repeats whereas affected individuals have 30 or more repeats, usually 
greater than 700 repeats. Expansions of greater than 30 repeats have been 
identified at a frequency of 37% in familial ALS, 6-7% in sporadic ALS, 21-25% in 
familial FTD and 6% in sporadic FTD in North Americans and Europeans in several 
large studies. As this mutation is inherited in an autosomal dominant manner with 
high age-dependent penetrance, a test for this expansion will have clinical utility for 
ALS and FTD patients and their family members. The purpose of this study was to 
develop a PCR-based test for the hexanucleotide repeat expansion in C9orf72 and 
clinically validate the analytic performance of this test. Methods: Both a repeat-
primed PCR and standard sizing PCR assay were developed to both qualitatively 
identify large GGGGCC expansions and to accurately quantify the number of 
GGGGCC repeats in samples harboring alleles of <35 repeats, respectively. Both 
PCR assays were run on an ABI 3130 capillary electrophoresis instrument. The 
assays were optimized by the alteration of thermocycling conditions and composition 
of the PCR reagents to improve their performance on the GC-rich C9orf72 template. 
In the validation study, a total of 99 samples were tested in a blinded fashion. These 
samples, obtained from Coriell cell repository and the UPenn Center for 
Neurodegenerative Disease Research, consisted of pathologically confirmed 
disease-free samples, a population control cohort, known expansion positive 
samples and samples with an intermediate number of GGGGCC repeats. Results: 
Optimization of the standard PCR revealed that, in addition to the inclusion of the 
DNA melting reagents, DMSO and betaine, the application of reduced ramp rates 
significantly improved the amplification of alleles with 34-37 GGGGCC repeats. 
Increased template DNA significantly improved performance of the repeat primed 
PCR. Validation testing revealed 100% concordance with expected results. 
Performance characteristics were determined. 
Conclusions: We conclude that the PCR based assay for GGGGCC expansion in 
C9orf72 demonstrates excellent performance characteristics. This assay will be used 
clinically to evaluate the genetic cause of ALS and FTD in patients presenting with 
symptoms and for presymptomatic screening of family members of affected 
individuals with a known expansion mutation. 
 
G13. High-Throughput Germline Mutation Screening for Hereditary Breast 
Cancer in Southern Chinese Patients by Massively Parallel DNA Sequencing 
C. Au1, F.B. Law1, D.N. Ho1, B. Ip1, A.T. Wong1, T. Chan1, A. Kwong2, E.S. Ma1 
1Hong Kong Sanatorium & Hospital, Happy Valley, Hong Kong; 2The University of 
Hong Kong, Pokfulam, Hong Kong. 
Introduction: Breast cancer is prevalent world-wide and has become the leading 
cause of cancer among the female population in Hong Kong. The Hong Kong 
Hereditary Breast Cancer Family Registry was established in 2007, and thus far 
1344 patients with breast and/or ovarian cancer who met the selection criteria were 
recruited for genetic testing in Hong Kong. Mutation screening of susceptibility 
genes, BRCA1 and BRCA2, was previously performed by Sanger full gene 
sequencing, and 631 cases were hitherto analyzed. Since 2011 we started to employ 
next-generation DNA sequencing to expedite analysis workflow and expand gene 
panel for sequencing. Methods: We sequenced BRCA1, BRCA2, TP53 and PTEN 
genes in peripheral blood samples of 410 patients, 51 positive controls and 107 
healthy local individuals using 454 GS Junior System. Generation of barcoded 46amplicon libraries was streamlined by microfluidic PCR using Fluidigm Access Array 
System. Sequencing data were analyzed by an in-house developed fully automatic 
bioinformatics pipeline, which mainly consists of GS Amplicon Variant Analyzer, 
SAMtools and Ensembl Variant Effect Predictor. All putative mutations identified 
were validated by Sanger sequencing. Results: Among the 410 patients, there were 
7 BRCA1, 6 BRCA2 and 1 TP53 positive cases. The identifiable mutations included 
novel recurrent and founder mutations, in addition to known recurrent mutations. 
Furthermore, to characterize BRCA1, BRCA2 and PTEN missense variants of 
unknown significance (VUS) identified in the cohort, we compared the VUS 
frequency with that among 107 healthy local individuals and 1000Genomes project 
samples. The VUS were also subjected to in silico prediction methods including 
PolyPhen and SIFT. Based on multiple criteria, 12 BRCA1, 12 BRCA2 and 1 PTEN 
VUS could be prioritized for further investigation. The bioinformatics pipeline was 
extensively evaluated with Sanger-validated controls. The evaluation determined 
minimum sequencing coverage needed for accurate analysis in the platform. The 
pipeline accuracy was demonstrated by successfully detecting mutations from 51 
positive controls, including single nucleotide variants, insertions and deletions in 
different sequence context. Conclusions: BRCA1, BRCA2, TP53 and PTEN 
mutation screening of 410 patients were expedited by high-throughput DNA 
sequencing. The screening revealed 14 positive cases, including recurrent 
mutations, in shorter period of time. High-risk patients who are negative for the gene 
panel need further investigation beyond BRCA1/2. To aid VUS analysis, genetic 
variation pattern of these four genes was characterized in 107 local healthy 
individuals. The in-house developed bioinformatics pipeline was validated to detect 
various types of mutations and also applicable to similar diagnostic settings. 
 
G14. Keeping Up with Advancing Technology in Next-Generation 
Sequencing (NGS): Validation of the Illumina MiSeq Platform for Use with a 
Previously Validated NGS Panel Test 
J.H. Blommel, N. Fadra, L.M. Peterson, E.W. Klee, M.J. Ferber 
Mayo Clinic, Rochester, MN. 
Introduction: The implementation of Next-generation sequencing (NGS) 
technologies within the clinical diagnostic laboratory is happening at a rapid pace. 
Institutions across the United States are offering a wide array of diagnostic tests from 
CLIA licensed laboratories. As new NGS platforms come to market, it becomes 
necessary to evaluate their potential for use in clinical testing. Instruments such as 
the Illumina GAIIx and HiSeq can generate orders of magnitude more data per 
instrument run than MiSeq. When NGS testing is limited to panels of a handful of 
genes however, the use of the larger sequencing platforms quickly becomes cost 
prohibitive unless sample volume is high and samples are heavily multiplexed. Here 
we discuss validation approaches and data analysis to transition a 13 gene panel 
test for hereditary colorectal cancer from the Illumina GAIIx to the Illumina MiSeq 
sequencing platform. Methods: Investigational runs were performed to ascertain the 
maximum number of samples per MiSeq run using previously prepared GAIIx 
sample libraries. A total of 48 samples were included in this validation study. Of the 
48 samples, 16 were previously sequenced during the GAIIx validation, and 32 were 
newly prepared libraries. Libraries were run as pools of eight samples on six MiSeq 
instrument runs. Precision, accuracy, sensitivity and specificity calculations as well 
as two limit-of-detection studies were performed for the 16 samples. The additional 
32 samples were used to assess inter-assay reproducibility and to assess end-to-
end performance of the assay on the MiSeq. Results: MiSeq results for analytical 
sensitivity, specificity, accuracy and precision all saw increases in comparison to 
results obtained from the GAIIx. Furthermore, MiSeq data eliminated two false 
positive results generated from the GAIIx, as confirmed by Sanger sequencing. Both 
limit-of-detection studies performed better than on the GAIIx and showed the 
potential to expand analytical range and analytical measurement range for the assay 
in the future. The additional 32 samples yielded identical variant calls between 
platforms and showed 100% concordance between replicates. 
Conclusions: We have demonstrated comparability between NGS platforms for this 
assay. The availability of two clinically validated NGS platforms will allow for 
scalability of the assay based upon variable patient volumes. 
 
G15. Analysis of Runs of Homozygosity (ROH) Using SNP Microarray in a 
Patient with Phocomelia Syndrome  
X. Li, K. Sund, S. Zimmerman, L. Dyer, T. Smolarek, H. Saal 
Cincinnati Children's Hospital, Cincinnati, OH. 
Introduction: Analysis of runs of homozygosity (ROH) holds great promise in 
identifying genetic susceptibility loci harboring recessive variants for complex 
diseases and traits. Al-Awadi/Raas-Rothschild/Schinzel (AARRS) phocomelia 
syndrome is a rare autosomal recessive disorder with a remarkably diverse clinical 
picture, which includes limb aplasia/hypogenesis, joint dysplasia, and cranial and jmd.amjpathol.org ■ The Journal of Molecular Diagnostics
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who was born to consanguineous parents, with congenital short limbs, phocomelia of 
all extremities, dysmorphic features, and hip dysplasia. Methods: Chromosome 
analyses using G- and C-banding were performed according to standard 
cytogenetics laboratory protocols. The microarray analysis was subsequently 
performed using the Infinium Assay with the Illumina HumanOmniExpressExome 
Beadchip platform. B-allele frequency and log2R ratio were analyzed with Illumina 
Genome Studio V2009.2 software. The ROH were identified using a web-based 
program that permits entry of regions of homozygosity and retrieves genes within 
these regions as well as their associated autosomal recessive disorders using 
OMIM, UCSC, and NCBI databases. The chromosomal imbalances including 
deletions, duplications, aneuploidy (if any) and ROH (>5Mb) were reported to the 
physician. Results: G-banding results revealed a normal female karyotype. C-
banding results were negative for premature centromere separation (PCS), which 
excluded the possible diagnosis of Roberts Syndrome for this patient. SNP array 
analysis detected no clinically significant chromosomal imbalances. However, there 
were several large regions (on chromosomes 1, 3, 5, 6, 7, and 9) showing 
homozygosity for alleles by analysis of the SNP array. This raised a concern for the 
potential for unmasking an autosomal recessive disorder in these regions. One 
region of homozygosity on chromosome 3 (3p25.1) contained the dorsoventral-
patterning gene WNT7A. Several studies show that homozygous mutations of this 
gene causes Schinzel phocomelia syndrome. The associated clinical features were 
consistent with the clinical presentations of the proband. Parents declined further 
sequence analysis of WNT7A at this time. Conclusions: This study demonstrates 
the clinical utility of SNP microarray testing in identification of regions of 
homozygosity associated with autosomal recessive disorders.  We identified a strong 
candidate gene WNT7A in one of ROH regions that is associated with phocomelia 
syndrome using SNP array analysis.  
 
G16. Genomic Approaches Uncover Causal Variants and Pathways in Two 
Affected Siblings Concordant for Mental Retardation and Dysmorphic Features 
but Discordant for Speech Defects 
M. Abedalthagafi1, J. Zhu1, R. Owen2, F. Chehab1 
1University of California, San Francisco, San Francisco, CA; 2Quest Diagnostics, 
Nichols Institute, San Juan Capistrano, CA 
Introduction: The discovery of culprit pathways in genetic disorders has been 
empowered by the implementation of genomic technologies to Trios (two parents 
and one affected child). However, the power of bioinformatics analysis in Quattros 
(two parents and two affected siblings) is further enhanced, especially when affected 
siblings are dissimilar in their phenotypes, thus raising the prospect of uncovering 
modifier genes. We applied this strategy to two siblings concordant for dysmorphic 
features and mental retardation but discordant for speech defects. Although a firm 
clinical diagnosis lacked, the genetics were consistent with an autosomal recessive 
disorder. Therefore, we set out to unravel the causative pathways that are 
associated with similar and dissimilar phenotypes in these two siblings. Methods: 
High Density Agilent 1M CGH and CytoScanHD SNP microarrays and Whole Exome 
Sequencing (WES) were used to study the two parents and two affected siblings. 
WES raw data were aligned to hg19 using the Burrows-Wheeler Aligner. SNPs and 
In/Dels annotations were performed using PICARD, SAMTOOLS and GATK 
pipelines. Variants were filtered on the Ingenuity platform and those in candidate 
genes confirmed by Sanger sequencing. Agilent CGH and Affymetrix SNP arrays 
were analyzed with the Agilent Genomics Workbench and the Affymetrix 
Chromosome Analysis Suite, respectively, with critical parameters encompassing 
gains set at >200 kb, losses >50 kb and LOH >10 Mb. Results: WES at 120x 
coverage and bioinformatics analysis of the family as a Quattro, revealed that both 
affected siblings harbored in three genes, rare predicted deleterious missense 
homozygous and compound heterozygous mutations, resulting altogether in 
centrosomal and actin-binding proteins loss of function. In addition, either sibling was 
homozygous for distinct variants in proteins involved in synapse formation and post-
translational protein modification pathways. Furthermore, findings of compound 
heterozygosities for different variants in each sibling may further contribute to their 
discordant phenotypic traits. Although CGH and SNP arrays revealed non-
deleterious gains or losses, none of these overlapped with any candidate gene 
identified by WES. Conclusions: Loss of function variants in centrosome and actin-
binding genes are associated with mental retardation in both siblings. However, 
variants causing loss and activating mutations in protein modification and synaptic 
plasticity pathways respectively, are likely to act as modifier genes and contribute to 
the differential anatomical-based speech defects. Moreover, bioinformatics analysis 
of this recessive disorder as a Quattro rather than Trios considerably increased the 
confidence of unraveled primary and secondary candidate genes linked to the 
common and differential traits in the two siblings.  The Journal of Molecular Diagnostics ■ jmd.amjpathol.orgG17. Development of Consensus Reference Material Tools for Clinical Next-
Generation Sequencing Tests 
D. Church1, B. Funke2, M. Hegde3, C. Chao4, J. Trow4, D. Slotta4, M. Halavi4, P.A. 
Meric4, V. Ananiev4, D. Frishberg4, W. Rubinstein4, C. da Silva3, S. Gowrisankar5, S. 
Ajay6, B. Chapman7, J. Compton8, S. Dames9, S. Das10, Y. Feng11, T. Hambuch6, S. 
Kulkarni12, R. Mao9, B.D. O'Fallon9, S. Shrivastava12, L. Toji13, V. Zhang11, J. Zook14, 
L. Kalman15 
1National Institutes of Health, Bethesda, MD; 2Massachusetts General Hospital and 
Harvard Medical School, Cambridge, MA; 3Emory University School of Medicine, 
Atlanta, GA; 4National Institutes for Health, Bethesda, MD; 5Partners Healthcare 
Center for Personalized Genetic Medicine, Cambridge, MA; 6Illumina, San Diego, 
CA; 7Harvard School of Public Health, Boston, MA; 8GeneDx Inc., Gaithersburg, MD; 
9ARUP Laboratories, Salt Lake City, UT; 10University of Chicago, Chicago, IL; 
11Baylor College of Medicine, Houston, TX; 12Washington University School of 
Medicine, St. Louis, MO; 13Coriell Institute for Medical Research, Camden, NJ; 
14National Institute of Standards and Technology, Gaithersburg, MD; 15Centers for 
Disease Control and Prevention, Atlanta, GA. 
Introduction: The genetic testing laboratory community has expressed an urgent 
need for reference materials for clinical Next-generation sequencing (NGS). These 
materials are required for test development, test validation, quality control and 
proficiency testing. To address this need, the Centers for Disease Control and 
Prevention (CDC)-based Genetic Testing Reference Material Coordination Program 
(GeT-RM) and the National Center for Biotechnology Information (NCBI), in 
collaboration with members of the genetic testing community, including academic 
and clinical genetic testing laboratories, IVD manufacturers, professional 
organizations, other government agencies and the Coriell Cell Repositories, have 
characterized two publicly available human genomes, NA19240 and NA12878 for 
use as reference materials. A web portal was created at NCBI to provide access to 
the data. Methods: Existing sequence data were collected from previous studies of 
NA19240 and NA12878. In addition, both DNA samples were distributed to 14 
laboratories that characterized them using over 30 different research and clinical 
NGS panels, exome, and whole genome sequencing tests. Many of these 
laboratories also performed Sanger sequencing to confirm clinically relevant variants 
or to provide data about entire genomic regions. All laboratories provided variant 
calls; some provided raw data, assay and technology platform information and basic 
performance values including quality scores, and coverage. For targeted tests, files 
defining the captured regions as well as the regions where calls were made (regions 
of interest) were also submitted. Additionally, many laboratories submitted reads 
and/or alignments of their reads to a reference assembly (GRCh37). NCBI validated 
and converted all data into a common format. Variant call concordance was 
calculated on a per gene basis. Results: The data were processed into a common 
format and are accessible on the NCBI GeT-RM site 
(http://www.ncbi.nlm.nih.gov/variation/tools/get-rm). Complete data sets are available 
via FTP, and targeted subsets of data can be downloaded through the web site. 
Users can view calls, capture reagents, regions of interest, alignments and call 
concordance scores within the browser site; download reference data from the site to 
compare to variants calls made from these samples in their own laboratory; or 
upload their variant calls to the GeT-RM browser and manually review differences. 
Conclusions: This project has created large amounts of curated sequence data and 
a versatile genome browser from two publicly available genomic DNA samples 
(available from Coriell Cell Repositories, http://ccr.coriell.org). Laboratories can use 
these DNA samples and the web portal to compare their results with those from this 
project for NGS test development and assay validation.  
 
G18. Analysis of PRKAR1A Mutations in Cardiac Myxomas Exhibiting 
Immunohistochemical Loss of PRKAR1A Expression: New Insights into the 
Pathobiology of Cardiac Myxomas 
N.S. Kip, B.T. Larsen, M.C. Costanguay, J.L. Winters, B. Kipp, J.J. Maleszewski 
Mayo Clinic, Rochester, MN 
Introduction: Cardiac myxomas are benign neoplasms, a minority (~5%) of which 
are believed to arise in the setting of the Carney complex (CNC or myxoma 
syndrome). Although mutations in PRKAR1A have been implicated in approximately 
two thirds of cases of CNC, the role that it may play in the development of non-
syndromic myxomas is not clear. We have previously evaluated a cohort of 103 
cardiac myxomas without other clinical features of CNC and found that 32% lacked 
immunohistochemically detectable expression of the PRKAR1A protein. In this study 
we aimed to determine the mutational status of the PRKAR1A gene in tumoral and 
germline DNA in otherwise clinically non-syndromic cases of cardiac myxoma not 
exhibiting immunohistochemically detectable levels of PRKAR1A protein. Methods: 
A cohort of 31 cardiac myxomas (resected between 1993 and 2011) exhibiting loss 
of PRKAR1A expression immunohistochemically was obtained from a previous 847
AMP Abstractsstudy. This cohort consisted of 3 cases of clinically diagnosed CNC and 28 myxomas 
that had no other clinical manifestations of CNC. Formalin-fixed, paraffin-embedded 
sections of these tumors and adjacent myocardium were obtained from the Mayo 
Clinic tissue registry. Scraped sections were subjected to PCR followed by bi-
directional Sanger sequencing of the PRKAR1A gene for the evaluation of the 11 
coding regions as well as the intron/exon boundaries. Results: Of the 28 apparently 
non-syndromic cases, 7 (25%) showed various frameshift, missense, deletion and 
nonsense mutations of the PRKAR1A gene, including: c.494_502+3del, 
c.522_523delCT, c.138delC, c.26G>A, c.503G>C, c.514delG, c.289C>T and 
c.1088C>T. These mutations are expected to result in splice site alteration, 
truncation or altered protein expression. Germline DNA has thus far been tested in 
two cases, neither of which has harbored the mutation identified within the tumor. Of 
the three CNC-associated cardiac myxoma cases, 2 (66%) exhibited previously 
reported mutations (c.891G>A and c.682delC) resulting in either a splice site 
alteration or frameshift mutation. Conclusions: Loss of PRKAR1A expression is 
seen in about a third of solitary cardiac myxomas arising in patients without other 
clinical manifestations of CNC. Of these, PRKAR1A mutations appear to be present 
in about a quarter. Determining whether this latter cohort represents cases of CNC in 
which a solitary cardiac myxoma is the sole manifestation or somatic mutations 
requires analysis of the adjacent germline DNA, which is currently ongoing in our 
laboratory. Early results (from evaluation of the germline in two cases) suggest that 
somatic PRKAR1A mutations are present in a subset of non-CNC-associated 
cardiac myxomas.  
 
G19. Concordance Assessment of CytoScan HD with qPCR Using High 
Resolution (<200 kb) Settings to Assess Patients with Developmental 
Delay/Intellectual Disability  
A. Chaubey1, K. Eaves1, F. Bartel1, K. Kwiatkowski2, E.T. Fung2, B.R. DuPont1 
1Greenwood Genetics Center, Greenwood, SC; 2Affymetrix, Santa Clara, CA. 
Introduction: High resolution microarrays such as CytoScan HD assay improve the 
identification of cytogenetic aberrations that may assist in the evaluation of patients 
with intellectual disability and/or developmental delay. Resolution depends on the 
density of probes on the physical array as well as the number of probes used in the 
software to define copy number change regions. The purpose of this analysis was to 
determine the impact of using high resolution settings, and determining the impact 
on false positive rates by confirmation with qPCR. Methods: Between May 2012 and 
May 2013, 1089 patients were evaluated using CytoScan HD assay using standard 
assay protocol as part of routine patient care. The clinical resolution setting for copy 
number variant (CNV) detection was a minimum of 5 probes per 40-kb region, lower 
than the standard clinical thresholds of 25 probes per 200 kb. All pathogenic CNVs 
were selected for qPCR confirmation. Results: Using these high resolution settings, 
632 patients (58%) had abnormal copy number variation changes. 327 CNVs were 
requested for family studies/confirmation using qPCR, and there was 100% 
concordance. 221 CNVs were inherited, 28 were de novo. 148 CNVs were <200 kb 
in size. Of the CNVs <200 kb, 4 were de novo and have clinical implications for the 
patient that would have been missed at the more conservative settings commonly 
used. Conclusions: Setting more lenient parameters for copy number variant 
identification improves diagnostic yield and clinically significant information without 
increasing the false positive rate. 
 
G20. Clinical Next-Generation Sequencing Panel Validation: Review of 
Findings 
L.M. Peterson, J.H. Blommel, N. Fadra, Z. Tu, E.W. Klee, M.J. Ferber 
Mayo Clinic, Rochester, MN. 
Introduction: Next-generation sequencing (NGS) panels have brought about a cost 
effective method to screen disease associated genes as compared to Sanger 
sequencing. Clinical validation of NGS panel tests has taken place at several CLIA 
licensed laboratories. Here we describe the results obtained during an end-to-end 
clinical validation of a hereditary colorectal cancer panel consisting of 17 genes (13 
by NGS, 2 by Sanger only, 2 by aCGH only). Our experiences highlight the benefits 
as well as the limitations of NGS. Methods: A validation plan following current 
institutional guidance documents on molecular assay validation was drafted, 
approved and experiments performed. This method validation was performed as an 
end-to-end process validation inclusive of library preparation, DNA sequencing, 
bioinformatics, and final result reporting. In total, we tested 148 blinded samples (115 
of them unique) processed across five Illumina GAIIx validation runs. The samples 
consisted of 80 previously genotyped (pathogenic variant positive) and 20 fully 
Sanger sequenced (for genes on the panel), normal samples to help us assess 
experimental accuracy, precision (inter- and intra-assay), sensitivity, and specificity; 
15 limit of detection (LOD) samples to test analytical measurement range (input 
gDNA) and analytical range (variant frequency detection). Results: Analytical 848outcomes were: sensitivity 97.6%, specificity 99.98%, accuracy 99.98%, and 
precision 78.3%. Of the 80 previously genotyped samples, 8 were omitted from 
these analytical calculations due to bioinformatics file definition errors or common 
limitations of the technology (homopolymer regions, large indels). All but 1 of the 72 
previously genotyped samples had variants identified and positive confirmation by 
Sanger sequencing. Our LOD studies showed that we have the technical ability to 
detect variants as low as 1%. However, with the goal of creating a robust and 
reproducible assay, our LOD has been set at 15%. Additionally, within the 20 normal 
samples, one MutYH positive and one CHEK2 positive sample were identified. 
Conclusions: We have validated a robust, next-generation sequencing assay for 
hereditary colorectal cancer with an estimated cost of $3,900 and a six week turn-
around time. Our data indicates this test to be a viable and a more cost-effective 
alternative to screen these 13 genes as compared to Sanger sequencing. 
 
G21. More Than Meets the Eye: The Role of Karyotype with a Discordant 
Result for Gender and Sex Chromosome Aneuploidy Following Noninvasive 
Prenatal Testing (NIPT) 
J.M. Gonzales1, T. Boomer1, L.A. Limone2, R.C. Miller2, A.T. Bombard3, J. Saldivar1 
1Sequenom Center for Molecular Medicine, San Diego, CA; 2St. Barnabas Medical 
Center, Livingston, NJ; 3Sequenom, Inc., San Diego, CA. 
Introduction: Since the introduction NIPT in October, 2011, use of circulating cell-
free fetal DNA (cffDNA) for prenatal aneuploidy assessment has enhanced 
traditional testing paradigms. With excellent sensitivity and specificity, cffDNA testing 
has become an important resource for evaluating at-risk pregnancies for trisomies 
13, 18, and 21. More recently, labs have begun reporting sex chromosome 
aneuploidies (SCAs). Maternal and/or fetal mosaicism, or other sex chromosome 
aberrations can complicate counseling of abnormal results, especially when clinical 
findings contradict the NIPT result.  
Methods: An NIPT using whole genome sequencing of ccffDNA was validated by 
the Sequenom Center for Molecular Medicine in a large clinical study. This 
laboratory developed test assesses the X and Y chromosome for gender and SCAs; 
specifically, 45,X; 47,XXX; 47,XXY; and 47,XYY. Herein, we describe two cases with 
important implications for counseling and evaluation of discordant findings. Results: 
Case Study I - A 35 y/o G3 P0020 woman presented at 11 6/7 weeks’ gestation with 
age-related risk for aneuploidy. NIPT suggested a male fetus. However, an 
ultrasound at 19 weeks’ gestation showed normal female external genitalia. Repeat 
NIPT confirmed the presence of the Y chromosome. Amniotic fluid karyotype 
analysis was 46,XY, and FISH analysis for Sex-determining Region on the Y was 
positive. Testing for X-linked androgen insensitivity syndrome revealed the fetus was 
hemizygous for the A766T mutation. Subsequent testing confirmed the mother was a 
carrier; posing a 50% risk to each XY conception. Case Study II - A 37 y/o G4 P2012 
woman presented at 16 weeks’ gestation with age-related risk for aneuploidy. NIPT 
reported an underrepresentation of X chromosome material. Confirmatory 
amniocentesis was 46,XX. The mother was noted to be short at just under 5’. The 
maternal karyotype revealed an SCA: 45,X[5]/46,XX[45], consistent with Turner 
syndrome mosaicism. Conclusions: Sex chromosome assessment demonstrates 
the dynamic changes being ushered in by NIPT. Current recommendations are for all 
patients with positive NIPT results to be offered confirmatory testing by chromosome 
analysis on cells obtained by CVS or amniocentesis. Gender discordance between 
NIPT and ultrasound may not always prompt fetal or neonatal karyotyping, but 
should be considered in certain circumstances. Maternal history and physical 
features including short stature, menstrual irregularities, subfertility, and other 
findings should be scrutinized with an abnormal SCA result. Maternal and/or 
neonatal karyotype can be an important evaluation following an abnormal result, as 
NIPT will not only detect abnormalities in the fetus, but can also alert us to 
undiagnosed maternal conditions. 
 
G22. A Sequencing Assay for the Cytochrome P450 Oxidoreductase (POR) 
Gene 
B.E. Moore, L.M. Baudhuin, J.L. Black 
Mayo Clinic, Rochester, MN. 
Introduction: Cytochrome P450 Oxidoreductase (POR) is the obligate electron 
donor to all microsomal cytochrome P450 (CYP) enzymes including those involved 
in drug metabolism such as CYP1A2, CYP2C9, CYP2C19, CYP2B6, CYP2D6, and 
CYP3A4 and those involved in steroidogenesis such as CYP17A1, CYP19A1, and 
CYP21A2. The pharmacogenomic implications of this gene are complex since it is 
central to the function of several CYP isoforms that may have their own genetic 
variations, with substrate-dependent variability. Thus, the final pharmacogenomic 
impact of POR varies according to i) the POR variant present, ii) the impact of a 
given POR variant upon a specific CYP enzyme isoform, iii) the CYP isoform variant 
present, and iv) the substrate. Therefore, POR pharmacogenomics has the potential jmd.amjpathol.org ■ The Journal of Molecular Diagnostics
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performed on gDNA, obtained from a de-identified donor set of 10 samples, utilizing 
duplex polymerase chain reaction (PCR) that amplified the POR gene to create 16 
tagged products including the promoter, exons 1-16, and the 3’-UTR. Unincorporated 
dNTP’s were removed enzymatically and the product underwent sequencing with 
universal sequencing primers, resulting in 32 sequencing traces. The sequences 
were analyzed using Mutation Surveyor software. The results were compared to a 
known reference sequence. The detected alterations were evaluated according to 
star allele nomenclature as published by the Human Cytochrome P450 (CYP) Allele 
Nomenclature Committee. Results: Sequencing was successfully completed on all 
samples. Six samples with coding variations in POR were identified. Two 
homozygous POR *28/*28 samples were observed as well as four POR *1/*28 
samples. Conclusions: The genetic polymorphisms of POR are increasingly being 
described as playing an essential role in variations of drug metabolism. The 
interpretations of POR variations in drug metabolism is somewhat more complex 
then previous pharmacogenomic candidates due to the need to not only take into 
account the substrate of interest but also potential variation in additional enzymes 
involved in the metabolic process. Pharmacogenomic uses of this new clinical 
genotyping assay include evaluation of patients with genotype- phenotype discord 
after CYP testing and evaluation of samples where complete pharmacogenomic 
testing is required either for clinical or research purposes or for clinical trials.  
 
G23. Analysis of the Complement Pathway Exome with Next-Generation 
Sequencing 
P.R. Reynolds1, P.C. Giclas1, A.M. Lynch2, L.A. Myers2, J.L. Marola1, P. 
Ramamoorthy1 
1National Jewish Health, Denver, CO; 2U. Colorado Health Sciences Center, Aurora, 
CO. 
Introduction: Complement is an essential part of innate immune surveillance. It is a 
powerful and tightly regulated enzyme cascade that is designed for homeostasis. In 
rare instances mutations may lead to uncontrolled activation, resulting in tissue 
damage and potentially fatal outcomes, such as in aHUS. Given the inefficiency of 
mutation analysis via PCR and subsequent Sanger sequencing in clinical testing, we 
looked to next-generation sequencing to provide comprehensive detection of 
variants in the Complement Pathway. Methods: Fifty genes were selected for the 
panel, with approximately 1000 targets whose coordinates were derived from the 
UCSC Genome Browser; the Region of Interest (ROI) was about 300 kb. Targeted 
capture of an ROI may be effected through PCR-based or solution enrichment 
protocols, and after evaluating predicted coverage from design programs at Life 
Tech, Agilent, and Illumina, we selected Agilent Haloplex (predicted coverage, 92%), 
and the Illumina Nextera Custom Enrichment (98%). Fifteen libraries were prepared 
with the Haloplex kit: 9 with known mutations, 2 normal, and 4 of unknown 
complement genotype. Forty seven libraries were prepared with Nextera CE; the 
same samples plus an additional 32 unknowns. Libraries were sequenced with 
paired-end technology on an Illumina MiSeq. All 15 Haloplex libraries were included 
in one run; four runs of 12 each were performed for the Nextera preparations. 
Mapping and variant calling were performed with Galaxy and NextGENe 
(softgenetics). Results: Certain templates did not support library preparation with the 
Haloplex protocol, although the DNA quality appeared to be equal to those that did. 
Coverages ranged from the single digits to more than several thousand. Skewing of 
inter-target coverage was more pronounced with the Custom Enrichment kit, but it 
also yielded greater overall coverage. This pilot study was successful, in that all 
known mutations were identified. However, there are improvements to be made in 
the next iteration. Conclusions: Due to the uneven coverage of the targets, and 
many individual target coverage profiles that look more like peaks than mesas, a 
redesign of the ROI is necessary. Flanking regions of each exon need to be 
increased and promoter regions will be deleted from the next design.  The refined 
design should enable us to detect mutations in at least 95% of all coding sequences 
and splice sites in the Complement pathway. This project has also served as tutorial 
for our next goal, which is to expand the panel to include all genes involved in 
Primary Immune Deficiencies. 
 
G24. Three Cases of the Fourth Apolipoprotein E Haplotype Identified 
During Routine Clinical Testing 
W.R. Higgins, D. Thiselton, T.L. Dall, J. McConnell 
Health Diagnostic Laboratory Inc., Richmond, VA 
Introduction: Apolipoprotein E (APOE) is a lipoprotein constituent found in very low-
density lipoprotein particles and chylomicrons. The gene encoding apolipoprotein E 
(APOE) is located on chromosome 19q13.2. The atherogenic potential of an 
individual is modulated by the genotype. The PCR assay used at Health Diagnostic 
Laboratory Inc. tests for the point mutations in codons 112 (rs429358) and 158 The Journal of Molecular Diagnostics ■ jmd.amjpathol.org(rs7412) of the APOE gene. There are three well-documented protein isoforms (E2, 
E3, and E4) corresponding to three of four possible haplotypes for these two SNPs. 
The fourth haplotype (E3r) is much rarer and, to our knowledge, reported to date in 
only three families (five individuals) worldwide.  
Methods: Two patient DNA samples possessing a unique APOE genotype were 
identified during routine clinical testing. TaqMan real-time PCR assay (Applied 
Biosystems Inc., Foster City, CA) revealed a homozygous C at the first nucleotide of 
codon 112, with heterozygosity for C and T at the first nucleotide of codon 158. A 
third sample was identified to be heterozygous for C and T at the first nucleotide 
position of codon 112 and homozygous T at the first nucleotide position of codon 
158. The genotypes of these three samples were confirmed using an end-point PCR 
assay with a separate set of primers and BHQPlus probes from Biosearch 
Technologies (Novato, CA). Results: In the first two patients (an African-American 
female and a male of unknown ethnicity), APOE gene copy would code for the E4 
isoform (Arg112/Arg158), whereas the other copy would code for the rare, fourth 
APOE haplotype (Arg112/Cys158), identified in the literature as E3r (or E1y). These 
patients would therefore have a genotype of E4/E3r. This genotype has been 
previously identified in a Caucasian patient with motor neuron disease (Seripa et al. 
2007) and a healthy Nigerian female and her son (Murrell et al. 2006). The third 
patient (an African-American male) had one APOE gene copy encoding the E2 
isoform (Cys112/Cys158), whereas the other gene copy would code for the rare 
fourth isoform E3r (Arg112/Cys158). The corresponding genotype, reported as 
E2/E3r, was previously identified in an autistic child and his mother (Persico et al. 
2004). All three patients in our study showed optimal plasma levels for total 
cholesterol, LDL-C, HDL-C, triglycerides, non-HDL-C, APOB, and small dense LDL. 
Conclusions: The three patients we report here almost double the number of 
reported E3r cases, bringing the total to eight. The clinical implications of this 
genotype are still unknown.  
 
G25. Reproducibility and Accuracy of a Bead-Based Multiplex xTAG 
CYP2D6 Kit v3  
W. Lau, S.I. Jap, Y. Wong, F. Merante, H. Zhang 
Luminex Molecular Diagnostics, Toronto, Ontario, Canada 
Introduction: Cytochrome P4502D6 (CYP2D6) is a member of the cytochrome 
P450 superfamily. This large superfamily of enzymes is involved in the metabolism 
of drugs and xenobiotic compounds, as well as the catalysis of steroid hormone 
biosynthesis. CYP2D6 is involved in the metabolism of more than 65 commonly used 
prescription medications, including: ȕ-blockers, antipsychotics, antidepressants, 
analgesics, and antiarrhythmics. As the CYP2D6 gene is highly polymorphic, the 
detection and determination of the genotypes for CYP2D6 can be a time consuming 
process. In this study, the reproducibility and accuracy of a FDA cleared bead-based 
multiplex assay (xTAG CYP2D6 Kit v3) developed by Luminex Molecular 
Diagnostics (LMD) was evaluated. This multiplex panel is designed to detect 17 
genotypes that are formed from the combination of 22 mutations and polymorphisms 
including gene duplications and deletions. Methods: The Reproducibility of the 
xTAG CYP2D6 Kit v3 was assessed using a multiple-operator, multiple-lot, multiple-
thermal cycler type, blinded study design. Each reproducibility sample set (RSS) was 
comprised of five whole blood samples collected in tubes containing either EDTA or 
citrate and six pre-extracted genomic DNA samples from the Coriell Cell Repository. 
The accuracy of the xTAG CYP2D6 Kit v3 was evaluated using de-identified 
archived left-over genomic DNA originally extracted from primary clinical specimens 
(peripheral blood samples) and the results compared to DNA sequencing. Results: 
The reproducibility study produced a total of 198 data points. The overall 
reproducibility of the xTAG CYP2D6 Kit v3 after allowable reruns was 100.0%. Two 
hundred seventy-nine (279) clinical samples were analyzed in the accuracy study. 
Accuracy of 100.0% was obtained for xTAG CYP2D6 Kit v3 across all mutant and 
wild type alleles when compared to DNA sequencing. Conclusions: This study 
showed that the xTAG CYP2D6 Kit v3 is highly reproducible and accurate for the 
detection of 17 genotypes of CYP2D6. Both the star genotypes and the related 
mutations and polymorphisms from the clinical sample can be evaluated within a 
single reaction.  
 
G26. Removal of the PCR Inhibitor Melanin from gDNA Extracted from 
Melanoma FFPE Tissue Using Agarose Gel Electrophoresis and Comparison 
with Other Melanin Removal Techniques  
J.N. Landreth, S.M. Jones, K.J. Matteson 
University of Tennessee Genetics Center, Knoxville, TN. 
Introduction: FFPE tissue provides a versatile source of nucleic acids for molecular 
testing; however, often with melanoma tissue, the copurification of melanin with 
nucleic acids creates a challenge for PCR-based analysis because melanin is a 
strong PCR inhibitor. Chemical similarities between melanin and nucleic acids make 849
AMP Abstractsit difficult to separate the two by traditional purification techniques. In this study, we 
developed a novel approach utilizing size separation by agarose gel electrophoresis 
to remove melanin from extracted gDNA samples. In addition, two commercial 
agarose gel DNA extraction kits were evaluated as well as an additional PCR 
inhibitor removal kit to establish the most efficient method for routine use. Methods: 
Although melanin and gDNA exhibit similar chemical behavior, the relatively low 
molecular weight of melanin caused it to migrate faster through agarose gel and 
separate from lagging gDNA. The agarose section containing only the gDNA was 
excised and purified. PCR amplification followed by capillary electrophoresis 
confirmed the removal of inhibition from the gDNA samples. To test the method's 
effectiveness, clean gDNA samples were mixed with increasing concentrations of 
synthetic melanin and subjected to agarose gel purification. The Promega Wizard SV 
Gel and PCR Clean-Up System and QIAGEN QIAEX II Gel Extraction Kit were 
compared for both quantity and quality of gDNA recovered. For further comparison, a 
spin column and silica matrix based method (Zymo Research OneStep PCR Inhibitor 
Removal Kit) was evaluated using the same samples. PCR amplification/CE analysis 
was used to compare all three kits. Results: Both agarose DNA extraction kits were 
effective in recovering clean gDNA from melanin inhibited samples, regardless of the 
concentration of melanin present. The Zymo OneStep columns removed moderate 
levels of melanin but were inefficient with higher concentrations. When processing 
PCR grade gDNA, all three kits recovered 20% to 50% of the input DNA; however, 
with high molecular weight gDNA, the Promega Wizard kits showed significant 
decrease in DNA recovery (10% to20%). Conclusions: Agarose gel electrophoresis 
is an effective method for removing the PCR inhibitor melanin from gDNA samples. 
The process can remove high concentrations of melanin and utilizes resources 
already common to molecular genetic laboratories. The QIAGEN QIAEX II kit proved 
most versatile, but the low hands-on time of the Promega Wizard kit makes it more 
appealing for processing PCR grade samples. The Zymo OneStep columns were the 
quickest method, but their inability to remove higher concentrations of melanin 
makes them less appealing as a sole method of melanin removal. 
 
G27. Detecting Aneuploidy in Degraded DNA from Early Pregnancy Failure 
L.D. McDaniel, S. Silvestri, J.A. Rosenfeld, R.A. Schultz 
Signature Genomics Laboratories, PerkinElmer, Inc, Spokane, WA 
Introduction: Early pregnancy failure (EPF) occurs in up to 20% of all recognized 
pregnancies. About half of these failures are attributed to chromosome 
abnormalities. Development of karyotyping, array comparative genomic hybridization 
(aCGH) and other testing has provided an answer for many families. However not all 
EPFs are detected and tested in a time frame that provides viable cells. The 
resulting culture failures and yield of degraded DNA are often not useful for aCGH or 
other hybridization techniques. Methods: PCR assays are useful in amplifying small 
DNA fragments. The Promega PowerPlex 16HS is a multiplex STR system for typing 
DNA. It is used for detecting maternal cell contamination (MCC) in our laboratory and 
has detected aneuploidy in cases routinely screened for MCC. The principle that this 
assay can be used on small degraded DNA was investigated. A maternal sample 
tested simultaneously confirms the fetal identity is unique from the mothers. Inclusion 
of STR markers for chromosomes 13, 16, 18, and 21 and the ability to detect 
polyploid samples, increases the expected clinical utility of the assay for indications 
of EPF. Results: In addition to detecting aneuploidy, triploids have also been 
detected in in routine prenatal cases where MCC was ordered. The detection of two 
different alleles for a STR marker in a sample with equal peak heights or one allele 
with twice the height indicates a diploid result. When three different alleles are 
detected with equal peaks height for one STR marker, aneuploidy is probable and 
was confirmed in all cases. When two unequal peaks are seen in cases of trisomies, 
the ratio of the two alleles averaged 1.98 and ranged from 1.64 to 2.62. For the 
cases of 69,XXX the ratio of the peak heights of the marker AMEL on the X 
chromosome to the autosome marker vWA, averaged 2.48. Samples that have failed 
to grow in culture and have failed in multiple hybridization techniques were tested 
using this assay and all samples were successful in amplifying all of the STRs 
included in the assay. One of those samples had three alleles in D13S317. 
Conclusions: The use of the PowerPlex 16HS assay can be a useful tool in the 
analysis of samples that fail to culture and samples with degraded DNA that is not 
useful for hybridization techniques. Although rare cases of mutations of alleles and 
allele duplications have been reported, this assay may provide answers to cases 
where no other tests have been successful. 
 
 
 
 850G28. Evaluation of the Relationship between Serum Concentrations of 
Clomiphene Metabolites and CYP2D6 Polymorphisms in Korean Anovulatory 
Women Treated with Clomiphene Citrate  
M. Ji1, T. Jeong2, W. Lee2, S. Kim3, K. Kim4, S. Chun 2, W. Min2 
1Eulji University Hospital, Eulji University School of Medicine, Daejeon, Korea; 2Asan 
Medical Center and University of Ulsan College of Medicine, Seoul, Korea; 3Ilsan 
Paik Hospital, Inje University College of Medicine, Goyang, Gyeonggi-Do, Korea; 
4Mizmedi Hospital, Seoul, Korea. 
Introduction: Clomiphene citrate (CC) has been commonly prescribed for ovulation 
induction in patients with anovulatory infertility. Recently, several studies have 
reported that CYP2D6 is primarily responsible for the metabolism of CC and its 
genetic polymorphism affects clomiphene metabolism. The purpose of the present 
study was to correlate CYP2D6 genotype with major active CC metabolites and 
clinical response to CC treatment in Korean infertile patients treated with CC. 
Methods: A total of 42 patients with anovulatory infertility treated with only CC were 
enrolled between Feb 2011 and Jan 2013. Patients received a dose of 100 mg/day 
CC on days 3 to 7 of the menstrual cycle, and blood samples were collected on days 
3 and 10. Measurement of CC metabolites including (E)-4-hydroxy-clomiphene (4-
OH-Clom) and (E)-4-hydroxy-N-desethylclomiphene (4-OH-DE-Clom) was performed 
with use of HPLC-tandem mass spectrometry from the serum specimens. CYP2D6 
genotyping was performed with use of PCR-direct sequencing and multiplex long-
PCR. We included primers to amplify most CYP2D6 variants detected in previous 
studies of Korean population. Other clinical and laboratory characteristics were also 
collected including hormonal levels. Patients who ovulated on an initial dose of 100 
mg/day were regarded as CC responders, and those who did not ovulate on this 
dose were regarded as CC non-responders. Results: Among the 42 patients, 32 
patients were CC responders and 10 patients were non-responders. The mean 
concentrations of 4-OH-Clom and 4-OH-DE-Clom in non-responders were lower than 
those in responders. The mean 4-OH-Clom was 4.64 nM (range 0.90 to26.18) and 
8.89 nM (0.41 to 43.54) for each group and mean 4-OH-DE-Clom was 5.20 nM (0.65 
to32.59) and 13.92 nM (<0.3 to 56.01) for non-responder and responder group. The 
major genotypes detected were CYP2D6*1/*10 (31.0%) and *10/*10 (17.2%). 
CYP2D6*10 was found to be the most frequent allele among the 31 patients with 
completing genotyping. Eight patients with possessing more than 1 poor metabolizer 
allele such as *5 or 2 intermediate metabolizer alleles such as *10 or *41 were 
almost responders except only one non-responder. The mean concentrations of 4-
OH-Clom and 4-OH-DE-Clom of them were 23.48 nM (range 2.68 to 45.34) and 
38.61 nM (3.41 to 82.90), respectively. Conclusions: This is the first study of 
evaluating CYP2D6 genotypes and active clomiphene metabolites in Asian women 
taking infertility drug clomiphene. There was a trend of showing decreased 
concentration of active metabolites in non-responders. Relationship between 
CYP2D6 polymorphism and the mean concentrations of CC metabolites were 
unclear in this study. It might be due to ethnic variation of genotypes or role of 
additional covariates.  
 
G29. Comparison of Two Korean Genetic-Testing Services with 23andMe 
Service 
M. Ji1, S. Kim2, W. Lee3, S. Chun3, K. Um2, C. Cho2, T. Um2 
1Eulji University Hospital, Daejeon, Choongnam, Korea; 2Ilsan Paik Hospital, Inje 
University College of Medicine, Goyang-si, Gyeonggi, Korea; 3University of Ulsan 
College of Medicine and Asan Medical Center, Seoul, Korea. 
Introduction: Two companies provide genetic testing of disease prediction, drug 
responses and trait in Korea. However, there has been no evaluation study for the 
accuracy and usefulness of these genetic testing services. We compared 2 Korean 
genetic testing services to 23andMe service for the same individuals. Methods: We 
obtained and compared the results from 2 Korean genetic testing services 
(Hellogene by Theraen Bio Institute and DNAGPS by DNAlink) and 23andMe service 
for one man and one woman samples. Results: The concordance rates between the 
services for SNP data were > 97.69%. However, there were some marked 
differences in the relative disease risks reported by the 3 genetic services (e.g., for 
lung cancer, the range of relative risk was 0.9 to 2.09). A possible reason for this 
difference is that different SNP were used to calculate risk for the same disease. The 
algorithm for combining risk for each SNPs as well as the reference population also 
had an influence on the relative disease risk. Conclusions: Our study showed fair 
concordance between the SNP calls of 3 genetic services provided from different 
companies with different platforms, and we realized that risk prediction process 
should be standardized and validated.  
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 AMP AbstractsG30. Validation of Next-Generation Sequencing for the CFTR Gene in a 
Clinical Setting 
P.R. Reynolds1, J. Marola1, L. Mast1, V. Buchanan1, J. Talbert1, K. Jones2, P. 
O'Neill2, K. Gowan2, P. Ramamoorthy1 
1National Jewish Health, Denver, CO; 2University of Colorado, Denver, CO. 
Introduction: Cystic Fibrosis (CF) is a progressive inherited disease of the mucous 
glands primarily affecting the respiratory, digestive, sinus, sweat gland, and male 
reproductive systems. Mutations in the cystic fibrosis transmembrane conductance 
regulator (CFTR) gene lead to abnormal chloride conductance across the cell 
membrane. Greater than 1500 mutations have been identified that vary in 
pathogenicity. Targeted mutation panels are most often used by laboratories to 
screen for the most common mutations that cause classic CF, and then full gene 
sequencing may be pursued for further testing. Classic CF is most often detected in 
the newborn or pediatric population. Nonclassic forms of CF may not be detected 
until adulthood. Methods: The Molecular Diagnostics Laboratory at NJH has 
developed a full gene sequencing assay using Next-Generation Sequencing (NGS) 
to screen for the full spectrum of mutations in the adult CF population. A validation 
study to assess the analytical sensitivity and specificity of the CFTR full gene 
sequencing assay was conducted. A total of fifty-one Coriell control samples with 
known CFTR-causing variants and at least 20 previously characterized patient 
samples were included in the validation. Targeted capture of all 27 exons plus two 
intronic regions of CFTR was performed by conventional PCR for 24 samples per 
run. Amplified DNA samples were pooled, and libraries were prepared using the 
Illumina Nextera XT DNA Sample Preparation Kit. Library preparations were 
quantified by real-time PCR. All libraries were pooled and sequenced on an Illumina 
MiSeq using paired-end reads of 2 x 150 cycles. Results: A total of 96 samples 
were included during assay validation across six independent MiSeq experiments. 
Typical assay runs yielded coverages of 1500 to 7500, depending on the Flow Cell. 
NGS data were analyzed using two bioinformatics tools: NextGENe (SoftGenetics)) 
and a customized bioinformatics pipeline developed in collaboration with the 
Universityof Colorado Cancer Center’s Bioinformatics Shared Resource Center for 
clinical reporting of variants detected. Details of the clinical validation for our CFTR 
next-generation sequencing assay will be presented. Conclusions: Analytical 
sensitivity was >98% with amplicons drop outs accounting for decreased sensitivity. 
Analytical specificity was >99%. Our validation process demonstrated that using a 
combination of a commercially available bioinformatics tool in conjunction with a fully 
customizable bioinformatics pipeline and reporting system is the ideal route for entry 
of next-generation sequencing into the clinical laboratory. 
 
G31. Evaluation of Prenatal Diagnosis by Conventional Cytogenetics 
Including Karyotyping and FISH at the Greenwood Genetic Center: A 13-Year 
Retrospective Study 
B.R. DuPont, S. Ladd, E. Christensen, F.O. Bartel, A. Chaubey 
Greenwood Genetics Center, Greenwood, SC. 
Introduction: Chromosome analysis on amniotic fluid (amniocentesis) has been the 
mainstay for prenatal diagnosis for pregnancies at risk of cytogenetic abnormalities 
since the 1980’s. With the addition of clinical diagnostic fluorescent in situ 
hybridization (FISH) analysis in the 1990’s, laboratories have also been able to offer 
direct analysis on amniotic fluid cells for chromosomes X, Y, 13, 18, and 21. Reports 
on discrepancies between karyotype analysis and direct trisomy screening by FISH 
have varied.  
Methods: In the last 13 years, the Cytogenetics Laboratory at the Greenwood 
Genetic Center (GGC) has reported 1263 amniocentesis analysis where both 
chromosomes (karyotype) and trisomy screen analysis by FISH have been run. 
Results: 82.3% (1039) were normal for both chromosomes and FISH; 14.6% (185) 
were abnormal for both; 2.3% (30) were abnormal by chromosomes after a normal 
FISH result; and 0.7% (9) were abnormal by FISH and subsequently found to have a 
normal karyotype on chromosomes. Abnormalities that were in agreement between 
karyotype and FISH included:  43.2% (80) +21, 29.2% (54) +18, 10.2% (19) 45,X, 
8.6% (16) +13, 4.3% (8) 47,XXY, and 4.3% (8) 69,XXX/69,XXY. The discordant 
results between FISH and karyotype analysis had a variety of abnormalities that 
included 7 terminal deletions, 4 other trisomies, 4 derivative chromosomes from a 
balanced translocation in a parent, 3 Robertsonian translocations, 3 inversions, two 
apparently balanced translocations, two mosaic XX/XY or XO/XY, two complex 
chromosome rearrangements, and one each of dicentric, ring, and an additional iso- 
chromosome. Conclusions: The discordant cases with abnormal chromosomes 
represent 13.3% of the 224 total abnormal cases and these cases would have been 
missed by trisomy screen alone. The 9 (4.0%) discordant cases abnormal by FISH 
were all mosaics that were not observed by karyotype; three mosaic for XY/XX; three 
mosaic for +18; two mosaic for +21; and one was mosaic for XO/XX. These results 
show the clinical utility of both chromosome analysis and FISH analysis on cells The Journal of Molecular Diagnostics ■ jmd.amjpathol.orgisolated directly from amniotic fluid. They also reiterate the higher diagnostic yield 
and value of performing conventional cytogenetic analysis over a trisomy screen. 
 
G32. Exome Sequencing Identifies a Novel Mutation in HEXB Associated 
with Juvenile Sandhoff Disease in a Consanguineous Family with Movement 
Disorders and Intellectual Disability 
S. Kantarci1, N. Bissar-Tadmouri2, M.B. Johnson3, R.S. Hill3, A. Megarbane4, C.A. 
Walsh3 
1UCLA, Los Angeles, CA; 2Beirut Arab University, Tripoli, Lebanon; 3Boston 
Children's Hospital , Boston, MA; 4University Saint-Joseph, College of Medicine, 
Beirut, Lebanon. 
Introduction: Sandhoff disease is a rare, clinically heterogeneous, autosomal 
recessive lysosomal storage disease caused by mutations in the HEXB 
(hexosaminidase B) gene. Deficiency of beta-hexosaminidase A and B leads to 
excessive accumulation of GM2 ganglioside resulting in progressive 
neurodegeneration. The disease classically presents in infants who usually die by 
age 3 but rarely occurs in juveniles and adults. Juvenile Sandhoff disease typically 
presents between ages 2 and 10, and variable clinical manifestations include muscle 
weakness, ataxia and other movement disorders, progressive speech problems, 
seizures, visual problems, and intellectual impairment. Methods: In our study, we 
enrolled a large consanguineous Arab family with three siblings (two girls and one 
boy) affected by slowly progressive gait disturbance, action tremor, dysarthria, and 
mild intellectual disability. Chromosome analysis and Fragile X studies were normal 
in the male sibling. Autozygosity mapping using Affymetrix SNP Array 6.0 in the 
family members (3 affected and 2 unaffected siblings and unaffected parents) 
revealed two candidate loci: 5q13.2-q13.3 and 6p12.3-p21.2. Exome sequencing of 
three family members (mother, one affected boy, and one affected girl) to 50x 
average depth of coverage with 2x 100 paired-end reads on Illumina HiSeq 2000 
generated an average of 7.5 Gb of sequence for each sample. About 1100 novel 
variants were annotated using the GenomeQuest whole genome analysis software.  
Results: A homozygous c.1615C>T (p.Arg539Cys) mutation was identified in the 
HEXB gene located on the 5q13.3 homozygous region shared by all affected 
siblings, whereas the mother was a heterozygous carrier. This novel variant is 
predicted to be deleterious by PolyPhen, SIFT, and Condel bioinformatics tools. 
Conclusions: Here, we report a novel homozygous missense HEXB gene mutation 
in three affected siblings from a consanguineous family with a late-onset form of 
Sandhoff disease. Missense mutations are the most common type of mutations in 
this gene. To date, about 84 mutations have been reported in HEXB and most of 
them cause the severe infant form of the disease. In light of the data obtained 
through exome sequencing, clinical re-evaluation of the affected siblings for a late-
onset form of Sandhoff disease is in process. Our study highlights the importance of 
exome sequencing in the underlying molecular mechanisms of clinically 
heterogeneous known single-gene disorders. 
 
G33. From Genes to Genomes: Defining and Validating the Medical Exome 
for Clinical Diagnostic Applications 
A. Santani1, S. Gowrisankar2, D. Mandelker2, A. Sasson1, C. da Silva3, M. Sarmady1, 
T. Tischler1, Z. Yu1, R. Shakhbatyan2, M. Hegde3, B.H. Funke2 
1Children's Hospital of Philadelphia, Philadelphia, PA; 2Partners Healthcare Center 
for Personalized Genetic Medicine, Cambridge, MA; 3Emory University School of 
Medicine, Atlanta, GA. 
Introduction: Genetic testing for Mendelian diseases with locus and allelic 
heterogeneity is now routinely performed using disease targeted next-generation 
sequencing (NGS) assays. Although their moderate size allows for high coverage 
and the ability to generate data for every interrogated base, their clinical sensitivity is 
usually suboptimal. In contrast, exome sequencing offers enhanced detection rates 
but does not return data for the entire target region, thereby limiting its clinical utility. 
We sought to identify all currently known medically relevant genes, develop a 
framework for iterative curation of this “medical exome” and develop a clinically 
validated enhanced exome assay where coverage of medically relevant genes is 
optimized. Methods: Genes and basic annotations were downloaded from an array 
of databases housing disease-gene association information, the three main sources 
being HGMD, OMIM (morbid map), and ClinVar. Additional genes were contributed 
by gene lists from Jackson lab’s MGI database, locus specific databases, 
GeneTests, Orphanet, Cosmic, and expert curated disease specific gene lists. This 
draft medical exome was further enriched by adding disease risk loci (NHGRI GWAS 
catalog) and pharmacogenetic targets (PharmGKB). A base line curation was 
conducted to remove genes that had no evidence for a role in disease. In addition, 
exons with conserved paralogous sequences were excluded to avoid technical and 
analytical challenges. Exome sequencing was performed at 100x average coverage 
using Agilent’s v5 exome capture kit to determine the base line coverage of the 851
8AMP Abstractsmedical exome. Results: More than 5000 genes were extracted from the above 
databases, 877 of which were removed due to lack of evidence for a role in disease. 
An analysis of the remaining genes using exome sequencing revealed optimal 
coverage (all bases >20x) for ~2/3 of the exons, insufficient coverage (<40% of 
bases >20x) for ~10% and various gradations of completeness for the remaining 
~20%. Suboptimally covered exons were subjected to re-design by Agilent. 
Alternative approaches to boost coverage included “spike-in” of biotinylated DNA 
oligonucleotides (IDT). We will present a comparison of this enhanced medical 
exome to its base line version and present the results of a 3-site clinical validation. 
Conclusions: As comprehensive genetic testing via NGS is becoming reality, it is 
vital to eliminate deficiencies of exome capture assays, which are being used at 
rapidly increasing frequency to diagnose disease. Defining the medical exome, 
enabling iterative curation and sharing this knowledge with the genetic testing 
community will enable improved genetic care.  
 
G34. Early Recurrent Ischemic Lesion on Diffusion-Weighted MRI Based on 
the Cytochrome P450 2C19 Genotype in Stroke Patients Treated with 
Clopidogrel 
T. Jeong1, M. Ji2, S. Kim3, S. Kim1, W. Lee1, H. Kim1, S. Kwon1, D. Kang1, S. Chun1, 
W. Min1 
1University of Ulsan College of Medicine and Asan Medical Center, Seoul, Songpa-
gu, Korrea; 2Eulji University Hospital, Eulji University School of Medicine, Daejeon, 
Seo-gu, Korea; 3Ilsan Paik Hospital, Inje University College of Medicine, Ilsan, 
Goyang, Korea. 
Introduction: The early recurrent ischemic lesions on diffusion-weighted magnetic 
resonance imaging (DW-MRI) scan of brain are frequently observed in patients with 
stroke. The recurrent lesions on DW-MRI have been used as a possible surrogate 
marker for clinical recurrence of stroke. Clopidogrel is widely used for secondary 
prevention of stroke. The metabolism of clopidogrel is affected by cytochrome P450 
2C19 (CYP2C19) genotypes. We aim to access the incidence of DW-MRI recurrence 
rates based on the CYP2C19 genotype in stroke patients treated with clopidogrel. 
Methods: We enrolled 77 stroke patients treated with clopidogrel. The DW-MRI scan 
of the brain was performed at the onset of stroke and subsequent follow-up within 7 
days after diagnosis of stroke. The CYP2C19 genotyping was performed using the 
Verigene system (Nanosphere, USA). According to the CYP2C19 genotype, the 
CYP2C19 enzyme activity was classified into four groups including ultra-rapid 
metabolizer (UM), extensive metabolizer (EM), intermediate metabolizer (IM) and 
poor metabolizer (PM). We compared the recurrence rates of early ischemic lesion 
on DW-MRI based on the CYP2C19 genotypes. And the binary logistic regression 
analysis was performed to assess the association of recurrence rates of stroke on 
DW-MRI, CYP2C19 genotype and other risk factors of stroke such as hypertension, 
diabetes, hyperlipidemia, previous history of stroke, family stroke and thrombolytic 
therapy. Results: The overall DW-MRI recurrence rate was 48.1% (37/77). Based on 
the CYP2C19 genotype, 77 patients were classified into UM (n=1, 1.3%), EM (n=27, 
35.1%), IM (n=36, 46.8%) and PM (n=13, 16.9%). The highest recurrence rate on 
DW-MRI was observed in PM (84.6%), followed by IM (50.0%), and EM (25.9%) in 
descending order. The PM revealed a significantly high incidence of DW-MRI 
recurrence than EM (P < 0.001). In addition, the DW-MRI recurrence rates have 
largely been attributed to an increase a number of variant alleles of CYP2C19 (P = 
0.047). In the multivariate logistic regression analysis, the odds ratios of recurrence 
rate on DW-MRI adjusted age and gender were 2.32 (95% confidential interval, 0.69 
to 7.78, P = 0.174) for IM and 18.00 (95% confidential interval, 2.44 to 133.01, P = 
0.005) for PM, respectively. 
Conclusions: The recurrence rate of early ischemic lesion on DW-MRI was 
significantly higher in PM than EM. Therefore, alternative antiplatelet treatment 
should be considered in some stroke patients harboring two reduced-function 
CYP2C19 alleles.  
 
G35. Optimization and Heterogeneity Data for Methylation Results from a 
High Resolution Melt Assay Design for FMR1 Promoter Methylation 
A. Hamilton, D. Bost 
Celera, Alameda, CA. 
Introduction: A PCR-based Laboratory Developed assay for FMR1 methylation 
would supplement existing expansion-sizing PCR tests to assess expansion and 
methylation status of patient samples. Reagents for a High Resolution Melt (HRM) 
assay targeting a region of the FMR1 promoter allow the amplification of bisulfite 
converted DNA with an intercalating dye for HRM analysis to determine the overall 
methylation status of the FMR1 promoter. Methods: A High-Resolution Melt protocol 
was evaluated in experiments on the methylation status of 100 clinical samples. The 
samples included 13 full mutation male, 14 premutation male, 4 gray zone male, 1 
XXY male, and 11 normal-expansion male samples, and 17 full mutation female, 19 52premutation female, 5 gray zone female, and 16 normal-expansion female samples. 
The calculated areas under the derivative melt peaks for the unmethylated and 
methylated fractions of each sample were used to categorize samples. Sequencing 
data were used to examine the patterns of methylation of the CpG sites in the 
targeted region of the FMR1 promoter. Results: The assay was used to distinguish 
between fully methylated and partially methylated full-mutation males (as well as 
distinguishing these from the unmethylated samples). Two samples reported to be 
fully methylated using Southern Blot data had a minor unmethylated fraction. Of the 
full mutation female samples 6 had a previously-reported random or detrimental X-
chromosome inactivation bias that meant the normal allele was half or more 
methylated, whereas 4 had reported X-chromosome inactivation bias that meant the 
normal allele was mostly unmethylated. The assay results successfully distinguished 
the former from the normal methylation range female samples. We attempted to 
define an “intermediate” category between high and normal that might separate out 
the full mutation females with a mostly active normal allele but this category was too 
narrow and could not consistently distinguish borderline samples from normal 
expansion+methylation samples. Conclusions: Optimization experiments were 
done on different HRM-capable instruments and bisulfite conversion kits, to examine 
effects on the balance between methylated and unmethylated allele amplification. 
Sequencing data shows that differences in the shape of melt curves is related to 
heterogeneity differences in the pattern of methylation of the individual CpG sites 
along the amplicon, which has implications for the selection of control samples and 
category definition for Laboratory Developed High Resolution Melt assays. The HRM 
analysis method was shown to allow the categorization of samples by overall 
methylation of FMR1.  
 
G36. Toward the Detection of Fetal Single Gene Disorders from Circulating 
Cell-Free DNA Using Massively Parallel Sequencing: A Technical Feasibility 
Study 
T.J. Jensen, P. Liu, C. Chin, Z. Zhu, E. McCarthy, F. Ehya, C. Deciu, D. van den 
Boom, M. Ehrich 
Sequenom Center for Molecular Medicine, San Diego, CA. 
Introduction: Massively parallel sequencing (MPS) of circulating cell-free (ccf) DNA 
from maternal plasma has been widely accepted for non-invasive prenatal testing for 
trisomies of chromosomes 13, 18, and 21. The extension of MPS to single nucleotide 
variants or small indels presents challenges including the depth of coverage required 
to accurately assess variant frequency, especially since the variant of interest is 
derived from the fetus and thus the minority DNA species. We evaluated solutions to 
these challenges by adapting the use of a target enrichment panel originally 
designed for neonatal screening. 
Methods: Whole blood (10 mL) was collected from pregnant female donors and 
plasma separated using centrifugation. Ccf DNA was isolated from plasma (4 mL) 
according to manufacturer’s recommendations (Qiagen). Genomic DNA (gDNA) 
samples from a single family (mother and three children) with known mutational 
status for the CFTR gene were purchased from the Coriell Institute. Sequencing 
libraries were subsequently prepared according to a modified version of the 
manufacturer’s protocol (TruSeq, Illumina, San Diego, CA). All libraries were 
subjected to capture enrichment using a custom panel targeting >500 genes 
associated with inherited disorders (TruSeq Custom Enrichment, Illumina) according 
to the manufacturer’s protocol. All libraries were paired-end sequenced (2x 100 bp) 
using a HiSeq2000 sequencer (Illumina). Sequencing reads were aligned using BWA 
and variants called with the GATK variant caller. Results: We addressed the 
feasibility of this approach in two ways: performing target enrichment sequencing on 
ccf DNA from women carrying a fetus without a known genetic disorder and 
detecting known mutations in mixtures of genomic DNA samples designed to 
simulate maternal plasma. We sequenced 35 pregnant ccf DNA samples to a 
coverage level of 142-313x, enabling the calculation of allele frequencies at 4813-
6454 genomic locations. In gDNA mixture models, we show that sequencing to a 
mean variant coverage of 229x enables the identification of affected individuals when 
the minority contribution is greater than 10%. Overall, these preliminary data suggest 
the feasibility of identifying fetal mutations by sequencing ccf DNA from maternal 
plasma. Conclusions: Although the medical community must ultimately dictate the 
clinical applicability, these data suggest the feasibility of detecting genetic variants 
and provide the foundation for future work in the area of prenatal detection of 
mutations associated with single gene genetic disorders, potentially enabling earlier 
nutritional or pharmaceutical intervention where appropriate. 
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by Incorporating Systematic High Resolution Copy Number Analysis 
B.H. Funke1, M.J. Bowser2, S. Gowrisankar2, H. Duzkale2, S.S. Amr2, O. Ceyhan-
Birsoy2, J. Shen2, E. Hynes2, L.M. Mahanta2, H.L. Rehm2, T.J. Pugh2 
1Laboratory for Molecular Medicine, Cambridge, MA; 2Partners Healthcare Center for 
Personalized Genetic Medicine, Cambridge, MA. 
Introduction: Next-generation sequencing (NGS) testing has dramatically increased 
the number of genes that can be sequenced simultaneously and has begun to 
eliminate diagnostic odyssey. Truly comprehensive testing, however, must include 
detection of copy number variants (CNVs), which are part of the pathogenic variant 
spectrum for many disease genes. CNV detection is possible but non-trivial using 
targeted NGS panels, which are the predominant NGS test in many clinical 
laboratories. Methods: We evaluated two CNV callers (CoNIFER and VisCap) using 
up to 15 samples with known CNVs. VisCap, an in-house developed tool, was 
clinically validated using these 15 positive controls as well as 27 predicted CNVs that 
were confirmed by droplet digital PCR (ddPCR). This data set was also used to 
determine the accuracy of visual scoring based on VisCap output. We subjected 960 
anonymized samples that had received clinical NGS gene panel testing for up to 51 
inherited cardiomyopathy genes (n=838) or up to 71 hearing loss genes (n=122) to a 
retrospective CNV analysis to identify previously missed disease causing variants. 
Results: CoNIFER detected 0/11 known CNVs with its default settings and was not 
further evaluated. VisCap showed optimal sensitivity (15/15 known CNVs spanning 1 
to 60 exons correctly identified) but a high false positive rate (63%, n=17/27). 
However, a blinded visual inspection correctly differentiated all 10 confirmed true 
positives from confirmed false positives. Based on these results, we have clinically 
implemented CNV analysis for targeted NGS gene panels using a combination of 
automatic calling, visual inspection and ddPCR confirmation. This was achieved 
without increasing the established turn-around time for 4 disease targeted NGS gene 
panels. A retrospective analysis of patients with hearing loss (n=122) and inherited 
cardiomyopathies (n=838) revealed likely or possibly disease causing CNVs in 7 
cardiomyopathy patients (0.8%) and 5 hearing loss patients (4%). In addition, we will 
report the results of an analysis of an expanded cohort of several hundred samples 
from patients with 4 different test indications (Noonan spectrum disorders, hearing 
loss, inherited cardiomyopathies and respiratory diseases). Conclusions: CNV 
analysis using targeted NGS data is non-trivial but can be implemented into routine 
clinical diagnostics at high accuracy and in a cost effective manner. Its clinical utility 
is evident from the positive impact on diagnostic sensitivity, particularly for our 
hearing loss gene panel. 
 
G38. Evaluation of the Luminex xTAG CYP2C19 Kit v3 (EU) with Clinical 
Specimens Collected from Diversity of Ethnic Background 
M. Dunnell 
Luminex, Toronto, Ontario, Canada. 
Introduction: The CYP2C19 gene, located on chromosome 10q24, is a highly 
polymorphic gene that is involved in the metabolism of drugs including clopidogrel, 
anticonvulsants, diazepam, omeprazole, tricyclic antidepressants and proton pump 
inhibitors. Inter-ethnic variations in the CYP2C19 gene have previously been 
observed. Genotyping of the CYP2C19 gene can aid clinicians in determining 
metabolizer phenotype. Luminex Corporation has developed an xTAG CYP2C19 
assay. The Luminex xTAG CYP2C19 Kit v3 is a batch-mode assay and 
simultaneously detects CYP2C19 variants such as *1, *2, *3, *4, *5, *6, *7, *8, *9, 
*10, and *17 for up to 48 independent samples in one batch. The Luminex xTAG 
CYP2C19 Kit v3 (EU) can accomplished this within 5 hours starting from extracted 
clinical samples. Methods: Six hundred thirty-one distinct whole blood specimens 
were collected in either EDTA or citrate blood collection tubes from individuals of 
various ethnic backgrounds. The genotype of each clinical specimen was determined 
by dideoxy-sequencing. All clinical specimens were extracted, and assayed using 
the xTAG CYP2C19 Kit v3 (EU) in a double-blinded randomized fashion. All 
specimens tested were run on both the Luminex 100/200 and MAGPIX systems. 
Results: All genotypes, except *5 and *7, probed by the xTAG CYP2C19 Kit v3 (EU) 
were represented by this clinical sample set. After allowable re-run, genotype results 
determined by the Luminex xTAG CYP2C19 Kit v3 (EU) on both Luminex 100/200 
and MAGPIX were 100% concordant with genotype results determined by the 
sequencing. Conclusions: The xTAG CYP2C19 Kit v3 (EU) is shown to be a highly 
accurate method for determining the genotype of the CYP2C19 gene. The xTAG 
CYP2C19 Kit v3 (EU) has the ability to be a useful clinical tool in evaluating 
CYP2C19 genotypes, and as an aid to clinicians in therapeutic decision making, 
when used with other clinical and laboratory findings, due to its accuracy and short 
turn-around time. 
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Landscape 
W.S. Rubinstein, B.L. Kattman, A.J. Malheiro, J. Lee, V. Hem, M. Ovetsky, G. Song, 
D. Maglott 
National Institutes of Health, Bethesda, MD. 
Introduction: The NIH Genetic Testing Registry (GTR; 
http://www.ncbi.nlm.nih.gov/gtr) is a free, centralized, voluntary, international registry 
of comprehensive genetic test information covering clinical and research tests for 
Mendelian disorders and drug responses, including multigenic, array-based, 
biochemical, cytogenetic, and molecular tests. As of May 2013, submitters have 
provided detailed information on over 6000 registered tests for over 2500 conditions 
and 4900 genes. The GTR scope will expand to somatic tests in late 2013 and 
include registration of kits by manufacturers. Active submitter participation coupled 
with GTR’s rich data structure enables many questions to be answered about the 
current status of genetic testing. Methods: Concepts to be represented in the GTR 
database were developed with extensive stakeholder input and in consultation with 
advisory boards. All registered tests provide detailed information about methodology, 
tested conditions and test targets (genes and variants, chromosomal or 
mitochondrial regions, proteins or analytes). Clinical tests have fields for purpose, 
test performance characteristics, target population, ordering information, AMA 
molecular pathology codes, proficiency testing, and regulatory information such as 
FDA review status. Research tests provide a study description, eligibility criteria, 
consent form, and information about how to enroll. In addition, GTR staffs augment 
content with practice guidelines, position statements and recommendations from 
expert sources and the website integrates information from authoritative sources. 
Results: As of May 2013, a total of 346 laboratories from 37 countries have 
registered 6096 tests employing molecular (N=5844; 96%), cytogenetic (N=153; 
2.5%) and biochemical (N=222; 3.6%) methods (combinations included). Next-
generation sequencing is a component of 6.1% of molecular tests. Seventeen 
registered labs offer whole genome or whole exome sequencing services. All clinical 
tests have analytical validity statements. Clinical validity statements for 652 tests 
(with 253 supporting citations), target population statements for 890 tests (with 267 
supporting citations), and 551 clinical utility statements (with 329 supporting 
citations) have been submitted. Among tests registered by US labs, 0.2% report FDA 
status cleared/approved. A total of 158 practice guidelines, position statements and 
recommendations pertaining to 289 conditions have been assembled by GTR staff. 
These results will be updated at the time of presentation. Conclusions: GTR 
provides a snapshot of the genetic testing landscape. As submissions proceed 
apace and the scope broadens to somatic tests, GTR enables informed selection of 
tests by clinicians and helps identify knowledge gaps of interest to professional 
societies and regulatory agencies. 
 
G40. Performance of Haloplex Custom Capture for Clinical Testing of 
Primary Immunodeficiencies by Next-Generation Sequencing 
E.M. Coonrod, J. Durtschi, H.R. Hill, K.V. Voelkerding, A. Kumanovics 
ARUP Laboratories, Salt Lake City, UT. 
Introduction: Severe combined immune deficiency (SCID), common variable 
immune deficiency (CVID), agammaglobulinemia, and hyper IgM syndrome are 
genetic immunodeficiencies that predispose to recurring and sometimes life 
threatening infections. Diagnoses can prove challenging because of phenotypic and 
genetic heterogeneity. Development of a next-generation sequencing (NGS)-based 
gene panel would offer a more comprehensive genetic test compared to current 
single gene assays and should provide a lower overall cost and faster turn-around 
time. Here we report the performance of an Agilent Haloplex custom capture coupled 
with sequencing on an Illumina MiSeq instrument for a multi gene panel for these 
four disorders. Methods: Haloplex custom capture probes were designed to 94 
genes for a capture size of 281.5 kb for the four disorders mentioned above along 
with six additional disorders. Libraries were prepared for 40 samples including 
HapMap NA12878, 7 samples with known mutations, 1 unaffected individual, and 28 
samples from CVID patients with an unknown genetic etiology. Four samples were 
multiplexed per MiSeq run and read data were trimmed, aligned, and analyzed using 
Cutadapt, BWA, and GATK softwares, respectively. Results: Library preparations 
were successful for 38 of the 40 samples. Analysis of these 38 samples showed that 
the average coverage of genes was similar to the Haloplex design software 
theoretical coverage. Average coverage for genes in the SCID and CVID panels was 
99% and 99.5% for genes in the Hyper IgM and Agammaglobulinemia panels. 
Detailed coverage analysis showed that exons with less than 100% coverage reflect 
systematic errors with lower coverage across all samples rather than being random 
capture or alignment error. To reach 100% coverage in each panel, supplemental 
sequencing will be required. Between run SNV concordance rates for two unique 
samples were 100% and 98.7%. Three unique within run samples showed SNV 853
8AMP Abstractsconcordance rates of 100%, 98.7%, and 97.4%, respectively. Discordant variants 
were false positive due to low coverage and/or low quality in one of the samples. All 
known causative variants in positive samples were correctly called. Conclusions: 
This study demonstrates the feasibility and performance of Haloplex custom capture 
for NGS of primary immunodeficiency genes. We observe reproducibly high 
coverage with predictable gaps that can be addressed by targeted Sanger 
sequencing. A turnaround time of four days from DNA extraction to completed 
sequencing is an advantage of this method.  Our findings will be applicable to the 
design of other clinical genetic tests.  
 
G41. The Worldwide Burden of Mendelian Disease: Carrier Frequencies for 
423 Variants in 107 Genes in an Ethnically-Diverse Collection of 76,940 
Samples Show Unexpected Geographic Distributions 
E.A. Evans, I.S. Haque, D. Davison, J. Maguire 
Counsyl, South San Francisco, CA. 
Introduction: Current carrier screening guidelines focus on a handful of diseases 
studied in many populations (such as spinal muscular atrophy (SMA)) and some 
characterized in only a few populations (e.g., Tay-Sachs disease in Ashkenazi Jews 
(AJs)). We present a comprehensive analysis of allele distributions and carrier 
frequencies for 423 disease-causing variants in 107 genes over 76,940 samples 
from a diverse set of ancestries. We further use disease markers to estimate 
population admixture and misclassification in ethnic self-identification. Methods: 
N=76,940 blood and saliva samples received for routine carrier screening (i.e., 
reported neither family history nor infertility) were assayed for disease-causing 
mutations in 107 genes. Single-ethnicity self-reporting was used to assign a nominal 
ancestry to each sample. We used a binomial test comparing variant frequency in a 
single population to that in the entire tested population to assess geographic 
associations of variants. We further use these tests to find markers highly enriched in 
particular populations, and use these as pseudo-ancestry-informative markers to 
estimate the frequency of misclassification in clinical ethnicity self-reporting. 
Results: We reproduce reported carrier frequencies for well-studied diseases 
including cystic fibrosis in Europeans, HEXA deficiency in AJs, sickle-cell anemia in 
African-Americans, and SMA worldwide. We find that several deleterious mutations 
are more prevalent in particular populations than previously believed, including a 
possible founder effect for DHCR7:IVS8-1G>C in AJs and high frequencies of 
GJB2:W35X (causing hearing loss) and CNGB3:R403Q (causing progressive cone 
dystrophy) in South Asians. We further find unreported disease levels in various 
populations, including a 1/57 carrier rate for cystic fibrosis in South Asians, versus 
1/118 predicted in the literature. Using a simple model of population genetics for 
disease-causing founder mutations, we estimate that 6% to 10% of the population 
clinically reporting themselves as "Northwestern European" or "Southern European" 
have clinically-relevant AJ ancestry that should be considered when administering 
screening. We also find admixture between self-reported Hispanics and African-
Americans. Conclusions: Pan-ethnic-expanded carrier screening exposes 
previously unknown population structure in known disease-causing mutations and 
shows that the geographic distribution of genetic disease is broader than previously 
appreciated. Additionally, we show that the standard clinical practice of single-
ethnicity self-reporting significantly misclassifies patients, with approximately 8% of 
“European” patients likely to have unreported or unknown clinically-relevant 
Ashkenazi Jewish ancestry. 
 
G42. Automated Population-Scale Screening for Fragile X Syndrome: 
Validation and Experience on >60,000 Samples 
I.S. Haque1, A.S. Patterson1, M.R. Theilmann1, Z. Chen2 
1Counsyl, South San Francisco, CA; 2Stanford University, Stanford, CA. 
Introduction: CGG-repeat-primed PCR for Fragile X syndrome has analytical 
performance comparable to Southern blotting with much higher throughput. PCR 
without a third CGG-repeat primer is vulnerable to false negatives on full-mutation 
alleles, but this primer’s “stutter” signal defeats existing automated calling algorithms. 
We have developed an automated calling algorithm for CGG-repeat-primed PCR 
and applied it to population-scale screening. We use the algorithm to screen over 
60,000 samples from the United States and report allele-size distributions broken out 
by ethnicity. Methods: CGG-repeat-primed PCR was run using AmplideX FMR1 
PCR kits (Asuragen) and samples were analyzed on 3500/3500xl Genetic Analyzers 
(Applied Biosystems). 48,168 samples with neither indicated family history nor 
infertility were used for population analysis; caller validation used all >60,000 
samples. Our algorithm separates peak and stutter content by frequency and calls 
peaks in the time domain using spline interpolation and differentiation. We validated 
the caller on 60 externally-characterized samples from Coriell and further assessed 
its accuracy by manual review of its performance on 60,000 clinical samples. To 
evaluate speedup, we timed the performance of two clinical laboratory scientists in 54manually calling peaks in 192 electropherograms each. Results: On external 
validation samples, the caller achieves 100% accuracy in clinical category 
classification and 0.7 average signed error in repeat count. On patient samples, the 
automated algorithm called 96,906 peaks with 204 false peaks and 702 missed 
peaks for a total sensitivity of 99.3%. On one CPU, the automated caller was 23x 
faster than manual calling.  
We find significant (P < .01) population structure in allele size distributions. East 
Asians had a lower probability of intermediate or larger alleles and Middle Easterners 
had a higher probability. European and Ashkenazi Jewish allele sizes cluster 
together; South Asians, African-Americans, Middle Easterners, and Hispanics form a 
second cluster; and East and Southeast Asians form a third distinct cluster. 
Conclusions: Our automated algorithm enables accurate high-throughput 
population screening for Fragile X using CGG-repeat-primed PCR. Automation 
enables a laboratory director to review a batch in 90 seconds rather than the half-
hour required for manual calling. We present the first worldwide catalog of fragile X 
allele sizes. We find that East Asians tend to have shorter alleles and Middle 
Easterners longer ones, but that other groups appear to not be significantly 
differentiated for intermediate or larger alleles. 
 
G43. Using MMQCI 2C19 Panel as External Control and Verification Material 
on the Verigene 2C19 Assay 
N. Mitilenes, E. Geltser, A. Amador, J. Spina, G. Mitilenes 
MedLabs Genetics, Cedar Knolls, NJ. 
Introduction: CYP450 2C19 is a gene involved in the drug metabolization pathway 
for many drugs. It’s association has been mainly shown with the drug Plavix. A 
patient’s ability to metabolize the drug is determined depending on the genotype of 
each individual across three different alleles (*2, *3, and *17). Rapid and accurate 
detection is important for a person’s 2C19 genotype to establish a correct dosing 
regimen for Plavix. This study determines whether the MMQCI 2C19 Control panel 
can be used for verification and control purposes on the Verigene 2C19 assay and 
also study the stability and reproducibility of the panel. Methods: A total of 102 
dilutions made from the three different genotype vials provided in the MMQCI 2C19 
panel ( P10601, P10701, P10801) were tested for the *2, *3, and *17 allele 
mutations via the Verigene 2C19 Assay. First, each diluted control was run on the 
instrument 4 times over the same day on the same instrument to qualify 
consumables and controls. Then, for the reproducibility study two lots of diluted 
controls were tested in triplicate daily on the Verigene CYP2C19 test for 5 days 
varying the operator and instrument. Any initial no calls were repeated as per the 
package insert. The MMQCI2C19 panel was mixed thoroughly and diluted at 1:100 
prior to each run. The dilution was discarded after it was used. Results: In the 
qualification of consumables and controls study there was 100% correlation between 
the genotype of the diluted sample and the known genotype as per the MMQCI2C19 
package insert. There were 4 initial no calls, which were repeated, thus the final call 
rate was 100%. During the reproducibility study all calls were 100% accurate. There 
were a total of 4 initial no calls, which all came out as accurate results after retesting. 
Conclusions: The MMQCI2C19 panel is a viable source of verification and external 
control material for the Verigene 2C19 assay.  
 
G44. Prevalence of the G622D Mutation in CFTR among Prenatal and 
Perinatal Patient Populations Indicates Need for Further Investigation of 
Clinical Phenotypes 
J.A. Sugalski, C. Holland, T. Goodman, J. Stoerker 
AMDx Laboratory Sciences, Farmington Hills, MI. 
Introduction: Mutations in the CFTR gene are known to cause cystic fibrosis (CF), 
fertility issues including congenital bilateral absence of vas deferens (CBAVD), and 
pancreatic insufficiency. Over 1800 mutations in this gene have been identified, with 
widely variable and difficult- to- predict clinical consequences. The American College 
of Medical Genetics (ACMG) created a standard panel of 23 mutations was created 
to cover what were known at the time to be the 23 most common mutations. 
However, as panels of larger numbers of mutations have become more common-
place, other common mutations have been identified, particularly in non-Caucasian 
populations. A threshold of a carrier rate of 0.1% has been suggested by ACMG for 
prioritizing inclusion of a mutation in a screening panel. The clinical implication of 
many of these mutations has not yet been well characterized. Of particular concern 
are potential compound heterozygotes that combine with mutations with a deltaF508 
allele. Methods: DNA was extracted from buccal cells collected in mouthwash or 
blood from 27,674 prenatal and perinatal patients. These samples were tested with 
the CFnxt assay, a 147-mutation panel that has previously been described. Samples 
were collected and analyzed between April 2012 and April 2013. This screening test 
is based on allele-specific primer extension, and built on the Illumina BeadXpress 
technology. All positives were confirmed by repeat assay. Results: Out of 27,674 jmd.amjpathol.org ■ The Journal of Molecular Diagnostics
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965 patients, 30 patients were identified as carriers of the G622D mutation. This 
represents a population allele frequency of 0.11% and 3.11%, respectively. It was 
the third most common mutation identified behind deltaF508 (576 patients) and 
R117H (84 patients), and equivalent in number to W1282X. Among the observed 
G622D positive patients, three provided racial demographic information, and all three 
self-identified as non-Caucasian (2 Asian, 1 African-American/Black). Conclusions: 
G622D is a relatively common mutation in the CFTR gene, and should be given 
consideration when assembling carrier screening panels. Additionally, as the G622D 
mutation appears to have a frequency comparable to the standard ACMG panel 
mutations, additional studies undertaken to better elucidate its potential clinical 
implications, particularly when combined with deltaF508 allele, would be of 
significant value.  
 
G45. Multi-Site International Validation of a PCR-Only Workflow for Fragile X 
Analysis 
A.G. Hadd1, M. Grasso2, E.M. Boon3, P. van Bunderen3, E. Gennaro2, S. Filipovic-
Sadic1, G.J. Latham1, D. Coviello2 
1Asuragen, Inc., Austin, TX; 2Galliera Hospital, Genoa, Italy; 3Leiden University 
Medical Center, Leiden, The Netherlands. 
Introduction: The increasing association of a wide variety of developmental, mental 
and reproductive criteria for fragile X testing relies on accurate assessment of 
methylation status of the fragile X mental retardation-1 (FMR1, NM_002024.4) gene. 
Excessive CGG repeat expansion is directly linked with hypermethylation and 
consequent silencing of the FMR1 gene. Methylation of full mutation expansions 
(>200 CGG), however, can be incomplete, and less severe phenotypes may be 
associated with methylation mosaicism. Recent advances in targeted therapies for 
fragile X have shown a predictive response based on the degree of FMR1 
methylation further driving the need for accurate and standardized testing methods. 
Although Southern blot (SB) has been the gold standard for methylation analysis, the 
method is cumbersome, requires large quantities of DNA, has variable performance 
between laboratories and lacks sensitivity for low abundance mosaicism. Herein, we 
demonstrate a simplified PCR-only workflow for FMR1 methylation analysis and 
compare results to SB across a range of challenging clinical samples obtained from 
two European laboratories. Methods: A set of 56 archived residual DNA samples 
were analyzed using AmplideX mPCR, a method for determining the CGG repeat 
length and methylation status using restriction digestion, dye-labeled PCR primers, 
and two-color capillary electrophoresis. The PCR included digestion and DNA 
reference controls. The results were correlated to SB analysis for detection of full 
mutation alleles and size and methylation mosaicism. 
Results: Using mPCR, full mutation mosaicism was detected down to 1% analytical 
sensitivity with 50- to 100-fold less DNA than required for SB. Overall, the diagnostic 
sensitivity was 100% [95% CI: 85% to 100%] for full mutation alleles with an 
accuracy of 98% [95% CI: 90% to 99%] compared to SB. A low level of full mutation 
mosaicism in one sample was detected using mPCR but not observed using SB. 
mPCR analysis of DNA from individuals with Klinefelter and Turner syndrome, and 
matching DNA from sperm and blood were consistent with SB. Conclusions: The 
results of our study suggest standardization of fragile X testing schemes without the 
need for SB analysis. In addition, the sizing accuracy of mPCR compared to SB may 
improve the classification of borderline full mutation allele sizes and genotype-
phenotype correlations for molecular features that are obscured on SB. Finally, the 
use of mPCR can enhance the detection of low abundance mosaic alleles that may 
be important to the diagnosis and treatment of FXS.  
 
G46. Mutations Outside the ACMG Panel: 147-Mutation CFTR Carrier 
Screening of 27,000 Prenatal and Perinatal Patients  
J.A. Sugalski, C. Holland, T. Goodman, J. Stoerker 
AMDx Laboratory Sciences, Farmington Hills, MI. 
Introduction: The American College of Obstetrics and Gynecology (ACOG) 
currently recommends offering screening for cystic fibrosis (CF) carrier status to all 
women of reproductive age. Although the standard 23 mutation panel recommended 
by the American College of Medical Genetics (ACMG) covers many of the most 
common CF-related mutations, increasing sophistication of modern molecular 
biology allows for the interrogation of a far larger number of mutations, and provides 
greater risk reduction for individuals screened. In addition, data acquired from 
applying expanded panels to large patient populations offers insight into the 
frequency of the less commonly studied mutations. Methods: DNA was extracted 
from buccal cells collected in mouthwash or blood from 27,674 prenatal and perinatal 
patients and tested with the CFnxt assay, a 147-mutation panel that has previously 
been described. Samples were collected and analyzed between April 2012 and April 
2013. This screening test is based on allele-specific primer extension, and built on he Journal of Molecular Diagnostics ■ jmd.amjpathol.orgthe Illumina BeadXpress technology. All positives were confirmed by repeat assay. 
Results: Of the 27,674 patients tested, 975 mutations were identified in 970 (3.51%) 
patients; 965 were heterozygotes and 5 were compound heterozygotes. A total of 68 
different mutations were observed, including all 23 ACMG panel mutations, and 45 
non-ACMG mutations. Non-ACMG mutations were identified in 149 heterozygous 
individuals, along with 3 compound heterozygotes where one of the alleles present 
contained a non-ACMG mutation; these represent 15.88% of all identified positives, 
and 0.55% of all patients tested. The most common non-ACMG mutations observed 
were G622D (30 mutations, 3.1% of all mutations), D1152H (18 mutations, 1.8% of 
all mutations), 2307delA (9 mutations, 0.92% of all mutation), L206W (9 mutations, 
0.92% of all mutations), E60X (6 mutations, 0.62% of all mutations), and 2184insA (6 
mutations, 0.62% of all mutations.) This is comparable to the frequency of a number 
of common ACMG mutations including G542X (26 mutations, 2.66% of all 
mutations), 3849+10kbC>T (16 mutations, 1.6% of all mutations), G551D (12 
mutations, 1.2% of all mutations), and R553X (11 mutations, 1.1% of all mutations.) 
Conclusions: Large-scale screening of patient populations with an expanded panel 
of CFTR mutations indicates a strong likelihood that many non-ACMG mutations 
have allele frequencies that are comparable to those on the standard ACMG panel.  
 
G47. Identification of Clinically Significant Genetic Variants by Exome 
Sequencing of DNA Extracted from Dried Blood Spots: A Model for Newborn 
Screening 
T. Guettouche, J. Rantus, W. Hulme, A. Diaz, A. Andersen, M. Gonzalez, S. 
Zuchner, O. Bodamer 
University of Miami, School of Medicine, Miami, FL. 
Introduction: Current analytical methods for newborn screening are based on 
detection of small metabolites for the diagnosis of inborn errors of metabolism (IEM) 
to prevent long-term complications. However an analytical gap exists as there is an 
increasing number of genetic disorders that lack the analytical screening technique 
that is needed for reliable detection. Genomic methods allow early identification of 
clinically relevant genetic variants and hold the promise to augment or replace 
currently used new born screening techniques and reduce the analytical gap. Whole 
exome sequencing (WES) is a primary method for screening of genomic variants but 
standard methods require significant amounts of DNA for successful analysis. The 
most common method for storage of newborn patient blood samples are dried blood 
spots. However, a major challenge using dried blood spot samples for genetic 
studies is the small amount of DNA (typically less than 300 ng/3 mm punch) that can 
be extracted, which is significantly below the input required for standard WES 
protocols. Methods: Here we present a protocol that allows WES from as little as 
50ng of genomic DNA extracted from a dried blood spot. We used a fully automated 
DNA extraction method for IVD and research use that allows extraction of DNA from 
up to 48 dried blood spot samples. After extraction of genomic DNA from one 3mm 
punch, we performed exome capture using a protocol that was optimized for low 
genomic DNA input. We deep sequenced the exomes of 4 patients with previously 
identified lysosomal storage disorders. Results: The sequencing results generated 
by our method are comparable to results obtained by standard WES protocols and 
allowed identification of the pathogenic variant and confirmation of the diagnosis in 
these patients. All steps of our protocol are amenable to automation and therefore 
adaptable to high-throughput processing.  
Conclusions: To our knowledge this is the first report of the successful identification 
of a genetic variant by whole exome sequencing from DNA extracted from a dried 
blood spot. 
 
G48. Characterization of the INFINITI Platform for Custom-Built CYP2D6-
3A4-3A5 Genotyping Applications 
Y. Fu1, M. Zeller1, C. Smith1, M. MacDonald1, A. Ting2, M.H. Kalnoski2, J. Sistonen3 
1AutoGenomics, Inc., Vista, CA; 2Natural Molecular Testing Corporation, Renton, 
WA; 3Institute of Clinical Chemistry Inselspital, Bern University Hospital, Bern, 
Switzerland. 
Introduction: A comprehensive set of genetic variations in key enzymes involved in 
drug metabolism pathways should be considered simultaneously in the design of a 
pharmacogenomics study aimed at characterizing the inherited basis of variation in 
drug efficacy or toxicity. AutoGenomics INFINITI platform offers a variety of 
applications to genotype the major drug-metabolizing enzymes CYP2D6, CYP3A4, 
and CYP3A5 that all exhibit high levels of functional variation. Methods: A core 
CYP2D6-3A4-3A5 panel including variants CYP2D6 [*2, *3, *4, *5 (deletion), *6, *7, 
*8, *9, *10, *12, *14, *17, *29, *41, and *XN (duplication)], CYP3A4 [*1B, *2, *3, *12, 
*17, and *22], and CYP3A5 [*1D, *2, *3, *3B, *6, *7, *8, and *9] was developed. This 
assay combines two multiplex PCR reactions into one multiplex analyte specific 
primer extension (ASPE) reaction, followed by hybridization of ASPE primers to 
specific capturing probes addressed on the BioFilmChip to be scanned by a confocal 855
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panel can be custom-modified by adding or replacing variants relevant for each 
study design. Results: Based on the study results, the custom panel can be further 
developed to include only the clinically relevant genetic variants. Two additional 
panels (CYP2D6-D and CYP3A4-3A5-D) based on a duplex (D) format were also 
developed allowing two samples to be tested per single chip for doubling the 
throughput and increasing the cost effectiveness of the analysis. These applications 
have been optimized for testing DNA samples extracted from blood, saliva, or bucal 
swab. Conclusions: The AutoGenomics INFINITI platform represents an effective 
and flexible tool for conducting research and clinical studies. Ultimately, a well-
defined application panel targeting the clinically relevant genetic variants can be 
used to achieve the goal of personalized therapeutics. 
 
G49. The Use of SNP Array to Diagnose Molar Pregnancies 
K.A. Lebel, C.L. Bissaillon, A.M. Tyropolis, S.M. Pflueger 
Baystate Health, Springfield, MA. 
Introduction: Determining the cause of early pregnancy loss can be a difficult 
process involving many modalities. Hydropic villi can be particularly troublesome, 
especially when a normal karyotype is resulted. Complete hydatidiform moles 
typically exhibit normal appearing 46,XX or 46,XY karyotypes, but both haploid sets 
are paternal in origin with loss of the maternal contribution. Partial moles, on the 
other hand, are most often triploid with an extra paternal haploid set. The distinction 
is important as complete moles are associated with increased risk for persistent 
trophoblastic disease, necessitating careful surveillance to ensure complete 
evacuation and requiring a wait before attempting another pregnancy. Here we 
discuss the use of SNP array as a means to resolve molar pregnancy questions. 
Methods: Five samples of chorionic villi collected from molar pregnancies were 
submitted for tissue culture and chromosome analysis. Samples were cultured in 
Amnio Max C-100 (Life Technologies, Grand Island, NY) and harvested for 
chromosome analysis and DNA extraction. DNA extraction was performed utilizing 
the automated EZ 1 DNA tissue kit (Qiagen, Germantown, MD). DNA concentration 
and purity was assessed by the NanoDrop 2000. SNP array analysis was performed 
and data analyzed per protocol utilizing the CytoScan HD kit and CHAZ software 
(Affymetrix, Santa Clara, CA).  Data parameters included regions of homozygosity, 
number of allele tracks and median copy number state. Results: SNP array and 
chromosome analysis of each case was performed. Of the 5 cases analyzed, 3 were 
reported with a normal female karyotype, 46,XX, and 2 cases were reported as 
triploid, 69,XXY. CMA results confirmed the two triploid cases with identification of 4 
allele tracks, normal degrees of heterozygosity across the genome and copy number 
state of X and Y at 1.4 and 0.7, respectively. SNP analysis of the normal female 
karyotypes allowed confirmation of complete molar pregnancies. Two of the 
complete moles were identified with 2 allele tracks, complete homozygosity across 
the genome and an X copy number state average of 1.9, indicating endoduplication 
of a single paternal haploid karyotype.  The third normal female case had 3 allele 
tracks, average heterozygosity across the genome, and an X copy number state of 
2.0. This most likely reflects a dispermic molar pregnancy, although comparison with 
a maternal sample would be needed to rule out maternal cell contamination 
Conclusions: The use of SNP array, when histology is inconclusive and 
chromosome analysis appears to be normal, can be a definitive diagnostic tool. 
 
G50. Enabling Clinical Variant Classification through Intelligent 
Autocategorization 
C. Mead, T. Mann, M. Källberg, S.S. Ajay, E. Ramos, J.D. Mayfield, S. Kruglyak, 
T.M. Hambuch 
Illumina, San Diego, CA. 
Introduction: Barriers to accurate human genome re-sequencing have largely been 
surmounted, enabling consideration of routine clinical applications. However, 
significant challenges remain for interpretation of whole genome data for diagnostic 
or prognostic purposes. The shift from genetic to genomic scale testing significantly 
increases the interpretation burden, and yet there is a lack of cohesive information 
that facilitates genome scale interpretation. Variant interpretation of whole genome 
sequencing (WGS) results based on literature alone produces numerous variants of 
unknown significance, which do not yield actionable information for clinicians. For 
Mendelian conditions, the relationship of disease prevalence to variant prevalence is 
well established, and this relationship can be used to identify variants that can be 
confidently excluded from disease involvement. To accomplish this, some 
laboratories currently employ rules such as variant frequency cut-offs. We have 
refined this approach by creating an algorithm that generates a statistical score 
specific to the characteristics of the variant and disease being assessed. Methods: 
We have established a clinical service for WGS and interpretation. The interpretation 
service is currently limited to exons of 1600 genes of which the clinical validity and 6involvement in 1221 monogenic conditions have been established. Here we describe 
a disease-specific autocategorization algorithm that generates a statistical score for 
each variant to help rule out disease causality using information including disease 
penetrance, prevalence, inheritance mode, and variant frequency. Results: As part 
of our pilot study on the utility of autocategorization scoring for supporting genome-
scale interpretation, we sequenced and interpreted 1600 genes in approximately 100 
individuals. Over 28,000 unique variants were identified within exons +/- 15 
nucleotides for this dataset. Statistical analyses were performed to determine 
thresholds whereby variants could be confidently classified as Benign or Likely 
Benign. Based on this method, over 17,000 variants were confidently ruled out of 
disease involvement, significantly reducing the number of variants classified as 
unknown significance. Conclusions: WGS methods result in a significant clinical 
interpretation burden that must be addressed to enable effective integration with 
medical practice. Although peer-reviewed literature sources provide the strongest 
evidence for interpretation classifications, this information is currently scarce on the 
whole genome level. In the context of variant interpretation for monogenic diseases, 
where literature information is not available, our understanding of biology can enable 
the development of algorithms that are more refined and disease specific, which can 
improve interpretive reporting. Additionally, having a quantitative statistical score can 
help in the evaluation of the confidence we have in clinical variant classifications. 
 
G51. Approaches to Increase Diagnostic Yield for Clinical Genomic 
Sequencing 
S.T. Garcia, G. Chandratillake, M. Pratt, H. Lam, J. Harris, S. Luo, G. Bartha, M. Li, 
S. Chervitz, M. Clark, N. Leng, J. West, R. Chen 
Personalis, Inc, Menlo Park, CA. 
Introduction: Exome and genome sequencing is increasingly utilized to diagnose 
individuals where other genetic testing has been unsuccessful or would be cost-
inefficient. However, diagnostic yield estimates from clinical exome testing remain 
low (~25%). We have developed a comprehensive approach aimed at improving 
accuracy and completeness in genomic sequencing with specific improvements 
made in sequencing, variant calling, and interpretation to increase diagnostic yield. 
Methods: Our approach has three parts: i) Increased sequence coverage over 
regions of biomedical importance with the aim of creating a finished medical exome. 
On many samples, we quantified average coverage over all exons and developed 
specialized sequencing libraries to improve performance over regions with low 
(<20x) or absent coverage. We also targeted regulatory regions and other non-
exonic regions known to contain disease and pharmacogenetic-associated variation. 
ii) Development of an approach integrating four orthogonal methods to identify and 
rank SVs based on their predicted likelihood of causing disease. iii) Implementation 
of a novel, knowledge-based ranking system to rank detected variation by likelihood 
of being causally related to the observed phenotype. Samples with described clinical 
features and known causative variants representing a broad range of conditions and 
variant types (including SVs) were obtained, sequenced, and our proprietary pipeline 
was used to align reads and call variants. Our internal database linking clinical 
features to genes was used to identify and rank candidate genes for each sample. 
We identified all possible inheritance patterns, and allowed for de novo events and 
non-penetrance, ranking genotype expectations by likelihood. Results: Our 
approach results in greater sensitivity to detect causal variation: i) We increase the 
number of biomedically-relevant genes covered at >99% sensitivity for variant 
detection from 2000 to >3000. ii) We have substantially greater sensitivity (96.27% 
compared to 55.6% average), and a lower false discovery rate (1.37% compared to 
27.55% average) on SV detection in genome sequence than any of the four methods 
used independently. 
iii) We reduce the number of candidate variants requiring manual review and in all 
cases tested the known causative variant was ranked first by our approach. 
Conclusions: By increasing sequencing coverage over genes and variants of 
biomedical importance, improving detection of structural variation, and developing 
ranking approaches to highlight those variants most likely to be causally related to 
phenotype, we increase the likelihood that the underlying genetic etiology of cases 
submitted for exome or genome sequencing will be determined. 
 
G52. The Development and Validation of a Next-Generation Sequencing 
Panel for Skeletal Dysplasias 
M.J. Basehore, S. McGee, K. Kubiak, K. King, J. Butler, J.A. Lee, J.R. Jones, M.J. 
Friez 
Greenwood Genetic Center, Greenwood, SC. 
Introduction: Skeletal dysplasias, as a whole, represent a large and diverse group 
that consists of more than 450 recognized conditions. Since there is a great deal of 
phenotypic overlap and genetic heterogeneity among the skeletal dysplasias, a 
diagnosis is often made based on a combination of clinical and radiological findings jmd.amjpathol.org ■ The Journal of Molecular Diagnostics
 AMP Abstractsthat is further supported by molecular, and in some cases, biochemical findings. 
Methods: Using RainDance microdroplet enrichment and the SOLiD next-generation 
sequencing (NGS) platform, we have developed and validated an assay that can 
simultaneously analyze ten genes known for their association with various skeletal 
dysplasias: COL1A1, COL1A2, COL2A1, COMP, SLC26A2, FGFR3, FLNA, HSPG2, 
SOX9, and TRPV4. Collectively, these genes account for more than 30 distinct 
clinical phenotypes, and an estimated 90% of individuals with a skeletal dysplasia 
have a mutation in one of these ten genes. The current design of our skeletal 
dysplasia panel includes the coding and flanking intronic regions for all ten genes. 
Results: Our initial cohort includes 21 patients with an undiagnosed skeletal 
dysplasia and testing was performed using our diagnostic NGS panel. We have 
identified a likely pathogenic mutation in nine of the 21 patients (43%), with the 
COL2A1 gene having the greatest number of likely pathogenic alterations. Eight 
patients (38%) had at least one variant of unknown clinical significance detected by 
our analysis, and the remaining four patients (19%) were considered to have normal 
results, with no molecular findings reported. Conclusions: These initial findings 
suggest that this NGS panel has a high detection rate for patients suspected of 
having a skeletal dysplasia. Furthermore, they support the notion that NGS testing 
has advantages over Sanger sequencing, even for a small panel comprised of only 
ten genes. 
 
G53. Phenotypic Implications of CYP2C19*4 and *4B Detection in the 
General Population 
M.P. Borgman, K.K. Reynolds, R. Valdes, M.W. Linder 
PGXL Laboratories, Louisville, KY. 
Introduction: Cytochrome P450 2C19 (CYP2C19) is responsible for the 
bioactivation of the antithrombotic pro-drug clopidogrel. The CYP2C19 gene is highly 
polymorphic and mutations lead to altered metabolic capacity, thereby affecting 
therapeutic efficacy. In 2010, the FDA added a box warning to clopidogrel indicating 
CYP2C19 poor metabolizers (PM) should avoid the use of clopidogrel. Additional 
studies have demonstrated an increased risk of bleeding events in patients who are 
ultra-rapid metabolizers (UM) carrying the *17 allele. FDA cleared kits to assess 
CYP2C19 genotype status commonly detect the *2 (681G>A) and *3 (636G>A) PM 
alleles in addition to the ultra-rapid metabolizer (UM) allele *17 (-806C>T). Additional 
rare PM variants that have been identified include *4 (1A>G), *5 (1297C>T), *6 
(395G>A), *7 (819+2T>A), *8 (358T>C). Recent studies have identified the *4B 
haplotype containing both *4 and *17 variants. Assays that do not detect the *4 allele 
can lead to misinterpretation of the CYP2C19 phenotype. Our study assessed the 
phenotypic impact of detecting the *4 allele in clinical testing for CYP2C19. 
Methods: Genotypes were determined on a cohort of 22,000 patient samples 
submitted to PGXL Laboratories for routine CYP2C19 genotyping. The buccal 
samples were tested using a combination of ASPE and real-time PCR assays that 
detect 10 CYP2C19 variant alleles including *4 and *17 alleles. Genotype results 
were reviewed for presence of the *4 and *4B alleles and frequencies calculated. 
Results: We detected the *4 allele in 118 patients in our cohort, translating to a 
0.28% *4 allele frequency. Previously published *4 allele frequencies ranged from 
<1% up to 2%. Among the samples with *4 alleles, 8 had *4B, translating to an allele 
frequency of 0.02% in the cohort. Phenotypically, 118 patients (0.54%) would have 
been misidentified. The phenotypic error associated with not detecting *4 or *4B can 
result in misclassification of actual PMs, those who should avoid clopidogrel therapy. 
In our cohort, this accounted for 24 actual PMs who without *4 and *4B detection 
would have been classified as non-poor metabolizers. Conclusions: Analysis of the 
*4 allele allows for identification of potential *4 PMs as well as accurate identification 
of *4B PMs, thereby differentiating them from *17 allele carriers that would 
inappropriately be assigned UM status in the absence of *4 allele detection. This 
approach maximizes the clinical sensitivity of CYP2C19 genotyping and is an 
invaluable approach when clopidogrel treatment decisions are based on genotype 
results. 
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H01. Comparing Translocation-Driven Double Hit Lymphomas versus MYC, 
BCL6, BCL2 Gene Copy Gains 
B. Bryant1, C. Yeung2, D. Wu1 
1University of Washington Medical Center, Seattle, WA; 2Fred Hutch Cancer 
Research, Seattle, WA. 
Introduction: The WHO lymphoma classification B-cell lymphoma, unclassifiable, 
with features intermediate between diffuse large B-cell lymphoma and Burkitt 
lymphoma (BCLUDLBCLBL) is a heterogeneous category of morphologically 
intermediate and molecularly complex lymphomas that generally show an aggressive The Journal of Molecular Diagnostics ■ jmd.amjpathol.orgcourse. MYC rearrangement with BCL2 and/or BCL6 is common, and termed 
Double-Hit Lymphoma (DHL). Occasionally, additional copies of one of the above 
genes are noted without a translocation. The appropriate classification and 
management of these cases is unclear. We hypothesize that increased copy number 
without translocation will confer the similar aggressive behavior as DHL. Methods: 
Cases of BCLUDLBCLBL with increased copy number of MYC, BCL2, or BCL6 were 
compared against DHL. FISH was used to assess for translocation or copy number 
chance of these genes and correlated with relapse and survival data. Results: A 
search of the UW/SCCA archives from 2002 to 2012 revealed: 10 BCLUDLBCLBL in 
total. 4 BCLUDLBCLBL have translocations (2 involving MYC, 1 BCL6, 1 MYC and 
BCL2, and 1 MYC, BCL2, and BCL6). Six BCLUDLBCLBL had no evidence of 
translocation but did have increased copy numbers of MYC, BCL2 or BCL6.  
Relapse and mortality data were available for 8 patients. Relapse rates and mortality 
in the BCLUDLBCLBL with translocation group was 25% and zero versus 50% and 
25%, respectively, in the increased copy number group. Conclusions: Our 
preliminary data shows that BCLUDLBCLBL with increased copy number of MYC, 
BCL2, and/or BCL6 may carry worst prognosis and may warrant sub classification 
within the heterogeneous group of BCLUDLBCLBL. Future studies to correlate 
cytogenetic data with protein expression by IHC are underway and may provide 
additional prognostic information.  
 
H02. COLD/ICE-COLD-PCR Reanalysis of Myelodysplastic Syndrome 
Samples Reveals Low-Level Point Mutations with Independent Prognostic 
Significance in the NRAS Oncogene 
D.M. Murphy1, R. Bejar2, K. Stevenson3, D. Neuberg1, Y. Shi4, C. Cubrich4, K. 
Richardson4, P. Eastlake4, G. Garcia-Manero5, H.M. Kantarjian5, B.L. Ebert1, G.M. 
Makrigiorgos1 
1Dana-Farber Cancer Institute, Boston, MA; 2University of California, San Diego, CA; 
3Dana-Farber/ Harvard Cancer Centre, Boston, MA; 4Transgenomic, Omaha, NE; 
5The University of Texas MD Anderson Cancer Center, Houston, TX. 
Introduction: Myelodysplastic syndromes (MDS) are a group of hematopoietic 
disorders characterized by inefficient hematopoiesis, cytopenias, and an increased 
risk of progression to acute myeloid leukemia (AML). Common prognostic scoring 
methods, such as the International Prognostic Scoring System for MDS (IPSS), use 
clinical features and karyotypic abnormalities to stratify patients into risk groups. 
Recently, somatic mutations have been implicated as drivers of clinical phenotypes, 
however, the bone marrow of MDS patients is genetically heterogeneous that can 
result in low-abundance somatic mutations falling below the detection limit of 
established mutation screening techniques. It is not clear whether the rare sub-
clones containing these point mutations can influence clinical phenotype. To 
examine this question and to increase the sensitivity of the MDS mutation analysis, 
we employed COLD-PCR (co-amplification at a lower denaturation temperature) and 
ICE COLD-PCR (improved and complete enrichment), forms of PCR that 
preferentially amplify mutation containing sequences over wild-type alleles. 
Methods: We focused on detecting low-level mutations within NRAS, an oncogene 
associated with a shorter survival period and increased risk of progression to AML in 
MDS patients. We selected a group of 295 MDS patients with low/Intermediate-1 risk 
according to IPSS and then used highly sensitive COLD-PCR/ICE COLD-PCR 
assays to screen these samples, enabling the detection of mutant alleles with 
frequencies down to 0.02% to 0.1%. The overall survival of patients with detectable 
NRAS mutations was subsequently calculated using the Kaplan-Meier method. 
Results: In previous analysis of the 295 MDS patient samples, 9 NRAS mutations 
were identified with conventional means. COLD-PCR/ICE COLD-PCR confirmed the 
presence of these genetic changes and identified an additional 15 NRAS mutations 
within the cohort, essentially tripling the mutations detected. Survival analysis of 
patients with occult NRAS mutations detected by fast-COLD-PCR (estimated VAF 
0.5-2.0%) revealed substantially shorter overall survival than predicted by the IPSS, 
which was comparable to that of patients with higher frequency NRAS mutations 
detected by conventional methods. Conclusions: By employing highly sensitive 
mutational analysis to assess for NRAS mutations in a group of low/intermediate-1 
MDS patients, we demonstrated that i) patients with NRAS mutations at allele 
mutation frequencies down to ~0.5% have a worse outcome than would be expected 
based on their clinical features, demonstrating the independent prognostic 
significance of these low frequency NRAS mutations ii) assays with a detection limit 
down to 0.1% are needed for effective capture of clinically significant low-level 
mutations in myelodysplastic syndromes. ICE COLD-PCR provided appropriate 
sensitivity for detection of these rare mutations. 
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Myeloid Leukemia 
J. Lee1, K. Jun2, S. Song2, S. Oh1, J. Shin1, H. Kim1, J. Lee2 
1Inje University Busan Paik Hospital, Busan, Korea; 2Haeundae Paik Hospital, 
Busan, Korea. 
Introduction: Cytogenetically normal acute myeloid leukemia (CN-AML) represents 
the largest subgroup of adult AML, and within this molecularly heterogeneous group, 
many studies of gene mutations and epigenetic changes are being conducted to 
assess prognosis and guide risk-adapted treatment. Recently, the Tet oncogene 
family member 2 (TET2) gene mutations were identified in a variety of myeloid 
disorders. However, their frequency varied from 7% to 50% according to the myeloid 
malignancy study population and so the prognostic relevance of TET2 mutations 
remains controversial. In this study, we investigated the frequencies and distributions 
of TET2 mutations, and their associations with clinical and molecular characteristics, 
in Korean patients with CN-AML. Methods: Bone marrow samples from 24 AML 
patients with normal karyotypes were analyzed for the presence of TET2 mutations 
(exons 3 to 11). All TET2 sequence variats were compared with single nucleotide 
polymorphism databases to detect known polymorphisms. Results were correlated 
with data from molecular genetic analysis and clinical characteristics. Results: We 
identified variations in the TET2 coding sequence in 19 of 24 patients, with three 
patients exhibiting two mutations and one patient three mutations. Mutations most 
commonly affected exons 3 (n=13) and 11 (n=8) but also occurred in exon 6 (n=1). 
Most mutations were single nucleotide substitutions that led to missense mutations 
(n=17). A novel missense mutation (c.773A>T) and a frameshift mutation 
(c.2490_2491insA) were noted. One patient with a novel nonsense mutation in exon 
3 (c.1720C>T, p.Q574X) also had another nonsense mutation (c.3646C>T, 
p.R1216X) in exon 6. The same mutations were not found in a sample obtained from 
this patient at the diagnosis of complete remission, indicating that the nonsense 
changes were acquired. We found three synonymous mutations in exons 3, 9 and 
11. One synonymous mutation in exon 11 (c. 5985A>G) was a homozygous 
substitution, which is known to be a rare allele (minor allele frequency 0.001%) and 
is predicted by MutationTaster to cause a disease. In this study, FLT3-ITD mutations 
were less frequent in TET2-mutated patients than in patients with wild type TET2 
genes. We found no evidence of a prognostic effect of TET2 mutations on clinical 
outcomes, such as disease free and overall survival. Conclusions: In our study of 
CN-AML, TET2 mutations were detected more frequently than FLT3-ITD mutations 
However, TET2 mutations were not associated with a clinical phenotype or outcome. 
The effect of TET2 mutation should be further evaluated using additional gene 
mutations that influence epigenetic regulation in AML. 
 
H04. High-throughput Sequencing Using Ion Torrent PGM for Clinical 
Evaluation of IGHV Somatic Hypermutation (SHM) Status in Chronic 
Lymphocytic Leukemia (CLL) 
R.F. McClure, M. Mai 
Mayo Clinic, Rochester, MN. 
Introduction: CLL is a single diagnostic category but shows heterogeneity with 
respect to survival. SHM status of the immunoglobulin heavy chain gene variable 
region (IGHV) separates populations of CLL patients into prognostic categories, with 
the mutated group doing significantly better than the un-mutated group. Evaluation of 
SHM status in the clinical lab is technically challenging and involves nucleic acid 
extraction, PCR amplification of IGHV, sequencing of the most prominent 
fragment(s), alignment comparison with germline IGHV sequences, calculation of 
sequence deviation from the closest germ line match and evaluation of the sequence 
for positive functional status of the corresponding protein. High-throughput 
sequencing holds promise for improving SHM testing with the theoretical drawbacks 
being sequencing accuracy and read length (assay requires continuous reads of 
~350 bp). In this study, a clinically validated SHM assay was directly compared with 
a modified protocol that uses sequencing on an Ion Torrent PGM (Life 
Technologies). Methods: Sixty liquid CLL samples were tested. RNA was extracted, 
converted to cDNA and amplified using PCR (BIOMED-2 FR1 IGHV forward primer 
mix and IGHJ reverse consensus primer). The product was run in parallel. For the 
cinical protocol, each PCR mix was visualized by gel electrophoresis, the most 
prominent fragment subjected to Sanger sequencing, a consensus sequence 
created, and analysis performed using IMGT/V-QUEST. For the PGM protocol, each 
PCR mix had sequencing ends (include a patient-specific index) added to the 
fragments and 30 samples were pooled for sequencing using the Ion 400 bp 
template kit and 316 chip. The reads were aligned to a reference file containing all 
germ line IGHV sequences, the BAM files for each patient evaluated for the most 
prominent sequence using NextGENe, and reads visualized using IGV. A 
representative, full-length read was submitted for analysis to IMGT/V-QUEST. Thirty 
samples were evaluated in duplicate and also evaluated using the Ion 200 bp 8template kit. Five samples had unaligned reads evaluated using IMGT/highV-Quest. 
Results: There was 100% concordance for the 2 sequencing methods with respect 
to reportable clinical results. The PGM method is easier to perform and provides 
more analysis detail than the Sanger method. It is also more cost effective if multiple 
samples are to be evaluated simultaneously. The reproducibility of the PGM method 
is excellent and both 200 and 400 bp template kits produce concordant results. 
Conclusions: Performing SHM analysis on the Ion Torrent PGM is clinically feasible 
and has advantages over current, Sanger sequencing-based assay methods.  
 
H05. Clinical Utility of the Detection of Genomic Aberrations in Formalin-
Fixed Paraffin-Embedded (FFPE) Myeloid Sarcoma Samples 
Z. Li1, M. Mirza1, M. Sukhanova1, F. Stolzel2, K. Onel1, M.M. Sasaki1, P. Reddy1, L. 
Joseph1, G. Raca1 
1University of Chicago, Chicago, IL; 2Universitatsklinikum Carl Gustav Carus, 
Dresden, Germany 
Introduction: Myeloid sarcoma (MS) is a tumor consisting of malignant granulocytic 
precursor cells, localized outside of the bone marrow (extramedullary). The rarity of 
MS has been an obstacle to characterize its clinical features, prognosis, and in 
particular its cytogenetic and molecular aberrations. Although genetic abnormalities 
of the leukemic cells represent the strongest prognostic indicator for response to 
therapy and survival in patients with acute myeloid leukemia (AML), fresh tissue from 
MS is seldom made available for cytogenetic and molecular studies; this is due to 
the solid-tumor morphology and late recognition of the hematopoietic nature of MS. 
The objective of this study was to determine whether the analysis of FFPE samples 
using whole-genome SNP arrays and next-generation sequencing (NGS) allows 
detection of genetic abnormalities of prognostic significance in MS. Methods: The 
study included five cases of MS without bone marrow involvement, where 
cytogenetic and molecular studies were either not available, or did not identify 
prognostically significant genetic abnormalities. Array testing on DNA from FFPE 
samples utilized CytoScan HD arrays from Affymetrix (Affymetrix Inc., Santa Clara, 
CA). Targeted resequencing of AML associated genes was performed on the 
Personal Genome Machine (PGM) from Ion Torrent (Life Technologies, Carlsbad, 
CA), with two custom primer sets (AML and MDS panel) designed to amplify coding 
regions of 19 genes associated with myeloid malignancies. 
Results: Somatic, disease-associated genetic abnormalities were identified in all 
tested samples. Additionally, aberrations of clear prognostic significance were 
observed in four out of five cases. In two cases array analysis detected multiple 
unrelated copy number abnormalities and LOH events; the presence of numerous 
aberrations is analogous to a complex karyotype, which is associated with a very 
poor prognosis in AML. Additional two cases showed an NPM1 mutation without a 
concomitant FLT3-ITD, which is a genetic alteration associated with a favorable 
prognosis. In one case array analysis and NGS showed abnormalities whose 
prognostic significance could not be interpreted at this time (LOH 11p and an SF3B1 
mutation). Conclusions: Array analysis and NGS using FFPE material revealed 
previously unidentified disease-associated genetic abnormalities in all five samples 
of MS, and in four cases provided information that would have been of major 
prognostic importance if available at the time of diagnosis. Increased availability of 
whole-genome arrays and NGS in the clinical setting could allow detection of 
prognostic genomic aberrations in MS and, thus, could improve its clinical 
management. 
 
H06. BRAF Mutation Occurs More Frequently in Pulmonary Langerhans Cell 
Histiocytosis and in Younger Patients 
K. Alayed, K. Patel, Z. Zuo, S. Verma, R. Cason, J. Galbincea, R. Luthra, L. 
Medeiros, C. Yin 
University of Texas, MD Anderson Cancer Center, Houston, TX. 
Introduction: Langerhans cell histiocytosis (LCH) is a clinically heterogeneous 
disease characterized by a proliferation of Langerhans cells with distinctive cytologic, 
ultrastructural, and immunophenotypic features. The molecular genetic features of 
LCH are not well-studied. Recently, recurrent BRAF mutations have been reported in 
approximately 50% of LCH cases. We studied the clinicopathologic and 
immunophenotypic features and assessed for BRAF mutation in cases of LCH at our 
institution. Methods: We searched the database of our hospital for cases of LCH 
with paraffin-embedded tissues available for molecular study from 2000 to 2012. 
Clinical data were obtained by review of medical records. H&E-stained tissue 
sections and immunostained-slides were reviewed. DNA was extracted from paraffin-
embedded tissues and analyzed for BRAF p.V600E mutation by 
PCR/pyrosequencing. Results: Thirty-nine cases were selected including 25 men 
and 14 women (median age, 35 years; range, 1-78 years). Bones were the most 
common location (n=11), followed by skin (n=9), lung (n=5), lymph node (n=5), brain 
(n=3), soft tissue (n=2), orbit (n=2), thyroid (n=1) and vulva (n=1). A complete blood jmd.amjpathol.org ■ The Journal of Molecular Diagnostics
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hemoglobin, 13.8 g/dL; range, 10.5 to 15.8 g/dL), 4 had thrombocytosis (median 
platelet count, 277.5 k/L; range, 154 to569 k/L), and 2 had leukocytosis (median 
WBC, 7.8 k/L; range, 4.5 to 15.3 k/L). The serum LDH level was elevated in 1/18 
patients assessed (median, 474.5 IU/L; range, 361 to 982 IU/L). Serum b2 
microglobulin level was elevated in 2/5 patients assessed (median, 1.8 mg/L; range, 
1.6-2.8 mg/L). Morphologically, most cases showed lesions composed of cells with 
folded nuclear contours, grooved nuclei and abundant eosinophilic cytoplasm. 
Immunohistochemical studies showed that the LCH cells were positive for CD1a 
(39/39) and S-100 (34/35). All 7 patients assessed had a diploid karyotype. BRAF 
p.V600E mutation was detected in 7/39 (17.9%) cases. The median age of patients 
with BRAF mutation (29 years) was lower than those with wild type BRAF (37.5 
years). Noticeably, 3/5 (60%) cases of LCH involving lung had BRAF mutation. Other 
cases with BRAF mutation involved brain (n=1; 33%), skin (n=2; 22%), and bones 
(n=1; 9%). Conclusions: The overall frequency of BRAF mutation in our study group 
is lower than data published previously. However, we found that BRAF mutation 
occurs more frequently in younger patients and in pulmonary LCH. Our data suggest 
BRAF kinase inhibitors may be a therapeutic option for a subset of LCH patients with 
BRAF mutations. 
 
H07. AML Genetic Testing: When Clinical Utility Crosses Financial 
Responsibility 
J. Laser, S. Dhana, J. Goh, H. Lisa, J. Lee, R. Lee-Huang, S. Roy, S. Spitzer 
North Shore LIJ Health System, Manhasset, NY. 
Introduction: Genetic testing in AML has exploded in the past decade. Almost 
monthly, there is a new genetic association with some diagnostic, prognostic and/or 
theranostic implications. As most laboratories cannot perform all tests in house, for 
each analyte, there are many questions that medical centers need to answer. Among 
them: How does a lab determine which tests add value to the patient management? 
How to implement systems to control/monitor appropriate utilization? This abstract 
describes a successful utilization strategy for FLT3, NPM and CEBPA testing in AML 
implemented at North Shore-LIJ Health System for the past year. Methods: We 
employed a gatekeeper methodology for identifying the appropriate time/test to order 
on our AML population. Specifically, we created a "DNA and Hold" service, which 
enabled us to extract and store DNA from diagnostic specimens (bone marrow / 
peripheral blood). Since FLT3, NPM, and CEBPA have the greatest 
prognostic/theranostic implications in normal cytogenetics AML (CN-AML), we stored 
the DNA until a full cytogenetic analysis was complete. For patients that were CN-
AML, and had sufficient blasts present for successful analysis, the testing was sent 
out to a reference lab in a reflexive algorithm. The algorithm consisted of FLT3, if 
negative, then NPM, if negative then CEBPA. If at any point a positive result was 
identified, further testing was cancelled. Results: In 2011, our two tertiary hospitals 
spent around $80,000 on FLT3, NPM, and CEBPA testing. Through 2012, the DNA 
and Hold service had identified medically unnecessary testing (for example, no 
leukemia, abnormal cytogenetics, or below limit of detection for assay) and reduced 
the annual expenditure by 86% ($67,662 savings). Further, only 4 of the 20 patients 
that were sent out for analysis required the full testing algorithm (FLT3, NPM, and 
CEBPA) Conclusions: Molecular/Personalized Medicine has tremendous promise 
when used appropriately. Without fully understanding the value added and costs 
associated, it contributes to our already straining national healthcare system. More 
importantly, appropriate utilization improves patient safety by ensuring the test 
results represent the disease state at the appropriate time. A negative FLT3 result on 
a bone marrow that has been already treated could misclassify a patient as FLT3-, 
missing an opportunity for management alteration. Another added benefit to this 
process was the requirement for increased communication between the Hematology-
Oncology faculty and Pathologists. This only strengthened the collaborative, patient 
centered, care we try to provide. 
 
H08. A Novel Mutation in Bruton Tyrosine Kinase Confers Acquired 
Resistance to Ibrutinib (PCI-32765) in Chronic Lymphocytic Leukemia 
S. Cheng1, P. Lu1, M. Setty2, A. Perez2, A. Guo1, J. Racchumi1, K. Venkataraman3, J. 
Ma1, M. Coleman1, C. Leslie2, Y. Wang1 
1Weill Cornell Medical College, New York, NY; 2Memorial Sloan-Kettering Cancer 
Center, New York, NY; 3Harvard Medical School, Boston, MA. 
Introduction: Chronic lymphocytic leukemia (CLL) is a malignancy characterized by 
the accumulation of mature, activated, B lymphocytes. Ibrutinib (PCI-32765) is a 
Bruton agammaglobulinemia tyrosine kinase (BTK) inhibitor that covalently binds to 
cysteine 481 (Cys481) of BTK. It has produced durable remissions in more than 90% 
of patients with relapsed/refractory CLL. Fewer than 5% of treated patients have 
progressed while on ibrutinib treatment. Biomarkers that help identify these patients 
need to be defined. We investigated a CLL patient progressed while receiving The Journal of Molecular Diagnostics ■ jmd.amjpathol.orgibrutinib. Methods: Serial peripheral blood samples were collected before and after 
the progression. RNA-Seq was used to identify the potential gene mutations that 
might contribute to the resistance. Mutations identified were then verified with 
Sanger sequencing and Taqman genotyping assays. Structural impact of the 
mutation confirmed was modeled in silico with Glide docking. Molecular and cellular 
consequences of the mutation were investigated in both primary CLL cells and cell 
lines. Results: A cysteine-to-serine substitution in BTK was identified at position 
481. Structural modeling demonstrated that the C481S mutation would disrupt BTK-
ibrutinib covalent binding. In vivo assay in 293T cells showed that the mutation 
increased IC50 of ibrutinib for BTK by about 500 folds. Signal transduction and gene 
expression profiling studies revealed that BTK C481S mutation reactivated B-cell 
receptor signaling pathway and released inhibition of ibrutinib on CLL proliferation. 
Importantly, introduction of mutant BTK into a B lymphoma cell line, converted the 
cell line from being sensitive to being resistant to ibrutinib. Conclusions: First, we 
identified BTKC481S mutation in a relapsed CLL patient. Secondly, we 
demonstrated the mutation is responsible for ibrutinib resistance. Lastly, we 
established a robust Taqman genotyping assay that may be useful for detecting 
resistance and monitoring emerging mutation in CLL patients receiving ibrutinib 
before clinical relapse. 
 
H09. Detection of Epstein Barr Virus in Lymphoma by Multiplex Targeted 
Next-Generation Sequencing 
E. Chastain1, M. Hussaini1, E. Pfeifer2, H. Abel1, E. Duncavage1 
1Washington University School of Medicine, St. Louis, MO; 2Carnegie Mellon 
Univerisy, Pittsburgh, PA. 
Introduction: Epstein Barr virus (EBV) has long been associated with lymphoma 
and is of both diagnostic and prognostic significance in many lymphoma subtypes. 
Routine clinical detection of EBV is generally performed by  in situ hybridization 
(ISH) for EBER1 RNA, adding additional expense and complexity to the diagnostic 
lymphoma evaluation. As molecular oncology testing is rapidly expanding to include 
gene panel next-generation sequencing (NGS), we sought to determine if EBV could 
be detected reliably from lymphoma-derived DNA as part of a multiplexed NGS-
based assay. Methods: Formalin-fixed, paraffin-embedded blocks from 12 
lymphoma excisional-biopsies were identified including 5 mature T-cell lymphomas 
and 7 mature B-cell lymphomas. EBV ISH staining was performed on all cases and 
evaluated by averaging EBV positive and negative cells in fifteen 50x fields per 
quadrant within each case. DNA was then extracted, captured using Nimblegen 
probes targeting 20 lymphoma-related genes plus the complete ~170kb EBV 
genome, and sequenced on a single Illumina Hiseq2000 lane using 2x101bp reads. 
Reads were then aligned to a concatemerized hg19 and EBV reference and EBV 
levels determined by calculating the number of reads that mapped to EBV genome.  
Viral integration sites were evaluated by ClusterFASQ and viral contigs constructed 
using PHRAP. Results: Evaluation of EBV ISH demonstrated 4 cases (33%) that 
had appreciable EBV-positive cells (>0.1%), all of which were T-cell lymphomas. 
NGS generated an average of 7M on-target reads/case of which 0.000001% to 6.3% 
mapped to the EBV genome.  EBV-ISH positive cases had a mean EBV genome 
coverage of 126x, compared to 0.008x for ISH-negative cases (p=0.07). No cases 
showed evidence of human viral integration sites. In the case with the highest EBV 
coverage, de-novo alignment was used to construct viral contigs, the longest 
measuring 44kb, permitting further sub-classification of the virus as type 1 EBV with 
homology to the B95-8 strain. Conclusions: We demonstrate that EBV DNA can be 
identified from routine clinical lymphoma specimens as part of a targeted NGS panel 
and that EBV detection by NGS correlates with results obtained by ISH. We also 
show that additional information including further viral subclassification can be 
performed by NGS-based methods. Although the identification of EBV by NGS is 
impractical as a stand-alone assay, it can easily be incorporated in to existing gene-
based panels thus reducing the overall cost and complexity of diagnostic lymphoma 
testing. Finally, we note that other cancer-associated viruses such as HPV could be 
evaluated in a similar manner. 
 
H10. Report of a Large Series of Myeloid Neoplasms with CEBPA Mutations 
Detected by a Direct Sanger Sequencing-Based Assay 
A. Behdad, H.C. Weigelin, K.S. John Elenitoba-Johnson, B.L. Betz 
University of Michigan, Ann Arbor, MI 
Introduction: CEBPA mutations are prevalent in acute myeloid leukemia (AML) and 
are associated with superior survival and durable clinical remission. Recent literature 
indicates that favorable outcomes are limited only to cases with double (biallelic) 
mutations. In addition to prognostic implications, the same mutations are seen at 
diagnosis and relapse, making CEBPA a potential marker for detection of minimal 
residual disease. Diagnostic testing for CEBPA mutations is now standard of care for 
cytogenetically normal AML, but no standardized testing platform exists. Several 859
8AMP Abstractstesting strategies are employed, including direct sequencing and PCR with fragment 
analysis; however, widespread implementation of CEBPA mutation testing has been 
hampered by technical challenges associated with this GC-rich gene. 
Methods: We evaluated the performance of our Sanger-sequencing based CEBPA 
mutation test through retrospective analysis of testing data. Preclinical optimization 
of the assay required careful primer design and incorporation of DMSO into the 
amplification reactions. Efficient analysis and interpretation of sequence data were 
facilitated by good software, and required a familiarization with polymorphisms and 
the expected pattern of mutations. 1825 consecutive cases of suspected myeloid 
neoplasms were evaluated for CEBPA mutations using our direct Sanger 
sequencing-based assay. NPM1 and FLT3-ITD mutation status were determined in 
parallel. Results: CEBPA mutations were identified in 104 (5.7%) cases, including 
56 with double and 48 with single mutations. 9 cases harbored a single homozygous 
mutation. FLT3-ITD mutation was detected in 7(12%) cases with double mutations. 
One of these also harbored concurrent NPM1 and FLT3-D835 mutations. The 
CEBPA mutations included 43 deletions, 91 insertions/duplications, and 11 
nucleotide substitutions. Nucleotide substitutions were identified in the absence of a 
length mutation in 3 (5%) cases with double CEBPA mutations (including two cases 
with homozygote mutations), and 6 cases (12%) with single mutations. Also detected 
were 20 different nucleotide substitution variants of uncertain significance. 
Conclusions: We describe our experience with one of the largest reported cohorts 
of CEBPA mutations that can assist in developing a rational strategy for CEBPA 
testing. Although infrequent, we encountered several cases with nucleotide 
substitutions that would be missed by a fragment analysis test. Hence, direct 
sequencing is advantageous for CEBPA mutation testing, permitting detection of 
nucleotide substitutions and direct identification of cases with single vs. double 
mutations, and various polymorphisms. In our series, FLT3-ITD mutations occur in 
12% of cases with double CEBPA mutations; prognostic implications of which and 
thus incorporation into testing strategies may require further investigation. 
 
H11. Chromosome Microarray Identifies the Precise Breakpoints of the Most 
Promiscuous Jumping Translocation in an MDS Patient 
C.C. Yeung, M. Fang 
Fred Hutchinson Cancer Research Center, Seattle, WA. 
Introduction: Jumping translocation (JT) is rare and serves as a cytogenetic 
curiosity. Although intricate studies mapped the responsible locus to 1q21, JTs 
involving other loci such as 11q and 3q, have been described. Although JTs have 
been described in numerous malignancies, a literature review for cases of 
Myelodysplastic syndromes (MDS) with JT has been sparse. MDS is a 
heterogeneous group of diseases with ineffective hematopoiesis and a varied range 
of prognoses. Identification of the highest risk MDS patients are very important as 
they develop rapid progression to acute leukemia and/or have treatment refractory 
disease. Methods: We describe a fascinating case of a very promiscuous JT in a 
patient with MDS and our review of the literature for JT-MDS cases. The patient is a 
66-year-old man who presented with fatigue and anemia. Initial workup showed 
MDS, specifically refractory cytopenia with unilineage dysplasia and normal 
karyotype. Results: The patient progressed with increased blasts a year after initial 
diagnosis. He was started and maintained on Vidaza with good response, but 
relapsed (a year later) with increasing fatigue, cytopenias, and a new cytogenetic 
abnormality of 1q duplication. Pathology at this time showed a hypercellular marrow 
with trilineage dysplasia, marked erythroid hypoplasia, and overall blast count of 3%. 
Four months later, his karyotype now showed a very prolific JT involving 1q resulting 
in multiple unbalanced translocations and multiple gains of 1q. Further analysis by 
chromosome Genomic Array Testing (CGAT) showed the duplicated 1q breakpoints 
to be 1q21.1q42.13, confirming the involvement of JTB among other important 
cancer genes such as MLLT11, ABL2, and PBX1. With progression of his MDS into 
a high-risk category, the patient was transplanted with a HLA-DQ mismatched 
unrelated donor under a nonmyeloablative protocol with fludarabine and total body 
irradiation. The day 31 marrow shows minimal residual disease by FISH studies. Our 
literature review reveals 6 other JT-MDS cases. Hatakeyama et.al (1998) describes 
a JT-MDS patient who subsequently developed AML (reportedly 10 years after initial 
diagnosis, but unclear when the patient acquired the JT). In a summary letter by 
Najfield (2010), he details 5 MDS patients with 1q JT, four of which transformed to 
AML in a mean-time of 21 months from acquisition of JT. Conclusions: From our 
JT-MDS case and the 6 described in the literature, prognosis of JT-MDS appears to 
be poor. It may warrant classification of JT-MDS into high-risk category allowing for 
early aggressive therapy and marrow transplantation.  
 
 
 60H12. Genetic Risk Stratification of CD30-Positive Peripheral T-Cell 
Lymphomas: Results of a Multi-Institutional Study 
E.R. Parrilla Castellar1, E.S. Jaffe2, J. Said3, S.H. Swerdlow4, R.P. Ketterling1, R.A. 
Knudson1, J.S. Sidhu5, E.D. Hsi6, S. Karikehalli7, L. Jiang1, G. Vasmatzis1, S.E. 
Gibson4, S. Ondrejka6, A. Nicolae2, K.L. Grogg1, C. Allmer1, K.M. Ristow1, W.R. 
Macon1, M.E. Law1, J.R. Cerhan1, T.M. Habermann1, S.M. Ansell1, A. Dogan1, M.J. 
Maurer1, A.L. Feldman1 
1Mayo Clinic, Rochester, MN; 2National Cancer Institute, Bethesda, MD; 3University 
of California, Los Angeles, Los Angeles, CA; 4University of Pittsburgh Medical 
Center, Pittsburgh, PA; 5United Health Services Hospitals, Johnson 
City/Binghamton, NY; 6Cleveland Clinic, Cleveland , OH; 7Centrex Clinical 
Laboratories, Utica, NY. 
Introduction: Peripheral T-cell lymphomas (PTCLs) comprise a mixed group of 
generally aggressive tumors, with 5-year overall survival (OS) rates of ~35% for most 
subtypes. The only genetically defined PTCL subtype is ALK-positive anaplastic 
large cell lymphoma (ALCL), characterized by ALK translocations, expression of 
CD30 protein, and a favorable prognosis following conventional chemotherapy. 
Using next-generation sequencing, we previously identified translocations of 
DUSP22-IRF4 (6p25.3) and TP63 (3q28) in subsets of CD30-positive PTCLs. We 
undertook the present multi-institutional study to examine whether combining these 
genetic biomarkers with ALK status was useful for risk stratification of these patients. 
Methods: Systemic CD30-positive PTCLs from 7 institutions were analyzed by 
submitting diagnosis, morphologic similarity to ALCL, and immunophenotype. ALK 
immunohistochemistry was used as an established surrogate for ALK translocations 
in ALCL. DUSP22-IRF4 and TP63 translocations were assessed in paraffin tissue 
sections by fluorescent in situ hybridization. Associations between PTCL genetic 
subgroups and OS were assessed using Kaplan Meier curves and Cox proportional 
hazards models. Results: There were 124 patients (83M:41F) with a median age of 
68 years (range, 6 to 87 years). DUSP22-IRF4, ALK, and TP63 translocations were 
identified in 22 (19%), 32 (25.8%), and 6 (5.5%) cases, respectively, and were 
mutually exclusive. DUSP22-IRF4 translocations were associated with a submitting 
diagnosis of ALCL (p=0.001) and classic ALCL morphology (p=0.07); unlike most 
ALCLs, these cases did not express cytotoxic proteins (p<0.0001). Cases with TP63 
translocations were not significantly associated with features of ALCL. Five-year OS 
rates for patients with translocations of DUSP22-IRF4, ALK, and TP63 were 94%, 
84%, and 0%, respectively. On univariate analysis, after adjusting for the 
International Prognostic Index, the hazard ratios for DUSP22-IRF4, ALK, and TP63 
translocations were 0.17 (95% confidence interval, 0.04 to 0.71; p=0.015), 0.34 (0.14 
to 0.82; p=0.016), and 4.85 (1.94 to 12.1; p=0.0007), respectively. Conclusions: 
PTCLs with DUSP22-IRF4 translocations show pathologic features overlapping 
those of ALK-positive ALCL and have similarly favorable prognosis, but lack ALK 
translocations. In contrast, CD30-positive PTCLs with TP63 translocations appear 
distinct from ALCL and have poor outcomes. These findings may have therapeutic 
implications for treatment intensity in these patient subsets. Taken together, our 
results indicate that combined genetic testing for translocations of ALK, DUSP22-
IRF4, and TP63 is a useful tool for risk stratification of CD30-positive PTCLs. 
 
H13. Frequency, Interobserver Reproducibility, and Clinical Significance of 
Equivocal Peaks in Lymphoid Clonality Testing Using BIOMED-2 primers 
I. Park1, C. Cotta2, E.D. Hsi2, A.G. Jegalian2, R.R. Tubbs2, J.R. Cook2 
1Ajou University School of Medicine, Suown, Republic of Korea; 2Cleveland Clinic, 
Cleveland, OH. 
Introduction: PCR studies for lymphoid clonality are widely employed, but criteria 
for interpretation have proven controversial. The Euroclonality organization has 
advocated subjective interpretation of data in conjunction with pathologic information, 
whereas others have argued for quantitative cutoffs for positive results. At our 
institution, each BIOMED-2 primer set is first subjectively classified as: clonal (clearly 
dominant peak), nonclonal (lack of dominant peak), or abnormal (an equivocal, 
prominent peak on a polyclonal background). Final results are then reported as 
positive (at least one primer set clonal), negative (all primer sets nonclonal), or 
indeterminate (one or more primer sets with abnormal peaks) for a clonal population. 
In this study, we examine the frequency, reproducibility and clinical significance of 
abnormal (equivocal) amplification patterns. Methods: Two hundred seventy-four 
consecutive cases with corresponding tissue biopsies were reviewed, including 163 
T-cell (TRB and TRG) tests and 161 B-cell (IGH and IGK) tests. To determine 
interobserver reproducibility, 30 cases were selected based on the clinically reported 
final results. These cases included 15 B-cell and 15 T-cell tests, evenly distributed 
between final results of positive, negative and indeterminate for clonality. Each case 
was reviewed for each PCR set and for each final result by 5 experienced 
pathologists. Consensus interpretation was defined as agreement by >4 reviewers. 
Results: 44/161 (27%) B-cell cases contained at least one abnormal peak. Of these, jmd.amjpathol.org ■ The Journal of Molecular Diagnostics
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displayed at least one abnormal peak. Of these, 31 (62%) showed clonal results in 
another primer set. In the interobserver variability cohort, a consensus interpretation 
was obtained in 17/21 (81%), 99/102 (97%) and 13/27 (48%) primer sets initially 
reported as clonal, nonclonal, or abnormal, respectively. Final molecular results were 
concordant in 9/10 (90%), 10/10 (100%) and 6/10 (60%) of cases initially reported as 
positive, negative or indeterminate for a clonal population. Conclusions: Using a 
subjective diagnostic approach, abnormal (equivocal) peaks are frequently observed 
in routine practice. This pattern shows poor interobserver reproducibility compared to 
clonal and nonclonal patterns. However, most cases with abnormal peaks contain 
clonal rearrangements in other primer sets, facilitating overall interpretation of final 
results. The poor reproducibility of equivocal PCR results emphasizes the 
importance of a multiparameter approach to lymphoma diagnostics and need to 
avoid overreliance on molecular results alone.   
 
H14. Progress in TCR Gamma Clonality Testing: Comparing Lympho Track 
Targeted Deep Sequencing with BIOMED-2-Based T-Cell Gene Rearrangement 
Assays 
I.A. Rijo de Torres, Y. Liu, T.N. Mitchell, K. Nafa, C.V. Hedvat 
Memorial Sloan Kettering Cancer Center, New York, NY. 
Introduction: For patients with lymphoid neoplasm of T cell origin, the TCR gamma 
(TRG) gene rearrangement analysis provides the ability to monitor and track 
neoplastic cells. Recently, a new assay Lympho Track Deep Seq (TDS) from 
Invivoscribe using next-generation sequencing (NGS), promises significant 
improvement in detecting minimal residual disease and higher resolution for clonal 
populations, even those with the same size. We tested a variety of clinical samples 
with the new platform and compared the results with the existing BIOMED-2-based 
TCRG gene rearrangement assay via capillary electrophoresis. Methods: Genomic 
DNA from 5 bone marrow (BM), 2 blood and 3 FFPE samples were included in the 
study (4 clonal, 2 biclonal/biallelic, 1 polyclonal and 3 equivocal). These samples 
were subjected, in duplicate, to PCR-based assays with BIOMED-2-based primers 
from Invivoscribe followed by capillary electrophoresis and TDS using the Illumina 
Miseq. The sequencing results of the dominant clone in a subset of cases were 
confirmed with Sanger sequencing. Results: The observations are made based on 
adequate number of total reads (TR) in all samples (ranging from 65,750 to 
417,306). Samples demonstrating the single clone pattern via fragment analysis 
(n=4) showed a most dominant sequence read (DS1) in each case accounting for 
8.5% to -74.5% of the TR. The ratio of the % of TR between the two most dominant 
sequences (DS1/DS2) ranged from 7.3 to 57.1 in these cases. Two patients with 
biclonal/biallelic pattern via fragment analysis showed DS1/DS2 of TR as 
10.5%/10.2% and 28.0%/17.9% and a ratio between the second and third most 
dominant sequences (DS2/DS3) of 10.9 and 18.4, respectively. The sample 
demonstrating a polyclonal pattern via fragment analysis showed a DS1 accounting 
for 1.1 % of the TR. The DS1/DS2 ratio in this case was 1.3. Patients with equivocal 
results via fragment analysis (n=3) showed DS1 accounting for 1.4% to 4.2% of the 
TR and DS2 accounting for 0.67% to 3.3% of the TR. The DS1/DS2 ratio in these 
cases ranged from 1.1 to 3.0. All the DS1 sequences were reproducible in the 
corresponding duplicate. FFPE samples and blood/BM samples showed comparable 
performance by TDS. The sequences of 2 DS1 were confirmed by Sanger 
sequencing. Conclusions: TDS offers the possibility to identify the clonal 
rearranged sequence specific for each neoplastic clone with high specificity. The 
preliminary results comparing the existing assay with TDS showed that NGS is a 
promising method to detect and potentially follow specific clones following treatment. 
 
H15. Detection of Multiple BCR-ABL1 Transcripts from Degraded RNA 
Samples  
S. Verma1, P.D. Cotter2, M.W. Moore1 
1Custom Diagnostics, Irvine, CA; 2Pacific Diagnostics, Irvine, CA. 
Introduction: Quantitation of BCR-ABL1 transcript levels in peripheral blood 
samples is the method of choice to monitor minimal residual disease and treatment 
response in leukemia patients undergoing Tyrosine Kinase Inhibitor (TKI) therapy. 
Two typical BCR-ABL1 fusion transcripts, p210 and p190, are found in 95% of 
leukemia patients. However, there are other clinically important atypical BCR-ABL1 
fusion transcripts (e1a3, e13a3, e14a3, e19a3, e19a2, e6a2, etc.) that are also 
present in leukemia patients. Currently, no BCR-ABL1 assay on the market can 
detect these atypical BCR-ABL1 fusion transcripts. Moreover, the assays that can 
detect both typical transcripts usually involve long PCR amplicons and so have poor 
sensitivity. Additionally, the sensitivity of these assays drops even further with routine 
clinical RNA samples, which are usually poor quality for various reasons such as i) 
low WBC count in leukopenia patients on TKI therapy, ii) samples taking longer than 
72 hours to reach the processing lab, iii) poor handling, or iiii) use of poor quality The Journal of Molecular Diagnostics ■ jmd.amjpathol.orgreagents, resulting in significant RNA degradation. There is clinical interest in having 
a assay that can accurately detect all typical and atypical BCR-ABL1 transcripts with 
high sensitivity in sub-optimal clinical samples. Methods: We designed a Taqman 
probe based one step q-RTPCR assay to detect all known typical and atypical BCR-
ABL1 transcripts with high sensitivity and specificity. The assay was designed in a 4 
well format providing primer/probe mixes for detection of p210, p190, atypical BCR-
ABL1 transcripts including p230 (e13a3, e14a3, e1a3, e19a3, e6a2, e19a2), and an 
Abelson control gene. The RNA and DNA positive control included with the assay 
are aligned with WHO international standards for reporting of p210 results on the 
international scale. Results: The assay has a dynamic range over 7 logs (107 copies 
to10 copies) and sensitivity limit to 5 to10 copies of BCR-ABL1 transcript per 
reaction. An accuracy study performed on 54 samples showed 100% concordance 
between the Custom Diagnostics assay and a reference LDT assay. The Custom 
Diagnostics assay was on average 272-fold more sensitive than the reference LDT 
assay. Significantly, the assay yielded results from 13/15 specimens that failed by 
the LDT assay, indicating that the BCR-ABL1 assay works well even on poor quality 
RNA samples. Conclusions: The Custom Diagnostics BCR-ABL1 assay is a 
comprehensive one step quantitative real-time PCR assay to detect all known typical 
and atypical BCR-ABL1 fusion transcripts with high sensitivity in degraded RNA 
samples. 
 
H16. Frequencies of the Five Most Common IGH Translocation Partners in 
Plasma Cell Proliferative Disorders: The Mayo Clinic Experience 
 R.A. Knudson, R.P. Ketterling 
Mayo Clinic, Rochester, MN 
Introduction: Plasma cell proliferative disorders (PCPD) are a group of neoplasms 
characterized by a clonal expansion of terminally differentiated plasma cells. Current 
world health organization subcategories for PCPDs include monoclonal gammopathy 
of undetermined significance (MGUS), plasma cell myeloma, plasmacytoma, 
immunoglobulin deposition disease (amyloidosis), and osteosclerotic myeloma. 
Despite significant variability in clinical presentation and outcomes, the various 
PCPDs share the same genetic abnormalities, including IGH translocations, 
trisomies of the odd chromosomes, monosomy 13/13q deletion, and TP53 deletion 
on 17p. The most common structural chromosome abnormalities are IGH 
translocations that occur in approximately 35% of cases and have significant and 
variable prognostic impact at diagnosis. Although the IGH promoter upregulates a 
variety of gene partners due to these translocation events, the 5 most common 
partners and associated frequencies in plasma cell myeloma include CCND1 (20% 
to 25%), FGFR3 (10% to 15%), MAF (2% to 5%), MAFB (2% to 3%), and CCND3 
(2% to3%). Methods: A retrospective review of the clinical PCPD cases from 
5/1/2009 through 12/31/2012 was conducted. Our PCPD test utilizes cytoplasmic 
immunoglobulin staining (cIg) combined with a FISH panel to detect IGH 
translocations, monosomy 13/13q deletion, 17p deletion, and trisomy 3, 7, 9 and 15. 
D-FISH probes are used to identify CCND1/IGH, FGFR3/IGH, MAF/IGH, MAFB/IGH, 
and CCND3/IGH fusions. Results: Of 10,439 unique patients evaluated, 3,430 
(32.8%) had IGH translocations, and one of the 5 translocation partner genes was 
identified in 2,711 (79%) cases. Of the 3,430 IGH translocation cases, 1,623 (47.3%) 
had CCND1/IGH fusion, 514 (15%) had FGFR3/IGH fusion, 304 (8.9%) had 
IGH/MAF fusion, 144 (4.2%) had IGH/MAFB fusion, and 126 (3.7%) had 
CCND3/IGH fusion. Conclusions: Overall, the frequency of IGH translocations 
approximates the IGH translocation frequencies from published data with the 
exception of a nearly doubled rate of CCND1/IGH fusion (47.3% observed vs. 20% 
to 25% expected). Our higher frequency of patients with CCND1/IGH fusion may 
represent the inclusion of patients with amyloidosis, MGUS and other PCPDs that 
may have a higher frequency of CCND1/IGH fusion. Our undefined translocation 
partners represented our second largest group of patients accounting for 719 (21%) 
of all IGH translocations. As the 5 translocation partners currently evaluated have 
extremely variable prognostic impact on plasma cell myeloma patients (e.g., CCND1, 
CCND3 are favorable; FGFR3 is intermediate; MAF and MAFB are unfavorable 
prognoses), it will be important to identify the remaining IGH translocation partners to 
deduce the prognostic impact of the currently undefined genes. 
 
H17. Clinical Validation of an Amplicon-Based Next-Generation Sequencing 
Assay for Myeloid Malignancies 
A. Oultache, K. Nafa, W.J. Chen, N.T. Mensah, T.N. Mitchell, A. Syed, A. Zehir, D. 
Cheng, M.E. Arcila, R.L. Levine, M.F. Berger, C.V. Hedvat 
Memorial Sloan-Kettering Cancer Center, New York, NY. 
Introduction: Myeloid malignancies are characterized by numerous genomic 
alterations that have diagnostic, therapeutic and prognostic impact. As large scale 
sequencing efforts are broadening the catalog of mutations in myeloid malignancies, 
it is imperative to establish high throughput testing with comprehensive profiling in 861
8AMP Abstractsthe clinical laboratory. In this study, we describe the clinical validation, according to 
NYSDOH guidelines, of a Raindance DeepSeq custom designed 30-gene panel on 
an Illumina MiSeq for clinical testing of myeloid malignancies. Methods: Genomic 
DNA was extracted from 17 peripheral blood samples and 35 bone marrow aspirates 
of patients with a diagnosis of acute myeloid leukemia or BCR-ABL negative 
myeloproliferative neoplasms. All mutations were confirmed by either Sanger 
sequencing or fragment analysis. 500 ng of DNA was used to create a library of 849 
amplicons, which was sequenced on the Illumina MiSeq platform. A negative control 
(Hapmap), a mixed positive control and a “no-template” control were used as run 
QC. We assessed intra- and inter-assay reproducibility by testing NPM1 and JAK2 
positive cases in triplicate. Assay sensitivity was determined by serial dilutions of a 
triple positive NPM1/FLT3-ITD/IDH1 and a JAK2 V617F sample. Alignment and 
variant calling was performed by our bioinformatic team using open source tools. 
Results: We tested 12 cases negative for NPM1, FLT3 and/or CEBPA, and 40 
cases with known mutations in CEBPA (n=3), KIT/ex17 (n=3), IDH1 & IDH2 ex4 
(n=2), FLT3/ex20 (n=3), FLT3/ex14 (n=10), MPL/ex10 (n=1), JAK2/ex14 (n=13), 
NPM1/ex11 (n=16), DNMT3A/ex23 (n=8). More than 90% of the amplicons were 
sequenced to a depth of coverage greater than 500x with 12 samples per run. Good 
coverage uniformity was observed except for GC rich genes such as CEBPA. Based 
on our reproducibility studies, we applied a filter of variant frequency (VF)>10% for 
SNVs and a VF>5% for indels. We detected all expected SNVs and indels, including 
FLT3 ITDs (up to 93 bp). Reproducible coding variants in genes not previously 
tested, but well described in myeloid malignancies such as ASXL1, ETV6, JAK1, 
JAK3, NRAS, PHF6, PTEN, SF3B1, SUZ12, TET1, TET2, TYK2, and WT1 were also 
identified. Conclusions: Our results demonstrate that our Raindance DeepSeq 30 
gene panel sequenced on a Miseq instrument generates highly reproducible results 
and can be applied in a clinical setting to replace several single gene tests. 
 
H18. High Resolution Analysis of Post-Allogeneic Stem Cell Transplant 
Chimerism Using Next-Generation Sequencing 
M. Mai, D.S. Viswanatha
Mayo Clinic, Rochester, MN. 
Introduction: Current laboratory chimerism assays are performed using multiple 
PCR-amplified short tandem repeat (STR) markers with PCR product analysis by 
fluorescent capillary electrophoresis. Use of single nucleotide polymorphisms (SNP) 
is a potential alternative to STR approaches, but suffers from the potential for many 
non-informative loci, unless careful selection for maximally informative SNP 
combinations is performed. Although there are even more informative small 
polymorphic human DNA markers (e.g. short in/del variants), the process of 
“singleplex” fragment analysis or detection by relatively insensitive Sanger 
sequencing prohibits the development of SNP-based chimerism assays in the clinical 
laboratory. We explored the potential of deep sequencing of SNP loci using the Ion 
Torrent PGM next-generation sequencing platform (Life Technologies, Grand Island, 
NY) and a commercially available multiplex SNP Kit (Life Technologies), for the 
purpose of chimerism detection and quantification. Methods: Eight pairs of primers 
for 8 highly informative SNP loci were evaluated in pre-transplant recipient, pre-
transplant donor, post transplant patient (recipient) DNA samples. One ng of high 
quality DNA was used per sample for locus-specific PCR amplifications 
encompassing the SNP region. Libraries for each PCR were generated by using the 
Ion torrent Fast NEXTgen library kit (New England BioLabs, Ipswich, MA). Each 
library was quantitated using Qbit technology (Life Technologies, Grand Island, NY). 
Samples for each library were labeled using the IonXpress 1- 16 barcode kit (Life 
Technologies, Grand Island, NY). Next-generation sequencing was performed using 
the PGM 314 chip simultaneously analyzing 3 chimerism sample sets (total of 9 
library-coded PCR products). IGV 2.2 Viewer (The Broad Institute, Boston, MA) was 
adopted to calculate the informative allele proportions.  
Results: PGM sequencing returned 150 megabase pairs (Mbps) of Q20 reads with 
an average read length of approximately 130 bps. Average coverage depth for the 
amplicon regions was approximately 8000-fold. Results for the 3 cases are shown in 
the table:  
Case No. STR Results    NGS (PGM) Results 
(%Donor/%Recipient)  (%Donor/%Recipient) 
1  95/5    97.2/2.8 
2  90/10    88.9/11.1 
3  90/10    82/18 
Conclusions: SNP analysis by next-generation sequencing (Ion Torrent PGM) can 
reveal detailed and more precise proportions of donor and recipient DNA content 
compared to the limit of detection of standard STR-based analysis. However, this 
proof-of principle 8 SNP marker panel has only limited population-based 
discriminative utility (approximately 1:5000), precluding its use in the routine clinical 
laboratory setting. Despite the attractive features of NGS-based SNP determination 62for post-transplant chimerism studies, more numerous and informative combinations 
of SNP markers are needed. 
 
H19. A Triple-Hit Follicular Lymphoma with 
t(3;22)(q27;q11),t(11;14)(q13;q32),t(14;18)(q32;q21) 
P. Koduru, F. Fuda
University of Texas Southwestern Medical Center, Dallas, TX. 
Introduction: Oncogene activation through juxtaposition to the regulatory region of 
immunoglobulin genes is considered as one of the underlying pathogenetic events in 
the genesis of B-cell neoplasm. Translocations involving specific oncogenes are 
associated with development of particular types of lymphoma; however, some 
lymphomas are associated with two or more of these oncogenes either concurrently 
or sequentially. Such lymphomas are termed either double hit or triple hit depending 
on the number of genes involved. These lymphomas often have bone marrow and 
CNS involvement; they have a high IPI score, and they portend a poor prognosis. A 
recent review of this group of lymphomas has identified sporadic cases of triple hit 
tumors in which two BCL genes are deregulated along with MYC; all these are 
aggressive tumors with an even worse prognosis. Methods: Standard cytogenetics 
and FISH methods were used to characterize tumor cells. Results: We present here 
a case of triple hit follicular lymphoma with deregulated BCL2, BCL6 and BCL1 
genes in a 55-year-old male. At diagnosis the patient had lymphadenopahty, and a 
biopsy confirmed involvement by follicular lymphoma. Cytogenetic studies were not 
performed on this tumor. A biopsy of a left groin lymph node at first clinical relapse 
(13 years and 8 months after initial diagnosis) showed a grade I follicular lymphoma 
with focal grade II lesions. Karyotype of this tumor was 
46,XY,t(3;22)(q27;q11.2),t(14;18)(q32;q21),der(22)t(9;22)(q13;p11.2). Clinically the 
patient lacked symptoms and, therefore, was not treated. Peripheral blood was 
involved 14 years and 10 months after initial diagnosis. This time, the lymphoma 
showed a t(11;14)(q13;q32) in addition to the t(3;22) and t(14;18); this was confirmed 
by interphase FISH analysis that showed a fusion between CCND1 and IgH. This is 
the first case of a triple hit lymphoma with three lymphoma related reciprocal 
translocations not involving MYC. Conclusions: This unique case is a germinal 
center B-cell lymphoma with a concurrent double translocation involving Ig genes, 
BL2 and BCL6 genes at diagnosis and has acquired a third translocation involving 
BCL1 gene at the leukemic phase. This is the first report of a low grade lymphoma 
transformed into leukemic phase through acquisition of a deregulated BCL1 gene. 
This is in contrast to several cases of dual and/or triple hit lymphoma in which the 
second hit or the third hit invariably included deregulation of MYC by fusion with Ig 
genes or with non-Ig genes followed by aggressive disease that ended in a poor 
outcome.  
 
H20. Natural History and Clinical Utility of PML-RARį Fusion Transcript 
Surveillance in Acute Promyelocytic Leukemia 
K.E. Fisher, C.L. Appin, C.E. Hill
Emory University School of Medicine, Atlanta, GA. 
Introduction: The PML-RARĮ fusion transcript is a diagnostic hallmark of acute 
promyelocytic leukemia (APL). Molecular quantitation using real-time PCR (real-time 
qPCR) is a highly sensitive methodology for detecting disease recurrence prior to 
morphologic or cytogenetic manifestations. However, limited literature exists 
regarding the natural history of PML-RARĮ transcripts, and whether quantitative 
thresholds can influence subsequent clinical intervention. In this pilot study, we 
followed serial real-time qPCR PML-RARĮ measurements from APL patients to 
assess if variation existed and if numerical thresholds correlated with clinical data. 
Methods: The medical records from 24 patients diagnosed with APL from 2006 to 
2012 were reviewed. All patients had serial real-time qPCR testing performed on 
either bone marrow aspirates or peripheral blood in the Emory Molecular Diagnostics 
laboratory using an ABI Prism 7500. Serial quantitative PML-RARĮ transcript values 
collected from initial diagnosis were compared to clinical data during the course of 
APL treatment. Results: The number of serial PML-RARĮ measures ranged from 1 
to 36 with 6 median measurements per patient (mean 10). One patient died within 2 
days of diagnosis and a second patient had only one documented PML-RARĮ 
measurement. Of the 22 patients with more than one measured PML-RARĮ value 19 
(86.4%) had 3 log-fold reductions in transcripts within one month of starting induction 
therapy and 21 (95.5%) patients reached undetectable levels within 3 months. 
Twenty-one patients with undetectable PML-RARĮ transcripts remained at 
undetectable levels throughout the course of their treatment. One patient 
experienced with and undetectable level of transcript experienced a relapse with 
slightly higher transcript levels than the original diagnostic material (1.41 vs.4.29). 
One patient’s peripheral blood continually expressed transcript levels ranging 
between 1.30 and 7.00 and the patient died six months after initial diagnosis. One 
patient had two consecutive peripheral blood samples that showed positive transcript jmd.amjpathol.org ■ The Journal of Molecular Diagnostics
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that was negative for APL by morphologic, molecular, and cytogenetic criteria. 
Conclusions: A majority of patients with APL have PML-RARĮ transcripts that 
remain undetectable after treatment. In persistent disease, transcript levels remain 
relatively uniform. In one case, two consecutive “low positives” triggered a diagnostic 
bone marrow that revealed no evidence of disease. These data may support 
investigation of a quantitative action threshold rather than using qualitative positive 
or negative results as a monitoring tool. 
 
H21. Performance Comparison of TCR Gamma Gene Rearrangement Assay 
2.0 with the BIOMED-2 TCRG Gene Clonality Assay 
Y. Liu, I. Rijo de Torres, K. Nafa, M.E. Arcila, C.V. Hedvat 
Memorial Sloan-Kettering Cancer Center, New York, NY 
Introduction: PCR-based TCR gamma (TRG, formerly TCRG) clonality assays have 
been largely standarized by the InvivoScribe BIOMED-2 concerted action. The 
results generated by capillary electrophoresis of the multiplexed PCR products are 
not quantitative, and requires interpretation of the profile to determine clonality. It has 
been recognized that assay design can affect the interpretation of TRG gene 
rearrangements. Here we evaluate the performance of TCRG gene rearrangement 
2.0 (TCRG-2.0). The TCRG-2.0 assay is a single multiplex PCR assay whereas the 
BIOMED-2-TCRG design is based on multiple PCR reactions. The aim is to 
demonstrate the potential impact of clonality interpretation generated by the assay 
design and correlate the results with clinical findings, which would help elucidate the 
significance of the clone identified by each assay. Methods: From archived cases 
with available results of the TCRG gene rearrangement mix 2 (TCRG-mix-2) and 
BIOMED-2-TCRG assays, 45 cases [32 blood/bone marrow (BM), 13 FFPE] were 
selected enriching for cases with discrepancy between the two existing assays 
(30/45). Genomic DNA was subjected to TCRG-2.0 testing. The fluorescently-
labelled PCR products were resolved by capillary electrophoresis on an ABI 3730 
DNA Analyzer. Medical charts of all patients were reviewed to identify clinical 
evidence of disease. Results: 34/45 cases showed concordant results between the 
TCRG-2.0 and BIOMED-2-TCRG assay. All the 11 discordant cases were polyclonal 
via TCRG-2.0 but clonal by BIOMED-2-TCRG assays. Among them, 8/11 cases with 
slides available for morphologic evaluation, all showed no morphologic evidence of 
disease. Six of them (6/11) were considered to be post-treatment pseudoclones 
clinically. Three BM cases had either a different clone from the original or had no 
original clone to compare with, unlikely to be involved by the neoplastic process. 
17/45 cases showed discordant results between TCRG-mix-2 and TCRG-2.0. All 17 
discordant cases were polyclonal via TCRG-mix-2 but clonal via TCRG-2.0. The 
clinical presentation and morphologic diagnoses in these cases suggest evidence of 
disease or possible cross-lineage rearrangement except one BM sample, with no 
morphologic involvement and the clone was different from the original. 
Conclusions: Examining cases with discrepant results, separation of PCR products 
into multiple reactions and size distributions in BIOMED-2-TCRG results in the 
identification of clones that are clinically insignificant including post-treatment 
pseudoclones and clones irrelevant to the original neoplastic process. The single 
mulitplex PCR reaction of TCRG-2.0 appears to offer the same degree of sensitivity 
with improved specificity. When compared with the TCRG-mix-2, TCRG-2.0 shows 
improved sensitivity and comparable specificity.  
 
H22. Utilization of Genomic Information from Single Nucleotide 
Polymorphism Arrays to Identify and Quantitate Tumor Subclones in Chronic 
Lymphocytic Leukemia 
E.M. Azzato, J. Zhao, A. Fox, D. De Sloover, A. Bagg, J. Morrissette, R. Daber 
Hospital of the University of Pennsylvania, Philadelphia, PA. 
Introduction: Single nucleotide polymorphism (SNP) arrays provide a hypothesis-
free way to evaluate copy number and copy-neutral loss-of-heterozygosity (cnLOH) 
across the genome. These arrays have increasing diagnostic utility in cancer, 
especially in diseases where copy number abnormalities are helpful in 
prognostication, such as chronic lymphocytic leukemia (CLL). Since tumor 
specimens are by nature mixed mosaics, mosaicism quantification using SNP array 
data also allows for quantitation of tumor load and identification of tumor subclones. 
To better understand the relationship between SNP array data and mosaicism for 
deletions and duplications, we evaluated concordance between SNP array data, 
interphase fluorescent in situ hybridization (FISH) and flow cytometry to validate the 
quantitative nature of the array. Methods: The Cytoscan HD array (Affymetrix, CA) 
was used to analyze 20 CLL peripheral blood samples. Percent mosaicism was 
modeled using expected genotype allele frequency and copy number information. 
Interphase FISH was performed at selected loci (ATM, del13q14, TP53 and 
chromosome 12) and tumor subclone percentages were calculated for each. Where 
available, concurrent flow cytometry was utilized to provide additional data The Journal of Molecular Diagnostics ■ jmd.amjpathol.orgsupporting percent tumor burden. Results: Our sample cohort included low (n=8), 
intermediate (n=6) and high (n=6) Rai stage disease, with 60% of patients being 
chemotherapy naïve. We observed 100% concordance with FISH results for 
del13q14 (n=12), TP53 deletion (n=4), trisomy 12 (n=3), and ATM deletion (n=5). In 
twelve samples, we found one or more copy number changes by SNP array that 
were outside the regions interrogated by FISH. We also identified one instance of 
cnLOH over ATM.  Percent tumor estimated from the array was well correlated with 
the percent tumor burden reported by both interphase FISH and flow cytometry. 
Tumor subclones could be differentiated and quantitated using the array, which also 
correlated well with interphase FISH results. Conclusions: SNP arrays have 
excellent concordance with interphase FISH for commonly interrogated genetic 
lesions in CLL, while detecting additional chromosomal aberrations. Using SNP 
arrays to quantitate mosaicism provides an additional method to confirm tumor 
burden and tumor subclones in peripheral blood specimens.  
 
H23. Identifying and Monitoring IGH Clonality Using Massively Parallel 
Sequencing and Associated Bioinformatics 
M.R. Klass1, H. You1, Y. Huang1, T. Fodrie2, J. Panning1, J. Thornes1, J. Miller1 
1Invivoscribe, Inc., San Diego, CA; 2LabPMM, San Diego, CA. 
Introduction: Assays that identify clonal lymphocyte populations in clinical 
specimens are used on a routine basis to assist in the diagnosis of 
lymphoproliferative disease. Subsequent minimal residual disease (MRD) testing to 
track the patient- and tumor-specific V-J DNA sequences identified in diagnostic 
samples, can also be used to assist in determining therapeutic efficacy and often 
provide the first indication of clinical relapse. PCR-based methods run on capillary 
electrophoresis instruments are the current gold standard for clonality testing. 
However, these methods often do not provide sufficient diagnostic sensitivity, as they 
are sometimes difficult to interpret, and, absent separate sequencing steps, are 
incapable of identifying the specific V-J DNA sequence data required to track clones 
in follow up MRD testing. The emergence of massively parallel sequencing (MPS) 
platforms has led to development of powerful new approaches for clonality detection 
and monitoring. Here we report performance of an MPS assay and associated 
bioinformatics developed for the MiSeq platform to detect and monitor IGH clonality. 
Methods: Optimized FR1 and J consensus primers targeted all IGH variable (V) and 
joining (J) region gene segments that are rearranged in lymphoid malignancies. 
Multiplex PCR master mixes amplified IGH gene rearrangements and incorporated 
sequence indices into products allowing simultaneous sequencing and tracking of as 
many as 23 individual samples, plus controls, in each run. Amplicons were purified, 
quantified and pooled for library formation. Up to 20 pM of the library was loaded 
onto the MiSeq. Data were generated using the MiSeq v2 Reagent kit (500 cycles). 
Data were analyzed using Invivoscribe proprietary bioinformatics software run on 
standard Windows platforms. Results: This assay and bioinformatics package 
reproducibly identified clonality and DNA sequences for each V-J gene 
rearrangement. Automated data outputs include frequency distributions and V-J 
gene usage. Cell line DNA, serially diluted into tonsil DNA, confirmed the linearity 
and low run-to-run variance of the assay. Good linearity, reproducibility, and 
sensitivity were demonstrated. Genomic DNA from peripheral blood (PB), tonsil, and 
bone marrow aspirates were tested for IGH gene rearrangements. Conclusions: We 
have developed an IGH MPS assay, LymphoTrack DeepSeq, for the Illumina MiSeq 
and HiSeq platforms that identifies clonal IGH V-J rearrangements, associated 
patient-specific V-J region DNA sequences, and provides frequency distribution of V 
region and J region segment utilization. This assay can be used both to detect and 
monitor lymphoproliferative disease. When coupled with the bioinformatics and 
visualization software this assay provides robust detection and enhanced data-rich 
outputs.  
 
H24. Strong HDAC6 Expression Is Associated with Poor Prognosis of 
Diffuse Large B-Cell Lymphoma 
X. Zhou, Y. Cai, W. Cui, W. Wang, Z. Liu, P. Wei,. Bi 
Fudan University Shanghai Cancer Center, Shanghai, China. 
Introduction: HDAC6 is a Class IIb HDAC that contributes to the degradation of 
aggresomal proteins. It had been reported that HDAC6 deficient cells were more 
resistant to oncogenic transformation and the inactivation of HDAC6 reduced tumor 
formation in mice. Recent reports have revealed variant expression of HDAC6 in 
different DLBCL cell lines and aberrant expression of HDAC6 in lymphoma tissues. 
We therefore investigated the prevalence and the prognostic impact of expression of 
HDAC6 and Ac-alpha-tubulin, its main substrate, in diffuse large B-cell lymphoma 
(DLBCL). Methods: Five 10×12 dots tissue microarrays consisting of 151 DLBCL 
cases and 10 cases of RLH (Reactive Lymphoid Hyperplasia) were constructed, with 
two cores for each case. All the paraffin-embedded tissues were retrieved from the 
files of the Department of Pathology of Fudan University Shanghai Cancer Center 863
8AMP Abstractsbetween 2005 and 2010 and all the histological slides were reviewed to confirm the 
diagnosis by two senior pathologists. Immunohistochemistry was used to detect the 
expression of HDAC6 and Ac-alpha-tubulin and their relationship with the 
clinicopathologic significance, respectively. The survival analysis was performed 
according to the method by Kaplan and Meier, and the associations between 
individual clinical features were compared with the log-rank test. A Cox model was 
used to identify prognostic variables. A limited backward-selection procedure was 
used to exclude redundant or unnecessary variables. SPSS software (version 16.0) 
was used throughout and P values less than 0.05 were considered statistically 
significant. Results: HDAC6 was expressed in the cytoplasm and Ac-alpha-tubulin 
was expressed in nuclear. Strong HDAC6 expression was found in plasma cells in 
RLH and in 31.8% of all the DLBCL cases. Ac-alpha-tubulin was strongly expressed 
in follicular dentritic cells and its moderate expression was found in endothelial cells, 
whereas a positive expression rate of 47.7% was found in DLBCL case. Strong 
positive expression of HDAC6 was significantly correlated with tumor stage (P = 
0.013) and it was significantly associated with shorter overall survival by univariate 
analysis (P = 0.030) and Cox multivariate analysis (P =0.014).Negative association 
between HDAC6 and Ac-alpha-tubulin was found by Spearman correlation analysis 
(P = 0.039, r =-0.168). No significance was found between Ac-alpha-tubulin and the 
clinicopathological features. Conclusions: The positive correlation between strong 
expression of HDAC6 and short overall survival suggest that HDAC6 may be an 
independent prognostic factors for predicting inferior DLBCL patients and a potential 
new therapeutic target for DLBCL.  
H25. Validation and Implementation of a Pyrosequencing Assay to Detect 
the NOTCH1 c.7541_7542delCT Mutation in Chronic Lymphocytic Leukemia 
M.J. Kluk1, D.J. Oh1, J.L. Klitgaard2, S.M. Fernandes2, J.C. Aster1, J.R. Brown2, N.I. 
Lindeman1
1Brigham and Women's Hospital, Boston, MA; 2Dana Farber Cancer Institute, 
Boston, MA. 
Introduction: NOTCH1 mutations occur in approximately 10% of chronic 
lymphocytic leukemia (CLL) cases and are associated with adverse biologic features 
and more aggressive clinical course. The most prevalent NOTCH1 mutation among 
CLL cases is the c.7451_7542delCT, PEST domain frameshift mutation. To readily 
identify CLL cases with this mutation, we designed and validated a pyrosequencing 
assay for use on peripheral blood samples and then implemented testing on clinical 
samples from patients with CLL. Methods: This pyrosequencing assay was 
designed to detect the NOTCH1 c.7541-7542delCT mutation and has been validated 
using genomic DNA isolated from whole blood samples. PCR amplification of part of 
exon 34 of NOTCH1 is followed by pyrosequencing of coding nucleotides 7530-7543 
per standard protocol. Results: Validation was accomplished through method 
comparison using samples genotyped in an independent laboratory by a different 
platform. The overall concordance rate was 95% (35/37). The two discordant 
samples were negative by pyrosequencing and were positive by whole exome 
sequencing. The cause for discrepancy is uncertain, but is possibly due to increased 
analytical sensitivity of the reference, whole exome sequencing platform.  Analytical 
sensitivity experiments demonstrated the limit of detection for the NOTCH1 c.7541-
7542delCT mutation by pyrosequencing was reached when lymphocytes comprised 
approximately 15% of white blood cells. Reproducibility was demonstrated by 
achieving the same pyrosequencing result for various positive and negative samples 
tested numerous times (4-15 replicates). After validation, we implemented routine 
testing of clinical specimens with this pyrosequencing assay; over the past 7 months 
we have tested 185 CLL/SLL cases of which 20 cases (10.8%, 20/185) were positive 
for NOTCH1 c.7541-7542delCT mutation at various levels. One CLL/SLL case was 
positive for NOTCH1 c.7538C>T mutation (0.5%, 1/185). We also tested 19 cases of 
monoclonal B cell lymphocytosis that were negative. The CLL/SLL cases positive for 
the NOTCH1 mutations demonstrated a range of clinical, pathologic and cytogenetic 
findings including: del13q (33%, 7/21), trisomy 12 (29%, 6/21), del11q (9.5%, 2/21), 
del17p (4.8%, 1/21) or normal cytogenetics (24%, 5/21) per Dohner hierarchy. 
Conclusions: These findings demonstrate that this is an accurate, sensitive, and 
reproducible method for detection of the NOTCH1 c.7541-7542delCT mutation in 
genomic DNA isolated from peripheral blood of CLL patients. We have successfully 
implemented this assay for routine testing and believe it will be a helpful tool in the 
molecular assessment of NOTCH1 c.7541-7542delCT mutation status in CLL 
patients in appropriate settings.  64H26. WITHDRAWN 
H27. Validation of a Targeted Next-Generation Sequencing Panel to Screen 
for Mutations in Myeloid Leukemia 
F. Yang, C. Beadling, T.L. Neff, J. Dunlap, C.L. Corless, R. Press
Oregon Health & Science University, Portland, OR. 
Introduction: Acute Myelogenous Leukemia (AML) and Myelodysplasias (MDS) are 
heterogenous disorders characterized by the accumulation of somatically acquired 
alterations in genes involved in self-renewal, proliferation, and differentiation of 
hematopoietic progenitor cells. Screening for mutations in these genes provides 
increasingly important information for prognostic risk stratification and appropriate 
management of patients with AML/MDS. We used an advanced Next-Generation 
Sequencing (NGS) platform to develop and clinically validate a 42-gene AML/MDS 
sequencing panel. Methods: We designed the target panel with highly multiplexed 
Ion AmpliSeq Designer (Life Techologies) software. Genomic DNA was extracted 
from blood or bone marrow from 29 leukemia patients whose mutation profile had 
been previously characterized using mass spectrometry, Sanger sequencing, and/or 
single-gene assays, and from 10 normal wild type individuals. DNA (20 ng) was used 
to generate target amplicon-based libraries that were subsequently sequenced on a 
316/318 chip on an Ion Torrent PGM. The bioinformatics analysis was performed 
using the pipeline in the Torrent Suite v.3.2 for data processing, sequence alignment, 
target coverage analysis, and variant identification. Open source programs and lab-
developed algorithms were used for annotation and amino acid prediction. Results: 
The AML/MDS panel consists of 701 primer pairs that cover 65K bases in exons of 
42 cancer genes. The total hands-on analysis time, from blood sample to mutation 
report, was ~30 hours. A median of 1.1 million high-quality (AQ20) sequencing reads 
were generated across each of 39 samples. 94% of these reads mapped to targeted 
gene regions. The average depth of coverage per amplicon was 1600-fold, with 
coverage uniformity above 90%. Of 55 known variants in the AML validation set of 
29 samples, all 29 point mutations and 16 out of 26 indels were correctly detected. 
Five of the 10 false-negative indels were FLT3-ITD’s of >27 bp. The other 5 were 
heterogeneous mutations in CEBPA, in which amplicon dropouts were observed in jmd.amjpathol.org ■ The Journal of Molecular Diagnostics
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emulsion PCR step. Supplement tests, such as PCR/CE analysis for FLT3-ITD and 
direct Sanger sequencing for CEBPA, were validated to detect mutations in these 
two genes. Conclusions: An NGS panel targeting 42 key genes associated with 
leukemogenesis has been developed and validated, using the AmpliSeq technology 
on the Ion PGM. Our results demonstrate that the panel can reliably detect mutations 
with a short turnaround time, at a relatively low cost, and can benefit personalized 
cancer care in the clinical setting.          
 
H28. Current Trends in Ccute Myeloid Leukemia Triaging and Testing 
Protocols: A Nationwide Survey 
A. Hariharan, K.H. Karner 
Henry Ford Hospital, Detroit, MI. 
Introduction: Recent guidelines recommend that all cytogenetically normal cases of 
acute myeloid leukemia (AML) be tested for certain molecular mutations. This 
protocol is impractical for many laboratories that lack the means to bank these 
specimens. We conducted a survey to ascertain how various laboratories are 
actually triaging AML cases as well as the types of testing that laboratories are 
offering in the work-up of AML. Methods: A 23-question survey was distributed via 
pathology listservs and alumni email lists to canvas a large number of laboratories 
across the country. Responses were recorded. Results: From 60 responses, 40% 
were from academic institutions, 23% from hospital based private practice, 22% 
hospital based/employed by hospital and 12% from reference laboratories. 42% 
conducted the majority of molecular testing "in-house," 37% only performed common 
molecular tests "in-house" and 17% sent out all molecular testing. 29% ordered 
molecular testing on all new AML cases without waiting for cytogenetic results. 
Another 29% had a method of banking specimens to order tests at a later date. 25% 
did not routinely order molecular testing on AML cases unless explicitly ordered by 
the clinician. Among those who waited for cytogenetic results, 36% isolated and held 
DNA or RNA, 13% saved the cytogenetic cell pellet, 9% held the bone marrow 
aspirate tubes, and 18% didn’t have any system in place, whereas 11% sent marrow 
specimens to a reference lab who dealt with these matters. Although 39% of 
laboratories owned a next generation sequence (NGS) platform, only 7% currently 
offered NGS tests in their clinical testing menu. Conclusions: Despite current 
recommendations, a significant proportion of laboratories are ordering molecular 
tests on all AML cases before cytogenetic test results are complete, possibly to avoid 
the hassles of banking and following up on cytogenetic test results. An equal 
proportion, however, have established reliable methods for banking that may prove 
useful in the future when new mutations are discovered. Interestingly, the high 
number of laboratories who own NGS systems, although not currently offering this 
method of testing in their clinical test menus, might suggest that many laboratories 
may be in research or early validation stages to offer these tests in the near future. 
The rapid advances in leukemia research require a degree of flexibility on the part of 
the laboratories to adopt new testing as needed. Thus there may be utility in 
developing banking and archiving methods of older specimens as new discoveries 
are made. 
 
H29. Molecular Profiling of Patients with Acute Myeloid Leukemia Using a 
SNaPshot Multiplex Assay 
S.R. Wheeler, M. Jagasia, S.A. Strickland, S.R. Mohan, C.L. Vnencak-Jones 
Vanderbilt University Medical Center, Nashville, TN. 
Introduction: NPM1+/FLT3-ITD- cytogenetically normal (CN) AML accounts for 
30%-45% of all CN AML and is considered a “good” risk. Current guidelines do not 
recommend allogeneic stem cell transplantation in first remission. However, not all 
NPM1+/FLT3-ITD- patients do well leading us to hypothesize that the presence of 
mutations in IDH1, IDH2, FLT3-TKD or DNMT3A could explain differences in clinical 
outcome among these patients. To provide more precise risk assessment and 
prognostic indicators to optimize AML patient management and improve clinical 
outcome, we developed an expanded AML mutation assay. The clinical utility of the 
assay was applied to a cohort of NPM1+/FLT3-ITD- patients to determine if 
additional mutations could explain differences in clinical outcomes. Methods: 
Banked DNA from 45 NPM1+/FLT3-ITD- patients with a new diagnosis of AML 
(n=32) or at relapse (n=13) was analyzed. A panel was developed to detect 51 
common recurrent point mutations associated with AML using multiplex PCR 
coupled with the SNaPshot single base extension assay. Genes interrogated include 
IDH1, IDH2, DNMT3A, FLT3-TKD, KIT, and BRAFBRAF. Data were abstracted from 
electronic medical records for previously identified risk factors (age, WBC at 
diagnosis, cytogenetics, day 14 and recovery marrow biopsy) and outcome data. 
Statistical analyses was done using SPSS version 20. Results: The cohort had a 
median age of 58 (range 19-79) and a median WBC count of 11,000/L (range 1 to 
322). Conventional cytogenetics showed a normal karyotype in 27 (60%) patients. he Journal of Molecular Diagnostics ■ jmd.amjpathol.orgSNaPshot studies showed that 22 (49%) patients harbored previously unidentified 
mutations; 13 (29%) with IDH1 (8) or IDH2 (5), 7 (16%) with DNMT3A and 2 (4%) 
with FLT3-TKD. IDH1 SNP c. 315C>T (p.G105G) was seen in 8 (18%). Although 
there was no correlation between relapse and presence of additional mutations at 
diagnosis, day 14 marrow was positive in 8/19 (42%) patients as compared to 15% 
of patients without any mutation (p=0.082). This effect was more apparent in 
samples obtained at initial diagnosis (50% vs. 6%, p=0.019). Ten patients underwent 
transplant for relapsed disease after achieving subsequent remission, 4 of whom 
have relapsed. Our sample was limited and could not identify survival differences 
among the various mutation subtypes. Conclusions: Our study demonstrates that 
49% of patients with NPM1+/FLT3-ITD- AML harbor additional mutations and have a 
higher incidence of a positive day 14 marrow biopsy. These results indicate that 
expanded molecular stratification may identify a more chemotherapy resistant subset 
of AML and provide more precise clinical risk stratification that can impact 
therapeutic decisions. 
 
H30. Assessment of Sensitivity and Specificity of Variant Calling in a 
Validation Set of AML/MPN Samples Profiled by Microdroplet PCR and Deep 
Sequencing 
D.T. Cheng1, W.J. Cheng2, T. Mitchell1, N.T. Mensah1, A. Oultache1, K. Nafa1, A. 
Syed1, A. Zehir1, M.E. Arcila1, R.L. Levine1, M.F. Berger1, C.V. Hedvat1 
1Memorial Sloan-Kettering Cancer Center, New York, NY; 2BioReference Laboratory, 
Inc., Elmwood Park, NJ. 
Introduction: Targeted sequencing of select cancer genes has gained traction in the 
clinic as a strategy for molecular diagnostic testing, and several amplicon-based 
systems have been developed for use with deep sequencing technologies. In this 
study, an 856-amplicon panel was designed for use with the Raindance DeepSeq 
system, covering most exons of 30 genes relevant to acute myeloid leukemia (AML) 
and myeloproliferative neoplasms (MPN). We developed an analysis pipeline for 
variant calling, and sought to assess its sensitivity and specificity relative to a set of 
AML/MPN samples with previously identified mutations. Methods: DNA extracted 
from blood or bone marrow samples was sheared and subjected to microdroplet 
emulsion PCR. Samples were sequenced on an Illumina MiSeq to an average depth 
of at least 500x. DNA from a Hapmap cell line was run with each pool as an 
unmatched normal control. Somatic variant calling was performed on tumor samples 
using the Hapmap normal as comparator: MuTect was used for calling point 
mutations, SomaticIndelDetector (GATK) for indels and Pindel was used to identify 
internal tandem duplication (ITD) events in FLT3. Results: 32 samples with 
previously identified mutations in JAK2, NPM1, DNMT3A, MPL, IDH1/2, CEBPA, and 
FLT3, were profiled for assay validation. Of these, 4 samples positive for JAK2 
V617F and 5 samples containing both a FLT3-ITD and a 4bp insertion in NPM1 were 
profiled in triplicate or greater, for a total of 32 replicates containing 49 known 
variants. 1,366 unfiltered variants were called, of which 56% (767) were reproducible 
across all replicates for a given sample, and 22% (452) were non-reproducible, 
singleton calls. Reproducible calls had distinctly higher variant allele depths and 
frequencies compared to singleton calls, suggesting that singleton calls were likely 
false positives. Based on these differences, filters on variant allele depth and 
frequency were selected to retain all 49 true positive variants (100% sensitivity) while 
removing all but 1 singleton call (0.2% false discovery rate). The pipeline called 5-7 
variants for each remaining sample in the validation set, each time successfully 
retrieving the associated known variant. We also uncovered previously unidentified 
mutations in some samples corresponding to well-characterized hotspot mutations in 
AML (e.g. IDH1 R132S, DNMT3A R882H). Conclusions: We have developed an 
analysis pipeline capable of calling variants from Raindance amplicon sequencing 
data with high sensitivity and specificity. Filters on variant allele depth and frequency 
derived from analysis of replicate samples enable robust identification of high-
confidence calls. 
 
H31. Practical Issues in Identifying and Communicating Incidental and 
Unexpected Findings Arising from Mutation Analysis Utilizing Next-Generation 
Sequencing for Clinical Oncology 
R. Bender, A. Ghazalpour, Z. Tan, W. Wen, D. Bender, J. Xiu, R. Feldman, G. Basu, 
Z. Gatalica 
Caris Life Sciences, Phoenix, AZ. 
Introduction: With the maturation of next-generation sequencing platforms in clinical 
diagnostics the wealth of data that is generated in a time efficient and cost effective 
manner. One consequence of generating increased amounts of clinical data is the 
detection of incidental and/or unintended findings. A key consideration for many 
clinical labs is how to report or communicate these incidental findings to the ordering 
physician. Recently the ACMG has released a set of guidelines for reporting 
incidental findings; however, this article does not meet the needs of a genetics 865
8AMP Abstractsoncology laboratory on several fronts. Therefore, it is essential to identify and adopt 
a set of standards for reporting incidental findings detected in tumor samples that 
addresses the special needs of personalized medicine in oncology. Methods: 
Mutation analysis was performed using the Truseq Amplicon Cancer Panel (Illumina) 
to determine the mutation status of select regions of 44 genes. Ordering physicians 
have the ability to order mutation analysis for single genes, a subset of 9 genes 
associated with therapy response or the full set of 44 genes for clinical trial 
associations. For all genes not reported, all mutation positive results are evaluated 
by a clinical geneticist to determine if the case merits further discussion. Mutations 
that have implications for clinical trials, potential germ line inheritance, therapeutic 
response to chemotherapy or diagnosis are flagged and discussed in a greater 
group comprised of geneticists, pathologist and literature scientists. To appropriately 
identify patients with potential germ line inheritance of a mutation we employed 
several criteria that included examining age at cancer diagnosis, allele frequency of 
the mutation and the gene that is mutated. Results: In our analysis of over 3,000 
samples that received mutation analysis by next-generation sequencing ~75% of 
cases did not report results for all 44 genes. Of those cases we identified 9 eligible 
for clinical trial enrollment, 11 of potential germ line inheritance, 5 with a diagnostic 
dilemma, and 3 with FDA approved therapy implications. Two of the cases that 
posed a diagnostic dilemma resulted in a change of diagnosis following a 
consultation with the ordering physician and pathologist. Conclusions: Establishing 
a standard procedure for dealing with incidental or unexpected findings in oncology 
will be necessary as more labs adopt next-generation sequencing platforms. Using 
our current method of identifying incidental findings ~1% of cases are flagged for 
review making this procedure tenable for high throughput oncology labs. 
 
H32. Frequency of Copy Neutral Loss of Heterozygosity Detected by High 
Density SNP Chromosomal Microarray Analysis in Hematologic Neoplasms  
E.B. McQuitty1, K. Alvarez1, S. Virani1, J.R. Cook2, F. Monzon1 
1Baylor College of Medicine, Houston, TX; 2Cleveland Clinic, Cleveland, OH. 
Introduction: Determination of chromosomal imbalances and rearrangements for 
diagnosis and risk stratification of hematologic neoplasms historically has relied on 
conventional cytogenetics and/or fluorescence in situ hybridization (FISH). 
Importantly, deletion/reduplication events that give rise to copy neutral loss of 
heterozygosity (cnLOH; also known as acquired uniparental disomy or LCSH) are 
undetectable by these methods. We examined the frequency of cnLOH in specimens 
with known or suspected hematologic malignancy by high density SNP chromosomal 
microarray analysis (CMA) over an 11-month period. Methods: DNA extracted from 
consecutive bone marrow and/or peripheral blood specimens with known or 
suspected hematologic neoplasm submitted from June 2012 to May 2013 was 
profiled using the Affymetrix Cytoscan HD Array.  We examined the frequency of 
cnLOH (>10 Mb unless involving critical genes), the genomic region(s) involved, and 
the correlation of cnLOH with specific hematologic malignancies. Results: Twenty-
three percent (52/231) of hematologic specimens had regions of cnLOH ranging in 
size from 1.08 to 115.95 Mbp (median=27.65 Mbp). The diagnosis in 51 (98%) cases 
was a myeloid neoplasm, including myeloproliferative neoplasms (MPN), 
myelodysplastic syndromes (MDS), overlap syndromes, and acute myeloid 
leukemias (AML). 3q cnLOH was identified in 6 cases (5 MDS, 1 MPN). 7q cnLOH 
was identified in 6 cases (3 MDS, 1 AML, and 2 cases concerning for myeloid 
neoplasm). 9p cnLOH involving the JAK2 gene locus was identified in 13 cases (11 
MPN, 1 MDS/MPN overlap syndrome, and 1 AML arising from a poorly characterized 
myeloid neoplasm), with 100% correlation with mutated JAK2 in all cases with known 
mutation status (8 of 8). 11q23 cnLOH involving the MLL gene locus was present in 
4 cases (1 MDS, 1 evolving myeloid neoplasm, 2 AML), including one case with 
partial tandem duplication of MLL, another finding not detectable by cytogenetics or 
FISH. Finally, 1 case of MDS post chemotherapy had cnLOH in 17p involving the 
TP53 gene suggestive of TP53 mutation with LOH. Conclusions: High density CMA 
profiling is a useful tool for evaluation of cnLOH, which was found in 23% of 
hematologic, and particulary myeloid, neoplasms in this series. This approach is an 
adjunct to conventional cytogenetics and allows the identification of chromosomal 
lesions not detectable by conventional approaches. cnLOH was identified in 
chromosomal regions that are often deleted in myeloid malignancies and some of 
these deletions are important for prognostic stratification of patients. Follow-up 
studies are necessary to determine whether cnLOH has similar prognostic value as 
deletions in these regions. 
 
 
 
 
 66H33. Development of a BRAF V600E Allele-Specific qPCR Assay for 
Langerhans Cell Histiocytosis Disease Monitoring 
S.F. Sarabia1, J.M. Jakacky2, C.R. Webb2, P.K. Lim1, T.L. Peters1, A. Shih1, C.E. 
Allen1, K.L. McClain1, M.J. Hicks1, A. Roy1, D.H. Lopez-Terrada1 
1Baylor College of Medicine, Houston, TX; 2Texas Children's Hospital, Houston, TX. 
Introduction: BRAF V600E mutations can be detected in approximately 57% of 
langerhans cell histiocytosis (LCH) lesions. The presence of circulating BRAF V600E 
cells in LCH patients with active disease has prompted this study to optimize and 
evaluate the performance of peripheral blood allele-specific qPCR assays for 
minimal residual disease monitoring in this patient population. Methods: The Qiagen 
BRAF RGQ PCR Assay and the Qiagen qBiomarker BRAF Somatic Mutation PCR 
Assay were both tested using the Roche LC 480 instrument and software. Reaction 
conditions were optimized and standard curves were generated from cell line DNA 
prepared by mixing heterozygous BRAF V600E A-375 cells with BRAF wildtype HEK 
cells. Quantitation is performed using a delta Ct method with a separate control 
assay that amplifies a non-variable region of the BRAF allele. The curves, plotted 
using mean delta Ct values against log-transformed mutant DNA concentration, 
showed a linear correlation (R2=0.99). Diagnostic sensitivity and specificity were 
assessed with buffy coat DNA specimens obtained from BRAF V600E mutation 
positive LCH patients and mutation negative non-LCH patients. Results: Our initial 
experiments demonstrated a linear response for both assays with 0.1% to 100% 
mutant A-375 cell standards. Increasing DNA input from 50 to 200 ng/reaction 
improved analytical sensitivity to 0.01% (80% detection rate) without a decrease in 
analytical specificity. Based on probit analysis with IBM SPSS Statistics software, the 
RGQ and qBiomarker assays have a similar limit of detection of ~0.06% mutant cells 
in a background of wildtype cells (95% confidence limits). Testing of 8 BRAF V600E 
mutation positive specimens demonstrated a diagnostic sensitivity of 100% and 88% 
with the RGQ and qBiomarker assays, respectively. Testing of 6 additional BRAF 
V600E mutation negative clinical specimens demonstrated a diagnostic specificity of 
100% with both assays. Conclusions: We have implemented a sensitive and 
specific allele-specific PCR assay to quantitate circulating levels of BRAF mutation 
positive Langerhans cells that may be useful to monitor in relapsed/resistant LCH. 
 
H34. Detection of EZH2 Mutations in Follicular and Diffuse Large B-Cell 
Lymphomas Using PCR Followed by High Resolution Melting Curve Analysis 
A. Mahmoud1, J.M. Gale2, M.A. Vasef1 
1University of New Mexico Health Science, Albuquerque, NM; 2University of New 
Mexico/TriCore Ref Lab, Albuquerque, NM. 
Introduction: EZH2 methyltransferase is highly expressed in germinal center-
derived B-cells and is required for formation of germinal centers. Somatic mutations 
of EZH2 gene may enhance germinal center formation and in cooperation with BCL2 
may contribute to lymphomagenesis via silencing of target genes. A recurrent gain of 
function mutation involving codon 641 of EZH2 gene has been identified in follicular 
lymphomas (FL) and diffuse large B-cell lymphomas (DLBCL) of germinal center 
(GC)origin. More recently, it has been shown that inhibition of EZH2 suppresses the 
proliferation of EZH2-mutant cell lines derived from DLBCL. There is inconsistency in 
the prevalence of reported EZH2 mutations that range from 7% to 22% in follicular 
lymphomas and 14% to 22% in DLBCL of GC-origin. In this study, we analyzed the 
incidence of EZH2 mutations on DNA extracted from several cases of germinal 
center cell lymphoma as well as activated B-cell lymphoma using PCR followed by a 
rapid high resolution melting curve analysis. Methods: Formalin-fixed paraffin 
embedded tissue blocks from 38 cases with diagnosis of non-Hodgkin lymphoma 
were retrieved from archived file of Department of Pathology at the University of New 
Mexico. The cases included 17 FL, 18 DLBCL, 1 composite DLBCL and T-cell 
lymphoma, and 2 lymphomatoid granulomatosis. Among the DLBCL cases, 11 were 
GC-derived and 7 were activated B-cell phenotype (ABC) according to the Hans 
algorithm. DNA was isolated from diagnostic paraffin blocks and was PCR amplified 
using primers flanking the codon 641 of exon 15 of the EZH2 gene. The PCR 
products were then subjected to high resolution melting curve analysis (Idaho 
Technologies). Results: High resolution melting curve analysis demonstrated an 
abnormal melting curve with a shouldering in 4 out of 38 cases including 3 out of 17 
(18%) FL cases and 1 out of 11 (9%) of GC-derived DLBCL. The Y641H mutation 
was confirmed by Sanger sequencing. Conclusions: Our results demonstrate that 
high resolution melting technology is a useful and rapid method to screen and detect 
EZH2 mutations in non-Hodgkin B-cell lymphomas. In addition, the results of our 
study confirm the prior reported higher incidence of EZH2 mutations in cases of FL. 
However, the prevalence of EZH2 mutation in GC-derived DLBCL in our study is 
lower than the one reported previously (9% versus 14% to 22%). This might be due 
to smaller number of cases in our study. Similar to prior studies, we did not identify 
EZH2 mutations in ABC type DLBCL cases. 
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 AMP AbstractsH35. DiaSorin QLAMP Amplification Technology Coupled with Liaison Iam 
Instrument as a Rapid and Reliable Diagnostic System for Detection of 
Molecular Markers Associated to Leukemias 
G.M. Amicarelli1, R. Mesturini1, E. D'Agostini1, V. Tettamanzi1, G. Rizzo1, F. Rigo1, C. 
Pultrone1, O. Spinelli2, C. Boroni2, S. Salmoiraghi2, P. Zanghì2, A. Rambaldi2, F. 
Colotta1, M. Giulia1 
1DiaSorin SpA, gerenzano, Italy; 2Ospedale Papa Giovanni XXIII, Bergamo, Italy. 
Introduction: After the initial morphologic evaluation of blood cells, the diagnostic 
work-up of leukemias contemplates the detection of molecular markers associated 
with diagnosis and risk stratification. Such information drives the therapy choice and 
impact on the patient management and outcome. RT-PCR is the method of choice, 
consisting in a laborious and long multi steps procedure.  
Methods: to overcome limitations of current RT-PCR, we have developed a novel 
isothermal molecular assay, based on the LAMP (loop-mediated amplification) 
reaction. Our assay, called RT-QLAMP, detects in a multiplex format up to two fusion 
transcripts and the mRNA of the housekeeping gene GUSB as internal control for 
validation of negative results. The reaction is performed in less than one hour 
starting directly from RNA. The analytical and clinical performances have been 
established using the Liaison Iam instrument (DiaSorin), an 8-wells instrument 
designed for retro-transcritpion and DNA amplification in one step and at constant 
temperature. The Liaison Iam monitors the fluorescent signals of amplified DNA and 
analyzes the data producing objective results. Results: We developed RT-QLAMP 
assays for the detection the following chronic and acute myeloid leukemias 
molecular markers: BCR-ABL (p190 and p210), PML-RARA (Bcr1, Bcr2 and Bcr3), 
AML1-ETO, and CBFB-MYH11 (type A and type D/E). The level of sensitivity, tested 
on serial dilutions of mutant RNA into wild type RNA, ranged from 10-5 to 10-2. The 
specificity was 100% as established on RNA from wild type cell lines (n=878) and on 
RNA from healthy donors (n=182). The RT-QLAMP assays have been validated on 
clinical samples previously diagnosed by conventional RT-PCR (n=130), obtaining 
perfect agreement. All the reactions terminate within 50 minutes and, thanks to the 
real-time signal monitoring, amplification of positive clinical samples was visible 
between 10 and 15 minutes of incubation. Conclusions: The DiaSorin RT-
QLAMP/Liaison Iam molecular system allows detecting traslocations in less than one 
hour starting from patient RNA. The assay set-up is simple and the one-step 
procedure decreases complexity and risk of errors and contaminations. The 
fluorescent format allows real-time monitoring in the Liaison Iam instrument, further 
decreasing the time-to-results. The user friendly software analyzes data returning 
objecting results, improving reliability and efficiency. All in all, the DiaSorin molecular 
system represents a novel powerful tool for timely, sensitive and efficient diagnosis 
of myeloid leukemias. 
 
H36. Multi-Gene Mutational Profiling of Acute Myeloid Leukemia Specimens 
on the Ion Personal Genome Machine in a Clinical Diagnostics Laboratory  
R. Kanagal-Shamanna, R. Singh, B.A. Barkoh, N.G. Reddy, K.P. Patel, M.J. 
Routbort, K.D. Aldape, L. Medeiros, R. Luthra  
The University of Texas MD Anderson Cancer Center, Houston, TX. 
Introduction: Multi-gene mutational profiling of acute myeloid leukemia (AML) is 
essential for diagnosis, prognostication and guiding targeted therapy. Testing the 
mutational status of each clinically actionable gene individually by conventional 
platforms such as Sanger and pyro sequencing is labor-intensive, requires high 
amount of DNA and leads to increased turn-around-time. Recently, we have shown 
(J Mol Diagn, in press) that these limitations in a clinical molecular laboratory can be 
overcome by using affordable benchtop next-generation sequencing (NGS) 
platforms, such as the Ion Torrent Personal Genome Machine (PGM) (Life 
Technologies) for solid tumors. Here, we describe successful use of PGM for 
mutational profiling of AML. Methods: Study group included 51 archival DNA 
samples isolated from bone marrow (BM) aspirates of AML patients. These cases 
were selected based on their mutational status ascertained previously by standard 
mutation detection platforms in the laboratory. Library was prepared from 10 ng of 
DNA per sample by multiplex PCR amplification of hotspots across 46 genes (Ion 
AmpliSeq cancer panel) using 191 primer-pairs. This was followed by barcode 
adapter ligation, emulsion PCR, IonSphere enrichment and sequencing on a 318 
chip on PGM. A minimum coverage of 250x with at least 10% allelic frequency was 
used as cut-off for variant calling. Results: The median BM blast count was 57% 
(range, 33-81). The median number of AQ20 alignment reads was 446,292 (range: 
303,483– 681,240). The average turn-around-time from sample receipt to result 
reporting was 4 days. All expected point mutations were identified by the PGM 
(100% concordance) in the following genes: FLT3-D835, JAK2, IDH1, KIT p.D816V, 
KRAS, MPL, NRAS, and TP53. A mutation that is not commonly interrogated in 
FLT3, p.Y842H, was also detected. Several variants in other genes, ABL1, APC, 
ATM, KDR, KIT M541L, IDH2, MET, PDGFRA, PTPN11, and RET, were identified in The Journal of Molecular Diagnostics ■ jmd.amjpathol.org42 of 51 (82%) AML cases increasing the utility of analysis. PGM Variant Caller 
software detected 2 of 8 (25%) AML cases with FLT3 internal tandem duplication 
(ITD). However, ITDs were visible in Integrated Genomic Viewer in the remaining 
cases. Conclusions: The Ion Torrent PGM is a highly useful platform for 
comprehensive detection of mutations in AML in a clinical molecular diagnostics 
laboratory. Advantages include i) requirement of small amount of DNA, making it 
feasible to use formalin-fixed paraffin embedded BM specimens when fresh BM 
aspirates are not available; ii) rapid turn-around-time; and iii) identification of 
additional potentially significant variants not commonly assessed by conventional 
platforms. 
 
H37. Correlation of BCR-ABL Transcripts with Molecular Response in 
Chronic Myeloid Leukemia of Indian Population: A Single Center Study  
A. Choughule, B. Bagayatkar, P. Amare, S. Banavali 
Tata Cancer Hospital, Mumbai, India 
Introduction: The aim of the present study was to determine whether there is any 
impact of two major mRNA transcripts (b3a2, b2a2) on clinical and hematological 
parameters at diagnosis and whether these two transcripts responded differently or 
similarly to Imatinib treatment at molecular level. Methods: Multiplex RT-PCR was 
performed in 286 cases for detection of BCR/ABL transcripts in newly diagnosed 
chronic myeloid leukemia cases from January 2010 to December 2012. 68 % were 
of b3a2 and 32% were of b2a2 transcript. We also monitored and correlated these 
transcripts in 86 patients with the nested RT-PCR, real-time qPCR using TaqMAN 
probes for the molecular response, and FISH for cytogenetic response. The real-time 
PCR machine platform used was LC 480 II.Q-RT-PCR results detected the lowest 
value up to 10 -5. Results: No correlation was found between the hemoglobin 
distribution, TLC and the type of transcripts. There was no significant association 
between the transcripts and thrombocytosis. However, we found that b2a2 was 
significantly associated with blast crisis (OR = 2.2) and with myeloid blast crisis as 
compared to b3a2 (OR = 0.4), which was associated with lymphoid blast crisis. In 
correlation with FISH data, interestingly, 5’ ABL deletion was found to be significantly 
associated with b3a2 (OR = 3.3) compared to b2a2 (OR = 0.3). Response to 
treatment:  86 patients analyzed for molecular response were analyzed at 1 year. 
45.2 % of b3a2 showed molecular remission at 1 year as compared to 43.2% of 
b3a2, but again this was not significant with a p value of 0.8. When nested RT-PCR 
was compared with real-time qPCR for MRD, nested RT-PCR was negative whereas 
real-time qPCR was detected in 42/45 (93.3 %) with a P value <0.001 %. Sensitivity 
of FISH to BCR-ABL-positive samples documented at first FU, second FU, and third 
FU were 66%, 24.8%, and 19.2%, respectively. Conclusions: Our findings indicate 
that the type of transcript does not correlate with the clinical parameters at the time 
of presentation. However, short transcript, b2a2, occurs more frequently with myeloid 
blast crisis, whereas b3a2 occurs with lymphoid blast crisis, which needs further 
evaluation of their impact on different behavior pattern of CML stem cells. And in 
contrast to the published literature we did not find any difference in treatment 
response between the two transcripts. Though FISH and real-time qPCR were found 
to be useful complimentary tool, real-time qPCR might be the most useful assay for 
MRD monitoring.  
 
H38. Clinical Significance of Acquired Copy-Neutral Loss of Heterozygosity 
in Acute Myeloid Leukemia 
C. Berube, S. McElhone, K. Kroeger, E. Estey, M. Fang 
Seattle Cancer Care Alliance, Seattle, WA. 
Introduction: Chromosomal abnormalities are important in the diagnosis and 
prognosis of patients with acute myeloid leukemia (AML). Identification of genomic 
imbalances has become more sensitive and precise with microarray techniques. In 
addition to copy number aberrations, copy neutral loss of heterozygosity (cnLOH) 
can also be detected; however, the prognostic significance is unknown. In this study, 
acquired cnLOH is investigated in AML patients and correlated with FLT3-ITD and 
NPM1 mutations, cytogenetic risk classification, and treatment response, including 
complete remission (CR) rate and CR duration, as well as overall survival (OS). 
Methods: To identify cnLOH, we performed chromosome genomic array testing 
(CGAT) on DNA from bone marrow or blood specimens of AML patients using 
Affymetrix CytoScanHD and analyzed the data with ChAS and Nexus software. G-
banding and FISH were performed on the concurrent sample whenever possible. Of 
119 AML patients analyzed, 33 demonstrated cnLOH with a filter size of 10 Mb. Only 
recurrent cnLOH events were evaluated. 
Results: The most common cnLOH is 13q seen in seven patients (21%), followed by 
1p and 11p in four patients (12%) each and 21q in three patients (9%). Seventeen of 
the 33 patients with cnLOH (52%) achieved CR; with an average CR duration > 5.4 
months. The prognosis, based on CR rate, ranked from worst to best is: 17p and 19q 
(0% CR) < 13q (27% CR) < 2q, 7q, 11p, and 11q (50% CR) < 1p, 2p, and 21q (100% 867
8AMP AbstractsCR). Of the latter, CR duration was longest in patients with 21q cnLOH (>7.7 
months), followed by 1p (>7.2 months), and 2p (1.75 months). With an average 
follow-up time of 39.5 months, the average OS time for the 33 cnLOH patients is 
18.7 months ranging from >3.5 months for 11q to >50 months for 2q and 21q. Of 
patients classified as poor or intermediate cytogenetic risk, 100% with 21q cnLOH 
achieved CR and 25% to 50% with 1p, 2p, 2q, and 7q cnLOH achieved CR. None of 
those with 19q cnLOH achieved CR despite intermediate cytogenetic risk. FLT3-ITD 
mutation is clearly associated with 13q cnLOH, seen in 100% of patients (6/6) tested. 
Presence of NPM1 mutation in 13q cnLOH cases does not appear to negate the 
poor prognosis in these cases. Conclusions: Our data shed light on the prognostic 
impact of cnLOH in AML. Treatment outcome and OS appear poor in patients with 
cnLOH of 13q, 17p and 19q and better with cnLOH of 1p and 21q.  
 
H39. Molecular and Cytogenetic Changes in Ph-Negative Yeloproliferative 
Neoplasms and Yelodysplastic/Myeloproliferative Neoplasms at Diagnosis and 
Transformation 
Y. Kim, Y. Cho, H. Chi, S. Park, S. Jang, E. Seo, C. Park 
Asan Medical Center, Seoul, Korea. 
Introduction: Progression or transformation into other malignancies may occur over 
time in patients with Ph-negative myeloproliferative neoplasm (MPN) or 
myelodysplastic/myeloproliferative neoplasm (MDS/MPN). In the recent studies, a 
certain mutations and cytogenetic abnormalities showed an independent association 
with inferior overall and leukemia-free survival in these disease entities. We 
examined clinical relevance of molecular and cytogenetic changes in MPN and 
MDS/MPN. Methods: A total of 192 patients with Ph-negative MPN (N=173) and 
MDS/MPN (N=19) were included in this study. We examined the clinical and 
laboratory data including isocitrate dehydrogenase (IDH) and SRSF2 mutation status 
and cytogenetics. Results: Among patients at presentation, 5% (6/120) of patients 
harbored IDH2 mutations affecting residue R140 and 5% (6/120) of patients 
harbored SRSF2 mutations affecting residue P95. The significant association was 
seen between the presence of these mutations and higher incidence of progression 
or transformation (P < 0.0001). In patients with MPN, these mutations were 
associated with shortened overall survival (OS) and leukemia-free survival (LFS) (P 
= 0.0001 and P < 0.0001, respectively). Of note, three patients demonstrated SRSF2 
mutations at both presentation and acute leukemic transformation, whereas IDH2 
mutation was detected either at presentation or at leukemic transformation. Among 
patients with available cytogenetic data at presentation, 19.7% (31/157) of patients 
showed cytogenetic abnormalities. In patients with MPN, patients with cytogenetic 
abnormalities (CA) showed shortened OS and LFS (P = 0.02 and P < 0.0001, 
respectively). Multivariate analysis of LFS confirmed the independent prognostic 
relevance of the CA (P=0.01, HR 5.75, CI 1.52-21.6) and the mutation (P=0.012, HR 
6.11, CI 1.5-24.88). The presence of mutation and CA did not affect the prognosis in 
patients with MDS/MPN. At the time of progression or transformation, the incidences 
of the mutation and CA were remarkably elevated (23.3% and 62.1%, respectively). 
Conclusions: The IDH2 or SRSF2 mutations and CA in MPN or MDS/MPN has the 
poor prognostic effect for both survival and the risk of disease progression. In 
addition, SRSF2 mutation at chronic phase may play a role for the prediction of 
leukemic transformation. 
 
H40. PML/RARA Fusion Resulting from a Cryptic Insertion of RARA Gene 
into PML Gene without the Reciprocal RARA/PML Fusion: Clinical, 
Cytogenetic, and Molecular Characterization and Prognosis 
V. Ortega, Y. Wang, H. Fan, C. Mendiola, G. Mohamed, K. Vadlamudi, G.V. 
Velagaleti 
University of Texas Health Science Center, San Antonio, TX. 
Introduction: The diagnostic hallmark of acute promyelocytic leukemia (APL) is the 
characteristic t(15;17) resulting in reciprocal PML/RARA and RARA/PML fusion 
genes in 95% of cases. According to WHO classification, demonstration of 
PML/RARA, or RARA gene rearrangement, is essential for diagnosis of APL. The 
PML/RARA fusion transcribed from add(15q) is reported to retain functionally critical 
oncogenic properties essential for leukemogenesis. Molecular analysis has 
demonstrated the PML/RARA fusion resulting from a variant non-reciprocal cryptic 
insertion of the RARA gene into PML gene on chromosome 15q in cases of APL with 
normal karyotypes. Due to paucity of such cases, the prognostic significance is not 
established. Methods: We report a case on a 61-year-old woman with suspicion of 
APL who presented to the ER with bruising on her body without history of trauma. 
Her peripheral blood smear showed blasts and promyelocytes with Auer rods. 
Peripheral blood and bone marrow samples were submitted to our lab for both 
cytogenetic and molecular studies. Results: The initial FISH studies on a peripheral 
blood sample showed an atypical abnormal signal pattern with 1F1O2G in 52.5% of 
the nuclei and was later confirmed on bone marrow with 42% of the nuclei showing 68the same abnormal pattern. However, the chromosome analysis showed no 
evidence of t(15;17), but trisomy 8. This discrepancy led to additional studies to 
characterize the single fusion observed on FISH. Metaphase FISH showed a non-
reciprocal translocation with the fusion signal on chromosome 15 and absence of 
fusion signal on chromosome 17. Metaphase FISH using whole chromosome paint 
15 (orange) mixed with the PML/RARA (orange/green) dual fusion probe showed 
presence of a RARA signal on chromosome 15 without the corresponding PML 
signal on chromosome 17, demonstrating an insertion. Molecular analysis by both 
qualitative reverse transcriptase-polymerase chain reaction and real-time 
quantitative-polymerase chain reaction with primers targeting the typical PML/RARA 
and RARA/PML fusions showed PML/RARA fusion transcripts with no evidence of 
the reciprocal RARA/PML fusion transcripts consistent with cytogenetics and FISH 
results. The patient was treated with ATRA therapy achieving complete remission. 
Conclusions: Our case demonstrates that absence of the t(15;17) does not rule out 
a morphological diagnosis, and demonstration of PML/RARA as the sole fusion gene 
further proves its crucial role as facilitator of leukogenesis in APL. Although such 
cryptic insertions leading to a PML/RARA fusion have been previously reported, we 
show for the first time, such variant insertions have the same prognostic significance 
as the classical t(15;17).  
 
H41. Comparison of Quantitative BCR-ABL1 PCR Testing Results on Paired 
Peripheral Blood/Bone Marrow Aspirate Specimens 
P. Szankasi1, D.S. Anderson1, T.W. Kelley2 
1ARUP Laboratories, Salt Lake City, UT; 2University of Utah, Salt Lake City, UT. 
Introduction: The introduction of tyrosine kinase inhibitors (TKIs) has transformed 
chronic myelogenous leukemia (CML) into a manageable disease. However, a 
subset of patients will be refractory to TKI therapy or will develop resistance over 
time. Serial monitoring of BCR-ABL1 transcript levels by quantitative RT-PCR (RT-
qPCR) is therefore essential. It is usually assumed the results derived from blood 
and bone marrow are interchangeable, essentially yielding the same values. 
However, the few prior studies that exist indicate that there may be subtle 
differences. To this end we compared BCR-ABL1 qPCR results obtained from paired 
patient peripheral blood and bone marrow specimens in a series of CML patients. 
Methods: Quantitative testing of BCR-ABL1 (p210) mRNA levels was performed as 
follows: Total RNA was prepared from peripheral blood or bone marrow aspirate-
derived white blood cells and converted into random-primed cDNA. Real-time PCR 
was then performed using the Ipsogen BCR-ABL Mbcr Kit (Qiagen). BCR-ABL1 
mRNA levels are expressed as a normalized copy number on the international scale 
(IS). For this study we compared the results obtained on 36 paired peripheral blood 
and bone marrow aspirate specimens from the same patients and collected at the 
same time (within 1 week of each other). Results: Overall there was good 
agreement between quantitative BCR-ABL1 values obtained from the two specimen 
types (R2=0.8984). Over 80% of the values from the specimen pairs were within 5-
fold of each other. Among all specimens there was a slight bias towards higher 
values in bone marrow aspirate specimens. Interestingly this effect was more 
pronounced among high BCR-ABL1 burden specimens (>1% on the IS) with 75% of 
the bone marrow aspirate specimens yielding a higher BCR-ABL1 value (average 
2.4-fold). No bias was observed in specimen pairs with a low BCR-ABL1 burden 
(<1% on the IS). Conclusions: We compared quantitative BCR-ABL1 (p210) data 
from matched peripheral blood and bone marrow aspirate specimens collected within 
one week. There was overall good agreement between the specimen types. 
However, a distinct bias was observed at high tumor burden with bone marrow 
aspirate specimens demonstrating higher values. The reasons for this are unclear. 
We conclude that the lack of bias at RT-qPCR values typically seen in patients 
undergoing treatment (<1% IS) indicates that peripheral blood could be substituted 
for bone marrow for ongoing monitoring. 
 
H42. A Comparison of PCR Primer Sets for Enrichment of TRG 
Rearrangements for Next-Generation Sequencing of the T Cell Gamma 
Repertoire  
J.A. Schumacher1, P. Szankasi1, T.W. Kelley2 
1ARUP Laboratories, Salt Lake CIty, UT; 2University of Utah, Salt Lake CIty, UT. 
Introduction: T cell receptor gamma (TRG, formerly TCRG)-based clonality testing 
can be an important component of the workup of T cell lymphoproliferative disorders. 
Recently, next-generation sequencing (NGS) clonality assays have been developed 
and have the advantage of increased sensitivity and specificity.  However, the 
optimum methods have not been established.  We compared the results obtained 
from NGS analysis using two commonly used TRG consensus primer sets for 
amplification of TRG rearrangements prior to sequencing, one of which generates 
amplicons over a range of distributions and the other that generates amplicons over 
a single size distribution. Methods: Nine samples (PB=6, BM=2, FFPE=1) that were jmd.amjpathol.org ■ The Journal of Molecular Diagnostics
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in this study. The TRG repertoire was amplified from genomic DNA using the 
Biomed-2 strategy (Van Dongen et al 2003) and using a highly multiplexed PCR 
method by Greiner et al. (2002). NGS libraries were sequenced on the Ion Torrent 
platform. Sequence data were analyzed by in-house developed software. Results: 
The analysis focused on the 10 most frequent TRG rearrangements identified by 
NGS. The top most frequent rearrangement was identical in 5 of 9 cases. In these 
cases, the frequency of this rearrangement varied by up to 2.8-fold between primer 
sets. In 8 of 9 cases the top 2 rearrangements were identical but in 3 of these cases 
were not in the same 1-2 order. In all 9 cases at least 50% of the top 10 
rearrangements identified were identical though, again, not always in the same 
order. The average total numbers of reads obtained were similar (70,698 vs 88,487). 
The average numbers of unique rearrangements were 4,648 (BIOMED-2) and 7,972 
(primers published by Greiner et al 2002). Conclusions: Our study demonstrates 
that both PCR strategies yield similar but not identical sequencing results. The 
choice of PCR primer sets does influence the data obtained by NGS analysis of the 
TRG repertoire. Additional studies are underway to further evaluate the influence of 
PCR on TRG sequencing and to determine which method yields superior results. 
 
H43. Application of Next-Generation Sequencing to Myeloid Malignancies 
Y. Sun, Z. Liu 
Histopathology Services, Ramsey, NJ. 
Introduction: Massively parallel next-generation sequencing provides a method to 
identify genetic variations in the patients with myeloid malignancies. It allows us to 
detect mutations in a single-base resolution, and facilitate the clinical diagnosis and 
prognosis. A detailed knowledge of mutations may also help to optimize the 
therapeutic plan. We developed a sensitive next-generation deep-sequencing assay 
for routine clinical. Methods: A total of 34 genes with relevance in myeloid 
malignancies providing both favorable and adverse molecular prognostic information 
were chosen: ABL1, ASXL1, BRAF, CBL, CDKN2A, CEBPA, CREBBP, CSF1R, 
DNMT3A, ETV6, EZH2, FBXW7, FLT3, HRAS, IDH1, IDH2, JAK3, KIT, KRAS, 
NORCH1, NPM1, NRAS, PDGFRA, PHF6, PTEN, RUNX1, SF3B1, SRSF2, TET2, 
TP53, U2AF1, and WT1. Targets of interest comprised either complete coding gene 
regions or hotspots. In summary, 409 amplicons were designed with a range of 125 
to 225 base pair long, representing a total target sequence of 44.6 kb. The coverage 
for the target area is 98.96%. DNA was extracted either from blood (48 cases) or 
bone marrow (12 cases) specimens. The sequencing library was amplified with 
starting of 20ng of genomic DNA per patient using AmpliSeq library kit. The 
Sequences were generated using the Ion PGM (Life Technologies, CA). The data 
were analyzed by using the IGV (v2.2). The median coverage for each site is 1266 
reads (range 830 to 3800). Novel variants were verified using direct capillary Sanger 
sequencing or CAST PCR. The sensitivity cut off for this test was 5%. In total, 60 
clinically well-annotated patients harboring myeloid malignancies were analyzed 
during the evaluation phase. These included 27 acute myeloid leukemia (AML) or 
myelodysplastic syndrome (MDS), and 33 mixed phenotype cases. The median age 
was 59 years. Results: Twenty-six mutations in 10 of 34 genes were detected in 
17/60 patients with a range of 1 to 3 mutations per case. The mutations were 
detected with genes of TET2, SF3B1, MPL, KRAS, NRAS, BRAF, TP53, NPM1, 
FLT3, KIT, JAK2, and MPL. In this cohort, the most frequently mutated genes were 
KRAS, KIT, TP53, and BRAF. The mutation types comprised missense, duplications, 
deletions, insertions, and insertion/deletions alterations. Conclusions: We here 
demonstrated that the 34 gene panel we developed is able to detect myeloid 
malignancies in a routine diagnostic environment. The NGS data have changed the 
landscape of molecular mutations in AML and MDS, which provides the potential to 
screen for prognostically relevant mutations in a fast and comprehensive way 
providing actionable information suitable to guide therapy. 
 
H44. Detecting Clinically Actionable Mutations in Leukemia Using a Novel 
Targeted Next-Generation Sequencing Panel 
F. Chang, L. Liu, E. Fang, G. Zhang, Y. Li, M.M. Li 
Baylor College of Medicine, Houston, TX. 
Introduction: Cancer gene mutations play important roles in the initiation and 
development of leukemia. These mutations can be biomarkers for disease diagnosis, 
prognosis, and for therapeutic selections. We studied 30 leukemia samples using a 
custom designed targeted next-generation sequencing (NGS) Panel and evaluated 
the efficacy and the clinical utility of the panel for personalized cancer care. 
Methods: Thirty leukemia samples were studied using the NGS mutation panel. The 
panel interrogates over 3,200 leukemia-associated mutations, including many 
clinically actionable mutations, in 48 cancer genes using multiplex PCR followed by 
ion semiconductor deep sequencing technologies. Two hundred eighty-seven 
amplicons were designed to cover 25.18 kb of genomic regions with an average The Journal of Molecular Diagnostics ■ jmd.amjpathol.orgamplicon size of 203 bp. Sequence results were analyzed using commercially 
available software. All variant calls were curated using home-brew software. 
Results: The average depth of coverage for targeted regions in this study is 
approximately 3000x and the mean 100x coverage of targeted mutations is 97.07%. 
A total of 51 variants involving 18 cancer genes in 24 of 30 leukemia samples (80%) 
were identified. These variants include 42 COSMIC listed mutations in 21 cases, 7 
novel variants in 3 cases, and 2 known rare SNPs in two cases. Nineteen variants 
are classified as benign based on the variant allele frequencies in the samples and 
the minor allele frequencies reported in general population. The remaining 32 
variants are classified as pathogenic or likely pathogenic mutations. TP53 gene is 
the most frequently mutated gene with 11 mutations in 9 patients. Other mutations 
are found in TET2, JAK3, NPM1, KRAS, IDH1, IDH2, SRSF2, CSF1R, DNMT3A, 
FBXW7, U2AF1, etc. All mutations identified were confirmed by second technology, 
such as Sanger sequencing. Conclusions: The targeted leukemia NGS panel can 
effectively detect mutations in the leukemia genome and provide important genomic 
information for disease diagnosis and differentiation, patient risk stratification, and 
treatment regimen selection. In addition, these mutations can be used as 
personalized biomarkers for monitoring patient response to treatments and minimal 
residual diseases. The turn around time of the test is as short as 3 to 5 days, which 
fits the needs of personalized oncology. Samples can be multiplexed using bar-
coding, which leads to tremendous increase of sequencing efficiency and decrease 
of cost while maintaining the high quality of sequencing results. 
 
H45. RNA in Situ Hybridization Demonstrates Overexpression of the 
Chemokine Receptor Gene, CCR8, by Peripheral T-cell Lymphomas with 
DUSP22-IRF4 Translocations 
X. Xing1, T.J. Flotte1, M.E. Law1, A.J. Blahnik1, W. Chng2, G. Huang2, J.C. Porcher1, 
S.M. Ansell1, A. Dogan1, A.L. Feldman1 
1Mayo Clinic, Rochester, MN; 2National University Cancer Institute of Singapore, 
Singapore. 
Introduction: We have used next-generation sequencing to discover recurrent 
translocations involving DUSP22-IRF4 on 6p25.3 in a subset of peripheral T-cell 
lymphomas (PTCLs), particularly those arising at cutaneous sites. Gene expression 
profiling suggested increased expression of the skin-homing chemokine receptor 
gene, CCR8, in samples from these PTCLs; however, these studies could not 
determine whether CCR8 was derived from the neoplastic cells or the 
microenvironment. Methods: CCR8 expression was measured by quantitative real-
time PCR (qPCR) in RNA extracted from frozen PTCLs and normalized to GAPDH 
expression. For in situ hybridization (ISH), paraffin tissue sections were hybridized 
with RNA probes (RNAscope; Advanced Cell Diagnostics, Hayward, CA) for CCR8, 
UBC (ubiquitin C), or dapB (negative control) at 40°C for 2 hours and visualized 
using RNAscope 2.0 Brown Reagent Kit. Cases were scored by two microscopists. 
Slides also were digitally scanned and digital image analysis (DIA) was performed on 
areas with >80% UBC-positive tumor cells using an algorithm for threshold detection 
followed by calculation of the percentage of total area thresholded. Results were 
analyzed using Student’s t test or Pearson’s correlation. Results: By qPCR, mean 
CCR8 expression was 8.5-fold higher in PTCLs with DUSP22-IRF4 translocations 
than in those without translocations (p=0.004; n=27), and correlated with previous 
gene expression array data (r=0.72; p=0.0002; n=22). In a blinded pilot analysis of 
12 cases analyzed by ISH, visually assessed CCR8 scores correlated with DIA 
values based on either CCR8 alone (r=0.70; p=0.011) or CCR8 normalized for UBC 
(r=0.71; p=0.001), and CCR8 values alone were used subsequently. Morphologic 
evaluation confirmed that most CCR8 staining was localized to tumor cells. We then 
analyzed CCR8 by DIA in 43 PTCLs (18 cases with and 25 cases without DUSP22-
IRF4 translocations). Mean CCR8 values (± S.D.) for PTCLs with and without 
translocations were 7.6 ± 7.8 and 2.6 ± 3.3, respectively (p=0.007). This finding was 
related specifically to the presence of the translocation and not to anatomic site 
alone, as CCR8 values were not significantly different in cutaneous and non-
cutaneous cases (5.0 ± 6.3 and 4.5 ± 6.2, respectively, p=NS). Conclusions: 
PTCLs with translocations of the DUSP22-IRF4 locus overexpress the skin-homing 
chemokine receptor gene, CCR8. This expression is almost exclusively localized to 
the neoplastic T cells, and may contribute to the observation that PTCLs with these 
translocations present disproportionately in cutaneous sites. The recent development 
of small molecule CCR8 antagonists that target T cells in inflammatory diseases 
might have a therapeutic role in these tumors. 
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AMP AbstractsH46. Acute Promyelocytic Leukemia (APL): Molecular Characterization by 
miRNA Expression Profiling, Deregulation of miRNAs May Identify Patients at 
Risk of Early Death 
R. Kolhe1, A. Rojiani1, A. Chaubey2, B. DuPont1, A. Jillela1, V. Kota1 
1Georgia Regents University, Augusta, GA; 2GHSU, Augusta, GA. 
Introduction: APL is a highly curable malignancy but cancer registry based data 
show that despite aggressive care 30% of patients die in the first month. 
Understanding the biology of the disease may help us identify the reasons for poor 
outcomes and allow for improving care. Recently, a class of noncoding RNAs called 
miRNAs has emerged as critical gene regulators in cell growth, disease, and 
development. Our study investigates the differences in expression of miRNAs in APL 
patients with early mortality. Methods: The miRNA expression profiles of surviving 
(n=7) vs dead (n=6) patients were evaluated using the Affeymetrix miRNA 
microarray platform on GeneChip miRNA 3.0 array in paraffin-embedded samples. 
Following hybridization and data acquisition, we used Partek Genomics Suite 
software for RMA normalization and to determine statistically significant differences 
in miRNA expression between experimental groups by ANOVA and pairwise 
comparisons (two-sided Į=0.05). Results: The miRNA expression profiles of dead 
vs alive patients shows statistically significant (1.5x to 14x, P<0.05) downregulation 
of a set of 30 miRNAs and upregulation of 6 miRNAs (P<0.05). Although the role of 
these miRNAs has not been studied in APL, they have been described in other 
tumors having a role in tumor suppression, differentiation, cell proliferation, 
chemoresistance and inflammation. miRNA-100 plays a key role in the myeloid 
differentiation & was among the highest miRNAs that were downregulated in our 
dead patients (14x). Conclusions: To the best of our knowledge, this study 
represents the first miRNA profiling exploration in understanding the early death in 
APL patients. Previous studies showed that miR-100 regulates G1/S transition and 
S-phase entry and blocks the terminal differentiation by targeting RBSP3 (a 
phosphatase-like tumor Suppressor).Other tumor cell lines have shown that a down 
regulation in miR-100 imparts chemotherapy resistance. Combined with down 
regulation in miR-27a (3.5x), which has been shown to impart chemoresistance in 
APL cell lines and dysregulation of miR 30c (down 5x) and miR-663 (up 2.3x) we 
predict that they have lower response to treatment. Reduction in tumor suppressor 
function is another way that tumors can be aggressive. Multiple miRNAs with tumor 
suppressive role were down regulated in dead patients. miRs 100, 125b, 150 (down 
14x, 10x, and 9x, respectively) have been shown to have tumor suppressive function 
although in non-APL studies. We hypothesize that this dysregulation of microRNAs 
leads to a sustained proinflammatory state and also might impart some decreased 
sensitivity to treatments that eventually leads to the poor outcomes. 
 
H47. Analytical Verification of the ICEPlex DLBCL Assay  
J. Nolling1, A. Collie2, J. Lin2, B. Hill2, E. Manilich2, E. Hsi2, L. Kong1 
1PrimeraDx, Mansfield, MA; 2Cleveland Clinic, Cleveland, OH. 
Introduction: Molecular profiling of diffuse large B-cell lymphoma (DLBCL) has 
emerged as an important prognostic tool for affected patients. We have recently 
developed a novel multiplex gene expression profiling assay on the automated 
ICEPlex System that allows differentiation between germinal center B cell-like (GCB) 
and activated B cell-like (ABC) subtypes of DLBCL from formalin-fixed, paraffin-
embedded (FFPE) specimens. Here we present data on the analytical verification of 
the ICEPlex DLBCL Assay. Methods: The 20-plex ICEPlex DLBCL Assay quantifies 
the expression of 17 genes previously implicated in DLBCL subtyping (Wright et al. 
2003). Normalized values were used to calculate a subtyping score (S-score) using 
the Wright classifier (Lossos et al. 2004). A quality score (Q-score) was introduced to 
assess the quality of assay results. RNA for the analytical verification study was 
isolated from two cells lines, SUDHL6 (GCB) and OCI-LY3 (ABC), and from two 
clinical DLBCL FFPE specimens of the ABC and GCB subtype, respectively. Limit of 
blank, dynamic range and PCR efficiencies for individual targets were assessed. 
Limit of quantification was determined for the assay as a whole using serial dilutions 
of RNA. Assay precision was evaluated under various operating conditions, including 
ICEPlex instrument, template input level, reagent lot and operator. Relative 
quantification of target gene expression was achieved by normalization to two 
reference genes. Results: Multiplex assay performance showed similar PCR 
efficiencies for all targets. The assay demonstrated a linear dynamic range over 3 
logs of input, from 100 ng to 1 ng of cell line and FFPE-extracted RNA. The assay 
was shown to generate consistent scores for tumor subtyping. Based on the results 
of assay precision, less than a two-fold change in expression levels can be 
discriminated. Introduction of Q-scores cut-off values proved valuable in assessment 
of validity of assay outputs. Conclusions: The analytical studies have demonstrated 
the robust and consistent performance of this 20-plex expression profiling ICEPlex 
DLBCL Assay that allows reliable classification of DLBCL FFPE specimens into GCB 
or ABC subtypes. The assay will be further challenged on a clinical validation set of 0DLBCL patients treated with immunochemotherapy. This assay has the potential to 
provide rapid and accurate subclassification and prognostic information in DLBCL. 
This work has been supported by NCI-IMAT grant 1R33CA160011-01A1. 
*ICEPlex and the assay are for Research Use Only. Not for clinical diagnostic use. 
 
H48. Copy Number Aberrations are Significantly Increased in High-Risk, 
Untreated CLL Patients with Chromosome 17p Deletion and TP53 Mutation 
A. Stone1, W. Carter1, L. Frederick2, C.S. Zent2, D.S. Viswanatha2, S.A. Schichman1 
1Central Arkansas Veterans Healthcare System, Little Rock, AR; 2Mayo Clinic, 
Rochester, MN. 
Introduction: In chronic lymphocytic leukemia (CLL), deletion of chromosome 17p13 
(17p-), detected by fluorescence in situ hybridization (FISH), and TP53 mutation are 
associated with unfavorable prognosis, chemoresistance, and short median survival. 
CLL patients previously characterized by FISH were analyzed with SNP-based 
whole genome copy number arrays to fully characterize copy number aberrations 
(CNAs) in the CLL genome. Methods: Copy number analysis and TP53 sequencing 
were performed on 24 early-intermediate stage, untreated CLL patients with high risk 
for disease progression based on molecular and immunophenotypic markers. CLL 
cells and normal cells were separated from patient peripheral blood by 
immunomagnetic beads. Copy number analysis was performed on purified genomic 
DNA from CLL and normal cells for each patient to distinguish acquired copy number 
changes in malignant cells from polymorphic copy number variants in the human 
genome. The Illumina human 660w-quad beadchip, a SNP-based microarray, was 
used for copy number analysis. Data were analyzed by GenomeStudio and 
cnvPartition. TP53 mutation analysis was performed by dideoxy sequencing of PCR 
products amplified from TP53 exons 4 to 9. Results: A total of 86 CLL-specific CNAs 
were identified among the 24 patients. Deletion of 17p was detected by copy number 
analysis in 6 out of 24 (25%) patients concordant with the FISH results. CLL patients 
with 17p- had numerous acquired CNAs located on chromosomes 1, 2, 3, 4, 9, 10, 
13, 15, 18, and 20, including hemizygous and homozygous deletions, duplications, 
and uniparental disomy. All 17p deletions included the region of TP53. Five out of 
the 6 patients with 17p- had mutated TP53 on the remaining allele. No TP53 
mutations were identified among patients without evidence of 17p-. Patients with 
17p- and TP53 mutation (n=5) had significantly more CNAs per patient (7.4 vs 2.6, 
p=0.003) compared to all other patients (n=19). In the 17p- and TP53 mutation 
group, deletions were more numerous than gains, with a mean of 6.4 losses versus 
0.8 gains per patient. Conclusions: Early-intermediate stage, untreated CLL 
patients with 17p deletion and TP53 mutation have a high number of acquired CNA 
events indicative of genomic instability and inferior prognosis. Numerous acquired 
CNAs in 17p- patients were observed on SNP arrays that were not detected by a 
conventional FISH panel. SNP arrays and TP53 screening are useful tools for 
prognostication and management of CLL patients who require treatment for 
progressive disease. 
 
H49. Bioinformatics Software for Automated Analysis of Data from NGS IGH 
and TCR Gamma Clonality Assays 
M.R. Klass1, T. Fodrie2, Y. Huang1, J. Miller1, H. You1, J. Panning1 
1Invivoscribe, Inc., San Diego, CA; 2LabPMM, San Diego, CA. 
Introduction: Massively parallel sequencing (MPS) assays generate large amounts 
of data, and analyses and interpretation generally require specialized software. The 
efficient, timely handling and analysis of these data remains a significant challenge 
for many laboratories. PCR-based clonality assays used to detect clonal 
rearrangements of the antigen receptor genes are routinely used to assist in 
diagnostic assessment of lymphoproliferative disease. Currently, capillary 
electrophoresis instruments are most widely used for resolving and interpreting the 
amplicon products generated using these assays. However, next-generation 
sequencing assays, such as the LymphoTrack DeepSeq Assays for TCRG and IGH, 
developed for the Illumina MiSeq and HiSeq platforms, provide more extensive and 
granular data outputs. These assays identify clonal V-J rearrangements, associated 
DNA sequences, and frequency distribution of V region and J region segment 
utilization. To facilitate the interpretation, analysis, and monitoring of data we 
developed software to process the data generated from the LymphoTrack DeepSeq 
TCRG and IGH Assays. Methods: The bioinformatics data analysis software 
package uses Invivoscribe's proprietary primer sequences and nucleotide sequence 
database as inputs to analyze LymphoTrack DeepSeq Assay data generated from 
MiSeq (fastq format). Using a standard computer with an Intel Core 2 Duo processor, 
a 40 GB hard drive, 2 GB RAM, Windows XP or 7, and Microsoft Office Excel 2007, 
this bioinformatics software generated complete outputs in approximately 8 minutes 
per 1 million reads (10 million reads approximately 80 minutes). As many as 24 
samples were analyzed simultaneously to generate csv files. The visualization 
component uses Microsoft Excel to present the resulting data analysis in a visual jmd.amjpathol.org ■ The Journal of Molecular Diagnostics
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Analyzed data confirmed that the DNA sequences from clonal cell lines match 
published sequences. Good linearity of sequence frequencies was obtained when 
clonal cell line DNA was serial diluted into tonsil or peripheral blood DNA. 
Visualization provided an accurate and reproducible representation of the data. 
Software was appropriately validated to quantify the sequence frequencies and 
corresponding identities. Conclusions: Software output demonstrated an accurate 
representation of the DNA sequence frequency distribution for the detection and 
monitoring of gene rearrangements and a visualization of the resulting analysis to aid 
in interpretation and tracking. This commercially available software package provides 
fast reliable analysis and visualization output that aids in the interpretation of data 
generated from LymphoTrack DeepSeq Assays. 
 
H50. Detecting Minimal Residual Disease Using a Massively Parallel 
Sequencing TRG Assay 
M.R. Klass1, T. Fodrie2, Y. Huang1, J. Miller1, J. Panning1, J. Thornes1, H. You1 
1Invivoscribe, Inc., San Diego, CA; 2LabPMM, San Diego, CA. 
Introduction: Multiparameter flow cytometry (MFC) and allele-specific 
oligonucleotide PCR (ASO-PCR) are currently used to monitor minimal residual 
disease (MRD) in patients with hematologic malignancies. However, both test 
methods suffer from major limitations. MFC methods are “test center centric” as 
performance is subject to instrument, operator, specimen, and reagent variability. 
Even when standardized, the limit of detection (~10-4) is approximately one full log 
less sensitive than ASO-PCR methods (10-5), and well above the optimal sensitivity 
desired for clinical decision-making. ASO-PCR is labor intensive, as it requires 
patient-specific test development and validation, and recurring clones are often 
missed because they were not targeted. The recent emergence of massively parallel 
sequencing (MPS) platforms and targeted assays are revolutionizing clonality 
detection and MRD testing. Since TRG rearrangements are found in a majority of T 
cell and some B cell tumors, clone-specific TRG V-J rearrangements represent 
sensitive and patient-specific biomarkers for MRD testing. The LymphoTrack 
DeepSeq TCRG Assay and associated bioinformatics identifies clonal TRG V-J 
rearrangements as well as the associated V-J region DNA sequences. The 
sequence information facilitates testing and subsequent tracking and monitoring of 
clonal populations. Methods: Clonal cell line DNA was serially diluted into peripheral 
blood DNA in the range of 1.0% to 0.00001% (10-2 to 10-7). Dilutions and controls 
were amplified using the LymphoTrack DeepSeq TCRG Assay. Amplicons were 
purified, quantified, and pooled into a library. 20 pM of the quantified library was 
loaded onto the MiSeq and sequenced using the MiSeq v2 Reagent kit (300 cycles). 
Data were analyzed with LymphoTrack DeepSeq Data Analysis and Visualization 
software run on a Windows platform. Outputs included clonal frequencies, specific V-
J DNA sequences, and V-J gene usage. Results: This assay identified clonality with 
associated DNA sequences of TRG V-J gene rearrangements with a linear response 
in clonal detection and minimum limit of detection of 10-6, which was dependent on 
Poisson sampling, not assay performance. Replicate testing of a 10-6 dilution of 
clonal cell line DNA diluted into peripheral blood DNA generated 10,323,848 total 
reads, identifying 35 clone-specific sequences. Conclusions: The LymphoTrack 
DeepSeq TCRG Assay with associated bioinformatics software run on the MiSeq 
platform reliably detects TRG clonal populations and identifies V-J sequence 
information required to track clones in subsequent samples. The minimum limit of 
detection is 1 in 106. When coupled with the bioinformatics and visualization 
software this MPS assay can provide robust detection and sensitivity. 
 
H51. Comparison of Two Non-BIOMED ASR Multiplex Assays for Assessing 
T-cell Clonality: Invivoscribe’s ASR TCRG V(1-8,9)J - 6FAM + TCRG V(1-8)J - 
HEX and TCRG V(2-5,8-11)J1+2+P - 6FAM 
S.W. Burkholder1, C. Gentile2, C.D. Watt2, T.B. Edmonston1 
1Cooper University Hospital, Camden, NJ; 2Hospital of the University of 
Pennsylvania, Philadelphia, PA. 
Introduction: T-cell receptor gamma (TRG) gene rearrangement studies by PCR 
are commonly used for the identification of clonal T-cell populations in samples 
suggestive of T-cell malignancies. However, canonical TRG gene rearrangements, 
clonal T-cell populations that are not malignant and false negative results can make 
the interpretation challenging. We compared two multiplexed non-BIOMED 
Invivoscribe (IVS) ASR assays TCRG V(1-8,9)J - 6FAM + TCRG V(1-8)J - HEX 
(“1.0”) and the more recently developed TCRG V(2-5,8-11)J1+2+P - 6FAM (“2.0”). 
The goal was to compare two commercially available assays for performance 
characteristics as well as ease of use and interpretation. Methods: Fifty-one clinical 
samples with and without clonal TRG gene rearrangements from a variety of sources 
including peripheral blood, bone marrow aspirates, paraffin-embedded tissue and 
extracted genomic DNA were evaluated with both the IVS “1.0” and the IVS “2.0” he Journal of Molecular Diagnostics ■ jmd.amjpathol.orgassays using 2.5 L of DNA irrespective of the concentration. Amplicons were 
analyzed by capillary electrophoresis on the ABI3130 and interpreted according to 
common criteria. TRG clonality results were compared to clinical data, flow cytometry 
and results from other laboratories using their lab-developed tests for TRG gene 
rearrangement. Analytical sensitivity was evaluated using two commercially available 
clonal samples; multiple dilutions and concentrations of clonal DNA were tested. 
Results: The analytical sensitivity for both clonal controls in each assay was 5%. 
The IVS “1.0” had higher clinical sensitivity and negative predictive value (NPV) 
whereas the IVS “2.0” assay had higher specificity and positive predictive value 
(PPV). It is of note that the IVS “1.0” assay consists of 2 master mixes with 2 
polyclonal distribution sets each, with size ranges between 55 and 270bp, whereas 
the “2.0” assay has one polyclonal distribution with a size range of 159 to 207bp. 
Conclusions: Both IVS assays are technically reliable and reproducible with an 
analytical sensitivity of about 5%. The IVS “2.0” assay is easier to interpret and 
perform as there is only one master mix with only one polyclonal distribution. As 
expected for an antigen receptor gene rearrangement assay, there is no single 
method with optimal clinical sensitivity and specificity. The decision of which assay to 
use clinically depends on whether higher specificity and PPV or higher sensitivity 
and NPV is desired. Regardless, interpretation of the assay has to be in the context 
of other clinical and pathologic findings. 
 
H52. Implementation of a Hematologic Malignancy Testing Algorithm 
Decreases Inappropriate Molecular Test Utilization  
A.M. Behlmann1, T.M. Cox2, G.L. Uy2, J.E. Payton2, C.M. Lockwood2 
1Barnes Jewish Hospital, Saint Louis, MO; 2Washington University, Saint Louis, MO. 
Introduction: In molecular diagnostics, appropriate utilization is particularly 
challenging given the rapidly growing volume and sheer cost of molecular testing. 
Nevertheless, in certain hematologic malignancies, molecular testing is integral to 
diagnostic work-up and disease monitoring. In collaboration with the medical 
oncology team, we developed a hematologic malignancy testing algorithm (HMTA) 
that determined the appropriate molecular test(s) for each specimen received for 
HMT. Here we report the changes incorporated in triaging specimens, the impact on 
lab workflow, and the ultimate effect on test volume in a 4-month period before and 
after implementation. Methods: An HMTA was developed through collaborative 
discussion between hematologic oncology and laboratory medicine that 
encompassed all major diagnostic categories of hematologic malignancy, including 
AML, ALL, MPN, MDS, B- and T-cell lymphomas. Importantly, the HMTA is based on 
ELN/NCCN guidelines and includes separate testing plans for diagnostic work-up 
and disease monitoring. The algorithm was implemented in August 2012. For each 
case, the molecular pathology fellow/resident used the HMTA to determine what 
molecular testing was indicated based on the hematopathologic diagnosis, 
cytogenetic findings, and clinical history. Laboratory policies and procedures were 
modified to accommodate these changes, including extracting and holding nucleic 
acids to prevent degradation of specimens when necessary. Results: Three 
hundred twenty-five hematologic malignancy cases sent for molecular testing were 
prospectively logged over 125 days. After application of HMTA criteria, it was 
determined that no further testing was indicated in 60% of cases (195/325). Ninety 
JAK2, 24 FLT3, 22 NPM1, 4 CEBPA, 8 KIT, 9 PML-RARA, and 4 CBFB tests were 
ordered. Review of testing for the same time period (125 days) 1 year prior to HMTA 
implementation demonstrated a 21% decrease in JAK2 testing, 73% reduction in 
FLT3 testing, 74% fewer NPM1 tests, and a 7% decrease in PML-RARA testing. No 
CEBPA, KIT, or quantitative CBFB/MYH11 testing was performed prior to 
implementation. Approximately 10% of specimens required nucleic acid extraction 
and holding prior to determination of appropriate testing. Conclusions: 
Implementation of a screening HMTA can significantly reduce unwarranted testing 
while identifying tests indicated for appropriate patient care. For example, CEBPA, 
KIT, and CBFB-MYH11 testing, while important, are only relevant in a limited context 
and may be missed. In addition, HMTA implementation can result in a potential cost 
savings of $38,500 over a 125 day period on FLT3 and JAK2 testing alone, which 
highlights the need for directed and efficient utilization of molecular testing in 
hematologic malignancy.  
 
H53. Detection of BRAF V600E Mutation in Hairy Cell Leukemia: 
Comparison of High-Sensitivity Locked Nucleic Acid-PCR Sequencing and IHC 
with the VE1 Mutation-Specific Antibody  
Y. Liu, J. Casanova, K. Nafa, J. Teruya-Feldstein, M.E. Arcila 
Memorial Sloan-Kettering Cancer Center, New York, NY. 
Introduction: The BRAF V600E mutation has emerged as an important biomarker 
for hairy cell leukemia (HCL) with immediate treatment implications. Because of the 
associated reticulin fibrosis intrinsic to this disease, tumor cells are often under-
represented in bone marrow (BM) aspirates. Testing by standard sequencing 871
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material is unsuitable for mutation analysis by molecular methods. In this study we 
assess the performance of 2 detection methods: A high sensitivity locked nucleic 
acid (LNA)-PCR sequencing assay (sensitivity of 1%) and the BRAF V600E 
mutation-specific antibody (VE1) for use in decalcified material. Methods: Eighteen 
HCL cases with available archival DNA were selected for the study (16 BM, 2 
Peripheral Blood). Decalcified corresponding BM sections were available in 14 
cases. Available flow cytometry, biopsy sections and aspirate smears were reviewed 
in all cases. Molecular testing was performed by Sanger sequencing with and 
without a locked nucleic acid probe to suppress the amplification of wild-type DNA. 
Decalcified tissue sections were stained by immunohistochemistry (IHC) with the 
BRAF V600E mutation-specific antibody, clone VE1. Results: Review of morphology 
and flow cytometry results confirmed the presence of HCL in all cases. Aspirate and 
blood sample involvement ranged from ~1% to 60%, biopsy samples from ~5% to 
90%. Based on standard Sanger sequencing, the BRAF V600E was detected in 61% 
cases (11/18). Using the higher sensitivity LNA method, the mutation detection rate 
increased to 94% (17/18). One sample was negative by both methods (60% 
involvement). By IHC, 57% (8/14) of cases showed unequivocal positivity, 29% 
(4/14) showed very weak/equivocal staining and 14% (2/14) were negative. 
Conclusions: The detection of the BRAF V600E in bone marrow and blood samples 
is often challenging when using low sensitivity assays. LNA-PCR Sanger sequencing 
is a valuable molecular testing method that allows the detection of the mutation in 
cases with very low level involvement.  IHC using the V600E mutation-specific 
antibody represents a valuable adjunct in mutation detection, which is rapid and 
allows immediate correlation with morphology and tumor content. Similar to other 
IHC studies, high variation in staining and weak/equivocal and negative results can 
be seen with decalcified material. This lowers its overall performance and sensitivity. 
Weak/equivocal and negative results should prompt confirmation by high sensitivity 
molecular methods. 
 
H54. MultiOmyx: A Novel Multiplex Methology for the Evaluation of Hodgkin 
Lymphoma  
L. Weiss1, D. Hollman2, M. Lazare2, A. Bordwell2, A.S. Ross2, B. Baravarti2, E. 
Zebadua2, P. Tripathi2, M. Li2 
1Clarient Pathology Services, Aliso Viejo, CA; 2Clarient Diagnostic Services, GE 
Healthcare, Aliso Viejo, CA. 
Introduction: The diagnosis of classical Hodgkin lymphoma is often difficult to 
establish due to the rarity of the neoplastic component and the necessity to perform 
immunostains on serial sections. We have developed a fluorescent multiplexed 
assessment of CD30-positive cells with eight additional antibodies in formalin-fixed, 
paraffin-embedded sections (MultiOmyx) that enables assessment of multiple 
antigens on a single tissue section and allows evaluation of specific cells within 
specific fields. Methods: Directly conjugated fluorescent antibodies were applied to 
a slide, followed by whole slide imaging. The dye was chemically inactivated, 
enabling a second round of staining with another fluorescent antibody. This process 
was performed multiple times on that single slide. The gray scale fluorescent images 
were transformed into virtual bright-field images that closely resembled conventional 
images, and also enabled direct comparison of antibodies within the same field. The 
antibodies used included CD30, CD15, PAX-5, CD45, CD20, CD79a, OCT-2, BOB.1, 
and CD3. The stains were analyzed for the cellular and subcellular staining 
distribution and whether any non-specific staining was present. Results: Forty 
samples were analyzed, including 34 unique specimens, of which 17 represented 
classical Hodgkin lymphoma and the rest included both reactive and lymphoma 
tissues in the differential diagnosis with Hodgkin lymphoma.  Appropriate cellular and 
subcellular localization was seen with the fluorescent MultiOmyx technology for all 
antibodies, with direct comparison of the results of one antibody with another. There 
were 5 process failures out of 360 imaging rounds for MultiOmyx vs. 2 out of 333 for 
immunohistochemistry. Concordance in specificity between the fluorescent images 
and their corresponding brightfield immunohistochemical stains was found in >97% 
of cases. Although not quantified for this assessment, the fluorescent staining 
intensities generally were similar to the immunohistochemical stains. Conclusions: 
This novel MultiOmyx technology has similar staining characteristics as standard 
immunohistochemical stains, and has the added advantage that it may be performed 
on a single section. This allows for better correlation of results between stains in a 
given case, particularly in cases with rare Hodgkin cells, since the technology allows 
direct comparison of stains within the same field of view. The MultiOmyx technology 
may be performed in small samples, in which full immunohistochemical profiles are 
not possible to obtain.   
 2H55. Development and Clinical Validation of a Targeted Next-Generation 
Sequencing Platform for the Detection of Somatic Mutations, Indels, 
Rearrangements, and Copy-Number Alterations in Human Tumors 
E.P. Garcia1, F.C. Kuo1, Y. Jia1, D. Zepf1, L. Crosby1, R. Joshi1, A.L. Manning1, M.N. 
Byrne1, J. Conneely1, J.E. Wade1, P.R. Shivdasani1, L.P. Chung1, X. Gong1, T.J. 
Pugh1, C.M. Leslin1, M.D. Ducar2, P. Van Hummelen2, L.M. Sholl1, B.J. Rollins2, N.I. 
Lindeman1, L.E. MacConaill1 
1Brigham & Women's Hospital, Boston, MA; 2Dana Farber Cancer Institute, Boston, 
MA. 
Introduction: It is currently common practice to screen for a small number of 
mutations in select cancer types however; simultaneous screening for multiple types 
of genomic alterations has not been routinely performed. Profile, a collaborative 
venture between the Dana Farber Cancer Institute and Brigham & Women’s 
Hospital, provides comprehensive infrastructure coupled with advanced technology 
platforms allowing high throughput genomic analysis. With the goal of advancing 
precision cancer medicine, we report the development and validation of a targeted 
next-generation sequencing platform offering cancer patients the option to have their 
tumor tissue scanned for multiple types of genetic alterations implicated in cancer. 
Methods: RNA baits were designed to capture exonic regions of 265 genes with 
relevance to cancer. Targets included 109 genes associated with copy number 
variations (CNVs) and 200 genes with known somatic mutations (SNVs) and small 
insertion/deletions (indels). To detect 29 rearrangements implicated in cancer, 
additional baits were designed that capture intronic sequences. DNA extracted from 
tumor samples was sheared, processed, and targeted genomic regions were hybrid 
captured in liquid phase and sequenced using an Illumina HiSeq 2500. Sequence 
data were aligned and run through several algorithms to simultaneously detect 
SNVs, indels, CNVs and rearrangements. Validation for precision, accuracy, lower 
limits of detection and minimum input DNA required was performed. Results: The 
targeted gene panel, termed OncoPanel, was validated by sequencing multiple DNA 
samples harboring known SNVs and indels (e.g., KRAS, EGFR, KIT, JAK2), CNVs 
(e.g., EGFR, ERBB2, CDN2KA) and rearrangements (e.g., ALK, BCR-ABL, PML-
RARA) previously detected by standard clinical tests. We selected a subset of 
genomic alterations in each class for technical validation that included 30 SNVs, 20 
indels, 20 CNVs and 20 rearrangements. Overall precision across SNVs, indels and 
CNVs was 98.8%. The LOD was established at a minimum of 50x coverage and 
10% allele frequency with 100% sensitivity and specificity for SNVs and indels. 
Concordance between OncoPanel and validated clinical results showed >95% 
sensitivity and specificity for SNVs, indels and CNVs. Finally, we established that 
75ng DNA starting material resulted in high quality sequence data showing 100% 
concordance with known clinical genomic variants. Conclusions: A targeted 
massively parallel sequencing platform designed to identify SNVs, indels, CNVs, and 
selected rearrangements in 265 genes implicated in tumorigenesis has been 
technically validated to show high sensitivity and specificity. This platform will provide 
invaluable genomic information for cancer patients currently in treatment within the 
BWH, DFCI and BCH cancer centers. 
 
INFECTIOUS DISEASES 
 
ID01. A Comparative Evaluation of HPV OncoTect E6 E7 mRNA and Cervista 
HPV 16/18 Tests on High-Risk HPV Samples 
M.A. Noy, J.R. Paz, A. Rosado 
Laboratorio de Patologia Dr. Noy, San Juan, PR. 
Introduction: The increasing number of high-risk Human Papilloma Virus (HPV) 
cases in Puerto Rico has made HPV screening a critical part of the Puerto Rican 
woman’s medical evaluation. Current cervical cancer screening relies on cytological 
diagnosis and HPV DNA detection. This screening method identifies women at risk 
of developing cervical cancer but fails to distinguish which low-grade lesion will 
progress. This study was designed to compare the over expression of viral 
oncoproteins E6/E7 using HPV OncoTect E6 E7 mRNA assay and the identification 
of HPV 16 or 18 using Cervista HPV 16/18 assay in high-risk HPV samples. 
Methods: Two-hundred and fifty high-risk HPV positive cervical samples were 
randomly selected from OB/GYN clinics around Puerto Rico. For clinical utility of the 
study, only negative (NEG), atypical squamous cells of undetermined significance 
(ASC-US) and low-grade (LSIL) samples were evaluated. Samples were tested by 
both methods, HPV OncoTect E6 E7 mRNA and Cervista HPV 16/18 tests. Both 
assays were performed according to manufacturer’s instructions. The HPV OncoTect 
E6 E7 mRNA method measures both the percentage of transforming cells and 
quantity of E6 E7 mRNA in each cell. It uses molecular in situ hybridization for 
detecting HPV E6 E7 mRNA in intact human cells and flow cytometry for cell-by-cell 
analysis. Cervista HPV 16/18 individually identifies and differentiates the two most jmd.amjpathol.org ■ The Journal of Molecular Diagnostics
 AMP Abstractsoncogenic and persistent high-risk HPV types, 16 and 18. It uses the Invader 
chemistry, a signal amplification method for detection of specific nucleic acid 
sequences. Results: The HPV OncoTect test detected overexpression of E6 and E7 
mRNA (>2.00%) in 61 of the 250 samples (24.4%). Based on cytology results; 27 of 
104 (25.9%) NEG, 13 of 56 (23.2%) ASC-US, and 21 of 90 (23.2%) LSIL samples 
had a positive result. The Cervista HPV 16/18 method detected positive HPV 16 or 
18 in 48 of the 250 samples (19.2%). Based on cytology results; 17 of 104 (16.3%) 
NEG, 11 of 56 (19.6%) ASC-US, and 20 of 90 (22.2%) LSIL samples had a positive 
result. Conclusions: Total agreement of both methods was 63.6%. The HPV 
OncoTect E6 E7 mRNA assay demonstrated a higher positive rate in NEG, ASC-US 
and LSIL samples. HPV OncoTect may prove to be a better screening test, since all 
high-risk types are detected. However, both tests seem complementary since HPV 
OncoTect can be used as a screening method and Cervista HPV 16/18 as a typing 
one.  
 
ID02. A Novel Deep Sequencing-Based HIV-1 Genotypic Assay to 
Simultaneously Monitor HIV-1 Coreceptor Tropism and Susceptibility to 
Maturation, Protease, Reverse Transcriptase, and Integrase Inhibitors 
C.L. Schmotzer1, R.M. Gibson1, A.M. Meyer1, D. Winner1, D.L. Robertson2, M.E. 
Quinones-Mateu1 
University Hospitals Case Medical Center, Cleveland, OH; 2University of 
Manchester, Manchester, UK. 
Introduction: There are 26 antiretroviral drugs, from six classes, approved for the 
treatment of HIV-1 infection. Thus, a combination of different phenotypic and 
genotypic tests is needed to monitor HIV-infected individuals for emerging resistance 
and to optimize drug regimens. In this study, we developed a novel HIV-1 genotypic 
assay based on deep sequencing to simultaneously assess HIV-1 susceptibility to all 
drugs targeting the three viral enzymes as well as to quantify HIV-1 coreceptor 
tropism. Methods: Baseline samples from two cohorts of antiretroviral-experienced 
patients enrolled on a maraviroc-based regimen were used to generate gag-
p2/NCp7/p1/p6/pol-PR/RT/INT and env/C2V3 PCR products. Purified amplicons 
were used to construct barcoded libraries and sequenced on the Ion Torrent 
Personal Genome Machine. Sorting, mapping, and aligning of reads were done 
using proprietary software. Reads spanning the 3’ end of Gag, PR, RT, INT, and V3 
regions were extracted, truncated, translated, and assembled for genotyping. Drug 
susceptibility was inferred using a proprietary variant caller and the HIVdb Program. 
HIV-1 coreceptor tropism was inferred using Geno2Pheno. Analytic sensitivity, 
specificity, reproducibility, and error rate were evaluated. Patient cohort results were 
compared with i) virological response to treatment, ii) genotyping based on 
population sequencing, iii) commercially available tropism assay (Trofile, 
Monogram/Labcorp) iv) tropism based on population sequencing and Geno2Pheno, 
and v) clinical response following an 8-day maraviroc monotherapy trial (MCT). 
Results: Our HIV-1 genotypic and tropism assay consistently detected both minority 
drug-resistant viruses and non-R5 variants from clinical specimens with viral loads 
1,000 copies/ml, and from B and non-B subtypes. Minority variants carrying 
mutations associated with resistance to PI, RTI, or INI were detected at different 
levels, many of which were undetected by standard population sequencing (minority 
variant level of 2.5-11.6%). Analytic threshold for minority variant detection was 
determined to be 2%. The new HIV-1 genotypic/tropism assay correlated with other 
HIV-1 tropism tests, i.e., Trofile (80%), population sequencing/Geno2Pheno (84%), 
as well as clinical response via MCT (83%) Conclusions: Our novel all-inclusive 
HIV-1 genotypic and coreceptor tropism assay, based on deep sequencing of the 
PR, RT, INT, and env C2V3 region, permits the multiplexed detection of low level 
drug-resistant and/or non-R5 viruses in up to 95 clinical samples simultaneously. 
This comprehensive test, the first of its class, could be instrumental in the 
development of new antiretroviral drugs and, more importantly, will aid in the 
treatment and management of HIV-infected individuals allowing future studies to 
evaluate the clinical significance of low-level minority variants.  
 
ID03. Coamplification and Detection Sensitivity of Viral RNA and DNA 
Targets from Swabs in Universal Transport Media Using BD MAX ExK TNA-3*, 
a New Automated Molecular Open System Reagent  
D. Dugourd, V. Jean, B. Leclerc, H. Galarneau, V. Blanchette, I. Paradis, J. Pinard-
Lachapelle, S. Simard, F. St-Pierre, C. Ménard, C. Roger-Dalbert 
BD Diagnostics, Québec, Canada. 
Introduction: The BD MAX System is a sample-to-answer automated molecular 
testing platform. The new BD MAX TNA (Total Nucleic Acid) suite, part of the Open 
System Reagent series, combines specimen-specific extraction kits (ExK for swabs 
in Universal Transport Medium (UTM) or cerebrospinal fluid (CSF)) and universal 
PCR reagents with or without specimen processing control (SPC) (MMK* and 
MMK(SPC)*). The TNA suite allows users to detect RNA and DNA targets from a The Journal of Molecular Diagnostics ■ jmd.amjpathol.orgsingle biological specimen with their own user defined protocols. Users can select 
specimen volume, and individually program thermocycling and analysis parameters. 
This study aimed to demonstrate the capability of BD MAX ExK TNA-3* combined 
with BD MAX TNA MMK(SPC) to detect combined RNA and DNA targets from 
nasopharyngeal swabs (NPS) with high sensitivity. Methods: Extraction and 
amplification of NPS in UTM specimens were performed on the BD MAX System. To 
determine viral limits of detection (LOD) for NPS in UTM specimens, 750 μL of 
specimen spiked with 5 dilutions of a RNA virus (63-1000 PFU of enterovirus type 
71) combined with 5 dilutions of a viral DNA target (19-300 PFU of adenovirus 7A) 
were added to the Sample Buffer Tube (SBT) and were co-extracted and co-
amplified using BD MAX ExK TNA-3* combined with the BD MAX TNA MMK(SPC). 
A SPC consisting of an armored RNA is formulated with the BD MAX ExK TNA-3 
extraction reagent, and the corresponding primers and probe are included within the 
BD MAX TNA MMK(SPC)* reagents. Target-specific primers and probes were added 
to reagents prior to use. The efficacy of extraction and amplification was confirmed 
by spiking individual specimens (n=30) with enterovirus and adenovirus at 5x 
determined LOD. Results: Within the same multiplex PCR reaction the detection 
sensitivity for the RNA and DNA viral targets were 42 PFU/SBT and 75 PFU/SBT, 
respectively. Extraction and detection efficiency of NPS in UTM specimens was 
confirmed when spiked with 5x LOD of viral RNA target (315 PFU/SBT) and DNA 
target (375 PFU/SBT) with 96.6% compliant results and endpoints significantly 
above cutoff. Conclusions: The BD MAX ExK TNA-3 and MMK can extract, co-
amplify, and detect DNA and RNA viral targets from swabs in UTM specimens in a 
single multiplex reaction with good sensitivity as confirmed by results at 5x LOD.  
*BD MAX ExK TNA-3, BD MAX TNA MMK, and BD MAX TNA MMK(SPC) are not 
available for sale or use. 
 
ID04. Rapid Next-Generation Sequencing for Detection of Ȗ-Lactam 
Resistance in Gram-Negative Bacteria Using the Ion Torrent Platform 
K. Chavda1, P. Zhang2, L. Chen1, R. Bonomo3, H. Fernandes2, B. Kreiswirth1 
1University of Medicine and Dentistry of New Jersey, Newark, NJ; 2UMDNJ / New 
Jersey Medical School, Newark, NJ; 3Louis Stokes Cleveland Department of Veteran 
Affairs Medical Center, Cleveland, OH. 
Introduction: Multidrug resistant Gram-negative infections are a major threat in both 
the community and the hospital setting. ȕ-lactams remain the most important broad 
spectrum antibiotics whilst the emergence of variable ȕ-lactamases has severely 
compromised clinical use of these antibiotics. Most clinical isolates have multiple ȕ-
lactamases, which confounds phenotypic testing and clinical response and there is a 
growing need to have rapid resistance information to direct rapid and appropriate 
treatment. We have used a Next-Generation Sequencing (NGS) platform to detect 
the most prevalent ȕ-lactamases in a comprehensive and clinically relevant assay. 
Methods: A rapid high-throughput Ion Torrent NGS platform was designed to detect 
18 ȕ-lactamases, including extended spectrum ȕ-lactamases (ESBLs) (TEM, SHV 
and CTX-M), AmpC type ȕ-lactamases (CMY-2-like, DHA, FOX, ACC-1, ACT/MIR 
and CMY-1-like/MOX) and carbapenemases (KPC, NDM, IMP, VIM, OXA-48, OXA-
23, OXA-40, OXA-51 and OXA-58). A 16S target was included for species 
identification, and two additional targets (Klebsiella pneumoniae tonB and 
Escherichia coli pabB) were included for detection of endemic K. pneumoniae ST258 
and E. coli ST131 clones. A panel of 42 well-characterized clinical bacterial isolates 
from 8 different species that were previously genotyped by real-time PCR/Sanger 
sequencing were tested on this NGS platform. Results: A total of 120 ȕ-lactamases 
genes were present in the 42 clinical isolates. Each isolate ranged in having 1 to 4 
different ȕ-lactamases, and their distribution was as follows: 19 KPCs, 10 NDMs, 4 
VIMs, 2 OXA-48s, 14 CTX-Ms, 34 non-ESBLs TEM, 2 ESBL TEM(238S and 164S), 
17 non-ESBLs SHV, 6 ESBLs SHV (3 238S240K and 3 238S240E), 3 CMY-2, 4 
ACT/MIR, 2 DHA, 1 ACC, 1 OXA-23, and 1 OXA-51. The ȕ-lactamase genes for 
each isolate were amplified in a single tube multiplex PCR assay and all 42 
barcoded and pooled samples were sequenced and compared to a reference library. 
The sequence analysis of each ȕ-lactamase gene in each strain was in complete 
agreement with the archived PCR/Sanger data. The 16s rRNA sequences correctly 
speciated each isolate and the tonB and pabB genes correctly subtyped K. 
pneumoniae to ST258 and E. coli to ST131 , respectively. Conclusions: This NGS 
method accurately detected a diverse variety of ȕ-lactamases genes in Gram-
negative bacteria, and can be used as a diagnostic tool for the early and accurate 
identification of multiple resistant organisms to implement precisely targeted 
antibiotic therapy as well as provide valuable data for epidemiological investigations 
and infection control. 
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System with Real-Time PCR for Detection of Cytomegalovirus (CMV), Epstein-
Barr Virus (EBV) and BK Virus (BKV) in Clinical Specimens 
M. Espy, M.J. Binnicker 
Mayo Clinic, Rochester, MN. 
Introduction: Solid organ and bone marrow transplant recipients are at increased 
risk of developing severe disease due to CMV, EBV, or BK virus. Real-time PCR has 
greatly enhanced the ability to diagnose these viral infections. However, the majority 
of real-time PCR assays target a single analyte, making detection of co-infections 
difficult. The ICEPlex system (PrimeraDx; Mansfield, MA) was developed for 
multiplex detection and quantification of nucleic acid targets through integration of 
PCR and capillary electrophoresis. In this study, we compared a multiplex viral panel 
on the ICEPlex system with real-time PCR for the detection of CMV, EBV, BKV, 
HHV6, and HHV7. Methods: Plasma (n=116), whole blood (n=117), and urine (n= 
59) specimens submitted for routine CMV, EBV and/or BKV real-time PCR 
(CMV/EBV, Roche Diagnostics, Indianapolis, IN; BKV, lab developed test) were also 
tested by the ICEPlex multiplex viral assay. Nucleic acid was extracted on the 
MagNA Pure (Roche Diagnostics, Indianapolis, IN) and routine testing was 
performed on the LightCycler 2.0 instrument (Roche). Samples positive for HHV-6 or 
HHV-7 by ICEPlex were analyzed by uniplex real-time PCR. We evaluated the limit 
of detection (LOD) of the ICEPlex assays, performed checkerboard studies, and 
monitored the potential for environmental contamination with the ICEPlex system. 
Results: Following testing of the 292 prospective specimens, the ICEPlex multiplex 
assay demonstrated sensitivities of 90% (9/10), 96.7% (29/30), and 75% (27/36) for 
the detection of CMV, EBV, and BKV, respectively. All of the discrepant results had 
low viral loads (<1,070 copies/mL). Percent specificities by ICEPlex were 97.9% 
(47/48), 96.6% (84/87), and 96.3% (78/81) for CMV, EBV and BKV, respectively. 
The ICEPlex multiplex assay detected multiple viral targets in 42/292 (14%) 
specimens, with 37/42 (88%) of these additional targets being confirmed by uniplex 
PCR. The LOD of the ICEPlex CMV, EBV and BKV assays was 244, 977, and 488 
copies/ml, respectively. No environmental contamination was observed during our 
study and checkerboard panels did not show carry-over contamination on the 
ICEPlex system. Conclusions: The ICEPlex transplant viral panel performed 
comparably to real-time PCR for the detection of CMV, EBV, and BKV with an 
overall percent agreement of 93.8% (274/292). Quantitative values varied between 
the ICEPlex assays and real-time PCR, confirming that routine monitoring of viral 
loads needs to be performed using the same test. Our findings show that the 
ICEPlex system has the ability to detect multiple targets in the same specimen, 
which may improve the management of transplant patients. 
 
ID06. A Combined Real-Time PCR and Sequencing Method for Detection of 
the Five Plasmodium Species Infecting Humans from Whole Blood 
M.I. Lefterova, I. Budvytiene, P. Buchner, N. Banaei 
Stanford University School of Medicine, Stanford, CA. 
Introduction: Malaria is the leading cause of fever and morbidity in returning 
travelers. Prompt diagnosis is critical for patient management and accurate species 
identification has therapeutic implication for P. vivax and P. ovale, which have 
dormant liver stages requiring treatment with primaquine. Microscopy is currently the 
gold standard for diagnosis, but its sensitivity and specificity are compromised by 
morphologic overlaps and strongly depend on the technologist’s expertise. A number 
of nucleic acid tests for malaria speciation have been developed and appear more 
accurate and sensitive than microscopy. These assays primarily target the 
Plasmodium 18S ribosomal RNA (rRNA) gene, which presents challenges for 
multiplexing because of primer competition and leads to decreased sensitivity 
compared to individual reactions. The use of fluorescent probes improves sensitivity 
and specificity, but is not cost effective for laboratories in low-prevalence areas. Here 
we present a simple and affordable real-time PCR assay for identification from whole 
blood of the five Plasmodium species known to infect humans. Methods: A real-time 
PCR assay with SYBR Green chemistry was developed to target different genes for 
each Plasmodium species to allow for multiplexing. A well-conserved area of the 18S 
rRNA gene is also amplified as control and subjected to bidirectional 
dideoxynucleotide termination sequencing for species confirmation. Positive controls 
for each species represent isolated genomic DNA or plasmid clones. Blood samples 
from returning travelers were used to measure assay accuracy. Results: Assay 
validation, using 12 P. falciparum, 10 P. vivax, four P. malariae, and one P. ovale 
specimens confirmed positive by microscopy, demonstrated 100% concordance with 
microscopy and no cross-reactivity between species for any of the primer sets. 
Sequencing of the ~320 base-pair pan-Plasmodium PCR product from the 18S rRNA 
gene could correctly distinguish all species. Duplex real-time PCR was shown to 
successfully detect single and simulated mixed species infections. We also discuss a 
challenging case of P. falciparum infection in an HIV-positive individual, in which 74application of the assay prevented unnecessary treatment with primaquine, which 
would have occurred based on P. ovale diagnosis on microscopy examination. 
Conclusions: The real-time PCR assay for Plasmodium species identification is an 
affordable and accurate diagnostic that can be used by laboratories with access to 
molecular tools in low malaria prevalence areas, either as six single reactions or 
three duplexed reactions. Sequencing of a pan-malarial amplicon provides 
confirmatory diagnostic information and can be especially useful in cases where 
allele drop-out may occur with species-specific primers.  
 
ID07. Effect of Glacial Acetic Acid Reprocessing on the Cervista HPV HR 
Assay 
E.B. Coffman, S.A. Hecht 
Hologic, Inc., Marlborough, MA. 
Introduction: The Cervista HPV HR test is a qualitative in vitro diagnostic assay 
used to detect the presence of high–risk human papilloma virus (HPV) in cervical 
specimens. Glacial acetic acid (GAA) reprocessing (10% glacial acetic acid prepared 
in CytoLyt Solution), is an FDA–approved wash procedure used for removal of blood 
from ThinPrep specimens deemed unsatisfactory for cytological evaluation. 
Previously published reports suggest that residual GAA solution interferes with 
Cervista performance, but these studies did not factor in the impact of potential cell 
loss that may occur during reprocessing from decanting after centrifugation. This 
study investigates the effects of GAA on the performance of the Cervista assay and 
the use of a pelleting additive to augment cell recovery during reprocessing. 
Methods: HPV-positive cell lines (positive for HPV types 16, 18, and 51) were 
prepared in a background of HPV-negative Jurkat cells in PreservCyt solution at low-
positive levels for the Cervista assay. Half of the contrived samples were spiked with 
whole human blood. Samples were either GAA reprocessed, reprocessed with 
CytoLyt (no GAA), or left untreated. A portion of the samples were also treated with 
Sample Conversion Buffer (SCB), a pelletizing agent used in the Digene Hybrid 
Capture 2 Sample Conversion Kit (QIAGEN, Gaithersburg, MD) for processing of 
ThinPrep specimens. In an additional study, pelleted Jurkat cells with the 
supernatant removed by aspiration were spiked with GAA at concentrations 
representative of residual material left behind in the reprocessing method, and tested 
in the Cervista assay. Results: The Cervista HPV FOZ ratios and average genomic 
DNA FOZ signals (i.e., internal control) for GAA and CytoLyt reprocessed samples 
were equally lower relative to unreprocessed controls. The addition of SCB to GAA 
reprocessed specimens prior to centrifugation elevated the signal to that of 
unreprocessed controls. Experiments with pelleted and aspirated Jurkat cells spiked 
with GAA or Cytolyt showed equivalent genomic DNA signals relative to controls that 
were not spiked. Conclusions: The reported inhibition of specimens reprocessed 
with GAA may not be due to residual acid, but appears to be the result of cell loss 
during decanting after centrifugation. The use of a pelleting agent or alternative 
supernatant removal techniques (e.g., aspiration versus decanting) may mitigate the 
risk of cell loss during GAA reprocessing. These findings are for investigational use 
only and a full scale validation study is required before current labeling to GAA 
reprocessing can be modified. 
 
ID08. Microbiome Characterization as a Diagnostic Tool in Fecal Microbiome 
Transplantation 
R. Luna, M. Pitashny, J. Runge, Y. Shang, E. Hollister, D. Nagy-Szakal, S. Mir, R. 
Kellermayer, J. Versalovic 
Texas Children's Hospital/Baylor College of Medicine, Houston, TX. 
Introduction: Fecal microbiome transplantation (FMT) can offer effective treatment 
of Clostridium difficile infection (CDI) and is being explored as a potential treatment 
option for other gastrointestinal conditions such as ulcerative colitis (UC). Extensive 
screening criteria are utilized for the selected donors, and microbiome 
characterization offers an in-depth look at differences in overall bacterial community 
structure. Beyond initial donor and patient matching and comparison, further 
longitudinal analyses of the changes in the intestinal microbiome of the transplanted 
patients will provide useful data that can be correlated to patient outcomes. 
Methods: Patients were selected for FMT based on clinical history, and all patients 
had either documented C. difficile infection (n = 2) or ulcerative colitis (n = 4). A 
universal donor was utilized for this study and successfully passed routine screening 
for a variety of viral and bacterial pathogens. Stool specimens from both the donor 
and patients were collected at various time points, and bacterial DNA was extracted. 
Next generation-sequencing targeting two areas of the 16S rRNA gene (V1V3 and 
V3V5) was performed, and bioinformatic analysis determined the bacterial 
composition of the intestinal microbiome of patients and donor. Results: The 
universal donor selected for this study was found to have an intestinal microbiome 
highly similar to the healthy adults characterized as part of the Human Microbiome 
Project. Pre-transplant specimens from patients were markedly different in bacterial jmd.amjpathol.org ■ The Journal of Molecular Diagnostics
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decreased abundance or complete absence of Bacteroides sp. in the patients. Each 
patient’s microbiome was unique, but each included one or more genera whose 
presence (e.g., Phascolarctobacterium sp.) or increased abundance (e.g., 
Escherichia/Shigella sp.) was a deviation from the typical intestinal microbiome. 
Post-transplant specimens varied in overall bacterial composition ranging from highly 
similar to the universal donor to distinct from both the donor and patient’s pre-
transplant microbiome profile. Conclusions: Microbiome characterization by next-
generation sequencing has shown clinical utility in the screening of donors and 
patients and subsequent ongoing evaluation of patients undergoing FMT. 
Comparison of intestinal microbiomes prior to transplant allowed for adequate 
matching of donors to patients, and periodic assessment of post-transplant 
specimens facilitated correlation with patient outcomes. Microbiome characterization 
will continue to be a valuable diagnostic tool in many patient care scenarios.  
 
ID09. VIVEST: A Revolutionary Ambient Temperature Storage and 
Transportation Device for Utilization in Infectious Disease Testing 
A.M. McClernon, A.B. Freeman, D.R. McClernon 
bioMONTR, Research Triangle Park, NC. 
Introduction: Infectious disease monitoring often requires collection sites to ship 
biological specimens to reference laboratories for molecular based testing. Standard 
specimen storage and transport methods have several disadvantages including 
temperature control and low-volume requirements. Studies discussed herein 
evaluate the use of ViveST, a novel dried ambient transportation matrix, for storage 
and transport of infectious plasma samples used with downstream molecular based 
quantitative viral load assays. Methods: For all testing described, infectious plasma 
(HCV, HIV-1 or HBV) was loaded onto ViveST, dried, capped and stored at room 
temperature. After recovery from ViveST, specimens were analyzed using each of 
the following commercially available FDA approved viral load assays: COBAS 
TaqMan HCV Test, v2.0 for use with the High Pure System (Roche Diagnostics, 
Indianapolis, IN), RealTime HCV Assay, RealTime HIV-1 Assay or RealTime HBV 
Assay (Abbott Molecular, Des Plaines, IL). To assess linearity for each analyte/assay 
combination, a high titer infectious plasma sample was diluted (7 levels) and each 
level was analyzed in triplicate on a single run (frozen vs. ViveST, n = 21 each).  To 
assess precision (inter- and intra-assay) for each analyte/assay combination, 3 
levels of infectious plasma specimens were analyzed in triplicate on 3 separate runs 
(n = 27). Results: For COBAS TaqMan HCV test: precision SD was <0.15 LOG 
IU/mL with 95%CI <±0.17 (intra-assay), <0.11 LOG IU/mL with 95%CI <±0.07 
(interassay) and linearity across range of ~4-6 LOG IU/mL with R2>0.99. For 
RealTime HCV assay: precision SD was <0.10 LOG IU/mL with 95%CI <±0.10 
(intra-assay), <0.07 LOG IU/mL with 95%CI <±0.04 (interassay) and linearity across 
range of ~1.3-6.6 LOG IU/mL with R2>0.99. For RealTime HIV-1 assay: precision 
SD was <0.11 LOG IU/mL with 95%CI <±0.10 (intra-assay), <0.10 LOG IU/mL with 
95%CI <±0.05 (interassay) and linearity across range of ~1.6-7 LOG IU/mL with 
R2>0.99. For RealTime HBV assay: precision SD was <0.13 LOG IU/mL with 95%CI 
<±0.14 (intra-assay), <0.10 LOG IU/mL with 95%CI <±0.06 (inter-assay) and 
linearity across range of ~1-7 LOG IU/mL with R2>0.99. Conclusions: These 
studies demonstrate ViveST utility for storing and transporting infectious plasma for 
subsequent analysis using various commercially available molecular based assays 
utilizing a range of viral targets (RNA and DNA). ViveST provides significant cost 
savings as compared to shipping samples on dry Ice and can enhance access to 
healthcare globally while significantly reducing the burden associated with shipping 
frozen samples. 
 
ID10. Searching the Universe for “Universal” 16S PCR Primers 
R.M. Rattray, R. Press 
Oregon Health and Science University, Portland, OR. 
Introduction: Broad-range amplification and sequencing of bacterial 16S rRNA 
genes directly from clinical specimens is a valuable diagnostic procedure for 
samples that are either difficult to culture, like tissue or joint fluids, or do not culture, 
possibly due to the use of antibiotics. There are many possible consensus PCR 
primer sets for “universal” amplification of the 16S gene, but little guidance on which 
ones to use for clinical application. Methods: We compared 113 published PCR 
primers and probes by computationally aligning them to the regions of the 16S gene 
that they were designed to target in 581 bacterial 16S sequences from all phyla, 
including bacteria of clinical relevance. Based on this analysis, we used a set of 
primers that targeted the first 530 bases of the 16S gene (V1 – V3) that covered the 
greatest diversity of organisms with the fewest ambiguities at the target sequence. 
Ribosomal DNA genes from bacterial isolates, blood cultures, and primary patient 
specimens were amplified and subjected to Sanger-based DNA sequencing. The 
sequences were compared to publicly available databases using free, web-based The Journal of Molecular Diagnostics ■ jmd.amjpathol.orgtools for identification. Results: Using the chosen primer pair for both amplification 
and sequencing, we interrogated a total of 41 unique bacterial species from 146 pure 
bacterial isolates and blood culture specimens that had been identified by traditional 
culture and biochemical methods. Overall, 16s sequencing was 94% concordant with 
bacterial culture. For specimens we were able to sequence, we were 92% 
concordant to culture at the genus level (5 positive samples had a genus call 
discordant with culture) and 70% concordant at the species level. Sensitivity studies 
indicated the ability to detect as few as 3 bacterial cells per PCR reaction for Gram-
negative species and as few as 70 bacterial cells per reaction for Gram positive 
species. We detected Enterobacter 16S rDNA in a pleural fluid sample that was 
culture negative. This result correlated with a subsequent culture of a different 
sample from the same patient. Conclusions: Using these 16S primers, we amplified 
a wide range of organisms from clinical specimens. We determined that the targeted 
region was sufficient for determining the identity of most organisms, independent of 
culture. We also demonstrated the sensitivity of these primers, and the ability to 
detect bacteria from traditionally low burden samples like pleural fluid. 
 
ID11. Validation of Viroseq HIV-1 Genotyping System V2.0 Using Automated 
Extraction: Easymag 
A.M. McClernon, A.B. Freeman, D.R. McClernon 
bioMONTR, Research Triangle Park, NC. 
Introduction: HIV-1 resistance testing is standard of care for HIV-1 patient 
management. The FDA approved ViroSeq HIV-1 genotyping assay utilizes manual 
ETOH extraction and gel electrophoresis for amplicon quantitation. Herein we 
describe performance of the ViroSeq HIV-1 Genotyping System v2.0 utilizing 
easyMag for automated extraction and NanoDrop for amplicon quantitation. 
Methods: Plasma samples (0.5 or 1.0 mL) extracted using easyMag platform 
(bioMérieux), RNA analyzed using ViroSeq HIV Genotyping system v2.0 (Abbott 
Molecular). Amplicons quantified using NanoDrop, normalized prior to cycle 
sequencing. Sequence analysis performed using ABI 3100 Genetic Analyzer. Data 
analyzed using ViroSeq Software v2.8. For precision, ten aliquots of previously 
characterized HIV-1 infectious plasma sample assayed different days/different 
operators. Results compared at nucleotide level.  To demonstrate accuracy, Thirteen 
HIV-1 infectious samples were assayed. Duplicate aliquots shipped to independent 
commercial testing laboratory and results from both laboratories compared at 
nucleotide and AA levels. To assess specificity, HIV-1 infectious plasma and normal 
human plasma spiked with HCV and HBV. Aliquots of each (neat and spiked) 
analyzed concurrently. Analytical sensitivity demonstrated by mixing non-congruent 
HIV-1 sequences post-PCR to create WT:mutant ratios of 85%, 75%, 50%, 25%, 
and 15%. Determination of majority species/mixture recorded for each sample. For 
assay sensitivity, HIV-1 infectious sample diluted to ~300 c/mL. Subtype analysis 
completed for commercially available nine-member panel of HIV-1 Group M 
subtypes. Results: All precision samples resulted in >99% concordance (intra-
assay) and >98% (inter-assay). Of paired accuracy samples analyzed, results were 
not obtained for 1/13. Results of remaining 12 paired samples were >98% 
concordance at nucleotide level and 10/12 (83%) returned 100% concordance at the 
AA level. A mixture at V75I (A/G) was identified in 1/12 samples whereas 
corresponding sample reported WT. A mixture at T215C/Y (A/G) was identified in 
1/12 samples whereas corresponding sample reported full mutant T215Y.  Samples 
spiked with HCV and HBV were >99% concordant at nucleotide level compared to 
neat samples. No result obtained for normal human plasma spiked with HCV and 
HBV. All mixtures/all dilutions detected with exception of 85:15 (M41). Resistance 
Reports generated on samples as low as 300 c/mL and all dilutions >99% 
concordant at nucleotide level with corresponding undiluted samples. Sequence 
analysis for 9-member subtype panel demonstrated 100% concordance with 
expected results.  
Conclusions: The easyMAG extraction platform can be utilized in combination with 
both ViroSeq HIV-1 Drug Resistance assays. EasyMAG platform combined with 
amplicon NanoDrop quantitation improves sensitivity, workflow and turnaround time 
for HIV-1 drug resistance analysis. 
 
ID12. Young Women with HPV-Positive Normal Cytology Are at Increased 
Risk for 5-Year Follow-Up Abnormal Cytology 
D. Olsen, M.F. Evans, C. Adamson, T.L. St. John, D. Weaver 
University of Vermont, Burlington, VT. 
Introduction: Testing for human papillomavirus (HPV) has been proposed as a 
primary cervical screening method among older (>30 years) women. Here we 
investigate the relationship between HPV detection in negative for an intraepithelial 
lesion or malignancy (NILM) cytology and subsequent cytological diagnoses among 
young women (30 years). Methods: The initial patient cohort was identified from 
October 2006 to February 2008 and consisted of 600 women diagnosed as NILM 875
AMP Abstractswho were tested for human papillomavirus (HPV) by GP5+/6+ PCR; 5-year follow-up 
cervical cytology data were available for 374 of these patients (age range: 13-30 
years). All normal and abnormal follow-up cervical cytology and subsequent biopsy 
information was recorded and correlated with the NILM HPV data. Results: At study 
inception, NILM HPV positive status correlated significantly (p=0.001) with age 
group: 40.5% HPV positive in the 13 to 18 years age group, 55.6% in the 19 to 24 
years age group and 33.7% in the 25 to 30 years age group. Follow-up abnormal 
cervical cytology (ASCUS, LSIL) was detected in 39.2% in the 13 to 18 years age 
group, 21.6% in the 19-24 years age group, and 12.9% in the 25 to 30 years age 
group (p<0.001). The association of incident HPV positive status with 5-year follow-
up abnormal cytology was significant among the 19 to 24 years (odds ratio 2.569, 
p=0.045) and the 25 to30 years (odds ratio 3.869, p=0.003) age groups. The 
incidence of abnormal cervical cytology among incident HPV negative patients 
ranged from 7.4% (25 to 30 years)  to 11.7% (19 to 24 years) and was not 
significantly different across groups (P>0.05). Conclusions: These findings suggest 
that HPV positivity varies among young women with NILM cytology based on age 
group sub-division and that HPV is most prevalent in the 19 to 24 years age range. 
Follow-up abnormal cervical cytology also varies according to age group and is most 
prevalent in the 13 to 18 years age range and decreases in frequency with 
progressive age group. HPV positivity correlates with follow-up abnormal cervical 
cytology in the 19 to30 years age groups and this association is due to a decrease in 
the number of abnormal cervical cytology specimens among incident HPV negative 
women. These data suggest care should be taken to ensure that teenage women 
are not lost to follow-up and that HPV testing of women aged 20 to 30 years could 
help identify patients at an increased risk for cytological abnormalities. 
 
ID13. A Comparison of the Luminex xTAG and Genmark eSensor 
Respiratory Viral Panels for Detection of Viruses in Respiratory Specimens 
P. Pancholi, J. Fink, J. Balada-llasat, K. Weiting 
The Ohio State University Wexner Medical Center, Columbus, OH. 
Introduction: Respiratory tract infections range from mild and self-limited to severe, 
life-threatening illnesses. Accurate and rapid diagnosis of viruses improves patient 
care. In this study we compared two multiplex respiratory viral panels (RVP), the 
Luminex xTAG RVP and the GenMark Dx eSensor RVP IVD (GM-RVP-IVD) in 
conjunction with the GenMark Dx eSensor RVP RUO (GM-RVP-RUO) for the 
detection of respiratory viruses. Methods: One hundred and eighty (180) 
prospective respiratory specimens (100 nasopharyngeal swabs, 54 bronchoalveolar 
lavage (BAL), 16 nasal swabs, 7 sputum and 3 other (lung tissue, throat) were 
collected from patients during the winter of 2012 to 2013. Specimens were extracted 
with NucliSENS easyMag (bioMerieux) and the extracted nucleic acids were 
amplified and detected with the above RVP panels as per manufacturer’s 
instructions. The assays detect influenza A (H1 and H3), influenza B, adenovirus, 
parainfluenza 1, 2, 3, respiratory syncytial virus A (RSVA), RSVB, human 
metapneumovirus, human rhinovirus (HRV). The GM- RVPs also detects influenza A 
2009H1N1 and differentiates adenovirus B/E and C. Additionally, the GM-RVP 
(RUO) detects parainfluenza 4 and coronaviruses (229E, OC43, NL63, HKU1). The 
Luminex xTAG does not differentiate Enterovirus and HRV. Results: Comparison of 
the GM-RVP IVD with the Luminex xTAG RVP across all sample types resulted in a 
percent positive agreement (PPA) of 97.7% and a negative percent agreement 
(NPA) of 97.6%. Performing xTAG RVP in close proximity to the GM-RVP required 
clear separation of workflow and decontamination of work surfaces to obtain reliable 
results. A comparison of all targets detected by both assays included FluA H1 (1), 
FluAH1N1 (7), FluAH3(7), FluB(14), RSVA(9), RSVB(9), hMPV(11), Adeno(5), 
PIV1(5), PIV2(4), PIV3(4), Rhino/Entero (26). The GM-RVP RUO detected an 
additional 11 samples containing Coronaviruses. The latter are not reported on 
Luminex xTAG. Twelve samples were detected with viral co-infection and one was a 
quad infection containing Flu B, PIV2, Corona OC43 and Corona NL63. Most of the 
discrepant results were due to differences in detection of rhinovirus/enterovirus. 
Additional studies to confirm detection of coronaviruses and for discrepant resolution 
are underway. The respiratory panels generated similar performance across the 
different sample types. A workflow comparison of GM-RVP to Luminex RVP revealed 
the GenMark assay was 2 hours faster to result with 80 minutes less hands-on-time. 
Conclusions: Overall, the GM-RVP performed well with various respiratory 
specimens, offering a robust and simple to use assay with a quicker time to result.  
 
ID14. Does Activation of Human Endogenous Retroviral Elements (HERVS) 
Modify HIV-1 Clinical Phenotypes? 
S. Ansari, F. Xu, H. Sun, J.C. Sarria, P. Keiser, J. Dong 
University of Texas Medical Branch, Galveston, TX. 
Introduction: Human endogenous retroviral elements (HERVs) are thought to be 
germline-integrated genetic remnants of exogenous retroviral infections and 876comprise approximately 8% of the human genome. HERVs have been implicated in 
the etiology of cancer, chronic inflammation, and other diseases, and emerging data 
support the regulation and functional interaction between HERV-K activation and 
HIV-1 viral infection. HERV-K has been associated with increased immune activation 
in HIV-1 positive patients. However, it is not clear whether the expression of HERV-K 
affects clinical or routine laboratory parameters of HIV-1 infection. Methods: HERV-
K expression was measured in plasma from 30 HIV-1 infected individuals using RT-
PCR and gel electrophoresis. Patient records were reviewed for CD4 count, HIV-1 
viral load, history of opportunistic infections and whether patients were on 
antiretroviral therapy. Mean CD4 and viral load were calculated based on HERV-K 
status using ANOVA techniques. Results: 16/30 (56%) patients were HERV-K 
positive. Clinical data were available on 27 patients. Mean CD4 count was 355 
cells/mm3. Mean viral load was 3.32 (log10/mL) and 29% had a viral load below the 
limits of detection. Antiretroviral drugs were prescribed to 62% of all patients and to 
38% of HERV-K positive patients. Mean CD4 cell count was lower in the HERV-K 
positive patients (370 cells/mm3 vs. 450 cells/mm3) whereas viral loads were higher 
in the HERV-K positive group (2.29 log10/mL vs. 3.62 log10/mL). There was no 
correlation between HERV-K status and history of opportunistic infections. 
Conclusions: HERV-K was expressed in over half of HIV-1 infected patients. CD4 
count was lower and HIV-1 viral load higher in these patients. Further studies are 
warranted to better understand the effects of HERV-K on clinical or routine 
laboratory parameters of HIV-1 infection. 
 
ID15. Comparison of the Aptima and Cervista Assays for Detection of High-
Risk Human Papillomavirus in Cervical Specimens 
F. Nolte, D.G. Ribeiro-Nesbitt 
University of South Carolina, Charleston, SC. 
Introduction: Molecular detection of high-risk human papillomavirus (hrHPV) is an 
essential component of cervical cancer screening. As new molecular assays for 
hrHPV become available, important questions regarding comparative performance 
characteristics among these assays arise; however, in most studies the comparator 
is the older Hybrid Capture 2 assay (Qiagen, Gaithersburg, MD). The Aptima assay 
(Hologic/Gen-Probe, San Diego, CA) detects hrHPV E6/E7 mRNA using 
transcription-mediated amplification whereas the Cervista assay (Hologic/Gen-
Probe) detects hrHPV genomic DNA using cleavase-invader technology. Methods: 
The Aptima and Cervista assays were compared for detection of hrHPV in 208 
cervical cytology specimens (ThinPrep, Hologic, Bedford, MA). Specimens with 
discordant test results were tested with Cobas HPV test (Roche Diagnostics, 
Indianapolis, IN) that detects hrHPV genomic DNA by real-time PCR. HPV test 
results were correlated with cytological findings for all specimens and concurrent 
cervical biopsy specimens when available. Results: The agreement between the 
results of the two tests was 88% (kappa, 0.76; McNemar test, p<0.001). HPV was 
detected by both Aptima and Cervista assays in 85, by Aptima alone in 2, and by 
Cervista alone in 23 specimens. Both assays gave negative results with 102 
samples. One of two (50%) specimens positive by Aptima alone, and only 5 of 23 
(22%) specimens positive by Cervista alone were positive by the Cobas test. Of the 
23 Cervista-positive/Aptima-negative specimens, 13 were positive in all three of the 
Cervista reaction mixes (clades A5/A6, A7, and A9) and 11(85%) of these were 
found to have high human genomic DNA signals (fold over zero ratio 15).  In 76 
specimens with normal cytology results Cervista was positive in 27 (35.5%) and 
Aptima was positive in 11 (14.5%). In 116 specimens with atypical squamous cells of 
undetermined significance (ASC-US) the positivity rates were similar for Cervista and 
Aptima at 56.9% and 52.6%, respectively. Both assays were positive in 13 (86.7%) 
of 15 specimens with cytological abnormalities >ASC-US. Concurrent cervical 
biopsies were available for 31 women and there was complete concordance 
between the results of the two tests for the six who had significant cervical 
intraepithelial neoplasia (CIN >1). Conclusions: The Aptima assay was as sensitive 
as, but more specific than the Cervista assay for detection of hrHPV in women with 
significant cervical disease. In addition, 85% of the Cervista triple-positive specimens 
could not be confirmed as positive with another test for hrHPV DNA and were likely 
false positives due to non-specific signal resulting high human genomic DNA input.   
 
D16. Detection of Mycobacterial and Viral DNA in Kikuchi-Fujimoto Disease 
in Relation to Histopathologic Changes 
Z. Xu1, L. Fu1, H. Li2, S. Meng2, L. Ma1, Y. Tang3 
1Beijing Children's Hospital, Capital Medical University, Beijing, China; 2Vanderbilt 
University Medical Center, Nashville, TN; 3Memorial Sloan-Kettering Cancer Center, 
New York, NY. 
Introduction: Kikuchi-Fujimoto disease (KFD) is a self-limited disorder in young 
children as painless cervical lymphadenopathy with fever, anemia, and leukopenia. 
The clinical and pathologic findings suggest a microbial etiology. We applied PCR-jmd.amjpathol.org ■ The Journal of Molecular Diagnostics
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herpesviruses and parvovirus B19 in lymph nodes of KFD. Methods: Formalin-fixed, 
paraffin-embedded (FFPE) lymph node biopsies from pathologically confirmed KFD 
were collected from pediatric patients between 2001 and 2010 from Beijing 
Children's Hospital. Each KFD case was classified as a i) proliferative, ii) necrotizing, 
or iii) xanthomatous type based on its histopathologic changes. DNA was extracted 
by using the Qiagen QIAamp DNA FFPE Tissue Kit. A broad-range PCR coupled 
with a suspension array was used to detect and identify 17 medically important 
Mycobacterium species. A colorimetric microtiter PCR was used to detect the eight 
herpesviruses (herpes simplex virus type 1 [HSV-1], HSV-2, cytomegalovirus [CMV], 
Epstein-Barr virus [EBV], varicella-zoster virus [VZV], human herpesvirus-6 [HHV-6], 
HHV-7, and HHV-8) and parvovirus B19. Results: A total of 153 KFD FFPE lymph 
code biopsies were collected during the ten-year study period. Mycobacterial DNA 
was detected in 19 (12.4%) tissues including one of M. intracellulare, M. avium, M. 
smegmatis, M. abscessus, M. conceptionense, M. riyadhense, M. vanbaalenii, and 
M. monacense, two of M. fortuitum, M. kansasii, and M. mucogenicum, and five of 
other unspeciated species. The PCR assays detected 10 (6.5%) parvovirus B19, 3 
(2.0%) EBV, 1 (0.6%) CMV, 1 (0.6%) HHV-6, 1 (0.6%) HHV-7, and 5 (3.3%) HHV-8. 
The KFD cases were divided into 102 (66.7%) proliferative, 44 (28.8%) necrotizing, 
and 7 (4.5%) xanthomatous histopathlogic types. Viral pathogens were detected in 
18 (17.6%) proliferative types that were significantly higher than those in 
necrotizing/xanthomatous types (5.9%, OR=3.43, p=0.046). Mycobacterial species 
were detected in 11 (10.8) necrotizing and in 7 (15.7%) xanthomatous 
histopathologic types, respectively (OR=0.65, p>0.05). Conclusions: Our results 
confirmed existence of mycobacterium- and virus-specific DNAs in lymph node 
tissues of KFD. Parvovirus and herpesviruses were detected in statistically higher 
frequencies in the proliferative rather than in the necrotizing/xanthomatous 
histopathologic types. 
 
ID17. Real-Time PCR Panel Testing for Twenty-five Bacterial and Viral 
Pathogens in Middle Ear Fluid from Children with Otitis Media with Effusion  
R. Slinger1, M. Duval2, D. Rajakumar1, J. Langill 2, L. Hyde1, M. Bromwich 1, J. 
MacCormick1, F. Chan1, J. Vaccani1 
1Children's Hospital of Eastern Ontario, Ottawa, Ontario, Canada; 2University of 
Ottawa, Ottawa, Ontario, Canada. 
Introduction: Detection of the wide range of bacterial and viral agents that can 
cause otitis media with effusion (OME) using conventional culture-based detection 
methods is labor-intensive and slow. Additionally, bacterial culture results may be 
negative if the patient has received antibiotics recently been or if bacterial biofilms 
are present in the middle ear. We therefore used real-time PCR panels for 25 
infectious agents, to determine which infectious agents were present in middle-ear 
fluid (MEF) collected from children at the time of tympanostomy tube insertion. 
Methods: The study was conducted at a pediatric tertiary care hospital in Ontario, 
Canada, in 2011 through 2012. MEF samples were obtained at tympanostomy tube 
insertion from 31 children with a Tymp-tap suction device and trap. Standard 
bacterial cultures including broth enrichment were performed. Samples were tested 
with pre-made room temperature stable panels for 25 infectious agents using 5’ 
exonuclease probe-based real-time PCR assays. Targets included OM-associated 
bacteria (Streptococcus pneumoniae, Haemophilus influenzae and Moraxella 
catarrhalis), atypical bacteria such as Mycoplasma pneumoniae and Bordetella 
pertussis, and 18 respiratory viruses. Results: Thirty-one children were enrolled with 
51 MEF obtained. Real-time PCR detected bacteria in 22/31 children (71%), 
whereas culture detected bacteria in 10/31 (32%), a statistically significant difference 
(p < 0.05). S. pneumoniae was the most frequently detected bacteria by PCR, found 
in 14/31 (45%) children, followed by M. catarrhalis (12/31, 39%), H. influenzae (6/31, 
19%), and M. pneumoniae (3/31, 10%). Viruses were detected by PCR in 7/31 (23%) 
of patients, with rhinoviruses most frequently detected (4/31, 13%). Overall, the PCR 
panel detected at least one pathogenic organism (bacteria and/or virus) in 24/31 
patients (77%). Conclusions: The real-time PCR panel method was able to detect 
bacteria and viruses in a majority of children requiring tympanostomy tube insertion 
for OME. These findings suggest infectious agents play an important role in OME. 
Notably, S. pneumoniae was detected by PCR in 45% of children. We now plan to 
investigate if the S. pneumoniae-PCR positive MEF specimens contain S. 
pneumoniae serotypes found in the new 13-serotype vaccine. If so, this might 
suggest a role for this vaccine in the prevention of OME. 
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 ID18. Evaluation of PCR Assay for Detection of B. pertussis and B.
parapertussis in Viral Transport Media without Nucleic Acid Extraction 
D.S. Chabot-Richards, K. Culbreath 
University of New Mexico, Albuquerque, NM. 
Introduction: Whooping cough is a highly contagious respiratory illness associated 
with severe, prolonged cough. The majority of infections are due to Bordetella 
pertussis, which also causes the most severe symptoms. Up to 20% of pertussis-like 
disease is due to infection with B. parapertussis. Despite widespread vaccination in 
the US, pertussis remains an endemic disease with epidemics and local outbreaks 
occurring every 3 to5 years. Simple, rapid testing for Bordetella infection is 
necessary to optimize treatment and prevent outbreaks. The prevalent diagnostic 
method is RT-PCR testing of extracted nucleic acid. The CT cut-off for positivity is 
not standardized. <35 is commonly used, but laboratories report cut-offs ranging 
from 30 to 50 cycles. We sought to evaluate the feasibility of performing RT-PCR on 
direct patient samples without extraction. Methods: Fifty-five (55) previously 
characterized, frozen nasopharyngeal swabs in viral transport media, including 50 B. 
pertussis and 5 B. parapertussis samples, were assessed in this study. RT-PCR was 
performed on the direct specimen using 6 ȝl of VTM and 4 ȝl of master mix. Samples 
were tested with Focus Diagnostics primers on the 3M Integrated Cycler. Discrepant 
results were re-extracted and tested using the manufacturer’s original method. Limit 
of detection calculation was performed using the extracted and direct methods. 
Results: Thirty nine of 55 cases positive with extracted samples were positive by 
direct testing. Samples with correlation between the direct and extracted specimens 
had CT values, on average, 1.6 cycles later in the direct specimens. In the 16 
discrepant cases, the CT values of the extracted specimens were later (ranging from 
33.2 to 42.7, avg. 37.5), compared to the concordant cases (ranging from 15.1 to 
37.0, avg. 26.4). The discrepant specimens were re-extracted and repeated to 
determine the effects of storage. Upon repeat extraction and RT-PCR, 11 of 16 
samples were negative. Agreements between the extracted and direct method above 
and below 35 CT were 27% and 88%, respectively. Conclusions: These data 
demonstrate that amplification of B. pertussis and parapertussis can be performed 
directly from VTM. However, there is a 1 log difference in limit of detection between 
extracted and unextracted specimens. This resulted in reduced positivity for 
specimens with lower organism burden. Clinically, pertussis is not usually suspected 
until late in the disease when organism burden is often lower. There is evidence in 
the literature that cases with CT values >35 are unlikely to represent true positives. 
The clinical impact of this protocol must be further evaluated. 
 
ID19. Universal 16S RNA-Based RT-PCR for Direct Detection of Bacteria in 
Patient Specimens 
K.H. Rand, H. Houck, H.J. Dong, K. Newsom, G. Wang 
University of Florida, Gainesville, FL. 
Introduction: Molecular detection of bacteremia in 2 to 3 hours would be a 
significant improvement over blood cultures taking 2 to 4 days. “Universal 16S” 
sequences would be ideal for this, except that Taq is heavily contaminated with 
bacterial DNA, severely reducing the limit of detection. We compared the sensitivity 
of ribosomal RNA based 16S RT-PCR to 16S DNA PCR, then used deep 
sequencing to determine end point sensitivity and the ability to discriminate the 
target RNA from those contaminating reagents. Methods: As proof of concept, serial 
10x dilutions of RNA and DNA were prepared from stock (3.5 x 106 cfu/ml) P. 
aeruginosa ATCC 25892. 16S DNA and RT-PCR were performed using “universal” 
sequences, EUB338 and 27F (E. coli numbering). Using EUB338 antisense to make 
cDNA by RT, a specific TaqMan PCR for P. aeruginosa was used to quantitate the 
RNA and DNA. Deep sequencing was performed on the same set of dilutions with 
the Ion Torrent (Life Technologies, Carlsbad, CA) 314v2 (400 bp) chip after training 
from the manufacturer. Sequences >100 bp were run against the Silva v108 16S 
SSU database using the USEARCH algorithm. Each dilution and reagent-only 
controls were bar coded and all run in a single sequencing reaction. Reads with 
97% identity in their alignable portion ( 80% of read length) to their best hit were 
retained for analysis (N=44,333). Results: Endpoint detection with the RT-PCR 
TaqMan assay was 1:100M and was about 3,000x higher than the endpoint found 
with the same TaqMan assay using DNA from the same preparation of P. 
aeruginosa. P. aeruginosa specific sequences were found only in the samples with 
P. aeruginosa RNA and their proportion decreased from 95.5% (1:10K) to 88.3% 
(1:1M) to 41.6% (1:10M) and 8.0% at the 1:100M endpoint, as the % unrelated 
sequences from the reagent contamination increased in proportion. Sequences from 
the reagent only DNA PCR, were almost all Corynebacteria, Sporosarcina, and 
Burkholderaceae, whereas those from reagent-only RT-PCR included these and 
multiple others, such as Bradyrhyzobium, Curtobacterium, Caulobacteraceae, 
Xanthomonadaceae, Propionibacterium, and Streptococcus sp. Conclusions: 16S 
bacterial RNA would be much more sensitive than 16S DNA in the direct detection of 877
8AMP Abstractsbacteremia from patient blood, but the reverse transcriptase and taq polymerase 
introduce a range of reagent-associated contaminating species. Deep sequencing 
should be very useful in separating the contaminating sequences from true 
pathogens while simultaneously identifying potential pathogenic bacteria. 
 
ID20. Validation of the Roche Cobas HPV Assay Using Liquid Cytology 
Media ThinPrep and SurePath 
S. Beqaj, D. Simmons, L. Luu, K. Oda 
Pathology, Inc, Torrance, CA. 
Introduction: Human papillomavirus (HPV) is one of the most common sexually 
transmitted infectious pathogens causing cervical cancer in women. Testing for HPV 
infection is a standard of care as a reflex for ASCUS cytology results in women 21 
and older and as a primary adjunctive screen with a Pap test in women 30 to 65 
years of age. The purpose of this study was to evaluate the performance of the 
Roche cobas HPV Test, which detects the presence of 14 HPV HR genotypes while 
simultaneously genotyping for HPV16 and HPV18 all from one vial, one sample, and 
within one run. Methods: A total of 297 patient specimens were tested for this study 
(187 ThinPrep and 110 SurePath). All specimens were tested on the Cobas 4800 
and results compared to Qiagen Digene HC2 or Hologic Cervista HPV. In addition, 
validation panels containing control specimens for genotypes 16 and 18 were used 
for genotyping. Also, 21 anal swabs collected in ThinPrep specimens were tested 
and compared to results from reference laboratories using Cervista and/or Roche 
methodologies. All discrepant results were verified by Linear Array. Precision, 
reproducibility, and repeatability were performed using AcroMetrix HPV controls in 
triplicate for four days and assay controls were tested in five replicates for five days. 
A stability study was performed on the SurePath specimens. Twenty SurePath 
specimens were stored at room temperature and tested on various days up to day 
30. Cycle thresholds (Ct) were used to compare reproducibility. Results: For 
ThinPrep specimens, after resolving any discrepant results by linear array, the 
sensitivity of the Roche HPV assay is 95.8% with a specificity of 98.3% and an 
overall agreement of 97.3%. For SurePath there is a sensitivity of 100% and 
specificity of 98.2% with an overall agreement of 99.1%. Results from 16/18 
genotyping matched Cervista and control results used for this study. The CV for the 
precision study ranged from 0.49% to 2.2%. Results from the stability study on 20 
SurePath specimens demonstrated good stability with no changes between day 30 
and the initial testing of day one. onclusions: The Roche cobas HPV assay, 
performed on the automated 4800 platform and used in our lab for HPV HR 
detection and genotyping is a reliable, sensitive, and specific assay for HPV 
detection and 16/18 genotyping. 
 
ID21. Feasibility of Testing Specimens Collected for the BD ProbeTec CT/GC 
Qx Amplified DNA Assays on the BD MAX System 
L. Kantham, A. Hoover, L. Galloway, D. Koffenberger, P. Madepogu, C. Zeman, B. 
Biederman, K. Thornton, T. Hellyer 
BD Diagnostics, Sparks, MD. 
Introduction: Nucleic acid amplification tests with high clinical sensitivity and 
specificity are the standard of care for detection of Chlamydia trachomatis (CT) and 
Neisseria gonorrhoeae (GC). In low prevalence settings there is often a need for 
confirmation of positive results to increase positive predictive value and, in the case 
of GC, to address potential cross-reaction with commensal flora. The BD ProbeTec 
Qx Amplified DNA Assays employ specimen collection and transport devices that are 
designed for use on the BD Viper System. We report the results of a feasibility study 
to investigate compatibility between these devices and a novel assay for CT, GC, 
and Trichomonas vaginalis (TV) on the BD MAX System*. 
Methods: Compatibility was assessed through testing 137 archived Urine 
Preservative Transport (UPT) specimens and 87 prospectively collected Qx 
endocervical swabs. Results from the BD MAX assay were compared to those 
obtained with the CT, GC, and TV* Qx assays on the BD Viper System. For urine, 
1mL of sample was transferred from the UPT to a BD MAX-compatible Sample 
Buffer. For the swabs, 0.5mL of residual Qx Swab Diluent that had previously been 
tested on the BD Viper System was added to the BD MAX Sample Buffer. Results: 
The bank of archived urine specimens was enriched for positive samples enabling 
estimation of both positive and negative percent agreement (PPA and NPA). For CT 
and GC in male and female urine, PPA was 96% (46/48) and 98% (42/43), 
respectively. NPA was 99% (91/92) for CT and 100% (96/96) for GC. For TV in 
female urine, both PPA and NPA were 100% (20/20 and 38/38). Among the 
endocervical swabs the prevalence of CT, GC and TV was very low but overall 
agreement between the Qx and BD MAX assays for each analyte was 98% (85/87), 
100% (87/87) and 100% (87/87), respectively. Conclusions: We have demonstrated 
the compatibility of specimen collection and transport devices for the BD ProbeTec 
Qx Amplified DNA Assays with a novel assay for CT, GC, and TV on the BD MAX 78System. Such cross-compatibility may have important implications for positive 
predictive value in low prevalence settings or whenever cross-reaction is suspected.  
* Not for sale, for investigational use only in the US. The subject of this abstract 
constitutes off-label use of both the BD ProbeTec Qx specimen collection devices 
and the assay for CT, GC, and TV on the BD MAX System. Performance 
characteristics have not been established. 
 
ID22. Comparison of Cobas AmpliPrep/Cobas TaqMan and Cobas Amplicor 
for Qualitative Detection of HCV RNA in Clinical Samples 
H. Kim1, Y. Park2, J. Sim3, Y. Kim3 
1Yonsei University College of Medicine, Seoul, Korea, Republic of; 2Kwandong 
University College of Medicine, Gangneung, Gangwon-do, Korea; 3Yonsei University 
Health System, Seoul, Korea 
Introduction: Cobas Amplicor HCV test, v2.0 (CAM, Roche Molecular Systems, 
Pleasanton, CA) has widely used for qualitative detection of Hepatitis C virus (HCV) 
RNA with low limit of detection (LOD) at 60 IU/ml in serum. Recently a lower 
detection limit of at least 15 IU/ml was required from new therapeutic guideline for 
follow-up testing of HCV treatment. The new Cobas AmpliPrep/Cobas TaqMan HCV 
test, v2.0 (CAP/CTM, Roche Molecular Systems) with LOD at 15 IU/ml could be 
suitable for new guideline. We evaluated and compared the results of CAP/CTM and 
CAM. Methods: Total 600 specimens (498 negative and 102 positive in CAM) were 
selected. Additionally, 22 specimens with gray zone result were selected for case 
comparison. CAP/CTM, Quantitative HCV RNA Real-time PCR (HCV real-time 
qPCR, Roche Molecular systems) and anti-HCV tests (Roche Diagnostics, Germany) 
were also performed.Results: Concordant results from the two qualitative assays 
were 586 of 600 (97.5%). HCV RNA was detected from HCV real-time qPCR in all 
positive cases of CAP/CTM. Concordance rate was 97.5% (kappa coefficient was 
0.93, 95% Confidence Interval 0.88-0.96, P<0.001). Repeat testing of CAM 
performed in 14 discrepant cases. Results of 3 cases were changed from positive to 
negative and were agreed with CAP/CTM. Two cases with gray zone results from 1st 
and 2nd CAM showed positive in CAP/CTM and each 1.93 x 102 IU/ml and 3.0 x 101 
IU/ml in HCV real-time qPCR. Negative results of 13 cases with gray zone in 1st 
CAM agreed as negative with CAP/CTM and HCV real-time qPCR. Conclusions: 
Two HCV RNA qualitative assays were compared. Differences of LOD of CAM and 
CAP/CTM could explain in several discrepant specimens (4 cases with negative in 
CAM were positive in CAP/CTM, three cases with gray zone in CAM were positive in 
CAP/CTM). In 2nd CAM, thirteen cases from gray zone and 3 cases from positive 
results were changed to negative results. It might be thought because of relative 
non-specific reactions in CAM than CAP/CTM. Gray zone results were shown in 
CAM only. The overall results of two assays showed good agreement. The new 
CAP/CTM was more sensitive with lower LOD and even no gray zone results.  
 
ID23. Validation of a Molecular Identification Assay for Aspergillus Species 
in a CLIA-Certified Molecular Diagnostics Laboratory 
J.R. Lindner, D.A. Sutton, A.W. Fothergill, B.L. Wickes, K. Vadlamudi, E.H. 
Thompson, D.I. McCarthy, J. Fu, N. Wiederhold, W. Furmaga, H. Fan 
University of Texas Health Science Center at San Antonio, San Antonio, TX. 
Introduction: The identification of fungi using molecular techniques has become an 
important tool for clinical diagnosis. The rapid and accurate identification of 
Aspergillus species is of particular importance, as they may be highly pathogenic in 
animals and immunocompromised patients. We report a validation study using 
Sanger sequencing to identify Aspergillus species targeting the internal transcribed 
spacer (ITS) and ȕ-tubulin gene regions. This assay was developed using the 
Clinical and Laboratory Standards Institute (CLSI) Guidelines MM18-A. Methods: 
DNA was extracted from 25 clinical strains of various Aspergillus spp. representing 
significant pathogens by using a combination of cetyl trimethyl-ammonium bromide 
(CTAB) buffer and physical disruption by bead beating, followed by manual 
chloroform/ ethanol extraction. The ITS and ȕ-tubulin regions were then amplified 
using M13-tagged ITS1/ITS4 and BT2a/BT2b primers, respectively.  Takara Ex Taq 
(Takara Biotechnology Co., LTD) with 4% DMSO was used for the PCR, and 
conditions for the two primer pairs were optimized. The resulting amplicons were 
sequenced bi-directionally with the M13F and M13R primers, BigDye sequencing 
reagents, and the ABI3130xl Genetic Analyzer (Applied Biosystems). The sequences 
were uploaded, aligned, and edited using the Lasergene software (DNASTAR, Inc). 
Finished sequences were then queried through the CBS-KNAW database search. 
Assay conditions were optimized, and the assay’s accuracy, specificity, sensitivity, 
and reproducibility were assessed. Results: All 25 Aspergillus isolates within the 
Sections Fumigati, Flavi, Terrei, Nidulantes, and Flavipedes amplified and 
sequenced successfully for both the ITS and ȕ-tubulin regions. Clean sequences 
with average read lengths of approximately 500 to 600 bp were obtained. All cases 
had query length coverage of >96% when searched through the CBS-KNAW jmd.amjpathol.org ■ The Journal of Molecular Diagnostics
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97%). The assay’s accuracy was confirmed using morphologic and physiologic 
identifications, as well as sequence data from the UTHSCSA Nucleic Acid Core 
Facility. Specificity was tested on various human, viral, and bacterial DNA, with no 
cross reaction observed. The assay was sensitive enough to produce sequence data 
on 2 nanograms of DNA. The reproducibility was evaluated by analyzing two 
Aspergillus samples in four runs on four different days by two different technicians, 
with all results in 100% agreement. Conclusions: The results of this validation study 
for the molecular identification of several Aspergillus spp. using Sanger sequencing 
targeting ITS and ȕ-tubulin was satisfactory by diagnostic standards. This assay can 
be used routinely for most Sections within the genus, excluding Section Nigri. 
 
ID24. An Evaluation of the Genmark eSENSOR HCVG Direct Genotype with 
the Siemens Versant HCV Genotype 2.0 (LIPA) Tests 
R. Faubel, K. Weiting, L. Rigali, J. Balada-Llasat, P. Pancholi 
The Ohio State University Wexner Medical Center, Columbus, OH. 
Introduction: Hepatitis C virus (HCV) genotyping is standard of care for HCV-
infected patients and is required to determine dose, duration and estimated 
therapeutic response. The objective of this study was to evaluate the GenMark 
eSensor HCV Direct Genotype (HCVg Direct) assay in comparison to the Siemens 
VERSANT HCV Genotype 2.0 (LiPA) assay. Methods: A total of 216 archived 
patient plasma specimens across all six clades of HCV were tested. Samples were a 
mix of fresh and previously extracted specimens on the EasyMag (BioMerieux). The 
LiPA method utilizes PCR amplification, probe hybridization (targeting HCV 5’UTR 
and core regions) and detection. The GenMark test employs binding of RT-PCR 
amplified DNA products from both the 5’UTR and core regions to proprietary, HCV 
genotype specific ferrocene-labeled signal probes and electrode bound capture 
probes followed by electrochemical detection inside the eSensor XT-8 instrument. 
Results: The GenMark HCVg Direct generated identical genotyping results for 197 
clinical samples. Concordance on valid calls with the HCVg Direct assay to LiPA on 
genotype 1a/1b, 2, 3, 5 and 6 were 98%, 100%, 100%, 75%, and 100%, 
respectively. The GenMark assay failed to detect or generated a discordant 
genotype call on 12 of 27 type 4 samples. Sequencing analysis of some samples 
revealed a novel type 4 sequence the HCVg Direct was not designed to detect. One 
of the type 4 discordants called 2b by the GenMark assay was confirmed by 
sequencing as a type 2b. Another type 4 discordant was called as 1b+4 mix by 
GenMark. Excluding the LiPA type 4 samples, HCVg Direct did not generate a result 
on 5 samples (2.3%) due to no detectable HCV signal. A workflow comparison of 
HCVg Direct to LiPA revealed the HCVg Direct was 4.5 hours faster to result with 
50% less hands-on-time. Conclusions: The performance of the GenMark HCVg 
assay generated 97.8% concordance with the LiPA assay on valid calls for 
genotypes 1a, 1b, 2a/c, 2b, 3, 5 and 6. During the course of the evaluation we 
discovered several novel HCV type 4 specimens not previously posted in publically 
available sequence databases. Due to the unique sequences, the HCVg Direct type 
4 signal probe failed to hybridize and generate signal. GenMark has created a new 
type 4 signal probe and samples with discordant results are being investigated 
further for resolution. As compared to LiPA, the HCVg Direct delivered significant 
workflow time and labor savings.  
 
ID25. Comparison of Illumigene Group A Streptococcus Assay and Culture 
for Detection of Group A Streptococcus from Throat Swabs 
E. Chan 
Trinity Medical Center, Birmingham, AL. 
Introduction: illumigene Group A Streptococcus assay (Meridian Bioscience), a new 
molecular assay using LAMP technology for the detection group A Streptococcus is 
compared with culture on patient throat specimens. Methods: One hundred ninety-
six throat swabs from 130 females and 66 males, ages ranging from 3 to 86 years 
old, obtained from physician’s offices and the hospital ED were submitted to the 
Microbiology laboratory for analysis. The throat swabs were plated on Blood and 
Blood agar with trimethoprim/sulfamethoxazole (SXT) plates. The blood agar was 
incubated aerobically whereas the blood with SXT was incubated anaerobically at 
37°C and examine daily for 48 hours. Identification of group A Streptococcus is 
based on Gram stain, PYR, and catalase. The swab was inoculated into extract 
buffer and stored at 4°C after plating and batch tested once or twice a week. 
Discrepancy results were tested with another molecular assay targeted another site 
than the illumigene assay. Results: There were a total of 187 negatives by both 
methods, six were positive by both methods and three were positive by illumigene 
but culture negative. These three discordant samples were from patients less than 
ten years old and were tested to be positive by a second molecular method. The 
resolved sensitivity, specificity, positive predictive value, and negative predictive 
value for illumigene and culture are 100%, 100%, 100%, 100%, and 66.7%, 100%, The Journal of Molecular Diagnostics ■ jmd.amjpathol.org100%, 98.4%, respectively. Conclusions: illumigene Group A Streptococcus assay 
is more sensitive with the same specificity as culture for the detection of group A 
streptococcus from patient throat swabs and has a one hours turnaround time. 
 
ID26. An Analysis of the Conversion to International Units in the Reporting 
of Epstein-Barr Viral Loads for Real-Time PCR in Various Matrices  
M.G. Roberts1, M.W. Durham1, T.K. Huard2 
1Quest Diagnostics, Chantilly, VA; 2Quest Diagnostics Nichols Institute, Chantilly, 
VA. 
Introduction: Epstein-Barr virus (EBV) is a ubiquitous human pathogen that is the 
causative agent in a number of infectious diseases and cancer, including infectious 
mononucleosis (IM), Burkitt's lymphoma, and post-transplant lymphoproliferative 
disorder (PTLD). Transplant patients who have been diagnosed with or identified as 
being at risk for PTLD are often tested for viral loads to monitor response to 
treatment and/or complications from emerging virus. Until recently, there was no 
standard measurement for Epstein-Barr viral loads. Thus there is no consensus as to 
what constitutes latent versus active infections due to inter-laboratory variability of 
viral load results. Methods: Using Simplexa Scorpion primers and the new WHO 
Standard (NISBC 09/260), we established a conversion factor from copies/mL to 
International Units (IU) for results from our lab-developed real-time quantitative PCR 
assay for EBV DNA. An individual conversion factor for each of four different 
specimen types relevant to testing for complications of human disease were 
determined. Additionally, we evaluated linearity, precision, and accuracy and were 
able to demonstrate that there was no significant matrix effect in any of the specimen 
types evaluated. The specimen types studied included whole blood, plasma, serum 
and CSF. Results: The conversion factors ranged from 2.26 to 3.19, with an 
average of 2.72. Comparison of the Expected IU/mL to the Measured log10 
copies/mL showed a high degree of correlation with all R2 values >0.99. To our 
knowledge, this is the first study for a laboratory developed test that demonstrates a 
common conversion factor for EBV to IU for all specimen types commonly tested for 
viral load determination. Conclusions: With further studies this may allow physicians 
to determine correlations between symptoms, their severity, and corresponding viral 
loads. 
 
ID27. Comparison of Two Commercial Isothermal Molecular Assays for 
Direct Detection of Clostridium difficile Toxin 
J.A. Daly1, P.L. Cernoch2, R. Parisi1, T. Barney1, J. Moore2, R. Alemayenu2, A. 
Blaschke1, K. Korgenski3, R. Grand-Pre3, M. Dickey3, A. Phillips3 
1Primary Children's Medical Center, University of Utah, Salt Lake City, UT; 2The 
Methodist Hospital, Houston, TX; 3University of Utah, Primary Children's Medical 
Center, Salt Lake City, UT. 
Introduction: Clostridium difficile infections (CDI) have increased in prevalence and 
severity in the US over the past decade. Rapid diagnosis allows prompt intervention 
such as antibiotic therapy and implementation of appropriate contact precautions, 
therefore decreasing the risk of horizontal spread of the microorganism. Nucleic acid 
amplification tests (NAAT) have emerged as the most sensitive method for 
diagnosing CDI. The objective of this study is to evaluate the performance 
characteristics of two isothermal molecular technologies for direct detection of 
toxigenic C. difficile using fresh stool specimens from patients with CDI. Methods 
evaluated included the AmpliVue C. difficile isothermal helicase dependent 
amplification (HDA [Bio helix]) assay (Quidel Molecular, San Diego, CA) and the 
illumigene C. difficile isothermal LAMP assay (Meridian Bioscience Inc., Cincinnati, 
OH). Methods: A total of 393 consecutive fresh, soft, or liquid stool specimens were 
enrolled in this study by two clinical centers. Additional inclusion criteria for testing 
were clinical signs and symptoms consistent with CDI and only one specimen per 
patient. All assays were performed according to the package insert. Cytotoxigenic 
culture was performed for discordant specimens or the PCR-based BD Gene Ohm C 
diff Assay (BD Diagnostics, Quebec, Canada). Results: The prevalence of CDI in 
the patients tested was 14.8%. The indeterminate/invalid/unresolved rate for both 
assays was less than 3%. Sensitivity, specificity, positive and negative predictive 
values for each of the C. difficile isothermal molecular assays was 97% and 100%, 
100% and 100%, 98% and 100%, and 99% and 100%, respectively, for AmpliVue 
and illumigene. Performance differences were not statistically significant between the 
2 assays. Conclusions: In patients with symptoms consistent with CDI, no 
statistically significant difference in the sensitivity of the two isothermal molecular 
systems was noted. Both assays have high specificities and allow labs to introduce 
DNA amplification without a major capital equipment purchase. Both assays can be 
performed in less than two hours. These results have implications for cost savings 
and improved patient care. 
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Using Taqman Primers to Reporting in International Units in Multiple Specimen 
Types 
D.S. Kim1, M.W. Durham1, T.K. Huard2 
1Quest Diagnostics, Chantilly, VA; 2Quest Diagnostics Nichols Institute, Chantilly, 
VA. 
Introduction: Parvovirus B19 is an erythrovirus that can cause mild to severe 
complications in immune-compromised individuals. Route of infection can occur via 
respiratory secretions, but can also be transmitted via contaminated blood and blood 
products. Screening for contamination of B19 in pooled blood products and removal 
of highly loaded donations is of major importance as a way to improve manufacturer 
safety of blood products. Until recently, there was no standardized reporting of 
results for Parvovirus B19 between different laboratories. The World Health 
Organization (WHO) has released standardized Parvovirus B19 material so that 
clinical laboratories around the world may move towards reporting in standard 
international units (IU). Here, we report our WHO conversion factor using Taqman 
primers and probes in our quantitative laboratory developed test for Parvovirus B19 
and revalidation of linearity, accuracy, precision, and limit of detection for various 
specimen types. Methods: After reconstitution of the WHO Parvovirus B19 standard 
with 1 mL of molecular grade water, 4 replicates of each concentration at 100,000 
IU, 10,000 IU, 1,000 IU, 500 IU, and 100 IU were tested in the following sample 
types: whole blood, serum, plasma, and amniotic fluid. The Roche MagNA Pure 32 
was used for the extraction of the samples. The Parvovirus B19 Taqman Assay was 
used for amplification. The samples were detected on the ABI 7900. The conversion 
factor is calculated by dividing Log IU/mL concentration with the mean Log 
copies/mL for all sample types. Results: The conversion ratio for Log copies/mL to 
Log IU/mL ranged from 1.10 to 1.53 in all samples tested. In addition to establishing 
the WHO conversion factor, we evaluated the linearity of our assay after conversion 
to IU reporting and found an R2 > 0.94 for all sample types. We evaluated our Limit 
of Detection for each specimen type, which was established as 347 IU/mL. 
Conclusions: The average conversion factor was 1.27*Log copies/mL = 1 Log IU. 
Due to physician needs for testing of alternate specimen types, we will begin 
reporting quantitative Parvovirus B19 viral loads for all accepted specimen types in 
International Units.  
 
ID29. Human Papillomavirus (HPV) Genotyping of Genital Warts in an STI 
Clinic in Singapore Using the Hybribio GenoArray 
M. Khoo1, Y. Yew2, P. SEN2, E. Koay3 
1National University Hospital Singapore, Singapore; 2National Skin Centre, 
Singapore; 3National University Health System, Singapore. 
Introduction: Human papilloma virus (HPV) that causes cervical cancer and genital 
warts, produces one of the most common sexually transmitted infections (STIs) 
worldwide. Most HPV infections are asymptomatic andgo unnoticed. There are >200 
different HPV genotypes. HPV types 16 and 18 cause 70% of cervical cancer cases 
and HPV types 6, 11 cause 90% of genital warts cases, via skin to skin contact. An 
HPV vaccine covering HPV 6 and 11 is now available. To evaluate its potential 
benefits, we present a research project to characterize the prevalence of the HPV 
genotypes in genital warts in Singapore. Methods: All clinical samples were 
collected in HPV DNA Pap cervical sampler from Department of STI Control Clinic 
(DSC), National Skin Centre, Singapore. Information on demographics, sexual 
history and clinical findings were collected with a self-administered questionnaire. 
After DNA extraction and PCR amplification, genotyping was performed with the 
HybriBio HPV GenoArray test that is designed to identify 21 HPV types including five 
(5) low-risk types (6, 11, 42, 43, and 44), using the Hybrimax hybridization platform. 
Results: Study population of 100 male and female patients specimens are tested for 
HPV genotyping. The most commonly affected patients were those between the 
ages of 20 to 40 years and 80% were single, with an average of 5 lifetime sexual 
partners. The ratio of males to females was ~2:1 and 80% of them did not use 
condoms consistently in the last 3 months. HPV genotypes were detected in 92 out 
of the 100 patients studied. Either HPV 6 and/or HPV 11 were detected in 87 of 
these 92 HPV-positive patients (94.6%), another 2 had HPV 81 (2.1%), another low-
risk HPV. Of the 87 with either HPV 6 or 11, 56 cases (60.9%) only had low-risk HPV 
genotypes, and the remaining 31 cases (33.7%) were co-infected with high- risk HPV 
genotypes (16, 18, 33, 35, 39, 45, 51, 52, 53, 58, 59, 66, 68). Three cases (3.3%) 
showed only high risk HPV genotypes. Conclusions: From our findings, the 
HybriBio HPV GenoArray test is effective in evaluating HPV genotypes in our 
population. The HPV genotypes detected in 94.9%of the study cohort having genital 
warts with readouts are either HPV 6 and/or HPV 11, and an HPV vaccine targeting 
HPV 6 and 11 may be useful in the prevention of genital warts in Singapore. 
 0ID30. Molecular Typing to Evaluate Effectiveness of a Surveillance Program 
that Includes Admission Screening and Decolonization of MRSA-Positive 
Patients, without Isolation 
M. Harazin, S. Das, M. Wright, A. Robicsek, L.R. Peterson 
NorthShore University HealthSystem, Evanston, IL. 
Introduction: Active surveillance is widely used for prevention and control of 
methicillin-resistant Staphylococcus aureus (MRSA) infections in hospital settings. 
NorthShore University HealthSystem (NorthShore) implemented universal 
surveillance in August 2005 to detect nasal carriage of MRSA on all admissions, 
followed by contact isolation and decolonization of MRSA-positives.A mental health 
unit was exempt from contact isolation; decolonization alone was performed on 
MRSA-positive patients. Discharge screening tracked MRSA conversions. This study 
evaluates the extent of MRSA transmission on that unit and whether MRSA 
acquisition can be linked to nasally-colonized patients on the unit. Methods: 
NorthShore's Enterprise Data Warehouse (EDW) was queried for all admissions to 
the unit to identify patients negative at admission yet positive at discharge for MRSA. 
Additionally the EDW was queried to determine which MRSA-positive patients were 
potential transmitters to any conversions, based on shared time on the unit. Nasal 
swabs that were positive by the screening method (using Real-Time PCR (rt-PCR)) 
were cultured on selective media to verify MRSA. 
Strain typing of the MRSA isolates was performed by Pulsed-Field Electrophoresis 
(PFGE) using Sma I restricted DNA. The resulting DNA banding patterns were 
compared using BioNumerics software, version 6.6 (Applied Maths, Inc., Austin TX). 
Results: Of 4677 admissions to the unit (May, 2007-Dec, 2011), 2806 (60%) were 
screened at admission, resulting in 181 positives (6.5%). Selective culture of 
positives yielded 113 (62%) MRSA isolates. Of 2625 admissions that tested 
negative, 25 qualified as having acquired MRSA during their hospital stay (0.95%). 
Selective culture yielded 8 (32%) MRSA isolates, 6 available for typing. Each 
acquisition isolate had at least 1 potential transmitter, and 12 of 21 potential 
transmitters yielded an MRSA isolate, leaving 5 acquisitions with at least 1 
transmitter to compare by PFGE. One MRSA acquisition was potentially linked to its 
transmitter by a closely-related PFGE pattern. Conclusions: Although discharge 
screening on the mental health unit identified 25 possible MRSA acquisitions during 
the study period, only 8 yielded viable MRSA. Comparison of PFGE patterns from 5 
acquisition isolates with potential transmitters revealed one MRSA acquisition that 
could be linked to a nasally-colonized patient. Despite 60% compliance with 
admission screening and exemption from recommended isolation precautions, 
acquisition of MRSA was less than 1% in this patient population over a course of 4.5 
years, including a single case of acquisition genetically similar to a known potential 
source. The results suggest decolonization of MRSA-positive patients is sufficient to 
minimize MRSA acquisition in this specialized population. 
 
ID31. Emm Genotyping and Multilocus Sequence Typing of Erythromycin-
Resistant Streptococcus pyogenes Isolated in Southern Part of Korea 
S. Kim 
Gyeongsang National University Hospital, Jinju, Gyeongnam, Korea, Republic of. 
Introduction: Streptococcus pyogenes is the major cause of bacterial pharyngitis. 
The emm typing and multilocus sequence typing (MLST) was used for the 
epidemiologic study of erythromycin-resistant S. pyogenes isolated in Southern part 
of Korea. MLST was performed to monitor clonal changes of erythromycin-resistant 
S. pyogenes over time. There is no MLST data yet in Korea for S. pyogenes. 
Methods: S. pyogenes were collected from 1995 to 2009 at the elementary schools, 
clinics, and hospitals in Jinju, Korea. Antibiotic susceptibility test was performed by 
disk diffusion and broth microdilution. Resistance genotypes were determined by 
PCR and gel electrophoresis. The emm typing and MLST typing was performed by 
PCR and DNA sequencing. One hundred and eleven erythromycin-resistant S. 
pyogenes strains were analyzed by emm typing and MLST. Results: Seven 
sequence types (STs) were identified. In 2002, when erythromycin (EM) resistance 
reached to 50%, emm12-ST36 was predominant (46.0%) and emm28-ST52 was 
rare (1.1%). However, emm12-ST36 decreased (7.1%) and emm28-ST52 increased 
remarkably (71.4%) in 2009, when EM resistance dropped to less than 10%. 
Concordance between emm genotypes and MLST ST was observed in 86.4% of 
isolates. The emm12/ST36-type strains harbored erm(B), whereas other ST strains 
carried the mef(A) resistance genotype. Conclusions: The major clonal type of S. 
pyogenes in southern part of Korea changed from emm12-ST36 in 2002 to emm28-
ST52 in 2009. ST was associated with EM-resistant genotypes. MLST and emm 
typing was complementary to understand the epidemiological characteristics of S. 
pyogenes. There was a close link between emm-MLST with macrolide resistance 
mechanism.  
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 AMP AbstractsID32. An Evaluation of Real-Time PCR for HSV 1 and 2 on the BD MAX 
Instrument  
B.L. Voss, K.A. Mangold, K.L. Kaul 
NorthShore University HealthSystem, Evanston, IL. 
Introduction: Molecular techniques are the gold standard for HSV detection and 
differentiation, although most real-time PCR assays require significant technical 
expertise, and hence performance in specialty laboratories. The BD MAX (Becton 
Dickinson, Franklin Lakes, NJ) is a commercially available automated system, 
designed to extract DNA and execute real-time fluorescence PCR. This study 
presents an evaluation of an optimized HSV 1/2 laboratory developed test performed 
on the BD MAX as compared to a commercially available real-time assay performed 
on the LightCycler (Roche Diagnostics, Indianapolis, IN). Methods: A published 
assay for detection and differentiation of HSV-1 and HSV-2 using fluorescently 
labeled TaqMan probes targeting the HSV glycoprotein B gene (Adelson et al., JCM, 
2005) was optimized and adapted to incorporate a BD MAX sample processing 
control. Quantitative standards were obtained from ZeptoMetrix (Buffalo, NY) for 
analytic sensitivity determination. Clinical validation was performed using 
retrospective de-identified Universal Viral Transport Media (VTM) containing 
cutaneous swabs or cerebrospinal fluid (CSF) samples that had been cryopreserved 
at 80°C. Originally, routine clinical testing of these samples included DNA extraction 
on the BioRobot EZ1 (Qiagen, Germantown, MD) and real-time PCR using the 
LightCycler HSV 1/2 Qualitative Kit on LightCycler 1.0/1.5 instruments. 
Results: The average limit of detection for HSV1/2 standards on the BD MAX was 
102 cp/mL compared to 1 cp/mL for the Roche assay. A total of 107 cutaneous 
swabs (36 HSV-1, 41 HSV-2, 29 negative, and one atypical HSV-1) were tested 
using the BD MAX, resulting in 96 (89.7%) matching the original results (34 HSV-1, 
37 HSV-2, 26 negative) and nine discrepant results. Five of these were resolved with 
repeat testing, yielding a final sensitivity of 95%. CSF samples (3 HSV-2, 5 
negative), which may contain fewer viral copies, were also tested with results 
matching the clinical PCR in 75% of cases. Conclusions: The BD MAX offers an all-
in-one instrument with walk-away capability that could be used in a multitude of 
laboratory settings. It reduces hands-on time per batch from 90 to 40 minutes, with a 
total time to result of approximately 3 hours, comparable to routine clinical molecular 
testing. This initial assessment of lab-developed HSV 1/2 reagents showed good 
performance relative to the routine clinical PCR assay; further optimization may yield 
improved sensitivity.  
 
ID33. Comparison of the Xpert MTB/RIF Sssay and the Real-Time PCR for 
Mycobacterium tuberculosis Detection in AFB Smear Negative Samples 
H. Lee1, M. Kim1, Y. Nam2, S. Cho2, T. Park2, J. Suh2 
1Kyung Hee University, Seoul, Korea, Republic of; 2Kyung Hee University Graduate 
School, Seoul, Korea, Republic of. 
Introduction: Prompt and accurate diagnosis of tuberculosis in suspected patients 
is important. Here we compare two methods of Xpert MTB/RIF assay and TB real-
time assay from diagnostic gold standard culture positive patients, by dividing groups 
into smear positive and negative. Also the drug sensitivity results are compared to 
evaluate the diagnostic usefulness of these methods in the diagnosis of tuberculosis. 
Methods: This study was conducted at Kyung Hee University Medical center, Seoul, 
South Korea, from October 2011 to June 2012. Fifty-seven clinical specimens were 
analyzed by standard smear-microscopy, mycobacterial growth indicator tube 
(MGIT) culture, solid culture, MGIT drug-susceptibility testing, TB real-time PCR and 
the Xpert MTB/RIF assay. Results: Diagnostic sensitivity of AdvanSure TB/NTM 
real-time PCR was 82.0%. As shown from smear positive and negative specimens, 
sensitivities were 87.5% and 79.4% respectively and specificity 85.7% (Table 2). The 
diagnostic sensitivity of Xpert MTB/RIF assay was 74.0%, and from smear positive 
and negative specimens, sensitivities were 93.8% and 64.7%, respectively, whereas 
specificity was 85.7%. There were 13 cases with discrepant results between two 
methods, 2 cases were found resistant to rifampin, although Xpert MTB/RIF assay 
was able to detect rifampin resistance in only one specimen. Conclusions: From the 
comparison of two methods of Advansure TB/NTM real-time PCR and Xpert 
MTB/RIF assay, Xpert MTB/RIF assay is an easier method to perform while its ability 
to detect rifampin resistance simultaneously is a benefit, its sensitivity from AFB 
smear negative-culture positive specimens was lower than Advansure TB/NTM real-
time PCR. Further investigation to increase the sensitivity and detect other drug 
resistances by kit-based assays is required for the rapid and accurate diagnosis of 
tuberculosis.  
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Assay 
N. Twining, S. Spirtovic, M. Costello, M. Michalov, L. Mazur 
ACL Central Laboratory, Rosemont, IL. 
Introduction: Gastroenteritis is challenging to diagnose. Although it is caused by 
multiple pathogenic organisms, it often presents with virtually identical symptoms 
and without an identifiable source. Currently there are a limited range of diagnostic 
tools and no standard testing algorithm. The xTAG Gastrointestinal Pathogen Panel 
(GPP) from Luminex Molecular Diagnostics is a qualitative, nucleic acid, multiplex 
assay designed for the simultaneous detection of viral, parasitic and bacterial 
pathogens in human stool. In this study, we examine the performance of the GPP 
LDT test in a patient population from the Midwestern United States. Methods: One 
hundred, twenty-five stool specimens were tested. Nucleic acid was extracted 
according to xTAG GPP protocol from 100 ȝl of 10% stool suspensions using the 
bioMerieux easyMAG extractor. GPP testing was performed according to 
manufacturer’s instructions. Briefly, reverse transcription and amplification was 
performed in a one-step reaction, amplified products were sorted on a bead-array 
incorporating the custom xTAG GPP Bead Mix and xTAG Reporter Buffer, and read 
on Luminex 100/200 platform using Xponent software. Results from 13 targets, 
including Salmonella, Shigella, STEC stx1 and stx2, Giardia lamblia, adenovirus 
40/41, rotavirus A, norovirus GI and GII, Cryptosporidium, Campylobacter, and E. 
histolytica, were compared to results from conventional diagnostic microbiological 
procedures. Analytical sensitivity and LOD were determined by run dilutions of 13 
quantitated targets form ZaptoMetrix. Additionally NoV positive samples were 
confirmed by LDT Norovirus RT-PCR assay. Results: In our hands, the GPP LDT 
method demonstrated the following performance: clinical specificity for all thirteen 
targets was 92% to 100%, with the exception of STEC stx1 (87%) and 
Campylobacter (73%); clinical sensitivity was 99% to 100%; average reproducibility 
for all assays was 97.3%; intrarun variability (%CV) ranged from 5% to 40%; 
analytical specificity was 100% when run against 43 different microbial targets; 
analytical sensitivity and limit of detection cutoffs showed very good correlation with 
FDA approved xTAG GPP assay. Based on our empirical results, the 
positive/negative “cutoff” for all targets was established at the 200 MFI level. The 
assay showed a relatively high failure rate due to the presence of inhibitors in the 
stool matrix (approximately 10% vs 16% described in the FDA-approved version). 
The GPP LDT assay was also able to detect seventeen additional targets (5-NOV 
GII, 4-Salmonella, 3-STECstx2, 2-Cryptosporidium, 2-adenovirus, 1-Giardia). 
Conclusions: The study demonstrates that the GPP LDT multiplex assay tested by 
our laboratory has very good performance characteristics and has the potential for 
immediate clinical impact in this challenging area of clinical medicine. 
 
ID35. An Update of the HIV-1 Subtypes and Drug Resistance-Associated 
Mutations Present in New HIV-1 Diagnoses in Singapore: A Retrospective 
Study from the National University Hospital, 2011-2012 
C. Ng, C. Lee, S. Archuleta, M. Khoo, L. Chiu, J. Tang, E. Koay 
National University Hospital, Singapore. 
Introduction: Since July 2011, an inexpensive and sensitive direct-sequencing-
based in-house HIV-1 genotyping resistance test (GRT) has been in routine clinical 
service at the National University Hospital (NUH). We conducted a retrospective 
study of HIV-1 subtypes and drug-resistance mutations (DRMs) in a Singapore HIV-
1-infected population. Methods: GRT data obtained from testing at the Molecular 
Diagnosis Centre was reviewed and compiled for all HIV-1 diagnoses presenting to 
NUH during July 2011-December 2012. Results: A total of 114 patients were 
identified in this study, of whom 103 (90.4%) were male and 43 (37.7%) were known 
to be treatment-naïve. Subtypes: Circulating Recombinant Form (CRF) strains were 
more prevalent (75.9%) than the pure subtypes (24.1%) and were distributed as 
follows: 80 (70.2%) CRF01_AE, 25 (21.9%) B, 6 (5.3%) CRF02_AG, 2 (1.8%) C, and 
1 (0.88%) CRF06_cpx. Consistent with previous local studies, CRF01_AE and 
subtype B were the main circulating strains (Figure). Genotyping: Of the 114 
samples, 60 (52.6%) were fully antiretroviral-susceptible. Among those with DRMs, 5 
(4.4%) were PI-resistant, 39 (34.2%) RTI-resistant, and 10 (8.8%) were resistant to 
both (Figure). A total of 184 DRMs (57 PR and 127 RT) were isolated. The in-house 
assay detected 14/36 PR and 26/32 RT drug-resistance associated codons listed in 
the HIV-1 DRMs 2011 update. Furthermore, E35G (decreased NFV/TPV 
susceptibility), K238T and Y318F (decreased NVP/EFV susceptibility) were 
detected. The majority of the DRMs (63%) were found in RT positions 69, 101, 103, 
138, 179, 184, 190 and 219, and PR position 10. Of the 43 treatment-naïve patients, 
14 (32.6%) harbored primary genotypic resistance in the following subtypes: 
CRF01_AE (7/28), B (4/11), CRF02_AG (1/2), C (1/1) and CRF06_cpx (1/1). 
Conclusions: The landscape of HIV epidemiology in Singapore has changed. 881
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significant number of treatment-naïve patients have primary genotypic resistance. 
 
ID36. Evaluation of Multiplex Realtime PCR Detection of B. pertussis, B.
parapertussis, and B. holmesii on the BD MAX  
B.L. Voss, K.A. Mangold, K.L. Kaul 
NorthShore University HealthSystem, Evanston, IL. 
Introduction: Resurgence of Bordetella pertussis infection in recent years has 
necessitated new detection methods; molecular approaches have facilitated rapid 
diagnosis. The BD MAX (Becton Dickinson, Franklin Lakes, NJ) offers an automated 
DNA extraction and real-time PCR system with minimal technologist hands-on time, 
making molecular detection more feasible in many laboratory settings. We have 
developed and validated assays for Bordetella pertussis (BP), B. parapertussis 
(BPP), and B. holmesii (BH) on the BD MAX platform. Detection and differentiation of 
all three organisms in clinical samples is recommended by the CDC. Methods: A 
published multiplexed real-time PCR assay (Tatti et al. JCM, 2011) identifying 
Bordetella species by amplification of specific insertion sequences was adapted for 
the BD MAX. The assay differentiates species by fluorescently labeled TaqMan 
probes (BP: FAM, BPP: HEX, BH: TEX), and includes a BD formulated sample 
process control (Cy5.5). Control strains (American Type Culture Collection, 
Manassas, VA) for BP, BPP, and BH were used for assay optimization and analytic 
validation. Clinical validation used cryopreserved nasopharyngeal swabs previously 
submitted for routine clinical testing (BP: 58, BPP: 24, Negative: 41); no clinical BH 
samples were available. Previous clinical testing used NucliSENS easyMAG 
(bioMérieux, Durham, NC) DNA extraction plus real-time PCR performed on the 
LightCycler (Roche, Pleasanton, CA) with MultiCode Bordetella reagents (Luminex, 
Madison, WI). Results: The detection limit for the BD MAX was approximately 10^3 
organisms/mL for each species, utilizing swabs dipped in the bacterial media, 
compared to 10 to 74 CFU/mL for the Luminex assay. Of 123 previously tested 
clinical swabs, 103 (83.7%) agreed with the standard real-time PCR assay 
performed in the clinical lab. The 20 discrepant samples included 18 BP and 1 BPP 
that failed to amplify the IS481 and IS1001, respectively, and tended to be samples 
with late amplification (>33 cycles) suggesting limited target in the sample. Analysis 
for discrepants could not be repeated as each swab was exhausted with BD MAX 
testing. Conclusions: Multiplex detection of BP, BPP, and BH was evaluated on the 
automated BD MAX platform. Time from sample receipt to results for a full run was 
approximately 3 hours, but the BD MAX reduced technician time by 60 minutes with 
walk-away capability. Although the BD MAX was inconsistently less sensitive when 
compared to other commercially available assays, this may be due to the loss of 
bacteria after initial clinical-testing of each swab or freezer degradation; testing of 
primary specimens may yield better sensitivity. 
 
ID37. Robustness and Ease of Use of a New Fully Automated Molecular 
Assay for the Detection of Methicilin-Resistant Staphylococcus aureus, the BD 
MAX MRSA XT* 
D. Roy, A. Charbonneau, M. Guillot, F. Hamel, M. Boutin, N. Dionne, S. Matte, E. 
Kadiric, C. Roger-Dalbert 
BD Diagnostics, Quebec, Quebec. 
Introduction: Health care-associated infections (HAIs) are the most frequent 
adverse event in health-care delivery worldwide. Hundreds of millions of patients are 
affected by health care-associated infections worldwide each year, leading to 
significant mortality and financial losses for health systems Methicillin-resistant 
Staphylococcus aureus (MRSA) is a common cause of HAIs. Despite significant 
improvements, the rate of infection remains high and is still a major risk for the health 
care system and its patient population. Timely availability of reliable MRSA results is 
essential to identify carriers and reduce its spread. The BD MAX MRSA XT assay 
detects an expanded range of new MRSA strains including mecC, MREJ junction 
variants and mecA dropout strains. The objective of this study was to evaluate 
robustness, hands-on time and turnaround time for the BD MAX MRSA XT Assay. 
Methods: The robustness studies focused on potential failure modes of the assay 
and the system (e.g. improper vortex speed and duration) and systematically tested 
to evaluate the impact on assay performance. MRSA-negative specimens and 
MRSA-positive specimens at 2 x to 3 x LOD95% (limit of detection) were tested in 
the presence of simulated nasal matrix in different conditions. The effect analysis 
was based on status analysis of positive and negative specimens as well as 
equivalency study on one selected PCR metric. In a clinical laboratory environment, 
time is of the essence. HOT and TAT were measured as an average of three 
independent runs performed by three trained technologists. Finally, carry-over and 
cross-contamination studies were performed. Results: The robustness tests 
revealed that the assay performance can be impacted by inadequate vortexing 
(vortex time or speed). Otherwise, minimal carry-over contamination was observed 882(1%), HOT was close to 30 seconds per sample and overall TAT, including manual 
preanalytic and automated sample preparation and complete PCR, was under 155 
minutes. Conclusions: The present study shows that the BD MAX MRSA XT Assay 
is a robust diagnostic test. Its ease of use and automation reduces technician time 
and ensures fast and reliable detection of MRSA-colonized patients. *The BD MAX 
MRSA XT Assay is not available for sale or use. 
 
ID38. Multi-center Prospective Clinical Trial of ICEPlex C. difficile Assay, 
Performed on True Multiplex Real-Time PCR platform, Based on PCR 
Combined with Capillary Electrophoresis Separation and Detection 
S. Voronov1, C. Burch2, C. Cummins2, J. Cuartes2, V. Diankov1, L. Doyle3, K. 
Madanahally Divakar1, K. Everhart2, M. Katanik3, D. Kohn3, C. Kubasek4, G. Procop3, 
S. Silbert4, M. Tuohy3, D. Uy4, D. Wilson3, B. Yen-Liberman3, R. Widen4, M. Marcon5, 
A. Leber2 
1PrimeraDx, Mansfield, MA; 2Nationwide Childrens Hospital, Columbus, OH; 
3Cleveland Clinic, Cleveland, OH; 4Tampa General Hospital, Tampa, FL; 5Ohio State 
University College of Medicine, Columbus, OH. 
Introduction: C. difficileiassociated disease (CDAD) has a potential to be fatal if left 
without proper follow-up. Rates of infection are reported to be on the rise in both 
hospital and community settings. With new approaches to patient management, 
proper laboratory-based diagnosis of the disease is of vital importance. Traditionally, 
stool culture with subsequent cell cytotoxicity assay is considered the most sensitive 
test for CDAD. This study compares clinical performance characteristics of the newly 
developed ICEPlex C. difficile Assay with Toxigenic C. difficile Culture Cytotoxicity 
Assay (TCCCA). Methods: The ICEPlex C. difficile Assay is a PCR-based test 
designed to target the C. difficile tcdB gene, encoding toxin B, a major virulence 
factor of the bacterium. The test is performed as a 7-plex PCR reaction including 
three internal calibration standards, one internal control and three independent target 
sites on the toxin B gene. The test workflow requires nucleic acid extraction that was 
performed on bioMerieux easyMag system. A reference method, TCCCA, was 
performed by isolation and identification of C. difficile bacteria from stool samples, 
followed by broth cell culture cytotoxicity assay. A clinical trial for the ICEPlex C. 
difficile Assay was designed as a prospective study utilizing remnant stool samples 
submitted for diagnostic testing for C. difficile, meeting study enrollment criteria: 
liquid or semi-solid samples of sufficient volume, enrolled within 48 hours of 
collection. Patient samples were enrolled and tested with ICEPlex C. difficile test at 
three independent clinical sites: Cleveland, OH; Columbus, OH and Tampa, FL. 
Reference testing was performed in a centralized laboratory. The study included 688 
fresh patient samples collected from 09/2012 until 04/2013. Results: ICEPlex C. 
difficile assay demonstrated first pass valid result rate at 96%. When compared to 
the TCCCA, the ICEPlex C. difficile Assay demonstrated 91% sensitivity (103 true 
positive results compared to 113 positive by reference method) and 97% specificity 
(543 true negative results compared to 557 negative by reference method). Overall 
prevalence rate for C. difficile infection was found to be at 17% and varied from 11% 
to 20% at different study sites. Conclusions: The ICEPlex C. difficile Assay has 
demonstrated high specificity and good sensitivity when compared to the reference 
method, Toxigenic C. difficile Culture Cytotoxicity Assay. Prevalence rate of C. 
difficile infection observed in this study is in-line with recently published results.  
*ICEPlex C. difficile assay is not approved for IVD use. 
 
ID39. Detection of BK Virus (BKV) in Selected Biopsies from Kidney 
Transplant Patients and Correlation with Results for BKV in their Blood and/or 
Urine 
M. Sabbath-Solitare, S.P. Marotta, M.J. Tortora, D. un Kim, N. Zauber 
St. Barnabas Medical Center, Livingston, NJ. 
Introduction: Reactivation of latent infection with BKV in renal transplant recipients 
is recognized as a cause of renal allograft failure. A major risk factor for BK 
nephropathy is aggressive immunosuppressive treatment. Quantifying BKV by PCR 
in blood and/or urine from renal transplant patients is the best noninvasive test for 
BK nephropathy although immunohistochemical (IHC) staining for SV40 polyoma 
virus (BK is a related member) on renal biopsies remains the definitive test. 
Correlation between IHC and blood/urine PCR results can be used as a guide for 
clinicians to monitor immunosuppressive therapy in transplant patients. In our 
laboratory, IHC results and BK viral load in blood/urine specimens correlated in over 
4000 specimens processed last year, except for two cases in which the IHC was 
positive for SV40 Polyoma virus, whereas the blood/urine results were inconsistent. 
Since immunosuppressive treatment is based on viral load, we decided to 
investigate whether the IHC results actually detected BKV, and if so, would low 
levels of BK virus in renal biopsies be of clinical concern. Methods: Forty formalin-
fixed, paraffin-embedded renal biopsies were selected (17 IHC negative, 14 IHC 
positive, and 9 non-transplant kidney (controls)), reviewed by one Pathologist who jmd.amjpathol.org ■ The Journal of Molecular Diagnostics
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blood/urine except for controls. Biopsy tissue was extracted using QIAamp DNA Mini 
Kit. Blood/urine specimens were extracted using Roche’s MagnaPure. All DNA 
samples were amplified on the ABI 7500 FAST PCR System using Luminex-Eragen 
multicode BKV reagents and software. IHC testing for SV40 Polyoma virus was 
performed at a reference laboratory. Results: Sixteen of 17 IHC negative biopsies 
were BKV PCR negative. The remaining one had significant levels of BKV in biopsy 
tissue and blood/urine. Eight of 14 IHC positive biopsies had significant levels of 
BKV in both tissue and blood/urine. The remaining 6 biopsies were from two patients 
(3 specimens each) all with low level BKV copy number in tissue and blood/urine. 
These two patients showed no progression of renal dysfunction, despite continuation 
of immunosuppressive treatment. All 9 non-transplant kidney biopsies were BKV 
negative by PCR. Conclusions: BKV can be detected in paraffin-embedded 
biopsies from transplanted kidneys even at low copy number. When present with low 
copy number in the kidney, low copy number is also low in blood/urine. Therefore, 
low BKV copy number in transplant kidney tissue may not be clinically significant 
even if detected by IHC. 
 
ID40. Rapid (10 Minute), Point-of-Care Determination of High Risk HPV 
Infection Using OncoTect 3Dx POC Parameters and Bioinformatics 
B. Patterson 
IncellDx, Inc., Menlo Park, CA. 
Introduction: Using a combination of morphometric, molecular, and inflammatory 
classifiers on liquid based cervical cytology samples, we were able to determine the 
presence or absence of high risk HPV in approximately 5 minutes without the use of 
molecular methods to detect HPV DNA. We determined the analytic performance of 
our POC assay using 65 normal cytology, HPV DNA+ samples and 43 normal 
cytology, HPV DNA- samples. Methods: Using four classifiers (ectocervical mean 
corpuscular volume (MCV), pyknotic/non-pyknotic ectocervical cell ratio, ectocervical 
Post G1% (cell-cycle), and PMN%), we developed a classification scheme that 
allows parameterization of SVM classifiers. By using cross validation and brute-force 
combinatorial sampling, we optimized combinations of parameters for two types of 
SVM classifiers to boost general classification accuracy, and particularly the 
Specificity (true negative predictive ability) of the classifier. Results: This has 
resulted in the following three classifiers with noted properties: 1) C_SVC Radial 
basis function SVM, 2) C_SVC Polynomial SVM, and 3) Nu_SVC Radial basis 
function SVM. The classifier performance yielded the following results: 1) clinical 
accuracy 88%, sensitivity 79%, specificity 95%; 2) clinical accuracy 89%, sensitivity 
84%, specificity 93%; 3) clinical accuracy 90%, sensitivity 87%, specificity 93%. 
Conclusions: Current iterations of the algorithm are being developed to maximize 
sensitivity knowing that false positive will go on to routine screening in cytology 
laboratories.  
 
ID41. Detection and Throughput Comparison of APTIMA Combo 2 (TIGRIS) 
and ProbeTec ET CT/GC QX (VIPER XTR) for Chlamydia trachomatis in Self-
Collected Vaginal and Urine Specimens 
M. Chernesky1, T. Hatchette2, D. Jang3, J. Gilchrist3, M. Smieja3, S. Ratnam4 
1McMaster University, Hamilton, Ontario, Canada; 2Capital Health, Halifax, Nova 
Scotia; 3McMaster University/St. Joseph's Healthcare, Hamilton, Ontario, Canada; 
4Public Health, St. John's , Newfoundland, Canada. 
Introduction: Second generation nucleic acid amplification tests are available for 
the diagnosis of C. trachomatis (CT) on automated platforms. The objectives were to 
determine the end point of CT detection (analytical sensitivity) for APTIMA Combo 2 
(AC2) on the TIGRIS (Hologic/GenProbe) and ProbeTec ET CT/GC QX on the 
VIPER XTR (Becton Dickinson) using first void urine (FVU) and self-collected vaginal 
swabs (SCVS) with and without a CT spike. Clinical sensitivity and specificity and 
inhibitor evidence were calculated for the 2 specimen types and a time and motion 
study was conducted. Methods: A total of 403 women attending STD clinics self-
collected an FVU and SCVS in a randomized order into each manufacturers 
transport tube. Samples were tested without and with a CT spike that was 100 fold 
higher than the endpoint level of detection. In determining clinical performance, 
samples were also tested by a third alternative test. Independent monitors observed 
and timed the steps of each assay including pre-analytical interactions, reagent and 
sample preparation and loading, in-process and post-analytical and maintenance. 
Weekly and monthly maintenance times on the TIGRIS were normalized. 
Turnaround times, automation times, total hands-on times, hands-on time per 
sample and mandatory instrument return visits were calculated. Results: Positive 
results in 10 of 10 replicates of spiked SCVS and FVU, respectively, were 10 to 7 
and 10 to 7 for AC2 and 10 to 6 and 10 to 5 for ProbeTec Qx. Spiked specimens 
showed no indication of amplification inhibition. Using an infected patient standard, 
the percent sensitivities for SCVS were 100% (38/38) for AC2 and 94.7% (36/38) for he Journal of Molecular Diagnostics ■ jmd.amjpathol.orgProbeTec QX; for FVU the values were 94.3% (33/38) and 73.7% (28/38), 
respectively. Specificities ranged from 99.7% to 100%. For a single run of 94 
specimens, automation times were 4.27 hours for TIGRIS vs 3.06 hours for VIPER; 
turnaround time for TIGRIS was 1.24 hours longer. Total hands-on times were 28 
minutes for TIGRIS compared to 100 minutes for VIPER; and hands-on times per 
specimen were 19 and 67 seconds respectively. Maintenance time for the single run 
was 8 minutes and 17 seconds for TIGRIS and 1hours, 5 minutes and 48 seconds 
for VIPER. Conclusions: AC2 was more sensitive than ProbeTec QX for detection 
of CT in SCVS and FVU. AC2 on TIGRIS is designed for automation of large 
batches of specimens. The ProbeTec ET CT/GC QX on VIPER demonstrated 
shorter turnaround but more hands-on time for 94 samples. Neither assay was 
susceptible to inhibitors of amplification. 
 
ID42. Frequency of rs12979860 and rs8099917 Il28B Polymorphisms in 
Donors and Receptors of Liver Transplantation Followed in a Brazilian 
Hospital 
R. Sitnik, L. Oyakawa, F.P. Carvalho, G.P. Lopes, L.V. Marins, M.D. Almeida, B. 
Della-Guardia, C.E. Matielo, A.S. Evangelista, C.L. Mangueira, J.R. Pinho 
Hospital Israelita Albert Einstein, São Paulo, Brazil. 
Introduction: Genetic variation in the IL28B gene region on chromosome 19 was 
recently identified for predicting response of patients chronically infected with 
genotype 1 HCV infection. This finding has been confirmed in several independent 
cohorts. The most strongly associated single nucleotide polymorphism (SNP) for 
treatment response, rs12979860, has also been shown to be significantly associated 
with spontaneous hepatitis C clearance. Other SNPs in close proximity to IL28B 
associated with treatment response and spontaneous clearance were described, 
such as rs8099917. Frequency of different alleles is different around the world and 
still there are few data about the distribution in our country. Methods: For this study 
genotyping at two sites of interest, rs12979860 and rs8099917, were tested using 
TaqMan custom designed probes (Applied Biosystems) on an ABI7500 instrument 
and the ABI TaqMan allelic discrimination kit from Applied Biosystems. Analytical 
performance characteristics of the assay were performed and the method was 
validated for whole blood, plasma and paraffin embedded liver biopsies. 
We analyzed 33 paired samples from donors and receptors of liver transplantation 
from a private hospital in São Paulo, Brazil. All patients had chronic HCV infection. 
Frequency of different alleles and genotypes were accessed and statistical analysis 
was performed using chi-square test with Yates’correction (BioStat 5.0 Software). 
Results: Frequency of different genotypes in both groups was accessed. For 
rs12979860, genotype CC was present in 15.2% and 21.2% among receptors and 
donors, respectively. For rs8099917, genotype TT was present in 33.3% in the 
receptors group, and in 48.5% in the donors group. The distribution of different 
alleles in both groups was not statistically significant. Among studied receptors 16 
had early recidive of HCV infection (less than one year after liver transplantation). 
The genetic profile of IL28 polymorphisms in the donor liver didn’t correlate to 
occurrence of early recidive. 
Conclusions: We validated an assay that can be performed in whole blood, plasma 
samples or paraffin-embedded tissues. This allowed us to use archived samples 
from paired receptors and donors of liver transplantation due to chronic HCV 
infection. Frequency of genotypes for these SNPs was determined in both 
populations and the frequency of them didn’t differ among donors and receptors. The 
genetic profile of IL28 polymorphisms in the donor liver or from the receptor didn’t 
correlate to occurrence of early recidive, but the number of studied patients is still 
very small. 
 
ID43. Molecular Genotyping of Hepatitis C Virus (HCV) Using the eSENSOR 
HCVg Direct Test with the XT-8 Multiplex Test System Compared to 
Sequencing and the eSENSOR Multiplex HCV Genotyping Test  
M.J. Bankowski, S. Ono, C. Ying, T. Koyamatsu, W. Kim 
Diagnostic Laboratory Services and the Queen's Medical Center, Aiea, HI. 
Introduction: HCV is a single-stranded RNA virus that has infected approximately 
2% of the world population. Chronic infection is extremely high at about 70% and 
hepatocellular carcinoma is one possible serious outcome. Six major genotypes 
(including many subtypes) are currently described. The most common subtypes are 
1a and 1b (~65%) and the other genotypes (2 to 6) vary in prevalence and 
geographic location. Major advances have been made in the treatment of HCV 
infection with the introduction of new antivirals (e.g. Telaprevir and Boceprevir). 
Laboratory testing is critical in the management and treatment of HCV infection, 
most notably HCV viral load and HCV genotyping. Therefore, accurate and timely 
HCV genotyping is critical in determining both the choice of therapy and predicting 
therapeutic response. Methods: Specimens (N=52) included in this study consisted 
of five genotypes and selected subtypes: 1a (n=14), 1b (n=31), 2b (n=2), 3 (n=3), 4 883
8AMP Abstracts(n=1), and 6 (n=1). The eSensor HCVg Direct Test (GenMarkDx) using the eSensor 
XT-8 instrument was compared to both HCV sequencing and the eSensor multiplex 
HCV Genotyping Test (v1) (GenMarkDx). HCV sequencing was accomplished using 
the TRUGENE HCV 5' NC Genotyping Kit (Siemens) with the OpenGene DNA 
Sequencing System and the OpenGene system software. Results: The 
genotype/subtype concordance between the eSensor HCVg Direct Test compared to 
sequencing and/or the eSensor multiplex HCV Genotyping Test (v1) test was 76.9% 
(40/52). The lack of concordance between the different genotyping tests mostly 
occurred within HCV genotype 1b. The eSensor Direct Test revealed a limit of 
detection for genotypes/subtypes 1a and 3 at 635 and 445 IU/mL respectively. 
Conclusions: The test performance of the eSensor HCVg Direct Test using the 
eSensor XT-8 instrument compared favorably with sequencing. Notable differences 
were found between the two eSensor tests, which is most likely due to the addition of 
the core region in the HCVg Direct Test. It does not offer the range of subtyping seen 
with the TRUGENE HCV 5' Genotyping Kit, but the labor and time savings and 
sensitive LOD using the eSensor HCVg Direct Test offers favorable advantages for 
routine use in the clinical laboratory.  
 
ID44. Laboratory Evaluation of the Vela DX Sentosa MRSA PCR RUO 
R.H. Widen, S. Silbert, D. Uy, C. Kubasek, E. Ventrone 
Tampa General Hospital, Tampa, FL. 
Introduction: Methicillin-resistant Staphylococcus aureus (MRSA) is a common 
infectious agent encountered in the health care setting and presents a significant 
nosocomial infection risk for patients. Screening for MRSA colonization using PCR or 
other amplification methods is now commonly performed in many institutions to 
control nosocomial transmission and to identify patients for aggressive 
decolonization prior to surgical or other procedures. This study tests the performance 
of the Vela Diagnostics Sentosa SA MRSA Test (VelaDx, Singapore) in comparison 
with the BD MAX MRSA assay (BD, Sparks, MD) for the detection of MRSA 
colonization. Methods: Specimens were collected and transported using ESwabs 
(Copan, Italy) and split to perform both tests. The BD MAX MRSA assay was 
performed following the manufacturer's instructions other than using the the ESwab 
for collection/transport. The Sentosa SA MRSA PCR Test was performed on the 
Vela Diagnostics Sentosa automated platform, comprised of extraction of 235 μL of 
PK treated ESwab media on the Sentosa SX101 followed by qPCR on the VelaDX 
RotorgeneQ. The Sentosa SX101 performs nucleic acid purification and qPCR setup 
on the RGQ ring of up to 44 samples simultaneously in about 2.5 hours. The 
Sentosa SA MSRA PCR Test is a multiplex qPCR that detects and differentiates 
between SA, MRSA, and “empty-cassette”-SA species by targeting the SA-specific 
genes eap and SCCmec:orfX and the MRSA specific mecA in the orange, yellow, 
and green channel, and amplifies an extraction control in the red channel. Results: 
A total of 131 samples were tested. The BD MAX assay detected 49 positive 
samples and 82 negative samples. The Vela DX assay detected MRSA in 45 
samples and was negative for 86 samples. There were 6 discrepant samples: 5 were 
positive only on the BD MAX assay and 1 was positive only on the Vela DX. Further 
study of the discordant specimens is indicated to determine if these specimens were 
empty-casette SA or MRSA. The overall agreement of results between the 2 
systems was 95.4%. Conclusions: The results indicate that the Vela DX assay has 
good sensitivity and specificity in detecting MRSA in nares samples collected and 
transported with Copan ESwab transport tubes. The agreement between the Vela 
DX and the BD MAX systems was greater than 95%.  
 
ID45. Comparison of AdvanSure HPV GenoBlot Assay with INNO-LiPA HPV 
Genotyping for Human Papillomavirus Genotyping 
H. Chung, M. Lee 
Ewha Womans University School of Medicine, Seoul, Korea. 
Introduction: We evaluated the performance of recently developed AdvanSure HPV 
GenoBlot Assay (AdvanSure; LG Life Science, Korea) compared to INNO-LiPA HPV 
Genotyping (INNO-LiPA; Innogenetics, Belgium) for the molecular genotyping of 
human papillomavirus (HPV). Methods: A total of 200 cervical swab specimens that 
were HPV DNA positive by Hybrid Capture 2 HPV test (Qiagen, USA) were collected 
and genotyped by AdvanSure and INNO-LiPA. AdvanSure can detect 35 HPV 
genotypes (20 high-risk and 15 low-risk HPV genotypes) and INNO-LiPA can detect 
28 HPV types (19 high-risk and 9 low-risk HPV genotypes). DNA extraction and 
genotyping assay were performed according to the manufacturer’s instructions. 
Samples that showed discrepancy were genotyped using sequencing. All data were 
analyzed using Cohen’s kappa and McNemar’s tests. Results: Among the 194 
samples (excluding 6 negative specimens), 192 were positive in AdvanSure; 133 
(68.6%) single genotypes and 59 (30.4%) multiple genotypes. The percent 
agreement of two assays was ranged from 95.4% to 100% according to genotype. 
Analyzing kappa values showed almost perfect agreement (>0.9) for high-risk HPV 84types 16, 18 and 33, and substantial agreement (0.724) for HPV type 31. The 
positive rates of two assays for frequent HPV types (16, 31, 33, 53, 58, 66, 68, and 
70) were not statistically different, but for HPV types 51, 52, and 56, INNO-LiPA 
showed higher positive rates than AdvanSure (P<0.05). All of HPV types that can be 
only detected by AdvanSure (HPV types 32, 34, 42, 55, 61, 62, and 81) were 
confirmed by sequencing. Most of 64 specimens showing discrepancy were due to 
multiple HPV infections. Conclusions: AdvanSure HPV GenoBlot Assay was 
comparable with well-established INNO-LiPA HPV Genotyping. AdvanSure HPV 
GenoBlot Assay is suitable for HPV genotyping in clinical laboratories. 
 
ID46. Development of AccuType HIV-1 and HIV-2 Subtype Reference Virus 
Panel for Assay Validation and Optimization 
B. Anekella, R. Meixell, W. Harwood, C. Huang, M. Unger, R. Vemula, L. Nguyen 
SeraCare Life Sciences, Inc., Gaithersburg, MD. 
Introduction: A major obstacle in controlling human immunodeficiency virus is its 
high genetic variability. HIV is divided into two major types, (HIV-1 and HIV-2), with 
several groups (M, N, O, and P within HIV-1). There is an unmet need among 
researchers to access well characterized viral isolates for basic research, assay 
development and validation. We acquired 44 cultured isolates of HIV-1 representing 
the major subtypes occurring worldwide, including A, B, C, D, E, F, G, H, and O as a 
part of the NED (NIH-ENVA-DOD) collection (Huang D et al). Since new variants are 
constantly evolving, SeraCare aims to add new isolates of currently circulating 
variants to this collection. Seven new isolates (A, D, and O) were added to the NED 
collection, including HIV-2 subtypes A and B. We sourced plasma samples 
worldwide and are currently rescuing additional HIV-1 isolates representing D, F G, 
J, and K. Methods: AccuType reference panels consisting of 51 HIV-1 isolates were 
tested on Roche HIV MWP v1.5, Roche Cobas TaqMan v2.0 and Abbott m2000 
(viral load); Siemens TRUEGENE assay (Genotyping), Perkin Elmer assay (p24 
Antigen) and MAGI assay (Co-receptor usage CCR5/CXCR4). Viral isolates were 
cultured under GMP conditions using PBMCs to manufacture large batches at high 
titer. New HIV subtypes were isolated from positive plasma samples through 
infection of PHA stimulated PBMC from uninfected blood donors. Culture 
supernatants were monitored for HIV infectivity by p24 Ag for 21 days and positive 
samples were further expanded. Results: Viral load data for all 51 HIV-1isolates 
tested on 3 assays will be presented. Comparison of viral load data showed good 
correlation between the assays for the Group M cultured virus. TRUEGENE 
genotyping results were concordant with the previously reported results (NED panel 
data) except for subtype H (BCF-KITA isolate) that was called as G with the 
TRUEGENE assay. Additional confirmation analysis will be performed by 
sequencing the entire genome. Since there are no approved assays for HIV-2, viral 
load and genotype for the HIV-2 were assigned based on lab developed assays. 
Conclusions: AccuType panels consisting of well characterized, high titer HIV-1 and 
HIV-2 subtypes have been manufactured. These reference materials are a good 
resource for use in assay development, validation, and evaluation.  
 
ID47. Occult Hepatitis B Virus Infection in Korean Patients with Anti-HBc 
Alone 
E. You, S. Kang, M. Kim, W. Lee 
Kyung Hee University College of Medicine, Seoul, Korea. 
Introduction: "Anti-HBc alone" or "isolated anti-HBc" is defined as the detection of 
anti-HBc in the serum without HBsAg or anti-HBs and can occur in various 
scenarios, but the most clinically relevant situation is occult hepatitis B virus (HBV) 
infection (OBI). The purpose of this study was to evaluate the prevalence and clinical 
relevance of anti-HBc alone and of OBI with anti-HBc alone from an unselected 
hospital population including individuals from a health promotion center (HPC). 
Methods: A total of 14,253 patients referred for hepatitis B surface antigen 
(HBsAg)/anti-HBs testing were classified into either the HPC group or the patient 
group. For patients who were negative for both HBsAg and anti-HBs, an anti-HBc 
test was additionally performed. An HBV DNA real-time PCR test was performed on 
571 anti-HBc alone patients, and their demographic and clinical data were reviewed. 
Results: The incidence of N/N for HBsAg/anti-HBs was 26.5% and anti-HBc positive 
(i.e. anti-HBc alone) among them was 22.4%. The measured prevalence of anti-HBc 
alone was 5.9% and was higher in males (7.4%), elderly patients (over 61 years, 
14.2%), and the patient group (6.4%) than in females (4.6%), the younger (under 40 
years, 1.1%), and the HPC group (4.6%), respectively. The prevalence of OBI with 
HBV DNA positivity was 4.7% (27 among 571 anti-HBc alone patients) and was also 
higher in males (4.9%), elderly people (over 61 years, 5.5%), and the patients group 
(5.3%) than in females (4.5%), the younger (under 40 years, 0%), and the HPC 
group (2.9%). The levels of HBV DNA load were very low (less than 200 IU/mL and 
most OBI individuals had no liver disease and no history of HBV infection. 
Conclusions: Based on this study, if 400 people were to be tested serologically for jmd.amjpathol.org ■ The Journal of Molecular Diagnostics
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isolated anti-HBc cases, and only one of these would be OBI and positive for HBV 
DNA. The prevalence of anti-HBc alone and OBI are affected by the methods of 
detection, subject population, and constituent factors such as sex and age. Although 
detection of HBV DNA does not always indicate infectivity, highly sensitive 
standardized HBV DNA tests are needed to exclude the possibility of OBI in clinical 
settings such as selecting blood donors, immunosuppression, transplantation and 
transfusion, especially in the advanced age group. 
 
ID48. Comparison of Illumigene C. difficile Assay and Portrait Toxigenic C.
difficile Assay for the Detection of Toxigenic Clostridium difficile in Pediatric 
Patients 
R. Mansilla1, R. Blanche1, D. Mahinan1, J. Dien Bard2 
1Children's Hospital Los Angeles, Los Angeles, CA; 2Children's Hospital Los 
Angeles, University of Southern California, Los Angeles, CA. 
Introduction: Toxigenic Clostridium difficile (CDT) is the causative agent of a 
spectrum of clinical manifestations ranging from mild diarrhea to 
pseudomembranous colitis and death. Accurate detection is imperative for disease 
management and control with molecular detection being well accepted as the 
diagnostic standard. We sought to compare the performance of two molecular 
assays, illumigene C. difficile (Meridian Bioscience) and Portrait Toxigenic C. difficile 
(Great Basin Corporation) for detection of CDT from stool samples. In addition, we 
investigate the workflow capabilities of the two assays in the microbiology laboratory. 
Methods: Both molecular assays were performed on 100 liquid or semi-formed 
clinical stool specimens collected from pediatric patients within 24 h of receipt. The 
assay was batched once daily and performed by Clinical Laboratory Scientists 
(CLS). In contrast, up to two stools were tested at a time using Portrait Toxigenic C. 
difficile (two bench-top analyzers were available); Clinical Laboratory Technicians 
(CLT) primarily performed all testing for this assay. Illumigene C. difficile was 
considered the reference method and all discrepant and invalid results were 
repeated. Results: When comparing Portrait Toxigenic C. difficile with illumigene C. 
difficile, 30 and 29 positives were identified, respectively. Both assays correctly 
identified 28 positive cases; Portrait Toxigenic C. difficile detected 2 more positives 
and missed 1 positive. Overall sensitivity, specificity, and concordance of Portrait 
Toxigenic C. difficile were 96.6%, 97.0%, and 96.8%, respectively. The positive 
predictive value was 98.5%, and the negative predictive value was 93.3%. Illumigene 
C. difficile had 3 (5/100, 5%) more invalid results compared to Portrait Toxigenic C. 
difficile (2/100, 2%). One specimen that was invalid by illumigene C. difficile was 
found to be positive by Portrait Toxigenic C. difficile. With regards to workflow, 
illumigene C. difficile is performed once daily by the CLS, yielding an average turn-
around-time (TAT) of 15 hours. In contrast, Portrait Toxigenic C. difficile is semi-
automated and tested on arrival by the CLT, significantly decreasing the TAT to 
about 1-2 hours. Conclusions: The performance characteristics of Portrait 
Toxigenic C. difficile are comparable to illumigene C. difficile and is an appropriate 
option for the diagnosis of C. difficile infection. In addition, a lower number of invalids 
were detected using Portrait Toxigenic C. difficile, decreasing the need for repeat 
testing. The semi-automated and sample-to-answer capability of Portrait Toxigenic 
C. difficile allows for true ‘stat’ testing of CDT in the microbiology laboratory, allowing 
for prompt therapeutic response and infection control. 
 
ID49. Characterization of a Novel Melt Curve Using the Roche LightCycler 
Real-Time PCR HSV 1/2 ASR: Frequency of This Novel (Low) and Commonly 
Encountered (Intermediate) Melt Curves 
A. Almradi1, J.P. Gibson1, A.E. Prada1, M.J. Espy2, B.S. Pritt2, B.L. Boyanton1 
1Beaumont Health System, Royal Oak, MI; 2Mayo Clinic, Rochester, MN. 
Introduction: Traditional methods to detect herpes simplex virus (HSV) have been 
largely replaced by more efficient and sensitive molecular methods. The commonly 
employed Roche LightCycler real-time PCR HSV 1/2 ASR (HSV PCR) assay 
amplifies a 215 bp product of the HSV polymerase (pol) gene with amplicon 
detection by FRET hybridization probes. Genotyping is performed by melt curve 
analysis, whereby expected polymorphisms within the amplicon yield different 
melting temperatures: HSV-1 (~55°C), HSV-2 (~70°C). Occasionally, polymorphisms 
within the amplicon produce “intermediate” melt curves (Tm range 60°C to 62°C) – 
these have been described previously. We recently encountered a novel variant of 
HSV-1 that yielded no visible amplification curve and was detected solely by melt 
curve analysis (~Tm 47°C). Herein, the frequency of this novel variant and the 
previously described intermediate melting curves are described. Methods: A swab 
specimen, obtained from a 24-year-old female with labia majora vesicular lesions (5 
days duration), was submitted to Beaumont Laboratory in M4-RT viral transport 
medium. Following nucleic acid extraction on the NucliSENS easyMAG (BioMerieux), 
HCV PCR was performed. Rapid shell vial (ELVIS, Diagnostic Hybrids) and he Journal of Molecular Diagnostics ■ jmd.amjpathol.orgconventional cell (A549 and MRC-5, Diagnostic Hybrids) cultures were performed. 
DNA sequencing was performed by Mayo Clinic. HSV PCR results (December 2011 
to April 2013) from Beaumont Laboratory were reviewed to determine the frequency 
of expected and variant melting curves. Results: Characterization of this variant by 
ELVIS yielded HSV-1. HSV PCR of the cultivated isolate confirmed the presence of 
the novel 47oC melt curve. DNA sequencing of the cultivated isolate yielded a 
unique probe binding-site polymorphism responsible for the 47°C melt curve. The 
novel 47°C melt curve has only been observed once at Beaumont Laboratory (1 of 
22,609 specimens = 0.0045%). The frequency of melt curves for HSV-1 (~55°C), 
HSV-2 (~70°C) and HSV-intermediate (60°C -62°C) was 13.58%, 12.40%, and 
1.35% respectively. Conclusions: The Roche HSV PCR assay yields robust 
genotype results in the vast majority of cases; intermediate melt curves are relatively 
uncommon and novel polymorphisms conferring unique melt curves are rare. When 
variant melt curves are encountered and genotyping is needed, DNA sequencing, 
cell culture-based methods (i.e., ELVIS) or an alternative real-time PCR assay 
should be employed. The 47°C melt curve described herein is extremely rare, but is 
noteworthy, as it highlights the need to review both the amplification and melt curves 
for every specimen. Failure to comply, especially with less skilled technical 
personnel may lead to spurious test results. 
 
ID50. Therapeutic Implications of Low-Frequency Drug-Resistance 
Mutations in HIV Patients Detected by Next-Generation Sequencing (NGS) 
A.M. Golembieski, A. Levin, C. Taramona Espinoza, D. Baxa, N. Markowitz 
Henry Ford Health System, Detroit, MI. 
Introduction: The role of NGS in the clinical management of HIV infection is still 
unresolved, and the relationship of low-frequency polymorphisms to treatment failure 
and their correlation to disease progression is a significant issue. We hypothesized 
that polymorphisms detected by NGS would provide a worst-case scenario for future 
therapy failure and constructed composite viral sequences to evaluate potential loss 
of antiretroviral susceptibility. Methods: The viral protease and the first 735 
nucleotides of the reverse transcriptase region were reverse transcribed and 
sequenced using the Ion Torrent PGM semiconductor sequencing system using 
residual clinical samples from 13 HIV-1 clade B patients. Alignment to the HIV 
reference sequence HXB2 and base calling was conducted using the Torrent Suite 
Software (version 3.0), with a sample viral variant detection frequency limit of 0.5%. 
Antiretroviral therapy (ART) susceptibilities for reverse transcriptase and protease 
inhibitors were then evaluated by virtual phenotype (VircoType) using all variants 
identified and only those detected at or above a frequency of 20%, to mimic the 
variant detection threshold achieved by clinical Sanger sequencing.  
Results: Patient characteristics were as follows: 8 were male; 76.9% were African 
American; mean time from diagnosis to the time of sequencing was 5.3 years; and 
69.2% were ART experienced. Almost all patients had small to moderate changes in 
ART susceptibility based on the VircoType interpretation. Relative to the 20% 
frequency threshold, clinically significant alterations in interpretation of drug activity 
from susceptible to reduced response/resistance were demonstrated in 7 persons 
(54%) when low frequency (< 20%) mutations were included. These changes in 
susceptibility were almost exclusively in the non-nucleoside (NNRTI) drug class. 
These additional mutations ranged in frequency from 0.72% to 18.96%. 
Conclusions: NGS technologies can detect minor variants below the 20% level. 
Evidence suggests that these minor variants are clinically significant and can be 
predictive of ART failure. In these unselected patients, more than half experienced 
changes towards decreased susceptibility particularly in the NNRTI class when 
minor variants were included in the interpretation. Our composite sequences that 
included the low frequency mutations detected by deep sequencing resulted in 
clinically significant resistance calls when entered in the interpretative algorithm. 
Although the impact on clinical disease progression and virologic failure will need to 
be borne out by continued follow up, the resistance profile determined by our 
process concurs with other studies that have detected low-frequency HIV-1 drug 
resistance mutations and a risk of NNRTI failure. 
 
ID51. Detection of Bordetella pertussis and B. parapertussis Using a Non-
Instrumented, Isothermal Assay 
T.R. Ott, W. Tang, M. Wilson, A.L. Kim, H. Kong, D. Cross, T.A. Ranalli, T.D. Pack 
Quidel Corporation, San Diego, CA. 
Introduction: Pertussis, or whooping cough, is a highly contagious bacterial disease 
causing uncontrollable, violent coughing fits that can result in permanent disability in 
infants, and even death. Pertussis is caused by the Bordetella pertussis (BP) or B. 
parapertussis (BPP) bacteria. An assay is being developed to detect the presence of 
BP or BPP in nasopharyngeal swab specimens in a little over an hour from sample 
to result. This non-instrumented molecular test combines simple sample processing, 
isothermal helicase dependent amplification (HDA) technology, and a self-contained 885
8AMP Abstractsdisposable amplicon detection device. This assay can be performed by personnel 
without extensive molecular biology training and does not require the use of 
expensive instrumentation. Methods: For AmpliVue Bordetella, 50 ȝl of transport 
media were transferred into a dilution tube with buffer. 50 ȝl of the diluted specimen 
were transferred to a lysis buffer tube, and the cells were briefly heat-lysed. 50 ȝl 
were then transferred to a tube containing lyophilized HDA reagents and 
amplification occurred at 64°C for 60 minutes. Detection of the amplified product 
occurred in lateral-flow detection cassettes. Bacterial stocks and genomic DNA of BP 
and BPP strains were serially diluted in contrived negative nasal matrix and tested 
using the AmpliVue Bordetella Assay to determine a limit of detection (LOD) and 
strain inclusivity. Potential cross-reactive bacteria and viruses were tested at 
clinically relevant levels to confirm specificity of the assay. Preliminary clinical 
performance was determined by testing 32 blinded and frozen clinical samples with 
AmpliVue Bordetella and Eragen Analyte Specific Reagents (ASR). Results: For 
genomic DNA, the LOD was determined to be 0.6 copies/reaction for BP strain 
ATCC 589, and 2.5 copies/reaction for BPP strain ATCC 15311. For intact bacteria, 
the LOD was found to be 0.3 cfu/reaction for BP strain ATCC 9797 and 20 
cfu/reaction for BPP strain ATCC 15311. The assay also was shown to detect two 
additional BP strains, and another BPP strain tested at near-LOD. No cross-reactivity 
was observed with any of the microorganisms tested. Of the 32 clinical samples 
tested, 12 samples tested positive for BP, 8 tested positive for BPP, and 12 tested 
negative for both BP and BPP. These results agreed 100% with the Eragen ASR. 
Conclusions: Results from preliminary studies indicate that the AmpliVue Bordetella 
Assay is highly sensitive, specific, and easy-to-use. 
 
ID52. Validation of the VELA Diagnostics Sentosa SA Real-Time PCR Assays 
for VRE and MRSA on the Sentosa SX Platform 
H.A. Webber, A. Orlando, M. Ianosi-Irimie 
NorDx, Scarborough, ME. 
Introduction: Hospital acquired infections (HAI') are contracted by approximately 
5% to 10% of patients admitted into US hospitals and are responsible for thousands 
of deaths each year. As a result, screening for the antibiotic resistant Enterococcus 
and Staphylococcus species organisms that cause many of these infections has 
become a priority for hospitals, long-term care facilities, and laboratories across the 
nation. Faster turnaround time demands lead us to compare a real-time PCR-based 
assay to our current chromogenic agar (Hardy Diagnostics, Santa Maria, CA; 
Biomerieux, Durham, NC) culture methods. In about 4 hours, the vanA/vanB and 
MRSA/SA PCR assays (VELA Diagnostics, Fairfield, NJ) can detect multiple genes 
associated with vancomycin and methicillin resistance in certain species of 
Enterococcus (VRE) and Staphylococcus (MRSA). Samples with colony growth on 
chromogenic agar are worked-up by a microbiology technologist and finalized over a 
period of 1-4 days. The purpose of these studies was to evaluate the performance of 
the VELA PCR assays as compared to our current methodology. Methods: Samples 
were collected in SP Brand CultureSwabs* (McGaw Park, IL) and then transferred to 
Copan ESwab (BD, Sparks, MD) after plating. Following the current microbiology 
work-up, an aliquot of the sample was subjected to an automated glass bead lysis 
protocol on the Sentosa SX and PCR using vanA/vanB and MRSA/SA real-time PCR 
assays (VELA Diagnostics). Results: Of the 205 rectal swabs tested for VRE, 6 
discrepant samples were identified (3%); all were negative by culture and positive for 
either vanA or vanB genes on the Sentosa SX platform (VELA Diagnostics) as well 
as by a different clinically approved PCR method. Out of 119 nares/groins swabs 
evaluated for MRSA, 4 discrepant samples were identified (3.4%), and 3 were 
negative by culture and positive by VELA PCR; 1 was positive by culture and 
negative by PCR. Alternate PCR assays from different vendors confirmed all 
discrepant results in favor of the VELA real-time PCR assays. Conclusions: These 
results indicate that both the vanA/vanB and MRSA/SA real-time PCR assays 
demonstrated a similar performance characteristic with other similar products 
available currently on the market and would improve the TAT compared to the 
current culture methods, allowing a more rapid identification and isolation of 
colonized patients and streamlining infection control practices to reduce the spread 
of HAIs.  
 
ID53. Evaluation of the Luminex xTAG Gastrointestinal Pathogen Panel and 
Analyte-Specific Reagents for the Detection of Enteropathogens in Stool 
S. Sefers, J. Chappell 
Vanderbilt University Medical Center, Nashville, TN. 
Introduction: The xTAG Gastrointestinal Pathogen Panel (GPP, Luminex Molecular 
Diagnostics, Toronto, ON, Canada) is a method for the simultaneous detection and 
differentiation of common bacterial, viral, and parasitic etiologies of gastroenteritis 
and colitis in stool. This assay operates on the principle of highly multiplexed PCR of 
pathogen-specific nucleic acid sequences followed by amplicon sorting on 86fluorescently addressed microspheres. GPP recently received FDA approval for the 
following targets: Campylobacter, Clostridium difficile toxins A/B, Cryptosporidium, 
Escherichia coli O157, Enterotoxigenic E. coli (ETEC) heat-labile and heat-stable 
toxins (LT/ST), Giardia, norovirus GI/GII, rotavirus A, Salmonella, Shiga-like toxin-
producing E. coli (STEC) stx 1/stx 2, and Shigella. Using specimens of known 
pathogen composition, we evaluated performance of GPP plus Luminex analyte-
specific reagents (ASRs) for Entamoeba histolytica, adenovirus 40/41, and Yersinia 
enterocolitica, which are deployable on the xTAG platform. Methods: A total of 109 
frozen stool samples (4 to 12 positive and 97 to 105 negative for each target) 
consisting of patient specimens and normal stool supplemented with commercially 
prepared and cultured reference materials (ZeptoMetrix and ATCC) were evaluated. 
Comparator methods included bacterial culture, microscopic examination for 
protozoan cysts, cytotoxicity assay, enzyme immunoassay, PCR, and bi-directional 
sequencing. GPP testing was performed according to the IVD protocol, and ASR 
targets were analyzed in similar fashion. Disagreements between GPP results and 
nominal specimen composition were resolved by real-time and conventional PCR 
and sequencing. Results: Crude positive and negative agreement of GPP relative to 
comparators was 100% and 94%, respectively. Following discrepant resolution, 1 of 
12 norovirus detections was deemed false-positive, yielding an adjudicated 
specificity of 92% for this target and final overall specificity and total agreement of 
98% and 99%, respectively, for the full set of analytes (Cohen’s Kappa, total 
agreement = 0.98 [0.95 to 1.02]). Studies to establish limits of detection and 
reproducibility for ASR targets are ongoing. Total hands-on time, including pre-
analytic specimen lysis and nucleic-acid extraction, was approximately 7 hours. 
Conclusions: The Luminex xTAG GPP performed favorably as a modality of parallel 
testing for multiple bacterial, viral, and parasitic enteric pathogens in unitary assay 
format. A combination of accuracy, broad pathogen coverage, high specimen 
capacity, and single-shift turnaround time enables this assay as a useful tool for the 
clinical laboratory evaluation of suspected gastrointestinal infections.  
 
ID54. Laboratory Evaluation of the Vela DX Sentosa SA vanA/vanB PCR Test 
(RUO) 
R.H. Widen, C. Kubasek, E. Ventrone, S. Silbert 
Tampa General Hospital, Tampa, FL. 
Introduction: Vancomycin-resistant enterococci (VRE) are a relatively common 
cause of infections in hospitalized patients. VRE also represent a nosocomial 
transmission risk within the health care setting. Screening for VRE colonization by 
PCR or culture methods using rectal swab samples represents a means of 
potentially limiting transmission, and the associated increase in treatment costs and 
length of hospital stay, through enhanced infection prevention protocols. PCR-based 
assays target the vanA gene, or the vanA plus the vanB genes, both of which confer 
vancomycin resistance. PCR offers improved turnaround time and enhanced 
sensitivity relative to culture-based tests. This study was designed to compare the 
performance of the Vela DX (Singapore) Sentosa SA vanA/vanB PCR Test (RUO) 
with the Cepheid (Sunnyvale, California) Xpert vanA PCR assay, our standard of 
care method. Methods: The Xpert vanA assay was performed following the 
manufacturer's instructions with a laboratory modification to use ESwabs (Copan, 
Italy) as the specimen transport method. The Sentosa SA vanA/vanB assay was 
performed on the Vela DX Sentosa automated platform, comprised of extraction of 
235 μl of protease K- treated ESwab media on the Sentosa SX101, followed by 
qPCR on the Vela DX Rotor-Gene Q MDx 5plex HRM (RGQ). The Sentosa SX101 
performs nucleic acid purification and qPCR set up on the RGQ ring for up to 44 
clinical samples simultaneously in approximately 2.5 hours. The Vela DX VRE assay 
includes primers specific to the vanA and vanB gene, as well as an internal 
extraction/amplification control. Results: A total of 198 samples were tested. The 
Xpert vanA assay detected 71 positive samples and 127 negative samples. The Vela 
DX assay detected VRE (vanA) in 67 samples; 131 samples were negative. There 
were 10 discrepant samples - 7 were positive only on the Xpert vanA assay and 3 
were positive only on the Vela DX assay. The overall agreement of results between 
the two systems was 95%. Conclusions: The results indicate that the Vela DX 
Sentosa SA vanA/vanB PCR Test (RUO) has good sensitivity and specificity in 
detecting VRE in rectal swab samples collected and transported with Copan ESwab 
transport tubes. The overall agreement between the Vela DX and the Xpert systems 
was 95%. The results indicate that the Vela DX Sentosa SA vanA/vanB PCR Test 
(RUO) would represent an effective option for VRE screening after achieving FDA 
clearance.  
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 AMP AbstractsID55. Evaluation of Alere i Influenza System for Rapid Detection of Influenza 
Viruses A and B 
S. Nie1, J. Stiles 1, A. Mikhlina1, X. Lu2, E. Babady1, Y.W. Tang1 
1Memorial Sloan-Kettering Cancer Center, New York, NY; 2Futian Hospital, 
Guangdong Medical College, Shenzhen, Guang Dong, China. 
Introduction: Influenza (Flu) viruses cause contagious respiratory illnesses 
associated with significant morbidity and mortality. Rapid and accurate diagnosis is 
important for healthcare-associated infection control as well as for patient 
management. The i Influenza A&B assay (Alere Scarborough, Scarborough, ME) is 
an isothermal amplification-based integrated system for detection and differentiation 
of FluA and FluB directly from nasopharyngeal swabs or after elution in viral 
transport media (VTM). The objective of this study was to evaluate the clinical 
performance of the Alere i Influenza A&B System with retrospective VTM specimens. 
Methods: VTM specimens, which were previously tested for respiratory pathogens 
by the FilmArray Respiratory Panel (FA-RP) assay at the Memorial Sloan-Kettering 
Cancer Center, were retrieved from storage at -80°C. Selected specimens were 
originally collected and tested between December 15, 2012 and March 1, 2013 
during the peak of an influenza outbreak. The clinical performance of the Alere i 
Influenza A&B System was determined by using the FA-RP as the gold standard. 
Results: A total of 210 VTM specimens including 40 FluA(H1N1), 40 FluA(H3N2), 40 
FluB as well as 90 Flu negatives as determined by the FA-RP were tested with the 
Alere i Influenza A&B System. The Alere system detected 34 FluA(H1N1), 37 
FluA(H3N2), 36 FluB, and 102 negative specimens, while generating one invalid 
result. Using the FA-RP as the gold standard, the sensitivity of the Alere System was 
88.8% (95% CI, 80.0%  to 94.0%) for FluA and 90.0% (95% CI, 77.0% to 96.0%) for 
FluB. The overall specificity was 98.9% (95% CI, 94.0% to 99.8%). The System was 
simple and easy to perform and the results were automatically reported within 15 
min. Conclusions: The diagnostic sensitivity and specificity of the Alere i Influenza 
A&B System were comparable to PCR when VTM specimens with a freeze-thaw 
cycle were tested. The integrated, rapid and simple characteristics of the system 
make it potentially suitable for point-of-care testing. 
 
ID56. Fungal Molecular Identification by Sequencing Internal Transcribed 
Spacer (ITS) and Domains 1 and 2 of the Large Ribosomal Subunit (D1/D2) 
Regions in a Clinical Setting 
J.R. Lindner, K. Vadlamudi, D.A. Sutton, A.W. Fothergill, D.I. McCarthy, E.H. 
Thompson, P.A. George, B.L. Wickes, N. Wiederhold, W. Furmaga, H. Fan 
University of Texas Health Science Center at San Antonio, San Antonio, TX. 
Introduction: DNA sequencing of the internal transcribed spacer (ITS) and domains 
1 and 2 of the large ribosomal subunit (D1/D2) has become a valuable tool for the 
molecular identification of clinically important fungi. The assay has been validated 
and offered in our CLIA certified molecular diagnostics laboratory since August 2012. 
This abstract presents results of fungal molecular identification using both ITS and 
D1/D2 regions. Methods: A total of 610 (440 mold, 170 yeast) isolates were 
received for molecular identification from 08/2012 to 05/2013. Many clinically 
relevant fungi were included, such as members of the Mucorales, Candida, 
Trichosporon, Cryptococcus, and Exophiala species. Some genera that require 
different loci for molecular identification (e.g., Aspergillus, Fusarium, 
Pseudallescheria/Scedosporium and some black molds) were excluded. Fungal DNA 
was extracted by a combination of cetyl trimethyl-ammonium bromide (CTAB) buffer 
and physical disruption by bead beating, followed by manual chloroform/ethanol 
extraction. The ITS and D1/D2 target regions were then amplified using the 
panfungal ITS1/NL4 primer pair. Takara Ex Taq (Takara Biotechnology Co., LTD) 
and 4% DMSO were used for PCR, and the products were sequenced bi-
directionally using the ITS1/ITS4 and NL1/NL4 primers, BigDye sequencing 
reagents, and the ABI3130xl Genetic Analyzer (Applied Biosystems). The sequences 
were uploaded, aligned, and edited using the Lasergene software (DNASTAR, Inc). 
The sequences were then queried in the CBS-KNAW database. Final identification 
was achieved by combining morphologic/physiologic characteristics with molecular 
sequence data. Results: In conjunction with fungal phenotypic data, molecular 
identification was successfully obtained to the species or genus levels in 87% 
(530/610) isolates when both ITS and D1/D2 sequence data were used. Failure of 
molecular identification in 13% (80/610) of isolates was caused by either technical or 
biological issues: 4 contaminated isolates or incorrect sample type, 6 failed DNA 
extraction, 17 failed ITS1/NL4 PCR (14/17 amplified the single ITS or D1/D2 region), 
23 showed sequence heterogeneity caused by either indels or homopolymeric 
sequences (clean sequence for single ITS or D1/D2 region was able to be obtained 
in 20/23 isolates), and 30 sequence results failed to produce high-similarity BLAST 
matches for one of the two gene regions, most likely due to a lack of database 
comprehensiveness (3/30 did not have matches for either ITS or D1/D2). 
Conclusions: Molecular identification using ITS and D1/D2 gene sequences is a e Journal of Molecular Diagnostics ■ jmd.amjpathol.orgpowerful tool for the identification of fungi. Combined with fungal 
morphologic/physiologic features, it provides a rapid and accurate method for 
identification of several clinically significant fungi. 
 
ID57. Performance Evaluation of the Cytomegalovirus DNA qPCR Artus 
System on the QIAsymphony RGQ System Using Small Plasma Sample 
M.F. Sabato1, P. Anderson2, P. Vo2, C.I. Dumur1, A. Ferreira-Gonzalez1 
1Virginia Commonwealth University, Richmond, VA; 2Virginia Commonwealth 
University Health System, Richmond, VA. 
Introduction: Cytomegalovirus (CMV) DNA quantification in plasma has become the 
standard of care for disease diagnosis in post-transplant patients. Data addressing 
the performance characteristics of the QIAsymphony RGQ system for CMV 
quantification in plasma using Qiagen artus CMV reagents have been reported using 
a large input volume of plasma (1.2 ml). It would be desirable to have a method that 
provides a clinically useful quantification range with smaller input sample. A large 
volume of plasma is not always available from a patient sample, especially for 
pediatrics and when other tests are ordered on the same sample. In this study, the 
performance of the QIAsymphony RGQ system for CMV DNA quantification in 
plasma using artus CMV reagents (Qiagen) was evaluated using a small input 
volume of plasma. Results were compared to our Laboratory-Developed Test (LDT) 
for correlation and agreement. Methods: The Acrometrix CMVtc quantification panel 
with additional dilutions (1.74 x 106 to 1.74 x 102 IU/ml) was used to determine 
linearity, precision and lower limit of quantification (LoQ). The studies were 
performed in duplicates on 3 different days using the QIAsymphony DSP 
Virus/Pathogen Mini kit in combination with the Cellfree200 protocol (input/elution 
volume of 200 Land 65 ul, respectively). Each of the samples was analyzed using 
the artus CMV reagents (Qiagen, Valencia, CA). A multi-analyte transplant control 
with a low and a high IU/ml was included in each run for control evaluation. In 
addition, anonymized patient samples, previously tested with our LDT were used for 
clinical correlation.  Results: Measurable range spanned from 2.4 to 6.4 log10 CMV 
IU/ml (R2=0.99). The LoQ was 174 IU/ml, which is well below the clinical significant 
values. The method showed high precision with a total CV of 0.21log IU/ml. All 
undetectable samples by the LDT were below the LoQ established for the RGQ 
system. Positive samples analyzed by both methods were comparable but not 
identical. The difference in quantification between samples by both methods was on 
average lower for the Qiagen method than for the LDT (-0.3 log IU/ml). A Pearson’s 
correlation coefficient of 0.60 was obtained between methods. Conclusions: The 
Cytomegalovirus DNA qPCR artus System on the QIAsymphony RGQ System 
presented in this study with sample preparation and assay setup using the 
QIAsymphony RGQ system showed excellent analytical performance with the 
advantage of having a clinically useful quantification range using only 200 L of 
plasma. 
 
ID58. Transitioning from a Manual Nucleic Acid Extraction Method to a Fully 
Automated Hands-Off Process in the Analysis of Hepatitis B Viral Loads 
W. Lee, A. Omar, M. Wong 
Khoo Teck Puat Hospital, Singapore. 
Introduction: Hepatitis B virus (HBV), a 42-nm deoxyribonucleic acid (DNA) virus 
belonging to the hepadnavirus family, is one of the several viruses known to cause 
viral hepatitis. The determination of HBV DNA in serum has been reported to have 
prognostic value for the outcome of acute and chronic HBV infections. In our 
laboratory, HBV nucleic acid isolation prior to polymerase chain reaction is 
performed using the Roche High Pure System Viral Nucleic Acid Kit. This multi-step 
manual specimen preparation process, requiring dedicated skilled personnel is both 
time- and labour-intensive. A minimum of 150 to 180 minutes is required for 
specimen extraction for a batch size of 12 to 24 samples. In this evaluation, we 
automated the nucleic acid isolation process by using the QIAGEN QIAsymphony 
SP instrument with the Virus/Bacteria Mini Kit. Specimen extraction for a batch size 
of 12 to 24 samples can be realised in 90 to 105 minutes. Methods: Seventy-two 
cell-free serum and plasma samples, with HBV viral loads ranging target not 
detected to log10 7.22 IU/mL were extracted by both manual and automated 
extraction methods and the HBV viral loads determined after automated amplification 
and detection on the Roche Cobas TaqMan 48 analyser. Precision study was 
conducted using quality control materials at HBV viral loads of log10 2.20 and log10 
6.14 IU/mL. The data were assessed both qualitatively and quantitatively. Qualitative 
data were analysed using binary matrix. Quantitative data were analysed using 
regression analysis and Bland-Altman bias plots. Results: The automated extraction 
method yielded a diagnostic sensitivity and specificity of 92% and 83%, respectively, 
compared to the manual extraction method. A correlation of 0.9921x – 0.0049 
(R=0.9904) was obtained. A difference of (–)log10 0.61 to log10 0.51 IU/mL was 
observed between the two methods. Precision study gave coefficient of variation of 887
8AMP Abstracts3.61% (HBV; log10 2.20 IU/mL) and 3.20% (HBV; log10 6.14 IU/mL). Conclusions: 
Our data suggests the automated sample extraction on QIAsymphony SP correlates 
well with the manual extraction method. Imprecision of the 2 extraction methods 
were comparable. The observed imprecision and difference between methods also 
suggest minimal effects on the extraction yielded quantity. In addition, the 40% 
shorter processing time, coupled with minimal operator intervention reduces the risk 
of contamination and allows for traceability and fidelity of results. The ability for 
operator walk-away and 15% lower reagent cost increases productivity and 
manpower savings and ultimately, savings to the healthcare system. 
 
ID59. Comparison of the Three Real-Time CMV Assay Kits for the 
Quantitation of Cytomegalovirus DNA 
H. Lee1, M. Kim1, Y. Nam2, E. Cho3, J. Yang2, M. Lee2, S. Cho3, T. Park2, J. Suh2 
1Kyung Hee University, Seoul, Republic of Korea, Republic of Korea; 2Kyung Hee 
University Graduate School, Seoul, Republic of Korea; 3Kyung Hee Medical Center, 
Seoul, Republic of Korea. 
Introduction: Cytomegalovirus (CMV) infection is one of the important causes of 
morbidity and mortality in immunosuppressed patients. Assessment of CMV viral 
load has been regarded as clinically useful. The aim of this study was to evaluate 
three commercial real-time CMV viral load detection kits and the clinical diagnosis of 
positive cases. Methods: One hundred clinical specimens were analyzed 
retrospectively and prospectively (whole blood specimens, n=44; urine specimens, 
n=35; respiratory specimens, n=11; breast milk specimens, n=6; cerebrospinal fluid, 
n=2; other specimens, n=2). All specimens had been analyzed positive or negative 
by in-house PCR for routine diagnosis (positive specimens, n=50; negative 
specimens, n=50). All specimens were kept for freezing (-70°C) until analysis. DNA 
for testing for the Artus CMV RG PCR kit and the Biosewoom Real-Q CMV 
Quantification Kit was isolated using the QIAamp DSP Virus kit and tested following 
the manufacturers’ instruction. The COBAS AmpliPrep/COBAS TaqMan CMV test 
was performed according to the manufacturer’s instruction. Patient charts were 
reviewed retrospectively. Results: The clinical diagnosis of positive results was as 
follows: hematologic malignancy, 9 cases; respiratory infection, 13 cases; low birth 
weight infant, 5 cases; and so on. CMV DNA loads measured by three methods were 
as follows: Roche vs Artus, r2 0.95; Roche vs Biosewoom, r2 0.69; Biosewoom vs 
Artus, r2 0.93. The CMV DNA loads measured by three methods show no significant 
differences (P>0.05). Conclusions: The results of the Artus kit correlate well with 
that of the Roche and Biosewoom kit. These three commercial kits showed good 
agreement. We conclude that these three commercial kits seemed to be useful for 
the detection of CMV DNA quantification. 
 
ID60. Comparison of HCV RNA with the Positive Pattern of RIBA 
E. You, W. Lee, M. Lee, M. Kim, S. Kang 
Kyung Hee University School of Medicine, Seoul, Korea. 
Introduction: Negative Hepatitis C virus (HCV) RNA result cannot be used to 
determine the significance of a positive anti-HCV antibody screening result or the 
clinical status of a patient. In such circumstances, a more specific confirmative test of 
HCV antibody, the RIBA assay should be used. The aim of this study is to determine 
the usefulness RIBA patterns in predicting HCV RNA results and clinical status. 
Methods: Patients with positive anti-HCV antibody, between February 2012 and 
February 2013, and who were tested for both HCV RNA and core antigen were 
included. HCV RNA was measured using Cobas AmpliPrep/Cobas TagMan HCV 
assay (Roche Molecular Systems, Inc., Pleasanton, CA). Serum HCV core antigen 
was measured by Abott Architect i2000SR analyzer (Abbott Laboratories, Abbott 
Park, IL). The RIBA test was performed using HCV BLOT 3.0 (MP Diagnostics, 
Science Park, Singapore). Results: Total of 173 patients were enrolled and RIBA 
was performed in 136 subjects. The agreement of HCV RNA with core antigen was 
good (ț=0.97093), whereas RIBA showed moderate agreement with RNA or core 
antigen (ț=0.69697, ț=0.70395). Total 102 patients with positive RIBA were divided 
into RIBA+/RNA+ group (N=61) and RIBA+/RNA- (N=41) group. Laboratory finding 
of anti-HCV, core antigen, and RIBA positive patterns including reactive bands 
number and sum value differed significantly between the RIBA+/RNA+ and 
RIBA+/RNA- groups. Positive results for Core band were seen in all 102 sera 
(100%), and distribution of positive band for NS4 did not differ significantly between 
two groups. Other bands indicating NS3-1, NS3-2 and NS5 were more frequently 
observed in RIBA+/RNA+ group. The most common RIBA patterns (Core/NS3-
1/NS3-2/NS4/NS5) was the (+/-/-/-/-) pattern, in which RIBA+/RNA- group showed 
significantly higher frequency than the RIBA+/RNA+ group (17.6% vs. 4.9%). 
Another pattern of (+/+/+/+/+) was frequently observed in RIBA+/RNA+ groups (3.9% 
vs. 14.7%). RIBA+/RNA+ group had significantly higher sum values and more 
positive bands than RIBA+/RNA- group. Conclusions: In this study, anti-HCV, core 
antigen, and RIBA positive patterns including positive bands and sum values differed 88significantly between the RIBA+/RNA+ and RIBA+/RNA- groups. Agreement of RIBA 
with HCV RNA and HCV core antigen was relatively low. But the distinctive positive 
pattern of RIBA such as isolated core band in RIBA+/RNA- group or all positive 
bands in RIBA+/RNA+ enables predictive of HCV RNA result. In the absence of HCV 
RNA or core antigen assays, RIBA could be an useful method that could predict 
HCV viremia using its distinctive pattern.  
 
ID61. Use in Routine Clinical Practice of Two Commercial Real-Time PCR 
Assays for Detection of Mycobacterium tuberculosis Complex: Comparison of 
COBAS TaqMan MTB Test and AdvanSure TB/NTM Real-Time PCR 
S. Suh1, O. Lee1, H. Choi1, S. Kee1, J. Shin1, D. Ryang1, B. Park2 
1Chonnam National University Medical School and Hospital, Gwangju, South Korea; 
2Mokpo National University, Muan-gun, Chonnam, South Korea. 
Introduction: Two commercial real-time PCR assays for detection of Mycobacterium 
tuberculosis (MTB), COBAS TaqMan MTB Test (Roche, USA) and AdvanSure 
TB/NTM real-time PCR (LG, Korea), have been separately compared with the liquid 
culture method using BACTEC MGIT 960 system. The purpose of this study was to 
compare the diagnostic performance of two PCR tests. Methods: The two PCR 
assays have been routinely performed on clinical samples in our microbiology 
laboratory of Chonnam National University Hospital for 2 years from January 2011 to 
December 2012. Data for acid-fast bacilli (AFB) smear and culture have been 
collected and correlated to the PCR results. Results: Of 12,129 samples 
simultaneously tested with AFB smear, culture, and PCR, 3010 (24.8%) and 9119 
(75.2%) were assayed with COBAS TaqMan MTB Test and AdvanSure TB/NTM 
real-time PCR, respectively. Of 3010 allocated to the COBAS TaqMan MTB Test, 
189 (6.28%) M. tuberculosis and 131 (4.35%) nontuberculous mycobacteria were 
confirmed on culture, respectively. Of 9119 to the AdvanSure TB/NTM real-time 
PCR, 599 (6.57%) M. tuberculosis, 383 (4.20%) nontuberculous mycobacteria, and 1 
(0.01%) mixed culture were isolated. When compared with culture, total sensitivities 
and specificities were 67.2% and 98.4% for COBAS TaqMan MTB Test; 67.8% and 
98.3% for AdvanSure TB/NTM real-time PCR, respectively. For AFB-positive 
samples, 98.5% and 97.4% were detected by COBAS TaqMan MTB Test and 
AdvanSure TB/NTM real-time PCR, respectively. For AFB-negative samples, 
however, 49.2% and 49.0% were detected by COBAS TaqMan MTB Test and 
AdvanSure TB/NTM real-time PCR, respectively. Overall agreement with the culture 
was the same (ț= 0.6869) between COBAS TaqMan MTB Test and AdvanSure 
TB/NTM real-time PCR. Conclusions: Our data suggest that COBAS TaqMan MTB 
Test and AdvanSure TB/NTM real-time PCR might have the same diagnostic 
performance for the diagnosis of tuberculosis in routine clinical practice.  
 
ID62. Performance Evaluation of an EBV qPCR Asssay Calibrated to the 
World Health Organization International Standard (WHO-IS) on the 
QIAsymphony RGQ System Using Small Plasma Sample 
M.F. Sabato, P. Anderson, P. Vo, C.I. Dumur, A. Ferreira-Gonzalez 
Virginia Commonwealth University, Richmond, VA. 
Introduction: Epstein Barr virus (EBV) DNA quantification in plasma has become 
the standard of care for monitoring and disease diagnosis of post-transplant 
proliferative disorder in transplant patients. The first WHO-IS for the quantification of 
EBV has been available since 2011. Reporting results in IU/mL facilitates 
development of clinical practice guidelines for intervention that are independent of 
the testing laboratory. Data addressing the performance characteristics of the 
QIAsymphony RGQ system for EBV quantification using Qiagen artus EBV reagents 
have been reported using whole blood. It would be desirable to have a method that 
provides a clinically useful quantification range with plasma sample. In this study, the 
performance of the QIAsymphony RGQ system for EBV DNA quantification 
calibrated to the WHO-IS in plasma was evaluated using artus EBV reagents. 
Results were compared to our Laboratory-Developed Test (LDT) for correlation and 
agreement. Methods: The Acrometrix EBV plasma panel with traceability to the 
WHO international standard was used to calibrate the system and to determine 
linearity, precision and lower and higher limit of quantification (LoQ). The studies 
were performed in duplicates on 3 different days using the QIAsymphony DSP 
Virus/Pathogen Mini kit in combination with the Cellfree200 protocol (input/elution 
volume of 200 L and 60 L, respectively). Each of the samples was analyzed using 
the artus EBV reagents (Qiagen, Valencia, CA). A multi-analyte transplant control 
with a low and a high IU/ml plasma was included in each run for control evaluation. 
In addition, anonymized patient samples, previously tested with our LDT were used 
for clinical correlation. Results: Measurable range spanned from 2.0 to 6.0 log10 
EBV IU/ml (R2=0.99). The LoQ was 200 IU/ml of plasma, which is well below the 
clinical significant values. The method showed high precision with a total CV of 17% 
IU/ml plasma. All undetectable samples by the LDT were below the LoQ established 
for the RGQ system. Positive samples analyzed by both methods were comparable jmd.amjpathol.org ■ The Journal of Molecular Diagnostics
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was on average 1 log higher for the Qiagen method than for the LDT. A Pearson’s 
correlation coefficient of 0.93 was obtained between methods. Conclusions: The 
EBV qPCR assay on the QIAsymphony RGQ system using small plasma sample 
presented in this study showed excellent analytical performance with the advantage 
of having a clinically useful quantification range with only 200 L of plasma input.  
 
ID63. Performance Evaluation of the GenMark eSensor HCVg Direct for HCV 
Genotyping 
M.F. Sabato, E.J. Tully, A.L. Bowen, M. Lu, C.I. Dumur, A. Ferreira-Gonzalez 
Virginia Commonwealth University, Richmond, VA. 
Introduction: Hepatitis C virus (HCV) is a leading cause of chronic liver disease and 
liver transplantation in the United States. Recent advances in treatment options such 
as new direct-acting antiviral therapy for HCV have been successfully introduced in 
clinical practice. However, treatment decisions to predict successful outcomes rely 
on accurate identification of the HCV genotype among infected individuals. We 
aimed to evaluate the performance characteristics of the GenMark eSensor HCVg 
Direct (eSensor Direct) test, compared to the widely used Siemens Versant LiPA 
HCV assay version 2.0 (LiPAv2) in routine clinical practice. Methods: A total of 100 
archived RNA samples previously analyzed with LiPAv2 from HCV-positive patients 
with a wide range of viral loads, seen over a two-year period at VCUHS were 
evaluated. Both assays were performed according to manufacturer’s 
recommendations. For LiPAv2, biotinylated amplicons of the 5’UTR and Core 
regions of the HCV genome were hybridized to probes bound to a nylon membrane 
followed by binding of streptavidin-alkaline phosphatase and subsequent color 
development, in an automated fashion using the Siemens AutoLiPA 48 instrument. 
For the eSensor Direct test, amplicons of the 5’UTR and Core region of the HCV 
genome were converted to single-stranded DNA and hybridized in the eSensor 
cartridge, used on the eSensor XT-8 instrument for analysis. Results: Nintynine of 
the 100 samples were successfully genotyped by both assays. We obtained 100% 
concordance for both methods on the 99 samples, resulting in 39 samples HCV 
genotype 1a, 21 genotype 1b, 1 genotype 2, 1 genotype 2a, 11 genotype 2b, 2 
genotype 3, 15 genotype 3a, 3 genotype 4, and 1 genotype 6. Two samples 
demonstrated co-infection with genotypes 1a and 2b by both assays. Interestingly for 
3 samples with co-infection genotypes 1a and 4 by LiPAv2, only genotype 1a was 
detected by the eSensor Direct assay. The latter was able to genotype samples with 
an HCV viral load down to 400 HCV IU/ml of plasma for HCV genotypes 1a, 1b, 2 
and 3. The same sample failed to yield a genotype on both assays. Conclusions: 
The GenMark eSensor HCVg Direct system strongly correlates to the widely used 
LiPAv2 assay, with a good lower limit of HCV viral load for reliable HCV genotyping. 
Further investigations related to genotyping of samples with mixed HCV genotype 1a 
and 4 needs to be done. In summary, the GenMark eSensor HCVg Direct represents 
a viable alternative for reliable laboratory HCV genotyping.  
 
ID64. Evaluation of Verigene Gram-positive Blood Culture Nucleic Acid Test 
(BC-GP) for the Rapid Identification of Gram-Positive Isolates from Blood 
Cultures 
J. Kim, G. Kang, H. Kim, H. Kim, W. Song, K. Lee 
Hallym University College of Medicine, Seoul, Korea. 
Introduction: Gram-positive bacteria are the most common causes of positive blood 
cultures. The performance of a molecular test, the Verigene Gram-positive blood 
culture nucleic acid test (BC-GP; Nanosphere, Northbrook, IL), was evaluated for the 
identification of Gram-positive bacteria detected in blood culture bottles. Methods: A 
total of 100 blood cultures with Gram-positive bacteria were analyzed using BC-GP 
assay. Blood cultures were collected in Bactec plus aerobic/F and anaerobic/F 
bottles and incubated in Bactec Fx. The BC-GP results were analyzed for 
identification and susceptibility testing results of conventional methods with 
MicroScan. Results: The BC-GP assay correctly identified the presence of 
Staphylococcus aureus (n = 22) and their methicillin resistance except only one 
methicillin-susceptible S. aureus with no call result. Thirty-five Staphylococcus 
epidermidis were detected with BC-GP, but 3 of them were other staphylococci. All 
of enterococci (n = 7) were correctly identified including one vancomycin-resistant 
Enterococcus faecium. One Streptococcus viridians isolate was misidentified as 
Streptococcus anginosus. Mixed blood cultures of methicillin-susceptible S. 
epidermidis and S. viridians were correctly identified in a pediatric patient. 
Conclusions: The BC-GP assay showed high agreement compared with 
conventional identification and sensitivity tests. This test is useful for the rapid 
identification of Gram-positive cocci and the detection of clinically important resistant 
genes from positive Bactec blood cultures. 
 he Journal of Molecular Diagnostics ■ jmd.amjpathol.orgID65. Proficiency Testing as a Tool for Supporting Molecular Assay 
Standardization 
C. Di Lorenzo1, P.S. Wallace2, H.G. Niesters3, A.M. van Loon4 
1QCMD, Glasgow, Scotland, United Kingdom; 2Quality Control for Molecular 
Diagnostics, Glasgow, Scotland; 3University Medical Center Groningen, The 
Netherlands; 4University Medical Centre Utrecht, The Netherlands. 
Introduction: Pathogen load determination plays an important role in preventing and 
diagnosing disease. It also plays a central role in monitoring patients’ response to 
treatment as well as providing an indication of disease progression. For established 
clinical parameters such as HIV, the relationship between pathogen load and 
disease is well understood. In addition over the last decade the robustness and 
reproducibility of molecular assays for the determination of HIV pathogen load has 
improved significantly. To some degree the availability of International Standards has 
helped and this in turn facilitates the comparability of results from laboratory to 
laboratory. In addition, standardisation through traceability to a common International 
Standard has, in general, led to a better understanding of what constitutes 
“acceptable” assay variation within the clinical setting. However for the majority of 
disease states the clinical significance of pathogen load still remains unclear and the 
lack of suitable reference materials or International Standards means that assay 
variation impedes meaningful comparison of results at both the technology and 
laboratory level. In the absence of international standards, proficiency testing (PT) 
can provide a valuable tool in support of standardisation. The design of the PT 
challenge allows comparison across multiple laboratories using numerous molecular 
technologies. Methods: QCMD PT data from a range of quantitative pathogen load 
PT challenges was analysed. These included those pathogens where International 
Standards have been established for years, those where International Standards 
have only recently been introduced, and those where there are currently no 
International standards. 
Results: The results presented show that the introduction of an International 
Standard does not automatically improve standardisation. In addition, where there 
are currently no International Standards associated with a specific pathogen PT 
challenge, the general performance (as defined by variation in pathogen load) 
improves over time. Conclusions: The findings presented in this study investigate 
potential causes contributing to quantitation disparities observed across laboratories 
and highlight the challenges of achieving a general quantitative standardization.  
 
ID66. Multiplex Cliffhanger PCR Improves the Clinical Sensitivity for 
Detection of Diarrheagenic Escherichia coli Directly on Human Fecal Samples 
U.V. Schneider1, N.D. Mikkelsen1, A. Friis-Møller2, F. Scheutz3, G. Lisby2 
1QuantiBact A/S, Hvidovre, Copenhagen, Denmark; 2Hvidovre Hospital, Hvidovre, 
Copenhagen; 3Statens Serum Institut, Copenhagen. 
Introduction: Detection of diarrheagenic Escherichia coli (DEC) directly from human 
fecal samples is hampered due to fecal PCR inhibitors. Consequently, the gold 
standard method is growth on selective agar followed by PCR detection of specific 
toxin and virulence genes present in DNA extracted from subjectively selected 
colonies. This procedure is time consuming and has sub-optimal sensitivity. Here, 
we establish a novel method for detection of DEC directly on lyzed fecal samples 
with comparison to the current gold standard. The method utilizes a PCR inhibitor 
resistant KAPA2G Robust HS polymerase in combination with novel Cliffhanger 
primers. Cliffhanger primers increase the PCR robustness, freedom of primer design, 
PCR multiplexing capacity, and sensitivity of solid phase hybridization detection. 
Methods: Cliffhanger PCR primers are synthesized by standard oligonucleotide 
synthesis and designed as C-Z-P, where “C” is a 15-20 base pair custom designed 
single-stranded capture sequence, “Z” is the twisted intercalating nucleic acid (TINA) 
molecule and “P” is the specific primer sequence. Five hundred thirty-eight fecal 
samples were collected in fecalSwab transport medium and analyzed by current gold 
standard as well as by Cliffhanger PCR analysis. Prior to Cliffhanger PCR analysis, 
the fecal sample was lysed by boiling and used directly in a 8-plex PCR with rrs as 
internal control and detection on the Luminex MagPix platform. Cliffhanger only PCR 
positive samples were Sanger sequenced to verify the discrepant findings. Results: 
Positive samples were divided into i) positive by both methods (p/p), ii) only positive 
by gold standard (p/n), and iii) only positive by Cliffhanger PCR (n/p) plus 
sequencing. The distribution of toxin genes (a,b,c) was stx1 (0,0,11), stx2 (0,0,2), 
aggR (19,6,16), ipaH (1,0,8), eae (38,2,81), elt (4,0,20), estAp (0,0,10) and estAh 
(2,0,4). The internal control failed to amplify in eight samples by Cliffhanger PCR and 
two samples by gold standard method. In total, eight samples were missed and 152 
additional positive samples were identified using the Cliffhanger PCR assay. 
Compared to the gold standard method, multiple additional genes were occasionally 
identified, leading to additional identification of eight verotoxin producing E. coli 
(VTEC), 25 enterotoxin-producing E. coli (ETEC) and five VTEC plus ETEC positive 
samples. No ETEC or VTEC positive samples were missed by the Cliffhanger PCR 889
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 assay. Conclusions: This study describes a novel multiplex Cliffhanger PCR assay 
with significant higher clinical sensitivity, enabling PCR performed directly on lyzed 
fecal samples. The new method allows for more accurate patient diagnostics of 
clinical relevant DEC strains. 
 
ID67. Identification of Nontuberculous Mycobacterial Species in MGIT 
Cultures by GenoType Mycobacterium CM/AS: Two-Year Experience 
S. Suh1, H. Choi1, S. Kee1, J. Shin1, D. Ryang1, B. Park2 
1Chonnam National University Medical School and Hospital, Gwangju; 2Mokpo 
National University, Muan-gun, Chonnam. 
Introduction: GenoType Mycobacterium CM/AS (HAIN, Germany) has been used in 
routine clinical practice for identification of nontuberculous mycobacteria. The 
purpose of this study was to analyze the outcomes of this assay. Methods: The 
identification assay has been routinely performed on MGIT cultures of clinical 
samples in our molecular laboratory of Chonnam National University Hospital for 2 
years from Oct 2009 to Sep 2011. Results: Of 22,993 samples, 2493 (10.9%) were 
positive for MGIT cultures and classified by AdvanSure TB/NTM real-time PCR into 
1534 (61.5%) Mycobacterium tuberculosis and 959 (38.5%) non-tuberculous 
mycobacterial species. Of 959 cultures growing non-tuberculous mycobacterial 
species, 909 (94.8%) were submitted for the identification of non-tuberculous 
mycobacterial species. The assay clearly identified 555 (61.26%) M. intracellulare, 
172 (18.98%) M. avium, 90 (9.93%) M. abscessus, 14 (1.55%) M. kansasii, 11 
(1.1%) M. fortuitum, 10 (1.10%) M. chelonae, 8 (0.88%) M. gordonae, 3 (0.33%) M. 
interjectum, 3 (0.33%) M. lentiflavum, 3 (0.33%) M. peregrinum, 2 (0.22%) M. 
marinum, 2 (0.22%) M. scrofulaceum, 2 (0.22%) M. smegmatis, 1 (0.11%) M. 
mucogenicum, and 23 mixed cultures (2.54%) of two different mycobacterial species, 
but failed to identify 7 (0.77%) isolates. Conclusions: Our data indicate that 
GenoType Mycobacterium CM/AS can identify the majority (>99%) of mycobacterial 
species encountered in routine clinical practice.  
 
ID68. Detection of Group A Streptococcus with a Rapid, Non-Instrumented, 
Isothermal Molecular Assay on Throat Swab Specimens 
Y. Li1, H.J. Kim1, H. Kong1, T.A. Ranalli2, P.D. Olivo2, T.T. Stenzel2 
1Biohelix Corp, Boston, MA; 2Quidel Corp, San Diego, CA. 
Introduction: Streptococcus pyogenes or group A Streptococcus (GAS) is the 
leading cause of bacterial pharyngitis and is associated with serious infections and 
complications including sepsis, pneumonia, necrotizing fasciitis and rheumatic fever. 
A rapid and sensitive molecular method for the detection of GAS would aid in 
diagnosis of infection. Methods: Helicase-dependent amplification (HDA), an 
isothermal nucleic acid amplification platform that utilizes a helicase to separate 
strands of DNA or RNA, allows for target-specific amplification in the absence of 
thermocycling. The AmpliVue GAS assay combines HDA with a disposable self-
contained detection device that allows for the rapid detection of amplicons generated 
by primers and probes specific for the target. Briefly, a throat swab is placed directly 
into dilution buffer, and 50 L is transferred into a tube containing lysis buffer. The 
lysis tube is then heated at 95°C for 10 minutes and 50 L of the lysed specimen is 
transferred to a tube containing lyophilized reagents. The sample is incubated at 
64°C for 30 minutes and transferred to a cassette wherein the result is read via an 
imbedded lateral flow strip. The total turnaround time of the assay is less than one 
hour and “on-demand,” eliminating the need to batch samples. Results: Analytical 
LOD testing determined that the assay can detect as few as 5 copies of genomic 
DNA per reaction. The assay does not cross-react with any non-GAS organisms that 
have been evaluated. Comparison of AmpliVue GAS with an LDT PCR assay and/or 
bacterial culture on 42 clinical throat swab specimens revealed 22 samples positive 
by both methods with one additional sample positive by AmpliVue only. Prior to 
discordant analysis, the sensitivity and specificity were 100% and 95%, respectively. 
Conclusions: An HDA-based assay for the qualitative detection of GAS is sensitive 
and specific and can be run in a wide variety of settings without the need for costly 
instrumentation.  
 
ID69. Multiplex Loop-Mediated Isothermal Amplification (M-LAMP) Assay for 
the Detection of Legionella spp., M. pneumoniae, and C. pneumoniae Provides 
Specimen-to-Result Diagnosis in 75 Minutes 
J. Mahony1, S. Chong2 
1St. Joseph's Healthcare, Hamilton, Ontario, Canada; 2St Joseph's Hospital, 
Hamilton, Ontario, Canada. 
Introduction: Respiratory tract infections caused by M. pneumoniae (Mp), 
Legionella spp., and C. pneumoniae (Cp) account for approximately 15% of 
community acquired pneumonia. These infections present similarly and are difficult 
to diagnose using conventional methods that are time consuming, expensive and 
often unreliable. Improved molecular test methods are therefore required to 0accurately diagnose these infections. Methods: We developed a single tube M-
LAMP assay tageting the PI gene of Mp, 16 rRNA gene of L. pneumophila (Lp), and 
the ompA gene of Cp. M-LAMP reactions contained in a final volume of 25 L six 
primers for each gene target (two outer, two inner, and two loop primers designed 
using Primer Explorer v4 from Eiken), Bst 2.0 polymerase, a commercial master mix 
containing SYBR Green dye and 5 L extracted nucleic acid. Amplification was 
performed at 62°C for 30 minutes on a real-time fluorometer (Genie II, Optigene UK) 
that provides the amplification times as well as annealing temperature (Tm) for 
positives. Nucleic acid was extracted from either single colonies of Legionella, 
nasopharyngeal swabs and oral swabs using either the Qiagen QIAsymphony or 
easyMAG extractor. The lower limit of detection (LLOD) for each bacteria was 
determined by testing transcripts prepared from cloned targets. Environmental 
isolates were tested by M-LAMP whereas clinical specimens were tested by M-
LAMP and Focus Diagnostics Simplexa assay (RUO). Discordants were tested using 
published and in-house PCR assays. Results: The LLOD for Lp, Mp, and Cp was 
1100 and 100 copies/5 L, respectively. A total of 433 specimens including 110 
positives and 323 negatives were used in the evaluation. For the positives there 
were 61 Legionella spp. (including 20 Lp [serotypes 1, 2, 5, 8, 13, 14], 11 L. 
longbeache, 17 L. quinlivanii, 3 L. londiniensis, 4 L. anisa, and 2 dual L. 
quinlivanii/anisa), 41 Cp, 6 Mp, and 2 dual positives (1 Lp/Cp,1 Mp/Lp). M-LAMP 
detected 60/61 Legionella spp., 41/41 Cpn, and 6/6 Mp positive specimens and had 
an overall sensitivity of 99.1% (109/110). M-LAMP correctly identified 323/323 
negatives and had an overall specificity of 100%.   
Conclusions: Conventional methods for diagnosing pneumonia caused by atypical 
bacteria including Legionella spp., M. pneumoniae and C. pneumoniae are time 
consuming, expensive and often inaccurate. We developed a single tube M-LAMP 
assay for the detection of Lp, Mp, and Cp. M-LAMP had excellent overall sensitivity 
(99.1%) and specificity (100%) and provided a specimen-to-result diagnosis in 75 
minutes. Rapid multiplex molecular tests such as M-LAMP should significantly 
improve patient management. 
 
ID70. Detection of Group B Streptococcus with a Non-Instrumented, 
Isothermal Molecular Assay from Lim Broth Samples 
M. Wilson1, W. Tang1, T.A. Ranalli2, H. Kong1, P.D. Olivo2, T.T. Stenzel2 
1Biohelix, Boston, MA; 2Quidel Corp, San Diego, CA. 
Introduction: Streptococcus agalactiae or Group B Streptococcus (GBS) is the 
leading cause of neonatal sepsis, pneumonia and meningitis and is present in as 
many as 35% of pregnant women, most of whom are asymptomatic. To reduce 
transmission, screening is performed around 35 to 37 weeks in pregnancy; however, 
many women become re-colonized during the period of time between initial 
screening and delivery. Traditional methods for screening include culture, a less 
sensitive option, and molecular assays. Herein, we describe the development of a 
sensitive and specific molecular assay for the detection of GBS from Lim Broth. 
Methods: Helicase-dependent amplification (HDA), an isothermal nucleic acid 
amplification platform that utilizes a helicase to separate strands of DNA or RNA, 
allows for target-specific amplification in the absence of thermocycling. The 
AmpliVue GBS assay combines HDA with a disposable self-contained detection 
device that allows for the rapid detection of amplicons generated by primers and 
probes specific for the target. From Lim Broth, an aliquot of the culture is placed into 
a dilution tube and 50 L is transferred into a lysis tube that is briefly heated to lyse 
the cells, and then transferred to a reaction tube containing lyophilized reagents. The 
sample is incubated at 64°C for 60 minutes and transferred to a cassette wherein the 
result is read via a lateral flow strip. Either assay is performed in about 80 minutes 
and “on-demand,” eliminating the need to batch samples. Results: Analytical testing 
has determined that the LOD of the assay is between 188 and 464 CFU per assay 
when evaluated with 6 GBS strains. The assay does not cross-react with any non-
GBS organisms that have been evaluated. A preliminary clinical study performed 
with 70 previously archived LIM Broth specimens, 21 of which were positive, showed 
that AmpliVue had a sensitivity of 100% (95% CI of 85% to 100%) and a specificity 
of 100% (95% CI of 93% to 100%) when compared to BD Max GBS assay. 
Conclusions: An HDA-based assay for the qualitative detection of GBS is sensitive 
and specific assay and can be run in a wide variety of settings without the need for 
costly instrumentation.  
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 AMP AbstractsID71. Detection of Herpes Simplex Virus Types 1 and 2 from Lesions with a 
Rapid, Instrument-Free, Isothermal Molecular Assay Based on Helicase-
Dependent Amplification  
A. Messelaar1, H.J. Kim1, H. Kong1, T.A. Ranalli2, P.D. Olivo2, T.T. Stenzel2 
1Biohelix Corp, Boston, MA; 2Quidel Corp, San Diego, CA. 
Introduction: Herpes simplex viruses 1 and 2 (HSV-1 and HSV-2) are double-
stranded DNA viruses of the family Herpesviridae that cause genital and non-genital 
mucocutaneous and cutaneous vesicular lesions. The lesions result from either 
primary infection or from reactivation of latent virus that can recur. Diagnosis of HSV 
is traditionally made by viral culture, but molecular detection of viral DNA by real-time 
PCR is being employed more frequently. A rapid and less complex method to detect 
HSV DNA from lesions would facilitate the diagnosis of HSV and the differentiation 
between types 1 and 2. Methods: Helicase-dependent amplification (HDA), an 
isothermal nucleic acid amplification method, utilizes a helicase to separate strands 
of DNA or RNA, rather than heat, allowing for target-specific amplification in the 
absence of thermocycling. The AmpliVue HSV 1&2 assay combines HDA with a 
disposable self-contained detection device that allows for the rapid detection of 
labeled amplicons generated by target specific primers and probes and differentiates 
types 1 and 2. A liquid VTM sample containing a lesion specimen is diluted once and 
transferred to a tube containing the lyophilized HDA reagents. The sample is 
incubated at 64°C for 45 minutes and transferred to the cassette wherein the result 
is read via a lateral flow strip. The entire assay is performed “on-demand” in less 
than an hour, eliminating the need for batching of samples. Results: Analytical LOD 
testing using two strains each of HSV-1 and HSV-2 determined that the assay can 
detect less than 1.1 x 105 TCID50/mL of HSV-1 and less than 1.1 x 104 TCID50/mL of 
HSV-2. No cross-reactivity or interference was observed with 11 non-HSV viruses, 
bacteria, fungi, or parasites and no interference was observed when the test was 
performed in the presence of 10 substances that could be found in samples. 
Preliminary data on 81 clinical samples from vesicular lesion, prior to discordant 
resolution, revealed a sensitivity and specificity versus culture of 100% and 98% for 
HSV-1 and 93% and 95% for HSV-2, respectively. Conclusions: An HDA-based 
HSV assay that differentiates types 1 and 2 is rapid, simple, sensitive, and specific 
and can be run in a variety of settings by general laboratory personnel without the 
need for costly equipment. 
 
ID72. Detection of Trichomonas vaginalis with a Rapid, Non-Instrumented, 
Isothermal Molecular Assay  
J. Wang1, M. Wilson1, W. Tang1, H. Kong1, T.A. Ranalli2, P.D. Olivo2, T.T. Stenzel2 
1Biohelix, Boston, MA; 2Quidel Corp, San Diego, CA. 
Introduction: Trichomonas vaginalis, a flagellated protozoan, is the causative agent 
of trichomoniasis, a common sexually transmitted disease of the urogenital tract. 
Infection in men is generally asymptomatic, but T. vaginalis is a common cause of 
vaginitis in women. T. vaginalis was traditionally diagnosed via a wet mount and light 
microscopy or by overnight culture. Rapid antigen testing and molecular diagnostic 
methods are now used more frequently. A simple, rapid, and sensitive molecular 
method would facilitate diagnosis of trichomoniasis. Methods: Helicase-dependent 
amplification (HDA), an isothermal nucleic acid amplification platform that utilizes a 
helicase to separate strands of DNA or RNA, allows for target-specific amplification 
in the absence of thermocycling using only a single heat block for this assay. The 
AmpliVue Trichomonas uses HDA with a disposable self-contained detection device 
that allows for the rapid detection of amplicons generated by primers with probes 
specific for the target. The assay is performed from direct vaginal swabs. The swab 
is placed into a sample tube, diluted once, and then transferred to a reaction tube 
containing lyophilized reagents. The sample is amplified at 64°C for 25 minutes and 
transferred to a cassette wherein the result is read via a lateral flow strip. The assay 
is performed in less than 40 minutes and “on-demand,” eliminating the need to batch 
samples. Results: Analytical sensitivity testing determined that the limit of detection 
(LOD) is about 0.015 trophozoites/assay or 9.3 trophozoites/swab. An inclusivity 
study was performed using purified genomic DNA from ten clinical isolates of T. 
vaginalis from different geographic areas and two different phylotypes tested at 
concentrations 3 to 12 times of the LOD with all samples being detected. In a 
preliminary clinical study, 42 vaginal swab specimens collected from patients 
suspected of trichomoniasis were tested with the AmpliVue assay and compared 
with a wet mount/rapid antigen testing protocol. Twenty samples were positive by 
both methods whereas 4 additional samples were positive only with AmpliVue. 
Discordant resolution is underway. The sensitivity and specificity of AmpliVue, prior 
to resolution of discordant results, were 100% and 83%, respectively. Conclusions: 
An HDA-based assay for the qualitative detection of T. vaginalis is sensitive and 
specific and can be run in a wide variety of settings without the need for costly 
instrumentation. 
 The Journal of Molecular Diagnostics ■ jmd.amjpathol.orgID73. Isothermal Amplification and Detection of Chlamydia trachomatis and 
Neisseria gonorrhea from Urine and Genital Swab Specimens Using Illumigene 
Chlamydia and Illumigene Gonorrhea 
J.E. Mortensen 
Cincinnati Children's Hospital, Cincinnati, OH. 
Introduction: Illumigene CT/NG (not FDA cleared) is a rapid and simple molecular 
assay (Meridian Bioscience Inc., Cincinnati, OH) that uses loop-mediated isothermal 
amplification (LAMP) technology to detect Chlamydia trachomatis and Neisseria 
gonorrhea in less than one hour. It is designed to target the ORF4 of cryptic plasmid 
for C. trachomatis and the NGO0469 (phage associated protein) for N. gonorrheae.  
The reaction is performed on the Meridian illumipro-10 integrated incubator/reader 
under isothermal conditions. Following DNA amplification, magnesium-
pyrophosphate is produced as a by-product resulting in turbidity that is measured 
automatically by the instrument. Methods: Urine and/or genital swab samples were 
collected and submitted to the laboratory for testing. Urine samples were tested neat 
by BD ProbeTec ET System (BD Diagnostics, Sparks, MD), an amplified DNA assay 
for C. trachomatis and N. gonorrhea and by illumigene CT/NG. Swab samples were 
placed in the BD transport media then tested by both assays. Results:  95 swab 
specimens were tested by illumigene and BD. BD and illumigene were positive for C. 
trachomatis on 26 samples and positive for N. gonorrheae on 18 samples. 1 sample 
was positive for C. trachomatis and 1 sample was positive for N. gonorrheae by BD 
that was not detected by illumigene. 207 urine specimens were tested by illumigene 
and BD.  BD and illumigene were positive for Chlamydia on 54 samples and positive 
for N. gonorrheae on 18 samples. 3 illumigene Chlamydia-positive and 2 illumigene 
Gonorrhea-positive samples were negative by BD. Using BD ProbeTec as the gold 
standard, the sensitivity and specificity performance with swab samples for 
illumigene Chlamydia was 96.3% and 100%, respectively, and 94.7% and 100% for 
illumigene Gonorrhea. The sensitivity and specificity performance with urine samples 
for illumigene Chlamydia was 100% and 98.0%, respectively, and 100% and 98.9% 
for illumigene Gonorrhea. Conclusions: The illumigene Chlamydia and illumigene 
Gonorrhea assays are a rapid and sensitive method for the direct detection of C. 
trachomatis and N. gonorrheae from urine and genital swab samples. 
 
ID74. Evaluation of a Multiplex Real-Time PCR Assay for the Detection of 
Cryptosporidium spp. and Giardia lamblia 
L.A. Sahnow, L.N. Nguyen, L.S. Nelson, C.R. Icenhour 
Phthisis Diagnostics, Charlottesville, VA. 
Introduction: Cryptosporidium spp. and Giardia lamblia are intestinal parasites that 
cause infection that can lead to life-threatening diseases. Treatment is different for 
each organism, which makes differentiation of these parasites clinically important. 
This study evaluated the performance of a multiplex real-time PCR assay for the 
detection of these organisms. Methods: Clinical human stool samples were 
collected and preserved in Total-Fix at a 1:3 ratio of stool to preservative. One 
hundred fourteen samples were then extracted using an optimized extraction 
protocol on a NucliSENS EasyMAG automated extraction system. Extracted DNA 
was amplified and detected by the R-Sphere CG Assay (Investigational Use Only) on 
an Applied Biosystems 7500 Fast Dx. R-Sphere CG Assay contained lyophilized 
PCR reagents and an internal control DNA that identified PCR inhibition in the 
sample extracts. Limit of detection (LoD) was determined using quantified cultures of 
C. parvum and G. lamblia serially diluted and spiked into negative stool samples. 
The PCR efficiency and linearity of the assay were completed using G-Sphere 
Molecular Standards for C. parvum and G. lamblia. Results: LoD for C. parvum and 
G. lamblia was 500 organisms per mL (average Ct of 36.14 ± 0.85) and 105 
organisms per mL (average Ct of 34.57 ± 0.45), respectively. The PCR efficiency for 
the assay in detecting C. parvum was 109% and G. lamblia was 102%. The R2 of 
the linear regression over five orders of magnitude were 0.9998 and 0.9989 for C. 
parvum pDNA and G. lamblia pDNA, respectively. Clinical samples yielded a 
positivity rate of 0.88% for Cryptosporidium and 1.75% for Giardia. Conclusions: 
The multiplex real-time PCR assay can detect Cryptosporidum spp. and G. lamblia in 
clinical stool samples. The assay requiring only one-step reagent setup is fast, 
sensitive and efficient for both target parasites.  
 
ID75. Evaluation of Roche COBAS Ampliprep/COBAS TaqMan 
Cytomegalovirus (CMV) Assay for Monitoring of CMV Viral Loads  
E. Babady, J. Stiles, C. Brennan, P. Ruggiero, Y. Lim, G. Hagedoorn, N. Chein, G. 
Papanicolaou, Y. Tang 
Memorial Sloan-Kettering Cancer Center, New York, NY. 
Introduction: Cytomegalovirus (CMV) is a significant cause of mortality and 
morbidity in immunocompromised patients. Viral loads following transplantation are 
typically monitored using quantitative molecular assays. Several parameters have 
been confounding the accuracy of viral load results and affecting the decision 891
8AMP Abstractsmaking and management of disease in patients. The Roche COBAS 
Ampliprep/COBAS TaqMan CMV test (CAP/CTM CMV) has recently become FDA-
cleared for quantitative CMV monitoring on plasma samples. The purpose of this 
study was to verify the performance characteristics of the CAP/CTM CMV and 
correlate viral loads obtained by our laboratory-developed test (LDT CMV) (Roche 
ASR on the LightCycler 2.0) on whole blood specimens with those obtained on 
corresponding plasma specimens by the CAP/CTM CMV. Methods: The CAP/CTM 
CMV assay was performed according to manufacturer’s instructions. Performance 
characteristic measured included limit of detection/quantitation, precision, accuracy, 
linear range, and clinical sensitivity. Testing was performed using Acrometrix 
reagents (tested as is or diluted) and archived patient specimens. Plasmas were 
separated from whole blood specimens submitted to the laboratory for routine CMV 
monitoring by the LDT and stored frozen at -70°C. Results: The limit of 
detection/quantitation of the CAP/CTM CMV assay was confirmed at <137 IU/mL 
with a linear range of 300 IU/mL to 3,000,000 IU/mL as determined using the 
Acrometrix CMVtc Panel. The correlation between expected and detected viral load 
was excellent (R2=0.98). Intra-assay and inter-assay precision as determined by % 
CV for low and high positive controls was < 5%. Seven hundred sixty-four specimens 
(99 positives and 665 negatives) from 232 patients were tested by both the LDT 
CMV and the CAP/CTM CMV assays. The total qualitative agreement between the 
two methods was 87% (Kappa score = 0.58). One hundred samples had discordant 
results (96 specimens positive by the CAP/CTM CMV only and 4 positive by the LDT 
CMV assay only). The majority of specimens detected by the CAP/CTM CMV only 
had viral load values <137 IU/mL. The LDT assay generally yielded higher viral load 
values than the CAP/CTM CMV assay. Conclusions: The CAP/CTM CMV assay 
performed as stated by the manufacturer. Correlation between plasma and whole 
blood viral loads trends as measured by the CAP/CTM CMV and the LDT CMV 
assay, respectively, was good. However, the absolute value for individual viral load 
differed markedly with whole blood viral loads approximately 2 to 3 folds higher than 
in plasma. The CAP/CTM CMV assay provide sensitive and streamlined monitoring 
of CMV viral loads and should result in improved patient care.  
 
ID76. A Comparative Evaluation of the Use of On-Board Lysis Only versus 
both On-Board and Off-Board Lysis for the Detection of Group A 
Streptococcus from Throat Swabs 
J. Sen, K. Post, J. Reynolds, L. Cheng 
Indiana University Health, Indianapolis, IN. 
Introduction: The group A beta hemolytic Streptococcus (GAS) is primarily 
responsible for skin and throat infections, in addition to other common infections. 
Rapid diagnosis of GAS pharyngitis (strep throat) improves patient care by ensuring 
quick treatment and also by avoiding unnecessary use of antibiotics in those without 
GAS infection. The GAS-PCR assay includes two lysis steps: an off-board lysis in a 
heat block and an on-board lysis built into the PCR program. Some laboratories use 
both lysis methods whereas others use the on-board lysis only. The aim of this study 
was to determine if the elimination of the off-board lysis caused any loss of sensitivity 
to the assay. Methods: All throat swabs accessioned for GAS-PCR testing during a 
one month period were tested on the 3M Integrated Cycler (Focus Diagnostics, Inc.) 
using both the off-board lysis and on-board lysis. The samples that tested positive 
were further tested using on-board lysis only. Results with Ct< 40 were considered 
positive. 
Results: A total of 256 samples were tested for GAS-PCR using both off board lysis 
and on-board lysis, of which 30 samples tested positive. These 30 samples were re-
tested without any off-board lysis. Only 25 samples re-tested positive (83.3%). A 
review of the Ct values of the 25 samples that reproduced positive showed that the 
elimination of the off-board lysis resulted in a higher Ct when compared to the Ct 
when both off-board and on-board lysis were performed. The average Ct for both off-
board and on-board lysis was 30.05 cycles whereas the average Ct for only on-
board lysis was 31.39 cycles. It was also noted, that the original Ct of the five 
samples that failed to reproduce was on the higher side (average Ct 37.13 cycles). 
Conclusions: The elimination of the off-board lysis resulted in a significant number 
of false negatives and so at this time this method cannot be recommended. It is 
possible that the off-board lysis helps break up any mucus present in the throat 
swabs, thereby improving the sensitivity.  
 
ID77. Validation of a Laboratory-Developed Test for HSV Types 1 and 2 in 
Cerebrospinal Fluid 
C.M. Bissaillon, J.A. Fienman, K.A. Lebel, F.R. Moore 
Baystate Health, Holyoke, MA. 
Introduction: Patients presenting with symptoms of meningitis or encephalitis are 
routinely tested for HSV in cerebrospinal fluid. Results for this send-out test can take 
3 days to be reported. To better serve these patients, the Molecular Laboratory 92validated a PCR assay for the detection and typing of HSV 1 and 2. All new 
molecular diagnostic assays undergo stringent validation to ensure quality patient 
care. Here, the results of an assay using the Luminex MultiCode-RTx reagent for the 
qualitative detection and typing of HSV types 1 and 2 in CSF are reported. Methods: 
Linearity, accuracy, precision and analytical sensitivity and specificity was assessed 
using AcroMetrix control material. CSF, verified negative by an outside reference 
laboratory, was collected. The controls were used to spike the CSF at varying 
concentrations ranging from 2.4 to 5.5 log10 copies/ml for each HSV type. Linearity 
was assessed by using a seven sample dilution series ranging from 3.3 to 5.3 log10 
copies/ml. Accuracy was assessed using 59 samples created from the negative CSF 
and spiked with varying concentrations of HSV types 1 and or 2.  Analytical 
sensitivity and precision was assessed by testing twenty replicates of both HSV 
types at 3.3 log10 copies/ml over 5 days. Analytical specificity was assessed by 
testing for cross reactivity of 4 different viruses. A melt analysis and gel 
electrophoresis was also performed to confirm the appropriate amplicon was 
produced. Results: Linearity studies resulted in an R2 value of 0.9606 for HSV1 and 
0.9698 for HSV2. Accuracy studies yielded 100% concordance with 29 positive 
samples and 20 negative samples. Analytical sensitivity and precision at the limit of 
detection yielded standard deviations of 0.82 CT for HSV1 and 0.69 CT for HSV2. 
The %CV for the CT of HSV1 and 2 was 2.20 and 1.85 respectively. All positive 
samples for HSV 1 and 2 produced thermal melts in the defined range for each virus 
type with a mean and standard deviation of 84.1ÛC +/-0.24 and 87ÛC +/- 0.23 ÛC, 
respectively.  Gel electrophoresis showed the expected 74 base pair amplicon. No 
cross reactivity with other viruses was observed. Conclusions: Analysis of the data 
obtained from the validation showed the assay can consistently detect low levels of 
HSV types 1 and 2 in CSF. The ability of perform this test in-house enables Baystate 
Health to better care for patients by decreasing the turn around time from 3 days to 
24 hours.  
 
ID78. Verification of HSV Lesion Swabs on a Real-Time PCR Assay and the 
Benefits Over Viral Shell Culture 
C.M. Bissaillon, J.A. Fienman, K.A. Lebel, F.R. Moore 
Baystate Health, Holyoke, MA. 
Introduction: Lesion swabs have routinely been tested by viral culture. It takes 7 to 
8 days to confirm a negative result and all viral cultures need to be read daily. The 
Molecular Laboratory at Baystate Health validated lesion swab samples on the 
existing HSV 1 and 2 CSF assay run on the Roche LightCycler instrument. This 
assay takes approximately 3 hours to run, including extraction. Hands-on time is 
approximately 1 hour 15 minutes for a batch of 14 samples. This new assay will 
decrease turn around time from up to 8 to 3 days utilizing less technologist time. 
Methods: A total of 92 lesion swab samples, including genital, oral and skin 
specimens, were submitted to the Microbiology Laboratory for culture. The samples 
were then stored frozen for up to 1 month prior to extraction. Twenty negative and 72 
positive samples were identified. HSV type was not determined in any of the positive 
culture samples prior to submission. The samples were spiked with an internal 
control and extracted utilizing the Qiagen EZ1 Virus Mini Kit v2.0 on the Qiagen EZ1 
Advanced XL. They were then run on the existing LightCycler HSV 1 and 2 
MultiCode-RTx PCR assay developed in the laboratory. Results: All 72 (a sensitivity 
of 100%) of the previously positive HSV culture samples also tested positive for 
either HSV 1 or 2 by PCR. Thirty four of 72 (47.2%) samples were positive for HSV1 
and 38/72 (52.8%) samples were positive for HSV2. No dual positive samples were 
found. Eighteen of 20 (90%) samples negative by culture were also negative by this 
PCR method. One culture negative sample tested positive for HSV2. Another culture 
negative sample produced a valid HSV2 thermal melt and an indeterminate result 
based on a CT greater than 39.0 (CT of 41.1). Conclusions: The HSV lesion 
correlation study showed greater than a 95% limit of agreement for assay validation. 
Replacing the less sensitive and specific standard culture with PCR gives the 
physician more useful information to treat the patient more rapidly in the clinical 
setting.   
 
ID79. Direct Detection and Differentiation of S. aureus and Methicillin-
Resistant S. aureus from Nasal Specimens Using the Simplexa MRSA Direct 
Assay 
M. Nair, H. Vincent, H. Mai, M. Young, T. Dang, E. Eleazar, M. Aye, M. Exner, M. 
Tabb 
Focus Diagnostics, Cypress, CA. 
Introduction: Staphylococcus aureus commonly colonizes the skin and nasal 
passages of healthy individuals and can cause a broad range of infections, ranging 
from mild to life-threatening. Moreover, methicillin-resistant S. aureus (MRSA), which 
are resistant to antibiotics commonly used to treat staphylococcal infections, are a 
growing problem. We are developing the Simplexa MRSA Direct Assay (MRSA jmd.amjpathol.org ■ The Journal of Molecular Diagnostics
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MRSA from nasal specimens. The assay detects a S. aureus-specific gene and 
methicillin-resistance genes (mecA and mecC). Presence of MRSA is determined by 
an algorithm that provides the final results by comparing the fluorescence signals 
(Ct) of both targets. It is a sample-to-answer direct detection system that does not 
require nucleic acid isolation and provides results for up to 8 samples in about an 
hour. Methods: Performance of MRSA Direct was assessed with panels of positive 
and negative nasal swab clinical specimens collected in the ESwab Liquid Amies 
device. The results were compared to a reference culture method consisting of an 
enrichment step followed by susceptibility testing. Analytical performance was 
evaluated by performing limit of detection (LOD) and reproducibility studies. Cross-
reactivity studies were performed using a contrived panel of respiratory pathogens 
and normal flora; including coagulase-negative Staphylococcus. Assay 
inhibition/interference was tested with relevant concentrations of potentially 
interfering substances. Results: The performance of MRSA Direct was comparable 
to that of the reference culture method, while providing more rapid test results. 
Positive and negative agreements between the test and reference method were 94% 
(51/54) and 89.9% (482/536) for MRSA, respectively, and 92.8% (166/180) and 
95.9% (402/419) for S. aureus, respectively. The assay detected geographically and 
genetically diverse strains of SA/MRSA including BORSA (Borderline oxacillin 
resistant S. aureus) and MRSA strains with mecC, the recently identified methicillin-
resistance gene of bovine origin. The LOD was 56 CFU/reaction or lower. Inter and 
intra-assay reproducibility demonstrated CV of less than 3%. No cross-reactivity was 
observed with other organisms. Studies using potential interferents did not show any 
inhibition to target detection for the MRSA Direct assay. Conclusions: The sample-
to-answer Simplexa MRSA Direct assay is a rapid MRSA screening assay that has 
similar performance to the comparator culture method but with very little hands-on 
manipulation. The assay directly detects MRSA strains with mecA or the recently 
identified mecC methicillin-resistance gene in about an hour. The assay is in 
development, it is not currently available for sale, and it is not FDA cleared. 
 
ID80. Evaluation of the Multicode CMV and HSV ASR for the Diagnosis of 
Viral Pneumonia in Immunocompromised Patients 
E. Babady, P. Ruggiero, E. Miranda, J. Amuaro, Y. Tang 
Memorial Sloan-Kettering Cancer Center, New York, NY. 
Introduction: Cytomegalovirus (CMV) and herpes simplex virus (HSV) are the most 
common cause of viral pneumonia in immunocompromised patients. Diagnosis of 
viral pneumonia relies in part on the detection of CMV and HSV in lower respiratory 
tract specimens. We report here the development of two qualitative real-time PCR 
assays for the rapid detection of CMV and HSV in respiratory specimens and their 
utility in diagnosing CMV/HSV pneumonia. Methods: CMV and HSV ASR primers 
were obtained from Luminex Corporation (Austin, TX). These ASR are based on the 
MultiCode Technology, a probe-free real-time detection system that uses a unique, 
patented MultiCode base pair (isoC and isoG). Nucleic acids extraction was 
performed using either the MagNA Pure LC or the MagNA Pure Compact (Roche 
Applied Sciences) followed by amplification and detection on an ABI 7500 instrument 
(Life Technologies Corp.). The lower limit of detection (LOD) was determined by 
testing a dilution series of CMV/HSV whole viruses (Zeptometrix Inc.) spiked in 
negative BAL. The specificity of each assay was determined by testing a panel of 
potentially cross-reacting organisms. Accuracy was established by testing 95 BAL 
samples previously tested by viral culture. Clinical utility was determined by 
reviewing patient charts for established viral pneumonia diagnosis. Results: The 
LOD for the CMV assays was 214 copies/mL whereas the LOD of the HSV assay 
was 479 copies/mL. There was no cross-reaction with other pathogens tested. 
Agreement between the CMV PCR and CMV shell vials was 82%, 11 patients had 
discordant results. Agreement between the HSV PCR and HSV culture was 89%, 8 
patients had discordant results. Only 7/35 and 5/35 patients were clinically 
diagnosed and treated for probable HSV and CMV pneumonia, respectively, based 
on culture results. None of the patients with discordant results between culture and 
PCR were diagnosed or treated for CMV/HSV pneumonia. Conclusions: Real-time 
PCR using the Multicode based CMV/HSV ASRs can be useful for the diagnosis of 
viral pneumonia, with the added advantage of objective results and better turnaround 
time for results when compared to culture. The clinical significance of the additional 
cases detected by PCR only remains to be determined.  
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 ID81. Co-Amplification and Detection Sensitivity of Viral RNA and DNA 
Targets from Cerebrospinal Fluid Specimens Using BD MAX ExK TNA-2*, a 
New Automated Molecular Open System Reagent 
D. Dugourd, I. Paradis, H. Galarneau, V. Jean, B. Leclerc, S. Simard, J. Pinard-
Lachapelle, F. St-Pierre, V. Blanchette, C. Ménard, C. Roger-Dalbert 
BD Diagnostics, Québec, Canada 
Introduction: The BD MAX System is a sample-to-answer automated molecular 
testing platform. The new BD MAX TNA (Total Nucleic Acid) suite, part of the Open 
System Reagent series, combines specimen-specific extraction kits (ExK for swabs 
in Universal Transport Medium (UTM) or cerebrospinal fluid (CSF)) and universal 
PCR reagents with or without specimen processing control (SPC) primers and probe 
(MMK* and MMK(SPC)*). The TNA suite allows users to detect multiple RNA and 
DNA targets from a single biological specimen with their own user defined protocols. 
Users can select specimen volume, and individually program thermocycling and 
analysis parameters. This study aimed to demonstrate the capability of BD MAX ExK 
TNA-2* combined with BD MAX TNA MMK(SPC) to detect RNA and DNA targets 
from CSF with high sensitivity. Methods: Extraction and amplification of CSF were 
performed using the BD MAX System. To determine viral limit of detection (LOD) in 
CSF specimen a volume of 300 μL of specimen spiked with 5 dilutions of a RNA 
virus (43 to 680 PFU of enterovirus type 71) combined with 5 dilutions of a viral DNA 
target (21 to 340 PFU of adenovirus 7A) were added to the Sample Buffer Tube 
(SBT) were co-extracted and co-amplified using BD MAX ExK TNA-2 and the BD 
MAX TNA MMK(SPC). A SPC consisting of an armored RNA formulated with the BD 
MAX ExK TNA-2 extraction reagent, and the corresponding primers and probe are in 
the BD MAX TNA MMK(SPC) reagents. Target-specific primers and probes were 
added to reagents prior to use. Confirmation of extraction and amplification efficacy 
was performed by spiking individual specimen (n=30) with enterovirus and 
adenovirus at 5x determined LOD. Results: Within the same multiplex PCR reaction 
the detection sensitivity for the RNA and DNA viral targets were 170 PFU/SBT, and 
43 PFU/SBT, respectively. Extraction and detection efficiency of individual clinical 
CSF specimens was confirmed when spiked with 5x LOD of viral RNA target (850 
PFU/SBT) and DNA target (215 PFU/SBT) with 100% compliant results and 
Endpoint significantly above cutoff. Conclusions: The BD MAX ExK TNA-2 and 
MMK can extract, co-amplify, and detect DNA and RNA viral targets from specimen 
in a single multiplex reaction with relatively good sensitivity as confirmed by results 
at 5x LOD.  
*BD MAX ExK TNA-2, BD MAX TNA MMK and BD MAX TNA MMK(SPC) are not 
available for sale or use. 
 
ID82. A Comparison of Real-Time PCR Assays for the Simultaneous 
Detection of Bordetella pertussis and B. parapertussis from Nasopharyngeal 
Swabs Specimens 
C. Webb, L.A. Millecker, P.A. Revell 
Texas Children's Hospital, Houston, TX. 
Introduction: Whooping cough caused by Bordetella pertussis (BP) has re-emerged 
as an important disease in children and adults as one of the most commonly 
occurring vaccine-preventable diseases in the United States. Since Bordetella is a 
fastidious pathogen requiring specialized media for culture, PCR is often used for 
diagnosis. This study compares the performance of 3 real-time PCR tests for the 
simultaneous detection of BP and BPP from nasopharyngeal swab specimens. 
Methods: Nucleic acid (NA) was isolated from nasopharyngeal swab specimens 
collected in Amies charcoal media and resuspended in 200L PBS. NA was 
extracted on the Roche MagNA Pure LC using the TNAi kit. Before extraction, 5L of 
each swab suspension was set aside for direct testing. Each NA was tested in 
parallel using a lab-developed (LDT) test on the LightCycler 2.0 and the Focus 
Diagnostics B. pertussis and B. parapertussis ASR on the Integrated Cycler. The 
swab suspension was also tested directly using the Focus assay. A smaller subset of 
NA’s was also tested using the ELITech B. pertussis/parapertussis ASR on the 
LightCycler 2.0. BP/BPP cell suspensions and ATCC DNA were used to assess 
analytical sensitivity. A total of 86 NAs were tested, including 68 NP swabs, 14 
culture suspensions, 3 ATCC DNA dilutions, and 1 CAP Survey sample. Results: 
Using the LDT as the comparison method, diagnostic sensitivity and specificty of the 
Focus assay from NA was 97.4% (38/39) and 97.0%, (32/33), respectively. 
Diagnostic sensitivity and specificty of the Focus assay from direct specimen was 
97.2% (35/36) and 100.0% (30/30), respectively. Diagnostic sensitivity and specificity 
of the ELITech assay from extracted NA were both 100% (10/10). The Focus NA 
assay proved to have the highest analytical sensitivity for BPP, detecting 0.1 
cells/mL. For BP, the Focus and ELITech NA assays demostrated equivalent 
analytical sensitivities, detecting 0.01 cells/mL. Conclusions: All assays evaluated 
demonstrated excellent correlation, clinical sensitivity/specificity and analytical 
sensitivity. The Focus and ELItech NA assays performed with equivalent analytical 893
89
AMP Abstractssensitivities for BP, but the ELItech and LDT had superior clinical sensitivity. PCR 
setup was quicker for both commercial products, which utilize 4 to 5 individual 
reagents, as compared to the LDT that uses 12 reagents. Analysis time was 
comparable for all 3 assays. Although a slight decrease in clinicial sensitivity was 
observed for the Focus direct assay, the benefits it offers with elimination of 
extraction and increased ease-of-use could potentially enable daily testing thus 
significantly improving the TAT at our facility. 
 
ID83. Clinical Performance Assessment of the Luminex xTAG Investigational 
Assay for the Detection of Enteric Pathogens Directly from Clinical Specimens  
R. Manji, C.C. Ginocchio 
North Shore-LIJ Health System Laboratories, Lake Success, NY. 
Introduction: Diarrheal diseases represent one of the five leading causes of death 
worldwide with significant morbidity and mortality in the United States. Most cases of 
acute diarrhea are self-limiting and due to infections with viruses (norovirus, 
rotavirus, adenovirus 40/41, astrovirus, sapovirus), bacteria (Salmonella, 
Campylobacter, Shigella, enterotoxigenic E. coli, Yersinia, Plesiomonas, Aeromonas, 
Vibrio), and protozoa (Cryptosporidium, Giardia, Microsporidia, Entamoeba 
histolytica). Currently, detection of pathogens is performed using standard labor 
intensive microbiology culture techniques, antigen assays, stool concentration 
procedures and insensitive microscopy, which require experienced microbiologists 
and take days for the final results. Molecular-based methods have been developed 
to improve the time to pathogen detection. This study evaluated the clinical 
performance of the xTAG Gastrointestinal Pathogen Panel (xTAG GPP, Luminex) 
that incorporates multiplex reverse transcriptase polymerase chain reaction (RT-
PCR) with proprietary universal tag sorting system on the Luminex platform. 
Methods: A total of 595 discard clinical stool samples collected in either Cary Blair 
transport media or Remel Parasitology vials were selected based upon routine 
culture, microscopy or antigen test results. Positive (n=308) and negative (n=287) 
samples were tested using the Research Use Only (RUO) xTAG GPP assay that 
identifies 15 enteric pathogens. Results: Pathogen detection rate of xTAG GPP and 
conventional methods were as follows, respectively: Campylobacter 135/150 
(90.0%), 144/150 (96.0%); E. coli O157 6/6 (100%), 4/6 (66.7%); ETEC 5/5 (100%), 
0/5 (0.0%); Salmonella 62/63 (98.4%), 53/63 (84.1%); Shigella 45/45 (100%), 34/44 
(77.3%); Yersinia enterocolitica 3/14 (21.4%), 11/14 (78.6%); Giardia 22/23 (95.7%), 
21/23 (91.3%); Cryptosporidium 4/4 (100%); 2/4 (50%); Entamoeba histolytica 5/6 
(83.3%), 1/6 (16.7%); Vibrio cholera 0/1 (0%), 1/1 (100%). xTAG GPP detected 
Clostridium difficile in 44 samples versus 33 samples by the BD GeneOhm Cdiff 
PCR assay. Additionally, xTAG GPP positive samples included 2 with adenovirus 
40/41, 22 with norovirus, and 8 with rotavirus. Overall, an enteric pathogen was 
identified in 363/595 samples (61.0%) tested by xTAG GPP and in 346/595 (58.2%) 
samples tested with traditional methods (39 pathogens not in xTAG GPP). There 
were 2 pathogens identified in 7 cultures and 34 mixed infections identified by xTAG 
GPP. Conclusions: xTAG GPP can simultaneously detect the leading pathogens 
that cause acute gastroenteritis from stool collected in either Cary Blair or 
parasitology transport media. xTAG GPP was able to identify additional 
gastroenteritis cases missed by conventional methods.  
 
ID84. Processing Optimization of Chlamydia trachomatis and Neisseria 
gonorrhoeae Simulated Urine Samples from Proficiency Testing Panels on the 
Cobas CT/NG Test 
J. Engstrom-Melnyk1, V. Geraldo2, P. Rodriguez1, E. Ruiz2, J. Osiecki2 
1Roche Diagnostic Corporation, West Hartford, CT; 2Roche Molecular Systems, 
Branchburg, NJ. 
Introduction: The introduction of the Clinical Laboratory Improvement Amendments 
(CLIA) in 1988 established quality standards for all laboratory testing to ensure the 
accuracy, reliability and timeliness of patient test results. For laboratories to be CLIA 
certified and accredited, they must participate in proficiency testing (PT) programs, 
which are critical to verify the accuracy and reliability of testing. Routine reviews of 
PT reports by the laboratory staff and director will alert them to areas of testing that 
are not performing as expected and also indicate subtle shifts and trends that, over 
time, would affect their patient results. Thus, it is imperative, as a test manufacturer, 
to assess compatibility of each test with the most common PT material, which often 
consists of simulated specimen matrixes rather than true clinical specimens and 
collections, which can confound molecular assessment. This study was conducted to 
evaluate simulated urine samples provided for proficiency testing and to develop a 
processing protocol compatible with the cobas CT/NG test. Methods: Simulated 
urine proficiency material was obtained from a commercial PT provider and 
processed following several different protocols to assess compatibility with the cobas 
CT/NG test. The simulated urine was diluted at various concentrations into cobas 
PCR medium and processed on the cobas 4800 system following either the UT 4(400L sample processed) or UUT (850L) workflow. Additional protocols included 
spinning the PT material and re-suspending directly into cobas PCR medium as well 
as adding the provided 1mL PT aliquot directly into the cobas PCR Urine Sample Kit. 
Internal control (IC) and target CT values were assessed to determine amplification 
efficiency; ease-of-use of each protocol was also considered. Results: Dilution of 
the simulated urine PT specimen resulted in improved recovery of the IC (earlier CT 
values), although at the expense of target detection (later CT values); incubation 
time had little effect on the results. A clear distinction was observed between the two 
processing protocols (UT vs UUT), whereby the latter consistently resulted in later 
CT values for both the IC and target analyte. Incorporating a centrifugation step 
improved the IC and analyte detection, but proved to be non-user friendly and 
cumbersome. Conclusions: Analysis of each protocol determined that adding 1mL 
of the PT specimen directly into the cobas PCR Urine Sample Kit and processed 
using the UT workflow on the cobas 4800 system was ideal. 
 
ID85. Evaluation of a Real-Time PCR Assay for the Detection of Norovirus in 
467 Stool Specimens 
B.J. Davids1, D. Cross1, J. Kehle2, T.T. Stenzel1 
1Quidel, San Diego, CA; 2AnDiaTec, Kornwestheim, Germany. 
Introduction: Norovirus is a single-stranded RNA virus in the Caliciviridae family 
and one of the most common cause of gastroenteritis.  Norovirus infection is highly 
contagious and sometimes life-threatening requiring hospitalization. Only two of the 
five norovirus genogroups, designated as GI and GII, significantly impact human 
health. Genogroup IV also infects humans, though rarely. The genomes of these 
norovirus groups are heterogeneous, requiring norovirus group and antigen-specific 
(degenerate) PCR primers and fluorescent probe sets to detect each analyte. A 
sensitive and specific RT-PCR assay targeting norovirus would be advantageous not 
only for pathogen identity, but also aid in infection control practices of norovirus 
outbreaks in healthcare and non-healthcare settings. This study evaluated a 
norovirus assay that simultaneously detects GI, GII, and GIV. Methods: Nucleic 
acids were extracted from 467 stool samples and tested using the AnDiaTec 
Norovirus real-time RT-PCR assay. Forty-nine norovirus strains were tested for 
analytical inclusivity. Twenty viral isolates representing 7 non-norovirus viral 
pathogens were used for cross-reactivity testing. All sample testing was confirmed 
by amplicon sequencing or by an alternate RT-PCR assay. Analytical limit of 
detection (LOD) was tested by first quantifying viral copies of norovirus GI and GII 
specimens with serial dilutions of known concentrations of double-stranded norovirus 
synthetic templates. Norovirus-negative stool matrix was then inoculated with 
specific copy numbers of virus, extracted on the NucliSENS easyMAG (bioMérieux) 
and eluates were tested with the AnDiaTec assay. Results: Three hundred sixteen 
of the 467 stool samples were positive for norovirus. The results were confirmed by 
alternate methods. All 49 norovirus strains tested were positive including isolates 
from GI, GII, and GIV. Cross-reactivity was not detected on 20 isolates spread 
among 7 non-forovirus human viral pathogens. Preliminary LOD in stool matrix was 
determined to be as low as 250 copies per reaction for GI and 25 copies per reaction 
for GII. Conclusions: The AnDiaTec Norovirus real-time RT-PCR assay appears to 
be highly sensitive and specific for the detection of norovirus on clinical specimens. It 
does not cross-react with nucleic acid from other viruses tested and is easy to use. 
 
ID86. Performance of a Modified FilmArray Respriratory Panel for Improved 
Detection of Respiratory Adenovirs Serotypes 
B. Lingenfelter, K. Kanack, E. Amiott, K. Bourzac, W. Ramos-Jensen, M. Jones, M. 
Buccambuso, L. O'Conner, B. Bishop, S. Richards, S. Woodhouse, J. Hoge, R. 
Lems, T. Healy, R. Ajioka 
BioFire Diagnostics, Salt Lake City, UT. 
Introduction: The FilmArray Respiratory Panel (RP) is a user-friendly, highly 
multiplexed in vitro diagnostic test for the detection of twenty different agents of 
upper respiratory tract infection from a nasopharyngeal swab (NPS) specimen in 
about an hour. One of the 17 viral targets of the FilmArray RP test is adenovirus. 
Human adenoviruses (HAdV) are classified into 7 species (A-G) and further 
distinguished into over 50 distinct serotypes. Adenovirus species B, C, and E are 
associated with respiratory illness. The Adenovirus assay in the FilmArray RP will 
detect many but not all adenovirus species and serotypes. The original panel had a 
limitation on the detection of HAdV2 and HAdV6 serotypes (species C), and the 
sensitivity for detection of several other serotypes appeared to be lower than some 
published or commercial molecular assays. Methods: The FilmArray RP was 
recently modified to improve detection of all respiratory adenovirus serotypes from 
NPS specimens. Analytical studies were performed to characterize the sensitivity 
(limit of detection), reactivity (inclusivity), and specificity (cross-reactivity and 
performance in the presence of co-infecting organisms) for HAdV in the modified 
panel. The clinical evaluation involved a method comparison study in which 222 jmd.amjpathol.org ■ The Journal of Molecular Diagnostics
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modified and unmodified FilmArray RP. Performance was compared for all analytes 
on the panel. Results: The modified FilmArray RP detected 17 different respiratory 
HAdV serotypes within species B, C, and E (including HAdV2 and HAdV6) with a 3-
fold increase in analytical sensitivity compared to the original panel (Adenovirus LOD 
= 100 TCID50/mL). No cross-reactivity with other respiratory pathogens was 
observed and the panel accurately identified multiple pathogens from a single 
sample. In the clinical study, the modified FilmArray RP detected adenovirus in 73% 
more archived specimens than the unmodified test (26 vs. 15 specimens 
respectively). Improved detection was observed for serotypes HAdV2, HAdV5, 
HAdV6, and HAdV4. The archived specimen testing data also demonstrate 
equivalent performance between the two test versions for all other analytes with PPA 
of 93.4% to 100% and NPA of 97.9% to 100%. Conclusions: These data validate 
that the modified FilmArray RP, which recently received FDA clearance, has 
increased sensitivity for several adenovirus serotypes and is capable of detecting 
more Adenoviruses in clinical specimens than the previous unmodified version of the 
test. Data from these studies also confirm that the sensitivity of the other assays in 
the panel was unchanged by the modification.  
 
ID87. Development of Group B Streptococcus Multiplex PCR Panel 
Amendable to Bead-Based and Microarray Detection Systems  
L. Malone, S. Brzezinski, D. Hockman, C. Sesler, E. Grigorenko 
Diatherix Laboratories, Inc, Huntsville, AL. 
Introduction: Streptococcus agalactiae, also known as group B Streptococcus 
(GBS), is a common bacteria carried in the vaginal and/or GI tract of between 15% to 
40% of healthy women.  It has been implicated as a leading cause of life-threatening 
neonatal infections including pneumonia, sepsis and meningitis. The goals of this 
study were to develop and to validate target enriched multiplex PCR (tem-PCR) 
panel for detection of S. agalactiae in clinical samples and to evaluate different bead- 
and microarray-based detection platforms. Methods: To improve sensitivity and 
specificity, we used 2 gene targets for detection of S. agalactiae using target 
enriched multiplex PCR (tem-PCR). Each pathogen target is detected by a nested 
set of primers which, upon specific annealing to and amplification of extracted 
nucleic acids, will incorporate a biotin label into the resultant PCR product. PCR 
products were hybridized to detection-specific oligonucleotides on two different 
detection systems: bead-based (Luminex or IncellDx) or solid-surface microarray 
(Microarrays, Inc). Sensitivity and specificity of the tem-PCR panel was validated on 
titered S. agalactiae, followed by testing of clinical vaginal/rectal samples. Results of 
tem-PCR test were compared with cell culture. Results: The tem-PCR GBS panel 
has been tested for inclusivity on 11 reference GBS strains. All strains were 
evaluated at approximately 1660 GEq/rxn. All strains produced positive results with 
high S/N ratio. Assay specificity has been evaluated against a wide range of 
organisms (n=55 at 106 organisms/mL) that could be potentially recovered by 
vaginal/rectal swabs. No positive signal was detected with any tested organisms. 
Using serial dilutions of titered strains, the limit of detection (LOD95) for GBS was 
determined to be < 100 cfu/ml with the Reed-Muench method of analysis. The 
concordance of GBS detection between bead- and microarray-based platforms was 
100%. The comparison of bead-based platforms revealed the flexibility of the 
InCellDx flow cytometry system compared to Luminex, which consists of utilization of 
beads from different manufacturers for GBS detection and increased data points per 
target (100 vs 20) with a shorter read time. However, Luminex and microarray 
platforms produced a higher S/N ratio than IncellDx. 
Conclusions: The tem-PCR GBS panel provides rapid, sensitive and specific 
method for GBS detection directly from clinical samples. Usage of two independent 
gene targets allows for increased sensitivity and confirmation that negative results 
are not due to a strain genetic variation. This tem-PCR GBS panel can be adapted 
on different detection systems without compromising panel performance 
specifications. 
 
ID88. Neonatal Pasteurella multocida Meningitis: Molecular Linkage to Two 
Family Cats 
B.L. Boyanton1, B. Robinson-Dunn1, R. Luna2, J.K. Runge2, B.J. Freij3 
1Beaumont Health System, Royal Oak, MI; 2Texas Children's Hospital / Baylor 
College of Medicine, Houston, TX; 3Beaumont Children's Hospital / Beaumont Health 
System, Royal Oak, MI. 
Introduction: Pasteurella multocida is a rare cause of bacterial meningitis, with just 
over 20 cases reported in newborns (30 days of age) since 1963. Dog or cat 
exposure is implicated in most, but recovery of the organism from animals and 
establishing molecular linkage with that of the infants’ has rarely been attempted, 
including use of ribotyping/macrorestriction analysis and rapid amplification of 
polymorphic DNA. Case Report: A 17-day-old boy, born at term via cesarean The Journal of Molecular Diagnostics ■ jmd.amjpathol.orgsection, developed a temperature of 39.7°C. Sepsis work-up showed a peripheral 
white blood cell (WBC) count of 18.2 bil/L (N 11.4), Na 129, AST 61, ALT 50. 
Cerebrospinal fluid (CSF) studies showed 20,822 WBCs/mcL (N 73%), 1500 red 
blood cells/mcL, glucose 7 mg/dL, protein 148 mg/dL, and no organisms on Gram 
stain. P. multocida grew from blood and CSF. He was treated with cefotaxime (14 
days) and recovered without hearing loss or neurodevelopmental delays. The family 
had two cats (same litter) and one dog. Nasopharyngeal and gingival swabs were 
collected from the dog and cats, respectively. Methods: Blood and CSF specimens 
were subjected to conventional and automated (BacTAlert, BioMerieux) cultures. 
Animal specimens were placed onto conventional plate-based cultures. Organisms 
were identified using automated (MicroScan, Siemens; Vitek II, BioMerieux) 
biochemical methods. Commercially available extraction kits were utilized to obtain 
bacterial DNA from six P. multocida isolates: infant (n=1), each cat (n=2), archived 
clinical strains (n=3). Molecular strain typing, using repetitive element PCR (Rep-
PCR; Diversilab, BioMerieux), was performed using both a standard bacterial strain 
typing kit and Pasteurella-specific primers; microfluidics-based electrophoresis was 
employed for size separation of the amplified products. Resulting molecular profiles 
were analyzed for relative similarity. Results: P. multocida was recovered from the 
infant’s blood and CSF, and the gingival cultures of both cats.  P. multocida was not 
isolated from the dog. Molecular strain typing results showed that P. multocida 
isolates from the infant and both cats were indistinguishable when using the 
standard bacterial strain typing kit or the Pasteurella-specific primers. In contrast, the 
three archived P. multocida clinical isolates were distinct from each other as well as 
from the infant and cat isolates. Conclusions: This is the first report confirming the 
source of neonatal meningitis due to P. multocida using Rep-PCR technology. 
Molecular strain typing methods, including Rep-PCR, are valuable tools for 
identifying the source of infection. 
 
ID89. Detection of Mixed Hepatitis C Virus (HCV) Infection Using Abbott 
RealTime HCV Genotype II Assay 
J. Lampinen, D. Lucic, C. Esping, K. Kuper, G. Leckie, G. Cloherty 
Abbott Molecular, Des Plaines, IL. 
Introduction: HCV genotype testing is currently used as a treatment qualifier for the 
first generation protease inhibitors (PI) as well as pegylated interferon and ribovarin 
treatment. It is important that clinicians have a clear picture of the type of infection 
they are treating as some genotypes are more difficult to treat than others. Studies 
have demonstrated low prevalence of mixed infection in certain at risk populations 
such as intravenous drug users. Ability of genotype assay to identify mixed 
populations provides clinicians with additional information on how to best manage 
their patients. The objective of this study was to evaluate ability of HCV GT II assay 
to identify mixed infections. Methods: Mixed genotype panels were generated by 
mixing two known genotype samples (SeraCare Life Sciences, Milford, MA) to obtain 
the genotypic mixtures. The following mixtures were evaluated: 1a/3, 1b/2, 4/6, 
1a/1b, 1a/4, 1b/5 and 1a/6. For each samples tested the final concentration of mixed 
HCV virus was targeted to 4.87 log IU/ml. Mixed infection was evaluated at 80:20, 
50:50 and 20:80 concentrations. Three runs and three replicates of each panel were 
tested. Results: HCV GT II was able to detect 100% of the different permutations for 
possible 1a/1b, and 4/6 mixed infection. One replicate of 1b/5 mixtures was missed 
and reported as 1b only, and one replicate of 1a/6 mixtures was missed and reported 
as 1a only. Conclusions: Abbott RealTime HCV GT II assay is capable of detecting 
and distinguishing mixed HCV infections at 80:20, 50:50 and 20:80 concentrations. 
The ability of the HCV GT II to detect mixed infection even at low concentrations 
could demonstrate both clinical and epidemiological utility.  HCV GT II assay would 
give clinicians added confidence that they are treating the most difficult to treat 
genotype. 
 
ID90. Performance Characteristics of a Fully-Automated Assay on the Cobas 
4800 System to Detect Clostridium difficile from Stool Specimens  
Y. Ohhashi, S. Lowe, M. Davidson, R. Mababangloob, D. Yee, N. Dyer, N. 
Visomblin, D. Kosarikov, M. Lewinski, J. Osiecki 
Roche Molecular Systems, Pleasenton, CA. 
Introduction: Clostridium difficile is an anaerobic, toxin producing microorganism 
known to cause severe diarrhea following antibiotic therapy. Nucleic acid 
amplification tests provide sensitive and timely identification of patients with C. 
difficile infection. This study was conducted to evaluate performance characteristics 
of the newly developed cobas Cdiff Test using clinical specimens, C. difficile isolates, 
and QCMD panels. Toxinotype coverage, analytical sensitivity/specificity, specimen 
stability, and performance against cytotoxicity culture were evaluated. Methods: 
Polyester swabs were used to transfer stool specimens into sample vials that were 
loaded directly on the fully automated cobas 4800 system for processing, PCR 
setup, amplification and detection. Characterized culture isolates and clinical 895
8AMP Abstractsspecimens were evaluated. C. difficile colony isolation culture followed by the 
cytotoxicity assay was used as a reference method for comparison. Results: The 
cobas Cdiff Test detected all 31 toxinotypes as well as the 027/NAP1/BI 
hypervirulent strain. Over 120 other organisms, including non-toxigenic C. difficile 
and C. sordellii, were tested at 1 x 106 CFU/mL and no cross reactivity was 
observed. Preliminary specimen stability studies for routine laboratory workflow 
indicate 100% stability for fresh stool specimens for 48 hours at room temperature, 
and an additional 5 days at 2°C to 8°C. Alternatively, stool specimens transferred to 
cobas PCR media were determined to be stable for 7 days at 2°C to 8°C. With the 
cytotoxicity test as the gold standard, the sensitivity and specificity for the cobas 
Cdiff Test was determined to be 100% and 97%, respectively, evaluating 372 clinical 
unformed stool specimens. All of the C. difficile positive members in the QCMD 
panel were also detected. Conclusions: The cobas 4800 Cdiff Test, run on the fully 
automated cobas 4800 system, demonstrated excellent performance for detecting C. 
difficile in unformed stool specimens. 
 
ID91. Chlamydia trachomatis and Neisseria gonorrhoeae (CT/NG) Detection 
in SurePath and ThinPrep Specimens Using Abbot RealTime CT/NG Assay 
D. Lucic1, C. Eisenhut2, G. Cloherty1 
1Abbott Molecular, Des Plaines, IL; 2DCL, Indianapolis, IN. 
Introduction: CT/NG infections are the most common causes of sexually 
transmitted diseases in the US. Diagnosis of CT/NG infection is most generally 
performed by commercially available nucleic acid amplification tests (NAATs). 
Currently available NAATs are FDA-cleared based on a specific specimen type 
(vaginal swab, male urine, female urine or liquid cytology). Capability to process 
specimens such as SurePath and ThinPrep allows laboratories to process multiple 
tests (PAP and HPV) from a single specimen. This study evaluated the performance 
of the Abbott RealTime CT/NG assay using ThinPrep and SurePath specimens. 
Methods: SurePath (n=75) and ThinPrep (n=601) specimens were run using the 
Abbott RealTime CT/NG Assay and compared to reference methods APTIMA CT/GC 
combo assay on the TIGRIS instrument and ProbeTec Qx Amplified DNA Assay on 
the Viper instrument. For m2000, specimens (600 μl) were transferred to a 
laboratory barcoded tube without any pretreatment. Extracted DNA is then 
transferred to the 96-well reaction plate by the m2000sp. The plate is sealed and 
placed into m2000rt instrument for amplification and detection. Concordance was 
assessed if there was agreement between RealTime CT/NG assay and one other 
methodology. Results: Greater than 98% concordance was observed between 
RealTime and ProbeTec SurePath specimens whereas 88% concordance was 
observed between RealTime and Aptima. Similar concordance (89%) was observed 
between ProbeTec and Aptima SurePath specimens. All three methods identified 63 
specimens as CT and NG negative. With SurePath specimens CT positives were 
identified in 11, 10, and 2 samples with RealTime, ProbeTec, and Aptima, 
respectively. One specimen was identified as NG positive by RealTime and 
ProbeTec methods only. With ThinPrep specimens 7 specimens were identified as 
CT/NG positive by all 3 methods; CT positives were identified in 100, 95, and 97 
samples by RealTime, ProbTec, and Aptima, respectively. Four hundred ninety 
specimens were identified as CT and NG negative by RealTime whereas ProbeTec 
and Aptima identified 492 specimens. RealTime identified 3 specimens as NG 
positive whereas ProbeTec and Aptima identified 6 and 4, respectively. 
Conclusions: Overall good concordance was observed between all methodologies 
tested in this study. These results demonstrate that reliable and accurate detection 
of C. trachomatis and N. gonorrhoeae from SurePath and ThinPrep patient 
specimens using the Abbott RealTime CT/NG assay. 
 
ID92. Correlation of Polyomavirus-Associated Nephropathy and Plasma BK 
Virus Titers: A Community Hospital Experience 
S. Hurst, I. Montalvan, Z. Jobbagy 
Newark Beth Israel Medical Center, Newark, NJ. 
Introduction: Nephropathy caused by polyomavirus is an important cause of 
allograft dysfunction in renal transplant patients receiving multi-agent 
immunosuppressive therapy. It is important clinically as it can be difficult to 
differentiate from cell-mediated rejection. The treatment of those two options is vastly 
different in terms of changes to the patient’s immunosuppression regimen. The 
diagnostic gold standard for polyomavirus associated nephropathy (PVAN) is renal 
biopsy. However, in recent years, less invasive surrogate methods for the diagnosis 
have been developed. PCR-based assays became a leading modality to measure 
viral load in urine and plasma specimens. The viral load threshold that should prompt 
renal biopsy remained somewhat controversial; however it was suggested in the 
literature as 104 copies/mL for plasma and 107 copies/mL for urine. Values above 
these that persist for three weeks are considered highly suggestive of PVAN. Here, 
we describe the experience of a community hospital based renal transplant center 96using a commercial PCR assay to measure BK virus viral load. Methods: 
Measurement of BK viral load was performed using the Elitech MGB PCR analyte 
specific reagent (ASR) on the Roche LightCycler 2 platform. Renal biopsies that 
showed evidence of PVAN were correlated with the concurrent PCR-measured viral 
load. Polyomavirus infection was confirmed with SV-40 immunostain. Data collected 
within the last two years were analyzed. Results: Seven biopsies that showed 
histopathologic and immunohistochemical evidence of PVAN in six patients were 
identified. The plasma viral loads measured concurrently with these biopsies were 
2660, 27,900, 56,700, 339,000, 1,030,000, 1,140,000 and >5,000,000 copies/mL, 
respectively. Conclusions: To prompt renal biopsy, it has been suggested that 
threshold for a noninvasive diagnostic test for PVAN should be set at a value that 
provides a specificity of 94% for PVAN. In our series, all but one of these values 
were above the suggested threshold of 104 copies/mL. In that patient, only one 
plasma BK viral load was performed and the viral load level was 2660 copies/mL. 
The duration of this patient’s viremia is unknown. It is possible that early renal 
manifestations of PVAN occur even at levels below the threshold suggested in the 
literature. Large, multicenter studies with standardized assays could more clearly 
determine the appropriate thresholds for PCR- based BK virus detection methods. 
 
ID93. Development of a Rapid, Real-Time PCR Assay for the Detection and 
Differentiation of Group A and Group C/G Streptococci from Throat Swabs 
J. de Leon1, V. Armendarez1, T.R. Ott1, J. Ahle1, T. Curtiss2, T.M. Campbell2, J. 
Pappas2, T.D. Pack1 
1Quidel Corporation, San Diego, CA; 2Diagnostic Hybrids, Inc., Athens, OH. 
Introduction: Group A Streptococcus (GAS) is responsible for the majority of 
streptococcal throat infections. Early detection and treatment of streptococcal 
pharyngitis can reduce the severity of symptoms and serious complications such as 
acute rheumatic fever. In addition to GAS, severe streptococcal throat infections can 
also be associated with group C and G Streptococcus (GCS and GGS). The gold 
standard of diagnosis of streptococcal pharyngitis is 24 to72 hour culture. Physicians 
must treat patients presumptively or withhold antibiotic therapy until the presence of 
GAS, GCS, or GGS is confirmed with culture. The development of a confirmed GAS 
and GCS/GGS real-time PCR assay should therefore prove useful. Methods: The 
Quidel Molecular Direct Group A+C/G Strep Assay (QMol Strep assay) has been 
developed to detect DNA from throat swab specimens. The specimen is eluted off 
the throat swab by placing it in the Process Buffer (PB) containing Internal Control 
DNA, twirled for 5 seconds and the swab is discarded. The sample in PB is heated at 
95°C for 10 minutes to release DNA. Five microliters of processed specimen is then 
combined with 15 μL of rehydrated master mix in a PCR reaction. The entire assay 
takes approximately 1 hour from sample to result. In these studies, the ability to 
detect GAS from clinical specimens was determined. In the initial study unused 
secondary swabs were plated then tested using the QMol Strep assay. These results 
were then compared to results obtained with the primary swab on a Roche GAS 
Analyte Specific Reagents (ASR). In another study, frozen leftover secondary swabs 
were plated and run on the QM Strep assay and compared directly with the culture 
results. In a third study, 100 throat swabs from 50 asymptomatic individuals were 
tested to ensure clinical specificity. Results: The QMol Strep assay detected 71 of 
the 73 samples as GAS for a 97% positive agreement with the ASR assay. The 2 
samples that were not detected by the QMol Strep assay were also culture negative. 
In the second study, 8 samples were positive and 24 were negative by the QMol 
Strep assay whereas culture had 6 samples that were positive for a sensitivity of 
100% and specificity of 92.3% compared to culture. No positive results and no 
inhibition were observed with any of the swabs from asymptomatic individuals. 
Conclusions: These preliminary results demonstrate that the Quidel Molecular 
Direct Group A+C/G Strep assay is sensitive and specific for group A streptococci. 
 
ID94. Evaluation of Abbott RealTime Hepatitis C Virus (HCV) Genotype II 
Assay 
G. Leckie1, J. Lampinen1, C. Esping1, K. Kuper1, D. Toolse1, D. Lucic2, G. Cloherty2 
1Abbott, Des Plaines, IL; 2Abbott Molecular, Des Plaines, IL. 
Introduction: HCV genotyping is the primary tool used for assessing the response 
to antiviral therapy and determining treatment duration. Genotypes 1 and 4 are more 
resistant than genotypes 2 and 3 to the pegylated interferon and ribavirin 
combination therapy. The introduction of protease inhibitors (PI) significantly 
improved the rate of sustained virologic response (SVR) in genotype 1 patients. 
Studies have demonstrated that subtypes 1a and 1b have different risks of viral 
breakthrough on PI regimens. The objective of this study was to evaluate the 
reproducibility, limit of detection (LOD) and accuracy of the Abbott RealTime HCV 
GT II (HCV GT II) assay. Methods: Reproducibility of the HCV GT II assay was 
evaluated by testing a 36-member panel representing genotypes 1 to 5. Each 
genotype was evaluated at three concentration levels (500-1000, 5000-10000, > jmd.amjpathol.org ■ The Journal of Molecular Diagnostics
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10 runs at each site (1072 results). The assay LOD was estimated by diluting a HCV 
specimen in negative human plasma to concentrations: 1000, 500, 250, 100, and 25 
IU/mL. Probit analysis was used to estimate the LOD for each genotype. The 
accuracy was evaluated by testing 266 genotype 1 (144 of genotype 1a, 122 of 
genotype 1b), 116 genotype 2, 87 genotype 3, 79 genotype 4, and 27 genotype 5 
specimens. Sanger sequencing of the core region was used to determine the 
reference genotype of each specimen. Results: Overall HCV GT II assay 
reproducibility was 99.8% (1070/1072). LOD was 31 IU/mL for subtype 1a, 253 
IU/mL for subtype 1b, 356 IU/mL for genotype 2, 27 IU/mL for genotype 3, 448 IU/mL 
for genotype 4 and 34 IU/mL for genotype 5. LOD by probit analysis was 500 IU/mL. 
Accuracy of the HCV GT II assay was 99.6% (265/266) for genotype 1, 99.1% 
(110/111) for genotype 2, 100.0% (86/86) for genotype 3, 98.7% (76/77) for 
genotype 4, and 100.0% (24/24) for genotype 5, and 99.3% (139/140) for subtype 1a 
and 99.1% (114/115) for subtype 1b. Overall accuracy rate of HCV GT II assay was 
99.5% (561/564). Conclusions: HCV GT II assay on the m2000 platform is an 
automated method for genotyping and result reporting. Turnaround time is faster 
than sequencing assays, requiring approximately 8 hours for 48 samples versus up 
to 36 hours for a sequencing assay. Overall assay reproducibility was 99.8%, 
accuracy was 99.5%, and LOD was 500 IU/mL. 
 
ID95. Viral RNA Extraction from Swabs in Universal Transport Media Using 
BD MAX ExK TNA-3*, a New Automated Molecular Open System Reagent  
D. Dugourd, J. Pinard-Lachapelle, V. Jean, B. Leclerc, V. Blanchette, I. Paradis, H. 
Galarneau, S. Simard, F. St-Pierre, C. Ménard, C. Roger-Dalbert 
BD Diagnostics, Québec, Canada. 
Introduction: The BD MAX System is a sample-to-answer automated molecular 
testing platform. The new BD MAX TNA (Total Nucleic Acid) suite, part of the Open 
System Reagent series, combines specimen extraction reagents (ExK) with 
universal PCR reagents (MMK) allowing users to automate extraction, purification 
and amplification of multiple RNA and DNA targets from a single biological specimen 
(e.g., swabs in Universal Transport Medium (UTM) and cerebrospinal fluid) with their 
own user defined protocols. This study aimed to demonstrate the capacity of the BD 
MAX ExK TNA-3* to extract, amplify and detect viral RNA (enterovirus) from swabs 
in UTM when combined with BD MAX ExK DNase*. Methods: Sample preparation 
and amplification were performed from nasopharyngeal swabs in UTM using BD 
MAX System. A volume of 750 μL of clinical specimen spiked with 750 PFU of 
enterovirus (type 71) was added to the Sample Buffer Tube. To monitor for ExK 
DNase efficacy, a viral DNA target (adenovirus 7A) at 1.5 x 104 PFU was also added 
to the specimen. A Specimen Processing Control (SPC) consisting of an armored 
RNA formulated with BD MAX ExK TNA-3 extraction reagent, and corresponding 
primers and probe are included within the BD MAX TNA MMK(SPC)* reagents. 
Target-specific primers and probes were added to the reagent prior to use. Testing 
was performed with BD MAX ExK TNA-3* and BD MAX TNA MMK(SPC)* with and 
without BD MAX ExK DNase to monitor DNase efficacy. Results: Within the same 
multiplex PCR reaction both the RNA viral target and the DNA viral target 
(adenovirus) were extracted and amplified from the clinical specimen (n=12). The 
SPC was also detected in all samples confirming the success of the extraction. Upon 
the incorporation of the DNase in the automated workflow, the cycle threshold (Ct) of 
the adenovirus was delayed by an average of 8 Ct demonstrating a  99% DNase 
efficacy. The adenovirus endpoints were also significantly impacted by the presence 
of the DNase. The enterovirus Ct and endpoints were not significantly affected by the 
presence of the DNase. Conclusions: The BD MAX ExK TNA-3 can co-amplify DNA 
and RNA viral targets from a specimen in a single multiplex reaction and the BD 
MAX ExK DNase can enrich RNA by 99% from swabs in UTM.  
*BD MAX ExK TNA-3, BD MAX ExK DNase, BD MAX TNA MMK and MMK(SPC) are 
not available for sale or use. 
 
ID96. Comparison of Prognostic HPV Markers in Low-Grade Cervical 
Lesions in Puerto Rican Females Under the Age of 30: A Preliminary Study 
M.A. Noy, J.R. Paz, A. Rosado 
Laboratorio de Patologia Dr. Noy, San Juan, PR. 
Introduction: Infection of the genital tract with human papilloma virus (HPV) is very 
common in the Puerto Rican population and usually follows a benign clinical course. 
However, in an unfortunate minority of individuals, infection may progress to cancer. 
In women younger than 30 years, cervical cancer screening relies only on cervical 
cytology because of poor performance of HPV DNA-based testing in this age group. 
There is evidence that suggests that detecting direct or indirect viral gene expression 
may comprise a more specific approach for identifying clinically significant infections 
in comparison to HPV DNA-based testing. In this study, we compare the prevalence 
of the HPV oncogenic activity in our population with detection of viral E6, E7 mRNA The Journal of Molecular Diagnostics ■ jmd.amjpathol.organd cellular protein p16. Methods: We analyzed 372 cervical biopsies with low-
grade cervical dysplasia (CIN1) as well as 113 cervical cytology samples that 
included atypical squamous cell of undetermined significance (ASCUS) and low-
grade squamous intraepithelial lesion (LSIL) diagnosis. Samples were collected from 
women under 30 years of age who attended OB/GYN clinics around Puerto Rico. 
Cervical biopsies were tested for p16 using immunohistochemistry with Ventana 
Benchmark ULTRA. The p16 levels are increased in response to irregular cell 
inactivation due to loss of Rb/E2F repression and strong activation by free E2F 
caused by the HPV E7 oncogene. On the other hand, cervical cytologies were tested 
with HPV OncoTect E6 E7 mRNA that uses molecular in situ hybridization for 
detecting HPV E6 E7 mRNA in intact human cells and flow cytometry for cell-by-cell 
analysis. It measures both the quantity of E6 E7 mRNA in each cell and the 
percentage of transforming cells. Both tests were performed using manufacturer’s 
instructions and positive samples were identified. Results: A total of 125 of the 372 
cervical biopsies were positive for p16 immunostaining and 36 of the 113 cervical 
cytologies were positive for overexpression of E6 E7 mRNA (>2.0%). The frequency 
of positive samples for p16 and E6 E7 mRNA are 33.6% and 31.8%, respectively. 
Conclusions: The prevalence of HPV oncogenic expression has a good 
concordance between both assays, p16 in histology and E6 E7 mRNA in cytology. 
These findings might suggest the use of HPV E6 E7 mRNA detection in cytology to 
be beneficial in our population prior to undergoing biopsies, saving costs and 
decreasing patient discomfort. This study will be continued to verify a larger 
population.  
 
ID97. Hepatitis C Virus Genotype Results and Clinical Implications for a 
Rural United States Population 
H.H. Harrison, R.K. Rolston, A.E. Wehler, B.V. Paynton 
Geisinger Health System, Danville, PA. 
Introduction: HCV infects up to 2% of the UNited States general population, with 
higher rates in certain occupational subpopulations and various high risk groups. 
Chronic HCV is the most common cause of cirrhosis, end-stage liver disease, and 
hepatic transplantation. Recent advances in therapeutic options for HCV are 
impressive, yet pharmacologic choice and expected response remain genotype-
dependent. The Geisinger Health System is an integrated health network that 
provides primary through tertiary care for a large rural population in central PA. 
Although this is generally a low risk population, there are some pockets of higher risk 
in semi-urban and incarcerated populations. Determination of projected outcomes 
and population-based resource allocations requires knowledge of the genotype 
distribution in the population. The purpose of our present study was to review the 
most recent five years of HCV genotype data to determine distribution of the major 
types and subtypes and whether there has been recent trending of their proportions. 
Methods: Genotype and subtype analysis was performed with the Siemens 
VERSANT 2.0 HCV Genotype Line-Probe Assay system. Patient plasma samples 
and control materials were assayed per recommended protocol. The tested 
population included first-time tested individuals ascertained from primary screening 
as well as specialty clinic referrals. Results were analyzed retrospectively from 
January 2008 through December 2012. Results that were inconclusive or had 
insufficient viral RNA for analysis were not included in genotype tallies. Results: The 
genotype outcome distribution of the 2,110 unique analyses was: genotype 1 
(74.4%), as 1a (1,311), 1b (253), 1 mix (5), no subtype (5); genotype 2 (12.4%), as 
2a/2c (17), 2b (234), no subtype (11); genotype 3 (11.3%), as 3a (230), no subtype 
(8); genotype 4 (1.6%), as 4a/4c/4d (24), no subtype (11); and genotype 6a/6b (1).  
The various type and subtype totals and proportions were equally distributed across 
years; they did not show statistically significant deviation from the mean. 
Conclusions: The rural population of central PA has a relatively typical European / 
US distribution of HCV types, with genotype 1 and its subtypes being most prevalent, 
followed by genotypes 2 and 3, then genotype 4. Genotype 6 and mixed infections 
were uncommon. The relative lack of higher number genotypes is consistent with the 
area demographics. In view of the recent CDC recommendations for universal 
screening of persons born between 1945 to 1965 (MMWR, 61:1-31, 2012), the 
stability and distribution of these genotype results have important clinical implications 
regarding genotype-driven resource needs in our service region. 
 
ID98. Development of an Automated Assay for Detection of Influenza A, 
Influenza B, and RSV Using the Abbott m2000 System 
H. Reiske, S. Bradley, P. Labrousse, L. Sciarappa, M. Exner 
IntelligentMDx, Cambridge, MA. 
Introduction: Influenza A, influenza B, and respiratory syncytial virus (RSV) cause 
over 600 million infections annually. Molecular testing methods are being used more 
frequently to diagnose infectious caused by these viruses due to sensitivity 
limitations of rapid antigen-based testing methods. With to the large number of 897
8AMP Abstractscases, effective, high capacity automated systems can be advantageous. The Abbott 
m2000 system provides this capability, and we evaluated an assay designed for use 
on this instrument platform. Methods: A proprietary bioinformatics platform, NGENix, 
was used to engineer optimized oligonucleotide sets to create the IMDx Flu A/B and 
RSV for Abbott m2000 assay, which is a qualitative, multiplexed, real-time PCR-
based assay for the detection and differentiation of conserved gene regions from of 
each targeted virus. Following the initial design, the assay was optimized for use on 
the Abbott m2000 system. To evaluate the assay, multiple strains of each virus were 
tested for reactivity with the assay, and analytical sensitivity was determined for a 
subset of these viruses. Cross reactivity studies were performed with 
microorganisms commonly found in respiratory specimens. In addition a panel of 
patient specimens that were previously found to be positive or negative for the target 
viruses using an FDA cleared method was tested, and concordance between results 
was examined. Results: Analytical studies showed the assay to be sensitive and 
specific. Observed analytical sensitivities were as low as 1.56 TCID50, 12.5 TCID50, 
and 6.25 TCID50 for influenza A, influenza B, and RSV, respectively, and all influenza 
A, influenza B, and RSV strains tested were detected with the assay. No cross 
reactivity was observed with any of the non-target analytes tested. The assay 
exhibited 100% concordance with the FDA cleared method. Conclusions: The 
influenza A, influenza B, and RSV assay designed for the Abbott m2000 was 
sensitive and specific. The automated design eliminates hands-on time required for 
sample preparation, and the 96-well format of the assay facilitates high capacity 
testing. The IMDx Flu A/B and RSV for Abbott m2000 assay is not FDA cleared and 
is not available for sale in the United States or Canada. 
 
ID99. Metagenomic Sequencing for Virus Identification 
R. Dettloff, J. Farinas 
Caerus Molecular, Mountain View, CA. 
Introduction: Deep sequencing offers the possibility of identifying virtually any virus 
present in a clinical sample. As the cost of sequencing continues to plummet, other 
factors such as the long time required to perform data analysis will limit the 
application of metagenomic sequencing to clinical virus identification. Combining the 
use of short reads and a curated virus database could shorten analysis times and 
allow the identification of viruses in clinical samples. Methods: A data analysis 
pipeline was developed that took sequencing reads, removed human sequences and 
used nucleotide BLAST to find sequences in a curated viral database that matched 
the reads with a specified allowable mismatch level (from 0% to 20%). Matches that 
mapped to unique species in the database were compiled. The analysis pipeline was 
tested and optimized by generating mock sequencing data constructed from viral 
sequences obtained from GenBank. For each viral sequence, random sequences of 
specified length (50 to 200 nt) were selected and noise was added by randomly 
changing a fraction of the nucleotide sequences (from 0% to 10%). The optimized 
pipeline was used to process Illumina sequencing reads from samples containing 
known viruses. Results: For mock sequences, allowing a 5% mismatch between the 
query and database sequences resulted in the majority of query sequences mapping 
uniquely to a single viral type/serotype in the curated database. Trials using 0% and 
1% error rates in the query sequences (typical for next-generation sequencing) yield 
similar results. Surprisingly, even relatively short read lengths (50 nt) allowed the 
virus to be correctly identified. When 100 nt long Illumina sequencing reads from 
patient samples were run through the analysis pipeline, the viruses known to be 
present in the sample were correctly identified. The reads were trimmed to 50 nt and 
rerun through the pipeline. Consistent with the results of the mock sequence 
validation, the short reads were sufficient to identify the viruses in the samples. 
Conclusions: Use of a relatively small, curated database and short (50 bp) reads 
can enable the identification of viruses in patient samples in an acceptable amount of 
processing time. 
 
ID100. Performance Evaluation of the Sentosa C. diff PCR Assay in a Clinical 
Setting 
D.D. Fuller, W. Veros, R.J. Buckner, J.D. Talbott, A.L. June, K.L. Newcomer, T.E. 
Davis 
Wishard Health Services-Indiana University School of Medicine, Indianapolis, IN. 
Introduction: Clostridium difficile (Cdiff) is one of the most common and deadly 
healthcare-associated infections affecting nearly 700,000 people in the US annually 
according to the CDC. With the number of Clostridium difficile infections (CDI) on the 
rise, accurate and rapid diagnosis is imperative to aid in therapy selection, improve 
patient outcome, prevent disease spread and lessen negative impacts on healthcare 
systems. Conventional Cdiff tests (cytotoxicity neutralization tests, culture, and 
enzyme immunoassays) have recently been replaced by real-time PCR-based 
assays that have increased sensitivity, specificity and turn-around-time for diagnosis 
of CDI. The purpose of this study is to evaluate the Sentosa SA C. diff real-time PCR 98Assay (Vela Diagnostics, Fairfield, NJ) in a clinical setting to include assay 
performance and management, workflow , and ease of use. This research use only 
assay is configured for use on the Sentosa SX101 instrument, with the Sentosa SX 
Bacteria gDNA kit, in conjunction with the Roto-Gene Q MDx 5plex HRM instrument. 
Methods: Surplus, de-identified, liquid to soft stool samples from patients suspected 
of CDI were tested with the Sentosa Cdiff Assay and BD GeneOhm Cdiff Assay 
(BDCA) (BD Diagnostics, Sparks, MD). Each stool was collected, processed, and 
tested according to the institution’s standard of care and each assay was performed 
according to manufacturer’s package insert instructions.  If discordant results were 
obtained between Sentosa and BDCA, the Cepheid Xpert C. difficile assay (Cepheid, 
Sunnyvale, CA) was performed and results were used for sensitivity and specificity 
calculations. Results: To date, 150 stool samples have been included in this 
evaluation yielding 120 that tested negative with both Sentosa and BDCA whereas 
25 tested positive with both assays (17% prevalence). Five samples yielded 
discordant results (3 false positive and 2 false negative) as compared to BDCA. The 
sensitivity and specificity was 96.2% and 97.6%, respectively, following discrepant 
testing. Conclusions: The Sentosa SA C. diff real-time PCR Assay (utilizing the 
Sentosa SX101 instrument, with the Sentosa SX Bacteria gDNA kit, in conjunction 
with the Roto-Gene Q MDx 5plex HRM instrument) yielded excellent agreement as 
compared to the BD GeneOhm Cdiff Assay. The time frame for assay workflow 
(extraction/PCR ~90 minutes followed by amplification/data analysis ~2 hours) 
allows multiple runs of up to 48 samples to be easily performed within an 8-hour 
work shift. Although considered a highly complex assay, we found this assay was 
easy to use and fit favorably in to the general microbiology laboratory workflow. 
 
ID101. Assessment of a Quantitative, Real-Time PCR Assay for Herpes 
Simplex Virus 1 and 2 in CSF, Whole Blood, Serum, and Lesion  
D. Cross1, B.J. Davids1, J. Kehle2, T.T. Stenzel1 
1Quidel, San Diego, CA; 2AnDiaTec, Kornwestheim, Germany. 
Introduction: Herpes simplex viruses 1 and 2 (HSV-1 and HSV-2) are double-
stranded DNA viruses that cause lesions at a variety of body sites. The lesions result 
from either primary infection or from reactivation of latent virus, causing recurrent 
episodes of the disease. In immunosuppressed or compromised patients and 
neonates, HSV can also infect the central nervous system or systemically and be 
life-threatening. The viral load in cerebrospinal fluid (CSF) or blood is much lower 
than what is found in lesions and is often difficult to detect. Methods: To evaluate 
clinical sensitivity and specificity, nucleic acid extracted from samples of cutaneous 
and mucocutaneous swab lesions (118), CSF (64), whole blood (41), and serum (53) 
from symptomatic patients was tested using the AnDiaTec Herpes Simplex Virus 1/2 
real-time PCR assay. All sample testing results were confirmed by amplicon 
sequencing or alternative real-time PCR assays. Analytical limit of detection (LOD) 
was tested by inoculating HSV-negative CSF matrix with specific copy numbers of 
virus, extracted on the NucliSENS easyMAG (bioMérieux) and eluates were tested 
on the AnDiaTec assay. The quantitative ability of the assay was tested in a similar 
manner. Results: Sixty-four CSF samples were tested and 17 were positive for 
HSV-1 and 20 were positive for HSV-2. Forty-one whole blood samples were tested 
and showed 15 HSV-1 positive and 8 HSV-2 positive samples. Fifty-three serum 
samples were tested with 14 HSV-1 and 8 HSV-2 that were positive. One hundred 
and eighteen lesion swab specimens were tested and 38 HSV-1 and 29 HSV-2 were 
positive. One hundred and twenty-seven samples of various sample types were 
found to be negative. All results were confirmed by an alternate method. There was 
no cross-reactivity with any of 6 other viral pathogens tested (CMV, HHV6, HHV8, 
VZV, and EBV) and all 10 HSV-1 and HSV-2 viral isolates tested were reactive. The 
LOD for both HSV-1 and HSV-2 in CSF matrix was approximately 5 copies per 
reaction. The coefficient of determination (R2) for quantitative analysis was for each 
analyte greater than 0.999 and quantification was accurate within +/- 0.5 log. 
Conclusions: This preliminary evaluation of the AnDiaTec Herpes Simplex Virus 1/2 
real-time PCR assay showed it to be highly sensitive and specific. The measured 
LOD in CSF suggests it may be highly useful for this sample type. The assay’s 
quantification appears accurate and the assay was easy to use. 
 
ID102. Development of a New Diagnostic System Based on Real-Time PCR for 
Simultaneous Detection of Mycobacterium tuberculosis and Multidrug 
Resistance  
S. Lee1, J. Lim1, S. Kim1, S. Byun1, C. Lee1, Y. Choi2 
1Bioneer Corporation, Daejeon, Korea; 2Bioneer Inc., Alameda, CA. 
Introduction: Worldwide, 20% of multidrug-resistant tuberculosis (MDR-TB) patients 
acquire the condition after the treatment of the first TB infection, whereas 3.7% 
acquire during the treatment. Early detection and identification of TB and MDR-TB 
are very critical for efficient treatments in both TB and MDR-TB patients. In this 
report a new molecular diagnostic assay system has been developed to detect jmd.amjpathol.org ■ The Journal of Molecular Diagnostics
T AMP Abstractsmutations in the rpoB gene related with rifampicin resistance and the inhA and katG 
genes related with isoniazid resistance as well as Mycobacterium tuberculosis 
simultaneously, by utilizing a probe-based multiplex real-time method. Methods: To 
develop the molecular diagnostic system for simultaneous detection of TB and MDR-
TB the ExiStation system, which automates the whole processes from nucleic acid 
extraction/amplification to data analysis and can handle up to 48 samples 
simultaneously, was used. In addition, nucleic acid extracted from a single specimen 
by the system is automatically dispensed into the two real-time PCR tubes. The real-
time PCR assay was designed to utilize two reaction tubes: One tube was to detect 
and identify 9 mutant sites in 505 to 533 amino acid regions of the rpoB gene using 
four different reporter fluorescent dyes; the other tube, 3 mutant sites in inhA-15 and 
-8, 5 mutant sites in katG 315 and 463, and TB-specific IS6110 using four dyes. The 
real-time PCR assay was tested on 31 MDR-TB species obtained from Korea 
Tuberculosis Research Center, and its result was compared with those of sequence 
analysis to confirm the mutations in each species. Analytical performance 
characteristics on the kit including a measurement range were also determined. 
Results: The TB & MDR-TB real-time PCR assay detected TB in all the 31 MDR-TB 
species. Among the reported 29 mutations in 9 mutant sites of the rpoB gene, the 
assay determined 27 mutations in 8 sites – no mutation with 505Val and 509Arg. As 
for the mutations related with isoniazid resistance, 3 mutations in the inhA gene and 
5 mutations in the katG gene were determined. The results of sequence analysis 
demonstrated 100% agreement with the real-time PCR results. The dynamic 
measurement range determined by the assay was 102 to 107 copies/ml. 
Conclusions: We developed the AccuPower TB & MDR-TB Real-Time PCR assay 
for the simultaneous and early detection of TB and MDR-TB to benefit the patients 
with the right treatment at the right time. The assay enables determining TB infection 
as well as rifampicin and isoniazid resistance from a single test. 
 
ID103. Development of Real-Time Molecular Assays to Detect Adenovirus and 
Parinfluenza Viruses in Respiratory Specimens 
Y. Li, D. Daniels, B. McCutchan, P. Olivo, T.A. Ranalli, T.T. Stenzel 
Quidel, San Diego, CA. 
Introduction: Respiratory viruses are a leading cause of outpatient physician visits 
as well as a significant cause of hospital admission in elderly, pediatric, and 
immunocompromised populations. Adenoviruses and parainfluenza viruses account 
for a significant number of repiratory infections especially in pediatric populations. 
Molecular diagnosis of these respiratory viruses is important for effective patient 
management. Methods: The Quidel Molecular (QMol) Adenovirus (Adeno) and 
Parainfluenza virus (PIV) assays are real-time PCR assays developed for the ABI 
7500 FastDx but can be run on a number of different instruments. The parainfluenza 
assay was designed to differentiate types 1, 2, and 3. Briefly, respiratory samples 
are extracted using a common internal extraction control and common thermocycling 
parameters allowing assay multiplexing on the same plate. Five microliters of eluate 
are added to 15 L of resuspended, lyophilized mastermix. The comparator tests 
used for clinical performance evaluations were the Prodesse ProAdeno+ and 
ProParaFlu+. Results: Using 6 serotypes of Adenovirus, the preliminary LOD of the 
QMol Adeno assay was less than or equal to 16 TCID50/mL. Testing with samples 
containing 26 other respiratory viruses showed no cross-reactivity. No interference 
was found when the QMol Adeno assay was tested in the presence of 10 potentially 
interfering substances. Broad range reactivity is expected as the assay is positive on 
the 20 serotypes tested to date. Preliminary clinical performance was assessed on 
21 respiratory specimens with 13 testing positive by both the QMol Adeno and the 
comparator method. Of the 8 samples that tested negative with the comparator, 2 
tested positive with the QMol Adeno assay. The QMol PIV assay exhibited a 
preliminary LOD of between 2.5 and 125 TCID50/mL for PIV-1, 2, and 3. The QMol 
PIV assay exhibited no cross-reactivity when tested with 22 different viral and other 
respiratory pathogens. The assay successfully detected 21 isolates of PIV-1, 2, and 
3 and there was no competitive interference among the PIV types using samples 
containing all three virus types. Eleven potentially interfering substances showed no 
evidence of interference. In a preliminary clinical evaluation on 109 respiratory 
samples the QMol PIV exhibited 100% concordance with the comparator assay with 
identical results on 16 PIV-1, 13 PIV-2, and 21 PIV-3 positive samples and 59 PIV 
negative samples. Conclusions: In preliminary studies, the Quidel Molecular assays 
demonstrate excellent sensitivity and specificity for the identification of Adenoviruses 
and PIV 1-3. 
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 ID104. Manual and Automated Nucleic Acid Extraction from Multiple Clinical 
Specimen Types Using the Siemens VERSANT Sample Preparation Reagents 
Kits  
C.R. Wagner, S. Ho, G.M. Gorrin, J. Surtihadi 
Siemens Healthcare Diagnostics Inc., Berkeley, CA. 
Introduction: The ability to recover nucleic acids in multiple clinical specimen types 
helps provide insight into understanding the pathology of infectious diseases. 
VERSANT Sample Preparation 1.0 and 1.2 (SP1.0 and SP1.2) Reagents Kits were 
evaluated for their ability to recover DNA and RNA from a wide variety of clinical 
specimen types either manually or with the VERSANT kPCR Molecular System** 
(Siemens Healthcare Diagnostics, Tarrytown, NY, U.S.). Methods: Whole blood, 
serum, plasma, transport media from swabs (vaginal, endocervical, eye, 
nasopharyngeal, and buccal), CSF, urine, semen, sputum, stool, breast milk, 
cultured cells, PBMC, amniotic fluid, BAL, ascites, and cervical cells were collected 
with IRB approval for assessment of nucleic acid recovery. Human breast 
adenocarcinoma total RNA (MCF-7) and human genomic DNA (gDNA) were spiked 
into each sample. Endogenous (background) and exogenous (spiked) RNA and DNA 
amounts were quantified in each sample using in-house assays for house-keeping 
genes RPL37A (RNA) and PAEP (DNA). Bacterial DNA recovery was evaluated 
using Chlamydia trachomatis and analyzed with the VERSANT CT/GC DNA 1.0 
Assay (kPCR)**. When necessary, samples were pretreated with Lysis Buffer or PBS 
(SP1.0), or Pretreatment Buffer (SP1.2). Recovery was evaluated by comparing the 
concentration of gDNA or RNA in each sample (minus endogenous nucleic acid) to 
the same amount of RNA or gDNA amplified without going through the sample 
extraction process. Results: The results demonstrated that DNA and RNA could be 
purified from all clinical specimen types evaluated. Using the automated VERSANT 
kPCR Sample Prep (SP) Module*, the average recovery of RNA was 66% (range of 
38% to 94%) using SP1.0 reagents. The average recovery of DNA was 42% (range 
of 29% to 85%) using SP1.0 reagents and 84% (range of 47% to 120%) using SP1.2 
reagents. Manual extraction of DNA and RNA from plasma and serum using SP1.0 
reagents resulted in an average recovery of 77% (DNA) and 68% (RNA). Recovery 
of DNA from plasma, serum, and whole blood using SP1.2 reagents manually was 
on average 92%. Conclusions: The results demonstrate the ability of the VERSANT 
Sample Preparation 1.0 and 1.2 Reagents to extract nucleic acids from a wide 
variety of clinical sample types manually or using the VERSANT kPCR Sample Prep 
(SP) Module.  
* Product availability varies by country.  
** Product availability varies by country. Not available for sale in the UNited States. 
 
ID105. Detection of Bordetella pertussis and B. parapertussis Using a 
Multiplexed, Real-Time PCR Assay 
J. Stockwell, R. Kelly, J. Johnson, R. Lollar, B.J. Davids, D. Cross, T.A. Ranalli, T.T. 
Stenzel 
Quidel, San Diego, CA. 
Introduction: Pertussis, or whooping cough, is a highly contagious bacterial disease 
causing uncontrollable, violent coughing fits that can result in permanent disability in 
infants, and even death. Pertussis is caused by the Bordetella pertussis (BP) or B. 
parapertussis (BPP) bacteria. An assay has been developed to detect the presence 
of BP or BPP in nasopharyngeal swab specimens. Methods: The Quidel Molecular 
(QMol) Bordetella assay is a real-time PCR assay developed for the ABI 7500 
FastDx and the QuantStudio Dx instruments but can be run on a number of different 
instruments. The assay was designed to differentiate pertussis and parapertussis. 
Briefly, nasopharyngeal swab samples are extracted using a internal extraction 
control. Five microliters of eluate are added to 15 L of resuspended, lyophilized 
mastermix. The comparator tests used for clinical performance evaluations were 
LDTs. Bacterial stocks and genomic DNA of BP and BPP strains were serially diluted 
in contrived negative nasal matrix and tested using the QMol Bordetella assay to 
determine a limit of detection (LOD) and strain inclusivity. Potential cross-reactive 
bacteria and viruses were tested at clinically relevant levels to confirm specificity of 
the assay. Preliminary clinical performance was determined by testing 32 blinded 
and frozen residual clinical samples with QMol Bordetella and compared to LDT 
results. Results: The LOD was preliminarily determined to be less than 1 cfu/mL for 
BP and BPP. All strains of BP and BPP tested are reactive. No cross-reactivity was 
observed with any of the 16 microorganisms tested. Of 38 clinical samples tested, 11 
samples tested positive for BP, 15 tested positive for BPP, and 11 tested negative 
with both the QMol and LDT assays. One sample that tested negative with the LTD 
assay, tested positive by the QMol assay for parapertussis. Conclusions: Results 
from preliminary studies indicate that the Quidel Molecular Bordetella assay is 
sensitive, specific and easy-to-use. 
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9AMP AbstractsID106. Comparison of the Biofire Diagnostics Filmarray BCID IUO Assay to 
the Nanosphere Verigene BC-GP IVD Assay for Identification of Gram-Positive 
Bacteria from Positive Blood Culture 
K.J. Sparks Kilbourne1, L.S. Sender1, R.S. Liao2 
1CHOC Children's, Orange, CA; 2PeaceHealth Laboratories, Springfield, OR. 
Introduction: A study was undertaken to compare the Nanosphere Verigene 
(Northbrook, IL) Gram-Positive Blood Culture (BC-GP) In vitro Diagnostic (IVD) 
assay and the BioFire Diagnostics (Salt Lake City, UT) FilmArray Blood Culture 
Identification (BCID) Investigational Use Only (IUO) assay to detect and identify 
Gram-positive cocci obtained from positive blood culture bottles. Methods: Thirty 
eight blood culture aliquots were obtained from BacT/ALERT 3D blood culture 
bottles that were positive for Gram-positive cocci. Blood bottles were removed 
immediately from the instrument when positive and a Gram-positive blood bottle 
(aerobic/anaerobic) was tested using the BC-GP assay if <12 hours old. Specimens 
were subsequently frozen at -20°C, thawed, and retested using the FilmArray BCID 
assay. Briefly, for BC-GP testing, 350 μL of blood culture broth is used per test along 
with an extraction tray, test cartridge and utility tray. After a 2.5 hours runtime, the 
test cartridge is removed from the Verigene Processor instrument. The substrate 
holder slide is removed from the reagent pack, allowed to dry and is then analyzed in 
the Verigene Reader. For BCID testing, 100 L of blood culture broth is used per test 
along with 2 syringes, sample buffer, hydration solution and a film array. After a 1.08 
hours runtime, the film array is read by the instrument. The Verigene BC-GP (IVD) 
assay is approved to detect: Staphylococcus, S. aureus, S. epidermidis, S. 
lugdunensis, mecA, Streptococcus, S. agalactiae, S. pyogenes, S. pneumoniae, S. 
anginosus group, Enterococcus faecalis, E. faecium, vanA, vanB, and Listeria. The 
FilmArray BCID (IUO) assay will detect Gram-negative bacteria, yeast and 
Staphylococcus, S. aureus, mecA, Streptococcus, S. agalactiae, S. pyogenes, S. 
pnemoniae, Enterococcus, vanA/vanB, and L. monocytogenes. Results: The BC-GP 
and BCID test results were in 100% agreement for the detection and identification of 
Gram-positive cocci. The BC-GP and BCID assays compared well to the 
conventional microbiology laboratory results obtained by routine testing using 
biochemical tests along with identification and susceptibility testing using the Vitek 2 
(bioMérieux). One exception was the identification using conventional microbiology 
of a nutritionally variant Streptococcus that was missed by both the BC-GP and 
BCID assays. Conclusions: The Verigene BC-GP (IVD) and FilmArray BCID (IUO) 
assays compare very well to each other for the identification of Gram-positive cocci 
from aerobic and anaerobic BacT/ALERT 3D blood culture broth bottles. 
 
ID107. Comparison of Two Sample-to-Result Nucleic Acid Detection Methods 
for the Detection of Toxigenic Clostridium difficile in Clinical Stool Specimens 
A.T. Harrington, C. Peltier, S. Hwang, J.E. Clarridge 
VA Puget Sound Health Care System, Seattle, WA. 
Introduction: Toxigenic Clostridium difficile remains a significant cause of hospital 
associated diarrhea, and community associated cases are on the rise. Rapid 
diagnosis of C. difficile disease has been linked to improvements in infection control 
practices and antibiotic stewardship. The Nanosphere Verigene C. difficile test 
(VCD) (Northbrook, Il), which was recently approved by the FDA, and the Cepheid 
Xpert C. difficile test (XCD) (Sunnyvale, CA), are both rapid, random access, 
sample-to-result tests that detect toxogenic C. difficile directly from stool samples. 
chromID C. difficile (CCD) (bioMerieux, France) is a chromogenic agar for the 
isolation and identification of C. difficile in 24 hours. Methods: We evaluated 92 
fresh unformed stools for the detection of toxigenic C. difficile using XCD and VCD 
per the manufacturer’s instructions. All stools were also directly plated to CCD. If the 
results between the molecular methods were discrepant, the isolates from culture 
were tested for toxin by both molecular methods. Results: 84/90 (93%) of results 
were concordant by both molecular methods. We recovered non-toxigenic C. difficile 
from 8/90 (9%) of stools. Using toxigenic stool culture as the gold standard, the 
sensitivity, specificity, positive predictive value, negative predictive value for VCD 
was 91%, 98%,97%, 95% and for XCD was 100%, 98%, 97%, 100%. Toxigenic C. 
difficile were not detected (2) or indeterminate (1) by VCD for 3 specimens from 
which toxigenic C. difficile were recovered by culture and detected by XCD. Upon 
discrepant resolution, toxigenic C. difficile were subsequently detected by VCD from 
isolates recovered by culture. Conclusions: Both VCD and XCD have comparable 
performance characteristics, require minimal “hands-on” time, and deliver rapid 
results. 
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OTH01. Data Visualization Analysis to Optimize Molecular Laboratory 
Processes 
S. Hendrickson, J. Wilson, K. Walker, A. Rao 
Scott and White Hospital, Temple, TX. 
Introduction: Various data visualization software applications are utilized to analyze 
large amounts of data for diagnostic purposes in molecular laboratories. The new 
analytical methods involve attribution, optimization and allocation,which can also 
represent tabular data related to basic laboratory processes, including turnaround 
times (TATs) (Advertising analytics 1.0 W. Nichols, HBR March 2013 9 [59-68]). 
Methods: Data visualization was used to represent spreadsheet data in a circular 
format using the tableviewer utility, a module created by Circos software. It includes 
a parse-table script to format the data to be compatible with Circos, and a make-conf 
script that creates configuration and data files. Circos is then used to generate a 
circular image in which ribbons connect corresponding data fields with ribbon size 
analogous to the cell value in the spreadsheet.Results: Data were collected for 54 
CSF specimens for enterovirus testing and 65 CSF specimens for herpes simplex 
virus (HSV) testing from Scott & White Children’s Hospital. The TATs were averaged 
for each step in the process including: time from collection to receipt in Children’s 
Hospital laboratory, time to receive at Scott & White Memorial Hospital processing 
lab, time to receive in molecular pathology laboratory, time to run and result test, and 
time to be finalized by lab director. Data were further analyzed according to time of 
day the lumbar puncture was performed: 1st shift, 2nd shift, and 3rd shift collections 
throughout the weekdays, and weekend collections. As an alternative to producing 
several graphs to visualize this data, Circos was used to create a visual 
representation of all data in one circular graphical image. Conclusions: A Circos 
graph allowed simultaneous analysis of TATs for collections on different shifts for 
both Enterovirus and HSV and each process step of testing. By using Circos table 
viewer utility, all data were represented visually in one concise graph and the 
analysis of problematic process steps in TATs was candidly illustrated by larger 
ribbon size. The molecular laboratory assessed problematic process steps, instituted 
new procedures for HSV CSF specimens received on 1st shift, eliminated director 
sign out for Enterovirus CSF specimens, and established a director contact policy for 
specimens resulted on weekends.  
 
OTH02. Implementation of Value Stream Mapping (VSM) to Study RNA-Based 
Testing Workflow and Collect Performance Metrics in the Molecular Pathology 
Laboratory 
H.C. Hohendorf, L. Whiteley, J. Beher, M. Cankovic, D. Chitale, G. Sharma 
Henry Ford Hospital, Detroit, MI. 
Introduction: The advent of molecular diagnostic testing has revolutionized 
diagnostics, prognostication and monitoring of treatment in a wide variety of clinical 
settings. Although the role of the molecular laboratory is expanding, the changing 
healthcare climate is impacting reimbursement models. Successfully adapting to 
these new conditions requires close inspection of laboratory work processes to 
distinguish value-added (activity that contributes towards the end product) vs non-
value added (activity that does not contribute towards the end product, often defined 
as waste) steps. Value Stream Mapping (VSM) is a graphical LEAN tool that is used 
to improve workflow by identifying process delay(s) and studying movement of 
information and material in a family of related processes. We applied VSM to our 
laboratory's RNA-based testing menu for hematolymphoid malignancies. The goal 
was to study our workflow and capture baseline process performance metrics that 
could be utilized to validate future process improvements to accommodate increased 
workload. Methods: VSM of pre-, post-, and analytical processes was performed on 
specimens analyzed over 9 workdays by a team of three technologists. Specimens 
submitted for RNA-based testing for hematolymphoid malignancies (BCR/ABL p210, 
BCR/ABL p190, PML/RARA, AML1/ETO, and CBFB/MYH11 inv(16)) were tracked 
through each step. VSM metrics such as lead time (time between specimen receipt 
and result report), cycle time (time from start of a process to its completion), and takt 
time (pace to meet work demand) were calculated to define the baseline 
performance. Results: Analysis of VSM metrics for 16 specimens (14 peripheral 
bloods, 1 bone marrow, 1 CSF) yielded a process cycle efficiency of 27%, derived 
from a lead time of 1224 minutes and a cycle time of 337 minutes. Takt time was 406 
minutes/specimen. Seven distinct steps of value-addition were identified and the 
longest intermediate queue time was between RNA isolation and cDNA synthesis 
(330 minutes). These metrics demonstrated that the process performance was 
adequate for the current test volume. Conclusions: With VSM, baseline 
performance metrics were successfully captured and points of delay identified. We 
will now implement VSM for our other test families (example, fragment length jmd.amjpathol.org ■ The Journal of Molecular Diagnostics
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capacity and workflow are adequate to accommodate the current customer demand 
and objectively measure any impact due to anticipated increase in future test 
volume. Furthermore, we can now systematically select, plan and implement future 
process improvements. We strongly recommend that molecular laboratories utilize 
VSM to benchmark their performance and design efficient processes. 
 
OTH03. The Impact of Molecular Viral Load Assay Imprecision on Clinicians’ 
Decisions and on Test Value 
R.M. Madej1, E.J. Moler2, T.S. Nadder1, D.A. Holdford1, W.J. Korzun1 
1Virginia Commonwealth University, Richmond, VA; 2GE Healthcare, Aliso Viejo, CA. 
Introduction: Molecular viral load (VL) assays routinely inform medical management 
decisions. Their value to healthcare depends on the assays’ technical 
characteristics, and on clinicians’ appropriate interpretation and use of results. This 
research explores a method to determine test value, evaluates the impact of 
technical characteristics on clinicians’ use, and measures the impact of clinicians’ 
use on the determined test value. HCV VL informing a triple-combination therapy 
treatment decision was used as a model to determine the value of the test in cost 
savings/patient, examine clinicians’ use of the results knowing the assay imprecision, 
and measure the impact to that value based on clinicians’ use. Methods: A survey 
describing a simulated HCV patient, 12 weeks post triple-combination therapy 
(telaprevir/interferon/ ribavirin) was sent to 1491 hepatology clinicians. Participants 
were presented with HCV RNA results at five different levels and asked to choose 
between three decisions: continue therapy, discontinue therapy, or repeat the test. 
HCV VL values were presented both with and without the expected 95% confidence 
intervals (CIs), whereby three of the VLs had CI ranges that crossed the therapeutic 
decision point. Each participant saw both sets of results in random order. 
Demographics and practice preferences were also surveyed. To determine value, a 
Markov decision-tree model was developed. Transition probabilities, costs and QoL 
parameters for health states were populated from literature. Clinicians’ test use was 
represented by the survey data in the initial model inputs. Results: From the survey, 
138 responses were received. Strong clinical guideline adherence was demonstrated 
in self-reported behaviors and in decision choices recorded. However, repeat-test 
decisions up to 37% were also noted. The impact of knowing the assay imprecision 
was not statistically significant to clinicians’ use, except in one case. Regarding 
presentation of CI with results: 17% responded CIs confused results. Only 43% 
wanted to see them. Across all VLs, the calculated test value was up to $12,386 at 
higher VLs. The test held value through different decision scenarios, on the presence 
or absence of CI’s, and despite repeat testing. Conclusions: Survey findings 
demonstrated appropriate use of HCV VL results with or without CIs. HCV VL 
demonstrated a calculated value in cost savings/patient of up to 100 times its 
investment. It is important to consider laboratory tests as investments in the efficient 
use of healthcare resources and to understand that the proper interpretation and use 
is integral to that value. This type of analysis can foster discussions at organizational 
and policy levels.  
 
OTH04. EGFR/ALK Testing in Lung Cancer: Streamlining Preanalytic Phase 
Resulted in 80% Decrease in Diagnosis to Treatment Decision Times  
M. Cankovic, L. Whiteley, C.H. Stone, R.J. Zarbo, D.A. Chitale 
Henry Ford Hospital, Detroit, MI. 
Introduction: Patients with lung cancer, especially with metastasis, need to start the 
treatment soon after the diagnosis. Mutations in epidermal growth factor receptor 
(EGFR) and EML4/ALK translocations are detected in about 15% and 1-5% of lung 
adenocarcinoma, respectively, and are used to predict the benefit from targeted 
therapy with small molecule inhibitors as well as to identify patients who are likely to 
experience resistance. This has raised the challenge on the molecular laboratories to 
provide rapid, reliable, accurate and sensitive methods for mutation screening. 
Methods: Our aim was to streamline our entire process from preanalytic to reporting 
phase of molecular testing for EGFR/ALK mutations. The study period lasted from 
March 1, 2011 to September 5, 2012 and was divided in 4 phases. Phase 1 - EGFR 
testing performed in house; no established pathway for requests; lack of familiarity 
with process; lack of coordination; Phase 2 - ALK brought in house (Cytogenetics); 
Phase 3 - efforts to increase system clinicians' awareness of test availability 
(consultations, tumor boards, internet resources); Phase 4 - specimen handoffs 
between AP Molecular Lab and Cytogenetics Lab redesigned. Results: Diagnosis-
to-treatment-decision TATs: Phase 1 = 61 days (6 cases); Phase 2 = 35 days (25 
cases); Phase 3 = 17 days (56 cases); Phase 4 = 12 days (24 cases) -80% decrease 
in time from surgery/diagnosis to start of treatment. -Patients are treated more 
quickly - increase in patients' quality of life and possibly overall survival. Cost 
assessment: -43% decrease in handoffs involved in the process (14 steps cut to 8 
steps - $200/case x 150 cases/year = $30,000/year saved) -Outsourced testing The Journal of Molecular Diagnostics ■ jmd.amjpathol.orgbrought in house ($500/case x 130 EGFR negative cases/year = additional $65,000 
saved). Conclusions: Process stream map helped us identify opportunities for 
streamlining our processes, lowering costs, and improving overall testing TATs. By 
systematically focusing on the entire testing process, especially the preanalytic 
phase, we were able to decrease diagnosis to treatment decision times from 61 days 
to 12 days, while simultaneously eliminating $95,000/year of unnecessary expenses. 
Clinician awareness and ongoing communication with pathology staff ensure that 
testing is ordered in a timely manner. When specimens are shared between labs, 
paths for specimen handoffs and result reporting are well defined. Further reduction 
in TATs, even while our testing volumes continue to increase by approximately 40% 
per year, will occur once EGFR/ALK reflex testing becomes fully integrated across 
our entire system. 
 
OTH05. Utility of WebArrayDB Data Mining Tool in the Identification of 
Molecular Subgroups in Gastric Carcinoma 
K. Woodward, M.L. Gulley, W. Tang 
University of North Carolina Hospitals, Chapel Hill, NC. 
Introduction: The ability to utilize publically available genomic data for research 
purposes is useful for pooling data on rare diseases, increasing the geographic 
heterogeneity of tumor samples, and for planning protein or gene targets in 
developing research projects. In this paper, an open source online data mining tool, 
WebArrayDB (http//www.webarraydb.org) is investigated for its reliability in detecting 
previously identified molecular subgroups in gastric carcinoma. The benefits, cons, 
and overall ease of use of this online tool are also assessed. Methods: The Gene 
Expression Omnibus (GEO) database was mined for raw data on gene expression. 
After adjusting for platform compatibility and usefulness of sample type, five gastric 
carcinoma studies were selected. Out of the 438 data files available for re-analysis, 
60 data files were pooled and reanalyzed. Raw data on normal gastric tissue (n=8) 
and EBV-infected gastric carcinoma cell lines (n=3) were also included. Cross-
platform analysis was performed as described by Xia, et al., and results were then 
compared to previously identified molecular subgroups in Tang, et al. Results: The 
quality control plots were acceptable. Based on the first 150 statistically significant 
probes, two molecular subgroups of gastric carcinoma were identified on cluster and 
heat map diagrams. In comparison to normal mucosa, Molecular Group 1 (n=19) 
showed upregulation of TCF21, TENC1, PLD2, LBP4, and SGSM, all of which are 
involved in transcription and cellular signaling. Overexpression of RAB33A (an RAS-
associated GTPase), SYPL1, KCNQ1 (an ion channel), BIRC5, and NOUFSB, 
SPTAN1 (cytoskeletal protein), and LGI3 was predominantly noted in Molecular 
Group 2 (n=23). Variable expression of the same genes were noted in grossly 
normal tissues identified adjacent to carcinoma. Increased expression of FANCA, 
AMPD1, and MAP2K4 (a kinase) were predominantly noted in EBV infected cell 
lines. Conclusions: WebArrayDB was used to re-analyze randomly selected data 
files for gastric carcinoma. Two molecular subgroups were identified on cluster and 
heat map diagrams, with the expression patterns evident in grossly normal adjacent 
tissue samples most consistent with pre-neoplastic changes. Based on limitations of 
statistical analysis, the specific genes of interest on the microarray platforms could 
not be directly selected. As a result, many of the significant genes are involved in 
transcription or cell regulation and are not specific to gastric carcinoma or EBV 
infection. However, the WebArrayDB interface may offer this feature in the future and 
still represents a relatively easy-to-use online tool for the storage and re-analysis of 
publically available microarray data.   
 
OTH06. Verification and Validation of Multiplex cMET Point Mutations Assay on 
the ICEPlex System in a Single Reaction 
K. Madanahally Divakar, S. Gupta, V. Scialabba, S. Voronov, J. Riley, L. Kong 
PrimeraDx, Mansfield, MA. 
Introduction: cMET is a proto-oncogene encoding for hepatocyte growth factor 
receptor, a receptor tyrosine kinase, which plays an essential role in normal cellular 
function and oncogenesis. In cancer cells, cMET has been implicated in cellular 
proliferation, cell survival, invasion, cell motility, metastasis and angiogenesis. 
Recent studies have indicated cMET as a biomarker for various cancers as well as 
for drug resistance in the case of anti-EGFR therapies. Due to somatic point 
mutations in the tyrosine kinase domain, cMET protein can become constitutively 
active. Here, we developed, verified, and validated a novel multiplex assay, the 
ICEPLex cMET Mutation Panel, capable of detection and discrimination of 13 most 
frequently encountered cMET mutations in FFPE samples. Methods: cMET point 
mutation detection primers were designed and developed using PrimeraDx’s 
proprietary technology. All primers were analyzed in silico for primer-primer 
interaction. Cross-reactivity was determined using the ThermoBlast program. 
Reaction conditions were optimized using proprietary PCR chemistry on the ICEPlex 
System using gBlock gene fragment templates. gBlocks corresponding to each point 901
9AMP Abstractsmutation were synthesized from Integrated DNA Technolgies (IDT). cMET wild-type 
lung FFPE tissue were obtained from OriGene. All the verification studies were 
performed using gBlock spiked FFPE samples. The panel was validated by testing 
cancerous and non-cancerous FFPE specimens. Results: Assay PCR efficiency 
ranged from 90% to 125% with a log dynamic range of four to six. Analytical 
sensitivity studies indicated a limit of detection of few hundred copies per reaction, 
and 1% to 10% selectivity (mutant detection in wild type background). Analytical 
specificity studies indicated no cross-reactivity to wild type genomic DNA and to 
other to microbial genomes potentially present in lung and stomach. The assay has 
also been evaluated for endogenous and exogenous chemical interference near limit 
of detection, and results indicated no interference by sample preparation reagents 
but a significant interference by hemoglobin. In addition, the assay showed good 
concordance with sequencing results when tested on cancerous lung FFPE 
specimens. Conclusions: Here, we have verified and validated a novel multiplex 
assay, the ICEPlex cMET Mutation Panel, on the automated ICEPlex System. The 
assay showed high sensitivity, specificity, and tolerance to interfering substances. 
The ICEPlex cMET Mutation Panel is a useful molecular tool for accurate diagnosis 
of cMET SNP mutations in clinical specimens, which will help in personalized patient 
management.  
* ICEPlex System and this assay are for Research Use Only. Not for clinical 
diagnostic use. 
 
OTH07. Verification and Validation of a Novel, Single-Tube Assay for cMET and 
EGFR Copy Number Variation and cMET Gene Expression Profiling on the 
ICEPlex System 
K. Madanahally Divakar, J. Nolling, A. Leblang, V. Scialabba, S. Shekar, J. Riley, L. 
Kong 
PrimeraDx, Mansfield, MA. 
Introduction: cMET is a proto-oncogene encoding for hepatocyte growth factor 
receptor, which plays an essential role in normal cellular function and oncogenesis. 
Studies have indicated dysregulation of cMET gene expression as biomarker for 
various cancers as well as for drug resistance in the case of anti-EGFR therapy. 
cMET overexpression and gene amplification may indicate worse clinical outcome. In 
advanced gastric cancer, cMET amplification and overexpression frequencies are at 
nearly 20% and 50%, respectively. Here, we report the verification and validation of 
the ICEPlex cMET CNV Assay, a multiplexed and multimodal PCR assay, which 
combines cMET/EGFR copy number variation (CNV) and cMET expression in a 
single reaction on the ICEPlex System. Methods: A 5-gene panel, 18-target, 21-plex 
assay was constructed for both mRNA and gDNA target detection. The panel is 
designed to test cMET CNV, cMET mRNA expression, and EGFR CNV. The assay 
design allows amplification from FFPE tissue. Multiplexed reactions were optimized 
for target identification and amplification performance on the ICEPlex instrument 
using total nucleic acids from various cell lines. All the analytical studies were 
performed in accordance with CLSI and MIQE guidelines. The Assay was validated 
using 35 cancerous lung FFPE specimens. Results: Truly quantitative, single 
reaction 18-target assay to determine cMET/EGFR CNV and cMET expression on 
the ICEPlex System was verified and validated. PCR and reverse-transcription PCR 
efficiencies for each amplicon were calculated. For relative quantification of cMET 
CNV and EGFR CNV and cMET expression, an algorithm was developed. Dynamic 
range for each target was determined and nucleic acid input concentrations were 
established. Analytical performance characteristics such as precision, limit of 
quantification, and limit of detection were evaluated using total nucleic acids from cell 
lines and xenograft FFPE samples. Results indicate high precision, specificity, and 
accurate quantification of copy number and/or gene expression status using less 
than 100ng of total nucleic acids. The validation results were concordant with that of 
a reference method. Conclusions: We have developed a novel, quantitative, and 
multimodal assay to determine both CNV and expression profiling for multiple targets 
from FFPE material. The assay demonstrates superior analytical performances 
required for quantitative expression assays. This assay has the potential to provide 
rapid and accurate information on cMET and EGFR CNV and cMET expression 
status in a clinical setting with advantages over standard FISH and PCR 
approaches.  
* ICEPlex System and this assay are for Research Use Only. Not for clinical 
diagnostic use. 
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ST01. PTEN Del-Tect Four-Color FISH Assay Shows Improved Specificity and 
Sensitivity for the Detection of Genomic PTEN Deletion over the Standard Dual 
Probe FISH Method 
S. Phin, M.W. Moore, P.D. Cotter 
Pacific Diagnostics, Irvine, CA. 
Introduction: The phosphatase and tensin homolog gene on chromosome 10q23.3 
(PTEN) is a negative regulator of the PIK3/Akt pathway and a tumor suppressor 
gene that is frequently deleted in tumors such as lung, breast and prostate cancer. In 
prostate cancer, monoallelic loss of PTEN is present in up to 60% of localized 
prostate cancers and complete loss of PTEN is linked to metastasis and androgen 
independent progression. Because prostate cancer is a highly heterogenous 
disease, an accurate determination of the genomic status of PTEN is essential for 
patient stratification and clinical management of the disease. To date, the gold 
standard for identifying PTEN deletion in prostate cancer is a two-color fluorescence  
in situ hybridization (FISH) assay for copy number detection in formalin fixed paraffin 
embedded (FFPE) tissue preparations. However, this method does not account for 
"truncation effects" where part of the cell nucleus that is sliced out during sample 
preparation could still be scored falsely as gene deletion. We evaluated a novel four-
color FISH assay containing two additional control probes, WAPAL and FAS, 
flanking the PTEN locus that indicate with a higher degree of accuracy the presence 
of a PTEN deletion and differentiate it from a false positive resulting from truncation 
effects. Methods: We used a 177kb PTEN test probe (orange) at 10q23.31 flanked 
by a 410 kb WAPAL probe (orange) located centromeric to the test probe and 437 kb 
FAS probe (aqua) located telomeric to the test probe; a copy control probe (red) was 
included at the centromere of chromosome 10 (CymoGen Dx, Irvine, CA). A 
validation study using standard FISH methodology was performed for specificity, 
accuracy, and reproducibility of the assay. Results: The four color PTEN FISH 
probes localized to the target regions 100% of the time with no off-target binding in a 
localization study. The accuracy study, performed on 30 FFPE samples, showed 
96% concordance between test and reference results. The inter- and 
intrareproducibility showed 100% concordance. Conclusions: The four-color PTEN 
FISH assay is a novel assay that demonstrates high sensitivity and specificity for the 
detection of heterozygous or homozygous deletion of PTEN in FFPE tumor sections. 
 
ST02. The Prevalence of RET and ROS1 Gene Rearrangements in Advanced 
Lung Adenocarcinomas Pan-Negative for Other Known Drivers as Revealed by 
FISH Analysis 
L. Wang, N. Islamdoust, A.E. Drilon, N. Rizvi, P. Joubert, A. Hasanovic, M. Wynne, 
J. Intrieri, S.C. Jhanwar, M. Ladanyi 
Memorial Sloan-Kettering Cancer Center, New York, NY. 
Introduction: RET and ROS1 fusions have recently been identified in lung 
adenocarcinoma, both of which are targetable using currently available drugs. 
Clinical trials are ongoing to investigate whether patients with RET or ROS1 fusion-
positive lung adenocarcinoma benefit from the kinase inhibitors cabozantinib or 
crizotinib, respectively. We present here our data on the screening for RET and 
ROS1 rearrangements in a series of 80 patients with lung adenocarcinoma. 
Methods: Patients with a never or former smoking history up to 10 pack-years and 
advanced lung adenocarcinomas pan-negative for other known drivers (absence of 
mutations in EGFR, KRAS, NRAS, BRAF, HER2, and ALK rearrangements) were 
selected for testing. FISH analysis was performed on FFPE tumor samples using 
fluorescence-labeled dual-color break-apart probes for RET and ROS1. A minimum 
of 100 nuclei were examined per tissue section from 6 or more distinct tumor areas. 
A signal pattern with split of 5’ and 3’ signals and/or single 3’ signals (loss of 5’ DNA 
sequence) in 15% of tumor cells was considered to represent RET or ROS1 
rearrangement. Results: In this clinically and molecularly enriched group of patients 
(see above), RET rearrangement was identified in 9 cases (11%) and ROS1 
rearrangement in 9 other cases (11%). Positive FISH signal patterns observed in 
tumor cells included i) overlapping signal(s) plus split 5’ and 3’ signals; ii) overlapping 
signal(s) plus single 3’ signal(s); and iii) atypical pattern with only split 5’ and 3’ 
signals (no overlapping normal signal). The third signal pattern was seen in two 
ROS1 fusion-positive and one RET fusion-positive cases in the vast majority of 
tumor cells. Five patients bearing positive signal patterns were eligible for targeted 
therapy (three for cabozantinib and two for crizotinib) and we have recently reported 
on the radiologic response obtained in the former patients (Drilon et al. 2013). For all 
positive cases, RET or ROS1 rearrangement was detected in >40% of the cells 
scored. It is worth noting that one sample showed focal positivity for ROS1 
rearrangement with >65% positive cells in some tumor areas, whereas <10% 
positive cells were detected in other areas with high tumor content. This patient jmd.amjpathol.org ■ The Journal of Molecular Diagnostics
 AMP Abstractsachieved partial response to crizotinib. This type of striking intratumoral 
heterogeneity was not noticed in any other positive case. Conclusions: Our study 
demonstrated that 22.5% of never/light smokers with pan-negative advanced lung 
adenocarcinomas harbor either RET or ROS1 rearrangement.  
 
ST03. Verification and Reporting of Somatic Mutation Results from Massively 
Parallel Sequencing in a Clinical Setting: The UNCseq Experience 
N.M. Patel, D.A. Eberhard, D.G. Trembath, K.A. Kaiser-Rogers, K.W. Rao, M.L. 
Gulley, W.K. Funkhouser, L.B. Thorne, J.S. Parker, J. Grilley-Olson, N.E. Sharpless, 
D.N. Hayes, K.E. Weck 
University of North Carolina at Chapel Hill, Chapel Hill, NC. 
Introduction: As the number of drugs available to target specific mutations and 
pathways in cancer increases, procedures for identifying somatic alterations in 
cancer using next-generation sequencing (NGS) are being developed. UNCseq is a 
clinical trial intended to provide NGS-based profiling of somatic genetic alterations 
with potential clinical utility to support treatment decisions in patients with cancer. 
Methods: After patient enrollment, paired frozen tumor and germline DNA extracts 
were analyzed on an Illumina HiSeq following exome capture for selected genes. A 
summary report of somatic alterations was reviewed at an interdisciplinary molecular 
tumor board comprised of pathologists, oncologists, and bioinformaticians to 
determine which alterations are most likely to provide an impact on treatment, 
management, and/or prognosis. Information regarding biological effects of mutations 
and the availability of therapies targeting pathways of interest were researched via 
online databases and literature searches. Clinically actionable alterations were 
verified in a CLIA-certified laboratory by Sanger sequencing to confirm sequence 
changes, or by FISH to confirm copy number variants (CNV) using an FFPE sample 
collected from the same surgery as the frozen tissue sample that underwent NGS.  
Findings were reported in the patient's medical record by a molecular pathologist. 
Results: We have clinically reported 61 potentially actionable somatic alterations in 
enrolled cancer patients. Twelve CNVs from 11 patients were confirmed by FISH. 
Fifty-six mutations from 43 patients underwent Sanger sequencing for confirmation. 
Of these, 49 were confirmed with mutant allele frequencies (AF) from 12% to 94%. 
Of the 7 mutations that failed confirmation, 4 had allele frequencies below the limit of 
detection for Sanger sequencing (AF 10% to 15%). The remaining three 
discrepancies were single nucleotide changes occurring in samples with other 
sequence alterations with similar AF that were confirmed. The NGS data were re-
analyzed to eliminate mapping errors and misalignment as causes of false positive 
calls. These three discrepancies were attributed to probable tumor heterogeneity. 
DNA fingerprinting analysis confirmed correct specimen identity, consistent with 
tumor heterogeneity as the basis for discrepant somatic findings in a subset of tumor 
samples. Conclusions: UNCseq has established a pipeline for reviewing, verifying, 
and reporting somatic mutations in cancer patients. There was high concordance 
between NGS data and reflex Sanger sequencing data for a variety of genetic 
alterations. Low AF and probable tumor heterogeneity are the most common 
identified causes of a failure to confirm NGS findings, as opposed to errors in NGS 
data. 
 
ST04. Validation and Clinical Implementation of UW-OncoPlex for 
Simultaneous Detection of Actionable Mutation, Copy Number Variation, and 
Gene Rearrangement in Cancer Specimens 
C.C. Pritchard1, S.J. Salipante1, K. Koehler1, C. Smith1, S. Scroggins1, B. Wood1, D. 
Wu1, M.K. Lee1, S. Dintzis1, A. Adey1, Y. Liu1, K.D. Eaton1, R. Martins1, K. Stricker1, 
K.A. Margolin1, N. Hoffman1, J.E. Churpek2, J.F. Tait1, M. King1, T. Walsh1 
1University of Washington, Seattle, WA; 2University of Chicago, Chicago, IL. 
Introduction: Recent years have seen development and implementation of anti-
cancer therapies targeted to particular gene mutations, but methods to assay clinical 
cancer specimens in a comprehensive way for the critical mutations remain 
underdeveloped. Methods: We have developed UW-OncoPlex, a clinical molecular 
diagnostic assay to provide simultaneous deep-sequencing information, based on 
>500x average coverage, for all classes of mutations in 194 clinically relevant genes. 
UW-OncoPlex uses hybridization-based capture to target all coding exons and 
breakpoints of selected structural rearrangements, for a total of >850,000 bp of DNA 
sequenced. A customized bioinformatics pipeline detects copy number variation and 
genomic rearrangement directly by sequencing, in addition to point mutations and 
small insertions and deletions. To best guide existing and emerging treatment 
regimens and to facilitate integration of genomic testing with patient care, we 
developed a framework for data analysis, decision support, and reporting clinically 
actionable results. We defined actionable results as associated with response to 
FDA-approved treatments, and potentially actionable results as associated with 
response to therapies in late-phase clinical trials. The Journal of Molecular Diagnostics ■ jmd.amjpathol.orgResults: To validate UW-OncoPlex, we tested 98 previously characterized clinical 
tumor specimens, from 10 different cancer types, including 41 formalin-fixed, 
paraffin-embedded tissue samples. Mixing studies indicated reliable mutation 
detection in samples with 10% tumor cells. In clinical samples with 10% tumor 
cells UW-OncoPlex correctly identified 129/130 known mutations (sensitivity 99.2%), 
including single nucleotide variants (SNVs), small insertions and deletions (indels), 
internal tandem duplications, gene copy number gains and amplifications, gene copy 
losses, chromosomal gains and losses, and actionable genomic rearrangements 
including ALK-EML4, ROS1, RET, MLL, PML-RARA, and BCR-ABL. In the same 
samples, the assay also identified actionable point mutations in genes not previously 
analyzed and novel gene rearrangements of MLL and GRIK4 in melanoma, and of 
ASXL1 and of PIK3R1 and SGCZ in acute myeloid leukemia. Among the first 200 
patient samples tested following clinical implementation in August 2012, 134 (67%) 
were positive for at least one actionable or potentially actionable result. Nearly half of 
the reported actionable findings were copy number variants or structural variants. 
Conclusions: UW-OncoPlex accurately detects all classes of mutations in 194 
clinically relevant genes in clinical cancer specimens when there is 10% tumor 
purity. The ability to detect copy number variation and structural variation directly by 
sequencing, in additional to SNV and indel mutations, greatly expands the utility of 
the assay to identify actionable findings that guide precision cancer treatment. 
 
ST05. Comparison of Fully Automated and Manual Extraction Methods from 
Formalin-Fixed, Paraffin-Embedded Tissue for Use in a Prognostic Microarray-
Based Genomic Signature 
A.L. Ewing, N.J. Reitze, V. Plamadeala, A.W. Gilkey, S.M. Pace, K.G. Devinney, 
A.H. Uihlein, L.K. Huard 
Precision Therapeutics, Inc, Pittsburgh, PA. 
Introduction: Nucleic acid isolation from formalin-fixed paraffin-embedded (FFPE) 
tissue is challenging. An automated method for extracting quality RNA for use in a 
microarray-based prognostic stage II colon signature (GeneFx Colon) is desired to 
standardize workflow, reduce processing time, as well as increase batch size. 
Methods: Eight FFPE colon cancer patient tissue samples and one FFPE colon 
cancer cell line were selected for use in this study. Each sample was divided into two 
groups of four unstained slides (5 μm) and one H&E slide (5 μm). All H&E slides 
were reviewed by a pathologist and targeted to include 50% or greater tumor 
regions. Within each sample, one group of slides were extracted using the fully 
automated Tissue Preparation System (Siemens Healthcare Diagnostics, Tarrytown, 
NY) whereas the second group was extracted using a manual RNA extraction 
method (Roche High Pure Paraffin Kit), followed by microarray-based genomic 
profiling. Quality control checks included nucleic acid quantification and qualification. 
The signature was applied to each sample, generating a numerical risk score and a 
risk category (high, low) using methods previously established (Kennedy et al., 
2011). The level of agreement between each extraction method was evaluated. 
Results: All samples from both extraction methods passed QC criteria for sufficient 
RNA yield and cDNA yield following target preparation for microarray profiling. 
Samples extracted using the automated method yielded, on average, 54% less 
material when compared to the manual method. However, the RNA isolated using 
the automated method generated 24% higher average cDNA yields when compared 
to the material extracted using the manual method. After microarray data processing, 
6/8 (75%) patient samples fell within the known signature score repeatability of the 
assay when comparing between extraction methods. All automated samples had 
lower average signal absent (ASA) and 8/9 (89%) automated samples had higher 
percent present (%P) calls. Additionally, the risk category matched in eight of the 
nine (89%) samples. Both cell line replicates scored appropriately, demonstrating 
satisfactory amplifications in both methods. Conclusions: Yield, quality and 
microarray results for the samples extracted with the Siemens method demonstrate 
that the automated extraction process produced more transcripts overall, as well as 
longer transcripts, compared to the manual process. The level of agreement 
between extraction methods demonstrates that the standardized and automated 
method would be a suitable replacement to the manual extraction methodology. 
 
ST06. Quality Assurance Practice in Clinical Next-Generation Sequencing 
M. Durso, G. Mantha, A. Wald, S. Roy, Y. Ng, M.N. Nikiforova 
University of Pittsburgh Medical Center, Pittsburgh, PA. 
Introduction: Quality assurance (QA) practice is a critical but challenging 
component of next-generation sequencing (NGS) and requires identification of 
appropriate QA markers. These QA markers provide reliable benchmarks for 
validation and performance evaluation with constant upgrades in reagents, 
instrumentation and software. We present a practical approach to assure high quality 
results and improved patient care. Methods: Bar-coded libraries from 86 
consecutive clinical samples (84 FFPE, 2 frozen) were prepared using AmpliSeq v.1 903
9AMP Abstracts(Ion Torrent, Life Technologies) and analyzed on Ion Torrent PGM. Most cases were 
resected tumor specimens (80), 6 were small core biopsy samples. Chip metrics 
from vendor software and positive and negative controls were monitored to qualify 
expected performance. Positive controls were prepared from a mixture of cell lines 
and included 7 mutations in the KRAS, TP53, SMAD4, IDH1, BRAF and NRAS 
genes at different allelic frequency. Variant calls were confirmed by Sanger 
sequencing, real-time PCR or COLD-PCR. Results: Out of 86 consecutive cases 
submitted for testing, 85 (99%) were successfully sequenced. Ion Torrent AmpliSeq 
analysis allowed multiplexing of up to 6 barcoded samples and two controls on 318 
chip or 3 samples and 2 controls on 316 chip to obtain a minimum required number 
of reads (300,000x) per sample and minimum coverage limits (300x) per mutation 
hot spot. Average reads on target for all samples was 85% (52% to 96%) and 
average uniformity on target areas was 96% (93% to 98%). All expected sequence 
variants in positive controls were consistently called at the variant frequency from 7% 
(CV=1.9%) to 97% (CV=19.7%). Sporadic failures of the One Touch instruments 
continued to be an ongoing issue and were attributed to different causes. 
Supplemental validation was performed for every change in instrument, reagents or 
software and was documented accordingly. Proficiency program was established by 
samples exchange with another institution and by re-testing two samples every six 
months. Conclusions: We established a practical monitoring program for ensuring 
high quality of NGS testing. It includes ongoing performance evaluation of positive 
and negative controls, sequence and hot spot coverage, implementing supplemental 
validations of all changes in reagents and software upgrades and establishing a 
proficiency testing program. 
 
ST07. Frequency ofEGFR and KRAS Mutations in Non-Small Cell Lung 
Cancer (NSCLC) in a Brazilian Population and Correlation with Genetic 
Ancestry Markers 
C. Dias1, C. Scapulatempo1, L. Viana1, J. Miziara1, R. Pereira2, R. Reis1 
1Barretos Cancer Hospital / Fundação Pio XII, Barretos, Brazil; 2Institute of Molecular 
Pathology and Immunology of the University, Porto, Portugal. 
Introduction: Lung cancer is the leading cause of cancer death worldwide, including 
in Brazil. Currently, with the development of tyrosine kinase inhibitors (TKIs) of 
EGFR, the mutation profile of EGFR and KRAS in non-small cell lung cancer 
(NSCLC) patients is crucial to identify the best responders. The frequency of EGFR 
and KRAS mutations varies among populations, been higher in patients with an 
Asian ethnicity. The prevalence of these mutations in Brazilian patients is scarce, so 
we aim to characterize the profile of EGFR and KRAS mutations and correlate it with 
patient’s ancestry. Methods: A total of 396 FFPE resected NSCLC were collected at 
Barretos Cancer Hospital. 46,21% (183/396) were female and mean age of 
diagnosis was 66 years (range 17 to87 years). The presence of EGFR (exons 18 
to21) and KRAS (codon12/13) mutations were performed by PCR followed by direct 
sequencing. In a subset of cases (283), we estimate their genetic ancestry using a 
panel of 46 AIMs, and correlate it with patient’s mutation status. Results: We 
identified 18.68% (74/396) of cases with EGFR mutations and 21.46% (85/396) with 
KRAS mutations. The percentage of EGFR mutations was higher in women than in 
men. The most frequent EGFR mutations were exon 19 deletions (50.0%; 37/74), 
followed by the L858R substitution at exon 21 (31,08%; 23/74). Our NSCLC 
population exhibited a 74.0% of European ancestry, followed by 12.6% of African, 
7.0% of Asian and 6.5% of Amerindian proportions. When we stratified the NSCLC 
population by mutation profile, we observed an increased percentage of Asian 
ancestry in EGFR-mutated patients in comparison with wild-type patients, yet, not 
statistically significant. Conclusions: This constitutes the largest study of 
EGFR/KRAS mutation in Brazilian NSCLC. The frequency of mutations reported is in 
line with the international literature, and as expected the EGFR mutated patients 
exhibited a higher Asian ancestry. 
 
ST08. Identification of Human Viral Pathogens from Unmapped Next-
Generation Sequencing Exome Data 
J.K. Sehn1, P.J. Cimino1, J.S. Lewis1, S. Cao1, G. Zhao1, D. Wang1, E. Duncavage2 
1Washington University in St. Louis, St. Louis, MO; 2Washington University School of 
Medicine, St. Louis, MO. 
Introduction: Capture-based next-generation sequencing (NGS) of human tumor 
specimens is becoming increasingly common in research and clinical settings. 
Although vast majority of NGS reads from target-enriched or whole genome 
sequencing align to the human genome, in general 1% to 2% of reads do not, and 
are generally discarded from further analysis. The composition of these unmapped 
reads is largely unknown but may contain non-human pathogens. A subset of human 
malignancies are known to be associated with pathogenic viruses, exemplified by the 
well-known association of high-risk human papilloma virus (HPV) with non-
keratinizing squamous cell carcinoma of the head and neck (NKSCC) and Merkel 04cell polyoma virus (MCPyV) with Merkel cell carcinoma (MCC). We investigated 
whether HPV16, MCPyV, and other human pathogens could be identified in 
unmapped reads from NKSCC and MCC exome data. We further compared 
quantitation of this method to quantitative PCR in MCC. Methods: Exome 
sequencing data were obtained from 9 NKSCCs and 8 MCCs. Data were generated 
using 2x101bp paired end reads and sequened to a depth of ~100x. All NKSCCs 
were positive for HPV16 by RT-PCR and/or RNA in situ hybridization for E6/E7 
proteins. Five of 8 MCCs were positive for MCPyV by PCR.  Sequence data were 
aligned to the hg19 human reference using Novoalign.  Unmapped reads were then 
extracted and re-aligned to a custom database containing 2.5M redundant human-
associated virus entries. Quantative PCR for MCPyV was performed using 
previously published primer sets. Results: The depth of coverage of each 
sequenced exome averaged 106x, and 1.7% of reads did not align to the human 
genome. When unmapped reads were realigned to the human virus database, PhiX 
was the most commonly identified origin of off-target reads from both NKSCC and 
MCC cases. HPV16 sequences were identified in 7 of the 9 NKSCCs, with 174 to 
2153 reads per case. MCPyV was present in 4 of the 8 MCCs with 174 to 438 reads 
per case, corresponding to at least 0.1 viral copies/cell by qRT-PCR. Conclusions: 
Although generally discarded, unmapped sequence reads from targeted NGS data 
contain information regarding the presence of known oncogenic human pathogens, 
representing another source of clinically relevant information that can be acquired 
through high-depth sequencing of tumor samples. Such methods could be used to 
screen for novel viral pathogens in existing NGS sequence data. 
 
ST09. Gene Signatures Improve Overall and Cancer-Specific Survival 
Prediction Accuracy in Prostate Cancer Patients 
Z. Peng1, L. Skoog2, H. Hellborg 2, G. Jonstam2, I. Wingmo2, M. Hjälm-Eriksson2, U. 
Harmenberg2, G.C. Cedermark 2, L. Ährlund-Richter 1, S. Pramana1, Y. Pawitan1, M. 
Nistér1, S. Nilsson 2, C. Li 2 
1Karolinska Institutet, Stockholm, Sweden; 2Karolinska University Hospital, 
Stockholm, Sweden. 
Introduction: An accurate prediction of overall survival at the time of prostate 
cancer diagnosis is of the utmost importance for selecting the most appropriate 
treatment. The currently available clinical prognostic tools demonstrate an accuracy 
of 70% to -80% for the prediction of biochemical or PSA (prostate-specific antigen) 
recurrence, but these tools are less effective at predicting cancer-specific survival 
and even less accurate at predicting overall survival. This study aimed to identify 
biomarkers for accurate prediction of overall and cancer-specific survival in prostate 
cancer patients. Methods: To explore the importance of embryonic stem cell (ESC) 
gene signatures, we identified 641 embryonic stem cell gene predictors (ESCGPs). 
Selected ESCGPs and control genes were analyzed by multiplex quantitative PCR 
using prostate fine-needle aspiration samples taken at diagnosis from a Swedish 
cohort of 189 prostate cancer patients diagnosed between 1986 and 2000. Of these 
patients, there was overall and cancer-specific survival data for 97.9%, and 77.9% 
were primarily treated by hormone therapy only. Univariate and multivariate Cox 
proportional hazard ratios and Kaplan-Meier plots were used for the survival 
analysis. A published dataset was used for external validation. Results: An 
expression signature of F3, VGLL3 and IGFBP3, was sufficient to categorize the 
patients into high-risk, intermediate-risk and low-risk subtypes. The median overall 
survival times of the subtypes were 3.23, 4.00 and 9.85 years respectively. The 
difference corresponded to HRs of 5.86 (95% CI 2.91 to 11.78, P<0.001) for the 
high-risk and 3.45 (95% CI 1.79 to 6.66, P<0.001) for the intermediate-risk compared 
to the low-risk subtype. Conclusions: These results suggest that these novel gene 
markers and expression signatures could be used to improve the accuracy of the 
currently available clinical tools for predicting overall and cancer-specific survival and 
selecting patients with potential survival benefit from hormone treatment. 
 
ST10. Clinical Whole Exome Sequencing of Wilms Tumor and Paired 
Germline Samples Reveals both Well-Known and Novel Mutations in Cancer 
Genes 
A. Roy, D. Parsons, Y. Yang, D.M. Muzny, C.M. Eng, D. Lopez-Terrada, M. Hicks, P. 
Thompson, R.A. Gibbs, S.E. Plon, F.A. Monzon 
Baylor College of Medicine, Houston, TX. 
Introduction: Genomic sequencing of cancers has largely been a research 
endeavor to date. The BASIC3 trial at Baylor College of Medicine, part of the NHGRI 
Clinical Sequencing Exploratory Research program, is evaluating the impact of 
routinely incorporating tumor and paired germline whole exome sequencing (WES) 
results into the clinical care of children with newly diagnosed solid tumors. We 
present the findings for the first seven patients with Wilms tumor, the most common 
pediatric renal malignancy. jmd.amjpathol.org ■ The Journal of Molecular Diagnostics
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specimens. Exome capture was performed using Roche-NimbleGen VCRome 2.1 
and WES was performed on an Illumina HiSeq 2000 with average coverage of 294x 
(tumor) and 168x (germline). Bioinformatics analysis was performed using a 
clinically-validated pipeline. Somatic variants were grouped into categories I to IV, 
following a previously developed schema classifying genes and variants on clinical 
significance and utility. Clinical reports summarizing the exome results were 
uploaded to the electronic medical record. Results: Six patients had favorable 
histology Wilms tumor, including one with extra-renal Wilms tumor, and the 
remaining patient had Wilms tumor with anaplasia. All patients had unilateral tumors, 
without a family history or clinical features of Wilms predisposition syndrome. Tumor 
WES revealed a median of 9 somatic variants (range 2 to 13), including missense, 
nonsense, splicing and indel mutations. Mutations in genes reported to be 
recurrently mutated in Wilms tumor were identified, including WT1, CTNNB1, TP53 
and FBXW7. A mosaic germline 1-bp deletion in WT1 (c.867delC) was identified in a 
patient without features of Denys-Drash syndrome. This tumor also showed LOH of 
WT1 and an oncogenic mutation in CTNNB1 (p.S45del). The tumor with anaplasia 
demonstrated a somatic c.560-1G>T splice site TP53 mutation. One patient had 
biallelic somatic mutations at the same codon in the E3 ubiquitin ligase, FBXW7 
(p.R399G; p.R399X). WES also identified mutations in cancer genes not previously 
associated with Wilms tumor, e.g., the methylcytosine oxygenase TET2, the 
chromatin remodeling gene ZMYM3, and the homeobox transcription factor CDX2. 
Conclusions: Clinical tumor and germline WES revealed both somatic and germline 
mutations in genes important in Wilms tumor pathogenesis, including a germline 
WT1 mutation that impacts the risk of contralateral Wilms tumor. We anticipate 
sequencing approximately 30 Wilms tumors in the course of this trial. This initial 
series has revealed mutations in cancer genes not previously associated with Wilms 
tumor biology, highlighting the potential power of unbiased genomic sequencing 
techniques as both a research and clinical tool. 
 
ST11. A Methods Comparison Analysis of the Roche Cobas 4800 BRAF V600 
Mutation Test and the Qiagen BRAF RGQ Version 2 PCR Kit on Melanoma 
Specimens with Challenging Attributes 
J.W. Longshore1, S. Banawan2, H.N. Todd2, E.H. Lipford1, J.F. Palma3 
1Carolinas Pathology Group, Charlotte, NC; 2Carolinas Medical Center, Charlotte, 
NC; 3Roche Molecular Systems, Pleasanton, CA. 
Introduction: Activating BRAF mutations occur in many human tumors, 
predominantly at codon 600. These mutations occur in ~50% of malignant 
melanomas. The predominant change is a T>A transversion that results in a V600E 
mutation and constitutive activation of the BRAF kinase. The identification of 
activating mutations make patients eligible for treatment with the BRAF inhibitor 
vemurafenib.A variety of techniques have been used to test for the V600E mutation 
yet few direct comparisons exist between these methodologies. Given the increased 
emphasis on BRAF mutation status, two commercially available V600E detection 
methodologies were compared, the Qiagen BRAF RGQ PCR kit version 2 (CE-IVD) 
and the FDA-approved companion diagnostic cobas 4800 BRAF V600 Mutation 
Test. Methods: To evaluate test performance, comprehensive histological 
assessments were conducted on 126 FFPET melanoma samples with challenging 
attributes. Specimens were selected based upon small tissue size (<60mm²), >10% 
pigmentation, >50% necrosis, core needle biopsy, or unusual metastatic sites. For 
each method, a single 5 μm unstained slide was tested as recommended in the 
package insert. Discrepant results between the two methods were resolved by next-
generation sequencing. Results: From the 126 study samples, there were a total of 
13 discordant results. Following resolution analysis with next-generation sequencing 
5/13 results agreed with the cobas test, 5/13 agreed with the RGQv2 test, and 3 are 
pending additional analysis. There were two invalid results for both the Roche and 
Qiagen methods and an additional three samples that were invalid by the Roche and 
Qiagen methods each. Five of the RGQv2 results revealed multiple positive mutation 
calls and two of the Qiagen results had a sample control assay CT>33 but gave 
accurate mutation calls. The overall percent agreement was 90% (105/118) for both 
assays. Total time to result for a batch size of 24 samples was 5.65 hours for the 
cobas test and 5.08 hours for a batch of 7 samples with the RGQv2 assay. 
Conclusions: Two commercial real-time, probe-based BRAF mutation detection 
assays differ in their ability to detect V600 mutations in melanoma samples with 
challenging attributes. Based upon our initial analysis, both methods had a similar 
degree of mutation detection accuracy. However, the total time to result, assay 
hands on time, and diagnostic interpretation were more efficient and rapid with the 
cobas BRAF Test. 
 
 The Journal of Molecular Diagnostics ■ jmd.amjpathol.orgST12. Clinical Evaluation of Ion PGM and Illumina MiSeq Massively Parallel 
Sequencing (MPS) Platforms for Targeted Sequencing of Tumor Samples 
J.A. Woolworth, D.J. Wolff, F.S. Nolte 
Medical University of South Carolina, Charleston, SC. 
Introduction: MPS technologies are rapidly advancing and increasing accessible to 
clinical laboratories for oncogene profiling of solid tumors to inform both established 
and novel therapies of cancer. However, there is limited published data comparing 
results of different MPS platforms with routine clinical samples. Here we compare 
results obtained with the Ion PGM to the Illumina MiSeq somatic cancer panels using 
22 FFPE tumor samples. Our analysis included comparison of the two platforms for 
coverage, variant detection, and differences in base calls between platforms, as well 
as correlation to known single gene results for EGFR, KRAS, and BRAF. Methods: 
DNA was extracted from tissue containing metastatic melanoma (5), lung (9), and 
colorectal cancer (8). The DNA was used to generate an amplicon library for each 
platform. The Ion AmpliSeq Cancer Hotspot Panel v2 and the Illumina TruSeq 
Amplicon Cancer Panel were used to analyze variant regions in 50 oncogenes (207 
amplicons) and 48 oncogenes (212 amplicons), respectively. The coverage goal for 
each sample was 1,000 reads/amplicon. The results from both platforms were then 
evaluated with third party software (NextGENe by SoftGenetics, LLC) to assess 
platform-neutral quality scores, coverage, and variant calls (filter set at 2%). In 
addition, the MPS results were compared to allele-specific real-time PCR for EGFR, 
KRAS, and BRAF oncogenes (EntroGen). Results: A total of 369 discordant variant 
calls were observed in 33 oncogenes. These discordant samples fell into four 
categories: homopolymer region deletions (38%), insertions (31%), single-nucleotide 
substitutions (26%), and deletions (5%). Within these discordant calls, 100% of the 
insertions and 99.3% of the homopolymer region deletions were made by Ion PGM, 
whereas 62.9% of the substitutions and 23.8% of the deletions were made by 
Illumina MiSeq. The average discordant bases per sample was 17. Both MPS 
platforms failed to detect an insertion in exon 20 and a T790M variant in EGFR 
identified by allele-specific PCR. The two EGFR variants missed by MPS had high 
CT values in the allele-specific PCR. Conclusions: There was good correlation 
between the base calling of the two platforms with few discordant bases per sample. 
MPS technology is feasible in the clinical laboratory setting for solid tumor oncogene 
profiling. However, more sensitive methods may be required to ensure detection of 
clinically actionable mutations in samples with a low number of tumor cells or 
variants. 
 
ST13. NGS of FFPE Breast Cancer Specimens Demonstrates High 
Concordance in Calling HER2 Gene Copy Number Amplification and Gene 
Expression and Commonly Detects Other Clinically Relevant Genomic 
Alterations 
G. Otto1, J. He1, G. Young1, R. Yelensky1, V. Miller1, C. Sheehan2, K. Brennan1, M. 
Jarosz1, G. Palmer1, M. Cronin1, P. Stephens1, D. Lipson1, J. Ross1 
1Foundation Medicine, Cambridge, MA; 2Albany Medical College, Albany, NY. 
Introduction: To identify targeted treatment options, next-generation sequencing 
(NGS)-based assays are increasingly being performed on FFPE tumor samples to 
comprehensively characterize the genomic alterations driving an individual patient’s 
disease. DNA-seq can be optimized to detect base substitutions, insertions and 
deletions, copy number changes, and genomic rearrangements. RNA-seq 
compliments DNA-seq by measuring levels of gene expression and may identify 
additional gene fusions. Prior to use in the clinic, rigorous validation of assay 
accuracy is essential. This study assessed the performance of RNA-seq of FFPE 
breast tumors with known HER2 copy number status as determined by a CLIA-
validated DNA-seq assay. Methods: RNA-seq of 120 cancer relevant genes 
(including HER2) and DNA-seq of 182 cancer-relevant genes (including HER2) was 
performed on 31 FFPE invasive breast carcinomas. Thirteen specimens were HER2 
copy number positive (6 average copies), 17 were HER2 negative (<4 copies) and 
1 HER2 intermediate (4-5 copies) as determined by DNA-seq. HER2 gene 
expression was classified (blinded to DNA-seq results) as positive (2-fold increase), 
negative (1 to 2-fold increase) or intermediate (<1-fold change) based upon the 
relative HER2 transcript abundance. The data were also analyzed for additional 
clinically relevant genomic alterations. Results: High concordance was observed 
between RNA-seq HER2 gene expression and copy number status as determined by 
DNA-seq. Compared to the DNA-seq results, RNA-seq HER2 calls demonstrated an 
accuracy of 90% (28/31, 95% CI 74% to 96%), 100% sensitivity (13/13, 95% CI 75% 
to 100%) and 88% specificity (15/17, 95% CI  63% to 96%).  The 3 discordant 
samples, 1 positive and 2 intermediate by RNA-seq, were classified as intermediate 
(CN=5) and negative (CN=3 and CN=2), respectively, by DNA-seq. DNA-seq also 
identified 70 additional alterations (38 base substitutions, 10 insertions/deletions, 22 
copy number alterations) in 23 cancer genes (an average of 2.0 alterations per 
sample). Genomic alterations that predict sensitivity or resistance to targeted 905
90
AMP Abstractstherapies and thus plausibly influence treatment decisions were found in 71% of 
patients. Conclusions: We conclude that HER2 gene expression detected by 
targeted RNA-seq correlates well with DNA-seq copy number status in FFPE breast 
cancers and that NGS-based genomic profiling can also uncover additional 
actionable genomic alterations that could impact disease management in a high 
proportion of patients.  
 
ST14. Analysis of Genetic Variants in Aggressive and Non-Aggressive Basal 
Cell Carcinoma Using Next-Generation Sequencing 
A. Seth, T. Jow, P. Zhang, J. Chen, H. Fernandes 
University of Medicine and Dentistry of New Jersey/New Jersey Medical School, 
Newark, NJ. 
Introduction: Basal cell carcinoma (BCC) is the most common form of skin cancer. 
Although BCC is generally a slow growing tumor, it occasionally behaves 
aggressively, demonstrating invasion to the bone and dura, recurrence, and 
metastasis. Although there are several genes implicated in the pathogenesis of BCC, 
additional genotypic and molecular analyses are required to help understand 
aggressiveness of the tumor. In this study, we used targeted next-generation 
sequencing to compare cancer related variants in aggressive and non-aggressive 
BCC. Methods: A total of 12 BCC specimens, 7 aggressive and 5 non-aggressive 
were used in the study. DNA was extracted from the FFPE specimens and amplified 
using the hotspot cancer panel version 2.0 that targets 50 genes in a multiplex PCR 
reaction. Additional custom amplicons for the genes Patched 1 (PTCH1), TNF alpha 
(TNF), and suppressor of fused homolog (SUFU) were also generated using the 
short amplicon ion fragment library preparation and pooled with the cancer panel for 
further processing. The barcoded amplicons were enriched and sequencing was 
performed on a 316 chip using the Ion Torrent Personal Genome Machine. Data 
analysis was performed using the Variant caller software from Life Technologies. 
Results: Sequencing data analysis showed the average number of variants 
observed in the aggressive tumor specimens to be 42 versus 11 in the non 
aggressive group. The variations included single nucleotide polymorphisms, small 
deletions and insertions. Variants of TP53 and PTCH1 genes, involved in the 
signaling pathways for BCC were observed in all BCC tumor specimens. Similarly 
variants in APC and CTNNB1 involved in the Wnt signaling pathway were also 
detected in both aggressive and non aggressive groups of specimens. A larger 
number of NOTCH1 oncogene variants were present in the aggressive group of 
tumors whereas variations in the oncogene smoothened (SMO) were sporadically 
distributed between both groups. Variations in the SMARCB1 gene were present in 
40% non-aggressive BCC versus 57% in aggressive BCC. Conclusions: 
Significantly larger number of variants was detected in cancer-related genes in the 
aggressive versus non-aggressive BCC specimens. Although variants in tumor 
suppressor genes (TP53 and PTCH) were observed in all BCC specimens, variants 
in oncogene NOTCH were preferentially associated with aggressive BCC. The 
significance of NOTCH as a potential activating mutation for aggressive BCC needs 
further investigation. 
 
ST15. Spectrum of Actionable Variants Identified by Clinical Targeted Next-
Generation Sequencing in Cancer 
H. Al-Kateb, I. Hageman, C.E. Cottrell, C. Lockwood, T. Nguyen, E.J. Duncavage, D. 
Spencer, A. Bredemeyer, T. Cox, M. Hussaini, R. Head, S. Shrivastava, R. 
Nagarajan, K. Seibert, S. Kulkarni, J. Pfeifer 
Washington University, St. Louis, MO. 
Introduction: The goal of personalized molecular medicine in cancer is to customize 
patient treatment on the basis of molecular tumor profiling. We report the frequency 
of actionable variants identified by clinical targeted sequencing using Washington 
University Cancer Mutation Profiling (WUCaMP) in various cancer types. Methods: 
DNA was extracted from formalin-fixed, paraffin-embedded tumor tissue cores. A 
minimum of 100 ng DNA was used for library preparation. RNA capture probes were 
used to target cancer-related genes. Sequencing was performed on the Illumina 
HiSeq or MiSeq platform (2x101 bp or 2x150 bp paired-end reads), achieving 
coverage of 50x at 95% of positions and average coverage of 1018x over the target 
region. An analysis pipeline using the Clinical Genomicist Workstation was used for 
variant calling and interpretation. Results: Six hundred fifty-two cases were 
sequenced, including 177 (27%) lung cancers, 104 (16%) colorectal cancers, 64 
(10%) sarcomas, 53 (8%) pancreatic cancers, 21 (3%) high-grade gliomas, 17 (3%) 
hepatobiliary cancers, and 213 (33%) other malignancies. Predictive variants with 
established evidence were found in 149 cases (22.8%), 51% of which were 
targetable and 49% of which indicated resistance to targeted treatment. An 
additional 62 cases (9.5%) had variants with limited evidence for druggability. The 
yield of predictive variants was highest in GISTs (8 variants in 10 cases = 80%) 
followed by lung cancer (58 variants in 177 cases= 33%) and colorectal cancer (24 6variants in 104 cases = 23%). The KRAS gene had the highest frequency of 
predictive variants (64 cases), representing 43% of all cases with predictive variants 
and 88% of cases with predicted drug resistance. Other genes with frequent 
predictive variants included BRAF, PTEN, and PIK3CA. Seven cases (1% of all 
cases and 4.7% of cases with predictive variants) had more than one predictive 
variant. Further, WUCaMP cancer gene set sequencing identified actionable variants 
not typical of tumor type in 10 cases (7% of cases with predictive variants). Individual 
examples include BRAF V600E in duodenal cancer, JAK2 V617F in non-small cell 
lung cancer, and an EGFR exon 20 insertion in squamous cell carcinoma of the 
maxilla. Conclusions: Targeted NGS analysis detects variants useful for directing 
the choice of drug therapy, including variants not typical of tumor type that would not 
have been discovered by single-gene sequencing. Even in cases without a 
targetable variant by a specific chemotherapeutic drug, the lack of a mutation 
provides information that can be used to direct the search for other treatment 
options.  
 
ST16. The Neuroendocrine Developmental Transcription Factor INSM1 Is 
Overexpressed in Gastrointestinal Neuroendocrine Tumors 
J.N. Rosenbaum, R.M. Baus, H. Werner, W. Rehrauer, R.V. Lloyd 
University of Wisconsin Hospital and Clinics, Madison, WI. 
Introduction: As a class, gastrointestinal neuroendocrine tumors (GI-NETs or 
carcinoids) lack good histological or immunohistochemical markers of malignant 
potential. INSM1 is a transcription factor expressed during the normal development 
of neuroendocrine tissues and neuroepithelia, as part of the mechanism of terminal 
differentiation. In adult tissues, INSM1 expression has only been detected in 
neoplasms, including small cell carcinoma of the lung, pheochromocytoma, and 
medulloblastoma. The expression of INSM1 in GI-NETs has never been explored. 
The spatio-temporal restriction of INSM1 expression makes it an attractive candidate 
as a tumor marker, and as a marker of malignancy in GI-NETs. Methods: We use 
RT-qPCR and immunohistochemistry to investigate the utility of INSM1 as a 
quantitative and qualitative marker of GI-NETs. Eighty-five patient and control 
samples were collected from the surgical pathology archives of the Department of 
Pathology at the University of Wisconsin Hospital and Clinics. These samples were 
analyzed by RT-qPCR for expression of INSM1, and a subset of the samples were 
immunohistochemically stained with a monoclonal mouse anti-INSM1 antibody. 
Results: INSM1 is detected by RT-qPCR in tissue from GI-NETs, but not in control 
tissue. Detection of INSM1 by RT-qPCR has a calculated sensitivity of 61% and 
specificity of 100% for distinguishing GI-NETs from benign tissue. Among GI-NETs, 
expression levels correlate with malignancy (p < 0.05 by ANOVA). The highest 
expression levels are detected in primary tumors with known metastases. Notably, 
expression levels of INSM1 among metastases themselves are quite variable. 
Immunohistochemically, INSM1 is specifically detected in nuclei of GI-NETs, and in 
isolated normal neuroendocrine cells. Preliminary analysis positively correlates 
immunohistochemical detection with RT-qPCR data. Conclusions: INSM1 shows 
promise in both the diagnosis and prognosis of GI-NETs. Quantitatively, we show 
that INSM1 expression is 100% specific to neoplastic tissue, and expression levels 
of INSM1 correlate with malignancy. Qualitatively immunohistochemical staining of 
INSM1 confers advantages over traditional immunohistochemical markers, including 
its nuclear expression pattern and near-absence of expression in normal adult 
tissue. Overall, INSM1 is a promising tool in the diagnosis and prognosis of GI-
NETs.  
 
ST17. Highly Sensitive Somatic Mutation Profiling with Insight Onco NGS 
Panel Based on Mutant Enrichment System 
M. Song, D. Hur, J. Jung 
SeaSun Biomaterials, Yuseong-gu, Daejeon-si, Korea. 
Introduction: Somatic mutation profiling has the potential to quickly identify which 
signaling pathways drive proliferation of a particular tumor type. Somatic Mutation 
profiling may also be a useful clinical research tool in oncology. There are Real-Time 
PCR, MALDI-TOF, or next-generation deep-sequencing based on approaches for 
detecting mutations within a high background of wild-type DNA. However, identifying 
low level somatic mutations will continue to be a challenge for researchers. We 
developed a mutant enrichment system for somatic mutation panel to detect low 
level mutations in a mixed cell population. The mutant enrichment system is built into 
the Insight Onco Panel and is available in Next Generation Sequencer. next-
generation sequencing-based Insight Onco panel has been developed that can 
detect as few as 0.01% low level somatic changes in the background of wild-type 
genomic DNA. Methods: We investigated analytic performance of the Insight Onco 
NGS Panel, the method used to select low level somatic mutation with high-
throughput results. Sensitivity was assessed using mixture of plasmids or cell line 
DNA with low level of mutant alleles. Mutant-type (SNU601, A549, PC9, and H1975) jmd.amjpathol.org ■ The Journal of Molecular Diagnostics
T AMP Abstractsand WT cell lines, synthetic plasmid and FFPE specimens were processed to 
produce artificial mixture of mutant. Extracts from both mutant-type and wild-type 
samples were pooled separately, and the DNA concentration of each pool was 
quantified. Mutant sample pools were diluted and mixed by volume with the wild-type 
sample extract to achieve the somatic mutation percentage (100 to 0.01 and 0%). 
Sample mixtures were analyzed by the Insight Onco 100 panel. Results: The 454 
amplicon sequencing results revealed that the Insight Onco Panel offers a 
comprehensive screen of 6 oncogenes with 16 mutations in BRAF, 48 mutations in 
EGFR, 21 mutations in HRAS, 30 mutations in KRAS, 26 mutations in NRAS and 21 
mutations in PIK3CA. Furthermore, the Insight Onco 100 showed a higher sensitivity 
to detect 0.01% mutant level in the background of wild-type DNA with general depth 
of reads (< 1000). Conclusions: The Insight Onco Panel provides a useful tool for 
validation of clinical samples as well as cell line characterization for drug discovery 
and development.  
 
ST18. MLH1 Methylation Status versus BRAF V600E Mutation Testing for 
Separating MSI High Sporadic Cancer from Lynch Syndrome: Analysis of 40 
Specimens Using Pyrosequencing Technology 
D. Bustamante1, J.A. Dowling2, J.M. Gale2, M.A. Vasef3 
1University of New Mexico Health Science, Albuquerque, NM; 2TriCore Reference 
Laboratories, Albuquerque, NM; 3University of New Mexico, Albuquerque, NM. 
Introduction: Approximately 15% of colorectal cancer (CRC) cases develop via 
microsatellite instability (MSI) pathway. Most MSI-related cancers are sporadic due 
to silencing of MLH1 gene via MLH1 promoter region hypermethylation. However, 
approximately 3% of colorectal cancers are due to germline mutations in DNA 
mismatch repair (MMR) genes that lead to hereditary non-polyposis colorectal 
cancer (HNPCC) also known as Lynch Syndrome (LS). Testing for methylation 
status of MLH1 promoter region or BRAF V600E mutation has been proposed to 
separate the sporadic cases from Lynch-related tumors. However, studies 
comparing the discriminative power of MLH1 methylation versus BRAF V600E 
mutation are limited in the literature. In this study, we compared the discriminative 
power of MLH1 methylation versus BRAF V600E mutation in 40 MSI high cases to 
determine which assay can more reliably separate Lynch syndrome from sporadic 
cases. Methods: MSI analysis was performed on DNA extracted from paraffin-
embedded tumor tissue in parallel with corresponding benign tissue on 40 patients 
including 35 CRC specimens, 2 endometrial carcinomas, 2 sebaceous adenomas, 
and one urothelial carcinoma using Promega MSI kit followed by capillary 
electrophoresis (ABI3130 Genetic Analyzer). For MLH1 promoter methylation 
analysis pyrosequencing of bisulfite-treated DNA on the PyroMark Q24 (Qiagen) was 
used. For analysis of BRAF V600E mutation, the DNA was subjected to PCR 
amplification and the reverse strand of PCR amplified product was used for final 
sequence analysis using pyrosequencing. 
Results: MLH1 hypermethylation was identified in 20 of 40 (50%) MSI high cases 
whereas BRAF V600E mutation was detected in only 13 of 40 (33%) of MSI high 
cases. All BRAF V600E mutated cases demonstrated MLH1 hypermethylation 
whereas 7 out of 20 (35%) MLH1 hypermethylated cases lacked BRAF V600E 
mutation. Conclusions: Our results demonstrate that BRAF V600E test is not as 
sensitive as MLH1 methylation test in separating sporadic MSI high tumors from 
Lynch syndrome because 7 of BRAF wild type cases in this study were MLH1 
hypermethylated. The MLH1 methylation test appears to be a more sensitive and 
reliable assay in separating sporadic cases from Lynch syndrome-related cases and 
in avoiding costly genetic analysis of MMR genes. 
 
ST19. Detection of KRAS Mutations Using COLD-PCR-Enhanced Melting 
Curve Analysis for the Diagnosis of Pancreatic Cancer in Cytologic Specimens 
from Endoscopic Ultrasound-Guided Fine-Needle Aspiration  
C.F. Li, S.J. Bauer, O. Pangan, G. May, H. Ghaffar, V. Iakovlev, C. Streutker, S. 
Jothy 
St. Michael's Hospital, Toronto, Ontario, Canada. 
Introduction: We have previously reported the usefulness of detecting KRAS 
mutations for the diagnosis of pancreatic cancer in liquid based ThinPrep cytology 
samples obtained via endoscopic ultrasound-guided fine-needle aspiration biopsy on 
patients with pancreatic masses [J Mol Diagn14:712, 2012]. Adenocarcinomas 
carried with KRAS mutations, whereas benign lesions carried with wild-type KRAS. 
This study indicated that detection of KRAS mutation may be useful to supplement 
cytopathologic evaluations for pancreatic cancer in specimens from endoscopic 
ultrasound-guided fine-needle aspiration. However, the reality is that we usually do 
not have enough material in the cytology specimens to extract sufficient DNA to set 
up seven tubes of PCR reactions for detection of KRAS mutations. Therefore, we 
investigated the possibility of using co-amplification at lower denaturation 
temperature (COLD)-PCR enhanced melting curve analysis for detection of KRAS he Journal of Molecular Diagnostics ■ jmd.amjpathol.orgmutations. Methods: COLD-PCR is a recently described method that selectively 
amplifies mutant alleles in a wild type background with a sensitivity of 1%, and 
required only one PCR reaction per case. COLD-PCR enriches G:C to A:T mutations 
that lower the melting temperature (Tm) of the PCR amplicon, by using a critical 
denaturation temperature (Tc) that favors PCR amplification of the mutant allele. 
Since >90% of the KRAS mutations in codons 12 and 13 are G:C to A:T changes 
(G12D, G12V, G12S, G12C, G13D), and the remaining common mutations are Tm-
neutral G:C to G:C changes (G12R and G12A), COLD-PCR is expected to be 
adequate for this mutational analysis. Results: We first validated the COLD-PCR 
methodology using specimens with known KRAS mutation status (15 mutated and 9 
wild type) tested using an established real-time PCR assay (DxS/Qiagen KRAS 
mutation kit). Comparable KRAS mutation status was identified in 22 out of the 24 
specimens using COLD-PCR methodology, including one case with Tm-neutral 
mutation (G12A). Discrepancies were found in 2 cases (1 cytopathologically atypical 
/indeterminate case having G13D mutation using DxS/Qiagen kit and wild-type using 
COLD-PCR; 1 cytopathologically malignant case having wild-type using DxS/Qiagen 
kit and mutated using COLD-PCR). Since this COLD-PCR methodology only needs 
to set up one tube of PCR reaction, we should be able to identify KRAS mutation 
status in the majority of specimens from endoscopic ultrasound-guided fine-needle 
aspiration. We applied this COLD-PCR methodology to an additional 21 cases, and 
KRAS mutation status was identified in 20 cases. Conclusions: This COLD-PCR 
test has a high diagnostic yield, and it can be readily applied cytologic samples for 
which insufficient DNA quantity would otherwise preclude analysis. 
 
ST20. A Rapid, Integrated Approach Applied to Breast Cancer Diagnostics: 
An Emerging Solution to Current Inaccuracies 
A. Chargin 
Penfold Patterson Research Institute, Frankfort, MI. 
Introduction: The current practice in breast cancer diagnostics revolves around IHC 
studies for ER/PR and HER2 protein levels that may be reflexed to FISH in cases 
where the HER2 protein level is equivocal. Genomic studies may also be performed 
in an attempt to generate risk profiles for use in deciding an appropriate treatment 
strategy. In review of the current literature, it has been reported that IHC may be 
inaccurate in 20% of all cases. Additionally, the cost of current genomic studies is 
prohibitive to the general public costing on average $4000. Methods: In the current 
study, we procured ex vivo fine needle aspirations (FNA) that were placed in two 
sample fixatives: the current standard ThinPrep, and IncellFP a proprietary fixative 
optimized for multiparametric analysis. We have built a cell based diagnostic 
approach with the ability to simultaneously detect proteins (ER, PR, HER2, E-
cadherin), mRNA expression (HER2), and complete cell cycle analysis in what we 
term a cellular multiplex. Unlike current methods dedicated to the detection of single 
alterations, this approach provides an all-encompassing view of the cellular 
environment at multiple regulatory levels. The assay can be run in less than 4 hours 
on either a flow cytometer or an image cytometer for morphology. Proof of concept 
was determined using a model composed of WBCS, MCF-7, and SK-BR-3 cells to 
mimic a FNA and to establish analytic performance prior to sampling human tissue. 
Here we report an interim analysis of 7 breast tumors from a study of 40 breast 
tumors and 10 normal breast samples. Performance of the assay is compared to 
known receptor and pathology status obtained by pathology slide review and IHC. 
Results: In the first 7 breast tumor samples, the receptor (ER/PR/HER2) status of 
the assay is 100% concordant with patient metadata obtained using the current 
standard practice and matches the predicted analytic performance obtained in our 
cell line FNA model. Interestingly, the recovery of analyzable breast ductal cells in 
IncellFP is more than 2x (1.4 x 106 vs. 587,000) in comparison to the currently used 
ThinPrep preservative. Conclusions: The addition of normal breast tissues in this 
study provides a landscape picture of the cellular features of normal breast tissue. In 
addition to improving upon the current standard of care, this cell based approach 
may be applied to xenograft models for use in measuring drug efficacy. This 
approach may also be applicable to circulating tumor cell studies. 
 
ST21. Risk of Progression from Colorectal Adenoma to Carcinoma Assessed 
by Fluorescence in Situ Hybridization Analysis 
M. Song, S. Sitailo, F. Policht, I. Sokolova 
Abbott Molecular, Inc., Des Palines, IL. 
Introduction: Colorectal cancer (CRC) remains a leading cause of mortality 
worldwide despite the molecular events in the adenoma-to-carcinoma sequence 
being well-characterized. Identification and validation of novel molecular markers to 
assist the early screening for CRC would have significant clinical value. The 
objective of this study was to apply fluorescence in situ hybridization (FISH) to 
assess the frequency of characteristic genetic changes and correlated with clinical 
presence of cancer in colorectal adenoma specimens. Methods: Epithelial cells 907
9AMP Abstractswere extracted from human fresh frozen colon tissues for use in FISH analysis. 
Thirteen genomic regions were evaluated on CRC and normal tissues. With the 
highest frequency of chromosomal aberrations assessed, five candidate FISH 
probes (EGFR, MYC, 13q14, DCC, and CEP18) were selected. A set of 27 
colorectal adenoma tissues were tested with these 5 candidate probes. Among 
them, 11 adenoma tissues were obtained from patients with concurrent carcinoma 
(Group 1), and 16 adenoma tissues were obtained from patients without carcinoma 
diagnosed at the time when the specimens collected (Group 2). Results: 
Chromosomal pattern and the number of chromosomally abnormal cells were 
evaluated and quantified, and the cut-off point was suggested. Three distinct 
abnormal FISH patterns were identified: i) loss of DCC gene copy number only, ii) 
gain of EGFR gene copy number only, iii) abnormal (gain or loss) for all probes. 
Testing revealed that FISH positivity was 91% for adenoma patients in Group 1, 
comparing to 38% in Group 2. Conclusions: Our preliminary “proof of concept” data 
demonstrates that the level of FISH positivity in colorectal adenoma increases with 
adenoma-to-carcinoma progression. Therefore, accumulation of chromosomal 
changes detected by FISH could be a marker of progression. FISH testing has a 
potential utility in patient surveillance as an aid in early cancer detection or cancer 
risk assessment. 
 
ST22. BRAF and NRAS Mutations in Nodular and Superficial Spreading 
Melanoma  
A.D. Bossler, A.N. Snow, T.M. Knutson, A.M. Button, M.M. Milhem 
Carver College of Medicine, University of Iowa, Iowa City, IA. 
Introduction: Mutations of the BRAF kinase gene have been found in 40% to 60% 
of melanoma cases. Vemurafenib, a drug that inhibits progression of the BRAF 
V600E mutation along the MAP kinase pathway, was FDA approved for clinical use 
in 2011 for patients with metastatic melanoma. Response is negated by additional 
mutational events that confer resistance to vemurafenib. Activating mutations in 
NRAS kinase, a downstream target of BRAF activity, have been found to contribute 
to resistance to vemurafenib. This study examined the rates of BRAF and NRAS 
mutations in patients with nodular and superficial spreading melanoma prior to the 
use of vemurafenib and examined patient survival depending on the presence or 
absence of these mutations. Methods: Manual microdissection was performed on 
formalin fixed paraffin embedded tissue specimens to enrich for melanoma tumor 
cells before DNA extraction (UI IRB #200804792). Mutations were detected using a 
primer extension assay (SNaPshot reagent, Life Technologies). Overall survival 
probabilities were estimated with the Kaplan-Meier method and compared with log-
rank tests (univariate analysis). Results: Half of cases were positive for the 
BRAFV600E (40/79 cases) whereas 19% of cases had an NRAS codon 61 mutation 
(13/68). The presence of a BRAF mutation had no effect on overall survival rate 
(p=0.8124), whereas those testing positive for an NRAS mutation appeared to have 
better overall survival (p=0.0980) than those who tested negative.  
Conclusions: These results demonstrate that mutations in the BRAF and NRAS 
genes are frequently detected though rarely concurrently. Mutation of the BRAFgene 
does not affect rate of survival for melanoma patients consistent with previous 
reports, whereas the trend for those with NRAS mutations may have better survival. 
 
ST23. Rapid Fluorescence in Situ Hybridization (FISH) for HER2 Assessment 
in Breast and Gastroesophageal Cancer 
B.J. Dokus, S.F. Allen, H.B. Steinmetz, J.D. Marotti, G.J. Tsongalis, L.J. Tafe 
Dartmouth-Hitchcock Medical Center, Lebanon, NH. 
Introduction: Evaluation of HER2 gene amplification or protein expression is 
standard of care in breast (BR) and advanced stage gastroesophageal (GE) cancers 
to identify patients eligible for anti-HER2 therapies. Most fluorescence  in situ 
hybridization (FISH) assays used to detect HER2 gene amplification require two 
days for slide processing, delaying the reporting of results. Therefore, it is desirable 
to decrease this wait time so patients have quicker access to targeted therapeutics. 
Here, we evaluate a rapid FISH technology for detection of HER2 in BR and GE 
cancer patients. Methods: Twelve FFPE samples (7 BR needle biopsies, 2 BR 
excisions, 2 GE biopsies, and 1 biopsy of metastatic BR cancer to the liver) that had 
been previously evaluated with the PathVysion HER2 DNA Probe Kit were studied 
with the HER2 IQ FISH pharmDx Kit. After deparaffinization and rehydration, a 10 
minutes microwave oven pretreatment step is performed followed by pepsin 
digestion and dehydration.  Slides are then probed and sealed; in the hybridization 
oven they denature for 10 minutes and hybridize for 60 to 120 min. The probe 
chemistry is based on a combination of peptide nucleic acid (PNA) and DNA 
technology and contains Texas Red-labeled DNA probes for the HER2 gene and 
fluorescein-labeled PNA probes targeted at the centromeric region of chromosome 
17 (CEN-17). The slides then undergo a stringent wash and are mounted with a 
Fluorescence Mounting Medium containing DAPI. Twenty nuclei were enumerated 08by two technologists on a fluorescent microscope and the HER2:CEN-17 ratio was 
calculated. Cases were scored as positive (>2.2), negative (<1.8), or equivocal (1.8-
2.2). Results: Four samples were positive for HER2 amplification whereas eight 
were negative. There was 100% concordance between the IQ FISH and the 
PathVysion results. The IQ FISH was able to detect low level amplification 
(HER2:CEN-17 ratio 2.4) and intratumoral heterogeneity within two BR samples. The 
assay was performed in approximately four hours with about one hour of hands-on 
tech time. Conclusions: The HER2 IQ FISH pharmDx Kit is a FDA approved kit that 
offers a rapid turn-around-time and in our laboratory was 100% concordant with prior 
PathVysion results. An additional benefit is that the assay’s hybridization buffer 
chemistry is non-toxic because it does not use formamide. However, one potential 
drawback is that the slides are only able to be evaluated for seven days. Also, a 
DAPI filter in combination with a high quality Texas Red/FITC double filter is 
required, which might not be standard in all laboratories. 
 
ST24. Genomic Expression Profile of lincRNA in Papillary Thyroid Cancer 
(PTC) 
K. Arispe, M. Le, K. Schilter, S. Suster, A. Mackinnon 
Medical College of Wisconsin, Milwaukee, WI. 
Introduction: Human non-coding RNAs, including long intergenic non-coding RNAs 
(lincRNAs) are a recently described class of genes whose specific function is 
unclear. lincRNA expression is highly tissue specific and frequently dysregulated in 
cancer, yet their role in tumorigenesis is controversial. In PTC, two thyroid specific 
lincRNAs, PTCSC1 (papillary thyroid carcinoma susceptibility candidate 1) and 
PTCSC3, regulate cell growth and expression of DNA replication, recombination and 
repair genes. In this study we evaluate the genomic expression profile of lincRNAs in 
PTC compared with normal and hyperplastic nodules to identify a role in the 
diagnosis, classification, and prognosis of this neoplasm. 
Methods: lincRNA expression profiles were determined in 24 samples: 12 PTCs and 
6 paired normal thyroid and hyperplastic nodules using SurePrint G3 Gene 
Expression v2 Microarray covering over 40,000 total transcripts including lincRNAs 
described in the Broad Institute Human lincRNA Catalog. Statistical analysis was 
done using Genespring ver12.5. Relative lincRNA expression between PTC and 
normal or hyperplastic nodules was determined using one-way ANOVA; expression 
between paired samples was calculated using moderated t-test. Expression data 
were filtered by P < 0.05 and fold-change >2 from the normalized gene expression of 
these three groups allowing us to generate a list of lincRNAs with altered expression. 
Results: Ninety-three lincRNAs and 34 TUCPs demonstrating significant 
dysregulated expression were identified: 59 lincRNAs and 23 TUCPs in PTC with 
concordant expression in a minimum of 8 of the 12 cases and 34 lincRNAs and 11 
TUCPs in 5 of 6 paired samples. We identified similar expression of lincRNA 
PTCSC3 as previously reported in the literature. For the first phase of our 
experimental analysis, we used the Human lincRNA catalog from the BROAD 
Institute to assign 69 of these 93 total lincRNAs to one of three categories: lincRNAs 
with thyroid specific, lincRNAs with pan-tissue expression, and lincRNAs not 
normally expressed in thyroid. Validation of these lincRNAs is ongoing. 
Conclusions: Although the precise mechanism of lincRNA activity in PTC remains 
unknown, reports of altered lincRNA expression in numerous cancer types suggest 
that aberrant lincRNA expression plays a potential role in oncogenic pathways. 
Therefore it is tempting to speculate that dysregulated lincRNAs may regulate 
epigenetic modification or transcriptional activation to provide cellular growth 
advantages and promote thyroid cancer development. This raised the possibility that 
lincRNAs may become a class of clinically relevant biomarkers in PTC. 
 
ST25. Detection and Verification of Somatic Mutations in Solid Tumors Using 
Orthogonal Next-Generation Sequencing Technologies  
J.L. Winters, J.S. Voss, E. Barr Fritcher, Z. Tu, E.W. Klee, B. Kipp 
Mayo Clinic, Rochester, MN. 
Introduction: Next-generation sequencing (NGS) is rapidly advancing our ability to 
interrogate numerous cancer causing genes and genes amenable to targeted 
therapies. A current challenge for clinical laboratories is determining an efficient and 
sensitive method to confirm the presence of identified somatic mutations by NGS, 
especially when mutations are detected at low allele frequencies. In this study, we 
evaluate an orthogonal NGS approach by preparing template from a targeted cancer 
panel and then sequencing samples in parallel using two NGS platforms. Methods: 
Twenty-three FFPE samples were assessed for mutations in 207 amplicons covering 
50 genes, which were PCR amplified using the Ion AmpliSeq Cancer Hotspot Panel 
v2. The PCR product was equally split, platform specific adapters were ligated to the 
amplicons and sequenced using both Ion PGM and Illumina MiSeq platforms. PGM 
data were analyzed using the Ion Torrent Suite software v3.4 whereas the Illumina 
MiSeq data were analyzed using CLC Bio Genomics Server Program v4.1 software jmd.amjpathol.org ■ The Journal of Molecular Diagnostics
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average read depth for each sample ranged from 116 to 4248 (mean=1583) for PGM 
and 270 to 39559 (mean=9720) for MiSeq. For PGM, 19 samples had >90% of the 
207 amplicons with >100 read depth and all 23 samples had >90% of the 207 
amplicons with read depths >100 for MiSeq. MiSeq and PGM sequencing identified 
567 and 402 variant calls, respectively, consisting of both germline polymorphisms 
and somatic mutations. Of these variant calls, 342 were concordant between the two 
platforms, resulting in 40% of MiSeq calls and 15% of PGM calls that were not 
confirmed by the other method. Analysis of the discordant variants revealed that they 
were likely due to technical sequencing artifacts caused by homopolymer regions or 
read strand bias. Of the 23 cases, 20 had a previously known somatic mutation (18 
point mutations and 2 indels). Both platforms detected all 20 mutations and had 
concordant results for cases without a known mutation. The mutation frequencies 
between the two platforms had good correlation (R2 = 0.94) as the average percent 
difference was 2.67%. Conclusions: Using a NGS orthogonal approach is a viable 
option to interrogate mutations in solid tumors as it provides the adequate sensitivity 
to detect mutations at low allele frequency. The orthogonal NGS method is more 
sensitive than Sanger sequencing and more efficient than using a variety of single 
gene assays to confirm detected alterations.  
 
ST26. ALK Status Testing in Non-Small Cell Lung Cancer: Correlation 
between Ultrasensitive IHC and FISH 
X. Zhou, F. Yang, S. Tang, X. Cai, Y. Lu, Q. Yu 
Fudan University Shanghai Cancer Center, Shanghai, China. 
Introduction: Anaplastic lymphoma receptor tyrosine kinase (ALK) gene 
rearrangements occur in a subgroup of non-small cell lung cancer (NSCLC). 
Identification of these rearrangements is important for guiding ALK inhibitor 
treatment decisions. Fluorescent in situ hybridization (FISH) is the standard method 
for companion diagnosis, but requires specialized equipment and expertise. 
mmunohistochemistry (IHC) for ALK protein overexpression is a promising screening 
modality due to its easy operation and low price. However, regular IHC is challenged 
by low expression of ALK protein in NSCLC. IHC with enhanced sensitivity is needed 
for validation and comprision with FISH. Methods: We compared ultrasensitive 
automated IHC by VENTANA ALK D5F3 clone plus Optiview DAB IHC Detection Kit 
in Roche BenchMark XT with FISH using Vysis ALK break apart probe for detecting 
ALK status on total 294 FFPE lung cancer specimens with 265 NSCLCs and 29 
small cell lung carcinomas㧔SCLCs. Results: ALK IHC-positive tumor cells 
demonstrated strong and diffused granular staining in the cytoplasm. ALK IHC-
positive cases were confirmed in 43 out of 265 NSCLC and 2 out of 29 SCLC. FISH 
performed successfully in 290 cases that were used in the comparison of the two 
methods, including 261 NSCLC and 29 SCLC. Thirty-eight out of 39 ALK IHC-
positive NSCLC cases were confirmed to harbor ALK rearrangement by break apart 
FISH. One adenocarcinoma with negative FISH demonstrated focal granular staining 
in the cytoplasm in the ultrasensitive IHC. Two hundred twenty one out of 222 IHC-
negative NSCLC cases were FISH-negative and one IHC negative case showed 
FISH positive. Overall, IHC was concordant with FISH on 259 of 261 FFPE samples 
that showed 97.4%㧔38/39㧕sensitivity and 99.5% (221/222) specificity in NSCLC. 
Two out of 29 SCLC cases were ALK IHC-positive that showed strong diffuse 
staining in tumor cells. However㧘all the SCLC cases were FISH-negative that 
demonstrated ALK protein was not related with ALK gene translocation in SCLC. 
Conclusions: The ultrasensitive automated IHC is a reliable tool for identification of 
ALK rearrangement in NSCLC based on the high concordance with FISH. It can be 
used as the initial screening approach for clinical ALK testing based on its higher 
informative cases, lower price and easier judgment . False positive and negative 
may happen due to the focal abnormal expression of ALK protein and inappropriate 
tissue processing. SCLC should be strictly excluded for ALK rearrangement 
assessment at this stage.  
 
ST27. The Development of a Tailored Pancreatobiliary Fluorescence in Situ 
Hybridization (FISH) Assay to Improve Detection of Malignancy in 
Pancreatobiliary Brushings 
E.G. Barr Fritcher1, B.R. Kipp1, J.S. Voss1, S.M. Brankley1, M.E. Keeney1, M.B. 
Campion1, E.V. Pestova2, I.A. Sokolova2, M. Song2, L.R. Roberts1, G. Gores1, A.C. 
Clayton1, K.C. Halling1 
1Mayo Clinic, Rochester, MN; 2Abbott Molecular, Inc., Des Plaines, IL. 
Introduction: Fluorescence in situ hybridization (FISH) using UroVysion (Abbott 
Molecular, Des Plaines, IL), originally developed to identify bladder cancer, is 
currently used in conjunction with routine cytology for the diagnosis of malignancy in 
pancreatobiliary (PB) brushings. We recently developed a tailored FISH probe set 
targeting 1q21, 7p12, 8q24, and 9p21 for detection of PB carcinoma (i.e. PB FISH he Journal of Molecular Diagnostics ■ jmd.amjpathol.orgassay). The aim of this study was to determine if the PB FISH assay and/or KRAS 
mutation testing offer improved performance over the current testing algorithm of 
routine cytology and UroVysion FISH in the molecular cytology laboratory. Methods: 
Per clinical practice, routine cytology and UroVysion FISH were conducted on PB 
brushings. Residual samples from consecutive patients (n=112) were retrospectively 
identified to perform KRAS mutation analysis by quantitative PCR (Qiagen, MD) and 
hybridization with the PB FISH assay. Positive routine cytology and polysomy (copy 
number gain of at least two loci) FISH were considered positive test results for 
statistical analysis. The gold standard was clinicopathologic evidence of malignancy. 
Results: Sixty-five patients (58%) were found to have PB malignancy on follow-up. 
The sensitivity of the PB FISH assay (74%) for the detection of PB malignancy was 
significantly higher (P<0.001) than routine cytology (28%), UroVysion FISH (51%), or 
KRAS mutation analysis (32%). The combined sensitivity of routine cytology + PB 
FISH was significantly higher than the current clinical algorithm of routine cytology + 
UroVysion FISH (77% vs. 58%, P<0.001) with similar specificity (96% vs. 89%, 
P=0.18). The combination of routine cytology + PB FISH + KRAS mutation analysis 
had a sensitivity of 83% and specificity of 89%. Conclusions: This study validates 
that the PB FISH assay, which includes probes selected to detect PB malignancy 
(1q21, 7p12, 8q24, 9p21), offers clinical utility in endoscopic PB brushings. Our 
findings suggest that incorporation of the PB FISH assay into the cytology testing 
algorithm may improve clinical sensitivity for the detection of PB malignancy without 
compromising specificity. Addition of KRAS testing may further augment sensitivity; 
however, at risk of lowering specificity.  
 
ST28. Highly Sensitive and Specific Multiplex Mutation Panel for 
Simultaneous Detection of 17 KRAS and BRAF Clinically Actionable Point 
Mutations in a Single Tube 
S. Li1, K.M. Divakar1, S. Voronov1, J. Shea1, S. Patil1, F. de Abreu2, G. Tsongalis3, L. 
Kong1, J. Riley1 
1PrimeraDx, Mansfield, MA; 2Dartmouth Hitchcock Medical Center, Lebanon, NH; 
3Geisel School of Medicine at Dartmouth, Hanover, NH. 
Introduction: KRAS and BRAF mutations are implicated in the oncogenic 
RAS/RAF/MEK/ERK pathway, resulting in NSCLC and colorectal cancers, and are 
considered as prognostic or predictive markers. Here, we report the development 
and verification of the ICEPlex KRAS/BRAF Mutation Panel, a multiplex PCR assay 
that can detect 13 of the most clinically important KRAS mutations along with four 
other BRAF mutations using nucleic acids extracted from FFPE samples, in a single 
reaction on the ICEPlex System. Methods: KRAS/BRAF mutation detection primers 
were designed using PrimeraDx’s ICEPrimer in silico design and analysis software. 
Reaction conditions were optimized using proprietary PCR chemistry on the ICEPlex 
system and assay performance was determined using mutation specific ultramer 
oligonucleotides, cell line DNA or characterized mock block FFPEs standards 
(Horizon Diagnostics). Besides analytical verification, the assay was also evaluated 
using 35 clinical lung cancer FFPE samples acquired commercially. Results: The 
single-reaction ICEPlex KRAS/BRAF Mutation Panel targets 17 clinically important 
mutations in the KRAS and BRAF genes. The kit includes two KRAS wild-type 
control mechanisms to determine mutation status and to assess sample DNA 
fragmentation. Size markers for assigning size specific PCR amplicons are 
incorporated within the assay. Analytical studies demonstrate the assay is sensitive 
(percentage mutation), selective (mutant to wild type ratio), and specific (relative to 
wild type genomic DNA background). The status of these 35 samples was confirmed 
by Sanger sequencing. Of the 35 commercially acquired clinical lung cancer 
samples, four KRAS mutations were detected. Of the remaining 31 valid sample 
results, no mutations were detected. One hundred percent agreement has been 
demonstrated between the single-reaction multiplex ICEPlex assay and Sanger 
sequencing results. Conclusions: The ICEPlex KRAS/BRAF Mutation Panel 
provides an accurate and sensitive method for detecting 17 point mutations in a 
single reaction. This automated, multiplexed, all-in-one-tube assay offers a cost 
effective and efficient approach in the clinical laboratory setting for detection of 
clinically actionable KRAS/BRAF mutations, and may help in initiating appropriate 
treatment regimen.  
*ICEPlex System and the Assay are for Research Use Only. Not for clinical 
diagnostic use. 
 
ST29. Development and Validation of a qPCR Gene Expression Panel Using 
Archived FFPE Ovarian Carcinoma Samples for Modeling Predictive Treatment 
in Serous Ovarian Carcinoma 
M. Le1, W.H. Bradley1, K. Eng2, C. Kendziorski2, J.S. Rader1, A. Mackinnon1 
1Medical College of Wisconsin, Milwaukee, WI; 2UWM, Madison, WI. 
Introduction: Using microarray data from The Cancer Genome Atlas (TCGA), we 
developed a statistical model predicting clinical response to various cytotoxic 909
9AMP Abstractschemotherapies in serous ovarian carcinoma based on the expression patterns of 
984 genes regulating 15 core pathways. Applying selection criteria reduced the 
number of genes to 91 and the number of pathways to 9 making this analysis 
amenable to most molecular pathology labs. We verified the applicability of these 
refined microarray signatures to gene expression defined by qPCR in paired snap 
frozen and formalin-fixed, paraffin-embedded (FFPE) serous ovarian carcinoma 
tissue samples. These results permit validation of our statistical model from FFPE 
archival tissue matched with clinical follow-up data. Methods: RNA was isolated 
from stage III and IV, grade 3 snap-frozen serous ovarian carcinoma tissue samples 
and matched FFPE archival samples from our institution. All specimens were 
reviewed pathologically for >70% viable tumor. TaqMan Array 96-Plus Fast Plates 
were custom made for gene expression analysis of 91 target genes and 3 
endogenous control genes (GAPDH, HPRT1, and GUSB), along with one 
manufacture control (18S). “Best Coverage” probes, a group of proprietary exon 
covering probe sets, were used to target the genes of interest. The amplification was 
performed on a 7500 Fast Real-Time PCR System. Results: Normalization of 
microarray gene expression and qPCR to 3 control genes demonstrated good 
correlation across different array platforms. When these outputs are plotted against 
each other matched for gene and patient, the correlation is 0.65. Correlation of gene 
expression from 28 fresh and paired FFPE samples showed that a patient’s matched 
samples more closely correlated with each other than with mismatched samples 
from another patient. Variation of gene expression between snap frozen, FFPE, and 
de novo FFPE (i.e., FFPE from portion of snap frozen) is minimal. Conclusions: We 
describe initial results to bring genome wide microarray-based gene expression 
analysis in serous ovarian carcinoma towards validation in a routine clinical 
molecular diagnostics lab. We demonstrate that we can closely correlate fold 
changes between TCGA microarray gene expression and the same patient samples 
measured by qPCR. Furthermore we show strong correlation between matched 
patient samples in both snap frozen and FFPE tissue preservation, which facilitates 
future large scale validation studies. We hope these efforts will establish a gene 
expression-based assay to predict response to chemotherapeutic agents based 
upon high-risk or protective expression indices of 9 pathways critical in serous 
ovarian carcinoma. 
 
ST30. Clinical Next-Generation Sequencing: Automation of Result 
Interpretation and Reporting Workflow 
S. Roy, M.B. Durso, A. Wald, Y.K. Ng, Y.E. Nikiforov, M.N. Nikiforova 
University of Pittsburgh Medical Center, Pittsburgh, PA. 
Introduction: Next-generation sequencing (NGS) technology is emerging as a 
useful and potentially cost-effective tool in the clinical laboratory. A wide repertoire of 
bioinformatics applications exists for NGS data analysis; however, certain 
requirements of a clinical molecular laboratory limit their use; i) comprehensive 
report generation, ii) compatibility with existing laboratory information systems (LIS) 
and computer operating system, iii) kKnowledgebase development, iv) quality 
management (QM), and v) data security. Methods: SeqReporter, a web application 
based on client-server model, was developed using ASP.NET framework v4.0. The 
client-side was scripted using HTML5, CSS3 and Javascript. The server-side 
processing (VB.NET) relied on interaction with a customized SQL server 2008 R2 
database. The database was comprised of a well-annotated in-house knowledge 
base and external variant databases (COSMIC, dbSNP, RefSeq, dbNSFP). 
Machine-learning algorithm implemented in SeqReporter facilitated enrichment of in-
house knowledgebase during routine signout based on pathologists’ decision of 
variant classification and annotation. Variant management and workflow 
documentation in the application’s database was designed to ensure compliance 
with CAP 2012 recommendations for NGS testing. Appropriate SSL/TLS network 
protocols were implemented for securing protected health information. Results: 
Overall, 104 tumors were sequenced on Ion Torrent PGM and primary analysis was 
performed by Torrent Suite v3.4.2. 1062 variant calls (VC) from 104 tumors were 
analyzed by SeqReporter. Each VC was classified into one of five report levels: i) 
known clinical significance, ii) uncertain clinical significance, iii) requiring 
pathologists’ review, iv) synonymous and deep intronic, and v) platform specific 
sequence errors. SeqReporter correctly annotated and classified 99.9% (859/860) of 
sequence variants, including 68.7% synonymous SNVs, 28.3% non-synonymous 
SNVs, 1.7% insertions, and 1.3% deletions. One variant of potential clinical 
significance was re-classified after pathologists’ review. Automatically-generated 
reports, subsequent to pathologists’ review, were compatible to our existing LIS. 
SeqReporter also facilitated QM activities by monitoring variant trend and test order 
history. Conclusions: SeqReporter is an example of a customized and well-
designed informatics solution to optimize and automate the downstream analysis of 
clinical NGS data. It significantly minimized human introduced errors in variant 
classification and report drafting, therefore implementing efficient laboratory workflow 10and improving patient care. We propose it as a model, which may envisage the 
development of a comprehensive clinical informatics solution. 
 
ST31. Comparison of Two Methods for MGMT Promoter Methylation Status 
Determination 
M. Cuaresma1, L. Mazur1, B. Baltadjieva1, M. Mihalov2 
1ACL Laboratories, Rosemont, IL; 2Lutheran General Hospital/ACL Laboratories, 
Park Ridge, IL. 
Introduction: MGMT (O(6)-methylguanine-DNA methyltransferase) is an enzyme 
involved in the repair of damage caused by a variety of DNA cross linking 
compounds, including alkylating agents. MGMT methylation results in the loss of 
DNA repair capability, consequently tumor cells are more responsive to alkylating 
agents. This relationship has been shown for glioblastomas and alkylating agents 
such as Temodar (temozolomide). Approximately 40% to 45% of glioblastoma 
multiforme (GBM) tumors exhibit MGMT gene methylation. MGMT methylation has 
also been shown to be a predictor of radiographic tumor pseudoprogression after 
treatment. A number of methods have been developed and described to detect and 
quantify DNA methylation, however, the most reproducible technique used today 
remains the bisulfite conversion method combined with quantitative assay. Methods: 
Eighty four (84) brain biopsy (FFPE) samples were evaluated for per cent of tumor, 
extracted using PinPoint protocol and bisulfite treated utilizing EZ DNA Methylation 
Gold kit from Zymo Research Corp. Additionally serial dilutions of 100% methylated 
standard and 20 normal brain tissues were tested to establish analytical sensitivity, 
analytic specificity, precision and reproducibility for both methods. The MGMT 
promoter methylation status was performed using two quantitative methods. First, a 
laboratory-developed test utilized the MethyLight, real-time qPCR, custom-designed 
primers/probes, QuantiFast kit (Qiagen). It is normalized to COL2A1 quantification 
assay and run on LightCycler 480. The amount of methylated DNA (PMR – 
percentage of methylated reference) was calculated by dividing MGMT/COL2A1 and 
multiplying by 100. Second, PCR amplification and pyrosequencing (PS) detection of 
four CpG sites used Qiagen CpG MGMT kit and PyroMark Q24 instrument with data 
utilizing Pyro Q-CpG software, generating a final result as the average of four CpG 
sites. Results: Valid results were generated for 39 methylated and 43 un-methylated 
samples. There were two discrepant results (sent out for additional analysis). Both 
assays tolerated variability in tumor content (90% to 30%). Analytical sensitivity and 
reproducibility were 100% for both PS and ML. (PS results ranged from 100% to 5% 
methylation, with CV 0.5% to -5%; ML, results ranged from 100-25% methylation, 
with CV 5% to -26%. LOD was: 10% (PS), 20% (ML). Conclusions: Our study 
demonstrates that Pyrosequencing is a highly sensitive and reproducible method for 
quantitation of MGMT promoter methylation in FFPE brain tumor samples. We 
selected Pyrosequencing for implementation because of its superior performance 
and lower level of complexity. MGMT methylation Pyrosequencing assay will be 
useful as a screening tool to identify patients who will benefit the most from 
treatment with alkylating agents.  
 
ST32. Targeted NGS Panel (ThyroSeq) for Diagnosis of Thyroid Cancer 
A. Wald1, S. Roy1, M. Durso1, Y. Ng1, M. Andersen2, Y. Nikiforov1, M.N. Nikiforova1 
1University of Pittsburgh Medical Center, Pittsburgh, PA; 2Life Technologies, 
Carlsbad, CA. 
Introduction: Next-generation sequencing (NGS) allows for massively parallel 
sequencing of the human genome and becomes a powerful tool for the detection of 
genetic alterations. We report a novel targeted NGS panel (ThyroSeq) for the 
detection of mutations in thyroid cancer and demonstrate its performance in a clinical 
setting. Methods: ThyroSeq NGS analysis was performed on DNA from 229 thyroid 
neoplastic and non-neoplastic samples including 104 frozen, 74 formalin-fixed 
paraffin-embedded (FFPE), and 51 fine needle aspiration (FNA) samples. A custom 
library was designed to target 12 cancer genes implicated in thyroid carcinogenesis, 
encompassing more than 130 mutation hot spots. Sequencing was performed on Ion 
Torrent PGM (Life Technologies) using Ion 318 chip. Results: Just 5 to10 ng of input 
DNA was sufficient for successful sequencing of 99.6% of thyroid tissue and FNA 
samples using ThyroSeq NGS panel. Multiplexing 25 to 30 barcoded samples per 
318 chip allowed to achieve the average read depth of 3,500x per mutation hot spot. 
The analytical accuracy for mutation detection was 100% with sensitivity cutoff of 3% 
to 5% of mutant alleles. ThyroSeq NGS assay identified mutations in 19/27 (70%) of 
papillary thyroid carcinomas (PTC), 25/30 (83%) of follicular variant PTC, 14/18 
(78%) of conventional and 8/18 (44%) of oncocytic follicular carcinomas, 3/10 (30%) 
of poorly differentiated carcinomas, 20/27 (74%) of anaplastic (ATC), and 11/15 
(73%) sporadic medullary carcinomas. Most detected mutations (n=113) were non-
synonymous single nucleotide substitutions and 5 were indel mutations in BRAF, 
PTEN, and TP53. Most tumors were positive for a single mutational event; however, 
several PTC and ATC demonstrated simultaneous presence of two to three genetic jmd.amjpathol.org ■ The Journal of Molecular Diagnostics
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high analytical accuracy and high sensitivity of mutation detection in variety of thyroid 
tissues and FNA samples. It allows sequencing of multiple genetic targets including 
rare mutation types in a cost efficient way and provides qualitative and quantitative 
assessment of mutations.  
 
ST33. Molecular Investigation of Epidermal Growth Factor Receptor Mutation 
in Indian Non-Squamous Cell Lung Carcinoma: Incidence and Distribution 
Pattern of Exon 18 to 21 Mutation 
B. Da1, S. Bhaumik, F. Ahmad, A. Mandasaurwala, H. Satam 
SRL Ltd, Mumbai, Maharashtra, India. 
Introduction: Carcinoma of lung is one of the leading causes of cancer associated 
deaths worldwide. With the recent progresses in molecular genomics, the 
tumorigenesis of lung cancer is understood better, and clinical management is 
benefited. One of the most extensively investigated oncogene in lung cancer is 
mutation in the EGFR gene because of its strong predictive nature for therapy 
response. In the current study we sought to investigate the frequency, distribution 
pattern of EGFR mutation in Indian NSCLC patients. Methods: Molecular screening 
of the exons 18, 19, 20, and 21 of the EGFR was done on 400 NSCLC patients 
using nested PCR followed by direct sequencing. Results: EGFR mutations were 
observed in 116 cases (29%) whereas remaining 71% cases showed normal wild 
type alleles. Correlation with demographic data showed that EGFR mutations were 
significantly more prevalent in females in comparison to males, and a trend towards 
higher mutation frequency was seen in 30 to 60 years age group indicating that 
these mutations are more prevalent in older age patients. In addition, the presence 
of EGFR mutations were significantly higher adenocarcinomas (31%), followed by 
large cell carcinomas (25%), adenosquamous carcinomas (21.4%), and squamous 
cell carcinomas (16.2%). Nucleotide sequencing analysis demonstrated that both the 
mutations in exon 18 were novel variations, wherein one case harboured in frame 
deletion resulting in G709_T710>A whereas the other case showed missense 
mutation (K713R). Among exon 19 positive cases, 49.3% (37/75) were typical in-
frame deletions, of which E746_A750del was frequent. Similarly, ~47% (35/75) 
cases showed complex mutation involving indels. In contrast to exon 19, most 
mutations in exon 20 were substitution type, whereas all exon 21 mutations were of 
the missense types with L858R as the most recurrent type. Conclusions: To the 
best of our knowledge, this is the largest study on EGFR mutation from India. The 
frequency of EGFR mutation is comparable to worldwide literature, whereas 
identification of novel mutation added new insights into the genetic makeup of lung 
cancer. More ongoing studies with clinical follow up will further strengthen the 
association of this mutation in the disease outcome from this part of the world.  
 
ST34. Novel Amplification-Based NGS Approach for Detection of 
Chromosomal Fusions in Thyroid Cancer 
A. Wald1, S. Zhong1, S. Roy1, L. Kelly1, J. Schageman2, B. Setterquist2, Y. Nikiforov1, 
M.N. Nikiforova1 
1University of Pittsburgh Medical Center, Pittsburgh, PA; 2Life Technologies, Austin, 
TX. 
Introduction: Chromosomal rearrangements, including intrachromosomal inversions 
and interchromosomal translocations, are common in thyroid cancer. Conventional 
approaches do not allow for the detection of all fusion types at once and next-
generation sequencing (NGS) approaches (i.e. whole genome and RNA-Seq) 
require ample amount of nucleic acids for sequencing and complex bioinformatics 
analysis. We developed a novel amplification-based NGS approach for simultaneous 
detection of all known fusion types in thyroid cancer and evaluated its performance 
in a variety of clinical specimens. Methods: A custom AmpliSeq RNA fusion panel to 
target all known chromosomal fusions in thyroid cancer including all types of 
RET/PTC, PPARg, NTRK, and BRAF was developed in conjunction with Life 
Technologies Development team. In addition to fusions, several universal 
housekeeping genes and thyroid-specific genes were included for quality control of 
RNA and additional diagnostic value. Analysis was performed using Ion 318 chip on 
Ion Torrent PGM (Life Technologies). A custom pipeline was developed for results 
interpretation and visual assessment of fusions in Integrated Genome Viewer (IGV). 
Results: A total of 40 thyroid RNA samples (18 previously positive for fusions via 
qRT-PCR or RNA-seq analysis and 22 negative) were studied by thyroid 
amplification based NGS fusion panel. Only 10ng total RNA was needed for custom 
AmpliSeq RNA library preparation and sequencing. It performed well with RNA from 
frozen tissue (n=24), FFPE tissue (n=12) and thyroid FNA samples (n=4). We were 
able to multiplex up to 10 samples per 318 chip with average number reads per 
sample of 171,714 (range: 61,819 to 394,044). Thyroid NGS fusion panel correctly 
identified all cases previously positive for rearrangement including common types of 
RET/PTC1 and RET/PTC3, PAX8/PPARȖ and also rare types of fusions, i.e. he Journal of Molecular Diagnostics ■ jmd.amjpathol.orgRET/PTC6, BRAF/AKAP9. A custom pipeline for visual and quantitative assessment 
of fusion in IGV allowed accurate detection and quantitation fusions and evaluation 
of breakpoints sites. Conclusions: This novel approach for the detection of 
chromosomal rearrangements in thyroid cancer allows for simultaneous detection of 
all known fusion types in a cost effective way with minimal requirement for RNA. It 
provides accurate detection of common and rare type of thyroid fusions from all 
types of thyroid specimens and can be potentially used in clinical setting.  
 
ST35. Overexpression of HER2 and Mutations of PI3KCA and KRAS in 
Chinese Gastric Carcinoma 
S. Lv1, W. Lv1, L. Liu2, M. Li1, X. Li1 
1The Second Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, China; 
2The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, China. 
Introduction: Gastric carcinoma is one of the most common malignancies 
worldwide, especially in China. Although gastrectomy with adjuvant chemotherapy is 
a mainstay treatment for the patients, it has failed to yield a satisfactory therapeutic 
effect due to little knowledge about gastric carcinogenesis.It has been shown that 
aberrantly activations of signaling transduction pathways play a critical role in the 
pathogenesis of various human cancers. Targeted drugs, such as small molecular 
tyrosine kinase inhibitors (TKIs) and monoclonal antibodies, have achieved 
encouraging results due to high specificity and low cytotoxicity. We reported that 
some patients with gastric carcinoma harbored the mutation in exon 21 of epidermal 
growth factor receptor (EGFR) and would benefit from EGFR-TKIs. Mutant KRAS is 
believed to be a resistance biomarker to EGFR-TKIs. Additionally, trastuzumab 
targeting epidermal growth factor receptor 2 (HER2) has recently been approved for 
the treatment of gastric carcinoma. Although some studies have reported that 
activating mutations of PIK3CA may induce tumor cells to resist trastuzumab, 
specific inhibitors targeting mutant PIK3CA such as LY294002 have been proved to 
have clinical utility. According to data reported, gastric carcinoma may be induced by 
various genetic alterations, which were potential targets for therapeutics. Therefore, 
we detected some molecular targets in Chinese gastric carcinoma, indicating patient 
sensitivity to drugs. Methods: A total of 51 fresh-frozen and 65 paraffin-embedded 
gastric carcinoma specimens resected from Chinese patients were detected for 
expression of HER2 protein by immunohistochemistry (IHC) and mutations of 
PIK3CA and KRAS genes by high resolution melting (HRM) analysis. Results: 
HER2 over-expression was detected in 8 cases (8/81, 9.9%). PIK3CA mutations 
were present in 6 cases (6/116, 5.2%), including 1 in exon 9 and 5 in exon 20. KRAS 
mutations in exon 2 were present in 7 cases (7/116, 6.0%). HER2 protein expression 
was not significantly correlated with KRAS and PIK3CA mutations. Moreover, there 
was also no significant relation between mutations of KRAS and that of PIK3CA. All 
of the changes were not related with mutations in exon 21 of EGFR reported by us. 
Conclusions: These results indicated not only HER2 overexpression but also 
PIK3CA and KRAS mutations were involved in gastric carcinogenesis and that it 
would be difficult to make standard targeted therapy for patients with gastric 
carcinoma. Therefore, various genetic alterations, which were targets for molecular 
drugs, should be detected simultaneously. 
 
ST36. Analysis of MGMT Promoter Methylation in Glioblastoma Using the 
MethyLight Assay 
F.B. De Abreu, T.M. Smith, C.E. Fadul, C. Rhodes, W.F. Hickey, G.J. Tsongalis, J.A. 
Lefferts 
Dartmouth-Hitchcock Medical Center, Lebanon, NH. 
Introduction: Glioblastoma (GBM) is the most common and aggressive primary 
brain tumor in adults and accounts for ~40% of all central nervous system 
malignancies. Recently the understanding of the genetic alterations in GBM has 
progressed, but the need for new molecular markers that predict therapeutic 
response and prognosis of this disease are needed. O-6-methylguanine-DNA 
methyltransferase (MGMT) has been associated with resistance to alkylating agent 
cancer therapy. Lower expression or silencing of the MGMT protein by promoter 
methylation has been reported to improve survival in patients with GBM. Due to the 
predictive role of the MGMT promoter status for patients with GBM, we validated an 
assay that detects the status of MGMT methylation. Methods: Genomic DNA was 
isolated from 17 glioblastoma formalin-fixed, paraffin-embedded (FFPE) tissues 
using Gentra PureGene Blood Kit Plus (Qiagen). Fifty nanograms of DNA, 
CpGenome Universal Unmethylated DNA control and CpGenome Universal 
Methylated DNA control (Chemicon International), were subjected to bisulfite 
treatment using the MethylEdge Bisulfite Conversion System (Promega, Madison, 
WI). MGMT methylation status was assessed using MethyLight, a quantitative 
methylation assay that utilizes fluorescence-based real-time PCR (TaqMan) 
technology. Real-time PCR was performed using primers and TaqMan probes for the 
methylated MGMT gene and for the ȕ-actin gene (ACTB), which was used as 911
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methylated control DNA to obtain the relative amounts of methylated MGMT and 
ACTB amplicons in each sample. To evaluate the relative methylation level, we 
calculated the percentage of methylated reference (PMR) by dividing the MGMT 
sample/methylated control ratio by the ACTB sample/methylated control. A PMR cut-
off of 4 was previously validated. Samples showing PMR less than 4 were defined as 
unmethylated and samples with PMR equal or greater than 4 were defined as 
methylated. Results were compared to previous testing performed by a reference 
laboratory. Results: The standard curve showed primer efficiency of 94% for MGMT 
and 93% for ACTB. We identified seven methylated samples (PMR4) and nine 
unmethylated (PMR=0). Only one sample did not amplify for either MGMT or ACTB. 
For those samples that amplified this assay demonstrated 100% accuracy. 
Conclusions: MethyLight is a highly quantitative and accurate procedure. Since 
MGMT promoter methylation is an indicator of better prognosis for patients with 
GBM, the screening for the presence of a methylated MGMT promoter should be 
included in the routine workup of these patients. 
 
ST37. The Genetics of Glioblastoma: Towards Translation into Routine 
Diagnostic Pathology 
T. Tabone1, A. Nowak1, K. McDonald2, W. Erber1 
1University of Western Australia, Nedlands, Western Australia; 2Lowy Cancer 
Research Centre, University of NSW, Sydney, Australia. 
Introduction: Glioblastoma (GBM, grade IV glioma) is an aggressive and one of the 
most common forms of primary brain tumour. Treatment consists of surgery followed 
by temozolomide-based chemoradiotherapy and subsequent chemotherapy. 
Although it is known that there are substantial differences between tumours in 
different individuals, currently the same treatment regime is used for all patients. 
Despite improvements in therapy, tumour relapse is inevitable. About 30% to 40% of 
patients progress immediately during treatment, whereas the remaining 60% to 70% 
have initial treatment success before subsequently develop resistance to 
temozolomide. The mechanisms of this acquired temozolomide resistance are 
unclear. Our research efforts are focusing on identifying differing responses to 
therapy, and specifically genetic alterations that characterise treatment resistance in 
the de novo and acquired settings. The overall aim of this study was therefore to 
investigate the genomic landscape of GBM at diagnosis and compare this with 
recurrent disease to identify mutations that may predict temozolomide resistance. 
Methods: In this study we have investigated two cohorts of consented GBM 
patients: patients with primary refractory disease (Cohort 1; n=32 patient specimens) 
and  patients who had initial treatment success and subsequent recurrence and in 
whom paired pathology specimens were available (Cohort 2; n=64 specimens from 
32 patients). DNA was extracted from the 96 formalin-fixed paraffin embedded 
biopsy specimens (obtained from the Australian Genomics and Clinical Outcomes of 
Glioma biobank, AGOG). Next-generation sequencing was performed using the Ion 
Personal Genome Machine (PGM) Sequencer (Life Technologies) to individually 
profile 50 key oncogenes and tumour suppressor genes (AmpliSeq Cancer HotSpot 
Panel V2). Sequencing profiles in specimens from primary refractory disease (Cohort 
1) and acquired resistance (Cohort 2) were compared. Furthermore, comparison of 
sequencing profiles in matched samples from patients with acquired resistance was 
performed to identify genomic changes that may have occurred during, or as a result 
of, the combined temozolomide-based chemoradiotherapy. Data analysis was 
performed using Ion Reporter and ANNOVAR (Biobase) software. Results: Using 
the AmpliSeq Cancer HotSpot Panel we identified mutations in genes previously 
implicated in GBM (including TP53, RB1, PTEN, PIKCA3). Of particular interest, and 
currently undergoing further molecular investigation and follow-up, are mutations 
identified in PTPN11, KIT, PDGFRA, and EGFR. We are currently undertaking 
clinico-pathological correlation for primary therapeutic response, disease recurrence 
and temozolomide resistance. Conclusions: Understanding the genomic 
characteristics of acquired resistance may allow for rational combination therapies 
and better selection of patient-specific treatment regimens. 
 
ST38. Array Based Identification and Validation of an Optimal FISH Reference 
Probe (“D17S122”) for Resolution of HER2 Amplification Status in Breast 
Carcinomas with Putative Chromosome 17 Aneusomy  
B.P. Portier, Z. Wang, E. Mincae, C. Lanigan, E. Downs-Kelly, G.T. Budd, R.R. 
Tubbs 
Cleveland Clinic, Cleveland, Ohio, OH. 
Introduction: The Affymetrix OncoScan array offers high-quality copy number and 
genotype data with whole-genome coverage and high resolution for cancer genes. 
This assay is especially designed for use with formalin-fixed, paraffin-embedded 
(FFPE) tissue due to its design using small molecular inversion probes. We 
performed this genomic array using cases with apparent chromosome 17 aneusomy 2identified by HER2/CEP17 dual probe FISH assay. We hypothesized that performing 
a genomic screen in cases with aneusomy would reveal a highly conserved region of 
chromosome 17 and potentially lead to generation of a FISH reference probe that 
would resolve HER2 amplification status in cases with putative aneusomy. Methods: 
DNA was extracted from FFPE tissue (Qiagen, Valencia, CA) from invasive breast 
carcinomas following macrodisection. Samples utilized in this study segregated into 
three groups: 1) aneusomic 2) monosomic, and 3) eusomic cases as determined by 
FISH utilizing a centromere 17 probe (PathVysion; Abbott Molecular). Affymetrix 
OncoScan array was performed on all cases (Affymetrix, Santa Clara, CA). Analysis 
of array data was performed using Nexus software v6. Results: Detection of HER2 
amplification by OncoScan showed 100% concordance with single probe (HER2) 
FISH results. Only 1 case showed true polysomy of chromosome 17. The remaining 
aneusomic cases (identified by FISH centromere 17 copy number) showed great 
variability in regions of chromosome 17 with aneusomy. Analysis of chromosome 17 
aneusomic distribution in all cases, revealed one highly conserved region that was 
eusomic in 82% of cases. This non-aneusomic region, D17S122, was located on the 
p-arm and spanned 0.57 Mbs. Genes located in this region included PMP22, TEKT3, 
CDRT4, FAM18B2, and FAM18B. A series of BACs that spanned this genomic 
region were fluorescently labeled and FISH showed resolution of HER2 status by 
HER2/D17S122 ratio calculation following ASCO/CAP dual probe FISH scoring 
guidelines. Conclusions: Although OncoScan HER2 results strongly correlated with 
FISH HER2 scores, centromere amplification status could not be determined. This is 
due to the highly repetitive alpha-centromeric repeat DNA located in the centromere 
region. In evaluating copy number changes by OncoScan, one highly conserved 
region of chromosome 17 located on the p-arm “D17S122” was identified. Utilization 
of this D17S122 probe in place of centromere 17 allowed resolution of cases that 
were unresolved by standard HER2/CEP17 dual FISH testing. Therefore, use of 
OncoScan genomic data has revealed a highly conserved region of chromosome 17, 
which has clinical utility in resolving HER2 amplification in cases identified as 
anuesomic by standard FISH testing. 
 
ST39. Human Epidermal Growth Factor Receptor 2 (HER2) Testing in Breast 
Carcinoma: Comparison of Automated Immunohistochemistry and 
Fluorescence in Situ Hybridization Techniques 
S. Desai, T. Pai, A. Patil, T. Shet 
Tata Memorial Centre, Mumbai, Maharashtra, India. 
Introduction: Amplification of HER2 gene in breast cancer is associated with poor 
prognosis. The advent of targeted therapy and clinical effects of anti-HER2 treatment 
have put HER2 at a center of attention and investigation as it is of utmost importance 
to accurately identify patients who would benefit from this treatment modality. With 
this background, the present study was aimed at assessing the concordance of 
automated immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) 
in Indian breast cancer patients. Methods: HER2 testing using automated IHC and 
dual colored FISH was performed on 157 invasive breast carcinoma cases 
accessioned from May 2012 till May 2013 in the divisions of Surgical Pathology and 
Molecular Pathology of Tata Memorial Centre, Mumbai, India. Both in-house and 
referral cases were included in the analysis. All cases were evaluated for estrogen 
and progesterone receptors (ER, rabbit monoclonal antibody, 1:150 dilution, 
Diagnostic Biosystems, Netherlands; PR, rabbit monoclonal antibody, 1:75 dilution, 
Biocare Medical, CA) and c-erbB-2 protein expression by IHC (c-erbB-2/HER2 rabbit 
monoclonal antibody, 1:400 dilution, Biocare Medical, CA) stained by Benchmark 
XT, Ventana autostainer. HER2 gene amplification by FISH was performed using the 
PathVysion test (Abbott Molecular Inc., Des Plaines, IL) HER2 DNA Probe Kit. 
Automated IHC and FISH results were compared. Results: A total of 157 cases 
were initially evaluated by automated IHC, followed by FISH test. The study group 
comprised of 147 primary tumours and 10 metastatic tumors. In-house cases were 
90 (57.3%) and referral cases were 67 (42.6%). Of 157 cases, 43 cases (27.4%) 
showed HER2 gene amplification and 114 cases (72.6%) were non-amplified. Higher 
histological grade and non reactivity to hormone receptors had statistically significant 
association with HER2 amplification. On IHC, 107 cases were score 2+ (equivocal), 
33 cases were score 3+ (positive) and 17 cases were score 0 or 1+ (negative). 
Ninety-one percent (30/33) of IHC score 3+ cases were amplified and 94.1% (16/17 
cases) IHC-negative (score 0 and 1+) cases were non-amplified. Tweleve of 107 
cases (11.2%) with equivocal results were amplified. Conclusions: Automated IHC 
and FISH showed good concordance for Score 3+ and negative cases on IHC. A 
majority of IHC equivocal cases (88.7%) were nonamplified on FISH. A “2-tier” 
testing for the HER2 status--IHC as the screening test and FISH as the confirmatory 
test--should be adopted for HER2 testing. 
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Mutations in Heterogeneous Cell Populations (Solid Tumors) 
D. Luevano, R. Hodkinson, T. Vinayagamoorthy 
MultiGEn Diagnostics Inc, San Diego, CA. 
Introduction: We have developed a new molecular platform technology, allele-
specific multiplex sequencing (ASMS), for the detection of somatic mutations in 
heterogeneous cell populations (e.g. tumor biopsies). Methods: ASMS is a novel 
modification of Sanger sequencing technology that clearly separates the nucleotide 
sequence generated by the mutant tumor cell population from that of wild type on the 
same electropherogram. The region encompassing the mutations was amplified 
using specific primers (MultiGEN Diagnostics Inc). The amplicons were purified using 
Ampure (Beckman Agencourt, USA). Purified amplicons were sequenced using 
allele-specific sequencing primers (MultiGEN Diagnostics Inc, USA) and ABI PRISM 
Big Dye Terminator Cycle Sequencing Ready Reaction Kit version 1.1 (Life 
Technologies, USA). Unincorporated dye terminators were removed using Clean 
Seq (Beckman Agencourt USA). The samples were then dried in a speed vac (DNA 
120; ThermoSavant, USA) and re-suspended in 20 L of Hi-Di foramide. Samples 
were analyzed by capillary electrophoresis using the ABI PRISM Genetic Analyzer 
3130. Application of ASMS was tested detecting Braf (V600E), and EGFR (L858M) 
mutations from clinical samples. Results: Analytical validation of ASMS technology 
was determined using wild type and mutant Factor V Leiden achieving a lower limit 
of detection (LLOD) of 6pg of human genomic DNA, and a simultaneous detection of 
mutant and wild type in a ratio of mutant:wild type = 1:100,000. Similarly, segments 
of the gDNA that encompasses BRAF V600E, and EGFR ( L858M) were amplified 
separately. The amplicons generated were sequenced using mutant allele-specific 
sequencing primer and the corresponding wild type for BRAF (V600E) and EGFR 
(L858M). Each of these assays generated mutation-specific nucleotide sequence 
starting with very first nucleotide next to mutation site: BRAF V600E-CTGTAG; and 
EGFR L858M –TGGCCA Conclusions: In consequence, ASMS, when compared 
with existing methods, eliminates the need for the commonly needed initial tumor cell 
enrichment. ASMS not only significantly reduces the overall cost of testing, but also 
detects mutations in low frequency clonal variants, offers a substantial improvement 
in sensitivity and specificity, and overcomes the limitation of the very small sample 
volumes found with fine needle aspiration biopsies. The operational advantages of 
ASMS over status quo methods for the detection of tumor specific mutations 
translate into more cost-effective tests for the choice of predictably effective 
chemotherapy. In summary, we conclude that ASMS is a new platform technology 
that has the unique ability to detect mutational changes from samples carrying 
heterogeneous gDNA at higher sensitivity and specificity than existing methods. 
 
ST41. Distribution of cMET by IHC, FISH, and Next-Generation Sequencing in 
Cancer: A Large Cohort Analysis 
D. Arguello, R.A. Feldman, J. Xiu, S. Millis, R. Bender, Z. Gatalica, G. Basu, L. Paul 
Caris Life Sciences, Phoenix, AZ. 
Introduction: cMET overexpression and/or activation have been implicated in 
signaling pathways that promote cell proliferation, invasion, and survival. It has been 
identified as an oncogenic driver in various malignancies and is currently being 
investigated as a potential therapeutic target. The aim of this study is to provide 
insights into the distribution of cMET expression by immunohistochemistry (IHC), 
cMET amplification by FISH, and cMET mutation by next-generation sequencing 
(NGS) across a variety of tumor types. Also, we evaluate the correlation of cMET 
across technology platforms tested in a CLIA-certified oncology reference laboratory. 
Methods: In a cohort of 9161 patient samples, cMET protein expression was 
assayed by IHC (NCL-cMET and SP44, 9161 samples), FISH (BAC clone, 7435 
samples) and NGS (Illumina Truseq Amplicon – Cancer Panel, 3163 samples). 
Results: Our analysis has shown the highest cMET expression rates in the following 
tumor types: pancreatic cancer (56%, 231/411), cholangiocarcinoma (51%, 63/123), 
and colorectal cancer (46%, 389/843). The lowest expression rates of cMET by IHC 
included non-epithelial ovarian cancer (6%, 5/84), glioblastoma (6%, 11/198), and 
neuroendocrine tumors (6%, 18/296). A preliminary analysis of cMET by FISH 
identified the highest levels amplification in peritoneal/retroperitoneal sarcomas (9%, 
2/23), non-small cell lung cancers (7%, 65/983), and melanoma (7%, 12/165). In 
3163 samples tested by NGS platform, only 9 mutations were identified – all were 
variants of unknown significance and five were detected in non-small cell lung 
cancer specimens. The corresponding exon and protein changes in these five 
samples were as follows: D1028H (exon 14) in three samples; G391A (exon 2) and 
S203T (exon 2) in one sample each. The other four had the following mutations: 
S203T (exon 2) and G391E (exon 2) in melanoma; S203T (exon 2) in colorectal 
cancer; and K1121N (exon 16) in female genital tract malignancy. Preliminary 
concordance was poor, as demonstrated by the percent agreement between IHC 
and FISH in the following lineages: colorectal cancer (64.5%), cholangiocarcinoma he Journal of Molecular Diagnostics ■ jmd.amjpathol.org(52.8%), and pancreatic cancer (50.8%). Of those specimens with mutated cMET, 
five of nine were positive by IHC and none by FISH. Conclusions: Our data suggest 
that cMET overexpression and/or activation is prevalent in various malignancies. 
Ongoing clinical trials targeting cMET suggest that efforts should be made to 
accurately interrogate tumors for cMET testing. As shown by our preliminary 
concordance results, full cMET analysis is enhanced utilizing multiple technologies.  
 
ST42. Validation of the Ampliseq Cancer Hotspot Mutation Panel Using the 
Ion Torrent PGM 
J.D. Peterson1, C.D. Tunkey1, L.D. Strausbaugh2, J.L. Gonzalez1, V.A. Memoli1, A.R. 
Schned1, J.B. Brennick1, W.A. Wells2, C.I. Amos1, G.J. Tsongalis1 
1Dartmouth Hitchcock Medical Center, Lebanon, NH; 2University of Connecticut, 
Storrs, CT. 
Introduction: The surge in targeted therapies aimed at improving management of 
cancer patients has resulted in the need for more in-depth genotyping analyses. 
Whereas many clinical molecular diagnostic labs routinely perform single exon or 
single gene testing using PCR-based methods, the need for more information has 
outpaced this type of analysis. Mutation spectra for multiple genes in various tumor 
types are needed so that clinically actionable mutations can be used by the 
oncologist in designing appropriate treatment strategies. In this study, we evaluated 
performance of the Ion Torrent AmpliSeq Cancer Hotspot Panelv2. Methods: DNA 
from several well-characterized cell lines (HCT-116, RKO, MCF10A, SW48, SK-
MEL-28) were used as known positive controls. Engineered cell lines that were fixed 
and embedded in paraffin were used to mimic the formalin-fixed, paraffin-embedded 
(FFPE) process. Accuracy, precision, limit of detection, and specificity were 
evaluated in this study. Six previously tested, known mutation positive, FFPE tissues 
(2 BRAF, 2 KRAS, 2 EGFR mutants) were used to assess accuracy and precision. 
Normal kidney and colon FFPE tissues were used as controls. 10ng of starting 
material from each sample was used to prepare 8 barcoded libraries. The libraries 
were multiplexed and run through on 3 separate OneTouch reactions and then 
processed on 3 separate 316 chips over a period of two weeks. The data analysis 
pipeline included a first pass through the Variant Caller Plugin (3.4.51874) using the 
standard settings. Variant annotation and predicted significance of variants was 
performed with the Golden Helix SVS software (version 7.7.2). Remaining variants 
were assessed in the Broad’s Integrated Genome Viewer (IGV 2.2). Read depths 
across all positions and all libraries were assessed using SpotFire. Results: In our 
accuracy studies, there was 100% concordance between previous PCR results and 
the corresponding variants identified in each of the mutant FFPE samples using the 
Ion Torrent panel. Precision studies gave consistent results when libraries were 
prepared from the same original DNA and when libraries were run on multiple 316 
chips. The limit of detection was determined to be 5% for SNV’s and 20% for 
INDELS based on results of FFPE embedded cell line mixing experiments. 
Conclusions: We have evaluated the performance of the AmpliSeq Cancer Panel 
Hotspotv2 using previously characterized patient samples and cell line controls. 
Standard performance measures indicated that using the Ion Torrent PGM next-
generation sequencing platform and the AmpliSeq Cancer Panel Hotspotv2 is 
suitable for clinical practice.   
 
ST43. Microarray Analysis of Osteosarcoma and Quantification of Post-
Therapy Tumor Necrosis Identify Loss of P16 Expression and 18q23 Deletions 
as Key Negative Prognostic Indicators 
R.A. Schultz1, D. Borys2, R. Canter2, J. Gregg2, B. Hoch3, A. Horvai4, L.D. McDaniel1, 
V. Cawich1, S. Sulpizio1 
1Signature Genomics/ Perkin Elmer, Inc., Spokane, WA; 2University of California 
Davis, Davis, CA; 3University of Washingtion, Seattle, WA; 4University of California 
San Francisco, San Francisco, CA. 
Introduction: Osteosarcoma (OS) represents approximately 2.4% of childhood 
cancers and 56% of malignant bone tumors in children. Routine use of multi-agent 
chemotherapy has increased the 5-year survival (55-80%). Molecular and 
immunohistochemical (IHC) findings have been identified as potential prognostic 
markers for OS including negative IHC expression of p16 (p16-)(CDKN2A), RB1 and 
TP53 gene deletions, 18q23 deletion, and RUNX2 amplification. In the current study 
we used microarray analysis, IHC for p16 and tumor necrosis studies to determine 
which factors correlated with poorest chemotherapy response. Methods: Genomic 
DNA was extracted from FFPE OS specimens obtained prior to initiation of 
chemotherapy. Microarray analysis was performed using a Roche NimbleGen array 
[OncoChip(v2)] with oligonucleotide coverage to >2400 cancer features and 
backbone SNP coverage. p16 expression was determined by IHC staining and 
pathologic tumor response to chemotherapy was judged as tumor necrosis. Results: 
Microarray results were obtained on 46/59 DNAs extracted from OS FFPE samples. 
Results were complex characterized by a high level of chromosomal instability. Data 913
9AMP Abstractson both p16 expression and pathologic tumor response to chemotherapy were 
available on 25/46 samples. Summarizing, deletion of RB1 (72%), gain of RUNX2 
(68%), deletion of TP53 (52%), deletion 18q23 (44%) and p16- by IHC (28%) were 
common findings. Most abnormalities, particularly RB1 and TP53 deletion and 
RUNX2 gain, were ubiquitous and failed to correlate with chemotherapy response. 
Ten specimens exhibited a failed pathologic tumor response to chemotherapy as 
judged by <90% tumor necrosis (range 80% to 0%). p16- status correlated most 
strongly with failed chemotherapy response (6/10), whereas only 1/15 cases with a 
good response was p16- (P=0.0068). Importantly, for cases exhibiting poorest 
chemotherapy response (<25% necrosis), p16- status and deletion (or LOH) for 
18q23 were the most common of these alterations (4/5 and 5/5, respectively). 
Conclusions: Microarray identified complex genotypes in the OS samples including 
the frequent occurrence of previously identified biomarkers such as deletion RB1, 
deletion TP53, deletion 18q23 and gain of RUNX2. Comparison of genomic findings 
to p16- status and chemotherapy response revealed p16- status to be the best 
overall indicator of a poor chemotherapy response, with the poorest responders 
being both p16- and deleted for 18q23. The latter is the location for a mapped 
interval associated with Paget disease of bone, a disorder with approximately 1% of 
patients developing osteosarcoma. Additional studies are warranted to validate these 
findings and identify the specific gene(s) mapping to 18q23 that appear to 
exacerbate the poor outcome associated with p16- status. 
 
ST44. Screening for Lynch Syndrome: Expression of Annexin A10 Can 
Discriminate between Sporadic and Lynch-Associated Microsatellite-High 
Colorectal Carcinoma 
B.L. Shadrach1, B. Leach1, P. Carver1, K. Lai1, D. Hernandez Gonzalo1, J.M. 
Church1, J. Moline1, M. Kalady1, C. Burke1, R. Pai2, R. Pai1 
1Cleveland Clinic, Cleveland, OH; 2University of Pittsburgh Medical Center, 
Pittsburgh, PA. 
Introduction: Differentiating sporadic microsatellite high (MSI-H) colorectal 
carcinoma (CRC) due to hMLH1 promoter methylation from Lynch syndrome (LS)-
associated MSI-H CRC due to mutations in mismatch repair proteins is time 
consuming, cost intensive, and requires advanced laboratory testing. A mutation in 
BRAF has been shown to be highly specific for sporadic CRCs; however, ~30% to 
50% of sporadic MSI-H CRCs are BRAF wild-type. Analysis of hMLH1 promoter 
methylation can subsequently be used to differentiate LS and sporadic MSI-H CRC, 
but both tests require specialized labs and are expensive. Through previous gene 
expression profiling of sessile serrated polyps we identified ANXA10 as a protein 
highly expressed in these polyps. As sessile serrated polyps give rise to sporadic 
MSH-H CRC, we evaluated the ability of ANXA10 expression to discriminate 
between LS and sporadic MSI-H CRC. Methods: Sporadic MSI-H CRCs were 
determined by BRAF mutational analysis (allele specific PCR) and hMLH1 promoter 
methylation in BRAF wild-type cases (quantitative methylation specific PCR). 
Expression of ANXA10 mRNA was evaluated in sporadic MSI-H and LS CRC by 
quantitative RT-PCR. Immunohistochemical (IHC) expression of ANXA10 (1:250, 
Novus biologicals) was evaluated in 72 sporadic MSI-H CRC (53 BRAF mutated, 19 
BRAF wild type with hMLH1 promoter hypermethylation) and 52 LS CRCs from 49 
patients (30 definite LS and 19 presumed LS). Any nuclear or strong membranous 
expression in the CRC was considered positive. Results: A marked increase in 
ANXA10 mRNA was observed in sporadic MSI-H CRC compared to LS CRC (378 
fold increase, p<0.001). Using IHC, ANXA10 was expressed in 27/52 (51%) BRAF-
mutated sporadic CRC and 8/19 (42%) BRAF wild type/hMLH1 methylated sporadic 
CRC. Only 3/52 (6%) LS CRC were positive for ANXA10 (p<0.0001). One patient 
had a deleterious mutation in MSH2 and another had a variant of uncertain 
significance in MSH6. Only 1/24 (4%) LS CRC with loss of hMLH1 expressed 
ANXA10. This patient did not have a deleterious hMLH1 mutation, but rather 
germline promoter hypermethylation of hMLH1. Conclusions: Expression of 
ANXA10 shows promise in helping screen for LS CRC. Although 3 LS patients 
expressed ANXA10, 2 had abnormalities in MSH2/MSH6 and can easily be 
distinguished from sporadic MSI-H CRC using IHC for MSH6 and MSH2. 
Importantly, no patient with a deleterious hMLH1 mutation expressed ANXA10. 
Based on these results, IHC for ANXA10 may be a useful marker to distinguish 
sporadic from LS MSI-H CRC.  
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 ST45. FISH Validation for Identification of JAZF1, PHF1, and YWHAE 
Rearrangements in Endometrial Stromal Tumors and Discovery of an Unusual 
PHF1-Positive Case 
P.P. Bedroske, W.R. Sukov, K.E. Pearce, J.C. Hodge 
Mayo Clinic, Rochester, MN. 
Introduction: Endometrial stromal sarcoma (ESS) is a rare uterine malignancy with 
the potential for delayed aggressive behavior. ESS can be a diagnostic challenge 
due to an often long latency (20 years or greater) between diagnosis and 
development of metastases as well as variable pathologic and genetic features that 
can overlap with other mesenchymal neoplasms of the uterus including endometrial 
stromal nodules (ESN) and undifferentiated endometrial sarcoma (UES). 
Rearrangements of JAZF1 at 7p15 and PHF1 at 6p21 either fused together or with 
other partner genes are common in classic ESS and ESN but rare in UES. Recently, 
YWHAE at 17p13.3 was found to be rearranged in high-grade ESS associated with a 
poorer clinical course and is mutually exclusive from JAZF1 disruption. Therefore, to 
aid in the diagnosis and prognosis of endometrial stromal tumors (EST), FISH for 
JAZF1 rearrangement was expanded to a panel that also includes PHF1 and 
YWHAE. In addition, a single case was recently published describing PHF1 fusion to 
MEAF6 that prompted the development of a research FISH probe for MEAF6. 
Methods: Lab developed break-apart FISH probe sets were constructed using 
bacterial artificial chromosome (BAC) clones covering the 5’ and 3’ regions adjacent 
to the genes of interest (labeled in SpectrumGreen and SpectrumOrange, 
respectively). Each probe set was evaluated in a blinded manner by two 
technologists who scored 50 interphase nuclei (100 total). Nineteen paraffin-
embedded tissue samples of primary or metastatic tumors from patients suspected 
or diagnosed with ESN, ESS, or UES that were JAZF1-rearrangement negative as 
well as 6 that were JAZF1 rearrangement positive, 35 non-EST, and 26 normal 
endometrium/myometrium controls were tested. The specimens were processed and 
scored using standard FISH procedures. Results: YWHAE rearrangement was 
detected in 1 of 7 (14%) ESS and 1 of 7 (14%) UES. Rearrangement of PHF1 was 
identified in 1 of 7 (14%) ESS and in 1 of the 6 (17%) known JAZF1-rearranged 
cases. The 26 control specimens were normal for each probe set and used to 
establish reporting criteria. Interestingly, the PHF1 positive primary ESS tumor that 
was JAZF1 and YWHAE negative was also negative for MEAF6 rearrangement. 
Conclusions: A lab developed FISH panel detects JAZF1, PHF1, and YWHAE 
rearrangements to aid in the diagnosis and prognosis of EST. The finding of a PHF1 
positive tumor that was negative for rearrangement with JAZF1, YWHAE, or MEAF6 
suggests that the genetic heterogeneity of these tumors is continuing to expand. 
 
ST46. Optimization of Fully Automated Bright Field Dual ISH for Detection of 
NSCLC ALK Rearrangements in ThinPrep Cytopathology Specimens 
C. Lanigan, K. Wang, S. Sanda, J. Reynolds, R.R. Tubbs, Z. Wang 
Cleveland Clinic Foundation, Cleveland, OH. 
Introduction: The anaplastic lymphoma kinase (ALK) gene is involved in many 
chromosomal rearrangements producing a variety of fusion oncoproteins. One 
inversion, producing EML4/ALK, is implicated in the oncogenesis of ~5% of non 
small cell lung carcinoma (NSCLC). Most of the fusion breakpoints are located near 
exon 20, allowing the use of 3’ and 5’ break-apart probes for dual color, bright field 
detection. Current ALK testing methods include labor-intensive FISH and RT-PCR or 
IHC, which cannot distinguish between amplification, aneusomy, or rearrangement. 
Using a break-apart probe format with an automated staining platform, we 
determined conditions necessary for ALK gene status in liquid based ThinPrep slides 
from NSCLC. Methods: Controls were prepared with equal numbers of SU-DHL-1 
and HL-60 cells suspended in PreservCyt Solution (Hologic Inc.) and mounted onto 
ThinPrep slides. Slides emerging from the ThinPrep processor were placed in 95% 
dehydrant (Themo Scientific) overnight, and then air-dried before staining. Dual color 
/ dual hapten bright field in situ hybridization (DISH) was performed using a 
VENTANA Benchmark XT automated stainer with XT Dual Color Open Probe 
Software (Ventana Medical Systems, Inc.). The break-apart probes cocktail 
(40L/ml) used 5’ALK-DNP and 3’ALK-DIG, and were detected using ultraView 
Silver and Red detection respectively. The staining protocol selected cell 
conditioning (CC2) for 8 minutes at 80°C. Denaturing was 12 minutes at 82°C. The 
conditions for both silver anti-DNP antibody and silver chromogen C were 20 and 8 
minutes, respectively. Red mouse anti-DIG antibody and fast red chromogen 
required 24 and 12 minutes, respectively. Hematoxylin II and bluing reagent required 
8 and 4 minutes. Results: We identified a narrow range of denaturing temperatures 
necessary for consistent signal generation. Denaturing succeeded only between 
79°C and 85°C, so 82°C was chosen as the optimum condition. CC2 temperatures 
were also examined and were found to generate signals between 67 and 94°C. 
Three NSCLC clinical cases were identified by FISH; one having the EML4/ALK 
rearrangement and two with no detected rearrangement. Using the pre-treatment jmd.amjpathol.org ■ The Journal of Molecular Diagnostics
 AMP Abstractsand optimized staining protocol as previously described, each ALK-negative case 
resulted as either amplified at 2p23 or aneusomic for chromosome 3, and ultimately 
all 3 cases matched the established genotype. Conclusions: Fully automated bright 
field detection of NSCLC ALK gene status can be achieved under specific conditions 
in ThinPrep cytology specimens. 
 
ST47. Evaluation of MDM2 Amplification in Cases with Adipocytic Tumors 
Using Chromogenic in Situ Hybridization (CISH) Technique 
S.K. Mardekian, C.C. Solomides, J.Z. Gong, S.C. Peiper, Z. Wang, R. Bajaj 
Thomas Jefferson University, Philadelphia, PA. 
Introduction: Atypical lipomatous tumor/well-differentiated liposarcoma (ALT-
WDLPS) and dedifferentiated liposarcoma (DDLPS) are often difficult to distinguish 
morphologically from benign adipocytic tumors and other high-grade sarcomas, 
respectively. ALT-WDLPS and DDLPS share the same basic cytogenetic 
abnormality characterized by a 12q13-15 amplification involving the MDM2 
oncogene. In contrast, none of the various benign tumors of adipocytes has an 
amplification of this locus. Therefore, fluorescence  in situ hybridization (FISH) is 
used frequently to detect the MDM2 amplification and aid with the diagnosis of these 
entities. Recently, bright-field in situ hybridization techniques such as chromogenic in 
situ hybridization (CISH) and silver-enhanced in situ hybridization (SISH), which 
combine features of immunohistochemical analysis and FISH, have been introduced 
for the determination of MDM2 amplification status. These new techniques use a 
peroxidase enzyme-labeled probe with chromogenic detection, instead of a 
fluorescent-labeled probe, allowing results to be visualized by standard bright-field 
microscopy. Methods: The present study compared the results of the FISH and 
CISH methodologies for detecting MDM2 amplification in cases with adipocytic 
tumors with an established histopathologic diagnosis. A total of 44 cases (Benign 
n=15, Borderline/malignant n=29) were tested with FISH and CISH. For each case, 
50 cells were examined for the presence of red (chromosome 12 copies) and black 
(MDM2 copies) signals using dual color MDM2 and CEN12 CISH probes (Ventana 
Medical Systems, Inc). The overall ratio of black to red signals was calculated, and a 
ratio of 2 or greater was considered to be amplified. Results: Eleven of the cases 
showed amplification with both FISH and CISH, and 24 cases showed no 
amplification. CISH technique was found to be equally effective as FISH for testing 
adipocytic tumors. Conclusions: CISH is advantageous for allowing pathologists to 
evaluate the histologic and molecular alteration occurring simultaneously in a 
specimen. Moreover, CISH is found to be more cost effective when used with 
automation, and the signals do not quench over time. This establishes clinical utility 
of CISH testing for MDM2 to establish diagnosis of adipocytic tumors. 
 
ST48. Optimization of the Illumina TruSeq Amplicon Cancer Panel Protocol 
for Clinical Use 
T.N. Mitchell, A. Oultache, K. Nafa, J. Sadowska, A. Zehir, D.T. Cheng, M. Arcila, 
M.F. Berger, C.V. Hedvat 
Memorial Sloan-Kettering Cancer Center, New York, NY. 
Introduction: Implementation of a complex assay workflow, exemplified by next-
generation sequencing, can be very challenging in a clinical laboratory. In this study, 
we evaluated the impact of a number of experimental parameters on the data quality 
produced by Illumina TruSeq Amplicon Cancer Panel (TSACP) to improve workflow 
for clinical implementation. Methods: Previously tested genomic DNA extracted from 
FFPE tumor tissue harboring hotspot mutations in EGFR, KRAS, BRAF, IDH1, 
PIK3CA, NRAS, and KIT were used for targeted resequencing library preparation 
using the Illumina TSACP assay and sequencing on an Illumina MiSeq. A batch size 
of 24 to 32 samples enabled the optimal use of reagents and achieved a mean depth 
of coverage >500x. Data analysis was performed using MiSeq Reporter. Results: 
We found that quantification of DNA by Qubit was a poor predictor of assay 
performance. Although using less than the recommended 250 ng of input DNA still 
resulted in a PCR product, the number of non-reproducible low frequency variants 
increased significantly. To reduce the noise in the data, we decreased the number of 
PCR cycles from 30 to 27, which decreased the average number of variants passing 
filter (AD>50, VF>10%) per case from 15 to 4, with 100% retention of reproducible 
calls. In an attempt to improve coverage for samples with a low PCR yield, we 
doubled the amount of PCR product pooled into the final library to be sequenced, 
which led to a significant increase in the average number of variants from 6 to 17 per 
sample, many of which had an allele frequency of 10% to 15%. An evaluation of 
inter-assay replicates showed the increase in the overall number of variant calls with 
low variant allele frequencies were not reproducible and therefore likely false 
positives. We found that the intensity of the PCR product on LapChipGX tracings 
was an accurate predictor of sequencing coverage with samples showing low 
intensity (less than 16) demonstrating low coverage and a high number of artifactual 
variants. Most notably, adjusting the sequencing read lengths from paired-end The Journal of Molecular Diagnostics ■ jmd.amjpathol.org2x150bp to 140+160bp improved the bidirectional coverage of known hotspot 
variants mutations that were located at the 5’ end of several amplicons. 
Conclusions: We effectively optimized multiple components of the standard 
workflow to create an enhanced customized assay to better fit the demands and 
address challenges encountered in a clinical environment and improved confidence 
and reliability of the results. 
 
ST49. Reproducibility and Accuracy of Cross Platform RT-qPCR Testing for 
the Detection of mRNA from Surface Squamous Cells Overlying Pigmented 
Skin Lesions 
H.S. Robin, T.J. Palmer, J.P. Alsobrook 
DermTech, La Jolla, CA. 
Introduction: Clinical and pathologic identification of pigmented skin lesions is 
dependent on visual pattern recognition, leading to less than acceptable sensitivity 
and specificity for the accurate identification of melanocytic neoplasms. We 
previously demonstrated removal of epidermal cells overlying melanoma using tape 
stripping technology permits the isolation and measurement of mRNA that accurately 
discriminates benign pigmented skin lesions from malignant melanoma and  in situ 
melanoma. The QuantStudio RT-qPCR platform previously was used to obtain 
clinical sensitivity in a multi-gene expression assay compared to histopathology of 
100% with specificity of 85%. Methods: Fifty-seven specimens were obtained by 
lesional tape sampling, followed by RNA extraction and cDNA synthesis. Replicate 
samples were run on both the Biotrove OpenArray NT system and on the 
LifeTechnologies QuantStudio system. The resultant RT-qPCR data were scored 
using a previously determined classifier that accurately discriminates between 
melanoma and nevi. The classifier scores for each specimen on the two platforms 
were compared by clinical concordance and linear regression. Within-run precision 
was measured using 20 replicates of a pooled human reference RNA source. 
Results: Interinstrument concordance was 100% on melanoma/nevi classification 
calls, with r-squared of classifier scores = 0.97; the slope of the regression line was 
0.98 with an offset of 0.01. The QuantStudio data were used to refine the classifier to 
2 signal genes and 3 housekeeping genes, with an AUC-ROC = 0.94. The within-run 
%CV of genes in the classifier was  1.2%. Conclusions: We demonstrated perfect 
clinical concordance between two types of OpenArray instruments, maintaining the 
high sensitivity and specificity previously demonstrated for melanoma detection. This 
excellent between-instrument precision indicates that OpenArry RT-qPCR is a 
reproducible tool for the evaluation and optimization of gene signatures on cells 
isolated from pigmented skin lesions. In the future, molecular signatures of 
neoplasms may supplant the highly subjective nature of clinical examination and 
histopathologic examination of pigmented skin lesions. Melanoma is on the rise in 
the US and early detection and appropriate therapy will reduce overall morbidity and 
mortality from this neoplastic disorder. Molecular signatures using RT-qPCR 
technology will bring new opportunities to accurately screen, diagnose and monitor 
neoplastic diseases. The specific platforms adopted to clinically analyze mRNA will 
be critical to reproducibility and accuracy of the test results. The use of a 
reproducible molecular signature using a non invasive specimen collection 
technology should improve patient outcomes, reduce unnecessary expenditures and 
enhance patient satisfaction. 
 
ST50. Utility of Thymidylate Synthase Genotyping for 5-Fluorouracil 
Chemotherapy in a Large,Colorectal Cancer Cohort Study 
D. Elsberry1, N.C. Welker1, M. Cho2, I. Kim2, A.R. Wilson1, M.P. Bronner1 
1ARUP Institute for Clinical and Experimental Pathology, Salt Lake City, UT; 2Yonsei 
University Wonju College of Medicine, Wonju, South Korea. 
Introduction: 5-Fluorouracil (5-FU) chemotherapy in combination with leucovorin is 
the routine regime for advanced colorectal adenocarcinoma. 5-FU targets the 
enzyme, thymidylate synthase (TYMS), which provides the only de novo source of 
thymidylate for DNA synthesis. Germline polymorphisms in the 5'-promoter enhancer 
region (5'-TSER) and the 3'-untranslated region (3'-UTR) of the TYMS gene have 
been variably correlated in the literature to TYMS expression levels, responsiveness 
to 5-FU therapy, and clinical outcome. Our previous colorectal cancer outcome study 
of 150 Korean patients identified TYMS genotyping as the best prognostic indicator 
of 5-FU efficacy, evaluating 5' and 3' polymorphisms independently. The current 
study assesses these and an additional 5'-TSER polymorphism (G>C SNP) for 
independent and combined effects. Methods: TYMS genotyping was assessed on 
156 Korean surgically resected colorectal cancers with long-term follow up (mean 
overall survival 71 months, range 1-147, S.D. 50). Patients received identical 
chemotherapy and results were controlled for cancer stage, age, gender, and tumor 
location. The chemotherapy regimen consisted of 24 weeks of 5-FU at 425 mg/m2 + 
leucovorin at 20 mg/m2, given on days 1 to 5, every 4 weeks. The evaluated TYMS 
polymorphisms included a 6 base pair deletion of the 3'-UTR (DEL) versus the wild 915
AMP Abstractstype insertion (INS), and a variable number (either 2 or 3) of tandem repeats (2R, 
3R) of the 5'-TSER, as well as a G>C SNP in the second repeat of the 3R allele 
(3RG, 3RC). Results: The TYMS genotype distributions for the 3'-UTR consisted of 
10/156 (6.4%) patients with INS/INS (normal expression); 59/156 (37.8%) INS/DEL 
(intermediate expression); and 87/156 (55.8%) DEL/DEL (low expression). For the 
5'-TSER the distributions consisted of 54/156 (34.6%) patients with 10-2R/2R, 21-
2R/3RC, 23-3RC/3RC (all low expression genotypes); and 102/156 (65.4%) 11-
2R/3RG, 54-3RG/3RC, 37-3RG/3RG (all high expression genotypes). Conclusions: 
The efficacy of 5-FU chemotherapy can be predicted by genotyping of the 
thymidylate synthase gene. 5'-TSER and the 3'-UTR polymorphisms predict 
expression levels of this anabolic enzyme involved in DNA synthesis, especially in 
rapidly dividing cancer cells. TYMS genotyping has implications for 
chemotherapeutic agent selection and dosing regimens.  
 
ST51. New Markers for Improved Detection of MSI in Early and Extra-Colonic 
Tumors 
J. Bacher1, I. Grimes2, D. Albrecht2, J. Weiss2, C. Sievers2, K. Richie2, R. Agni2, M. 
Reichelderfer2, J. Vidugiriene3, D. Kanopiene3, P. Ward4, G. Kim4, L. Dubeau4, J. 
Felix4, P. Mhawech-Fauceglia4, D. Samrao4, D. Storts1, R. Halberg2 
1Promega Corporation, Madison, WI; 2University of Wisconsin , Madison, WI; 3Vilnius 
University Institute of Oncology, Vilnius, Lithuania; 4University of Southern California, 
Los Angeles, CA. 
Introduction: Identification of individuals with Lynch Syndrome (LS) is extremely 
important because these patients greatly benefit from more frequent cancer 
surveillance. Currently available markers for microsatellite instability (MSI) testing, a 
screening tool to help identify LS, are highly sensitive for the detection of MSI in 
colorectal cancers. However, sensitivity is low for other types of samples, including 
colon polyps and endometrial cancers. We have shown that mononucleotide repeats 
consisting of long polyA tracts of 40 to 60 bp are more likely to exhibit MSI than 
currently used microsatellite markers with shorter repeat tracts and therefore, are 
more likely to improve detection of MSI in problematic sample types. To test this, we 
investigated the use of long mononucleotide repeats for MSI testing of colon polyps 
and endometrial cancers. Methods: Five hundred patients 55 years of age with 
one or more polyps 5 mm were selected for the adenoma study. For the 
endometrial study, a total of 200 patients from two different sources were selected. 
MSI testing was performed using Promega’s MSI Analysis System (For Research 
Use Only), the Bethesda marker panel, and a new panel of mononucleotide repeats 
with long polyA tracts. Confirmation of tumor mismatch repair status was done by 
IHC analysis. Results: To date, we have tested a total of 740 colon polyps from 259 
patients for MSI. Overall, 7.7% of patients had one or more polyps that exhibited 
MSI. About 2.3% of the tumors were MSI-High with all marker panels and an 
additional 5.4% were MSI positive using the long mononucleotides. With roughly half 
of the endometrial samples completed, we found the sensitivity of the long 
mononucleotide repeats was significantly higher (p=0.004); with 19.3% of tumors 
being MSI positive using long mononucleotides versus 8.1% with the MSI Analysis 
System. The size change in tumors using the long mononucleotide repeat markers 
was also significantly larger (p=0.002); with an average change in allele size in MSI-
positive samples of 12.8bp for the long mononucleotides compared to 4.5bp for the 
MSI Analysis System markers. The MSI and IHC results were highly correlated. 
Conclusions: The results of our study indicate that testing colonic polyps and 
endometrial cancers for MSI using the new long mononucleotide repeat panel 
increases detection of MSI by 2 to 3-fold over current marker panels. The increased 
MSI sensitivity should facilitate the detection of Lynch Syndrome when analyzing 
problematic sample types that exhibit an attenuated MSI phenotype. 
 
ST52. Epithelial Mesenchymal Transition Gene Sequencing in Stage I Breast 
Cancer Patients  
L. Watson, K. Walker, P. Zhang, B. Leng, J. He, A. Rao 
Scott and White Memorial Hospital, Temple, TX. 
Introduction: The etiology of distant metastasis in early stage breast cancer 
patients remains unclear. Recent studies have demonstrated dynamic interactions 
between the neoplastic cells and the tumor microenvironment play an important role 
in the metastasis of malignant neoplasms. In this study, we selected stage I breast 
cancer cases with distant metastasis for target gene sequencing. Methods: 
Retrospective chart review of patients diagnosed with Stage I and II Breast Cancer 
from 2001 to 2003 was performed. 988 registered breast cancer cases were 
identified, of which 413 patients with pathology, receptor status, treatment, and 
follow-up data. 6 stage I cases with distant metastasis were matched with 6 cases 
without metastasis by stage, age, ethnicity, ER/PR, and HER2 status. Cases that 
showed the differential protein expression were selected for gene sequencing using 
the Comprehensive Cancer Panel and the Ion PGM system (Life Technologies, 916Carlsbad, CA). DNA was extracted from FFPE breast cancer tumor samples using 
Ambion RecoverAll Total Nucleic Acid Isolation Kit (Life Technologies, Carlsbad, 
CA). Sequencing data were analyzed using the Torrent Variant Caller software. 
Results: Differential gene expression was noted for CK19, FAK, caldesmon, GSC, 
and desmoplakin genes. Immunohistochemistry demonstrated differential staining for 
CK19, FAK, and GSC proteins. Preliminary analysis on representative samples 
revealed a homozygous mutation of the FN1 gene and a heterozygous mutation of 
the PDGFRB gene, both of which are involved in cell metastasis and proliferation, 
respectively. Conclusions: Our study suggests upregulation of EMT gene 
expression plays an important role in metastasis in early stage breast cancer 
patients. The significance of these mutations are currently being explored and 
confirmed in a larger study set. 
 
ST53. Targeted Resequencing of Formalin-Fixed, Paraffin-Embedded (FFPE) 
Specimens for Mutation Diagnostics in Solid Tumors 
J. Botling1, L.N. Moens1, E. Falk.Sörqvist1, M. Sundström1, P. Micke1, M. Nilsson2 
1Uppsala University, Uppsala, Sweden; 2Stockholm University, Science for Life 
Laboratory, Stockholm, Sweden. 
Introduction: In recent years, the advent of massively parallel next-generation 
sequencing (NGS) technologies has enabled substantial advances in the study of 
many human diseases, including cancer. In combination with targeted DNA 
enrichment methods, high sequence coverage can be obtained for many different 
genes simultaneously, creating unique opportunities for clinical cancer diagnostics. 
However, the process of formalin fixation and paraffin embedding (FFPE) of tissue 
samples results in DNA-fragmentation by cross-linking to other biomolecules, posing 
a number of technical challenges for downstream biomolecular analyses. Methods: 
In this study, we have evaluated the HaloPlex target enrichment system for somatic 
mutation detection in 40 DNA extracts prepared from ten surgical lung- and colon 
cancer specimens with available paired tumor and normal tissue in FFPE blocks and 
matched fresh-frozen tumor and normal samples. In the design of the 28 gene panel, 
covering the most common mutations in lung and colon cancer, several 
modifications to the standard method were introduced, including a reduced target 
fragment length, molecular barcoding, and two-strand capturing. Results: We show 
that FFPE material can be used for HaloPlex based target enrichment and NGS 
using as little as 50 ng of DNA, i.e. compatible with yields readily available from 
small biopsies. By specifically capturing both strands for each target fragment, we 
were able to reduce the number of false-positive errors due to FFPE induced 
artifacts by a factor of 4. Furthermore, the combined approach of molecular 
barcoding and two strand capturing allowed us to identify two low frequency variants 
(7.8% and 3.6%), demonstrating a sensitive and accurate detection of somatic 
mutations. Conclusions: We believe that the HaloPlex method, provided some 
modifications are made, will be broadly applicable as a tool for somatic mutation 
detection. Genetic profiling of FFPE cancer tissues will add a new dimension to 
diagnostic tumor pathology and will open vast opportunities for research as large, 
complete, population-based patient cohorts will be available for comprehensive 
molecular characterization. 
 
ST54. Mutation Profile and Morphologic Spectrum of Advanced Thyroid 
Cancer: MSKCC Experience 
H. Chen, K. Nafa, L. Borsu, C.V. Hedvat, E.J. Sherman, R.A. Ghossein, S. Dogan 
Memorial Sloan Kettering Cancer Center, New York, NY. 
Introduction: A strong association between the genetic alteration and tumor 
histology has been well established across different thyroid tumor types. About two 
thirds of thyroid carcinomas (TC) of follicular cell origin harbor mutations in genes 
encoding proteins of Ras-Raf-MEK-ERK signaling pathway. Recent studies 
demonstrated the clinical benefit with reexpression of the sodium-iodide symporter 
due to molecular targeted therapy (MEK inhibitor) in a subset of advanced TC 
harboring mutations in NRAS or BRAF genes. Positive treatment response was 
strongly associated with the presence of NRAS mutation, whereas the similar effect 
was observed only in a minority of BRAF mutated cases. Methods: We analyzed our 
unique clinical data set comprised of 113 clinically advanced TC subjected to 
molecular profiling from April 2010 to May 2013. Nine cases were tested for BRAF 
exon 15 mutations by direct sequencing, 98 were analyzed by multiplex mass-
spectrometry assay (MassArray, Sequenom) interrogating 92 coding substitutions in 
EGFR, KRAS, BRAF, NRAS, PIK3CA, MEK1, AKT1, and ERBB2 genes, and 6 were 
examined for substitutions and small insertions/deletions in 45 cancer-related genes 
by next-generation sequencing (TruSeq Amplicon Cancer Panel, MiSeq). We 
examined the mutation status in respect to the tumor morphology with a particular 
emphasis on NRAS and BRAF mutated carcinomas. Results: The histologic types 
included 43 (38.1%) poorly differentiated TC (PDTC), 24 (21.2%) papillary TC-tall 
cell variant (PTC-TCV), 22 (19.5%) well differentiated papillary TC, 12 (10.6%) jmd.amjpathol.org ■ The Journal of Molecular Diagnostics
T AMP Abstractsanaplastic TC, 5 (4.4%) Hurthle cell carcinomas, 1 (0.9%) medullary TC, 1 (0.9%) 
moderately differentiated TC, and 5 (4.4%) TC of follicular cell origin, NOS. 
Activating mutations were present in 72 (63.7%) carcinomas including BRAF, NRAS, 
KRAS, and AKT1 mutations in 47 (41.6%), 22 (21.1%), 2 (1.9%), and 1 (1%) cases, 
respectively. NRAS and BRAF mutations occurred in none and 23 PTC-TCV (0% vs. 
95.8%; p=0.0004), and in 14 and 9 PDTC (37.8% vs. 21.1%; p=NS), respectively. 
However, presence of any tall cell component in PDTC was significantly more 
frequent in BRAF mutated than in NRAS mutated PDTC (6 of 9, 67% vs. 1 of 14, 
7%; p=0.005). Conclusions: A precise histologic subtyping of PDTC is needed as it 
may be of predictive value for presence of BRAF or NRAS mutations, and therefore 
possibly predictive of response to specific targeted therapies.  
 
ST55. Establishing Quality Control Criteria for the Ion AmpliSeq Cancer 
Hotspot Panel v2 Assay on FFPE Samples 
C.I. Dumur, M. Voelkner, J.A. Almenara, C.N. Powers, A. Ferreira-Gonzalez 
Virginia Commonwealth University, Richmond, VA. 
Introduction: Targeted next-generation sequencing (NGS) technology is rapidly 
being adopted to assess the mutational status of multiple genes on FFPE tumor 
specimens in clinical settings, where sample barcoding is becoming a common 
practice. Both, tumor heterogeneity and sample barcoding may have an impact on 
the limit of detection (LOD) of somatic mutations in fixed tumor specimens. Here, we 
have assessed the effect of formalin fixation and paraffin embedding, as well as 
sample barcoding, on the LOD of sequence variants using the Ion AmpliSeq 
chemistry on the Ion Torrent PGM instrument (Life Technologies) using fresh and 
FFPE cell line mixtures. In addition, quality control (QC) material was created to 
assess the assay reproducibility, repeatability and LOD stability across independent 
runs. Methods: DNA from fresh and FFPE cell pellets from pancreatic (MIA-PaCa-
2), colon (HCT116), melanoma (SK-MEL28), and lung (H1975) cancer cell lines was 
extracted and combined in different proportions, resulting in sample mixes harboring 
a total of 34 mutations, including small deletions, in 23 different genes. A mixture 
harboring a proportion of mutations at the LOD level was designated as QC material, 
and was included in every run. Library preparation and sample barcoding was 
performed from 10 ng DNA using the 50-gene Ion AmpliSeq Cancer Hotspot Panel 
v2 assay. Barcoded libraries were sequenced on 316 chips using the Ion PGM 
Sequencing 200 Kit v2. Data analysis, including primer trimming and sequence 
alignment to the Human Reference (hg19), was performed with the Torrent Suite 
(v3.4.2). The variantCaller plugin (v3.4.51874), with customized parameters, was 
used to detect sequence variants. Results: Excellent coverage was consistently 
obtained, averaging 3102x (± 594x) for 5 barcoded fresh samples; 2177X (± 320x) 
for 7 barcoded fresh samples; and 1430x (± 266x) for 7 barcoded FFPE samples. 
The latter was significantly lower then the same number of barcoded fresh samples 
(one-tailed p-value = 0.0037). The QC material showed a consistent LOD of 4% of 
sequence variant detection, when barcoding up to 7 samples per chip. A similar LOD 
was obtained when running 7 Barcoded FFPE cell line mixtures. Excellent 
repeatability (mean r = 0.997) and reproducibility (mean r = 0.999) of the variant calls 
was observed in multiple runs. Conclusions: Targeted NGS using the Ion AmpliSeq 
technology, with customized variantCaller plugin parameters, is a sensitive, 
reproducible and medium-throughput assay to detect sequence variants, including 
small deletions, in cancer-related genes in FFPE samples. 
 
ST56. ERBB2 (HER2) Mutation Spectrum in Solid Tumors 
W. Wen, W. Chen, S. Millis, R. Bender, A. Ghazalpour, Z. Tan, G. Basu, Z. Gatalica 
Caris Life Sciences, Phoenix, AZ. 
Introduction: The ERBB2 gene, which encodes for HER2, is a major proliferative 
driver for several cancer types. Gene amplification and protein expression are 
associated with sensitivity to Her2-targeting drugs. In some cancer types ERBB2 
mutations may be more relevant in carcinogenesis than gene amplification or protein 
expression. The mutation spectrum of ERBB2 in solid tumors is relatively unknown. 
The emergence of NGS methodology had enabled high throughput detection of both 
known and novel oncogenic mutations in human genome including the presence of 
activating mutations of ERBB2. Methods: Comprehensive genomic profiling was 
performed on tumors from 2962 cancer patients including 319 breast, 346 colorectal 
(CRC), 358 lung (NSCLC), 299 uterine/cervical, 543 ovarian and 128 pancreatic 
cancers. We also profiled 126 melanoma and 843 other solid tumors (e.g. 
glioblastomas, sarcomas, bladder carcinomas). Direct sequence analysis of ERBB2 
was performed on genomic DNA isolated from a formalin-fixed paraffin-embedded 
tumor sample using the illumina MiSeq platform. Specific regions of the genome 
were amplified using the illumina TruSeq Amplicon Cancer Panel. The HER2 protein 
expression and gene copy numbers were determined by immunohistochemistry and 
dual in situ DNA hybridization (dual ISH), respectively, (Ventana Medical Systems). 
Results: ERBB2 mutations in the kinase domain were detected in 30 patients (1% of he Journal of Molecular Diagnostics ■ jmd.amjpathol.orgall cases). These include previously published activating mutations 
(P780_Y781insGSP; V842I, L755S, V777L, D769Y) and several novel ones (such as 
I767F, R784C). 7 cases with coexisting HER2 amplification included: D769Y and 
L755S (breast), D769H (bladder), D769Y and T862A (ovary), and two cases with 
V777L (CRC). 25 of the 30 patients also had additional gene mutations (e.g. TP53, 
APC, PIK3CA, PTEN, KRAS). Five (17 %) patients had ERBB2 mutation identified 
as the sole driver mutation, including L755S in CRC, breast and ovarian cancer, 
D769H in bladder cancer and D769E in NSCLC (also showing HER2 gene 
amplification). Conclusions: 1) ERBB2 mutation might be the sole identified driver 
mutation in various solid tumors including breast, ovarian, CRC, NSCLC. 2) Her2 
protein over-expression was observed only when ERBB2 gene was amplified (5/7 
cases) but not in any of the ERBB2 mutated non-amplified cases (0/23). 3) Activating 
ERBB2 mutation can coexist with ERBB2 gene amplification and/or with mutations in 
various other key driver genes. 4) The effectiveness of targeted anti-Her2 therapies 
in non-amplified ERBB2 mutated cancers that do not over-express the protein needs 
to be established. 
 
ST57. Identification of Novel KIT Mutation in Papillary Thyroid Carcinoma 
Arising from Malignant Struma Ovarii and Thyroid by Next-Generation 
Sequencing 
D. Ma, L. Dahmoush, N.V. Guseva, R. Sompallae, R.A. Robinson 
University of Iowa Hospitals and Clinics, Iowa City, IA 
Introduction: Struma ovarii accounts for 3% of ovarian teratomas in which thyroid 
tissue is the predominant or exclusive element. Malignant transformation is rare (< 
0.3%) and the underlying molecular mechanism is poorly understood. We report for 
the first time a novel KIT p.V530I mutation in papillary thyroid carcinoma (PTC) 
arising from struma ovarii and a co-existent incidental PTC in the patient’s thyroid. 
Activating mutations in KIT play an important role in diagnosis and prognosis of 
multiple malignancies including mastocytosis, gastrointestinal stromal tumors, and a 
subset of melanoma and acute myeloid leukemia (AML). The p.V530I mutation has 
only been reported in two cases (AML and aggressive fibromatosis). The patient with 
fibromatosis responded to imatinib treatment. The identification of the p.V530I 
mutation in PTC may have implications for a new therapeutic target. Methods: The 
slides were reviewed by two surgical pathologists. Two different areas with PTC from 
the ovarian (foci containing tall cell and follicular variants) and thyroid tumors 
(containing foci of oncocytic and follicular variants) with tumor content >40% were 
selected for testing. Genomic DNA was isolated from microdissected formalin-fixed, 
paraffin-embedded tissue and analyzed by next-generation sequencing (NGS) using 
the Ion AmpliSeq Cancer Hotspot Panel v2 (Life Technologies). Mutational status for 
BRAF p.V600E was confirmed by primer extension assay. Results: A c.1588G>A 
(p.V530I) mutation was identified in all four areas of the tumors from the malignant 
struma ovarii and thyroid PTCs. This mutation is present in exon 10 of the KIT gene. 
NGS was repeated on two out of four samples and 100% concordance was 
observed. The lack of BRAF p.V600E mutation was confirmed by primer extension. 
A known polymorphism in the KIT gene (c.1621A>C, p.M541L) was detected in all 
four samples. Conclusions: This is the first report of KIT p.V530I mutation in 
primary PTC and malignant struma ovarii. This mutation is located in the KIT 
transmembrane domain and may interfere with receptor dimerization and activation. 
PTCs in both the ovary and thyroid were predominantly follicular variant but with foci 
of tall cell variant in the ovarian tumor and oncocytic variant in the thyroid tumor. It is 
known that the tall cell variant is associated with a more aggressive clinical course in 
the thyroid but it is unclear if that is the case when it occurs in struma ovarii. The 
dramatic response to imatinib in the patient with fibromatosis may also shed light on 
the implication of targeted therapy in PTCs harboring this mutation. 
 
ST58. Targeted Next-Generation Sequencing of Pancreatobiliary Tract 
Cytology Brushings 
J.S. Voss, E.G. Barr Fritcher, J.L. Winters, Z. Tu, E.W. Klee, F.J. Couch, K.C. 
Halling, B.R. Kipp 
Mayo Clinic, Rochester, MN. 
Introduction: Pancreatobiliary duct malignancies are often diagnosed by cytology 
due to the difficulty in obtaining adequate tissue from pancreatobiliary tract ducts. 
Since next-generation sequencing (NGS) of solid tumors has been performed 
primarily on fresh frozen or formalin-fixed paraffin-embedded tissue, little data is 
available describing the genetic landscape of pancreatobiliary ductal cancers. The 
goal of this study was to evaluate whether targeted NGS could be performed on 
pancreatobiliary tract cytology specimens and whether these finding may offer 
additional diagnostic or therapeutic information for the management of 
pancreatobiliary tract malignancy. Methods: DNA was extracted from 76 
pancreatobiliary brushing specimens consecutively collected during clinical practice 
for routine cytology and fluorescence in situ hybridization (FISH) UroVysion testing. 917
9AMP AbstractsSamples were amplified using the Ion Torrent AmpliSeq Cancer Hotspot Panel v2 
and sequenced on the Ion Torrent PGM system. Sequencing data were analyzed 
using the Ion Torrent Suite software v3.4 and variant calls were manually reviewed. 
Filtered variants were confirmed by performing a second PCR reaction using the 
same primer panel but with subsequent sequencing on the Illumina MiSeq 
instrument. There were 44/76 (58%) patients found to have malignancy based on 
clinicopathologic follow-up, which included 34 cholangiocarcinoma, 4 pancreatic 
adenocarcinoma (ADCA), 2 gallbladder ADCA, 1 ampullary ADCA and 3 metastatic 
ADCA. Results: Forty-two mutations were detected in 22/76 (29%) patients by NGS 
in 13 genes, including KRAS (n=12), TP53 (n=11), SMAD4 (n=4), BRAF (n=3), 
CDKN2A (n=3), PIK3CA (n=2) and one mutation in APC, ATM, FBXW7, MET, 
MLH1, PTEN and VHL. Somatic mutation frequencies ranged from 2% to 52% 
(median=10%). Of the 44 patients found to have malignancy, 17 (diagnostic 
sensitivity=39%) had a somatic mutation, whereas only one patient without 
malignancy had an identified somatic mutation (KRAS) (specificity=97%). The 
sensitivity of NGS was higher than routine cytology (27%), but lower than FISH 
(50%), whereas the specificity of NGS was similar to cytology (100%) and higher 
than FISH (88%). Conclusions: These data suggest that targeted NGS can be 
successfully performed on pancreatobiliary brushings, which suggest that this 
technology can be used to interrogate cytology specimens from other body sites. 
Further studies are needed to determine the role of NGS in the clinical management 
of patients undergoing evaluation for pancreatobiliary tract malignancy. 
 
ST59. Prospective Whole Exome Sequencing for Clinical Management of 
Patients with Advanced Lung and Colon Adenocarcinoma 
L.M. Sholl1, E. Van Allen2, N. Oliver2, J. Fostel3, D.L. Perrin3, D.C. Friedrich3, S.A. 
Fisher3, S. Gabriel3, A. Church1, V. Rojas-Rudilla1, E.P. Garcia1, S. Gray2, J. 
Garber2, N.I. Lindeman1, P. Janne2, S. Joffe2, N. Wagle2, L. Garraway2 
1Brigham and Women's Hospital, Boston, MA; 2Dana Farber Cancer Institute, 
Boston, MA; 3Broad Institute, Cambridge, MA. 
Introduction: Tumor next-generation sequencing is becoming an important tool in 
oncologic practice. However, the impact of prospective whole exome sequencing 
(WES) in clinical care is largely untested. We developed a WES pipeline for patients 
with metastatic lung or colon adenocarcinoma (ACA) and examined its potential for 
affecting clinical management. Methods: Patients enrolled in this institutional review 
board-approved protocol consented to WES of DNA from fixed tumor tissue and 
blood. Tumor tissue was reviewed by a pathologist and dissected to enrich for >30% 
tumor. WES was performed on the Illumina HiSeq according to standard protocols 
utilizing an average of 104 ng of DNA (range 60 to 175). Sequencing data were 
analyzed through Picard and Firehose (Broad Institute) utilizing MuTect, CapSeg, 
and dRanger. Results were curated according to variant type and known relevance 
to cancer. Those variants with known or potential clinical relevance were reviewed 
by a committee of pathologists, oncologists, and geneticists, which voted to return 
specific results to the patient and treating oncologist. Results: The first ten cases 
sequenced included 3 lung ACA and 7 colon ACA. Mean target coverage (MTC) of 
mapped, unique, high quality reads was 154 fold (range 102-201), with 82% to 92% 
of targets having >30 fold MTC. Allelic fraction ranged from 17% to 28% (median 
11% to 33%) and tended to be less that expected based on estimated tumor 
percentage at pathology review. Cases contained an average of 116 
nonsynonymous, somatic coding variants (range 12 to 202), of which an average of 
2.7 were considered to be clinically relevant (range 0 to 4). Of the lung cancers, one 
known ALK-rearranged tumor contained no other relevant variants, one contained 
KRAS and STK11 mutations, and another had BRAF and TP53 mutations. Among 
the colon cancers, APC was most frequently altered (8 variants in 5 cases), followed 
by TP53 (5 variants in 4 cases). KRAS variants were identified in 3 cases, including 
an unusual p.Ala59Thr variant. Uncommon variants included NRAS amplification, 
DDR2 mutation, and SMAD4 mutation predicted to encode loss of function. One 
case with few somatic alterations and a silent copy number profile was subsequently 
determined to contain normal tissue only. Conclusions: Tumor WES can be 
performed on small amounts of DNA from fixed tissues. In addition to yielding 
expected alterations in common oncogenes and tumor suppressor genes, this 
approach identifies less common and potentially novel therapeutic targets. 
 
ST60. Differential Signaling Patterns in HPV Positive and Negative HNSCC 
Identified by Next-Generation Sequencing 
P. Zhang, A. Seth, A. Baisre, H. Fernandes 
University of Medicine & Dentistry of New Jersey/New Jersey Medical School, 
Newark, NJ. 
Introduction: Head and Neck Squamous Cell Carcinoma (HNSCC) is the sixth most 
common cancer worldwide. Based on epidemiology and disease outcomes, 
histologically diagnosed HNSCC has been stratified into two distinct prognostic 18entities, directly linked to Human Papilloma Virus (HPV), specifically HPV 16 and 
HPV 18 subtypes. HPV-positive HNSCC patients have a significantly better 
prognosis than those with HPV negative tumors. The underlying mechanisms and 
detailed genetic profiles that distinguish these two clinical entities however, have not 
been characterized. We have used targeted Next-Generation Sequencing (NGS) to 
investigate oncogenic pathways that may be involved in the potential pathogenesis 
of HPV-positive and HPV-negative HNSCC. Methods: DNA extracted from 
microdissected FFPE tissue belonging to 51 HNSCC patients (20 HPV positive and 
31 HPV negative) were subject to NGS on the Ion Torrent Personal Genome 
Machine (PGM) platform to detect genetic variants. Single nucleotide polymorphisms 
(SNPs) in 48 cancer-related genes were interrogated and stringent standards were 
applied to data analyzed using variant caller software. SNPs in the promoter region 
of TNF alpha were also examined using Sanger sequencing. Fisher exact test and t-
test were used for statistical analysis. Results: SNPs present in 24 cancer-related 
genes from HPV positive and HPV negative HNSCC specimens were detected in our 
analysis. Five candidate genes, PDGRFA, PIK3CA, KIT, MET, and APC, were found 
altered in all HNSCC patients regardless of HPV status. 15/24 variant genes were 
present with higher frequency in HPV positive HNSCC specimens. Several of these 
genes, including FGFR3, EGFR, NRAS, KRAS, and JAK3 are known to signal via 
the receptor tyrosine kinase pathway. SNPs in AKT1, TP53, ABL1, and FLT3 were 
found primarily in HPV negative HNSCC specimens. There was no difference in the 
prevalence of the TNF-alpha SNP in either patient cohort. Conclusions: A greater 
number of SNPs present in genes from the Tyrosine Kinase receptors and their 
associated pathways were preferentially present in HPV-positive specimens. SNPs 
present in genes related to tumor suppressor functions were more prevalent in HPV 
negative HNSCC specimens. The differential patterns seen in HPV-positive and -
negative HNSCC may help to understand the mechanisms involved in the molecular 
pathogenesis of the two clinical subclasses of HNSCC. They could also be useful in 
the identification of potential gene targets. 
 
ST61. Clinical Cancer Exome Sequencing at Baylor College of Medicine: 
Initial Experience 
F.A. Monzon, A. Roy, Y. Yang, D. Muzny, J. Reid, D. Lopez-Terrada, R. Gibbs, D. 
Wheeler, D. Parsons, S. Plon 
Baylor College of Medicine, Houston, TX. 
Introduction: Our laboratory launched clinical cancer Whole Exome Sequencing 
(WES) in August 2012. Most specimens tested to date belong to patients on the 
BASIC3 study, a NHGRI Clinical Sequencing Exploratory Research (CSER) program 
project involving clinical tumor and germline WES of children with newly diagnosed 
solid tumors. We present our initial experience with clinical cancer WES. Methods: 
Genomic DNA was obtained from peripheral blood and snap-frozen tumor 
specimens. Exome capture was performed using NimbleGen VCRome 2.1 and 
sequenced on an Illumina HiSeq 2000 with >200x average coverage. Bioinformatics 
analysis was performed using a clinically-validated pipeline. Somatic variants were 
categorized following a previously developed schema based on clinical significance 
and utility. Known or potentially actionable variants were confirmed by an alternate 
sequencing approach. Cases were evaluated by a molecular pathologist and 
reviewed at a multidisciplinary tumor board before reporting. Results: To date, 59 
pediatric and 5 adult tumors have been submitted for tumor WES. Sufficient DNA (2 
to 18 ug/~30mg of tissue) was obtained from all. Technical and interpretative 
challenges have included the need for visual review of .bam files, false positive 
somatic variants due to alignment errors, prediction of the significance of novel 
variants, and paucity of evidence for clinical utility of known variants. On average, 34 
coding/splicing somatic variants were reviewed per tumor (range=12 to 162) with 
51% classified as alignment errors (false positives) after review. Only 8.3% of all 
variants reported (48/577) had been previously described (COSMIC). Twenty-eight 
percent of pediatric solid tumors (10/35) had variants considered actionable or 
potentially actionable and all cases had mutations in non-cancer genes (avg=12, 
range=1 to 35, non-validated). Adrenocortical carcinomas (n=2) and neuroblastomas 
(n=7) had the highest average number of somatic mutations among pediatric tumors 
(25 and 15, respectively). One adult case had actionable mutations. Adult tumors 
had a median of 35 non-cancer gene mutations (range=4 to 135). Conclusions: We 
have established a laboratory and bioinformatics pipeline for clinical cancer exome 
sequencing. Our initial experience suggests that widespread clinical exome 
sequencing, although technically challenging, is feasible and can yield results with 
clinical relevance in both pediatric and adult solid tumors. Improvement in 
interpretation software tools and shared cancer genomic databases is necessary. 
Our data revealed mutations in known cancer genes not previously associated with 
specific tumor types and in genes not previously associated with cancer biology. 
These results also suggest that complementary genomic approaches, such as copy jmd.amjpathol.org ■ The Journal of Molecular Diagnostics
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 AMP Abstractsnumber analysis and RNAseq, might be needed to identify all underlying molecular 
abnormalities in pediatric solid tumors. 
 
ST62. Concordance between PTEN Protein Expression and Gene Mutations 
in the Large Cohort of Cancer Patients 
A. Ghazalpour, W.S. Chen, R. Bender, W. Wenhsiang, G. Basu, Z. Tan, Z. Gatalica 
Caris Life Sciences, Phoenix, AZ. 
Introduction: PTEN is a tumor suppressor gene in signaling downstream of EGFR. 
Loss of PTEN protein expression is one of the more common occurrences in human 
cancers, and its loss potentially reduces the benefit from trastuzumab and EGFR-
targeted therapies and mTOR inhibitors. Loss of PTEN is usually assessed with 
immunohistochemistry (IHC). Mutation analysis of PTEN gene has been recently 
introduced in clinical use. In this study, we compared the concordance between 
PTEN IHC and PTEN sequencing technologies using the largest cohort of patients 
published thus far. Methods: 1636 patients and 29 tumor types were utilized in this 
study. TruSeq Amplicon - Cancer Panel on the Illumina’s Miseq that employs 7 
amplicons to sequence exons 1, 3, 6, 7, and 8 of PTEN gene, and IHC using anti-
PTEN clone6H2.1(DAKO) were used in this study. Results: Overall, 5% of the 
samples contained mutations in PTEN gene. Of the 83 variations identified, 46% 
were frameshift, 29% nonsense, 23% missense, 1% inframe deletion, and 1% 
affecting splicing. When compared to IHC results, significantly larger number (30% 
or 481 out of 1636) of patients lacked PTEN protein expression (defined as less than 
50% tumor cells staining positive). 26% of the samples that were called wild type by 
sequencing did not show PTEN expression and 32% of the samples that contained a 
mutation in PTEN expressed PTEN in IHC. Among PTEN mutations, the largest 
discrepancy was seen with missense mutation at 31%. In contrast, of the negatively 
stained samples only 13% were called mutant by sequencing whereas 96% of 
samples that stained positively by IHC were called wild type by sequencing results. 
Conclusions: These observations suggest that there is very little correlation 
between sequencing and IHC results for PTEN. We conclude that neither the IHC 
nor the sequencing alone have a full capability to predict PTEN status, but when 
combined, these two technologies provide a more complete assessment of PTEN 
status in patients. Additional methods (methylation assays, LOH assays) may be 
needed to correctly assess PTEN status in tumors. 
 
ST63. Ras-ERK and PI3k-mTOR Pathway Profiling in Solid Tumors and 
Implications for Clinical Oncology 
Z. Tan, W. Chen, S. Millis, R. Bender, A. Ghazalpour, W. Wen, Z. Gatalica 
Caris Life Sciences, Phoenix, AZ. 
Introduction: Ras-ERK and PI3K-mTOR pathways are chief regulators of cell 
proliferation, differentiation, survival, migration and metabolism. Alterations of these 
pathways are commonly seen in cancer pathogenesis. As next-generation 
sequencing (NGS) platforms become more accessible to healthcare, the use of 
highly multiplexed mutational analysis for personalized medicine is on the rise. The 
ability to profile multiple signaling pathways can provide basis for targeted single 
agent or combinatorial cancer therapy. Methods: Components of Ras-ERK pathway: 
KRAS, NRAS, HRAS, and BRAF, and components of PI3K-mTOR pathway: 
PIK3CA, PTEN, AKT1 and STK11 were tested by next-generation sequencing using 
the Trueseq Amplicon Cancer Panel on Illumina’s Miseq. Formalin-fixed, paraffin-
embedded tissue sections from 2520 patients were subjected to DNA extraction and 
NGS. Immunohistochemistry using anti-PTEN clone 6H2.1 (DAKO) was used to 
analyze protein expression. Results: Among 2520 cancer samples, a significant bias 
towards mTOR pathway was observed for breast carcinoma (56% cases mutated in 
mTOR pathway vs 0.70% cases mutated in ERK pathway), endometrial cancer 
(52.8% mTOR vs 2.8% ERK), ovarian surface epithelial carcinoma (21.7% mTOR vs 
6.8% ERK), which may explain the success of mTOR inhibitors in these female 
prevalent/restricted cancers. Significant bias towards ERK pathway was observed for 
pancreatic adenocarcinoma (4.9% mTOR vs 51.0% ERK), and a near significant 
trend towards ERK pathway was seen for melanoma (12.9% mTOR vs 29.7% ERK). 
Colorectal adenocarcinoma and pancreatic adenocarcinoma were more likely to 
have alterations in both ERK and mTOR pathways compared with other tumor types. 
When NGS data were used instead of IHC for PTEN analysis, there were 
significantly fewer cases with PTEN alterations, highlighting the differences of the 
two techniques. Conclusions: Pathway profiling reveals mTOR bias in female 
prevalent/restricted tumors and ERK bias in colorectal adenocarcinoma. Colorectal 
adenocarcinoma and pancreatic adenocarcinoma have tendency to have mutations 
in genes of both mTOR and ERK pathways, suggesting dual mTOR and ERK 
inhibitor therapy might be effective in these tumor types. Success of mTOR inhibitors 
in breast and endometrial cancers may also be a result of the low rate of ERK 
pathway activation. 
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Sequencing 
W.R. Geurts-Giele, P. Atmodimedjo, H.J. Dubbink, W.N. Dinjens 
Erasmus University Medical Center, Rotterdam, Zuid-Holland, Netherlands. 
Introduction: Cancer patients are often diagnosed with multiple tumors, which can 
represent either clonally related or multiple independent primary tumors. 
Discrimination between multiple independent primary tumors within one patient or 
one primary tumor and metastases is of prime importance for appropriate treatment 
of the individual patient. However, this discrimination is not always possible with the 
current pathological and molecular methods. We addressed the question whether 
targeted next-generation sequencing using the Ion Torrent Personal Genome 
Machine (PGM) can be of additional value in diagnostic questions regarding tumor 
clonality. Methods: From 25 patients each with multiple tumor localizations DNA was 
isolated from the tumor tissues and from patient-matched normal tissue. Routine 
diagnostics included TP53 immunohistochemistry, sequencing analysis of TP53 or 
other genes if applicable and loss of heterozygosity (LOH) analysis. Additionally, the 
samples were screened with the PGM using the Ion Ampliseq Cancer Hotspot panel. 
Results: With the PGM, mutations were detected in 42/58 tumor samples. In total, 
57 mutations were detected with the PGM, 40 mutations were validated and 
confirmed by Sanger sequencing. Overall, conclusive results about the clonal 
relationship between multiple tumors were found in 18 patients with the PGM, 
compared to 21 patients with routine diagnostics. Conclusions: Targeted next-
generation sequencing using the PGM can be of additional value in tumor clonality 
determinations, as for some patients conclusive results were found only with the 
PGM. However, the Ion Ampliseq Cancer Hotspot panel is not superior to the routine 
diagnostics strategy, as some important gene regions are not covered. Currently, we 
are designing a custom panel that covers more gene regions and includes SNPs for 
LOH detection, to improve the molecular diagnostics of patients with multiple tumors.  
 
ST65. Screening for Somatic Mismatch Repair Gene Aberrations Improves 
the Molecular Diagnostics of Patients Suspected for Lynch Syndrome 
W.R. Geurts-Giele1, C. Leenen1, I.C. Meijssen1, E. Post1, H.F. Sleddens1, H.J. 
Dubbink1, E.J. Kuipers1, A.M. van den Ouweland1, M.E. van Leerdam2, A. Wagner1, 
W.N. Dinjens1 
1ErasmusMC, University Medical Center, Rotterdam, Zuid-Holland, Netherlands; 
2Antoni van Leeuwenhoek, Netherlands Cancer Institute, Amsterdam, Noord-
Holland. 
Introduction: In approximately 30% of colorectal and endometrial cancer patients 
suspected for Lynch syndrome (LS) no germline mutations in the mismatch repair 
(MMR) genes are detected (van Lier et al., 2012; Leenen et al., 2012). Conclusive 
diagnosis for these patients is impossible as they potentially have sporadic tumors. 
The aim of this study was to screen for somatic aberrations in the MLH1, MSH2, 
MSH6 and PMS2 genes in patients suspected for LS without germline mutations. 
Methods: Multiplex snapshot assays and fluorescent in situ hybridization (FISH) 
probes were used to detect deletions of the MMR genes in 71 confirmed LS patients, 
27 suspected LS patients and 27 patients with MLH1 promoter hypermethylation. 
Additionally, the 27 tumor samples of suspected LS patients were screened for 
somatic mutations with the Ion Torrent Personal Genome machine (PGM) using a 
custom made MMR gene primer panel. Results: Preliminary results show loss of 
heterozygosity (LOH) at the indicated MMR gene locus in 15/24 tumors of confirmed 
LS patients, 12/14 tumors of suspected LS patients and 0/19 tumors of patients with 
MLH1 promoter hypermethylation. Somatic MMR gene mutations were detected in 
the tumors of 18/27 suspected LS patients. Overall, two or more somatic aberrations 
of the MMR genes were detected in 12/27 suspected LS patients, and in 8/27 of 
these patients 1 somatic aberration was found. Conclusions: Our study shows that 
44% of suspected LS patients without germline MMR gene mutations have two or 
more somatic MMR gene aberrations, indicating their sporadic origin. Therefore, we 
suggest to add LOH and somatic mutation analysis of the MMR genes to the 
molecular diagnostic workflow of LS. (van Lier MG et al. 2012;  
Leenen et al. 2012) 
 
ST66. UGT1A1 TA Dinucleotide Repeat Sizing Using Fragment Analysis  
A.N. Abou Tayoun1, F. de Abreu2, A.A. Suriawinata2, J. Pipas2, G.H. Ripple2, H.B. 
Steinmetz2, S.A. Allen2, L.J. Tafe2, G.J. Tsongalis2, J.A. Lefferts2 
1Geisel School of Medicine at Dartmouth, Lebanon, NH; 2Dartmouth Hitchcock 
Medical Center, Lebanon, NH. 
Introduction: A dinucleotide TA repeat length polymorphism in the UDP-
glucuronosyltyransferase (UGT1A1) promoter has been shown to affect expression 
levels in up to 10% of the general population. Although 6 TA repeats represents the 
wild type allele, the presence of 7 TA repeats is associated with lowered UGT1A1 
activity and the mild hyperbilinrubinemia manifested in Gilbert’s syndrome. Cancer 919
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doses of this chemotherapeutic agent compared to patients carrying the 6 TA repeat 
allele. Currently, there is a single FDA-approved assay for genotyping UGT1A1, 
which is scheduled to be taken off of the market. The use of irinotecan is common 
practice, therefore, the development of a reliable means of detecting this variant to 
deliver more efficacious therapy regimens is warranted. Methods: DNA from 5 cell 
lines of known genotypes was obtained from the Coriell Institute (NA17039, 
NA17119, NA17120, NA17139, NA17438) and used in assessing the performance 
characteristics of our new assay. Patient specimens that were previously tested with 
the FDA-approved Invader UGT1A1 assay (Hologic, Madison, WI) were used to 
assess acuracy. DNA was extracted using the Qiagen EZ1 Robotic Workstation 
(Qiagen, Valencia, CA) and all DNA was quantified using the NanoDrop 1000 
spectrophotometer (Thermo Scientific, Waltham, MA). The assay was based on PCR 
amplification and capillary electrophoresis for accurate sizing of the TA repeat copy 
number. Results: LOD was assessed by varying the amount of input genomic DNA 
used upfront in the PCR reaction. Our assay was able to give correct genotype calls 
using as low as 0.5 ng input DNA; however, the electropherograms began losing 
signal intensity at 1 ng or less so we established the LOD at 5 ng input DNA. We 
confirmed this by correctly identifying TA repeat sizes in 21/21 samples (100%) 
using 5 ng of genomic DNA. The accuracy of the UGT1A1 Fragment Analysis assay 
was validated using a total of 50 samples and all showed the expected results. Eight 
samples with common and rare genotypes (6/6, 6/7, 7/7, 5/7, 5/8) were tested in 
duplicate on multiple days to examine the precision of our assay. Reproducibility or 
the lack of inter-assay/within-assay variability was demonstrated when identical calls 
(100% precision) were made for the 8 duplicate samples at five independent runs 
generated by different operators. Conclusions: We have developed a simple and 
robust PCR fragment analysis assay for accurately determining TA repeat length in 
the UGT1A1 promoter. 
 
ST67. Development and Validation of a Clinical Molecular Diagnostic Test for 
TERT Gene Promoter Mutations C250T and C228T 
R. Gagnon, H. Yan, A.B. Rasheed, R.E. McLendon, P.J. Killella, Z.J. Reitman, M.B. 
Datto, S. Sebastian 
Duke University Medical Center, Durham, NC. 
Introduction: A recent study has identified a clinically relevant genetic alteration in 
the promoter region of TERT gene in malignant brain tumors. Patients exhibiting 
primary glioblastomas without a TERT mutation were observed to survive 
considerably longer (27 versus 14 months). All TERT alterations described in the 
study are point mutations described as C250T (g.-146C>T) and C228T (g.-124C>T). 
The promoter region of TERT is a highly GC-rich region (78%) that was particularly 
difficult to PCR amplifies to perform a standard Sanger sequencing test for a robust 
clinical assay using DNA from formalin-fixed, paraffin embedded (FFPE) specimens. 
Here we present the approach and methods used to successfully develop a clinical 
test for TERT mutations. Methods: This assay uses PCR followed by Sanger DNA 
sequencing to detect mutations C250T and C228T within the promoter region of 
TERT. Due to the paraffin sample requirement, the goal was amplify a <200 bp PCR 
product flanking the mutations. DNA was extracted from macrodissected FFPE 
biopsies. Successful amplification of the region required a proprietary Taq 
polymerase enzyme, DMSO, proprietary buffer, and MgCl2. The primers used 
contain M13 universal primer tails. PCR products are treated with ExoSAP-IT to 
remove excess PCR primers and nucleotides. These purified DNA amplicons were 
sequenced using M13 forward and reverse sequencing primers and the Big Dye 
Terminator v3.1 Cycle Sequencing Kit. These products were cleaned up using the 
Big Dye XTerminator Purification Kit and resolved using the ABI 3130xl Genetic 
Analyzer. Sequences were compared to the reference DNA sequence (GenBank 
Accession: NC_000005.9) for the TERT gene. Results: After a blinded 45-sample 
exchange with a translational clinical research laboratory, all results were 100% 
concordant. The limit of detection was established at 30% tumor content (15% 
allelic) with a DNA input limit of 1.2ng/L. Additional testing on a large number of 
archived brain tumor DNA specimens showed mutation frequency consistent with the 
published literature. Conclusions: Multiple different thermal cycling conditions and 
master mixes were attempted when trying to amplify the high GC rich promoter 
region of TERT gene. However, use of a proprietary Taq polymerase enzyme along 
with additives and PCR conditions were necessary to successfully develop this test.  
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 ST68. Optimizing Indel Detection for Next-Generation Sequencing In a 
Clinical Laboratory 
S. Roy, M.B. Durso, A. Wald, Y.K. Ng, Y.E. Nikiforov, M.N. Nikiforova 
University of Pittsburgh Medical Center, Pittsburgh, PA. 
Introduction: Detection of insertion and deletion (Indel) using NGS is a persistent 
challenge, especially with short read lengths. Although several bioinformatics tools 
focus on indel detection, none of the tools by itself assure enough accuracy and 
sensitivity required in a clinical laboratory or compatible with different sequencing 
platforms. However, appropriate combination of different algorithms in an analysis 
pipeline has been shown to improve sensitivity and specificity of indel detection. We 
present our laboratory’s experience in this domain. Methods: A total of 16 tumors 
(lung, colon, thyroid, breast, and hematopoietic) were sequenced on the Ion Torrent 
PGM platform using AmpliSeq v1.0 primer pool set starting with 10ng of DNA. 
Primary data analysis (Alignment, QC metric filtering, variant calling) was performed 
using the following: pipeline#1, Torrent suite v3.4.2, and pipeline#2, NextGENe 
v2.3.1. Pipeline#1 was executed automatically upon completion of sequencing 
reaction. FASTQ files generated from pipeline#1 were used as input for pipeline#2. 
Variant calls from both pipelines were reviewed and compared field by field. Manual 
review of sequence pileups were also performed for each indel event on IGV and 
NextGENe viewer of respective pipelines. Appropriate quality metrics were also 
recorded for each indel event. Results: A total of 16 indels (9 insertions and 7 
deletions) were detected across 16 samples in PTEN, TP53, EGFR, APC, MET, and 
KRAS genes. Overall sensitivity of indel detection by pipelines #1 and #2 was 68.8% 
and 75%, respectively. Use of both pipelines improved sensitivity to 87.5% (14/16). 
Sensitivity for detection of deletions was higher than insertions (100% vs 77.8%) 
using both methods. Four of the 14 indels (28.6%) detected were called at the 
incorrect position (few base pairs off) or had slightly different indel sequence. Two of 
the 16 indels (12.5%) were not detected by either pipeline. These two indels were in 
size range of 3-9 bps and occurred in a homopolymer region with borderline QC 
scores. Manual review of sequence pileups facilitated the detection of one of the 2 
missed indels and correction of the 4 mis-annotated indels. Conclusions: Use of 
two or more data analysis pipelines along with manual review of sequence pileups 
increases sensitivity of indel detection for targeted NGS panel. In a clinical laboratory 
this translates to more accurate results and improved patient care. 
 
ST69. Clinical Validation of an Amplicon-Based Next-Generation Sequencing 
Assay for Formalin-Fixed, Paraffin-Embedded Solid Tumors 
A. Oultache, K. Nafa, T.N. Mitchell, J. Sadowska, A. Zehir, D. Cheng, M.E. Arcila, 
M.F. Berger, M.R. Hameed, C.V. Hedvat 
Memorial Sloan-Kettering Cancer Center (MSKCC), New York, NY. 
Introduction: Somatic mutations in EGFR, KRAS, NRAS, and BRAF have been 
shown to play an important role in decision making of targeted therapeutics. This has 
paved the way towards discovery of new mutations and the potential to develop new 
drugs to target specific mutation associated pathways. Thus we are in the era to 
develop accurate, sensitive and high throughput genotyping assays to accommodate 
increasingly genotype-based therapeutic approaches. We describe the validation 
and clinical implementation of the Illumina TruSeq Amplicon-Cancer Panel (TSACP) 
interrogating hotspots in 48 cancer-related genes for routine testing. Methods: In the 
validation phase, we retrieved 84 FFPE DNA samples with known mutations in 
BRAF, KRAS, IDH1, PIK3CA, KIT, NRAS, ALK, EGFR, ERBB2, GNAQ, GNA11, and 
PDGFRA. All mutations were previously detected by either Sanger sequencing or 
Sequenom MassArray. DNA (250 ng) was used to prepare a library of 212 
amplicons, and sequenced on Illumina MiSeq platform. We used 140x160bp read 
length to improve the bidirectional coverage of variants located at the end of some 
amplicons. To assess reproducibility, nine samples were sequenced independently 
in triplicate in a single run and in three separate runs. Assay sensitivity was 
determined by serial dilutions of FFPE DNA with KRAS, BRAF, and IDH1 mutations. 
In the implementation phase 153 cases were tested (52 in duplicates). Alignment 
and variant calling was performed using MiSeq reporter analysis software followed 
by annotation with Annovar and Oncotator. Results: 84 solid tumor samples were 
successfully sequenced. Based on reproducibility studies, we established a minimum 
depth of coverage (DP) of 500x and a variant frequency (VF) of 10% to exclude low 
confidence calls that could not be confirmed and a lower DP threshold of 100x for 
reportable actionable variants. We also required that the specific mutation be 
covered bidirectionally with a Q-score of at least 20. Using these criteria, the known 
somatic mutations were successfully detected in 80 samples of the validation phase 
(95% concordance). Four mutations [GNAQ/Ex5(n=2), ERBB2/Ex20/ins12bp (n=1), 
KIT/Ex11/ins42bp (n=1)] were not detected. Although mutations could be detected at 
frequencies below 5%, artifacts introduced during the library preparation process 
required the application of a higher threshold to improve specificity. Duplicate testing 
showed that samples with multiples calls between 10% to 15% VF were not jmd.amjpathol.org ■ The Journal of Molecular Diagnostics
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TSACP cancer panel assay is a highly targeted approach enabling the screening for 
hotspot coding variants in a rapid and efficient manner for selected genes in a 
clinical setting. 
 
ST70. Development of an Array-Comparative Genomic Hybridization (aCGH)-
Based Algorithm to Assist Renal Tumor Subtyping in Needle Biopsies and 
Resected Specimens 
C. Ma1, B. Gowrishankar1, K.L. Stratton2, M. Spaliviero2, J.C. Durack2, S.B. 
Solomon2, A. Molina2, V.E. Reuter2, J.A. Coleman2, J. Houldsworth1 
1Cancer Genetics Inc., Rutherford, NJ; 2Memorial Sloan-Kettering Cancer Center, 
New York, NY. 
Introduction: Accurate diagnosis of renal cortical neoplasms is paramount in the 
management of patients with renal masses, including distinction between malignant 
(renal cell carcinoma [RCC]) and benign neoplasms (oncocytoma [OC]) or subtyping 
(clear cell, papillary, or chromophobe RCC [ccRCC, pRCC, chrRCC]) to guide 
therapeutic strategies. Challenges to diagnosis include a 15% non-diagnostic biopsy 
rate, morphologically similar benign (OC) and malignant (chrRCC) tumors, and the 
Unclassified-RCC subtype. Genomic alterations reported in RCC and OCs could be 
used in a clinical setting to assist in diagnosis. The goal of this study was to develop 
an algorithm to subtype renal cortical neoplasms based on copy number alterations 
(CNAs) detected in biopsy DNA by aCGH. Methods: Using publicly available The 
Cancer Genome Atlas (TCGA) aCGH datasets (489 ccRCC, 75 pRCC, 65 chrRCC) 
and an in-house fluorescence in situ hybridization (FISH) study, an algorithm to 
distinguish renal tumor subtypes was developed based on genomic gain and loss. 
After IRB approval, the algorithm was validated performing aCGH blindly on DNA 
extracted from 29 percutaneous needle biopsies using a custom-designed urogenital 
cancer array (UroGenRA) (4x44K), and from 126 resected specimens 
(predominantly ccRCC) using a 244K array (Agilent Technologies, Inc.). The subtype 
determined by the aCGH-based algorithm was compared with the reported histology. 
Results: Sixteen CNAs (seven gains, nine losses) classified ccRCC, pRCC and 
chrRCC in TCGA with a sensitivity of 90%, 71%, and 85%, and specificity of 92%, 
96%, and 98% respectively. Specimens exhibiting CNAs other than these 16 CNAs, 
were classified as “other neoplasms.” Those not exhibiting any CNAs were called 
“normal.” Of the 29 biopsies analyzed to date, four were non-diagnostic due to 
limited tissue availability and two were RCC-Unclassified specimens. Correct 
classification was obtained in 18/23 (78%) biopsies with sufficient material. For the 
two RCC-Unclassified specimens, aCGH afforded a classification. For resected 
specimens, 97/126 (77%) were correctly classified. Misclassification in both 
diagnostic settings could be due to low tumor burden, presence of other defining 
genetic abnormalities (mutation and rearrangements), and the inability of the 
algorithm to classify non-RCC tumors. Conclusions: This ongoing study suggests 
that aCGH could assist in the classification of renal neoplasms in a clinical diagnostic 
setting using the developed algorithm. Analysis of subtype-defining mutations (VHL 
and PBRM1) and reflex to FISH for the detection of rearrangements (CCND1) should 
be considered as ancillary assays to enhance diagnostic accuracy. 
 
ST71. Genotyping Multiple Somatic Mutations in Non-Small Cell Lung Cancer 
and Colorectal Carcinoma Using the SNaPshot Technology 
F.B. De Abreu, M.C. Schwab, C.C. Black, E.J. Gutmann, V. Padmanabhan, J.D. 
Marotti, J.R. Rigas, C.P. Erkmen, X. Liu, A.A. Suriawinata, G.J. Tsongalis, L.J. Tafe 
Dartmouth-Hitchcock Medical Center, Lebanon, NH. 
Introduction: In the past decade, significant advances in genomic technologies 
have allowed for better understanding of tumor cell biology and detection of somatic 
mutations in non-small cell lung cancer (NSCLC) and colorectal carcinoma (CRC). 
Some mutations occur in cancer-related genes that activate signaling pathways that 
are targeted by drugs already FDA approved or in advanced stages of clinical 
development. Since mutation profiling of tumors can contribute to a personalized 
therapeutic approach for cancer patients, we developed a genotyping assay 
designed to identify 57 mutations in eight genes (AKT, BRAF, EGFR, KRAS, MEK, 
NRAS, PIK3CA, and PTEN) using the SNaPshot Multiplex System technology. 
Methods: Genomic DNA was isolated from 14 formalin-fixed paraffin-embedded 
(FFPE) samples (eight NSCLC, three CRC, and three CRC cell lines) with known 
mutations using the Gentra PureGene Blood Kit Plus (Qiagen). The input DNA was 
normalized to 10 ng. All samples and a human control DNA (Promega) were 
amplified with unlabeled primers and subjected to a multiplexed extension primer 
reaction using the SNaPshot Ready Reaction Mix (Life Technologies). Capillary 
electrophoresis of PCR products was performed using the ABI 3500 Genetic 
Analyzer with POP-7 polymer and 50 cm capillary. The genotyping results were 
analyzed using Applied Biosystems GeneMapper 4.1 software. The results were 
compared with prior AmpliSeq results. Results: The human control DNA showed The Journal of Molecular Diagnostics ■ jmd.amjpathol.orgaccurate profiling of all wild-type alleles. All cell lines and 9 of 11 of the tumor 
samples were correctly genotyped (86%). Six of the NSCLC samples were positive 
for EGFR (1) or KRAS (5) mutations; one was wild-type and in another a KRAS 
mutation was not detected. Two CRC samples were positive for KRAS mutations 
(one KRAS mutation was not identified). Each cell line had 2-3 mutations detected in 
BRAF (2), EGFR (3), MEK1 (1) or PIK3CA (2), as expected. Conclusions: This 
multiplex assay allows us to interrogate eight of the most commonly mutated genes 
in NSCLC and CRC for detection of multiple actionable mutations in a single 
reaction. This SNaPshot assay is a highly sensitive and specific genotyping assay 
that allows us to create a prognostic and predictive tumor mutation profile. 
 
ST72. Minimally Invasive OligoFISH Prostate Cancer Screening Test 
S.T. Knuth1, M. Gildea1, R. Tinawi-Aljundi2, J. Day2, P. Yumpo2, P. Morgan2, M. 
Lutz2, J. Hafron2, J. Frontera2, C. Ng1, J. Dion1, J. Kahl1, K. Kernen 2, J. Aurich-
Costa1 
1Cellay, Inc., Cambridge, MA; 2Michigan Institute of Urology, St. Clair Shores, MI. 
Introduction: Many studies have investigated the polysomies that characterize 
prostate carcinoma, and aneusomies of chromosomes Y, 7, and 8 have been 
associated with poor prognosis. After analyzing the full karyotype of 100 cases of 
prostate carcinoma from the Mitelman database and 33 prostate cancer cases from 
Comparative Genomic Hybridization, we identified chromosomes Y, 7, 10, and 20 
and 6, 8, 13, 16, and 18, respectively, as those polysomies that occurred most 
frequently in prostate carcinoma. 
Trans-rectal prostate biopsies have a high false negative rate and don’t sample the 
entire prostate. This study utilized OligoFISH Probes for aneuploidy detection in 
voided urine immediately after prostate massage with the goal of finding a better 
prostate cancer screening method than PSA and prostate biopsy. Methods: On the 
day of biopsy, patients received a prostate massage by the urologist. The first urine 
was collected and slides were prepared, fixed in Carnoy and aged on a hot plate. 
Slides were pretreated at room temperature with protease, formalin and detergent. 
Cellular DNA was denatured at room temperature and the cells were hybridized for 
10 minutes with two 4-color FISH probe panels covering 8 total chromosomes: Y, 6, 
7, 8, 10, 16, 18, and 20. After washing, the slides were analyzed and 500 cells were 
scored for each set of probes. In this exploratory phase, 31 Caucasian men were 
recruited, and the OligoFISH results were compared to the biopsy and follow-up 
results. Results: Both the A (6, Y, 10, 8) and B (7, 16, 18, 20) probe panels were 
excellent in differentiating benign from cancer, with the area under the ROC curve 
being 0.87 and 0.91 respectively. Both panels showed an exceptional clinical 
specificity and sensitivity of 90%. In differentiating low grade (Gleason Score  6) 
from high grade (Gleason score > 6) lesions the area under the ROC curve was 0.71 
and 0.62, respectively. Both panels showed specificity of 78% and sensitivity of 64% 
between low grade and high grade lesions. Conclusions: Although this study 
includes a small sample (31 individuals), the results are very encouraging with 
regard to pursuing a full clinical trial. Use of this minimally invasive test could 
dramatically decrease the number of trans-rectal biopsies performed on men with a 
benign condition of the prostate. 
 
ST73. A Multi-Institutional Study: Evaluation of a Novel Technique that Uses 
Strand Specific Information to Increase Accuracy in a Next-Generation 
Sequencing (NGS) Assay to Identify Somatic DNA Variants 
N. Udar1, R. Haigis1, T. Gros1, N. Kerry1, B. Barnes1, D. Pokholok1, M. Ross1, G. 
Angelo2, G. Bien3, R. Daber4, M. Epstein5, K. Eterovic,Agda6, A. Elliott7, S. 
Roychowdhury8, E. Jaeger1 
1Illumina, San Diego, CA; 2Cancer Genetics, Rutherford, NJ; 3Clarient, GE 
Healthcare, Aliso Viejo, CA; 4University of Pennsylvania, Philadelphia, PA; 
5Response Genetics, Los Angeles, CA; 6MD Anderson Cancer Center, Houston, TX; 
7Ambry Genetics, Aliso Viejo, CA; 8The Ohio State University Comprehensive 
Cancer Center, Columbus, OH. 
Introduction: Formalin-fixed, paraffin-embedded tissues (FFPE) are a common 
sample source for molecular characterization of neoplasms (especially solid tumors). 
FFPE samples are problematic due to the inherent damage and degradation of DNA. 
This multi-institutional study was conducted to test the accuracy of a next-generation 
sequencing (NGS) targeted amplicon assay across FFPE samples collected at 
several clinical laboratories to evaluate the accuracy of somatic variant detection in 
solid tumors. Methods: DNA was extracted from FFPE samples and qualified for 
suitability for NGS analysis with a qPCR assay developed by Illumina. Illumina’s 
TruSight Tumor library preparation assay was used for this study with the MiSeq 
personal sequencer. This library preparation method achieves low-frequency variant 
detection below 5% by combining deep sequencing (1000x minimum and 20,000x 
average read depth) with two independent primer pools that confirm variants on both 
strands of targeted DNA regions, allowing for differentiation of true variants from 921
9AMP Abstractsfixation artifacts. Variants called concordantly on both strands are reported as 
passing, providing a high degree of confidence. This targeted re-sequencing assay* 
investigates ~21 kb across 26 genes commonly mutated in solid tumors. Here we 
evaluated more than 240 samples across 8 institutions, including commercially 
available tissue blocks and cell lines. Results: A total of 247 unique samples were 
evaluated after successful library preparation. Amplifiability of the DNA extracted 
from the FFPE samples was found to be a more reliable criterion for assay success 
than DNA mass measurement. In a subset of 44 FFPE samples, the two-strand 
approach was able to identify approximately half of calls in the 3% to 10% variant 
frequency range as on strand-specific only. For previously-characterized variants 
present at >3%, the false negative rate was 0%. In addition, a comparison of 
matched fresh-frozen and FFPE samples provided new insight into the number, type, 
and frequency of artifacts resulting from each of these preservation methods. Using 
reference cell lines for evaluation, a total of 1.7 million calls were verified, providing a 
sensitivity and specificity of >99.9%. Unique variants identified included SNVs and 
indels up to 25bp. Conclusions: The TruSight Tumor library preparation assay is 
able to robustly evaluate somatic variation from FFPE samples collected at multiple 
laboratory sites. The unique assay design is well-suited for FFPE due to its 
robustness and ability to differentiate true variation from artifacts at the lowest levels 
of detection, making it highly tolerant to the variety of samples encountered through 
routine testing. 
*Research Use Only 
 
ST74. Systematic Evaluation of KRAS Mutation Detection Using an AmpliSeq 
Custom Panel and Ion Torrent Sequencing in 113 KRAS-Mutated Lung Cancers  
L. Borsu, M. Cavatore, A. Yannes, E. Brzostowski, J. Casanova, N. Lailler, D. 
Cheng, A. Viale, H. Yu, G. Riely, M. Ladanyi 
Memorial Sloan-Kettering Cancer Center, New York, NY. 
Introduction: As more therapies targeting genomic alterations become available, 
there is an increasing need for Next-generation sequencing (NGS) technologies in 
clinical genotyping. As any new clinical laboratory technology, NGS must be 
validated in formalin-fixed, paraffin-embedded (FFPE) tumor samples and 
benchmarked against existing diagnostic methods. Methods: To evaluate NGS, we 
selected 113 FFPE lung adenocarcinoma specimens previously tested in our CLIA 
laboratory for mutations in KRAS (codons 12 and 13) by Sanger sequencing +/- 
LNA-PCR sequencing (Arcila et al. JMD 13:64, 2011), and for 91 point mutations in 8 
oncogenes (including KRAS) on the Sequenom Platform (Rekhtman et al. Clin 
Cancer Res 18:1167, 2012). DNA was extracted from 4 to 10 unstained FFPE 
sections. AmpliSeq custom library construction was performed with 20 ng of FFPE 
DNA by multiplexed amplification of 1191 regions tiled by amplicons covering 65 
clinically actionable and research genes. NGS on the Ion Torrent PGM Sequencer 
resulted in mean regional coverage of 412 uniquely-mapping reads and median 
coverage of 366x for targeted exons, with > 100x coverage for 96% of targeted 
exons. Variant caller files (VCF) were generated by the Ion Reporter software and 
filtered for 100x coverage and 5% variant allele frequency. Filtered variants were 
annotated using Oncotator and KRAS mutations were compared against prior 
mutation results. Results: Sanger sequencing data for 113 samples (including 30 
tested by LNA-PCR sequencing) and Sequenom data for 104 samples were 
compared to NGS KRAS mutation status. Using the above filters for the VCF files, 
the expected KRAS mutations were found in 89 (78%) FFPE lung samples. An 
additional 6 (5%) concordant KRAS mutations were found in the VCF at less than 
100x coverage and another 16 (14%) were found by reviewing individual reads using 
IGV. One case previously diagnosed as a double KRAS mutant G12C/G12V (or 
G12F) by Sanger showed only the G12C mutation by NGS and the latter result was 
further confirmed by additional LNA-PCR sequencing. Two samples previously 
diagnosed as KRAS mutated did not show any variant reads at codons 13 or 13 by 
NGS due to low DNA quantity. Conclusions: AmpliSeq+Ion Torrent sequencing 
identified the correct KRAS mutation in 111/113 (98%) FFPE tumor samples 
previously tested by other clinical laboratory methods. The KRAS mutations in 6 low 
coverage and 16 “IGV only” samples were not found using the default parameters of 
the PGM variant caller, indicating the need for further optimization of variant calling.  
 
ST75. Multi-Gene Mutational Profiling of Lung Carcinoma Using Next-
Generation Sequencing (NGS) 
S. Roy Chowdhuri, M. Routbort, K.P. Patel, R. Kanagal-Shamanna, R. Singh, G. 
Simon, R. Broaddus, K. Aldape, R. Luthra 
University of Texas MD Anderson Cancer Center, Houston, TX. 
Introduction: The prognostic and predictive role of molecular diagnostics in lung 
carcinoma patients has paved the path for targeted therapeutics in patients 
harboring clinically actionable mutations. The advent of next-generation sequencing 
(NGS) platforms in the realm of clinical molecular diagnostics has made multi-gene 22mutational profiling an affordable and highly successful methodology for massively 
parallel sequencing using small quantities of DNA. Methods: Tumor specimens from 
262 distinct samples of primary lung carcinoma including adenocarcinoma, 
squamous cell carcinoma, neuroendocrine carcinoma, small cell carcinoma and 
carcinosarcoma were selected for NGS testing. Tumor samples included formalin-
fixed paraffin-embedded surgical core needle biopsies, resection specimens, 
cytopathology cell blocks, as well as cytopathology direct smears. Ten ng of DNA 
from each sample was tested for mutations in hotspot regions of 46 cancer related 
genes (Ion AmpliSeq Cancer Panel) using either a 316 chip or a 318 chip on an Ion 
Torrent Personal Genome Machine (PGM) Sequencer (Life Technologies, CA). 
Results: EGFR mutations were detected in 62 (24%) cases as either point 
mutations (n= 28) or indels (n= 34). Concurrent mutations in EGFR were identified in 
10 cases including acquired resistance mutations (T790M, S768I and V769M) in 8 of 
the 10 cases. KRAS mutations were detected in 62 (24%) cases, most commonly 
involving codons 12 and 13 (n= 58) and less frequently involving codons 61 and 146 
(n= 3). Mutations in TP53 were detected in 77 (29%) cases of which 14 (5%) were in 
conjunction with EGFR mutations and 15 (6%) were in conjunction with KRAS 
mutations. No somatic mutations were detected in 24 cases (0.09%). Additional 
mutations were detected in STK11, ATM, BRAF, PIK3CA, CTNNB1, IDH1, NRAS, 
CDKN2A, KDR, RET, MET, FBXW7, APC, RB1, FLT3, GNAS, ABL1, HRAS, 
PTPN11, JAK3, NOTCH1, SMAD4, SMARCB1, SMO, MLH1, AKT1, and ERBB4. 
Conclusions: These results show that NGS-based 46-gene mutational profiling can 
be performed on lung carcinoma specimens and provide multi-gene mutational 
analysis that can be useful for directing personalized cancer therapy.  
 
ST76. SNP and INDEL Detection for Solid Tumors, Comparative Studies with 
Torrent Suite and CLC Genomics Server Bioinformatics Pipelines 
Z. Tu, J.S. Voss, E.G. Barr Fritcher, J.L. Winters, B.R. Kipp, E.W. Klee 
Mayo Clinic, Rochester, MN. 
Introduction: Ion Torrent PGM (Personal Genome Machine) is a next-generation 
DNA sequencing platform that has been used for clinical genome sequencing. The 
PGM includes a computer server with the Torrent Suite (TS) bioinformatics pipeline 
for sequence read alignment and variant detection. To investigate the optimal 
bioinformatics approach, we performed a study comparing results from CLC Bio 
Genomics Server (CLC) v4.1 software and the Torrent Suite v3.4. Methods: Solid 
tumor DNA was extracted from FFPE samples followed by PCR amplification for 
selected 50 genes. DNA sequencing was performed on the PGM. Sequence data 
were then aligned against the human genome (hg19) and variants called by TS 
using default settings. The raw fastq files were also exported and analyzed with 
CLC. Variants reported by both analytical packages were filtered by >50x depth of 
coverage and > 5% variant frequency. Filtered variants were compared between the 
two software packages and any discrepancy was further examined with DNA 
sequence data from an Illumina Miseq from the same tumor samples. Results: The 
CLC reported 339 SNPs and TS reported 267 SNPs from 18 tumor samples. The 
two software packages had 251 matching SNP calls that comprised 74% of CLC 
calls and 94% of TC calls. There were 71 (21%) out of 336 CLC SNPs that could be 
classified as likely false positives due to strand bias or read position bias. There 
were 5 SNPs CLC failed to call due to proximity to the end of the amplicon (false 
negatives). In contrast, there were 7 (3%) TS reported SNPs classified as false 
positives and 18 (7%) false negative SNPs. For small INDELs, CLC reported 
substantially more variants; however, more than 90% could be accounted for by 
matching the same site INDELS across specimens or filtering homopolymer stretch 
variants. For large INDELs, we examined 10 samples with known mutations. TS 
appeared to detect INDEL lengths up to 13 nucleotides. The CLC default aligner was 
limited to INDEL detection up to 8 nucleotides; however, utilizing the CLC beta-
aligner in parallel was able to detect INDELs up to 15 and 18 nucleotides. 
Conclusions: Our results demonstrate that it is feasible to use the CLC Genomics 
Server program to analyze Ion Torrent sequencing data by employing customized 
filters for artificial variants arising from homopolymer regions. CLC called slightly 
more variants than TS and was also able to detect large INDELs using the beta-
aligner.  
 
ST77. Evaluation of Absence of Heterozygosity at Testicular Germ Cell 
Cancer Susceptibility Loci in Metastatic Teratomas 
K.J. Ouyang, P. Matlock, H. Drendel, G.H. Vance 
Indiana University School of Medicine, Indianapolis, IN. 
Introduction: Testicular germ cell tumors (TGCT) are the most common malignancy 
in young males between the ages of 15 and 44 of European ancestry with an overall 
incidence that has more than doubled over the past 50 years. Teratomas represent a 
subgroup of TGCTs with immense histologic diversity, consisting of well 
differentiated, mature tissues only or also including immature, fetal-like tissues. The jmd.amjpathol.org ■ The Journal of Molecular Diagnostics
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disease, and is the third highest among all cancers. Several susceptibility loci for 
TGCT have been identified by genome-wide association studies (GWAS) in recent 
years. Although it has been reported that numerous cancer susceptibility loci in 
mouse models show somatic absence of heterozygosity (AOH) in acquired tumors, a 
correlation between the inherited and somatic aspects of TGCT in humans is 
unclear. This study aims to investigate if recently mapped susceptibility loci for TGCT 
show evidence of somatic AOH in a collection of metastatic teratoma tumors. 
Methods: High resolution SNP array analysis was performed on tumor DNA isolated 
from nine frozen tissue specimens of metastatic grade 2 or 3 teratoma tumors 
(Affymetrix CytoScan HD, Affymetrix, Santa Clara, CA). Absence of heterozygosity 
was assessed for SNPS surrounding recently identified TGCT susceptibility loci near 
the following genes KITLG (12q21.32), SPRY4 (5q31.3), UCK2 (1q24.1), TERT-
CLPTM1L (5p15.33), DMRT1 (9p24.3), HPGDS (4q22.2), MAD1L1 (7p22.3), 
RFWD3 (16q22.3), TEX14-RAD51C-PPM1E (17q22), ATF7IP (12p13.1), DAZL 
(3p24.3), and PRDM14 (8q13.3). Results: Regions surrounding the genes KITLG, 
SRY4, TERT-CLPTM1L, DMRT1, and RFWD3 showed evidence of absence of 
heterozygosity in more than 50% of samples analyzed, with AOH surrounding KITLG 
being the most prevalent (7 out of 9 samples). Furthermore, four out of nine samples 
showed evidence of AOH in more than half of the susceptibility loci evaluated, with 
the highest sample demonstrating AOH in 8 out of 12 loci. Conclusions: These 
results support a preliminary pattern of AOH in metastatic teratoma tumors 
surrounding susceptibility loci identified by GWAS and may provide further insight 
into the pathogenesis and prognosis of disease. 
 
ST78. Atypical Patterns of ALK Break-Apart FISH Analysis Indicate High 
Proportion of Positivity for ALK by Alternative Testing Methodologies 
D.L. Aisner1, R.C. Doebele1, F.R. Hirsch1, D.R. Hout2, A.T. Le1, L. Xian1, B.L. 
Schweitzer2, A.E. Baron1, K. Lawrence2, T. Boyle1, S.W. Morris3, D.R. Camidge1, M. 
Varella-Garcia1 
1University of Colorado, Aurora, CO; 2Insight Genetics, Nashville, TN; 3Morriss 
Laboratories, Memphis, TN. 
Introduction: Demonstration of ALK rearrangement has been shown to have 
significant clinical impact in the therapy of NSCLC patients. Currently, the largely 
used test for evaluation of ALK rearrangement is the Vysis ALK Break Apart FISH 
Probe Kit IVD approved by FDA as a companion diagnostic assay for the ALK 
inhibitor crizotinib. Criteria for scoring in this assay are well defined; however, 
occasionally results are observed that comprise a variety of 'atypical' patterns. It is 
unclear whether samples harboring these FISH patterns constitute cases in which 
patients could potentially benefit from targeted therapy. Alternative strategies for 
evaluation of ALK rearrangement status exist, including immunohistochemistry 
(IHC), quantitative RT-PCR for fusion events, and RT-PCR for ALK expression. We 
sought to determine whether cases that show atypical patterns are positive for ALK 
by alternative methods. Methods: Case files for ALK rearrangement were evaluated 
between October 2008 and December 2011 and 13 cases classified as 'atypical', 
due to presence of 3’ALK signal doublets or fused (5’ALK-3’ALK) signal doublets, 
pairs and clusters in the majority of tumor cells, and focal amplification in a minority 
of tumor cells, with material available for additional testing by alternative methods 
were identified. IHC using D5F3 antibody, RT-PCR for fusion products, and 
quantitative RT-PCR for ALK kinase domain region were performed. 
Results: Among 1426 NSCLC, atypical patterns were rare: focal amplification 
(0.8%), scanty amplification (<10% of tumor cells) (1.1%), duplication of the entire 
native ALK (2.9%) and of the 3’ ALK end (0.6%) for a cumulative identification in 
5.5% of all tested cases. 13 cases showing atypical patterns were identified with 
sufficient material for additional testing. Of the 13 atypical cases, 6 (46%) 
demonstrated positive findings by at least one other methodology, and 4 (30.7%) of 
these cases demonstrated positive findings by at least two alternate methodologies. 
Fusion was demonstrated by RT-PCR and sequencing with identification of fusion 
partner in 5 cases. Conclusions: These findings indicate that although criteria for 
scoring the break-apart FISH assay for ALK rearrangement are clearly defined for 
positive and negative calls, some cases may fall into a category warranting further 
evaluation. Laboratories should consider recording atypical patterns for reporting 
potential utility of alternate testing platforms, despite negativity by established 
criteria. Determination of whether these findings correlate to a positive response to 
targeted therapy merits further investigation. 
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 ST79. Development of a Sample Preparation Quality Control Pipeline for 
Large Scale Genomic Analysis from Needle Core Biopsy Material 
N.S. Kip, S.E. Kerr, L. Kane, T. Veldhuizen, J. Gorman, T. Plummer, A. Clayton, B. 
Kipp, K.M. Rumilla 
Mayo Clinic, Rochester, MN, Rochester, MN. 
Introduction: Large scale genomic analysis (LGA) of cancer (exome sequencing, 
array CGH) requires a large quantity of high-quality nucleic acid. Most pipelines for 
LGA require snap frozen samples of large tumor excisions, which are easily 
assessed for quality control (QC) parameters such as tumor percentage. Image 
guided needle core biopsies provide an attractive alternative from both a patient 
safety and outpatient billing perspective, but these limited tissue specimens provide 
a unique challenge for sample QC. We describe the preliminary development of a 
QC pipeline for needle core biopsies to be used in LGA of cancer. Methods: 
Consecutive needle core biopsies obtained by image guidance (120 patients with 
173 individual cores) were retrospectively reviewed. H&E stained slides were scored 
to evaluate three potential methods of QC: End verification (EV), bisection (BS), and 
whole core (WC). EV evaluated whether one (EV1) or both (EV2) 10% end 
segment(s) of each core predicted sufficient tumor in the middle 80% of the core. BS 
evaluated 50% of each core for QC. WC used one randomly selected core from a 
particular case as the QC tissue for the remaining cores. Highly fragmented cores 
were scored as a single core. A threshold of 50% non-necrotic tumor nuclei was 
considered sufficient for LGA. Concordance of the QC sample with the remaining 
tissue was considered as follows: true positive (TP) = QC correctly predicted 
sufficient tumor; true negative (TN) = QC correctly rejected insufficient tumor; false 
positive (false acceptance, FA) = QC falsely accepted insufficient tumor; and false 
negative (false rejection, FR) = QC falsely rejected a sufficient tumor sample. 
Results: Of 173 cores, 126 were found to contain tumor from which nucleic acid 
could be extracted. Concordance (TP + TN) rates for EV1, EV2, BS, and WC were 
75%, 70%, 79%, and 76%, respectively. FA rates were 11%, 2%, 7%, 12%, and FR 
were 14%, 28%, 14%, 12%, respectively. Conclusions: Although the lowest 
discordance rates were obtained with BS, the lowest false acceptance rate was 
obtained using EV2. In our view, the most important factors in this QC pipeline are 
limiting FA of insufficient tumor samples and obtaining enough tissue volume for 
optimum nucleic acid quantity. Balancing these factors, we have chosen EV for 
direct prospective comparison to frozen section evaluation of needle cores for the 
second phase of QC pipeline development, which will also evaluate nucleic acid 
quality and quantity from such samples.  
 
ST80. High Proportion of Gene Fusion Events Detected by FISH in Selected 
Lung Adenocarcinoma  
D.L. Aisner1, C. Bennati2, S. Mahale1, L. Xu1, A.T. Le1, E. Berge1, R. Chiari2, L. 
Crino2, D.R. Camidge1, P. Bunn1, R.C. Doebele1, M. Varella-Garcia1 
1University of Colorado, Aurora, CO; 2Azienda Ospedaliera Santa Maria della 
Misericordia, Perugia, Italy. 
Introduction: Identification of oncogenic fusions in NSCLC has major clinical impact 
for several recently identified fusion events, including ALK, ROS1, and RET 
rearrangements. In each of these examples, a positive finding may indicate 
substantial benefit from specific targeted therapy agents. These fusions have been 
evaluated in multiple cohorts previously, and are relatively uncommon in unselected 
populations of patients with NSCLC. We sought to investigate their frequency in a 
highly pre-selected population using FISH. Methods: We obtained material from 28 
advanced-stage lung adenocarcinoma from never-smoker patients demonstrated to 
be negative for EGFR and KRAS mutations (cohort 1, C1)) to be screened for the 
presence of gene fusion events in ALK, ROS1 and RET. To further explore the 
performance of the RET FISH probe, we extended the RET FISH analyses to a 2nd 
cohort of advanced-stage lung adenocarcinomas, including 51 patients--
predominantly never-smokers--whose tumors were previously determined to be wild 
type for EGFR, KRAS, ALK and ROS1 (Cohort 2, C2). Evaluations were performed 
using a combination of commercially available reagents and custom designed 
probes including a three-color combined fusion/break-apart probe for KIF5B:RET 
rearrangement. Positive cases were investigated by RT-PCR and sequencing. 
Results: Of the 28 C1 cases, gene fusion events were identified in 7 (25%), 
including 2 ALK+ cases (7.1%), 3 ROS1+ cases (10.7%) and 2 RET+ cases (7.1%, 
one compatible with KIF5B:RET and the other with non-KIF5B fusion partner). Of the 
51 cases in C2, 8 (15.6%) exhibited FISH patterns indicative of RET rearrangement. 
From those, 4 were compatible with KIF5B:RET and 2 were compatible with non-
KIF5B fusion partner, all confirmed by RT-PCR. One case showed an atypical 
KIF5B:RET pattern and was confirmed by RT-PCR to harbor a fusion. No abnormal 
PCR product was found in the 8th case with RET rearrangement detected by FISH. 
7 of 8 RET-positive patients in C2 were never smokers. Of all cases in C2, 34 were 
from never-smokers, indicating a final RET+ detection rate of 20.5% in never 923
9AMP Abstractssmokers from C2. Conclusions: These findings indicate a high proportion of 
detectable gene fusion events in NSCLC specimens from never-smokers selected 
for absence of other well characterized genetic alteration. This indicates the 
importance of evaluation for uncommon fusion events in cases in which other well 
characterized alterations have been excluded, and may be even more critical in 
never-smokers. The study also demonstrates utility of the FISH platform for detection 
of gene fusions in small FFPE lung cancer specimens. 
 
ST81. Comprehensive Genotyping of 4341 Lung Adenocarcinomas Using a 
Combination of Mass Spectrometry Genotyping, PCR Sizing Assays and FISH 
M.E. Arcila, L. Borsu, Y. Liu, M.F. Zakowski, M.G. Kris, M. Ladanyi 
Memorial Sloan Kettering Cancer Center, New York, NY. 
Introduction: Somatic mutations within several key components of tyrosine kinase 
signaling pathways have been shown to drive lung adenocarcinomas. With the 
advent of targeted therapies, prospective tumor genotyping for a growing number of 
clinically relevant genetic alterations is becoming necessary. Assays should allow 
the assessment of a wide range of tumors samples with highly variable DNA quality 
and quantity and of relatively low tumor content. In this study, we report on the 
largest single institution cohort of lung adenocarcinoma patients screened by mass 
spectrometry genotyping assays using the Sequenom platform. Methods: 
Consecutive tumors samples accrued in our clinical laboratory between 1/2009 and 
1/2013 were analyzed for 92 recurrent point mutations in EGFR , KRAS, NRAS, 
HER2, BRAF, PIK3CA, AKT1, and MAP2K1 using a multiplexed mass spectrometry 
genotyping (Sequenom) assay. All cases were also tested for indels in EGFR exon 
19 using a fragment analysis assay. Subsets were also concurrently tested for indels 
in exon 20 of EGFR and HER2 and, in mutation negative cases, for ALK fusions by 
FISH. Results: A total of 4,341 cases were successfully analyzed (failure rate <1%). 
Of these, 230 cases were excluded from final analysis due to duplicate testing (small 
biopsies & resection of same tumor, recurrences with same mutation profile) and or 
very low tumor content where a false negative result could not be ruled out. This left 
a total of 4,111 unique tumor samples; 61% showed at least one genetic alteration. 
The median age of the patients was 67 years (range 19 to 97), 60% were female and 
25% never smokers. KRAS mutations were found in 33%, 22% harbored EGFR 
mutations, 1% BRAFB, 2% PIK3CA, 1% ERBB2 and less than 1% MEK1, NRAS, 
and AKT1. In contrast to common EGFR mutations, minor EGFR mutations (codons 
S768, G719, L861, E709) were more prevalent among smokers (72% (49/68) vs 
43% (352/823), p=0.0001). Of cases tested by FISH, 7% showed ALK 
rearrangements, for an estimated overall rate of 3.5%. With the exception of 
PIK3CA, AKT1 and minor EGFR mutations, all mutations were mutually exclusive 
(excluding cases of EGFRT790M in the resistance setting). Conclusions: To our 
knowledge, this study represents the largest comprehensive analysis of currently 
known, recurrent oncogenic mutations in lung adenocarcinoma. The Sequenom 
platform is robust and applicable to a wide range of samples. Prospective testing 
allowed the identification of targetable oncogenic mutations in over 60% of cases 
with direct impact on the management of these patients. 
 
ST82. Profile: A Comprehensive Multiplexed Analysis of Critical Cancer Gene 
Mutations in Clinical Specimens from Every Patient in a Cancer Center 
E.P. Garcia1, F.C. Kuo1, Y. Jia1, D. Zepf1, L. Crosby1, M.N. Byrne1, J.E. Wade1, R. 
Joshi1, J. Conneely1, A.L. Manning1, P.R. Shivdasani1, L.P. Chung1, X. Gong1, C. 
Hatton2, M.D. Ducar2, P. Van Hummelen2, L.M. Sholl1, B.J. Rollins2, N.I. Lindeman1, 
L.E. MacConaill1 
1Brigham & Women's Hospital, Boston, MA; 2Dana Farber Cancer Institute, Boston, 
MA. 
Introduction: Detection of critical cancer gene mutations in clinical tumor samples 
enables identification of patients for whom novel or investigational targeted therapies 
afford a greater potential for cure than conventional cytotoxic chemotherapy. 
Traditional clinical cancer genotyping programs have focused on a limited selection 
of specific mutations in specific tumor types (e.g., BRAF in melanoma, EGFR and 
ALK in lung adenocarcinoma), but the recent pace of scientific discovery is such that 
continued reliance on a “one gene at a time” approach is becoming unsustainable. 
With the goal of advancing this vision of precision cancer medicine, we established 
Profile, a prospective study that combines a comprehensive administrative and 
information technology (IT) infrastructure with advanced technology to enable 
multiplexed molecular characterization of every cancer patient seen at the Dana 
Farber Cancer Institute and Brigham & Women’s Hospital. Methods: Mass 
spectrometry based nucleotide extension genotyping (OncoMap, Sequenom) was 
validated and performed in our clinical laboratory on fresh, frozen or formalin-fixed, 
tissues from all cancer patients in our institution who provide informed consent. The 
assay interrogates 471 specific single nucleotide variants or small 
insertions/deletions alterations across 41 different genes. Results are deposited into 24a secured research database that can be mined to identify trends and associations 
between cancer types, mutational status and patient outcomes. Results: Four 
thousand three hundred forty-five samples were analyzed between August 11, 2011 
and May 20, 2013. This represents 42% of all patients who consented to the testing; 
the remaining patients had samples that were either unavailable or insufficient for 
analysis. Of the samples that were tested, 42% showed at least one mutation 
detected by Oncomap; of these, 21% were clinically actionable. The results 
confirmed those reported by other groups: TP53, KRAS, and PIK3CA mutations 
were the most common alterations seen across all tumor types; KRAS and EGFR 
mutations were common in lung cancer, KRAS, TP53, and APC mutations were 
common in colon cancer, PIK3CA mutations were common in breast and 
endometrial cancers. Conclusions: Multiplexed genotyping of every cancer patient 
in a cancer center is feasible. Although many patients were not able to be tested, 
nearly 4500 samples were tested in an ~18 month period, with ~1800 patients 
showing a mutation that could, potentially, respond to a targeted therapy. The 
transition to next-generation sequencing in 2013 promises to increase both the 
number of patients with testable samples as well as the number of actionable 
mutations detected. 
 
ST83. Evaluation of the Qiagen EGFR RGQ Real-Time PCR Assay Versus 
Sanger Sequencing in Lung Cancer Tumors 
J. Sipley1, L. Cong1, V. Moroz1, J. Guo1, H. Rennert2 
New York Presbyterian Hospital-Weill Cornell Medical Center, New York, NY; 2Weill 
Cornell Medical College, New York, NY. 
Introduction: Sanger DNA sequencing of EGFR PCR products is a common 
method of EGFR analysis. A number of drawbacks of DNA sequencing include its 
low sensitivity (~20%), length of time and expertise needed to perform the assay and 
potential for contamination from post-PCR products. Methods: EGFR normal and 
mutant tumors from twenty five lung cancer patients were mounted as either PET or 
formalin-fixed FNA slides for the evaluation. Appropriate tumor areas were assessed 
for neoplastic content by the NYPH-Surgical Pathology Department and submitted 
for molecular testing. Additional FFPE samples harboring EGFR-mutated DNA 
control material were obtained commercially from Horizon Diagnostics (Cambridge, 
UK). Genomic DNA was extracted using an FFPE extraction method (Qiagen) and 
stored at 4°C until subsequent analysis. Testing was performed using the EGFR 
RGQ PCR Kit (Qiagen) for the detection of specific mutations, insertions, and 
deletions in the EGFR gene and 10 ng of template DNA in a total of seven separate 
PCR reactions per test on the Rotor-Gene Q thermal-cycler. Results: One hundred 
percent concordant results for mutations within the 29 somatic mutations panel were 
obtained using the new EGFR RGQ PCR Mutation Assay method for the 25 lung 
cancer tumors and five commercial FFPE-control DNAs versus testing results 
obtained by the previous in-house DNA sequencing method or reference lab 
(Integrated Oncology) PCR and DNA sequencing methods. Limit of detection studies 
using commercial FFPE controls detected Exon 18 G719S, Exon 19 delE746-A750, 
Exon 20 T790M, Exon 21 L858R and L861Q EGFR mutations at a sensitivity of 5%. 
The Sanger sequencing method detected three additional mutations in three lung 
cancer patients not within the 29 somatic mutation panel; including an insertion in 
Exon 20, an E709K mutation in Exon 18, and a G724S mutation in Exon 18. Two 
indeterminate results obtained by the in-house DNA sequencing method were 
identified by the EGFR RGQ PCR Mutation assay as a normal EGFR result, and an 
Exon 19 deletion mutation. Conclusions: The Qiagen EGFR RGQ PCR kit 
permitted more rapid and sensitive detection than the in-house DNA sequencing 
method for mutations within the 29 somatic mutation panel. Additional EGFR 
mutations that occur in patients not present within the 29 somatic mutation panel 
may not be detected by the EGFR RGQ PCR assay. 
 
ST84. Tumor Profiling: A Clinical Approach for Personalized Medicine 
A. Leon1, D. Dias-Santagata2, J.M. Marino1, K.D. Moreno1, R. Obrera1, Y. Kemel1, 
D.R. Borger2, L.P. Lee2, A.J. Iafrate2, J. Weisberger1 
1GenPath Diagnostics, BioReference Laboratories, Elmwood Park, NJ; 
2Massachusetts General Hospital and Harvard Medical School, Boston, MA. 
Introduction: Rapid identification of genetic alterations present in solid tumors is 
essential for personalized targeted therapy and patient outcome. Tumor molecular 
profiling of cancer patients has been demonstrated to be a better approach for the 
clinical management of cancer patients compared to conventional single 
gene/mutation analysis. OnkoMatch Tumor Genotyping, a laboratory developed 
multiplex amplification PCR and single-base extension assay was used to clinically 
profile 4000 cancer patients. This test enables the detection of the nucleotide 
present at 68 commonly mutated loci in 14 cancer genes (AKT1, APC, BRAF, 
CTNNB1, EGFR, IDH1, KIT, KRAS, MAP2K1, NOTCH1, NRAS, PIK3CA, PTEN, 
TP53) using genomic DNA from formalin-fixed, paraffin embedded tissues. jmd.amjpathol.org ■ The Journal of Molecular Diagnostics
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the DNeasy Blood and Tissue Kit (Qiagen) after macrodissection following pathology 
review. OnkoMatch Tumor Genotyping based on SNaPshot Multiplex system 
(Applied Biosystems) was performed using a minimum of 480 ng of DNA. PCR 
products were analyzed using the 3730 DNA Analyzer and data analysis was 
performed using the GeneMapper Analysis Software version 4.0 (Life 
Technology/Applied Biosystems). The average limit of detection across all loci was 
10% mutant/wild type allele. Results: A total of 5300 cancer patients have their 
tumor(s) molecularly characterized using OnkoMatch assay. The major groups 
analyzed include lung, colon, breast and skin malignancies. Approximately 47% of 
cases were positive for at least one pathogenic variant being 20% of them carriers of 
2 or more alterations. Genes commonly mutated were, in order of frequency: KRAS, 
EGFR, TP53, BRAF, CTNNB1, PIK3CA (lung adenocarcinoma, 55% positive cases); 
KRAS, TP53, BRAF, NRAS, APC, PIK3CA (colon adenocarcinoma, 72% positive 
cases); PIK3CA, TP53, AKT1 (breast carcinoma, 37% positive cases) and NRAS, 
BRAF (skin melanoma, 53% positive cases). In addition, multiple variants were 
detected in a significant number of cases such as 19% in lung adenocarcinoma and 
35% in colon adenocarcinoma, TP53 being the most common gene partner. 
Conclusions: These results demonstrate that tumor genotyping identifies 
prognostically and therapeutically relevant genetic alterations in a significant 
percentage of cases in a cost effective manner with a quick turnaround time. This 
approach should be considered for clinical guidance and treatment decisions. 
 
ST85. A High Frequency of Mutations Is Detected in Endometrial Cancer 
Using a Targeted Next-Generation Sequencing Approach  
J.S. Voss, B.R. Kipp, B.J. Winterhoff, G. Vasmatzis, C. Wang, A. Mariani, S.E. Kerr 
Mayo Clinic, Rochester, MN. 
Introduction: Recent studies have identified numerous genetic abnormalities in 
endometrial carcinoma using whole exome next-generation sequencing (NGS). The 
goal of this study was to assess a targeted NGS amplicon panel in endometrial 
carcinoma specimens collected during hysterectomy. Methods: Fresh frozen 
endometrial cancer samples were collected from 80 hysterectomy specimens. These 
patients were part of a case-control (43 cases, 37 controls) cohort matched for tumor 
subtype and grade, with cases either having positive lymph nodes at hysterectomy 
or recurrence of disease in follow-up. DNA was extracted from samples 
macrodissected from frozen tissue blocks to at least 60% non-necrotic tumor cells. 
DNA was processed for targeted NGS using the Illumina 48 gene Truseq Amplicon 
Cancer Panel per manufacturer’s instructions. Samples were subsequently 
sequenced on the Illumina MiSeq platform and data were analyzed by the MiSeq 
Reporter software v2.0 to detect variants with >10% allele frequency. Identified 
variants were manually reviewed to determine the final mutation calls. Results: 
Overall, 155 mutations were detected across 18 different genes, which included 
PIK3CA (n=41), TP53 (n=30), PTEN (n=17), KRAS (n=14), FBXW7 (n=14), CTNNB1 
(n=13), FGFR2 (n=8), APC (n=3), ERBB4 (n=3), ATM (n=2), KDR (n=2), MET (n=2) 
and one mutation in BRAF, EGFR, KIT, MLH1, RB1, and STK11. Tumor subtypes 
included 37 endometrioid-type grade 1 or 2, 17 endometrioid grade 3, 20 serous, 
and 6 clear cell carcinomas. Mutations were detected in 73/80 (91%) of all cancers. 
When analyzed by tumor subtype, mutations were detected in 33/37 (89%) of 
endometrioid grade 1 or 2, 15/17 (88%) of endometrioid grade 3, 19/20 (95%) of 
serous carcinoma and all 6 clear cell carcinoma. The most common genes mutated 
in endometrioid-type cancers were PIK3CA (35% of cases) and PTEN (31%); in 
serous cancers TP53 (85%); and in clear-cell cancers PIK3CA and KRAS (50%). 
There was no significant difference in the mutation occurrence when comparing 
cases or controls or lymph node status, even when only endometrioid cancers were 
considered. Conclusions: The results from this study suggest that mutations can be 
frequently detected in endometrial tumors using a targeted NGS multi-gene panel. 
The frequency of PTEN mutations in this cohort is lower than expected, suggesting 
that exon coverage for PTEN in this panel may not be adequate to detect all 
mutations. Further studies are needed to determine if NGS can be utilized to improve 
the detection of endometrial carcinoma in other samples types such as endocervical 
and endometrial cytology specimens. 
 
ST86. BRAF V600E Expression in Langerhans Cell Histiocytosis (LCH): 
Comparison of Immunohistochemistry with Molecular Studies  
N.S. Kip, E.R. Parrilla, K.M. Rumilla, A.C. Roden, X. Hu, R. Vassallo, J.H. Ryu, E.S. 
Yi 
Mayo Clinic, Rochester, MN. 
Introduction: Recently, a genomic study demonstrated the BRAF V600E mutation 
in 57% of LCH patients with subsequent reporting of this mutation in 40% of 
pulmonary LCH (PLCH) cases. We evaluated the BRAF V600E expression by The Journal of Molecular Diagnostics ■ jmd.amjpathol.orgimmunohistochemistry (IHC) in both PLCH and extrapulmonary LCH cases and 
correlated the IHC results with the mutational status of this gene by PCR.   
Methods: Following electronic search of LCH at Mayo Clinic Rochester during 1991-
2012, the glass slides were reviewed for confirmation of the diagnosis and the blocks 
harboring the most amount of LCH tissue were selected for both IHC and 
subsequent molecular studies. IHC slides were reviewed by 2 pathologists without 
the knowledge of molecular results. PCR study using formalin-fixed paraffin-
embedded tissue was done and the lesions were macrodissected from the unstained 
slides using the circled HE as a templated for DNA extraction. In cases with no initial 
amplification by PCR, the reaction was repeated using diluted DNA samples to 
reduce the effect of inhibitory substances that may interfere with PCR and scraping 
larger tissue sections to increase the yield of extracted DNA. The BRAF status by 
IHC and PCR was compared and the discordant cases were subjected to LNA-PCR 
with subsequent direct Sanger sequencing to verify the nature of the discordance. 
Results: Seventy nine LCH including 25 pulmonary and 54 extrapulmonary cases 
were evaluated with IHC. Seven cases did not have sufficient tissue for PCR and 72 
cases were attempted for molecular study. Nine of 72 (12.5%) cases were excluded 
due to insufficient material or no amplification in PCR reaction and the remaining 63 
cases were correlated for IHC and molecular results. Thirty six cases (57.1%) were 
negative and 22 cases (34.9%) were positive for BRAFV600E mutation by both IHC 
and PCR. Two cases (3.2%) were positive for IHC and wild type by PCR whereas 3 
cases (4.8%) were negative for IHC and mutant by PCR. LNA-PCR and sequencing 
were done on these 5 discordant cases and were successful in only 2 cases, which 
confirmed the PCR results in 2 mutant cases. Sequencing failed in the remaining 3 
cases including 2 wild types and 1 mutant. Conclusions: BRAF V600E protein 
expression by IHC correlated with mutational status by PCR in most cases (90.9%). 
LNA-PCR and sequencing on the discordant cases confirmed the PCR result, which 
indicates the occurrence of false positive and negative cases by IHC.  
 
ST87. Clinical Validation of Mutation Screening Assay Interrogating 409 
Cancer-Related Genes Using Ion Proton, a High Capacity Next Generation 
Sequencer  
R. Singh, J. Manekia, M. Harmon, H. Yao, R. Kanagal-Shamanna, K.P. Patel, M.J. 
Routbort, K.D. Aldape, R. Luthra 
The University of Texas MD Anderson Cancer Center, Houston, TX. 
Introduction: Detailed mutation profiling of tumors is warranted to identify mutations 
of prognostic and therapeutic significance. However, such analysis is frequently 
hindered by the amount of tissue available, especially in cases of solid tumors. Here, 
we describe validation of Ion Proton (Life Technologies, CA), a high capacity, semi-
conductor based next generation sequencer for mutational analysis of 409 cancer-
related genes using DNA from formalin-fixed-paraffin-embedded (FFPE) tissue. 
Methods: 28 archival FFPE samples (24 solid tumors, 4 cancer cell lines) with 
known mutations were sequenced. Genomic libraries were prepared using 
Comprehensive Cancer Panel (Life Technologies, CA). Genomic DNA (60 ng) was 
used to PCR amplify exonic regions of 409 genes, which were then clonally amplified 
and sequenced using Ion PI Template OT2 200 Sequencing 200 Kits (Life 
Technologies). Sequencing analysis and variant calling was performed by Torrent 
Suite software (V3.4.2 and V3.6.1). 20 sequencing runs were performed with 5 
multiplexed samples per run using Proton I chips. Assay sensitivity was determined 
using dilutions of cell line DNA (DLD1 into H460). Inter and intra-run reproducibility 
was also assessed. Results: All samples were sequenced successfully with more 
than 500,000 AQ20 reads/sample with an average sequencing output of 4.2 Gb and 
50 million sequencing reads/run. Out of 15992 amplicons, 92% and 76% had 
sequencing depth of 100x and 250x, respectively. Of the 74 previously identified 
mutations, Ion Proton detected 48 mutations (39/61 SNVs and 9/13 
insertions/deletions). Five mutations were missed due to lack of sequencing 
coverage (2 SNVs, 3 ins/del). Twenty-one mutations (20 SNVs, 1 ins/del) not called 
by the variant caller were evident in the aligned reads. Re-analysis via the latest 
software release V3.6.1 resulted in successful detection of all variants missed by 
V3.4.2. Sensitivity studies showed consistent lower limit of detection at 10% allele 
frequency. High levels of inter- and intra-run reproducibility were observed. The 
average turn-around-time was 4 days from the time of sample receipt. Conclusions: 
Our study demonstrates that Ion Proton is a sensitive and FFPE DNA compatible 
platform for comprehensive mutation analysis of solid tumors in a clinical laboratory. 
Advantages compared to other NGS platforms include requirement for small 
amounts of DNA and rapid turn-around-time. 
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AMP AbstractsST88. HER2/neu Amplification Assessed by an Amplicon Based Benchtop 
Next-Generation Sequencing Assay for Mutation Profiling 
M. Routbor, B. Portier, K. Patel, L. Medeiros, R. Singh, S. Hamilton, K.J. Aldape, R. 
Luthra 
University of Texas, MD Anderson Cancer Center, Houston, TX. 
Introduction: Next-generation sequencing (NGS) assays have the potential to 
incorporate simultaneous assessment of somatic mutations and copy number 
variation into a single platform. Although not specifically designed for this purpose, 
we noted numerous anecdotal examples of apparent gene amplification in our Ion 
Torrent (Life Technologies, South San Franscisco, CA) based 46-gene cancer panel. 
Methods: Existing amplicon coverage data from the TorrentSuite 2.0 (Life 
Technologies) pipeline were further processed to generate a HER2/neu coverage 
proportion, which we defined as the ratio between all HER2/neu amplicon reads and 
all other amplicon reads. We wrote a structured query language script to compute 
this ratio for 3316 unique previously analyzed clinical tumor samples. Our anatomic 
pathology system was then independently searched for molecular tests where the 
anatomic source material had either HER2/neu immunohistochemical (IHC) or FISH 
results. We correlated HER2/neu coverage proportions from 112 NGS samples 
where clinical HER2/neu amplification results were available. For this analysis, we 
did not restrict by tumor site/histology. Results: HER2/neu coverage proportions in 
the 3316 full sample population had a clearly non-normal distribution, with a median 
value of 0.0237 and a third quartile of 0.0281, but a fairly clearly defined population 
of outliers ranging from 0.05 to a maximum of 0.476. High HER2/neu coverage 
proportions correlated very well visually with samples that appeared to show 
evidence of amplification. In the 112 correlated samples, 17 showed a HER2/neu 
coverage proportion of > 0.05 (range 0.08 - 0.418). 16 of these 17 samples were 
also found to have HER2/neu amplification by IHC/FISH. One was classified as 
indeterminate (by IHC only). Of the 95 samples with NGS coverage proportion < 
0.05, 92 were negative for HER2/neu amplification by IHC/FISH, 1 was 
indeterminate, and two were positive with FISH ratios just above 2. This correlation 
between coverage proportion and IHC/FISH HER2/neu amplification was strong and 
highly significant (Spearman rank correlation rho 0.62, p < 1 x 10-10). Conclusions: 
Even on our limited somatic cancer panel involving less than 200 amplicons, 
clinically significant HER2/neu amplification can in most cases be readily identified. 
Strikingly, an additional finding was that 48 samples of the total 3316 studied had 
NGS evidence of amplification (coverage ratios > 0.05) but had never been 
assessed by IHC/FISH in the clinical record. We are in the process of reviewing 
these cases for possible clinical testing. These findings highlight the importance of 
considering copy number variation in NGS assays, even if intended for somatic 
mutation profiling.  
 
ST89. ABC Gene Expression in Tumor Cells Circulating In Peripheral Blood 
(CTC) in Patients with Ovarian Cancer: A Personalized Treatment 
E. Weismanova, P. Vitazka, L. Helpianska, J. Kaušitz , J. Mišíková , P. Weismann  
St. Elizabeth Cancer Institute Bratislava, Bratislava, Slovakia. 
Introduction: The ovarian cancer belongs to the malignant diseases with the 
highest mortality. One of the most serious problems in ovarian cancer therapy is the 
resistance to a wide spectrum of drugs.  
The ABC transporters are considered to be responsible for development of multi-
drug resistance.  
Our objective was to examine ABC gene expression in CTC and select drugs that 
are not substrates of over-expressed ABC transporters to personalize treatment. 
Methods: CTC were concentrated using antibodies EpCAM and anti-TAG-72. Total 
RNA was extracted by RNAzol RT, concentration, purity and RIN was determined. 
For cDNA reverse transcription was used the RNA with RIN>5. The cDNA was 
purified, concentration and purity was determined. The peripheral blood from healthy 
donor was used as wt sample in relative quantification. For RT-qPCR 50 ng of cDNA 
was used per reaction. The expression of selected ABC genes (8 genes) was 
quantified in paralelle using TaqMan Gene Expression Assays. Five reference genes 
were used for normalization. The RQ value was calculated when CtSD<2. The ABC 
genes with RQ>2 were considered as over-expressed. Results: Of total 35 patients 
we detected ABC over-expression in 19 patients (54.3%). The most frequently over-
expressed were ABCC3 (28,3%), ABCC4 (20.8%), ABCC1 (15.1%), and ABCC5 
(13.2%). The expression of remaining ABC genes (ABCG2, ABCC2, and ABCB1) 
was in interval <7.6% to 5.6%. ABCC11 was not expressed in any analyzed sample. 
Only one over-expressed ABC gene was detected in 7 patients, less than 4 ABC 
genes were detected in 7 patients and in 5 patients was detected from 4 to 7 over-
expressed ABC genes. Conclusions: Disease remission was confirmed in 9 ABC-
positive patients treated with combination taxans/platina. In these patients the over-
expression of ABCC1, ABCG2, ABCC3, ABCC4 and ABCC5 was detected (taxanes 
are substrates of ABCB1 and ABCC2 and platina is ABCC2 substrate). The therapy 926of this group of patients could be considered as optimal. Disease progression was 
confirmed in 10 ABC-positive patients. In 4 of them ABCB1 and/or ABCC2 over-
expression was detected. We can consider that progression in this group treated by 
taxans/platina could occurr as result of sub-optimal therapy. In 6 patients treated by 
taxanes/gemcitabine we detected preferentialy ABCC4 over-expression 
(gemcitabine is ABCC4 substrate). This group of patients was -comparable with 
previous group - treated sub-optimaly. According to the over-expressed ABC gene/s 
we could determine the drugs, which could be with high probability exported from 
cells and so less effective in therapy. 
 
 
TECHNICAL TOPICS 
TT01. A Sensitive and SiMPLe MPL Assay to Detect W515 L/A/R/K Mutations 
K. Pirelli, E. Biddle, C. Opansky, D. Dash, M. Parlow, I. Warshawsky 
BloodCenter of Wisconsin, Milwaukee, WI. 
Introduction: Somatic mutations in the MPL gene represent clonal markers in 
essential thrombocythemia (ET) and primary myelofibrosis (PMF) and serve as WHO 
major criteria for the diagnosis of these disorders. MPL exon 10 mutations are found 
in 5% to10% of patients with ET and PMF. At least five pathogenic mutations have 
been described, four at codon 515 (W515L, W515A, W515R, and W515K) and one 
at codon 505 (S505N). MPL mutations are usually found in cases that are JAK2 
V617F mutation negative, although a small number of patients have been reported 
with both mutations. MPL exon mutations have also been detected in patients who 
fall within the provisional WHO category of refractory anemia with ring sideroblasts 
associated with marked thrombocytosis (RARS-T). The purpose of this study was to 
develop a sensitive assay to detect MPL W515 mutations. Methods: MPL W515L, 
W515A, W515R, and W515K plasmid constructs were prepared and sequence 
verified for use as positive controls and to establish assay sensitivity. Following PCR 
amplification of MPL exon 10 in the absence or presence of a probe designed to bind 
and suppress amplification of wild-type codon 515, resultant PCR products were 
subjected to bi-directional sequencing using serial dilutions of plasmid DNAs mixed 
with genomic DNA. The assay was validated using 11 genomic DNA samples known 
to contain either W515K or W515L mutations and genomic DNA from 10 healthy 
controls. Results: Addition of the wild-type codon 515 blocking probe increased the 
sensitivity of mutation detection from ~20% to 2% using plasmids with four different 
MPL W515 mutations ( L/A/R/K). Six out of eleven genomic DNA samples known to 
be positive for MPL W515L and W515K mutations that were not detected by Sanger 
sequencing in the absence of a wild-type codon 515 blocking probe were 
unambiguously detected in the presence of the blocking probe. MPL mutations were 
not detected in any of the healthy controls. Conclusions: This is a simple method 
that can detect four MPL codon 515 mutations (W515L/A/R/K) in a single 
sequencing reaction, each with a sensitivity of 2%. The sensitivity of detecting MPL 
exon 10 mutations other than codon 515 is ~20%. This assay aids in the diagnostic 
work-up of PMF and ET where MPL codon 515 mutation burdens may be low. 
 
TT02. Design Software for Small Amplicon Genotyping by High Resolution 
Melting 
Z.L. Dwight1, R. Palais2, C.T. Wittwer1 
1University of Utah, Salt Lake City, UT; 2Utah Valley University, Orem, UT. 
Introduction: High-resolution melting is a straightforward technique for genotyping 
that relies on thermodynamic differences of PCR products and distinguishable 
melting profiles. Often, researchers use a variety of sources to design, validate, and 
assess PCR primers without the context of designing the final PCR product. To help 
aid researchers in designing assays with minimal input, we developed web 
accessible software, uDesign, to streamline the small amplicon design process by 
automating sequence retrieval, primer design, melting curve predictions for all 
products, and hairpin design if nearest-neighbor symmetry exists. Methods: The 
software requires only the rs# of the target SNV to create an assay. Public data for 
uDesign is queried via the user’s input rs#. The rs# retrieves the variant information 
as well as the surrounding sequence from NCBI through E-utilities. The resulting 
information is parsed from the query response and the primer design algorithm 
places the primers one base pair from the target SNV, continually adding bases until 
both primers have melting temperatures (Tm) close to 60°C (default value can be 
changed by user). Once primers are selected, the amplicon is assembled and 
predicted melting curves are calculated and displayed for all genotypes and 
duplexes using the uMelt algorithm. Product melting temperatures are derived from 
the curves along with the ǻT of the homozygous products. Primer melting 
temperatures are calculated using nearest-neighbor thermodynamics. If the ǻT of 
the homozygous products is less than or equal to 0.3°C, the algorithm appends a jmd.amjpathol.org ■ The Journal of Molecular Diagnostics
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formed after dilution. Results: Once the user has submitted a rs# and the design 
algorithm is completed, the full amplicon, individual primers, and melting curve 
predictions are displayed. Melting curves are plotted and labeled for both genotypes 
and duplexes. In addition Tms of both primers and the product, GC contents, the 
alleles present, and the frequency data retrieved from NCBI are displayed. Users 
may change the default primer melting temperature, adjust laboratory conditions, 
move primers or place constraints on primer length. A set of optimized PCR cycling 
conditions is also listed. Conclusions: By combining algorithms for primer design, 
nearest-neighbor thermodynamics, and melting curve prediction with NCBI web 
services, uDesign provides a singular, automated interface for design of small 
amplicon assays. The software was built with Adobe Flex 4.5 and is freely available 
without registration in a web application, uDesign 
(https://www.dna.utah.edu/udesign/index.html). 
 
TT03. Addressing CAP Inspection Question MOL 34900: A Universal Internal 
Positive Control to Detect False-Negative Allele-Specific PCR Reactions 
L. Yin, M. Parlow, I. Warshawsky 
BloodCenter of Wisconsin, Milwaukee, WI. 
Introduction: Allele-specific PCR (AS-PCR) is a sensitive method to detect low-level 
mutations that are important if the population of malignant cells carrying a mutation is 
small relative to the normal cell population. AS-PCR typically utilizes two separate 
PCR reactions – one amplifies the wild-type allele (or reference sequence) and the 
other amplifies mutant allele(s). One drawback to AS-PCR is the lack of an internal 
positive control in the mutant reaction to differentiate a true-negative result from a 
false-negative result due to either failing to add DNA to the mutant reaction or the 
presence of an inhibitor. One disorder where the population of malignant cells 
carrying a mutation is small and thus requires highly sensitive methods for mutation 
detection is systemic mastocytosis (SM). KIT codon 816 mutations (most often 
D816V) serve as a minor diagnostic criterion for SM in the WHO classification of 
hematopoietic malignancies, are found in mast cells in >95% of patients with SM, 
and are associated with resistance to imatinib mesylate. Detection of D816 variants, 
therefore, is important for diagnosis and treatment. Methods: A universal Internal 
Positive Control (IPC) reagent (primers and a VIC-labeled probe) (Life Technologies) 
to differentiate true negatives from false negatives was premixed with wild-type DNA, 
mutant DNA, no DNA, and DNA known to contain PCR inhibitors prior to AS-PCR. 
An AS-PCR assay designed to detect KIT D816 mutants with a sensitivity of 0.25% 
was performed by dividing the DNA/IPC reagent pre-mix into reactions containing a 
KIT specific FAM-labeled TaqMan probe and primers specific for D816 wild-type or 
D816 mutant alleles. Results: Premixing the IPC reagent with patient (or control) 
DNA distinguished true negatives from false negatives due either to failure to add 
DNA to the mutant reaction or the presence of an inhibitor without compromising the 
sensitivity of the assay. An inhibitor is suggested when the Ct of the IPC increases 
from an established reference range. Conclusions: The IPC reagent can be added 
to any AS-PCR assay that employs TaqMan chemistry to fully address CAP 
molecular inspection checklist questions pertaining to running internal controls to 
detect false negative reactions. In our example, assay sensitivity was not 
compromised by addition of the IPC reagent.  
 
TT04. Anglo-American Ring Trial Unveils Pre-PCR Error and False-Negative 
Results in BRAF and EGFR Clinical Cancer Diagnostics 
J.R. Kapp1, R.A. Hamoudi1, T. Diss1, I. Schrijver2, L.J. Jennings3, M. Li4, G.J. 
Tsongalis5, D. de Castro6, J. Bridge7, R. Butler8, A. Wallace9, S. Hing10, J. Spicer11, 
E. Verghese 12, G. Latham13 
1UCL Cancer Institute, London, Londonshire, England; 2Stanford University Medical 
School, Stanford, CA; 3Children's Hospital of Chicago, Chicago, IL; 4Baylor College 
of Medicine, Houston, TX; 5Dartmouth Hitchcock Medical Center, Lebanon, NH; 
6Institute of Cancer Research & Royal Marsden Hospital, London, England; 
7University of Nebraska Medical Center, Omaha, NE; 8All Wales Genetics 
Laboratory, Cardiff, Wales; 9St Mary's Hospital, Manchester, Machester; 10Great 
Ormand Street Hospital for Children, London, England; 11Guy's Hospital , London, 
England; 12Leeds Institute of Molecular Medicine, Leeds, United Kingdom; 
13Asuragen, Austin, TX. 
Introduction: Treating cancer patients with targeted kinase inhibitors relies on 
mutation testing employing sequencing methods that have improved exponentially in 
sensitivity, yet considering the association between pre-PCR and analytical 
accuracy, it is perhaps surprising that pre-PCR efficiency has not been 
systematically assessed in the clinical setting. In the present study, we employed 
novel FFPE reference materials containing pre-defined quantities of DNA, in turn 
harboring defined abundances of BRAF and EGFR mutations, to assess pre-PCR 
methods. Methods: We recruited 13 leading pathology centers from the US and UK The Journal of Molecular Diagnostics ■ jmd.amjpathol.organd distributed a total of 108 blinded FFPE specimens. The FFPE specimens were 
classed into 8 types. Types 1 to 4 were cell-line derived sections. Types 1 and 2 
carried EGFR p.G719S at 33%, BRAF p.V600E at 25% and EGFR p.L858R at 20%, 
BRAF p.V600E at 66% respectively. Types 3 and 4 carried corresponding wild-type 
alleles. Type 5 was a blank section devoid of amplifiable DNA. Type 6 comprised 
serial sections from a primary tonsil biopsy. Types 7 and 8 were duplicates of 1 and 
2. Each laboratory processed all 8 specimens according to their protocols. 
Participants returned specimens 1 to 6 for follow-up analysis, whilst specimens 7 and 
8 continued for sequencing. Results: Twelve of 13 centers reported nanodrop 
spectrophotometry for DNA quantitation. Self-reported measurements of DNA yields 
from 78 cell-line FFPE specimens were compared against expected and theoretical 
yields, resulting in an average recovery of 130.1% (95% CI, 104.7% to 155.4%) 
compared with theoretical yields, and an average recovery of 260.2% (95% CI, 
209.5% to 310.9%) compared with expected yields. Surprisingly, an average yield of 
235.8 nanograms(ng) (95% CI, 90.7 ng to 380.9 ng) was reported for the blank 
FFPE specimens. A total of 37 of 42 potential calls accurately reported the presence 
of mutations, with the 5 missed calls representing a false-negative rate of 11.9%. 
Conclusions: Follow up measurements with Qubit revealed a systematically lower 
value compared to NanoDrop. Across all labs, the median NanoDrop/Qubit ratio was 
5. Nanodrop users may wish to apply this ratio to normalise their values. Qubit 
measurements highlighted rather extraordinary disparities from lab-to-lab compared 
to NanoDrop. In conclusion, over quantitation of DNA yield compared to theoretical 
output was observed in relation to Nanodrop. A false-negative analytical rate 
approaching 12% was also associated with variation in quantitation, providing 
evidence for a causal relationship between pre-PCR and analytical accuracy. Further 
investigation and awareness is required to safeguard patients from errors stemming 
from pre-PCR analysis. 
 
TT05. Advantages of NanoString nCounter over RT-qPCR in Gene 
Expression Quantification of Severely Degraded RNA Samples 
B. Wei, K. Chang, M. Marton, J. Clair, L. Pang, R. Weiner 
Merck & Co., Inc., Rahway, NJ. 
Introduction: During initial evaluation of NanoString nCounter Analytical System for 
mRNA quantification of FFPE archived matched tumor versus adjacent normal 
specimens, we found poor correlations in tumor/normal ratios between NanoString 
and RT-qPCR with FFPE RNA, although good correlations existed between FFPE 
lysates and RNA with NanoString. To determine the cause of poor correlation, intact 
RNA samples from matched specimens were purposely degraded to varying extents 
and the tumor/normal ratios were examined to see if good correlations exist between 
NanoString and RT-qPCR in less degraded RNA, but not in severely degraded RNA 
due to poor RT-qPCR performance with these samples. Methods: Four RNA 
samples from matched human tumor and adjacent normal specimens from primary 
colon and lung tumors were degraded in TE buffer at 90°C at serial time points. At 
each time point, 100 ng of each RNA sample was evaluated with NanoString 
Customer Assay Evaluation Kit containing 48 genes. 600 ng of RNA was reverse 
transcribed to cDNA. Depending on gene expression levels, 1 to 4 ng of cDNA was 
utilized in each of the corresponding TaqMan qPCR assays. NanoString count data 
were log2 transformed and normalized with housekeeping genes ACTB and 
POLR1B, and compared with housekeeping gene-normalized Ct results from RT-
qPCR. Results: The correlations of tumor/normal ratios between NanoString and 
RT-qPCR in intact RNA samples were good, with Pearson correlation r = 0.96 for 
colon and 0.90 for lung specimens. The good correlations remain for the less 
degraded RNA samples with 90°C incubation time  5 hours. Although both 
technologies can work with short RNA fragments down to 70 bp, NanoString counts 
remain consistent and genes with count  20 in less degraded RNA samples usually 
remain quantifiable by NanoString in severely degraded RNA samples, whereas an 
increasing number of genes failed qPCR LLOQ starting from 6 hour time point, due 
to Ct value increase at gene-specific speed with increasing RNA degradation. The 
gene-specific Ct increases also create problem for the genes that degrade faster or 
slower than the housekeeping genes since their normalized Cts increased or 
decreased with increasing RNA degradation, causing their tumor/normal ratios 
potentially not reflecting biological difference, but difference in RNA degradation 
levels between the two samples. Conclusions: Although NanoString and RT-qPCR 
are comparable in gene expression analyses for intact RNA samples, for FFPE 
archived specimens that contain severely degraded RNA, NanoString offers better 
performance in sensitivity and accuracy and the advantage of utilization of FFPE 
lysate directly. 
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Quantitative Real-Time PCR in the Detection of MDM2 Amplification in Atypical 
Lipomatous Tumors/Well Differentiated Liposarcomas (ALT/WDL) 
S. Zhang, Q. Liang, M. Wei, D. Johnson, G. Wang 
The Joint Pathology Center, Bethesda, MD. 
Introduction: Atypical lipomatous tumors/well differentiated liposarcomas 
(ALT/WDL) represent the largest subgroup of aggressive adipocytic neoplasms. 
However, it is difficult to differentiate them morphologically from benign adipose 
tumors. MDM2 gene, an oncogene that inhibits P53 functions, is usually amplified in 
ALT/WDL and MDM2 gene amplification has been recognized as a useful marker for 
the differential diagnosis. We have developed interphase fluorescence in situ 
hybridization (FISH) and a quantitative real-time PCR (PCR) assays to detect MDM2 
amplifications in FFPE tissues. To better utilize these two assays in different clinical 
settings, this study explored the advantages and the disadvantages of these two 
assays. Methods: A total of 26 cases, including 11 WDL/ALT, 5 dedifferentiated 
liposarcomas, and benign adipose tumors, were included in the study. Dual-color 
probes, MDM2/Cep12, from Abbott Molecular, were used in FISH assay. An average 
ratio of MDM2/Cep12 FISH signals 2.00 or 10% cells with a MDM2/Cep12 signal 
ratio 3 with at least 100 cells counted are defined as positive for MDM2 
amplification. For PCR assay, a 70-bp MDM2 gene fragment and 74-bp ȕ-actin gene 
fragment were tested PCR. Ratios of MDM2/ȕ-actin PCR products 2.00 are defined 
as positive for MDM2 amplification. Results: Among 26 cases, 7 of 11 ALTs/WDLs 
and 5 of 5 dedifferentiated liposarcomas were detected as positive by FISH with 
signal ratio ranging from 2.01 to 9.86 (average 4.37). Except 1 FISH positive 
ALT/WDL case, the PCR assay yielded the same result as FISH did with MDM2/ȕ-
actin ratio from 2.01 to 16.80 (average 8.71). The concordance rate between FISH 
and PCR is 94%. None of 10 benign adipose tumors were detected in both assays. 
Conclusions: Results indicate that both FISH and PCR have high concordance rate 
for detecting MDM2 gene amplification. Both methods only require a small amount of 
tissue. FISH can detect MDM2 amplification in fewer cells among a majority of 
MDM2 non-amplified adipocytes, whereas PCR assay requires relatively high 
percentage of MDM2 amplified cells. Despite of these facts, PCR has its advantages 
over FISH assay in detecting MDM2 amplification. The PCR assay is easier and 
faster than FISH to get the results, which will be more important in a busy clinical 
setting. The PCR assay can be more accurate to quantitatively measure MDM2 
amplification than FISH when the MDM2 copy number is high. Therefore, it would be 
wise to select FISH or PCR according to your sample condition and the purpose of 
your study. 
 
TT07. Extreme PCR Amplification on an In-Line PCR Microfluidic System 
R.J. Pryor1, J.S. Farrar1, S.O. Sundberg2, J.S. Coursey2, C.T. Wittwer1 
1University of Utah, Salt Lake City, UT; 2Canon US LifeSciences, Inc, Rockville, MD. 
Introduction: PCR speed is not limited by chemical kinetic requirements but by 
instruments that are not able to temperature cycle rapidly. Extreme PCR, as recently 
introduced, is capable of pushing the chemistry to its limits and provides high 
efficiency PCR amplification in < 3 minutes. In addition to rapid amplification, 
analysis by small amplicon melting completes genotyping in 1 minute. We used a 
prototype microfluidic instrument to demonstrate sequential extreme PCR and 
genotyping by high resolution melting. Methods: Extreme PCR uses higher primer 
(10 ȝM) and enzyme (3.3 ȝM) concentrations than conventional rapid cycle or legacy 
PCR. Polymerases with fast extension rates, such as KlenTaq (AbPeptides) also 
speed reactions. CleanAMP dNTPs (TriLink) were used for hot start PCR on this 
microfluidic prototype. PCR primers were designed for small amplicon genotyping of 
factor V Leiden (1691G>A) with a product size of 43 bp. Reactions were 
thermocycled and melted using the Canon US Life Sciences, Inc. prototype genetic 
analyzer. The prototype instrument has unique features that enable rapid heat 
transfer. Reactions are run in a microfluidic chip containing eight discrete channels 
with embedded heaters. Control of the fluid flow within the microfluidic channels is 
performed by slight modifications of pressure at inlets and outlets. The thermocycling 
conditions were 95°C for 1 minute (to activate the dNTPs) followed by 40 PCR 
cycles, cycling between 95°C and 55°C, with a cycle time of 2.5 seconds. After 
completion of PCR, a melting ramp of 0.5°C/s was performed automatically for 
genotyping, requiring 1 additional minute. Results: We demonstrated automated 
SNV genotyping of factor V Leiden with amplification in 2.67 minutes and high 
resolution melting in 1 minute. Heterozygous PCR products were identified by the 
characteristic change in shape of the melting curve due to heteroduplex 
contributions. Homozygote PCR products were identified by their Tm differences, 
using internal controls for Tm adjustment. Conclusions: This system demonstrates 
the automation of extreme PCR amplification followed by high resolution melting in < 
4 minutes. Such extreme genotyping speed demonstrates the feasibility of genetic 
diagnosis “while you wait.” 28TT08. A Multiplex Real-Time PCR Assay for Detection of KRAS Mutations in 
Human Colorectal Carcinoma 
R. Zhao1, x. lyu2, R. Koka1, C. Sailey3, C. Hildenbrand1 
1University of Maryland Medical Center, Baltimore, MD; 2Henan Cancer Hospital, 
Zhengzhou, Henan, China; 3Arkansas Children's Hospital, Little Rock, AR. 
Introduction: In patients with colorectal carcinomas (CRC), seven well-described 
mutations in the KRAS gene are associated with poor prognosis and resistance to 
treatment with the epidermal growth factor receptor (EGFR) antagonists, e.g., 
Cetuximab and Panitumumab. Hence, ascertaining the mutational status of KRAS 
prior to initiation of anti-EGFR therapy could potentially reduce unnecessary medical 
cost and drug side-effect. In this study, we performed a clinical validation study of a 
multiplex PCR assay that enable us to provide this test on-site and to improve our 
ability to treatment and care of patients with CRC. Methods: The multiplex PCR 
assay used was primarily based on the Asuragen Signature KRAS 7 mutations kit. A 
total of 61 CRC tissue samples were tested, among which 36 tissue samples (Panel 
1) were procured from UMMC, 20 were from Hackensack University (Panel 2) and 5 
were from Mt. Sinai Medical Center in New York City (Panel 3). Results of the first 
panel were generated by a commercial laboratory that used an amplification 
refractory mutation system (ARMS) and RT-PCR-based Scorpion technology. The 
second panel used a laboratory-developed test with confirmation by a commercial 
test, and results of the third panel were obtained using a sequencing-based test. 
Results: Out of 61 samples tested, 4 of them were removed from the final data 
analyses because two samples generated discordant results due to different cuts of 
the tissue sections; the other two had poor DNA quality. The remaining 57 samples 
consisted of 29 KRAS positive and 27 negative samples. KRAS mutation status was 
determined in our study by the cut-off level of Median Fluorescent Intensity (MFI). 
The final results were correlated with the expected results. When MFI 550 was used 
as the cut-off per manufacture’s recommendation, 9 out of 57 samples (15.8%) 
showed discordance. However, when the cutoff was adjusted to MFI 1,200, 57/57 
(100%) of the samples were concordant after one mislabeled sample was 
reconciled. Under this cutoff, 100% sensitivity and 100% specificity were achieved. 
100% detectability was also observed with CRC tissues containing 5% tumor tissue 
with excellent reproducibility. Conclusions: The described assay is adequate for 
detection of KRAS mutations in human CRC.  
 
TT09. Comparing Sensitivities of Two Somatic Mutation Detection 
Methodologies for FFPE-Derived DNA  
K. Rao, S. Shell, S. Bacus 
Quintiles, Westmont, IL. 
Introduction: The sensitivity of molecular methods for profiling somatic mutations in 
fixed solid tumor samples is influenced by varying tumor content, tumor 
heterogeneity, lymphocyte infiltration, necrosis and degradation of DNA from 
formalin fixation. Furthermore, detection of somatic mutations at high sensitivity and 
specificity in limiting materials, whether from small biopsied material or circulating 
tumor DNA is critical for implementing personalized treatment and monitoring of 
therapeutic response. In the current study we evaluated the Competitive Allele-
Specific TaqMan PCR (castPCR) for sensitive and specific detection of somatic 
mutations in Formalin-Fixed Paraffin Embedded (FFPE) samples and compared it 
with Qiagen Scorpions-ARMS assay. Methods: DNA from FFPE cell line pellets and 
tissue blocks harboring various KRAS or NRAS gene mutations was extracted using 
QIAamp FFPE tissue DNA extraction kit (Qiagen). The castPCR assays were 
purchased from Life Technologies and KRAS RGQ PCR Kit was purchased from 
Qiagen. A cell line control harboring a KRAS G12C mutation at 6% allele frequency 
and a KRAS wild type control were purchased from Horizon Diagnostics as FFPE 
curls. DNA extracted from Horizon cell line controls was combined to generate KRAS 
G12C mutant samples ranging from 6% to 0.03% mutant for limit of detection 
experiments. Results: The specificity of the KRAS G12C and G12V castPCR 
assays was assessed using the DNA extracted from 10 FFPE cell line pellets that 
harbor various KRAS or NRAS mutations. The respective castPCR assays 
specifically detected KRAS G12C or G12V mutations in these samples. The lower 
limit of detection was 0.11% mutant for castPCR technology and 0.33% mutant for 
Scorpions-ARMS technology. DNA dilution studies of cell lines containing KRAS 
G12C or G12V mutations showed that both castPCR and Scorpions-ARMS assays 
detect the respective mutations with as little as 600 pg of total input nucleic acids (~ 
50 copies of genomic DNA). Subsequently, 15 colon and lung FFPE tissue samples 
previously characterized for KRAS mutation status by other in-house methodologies 
were tested using castPCR technology and castPCR showed 100% concordance. 
Conclusions: Our data show that Life Technologies castPCR and Qiagen 
Scorpions-ARMS assays are comparable in performance with castPCR 
demonstrating a slight edge over Qiagen assays for sensitivity. Both technologies 
can produce viable data with extremely low input of DNA and provide an excellent jmd.amjpathol.org ■ The Journal of Molecular Diagnostics
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Furthermore, the lower limits of detection may be useful for monitoring the mutation 
status in the circulating tumor DNA. 
 
TT10. Single-Tube Enrichment of Mutations in Cancer Gene Panels Using 
COLD-PCR Prior to Targeted Amplicon Resequencing 
E. Castellanos-Rizaldos1, G. Makrigiorgos2 
1Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; 2Dana-Farber 
Cancer Institute, Brigham and Women's Hospital, HMS, Boston, MA. 
Introduction: Targeted re-sequencing of cancer gene panels provides a major 
opportunity for integration of technology with clinical oncology. To this end, sample 
preparation kits for next-generation sequencing of cancer gene panels have recently 
emerged. Yet, there is still a missing link in providing a truly reliable identification of 
mutation fingerprints in patient tumor samples, as clinically-relevant low-prevalence 
mutations can still be missed. Although reliable NGS for DNA with high-prevalence 
mutations has been demonstrated, the required 'depth' of sequence interrogation 
remains a problem and detection of low-prevalence mutations at levels below ~2% to 
5% in tumors with heterogeneity, stromal contamination or in bodily fluids is fraught 
with false-positives irrespective of coverage. For example, below 2% to 5% mutation 
abundance there are persistent sequencing errors generating false-positive DNA 
changes that preclude reliable mutation calling (Milbury et al, Clin Chem 2012, 
58:580-9). This unavoidable ‘noise’ is independent of interrogation depth, i.e., 
increasing the number of reads does not improve the NGS detection limit, hence rare 
mutations in plasma, CTCs and mixed clinical samples cannot be sequenced 
reliably. Methods: To circumvent this problem, here we present the incorporation of 
a temperature-tolerant COLD-PCR (TT-COLD-PCR) approach into the current 
sample preparation workflow using cancer gene panels, prior to next-generation 
sequencing. In this approach (Castellanos-Rizaldos et al., 2012), denaturation 
temperatures are gradually increased in a step-wise fashion, allowing for a 
preferential amplification of mutated sequences in multiple targets using one set of 
cycling conditions, in a single tube. Samples with limiting dilutions of mutations were 
amplified with two different Ion Ampliseq panels (190 amplicons; and 16,000 
amplicons) to generate templates for the ligation of custom adaptors. Subsequenctly, 
TT-COLD-PCR was performed in a single tube on all amplicons by using a single 
primer. Evaluation of enrichment was then performed by Sanger Sequencing and by 
next-generation sequencing. DNA from cell lines and clinical samples were tested. 
Results: Mutations throughout all targets examined were simultaneously enriched 
by 5 to 10-fold. In the lower dilutions (<5%) and in clinical samples with mutations 
less than 5% mutations were only visible in chromatograms from the TT-COLD-PCR 
reactions, but not using conventional PCR. Conclusions: This is the first report 
where a PCR-based method incorporated within the existing sample preparation 
workflow for multi-gene panel targeted re-sequencing was able to successfully enrich 
sequences containing low level mutations. The implications for targeted re-
sequencing will be discussed. 
 
TT11. Validation of a Fully Automated Nucleic Acid Extraction from Fresh 
Frozen Tissue Using the Siemens Tissue Preparation Solution 
A. Ying, U. Vajapey, G. Hennig, H. Li 
Siemens Healthcare Diagnostics, Berkeley, CA. 
Introduction: Formalin-fixed, paraffin-embedded (FFPE) samples are standard 
material in routine molecular pathology and an invaluable source for biomarker 
discovery, validation, and biobanking. The Siemens Tissue Preparation Solution is a 
fully automated method for the extraction of nucleic acids, providing an efficient, 
standardized, and reproducible process for the isolation of high-quality nucleic acids 
from FFPE tissue. Fresh frozen (FF) samples represent another prominent sample 
format in routine pathology and biobanking activities. The goal of this study was to 
validate the performance of the existing FFPE method for the parallel extraction of 
nucleic acids from FF. Methods: Human colon, breast, prostate, rectum, pancreas, 
and lung tissues were used in this study. FF tissue samples were either thawed in 
RNAlater-ICE (Life Technologies Corporation), pulverized using the CryoPrep 
Impactors (Covaris), or sectioned using a cryostat. FF sample input amounts were 
either one 10 μm thick section or a tissue sample mass between 10 to 30 mg. Paired 
samples were processed in triplicates using the fully automated Siemens method 
and, as a benchmark, the manual Qiagen RNeasy Mini Kit according to the 
manufacturer’s protocol. Nucleic acids isolated using the Siemens method and 
manual method were qualified for purity with in-house DNA and RNA surrogate gene 
real-time PCR assays. The same set of eluates was also quantified for yield using 
Quant-It PicoGreen/RiboGreen fluorescence dye assays. Results: Both DNA and 
RNA were successfully extracted and qualified from all FF tissue samples. Nucleic 
acids isolated using the Siemens method met all internally established acceptance 
criteria, demonstrating that the purified nucleic acids were both amplifiable and free he Journal of Molecular Diagnostics ■ jmd.amjpathol.orgof inhibitory contaminants. Comparison of the fully automated Siemens method and 
the manual method showed similar yield and quality for amplifiable DNA and RNA. 
Conclusions: The Siemens Tissue Preparation System and VERSANT Tissue 
Preparation Reagents (TPR) kit successfully isolate high-quality nucleic acids and 
consolidate extraction of total nucleic acid (TNA) and RNA from both FFPE and FF 
tissue types in one run. This fully automated method provides state-of-the-art nucleic 
acid extraction capabilities using one robot, one script, and one kit. The method 
delivers high throughput (48 samples in 4 hours), improves large test volume turn 
around time, provides superior workflow advantages and offers the flexibility of TNA, 
RNA, or paired TNA/RNA extractions from a single sample. This makes it a 
standardized extraction solution for routine molecular pathology, research 
environments and biobanks. 
 
TT12. Sensitivity and Specificity of High Resolution Melting for Detection of 
Heterozygous and Homozygous Variants across Nine Instruments 
M. Li, L. Zhou, Y. Wang, C.T. Wittwer 
University of Utah Medical School, Salt Lake City, UT. 
Introduction: Molecular diagnostics plays a crucial role in differential diagnosis and 
personal therapy. Genotyping is a major part of molecular diagnosis. Recently, high 
resolution melting has become a popular method for genotyping due to its speed, 
sensitivity, low cost and reduced contamination risk. However, it is not clear if all 
instruments that claim high resolution melting have comparable sensitivity and 
specificity. Therefore, we evaluated genotyping by high resolution melting in various 
instruments with different fragments. Methods: The single nucleotide polymorphism 
(c. 3405-29A>T) of the CPS1 gene was amplified by PCR in the presence of 
LCGreen Plus in four fragment lengths (51bp, 100bp, 272bp, 547bp). This variant is 
nearest-neighbor symmetric and the wild type and homozygous variant are predicted 
to have identical melting temperatures. Amplicons were pooled for the three 
genotypes and used for blinded genotyping on all nine instruments (HR1, LS32, 
LightScanner96, CFX96, StepOne Plus, Rotorgene Q, LC480, ECO, Pikoreal). 
Homozygous variant (T) and heterozygous variant (A/T) were detected under default 
instrument condition or optimum high resolution melting conditions on all 
instruments. Data were analyzed with identical custom software. Results: The 
sensitivity and specificity of heterozygous variant detection of four fragments were all 
100% in nine instruments. However, for homozygous variants, there were wide 
differences in the sensitivity and specificity among the various instruments and 
among the four different fragments. Both the sensitivity and specificity were above 
90% in homozygous variant detection for 51bp fragment by Rotorgene Q (36 sample 
carousel) and CFX96; for 100bp fragment by HR1, Rotorgene Q (both 36 and 72 
sample carousels), CFX96, LightScanner96, LC480, ECO; for 272bp fragment by 
none of the instruments and for 547bp fragment by HR1 and LightScanner96. 
Conclusions: Heterozygous variants of four lengths are easily detected in each of 
the nine instruments. However, their ability to detect homozygous variants is 
variable. The length of fragments has a great effect on the sensitivity and specificity 
of instruments. The shorter fragments do not necessarily produce higher sensitivity 
and specificity in detecting the homozygous variant. Sometimes, longer fragments 
with multiple domains are more easily distinguished by some instruments. 
 
TT13. Comparative Analysis of Commercially Available Fluorescent in Situ 
Hybridization (FISH) Probes Targeting Chromosome 13 
L. Lafond-Shank, J. Laudadio, W. Bellamy 
University of Arkansas for Medical Sciences, Little Rock, AR. 
Introduction: Deletion/monosomy of chromosome 13 has an important prognostic 
role in hematopoietic tumors including CLL, t-MDS and multiple myeloma. FISH is an 
important tool used to evaluate such lesions. In an effort to optimize FISH results, 
the University of Arkansas for Medical Sciences (UAMS) molecular laboratory 
evaluated commercially available FISH probes targeting chromosome 13 to establish 
the best hybridization conditions of each. Methods: Probes targeting the 13q14 and 
13q34 loci were obtained from five commercial sources. Each probe was prepared 
according to manufacturer’s specifications. Previously tested control specimens were 
used to assess the probes. Isolated nuclei were dropped onto slides in batches and 
treated using several pretreatment protocols and hybridization temperatures to 
determine optimal conditions for each probe set. All nuclei and probes were co-
denatured followed by overnight hybridizations. All post-hybridization washes were 
performed using the UAMS laboratory standard protocol. The signal strength, 
characteristics, and patterns were assessed for each probe set and processing 
condition. Results: Five FISH probe sets were evaluated under several protocols 
including the manufacturer’s recommended protocol. Pre-hybridization treatments 
varied significantly among the protocols. Although the recommended probe 
hybridization temperature was identical (37°C), the denaturation time and 
temperature varied from a low of 73°C for 1 minute to a high of 78°C for 5 minutes. 929
AMP AbstractsCellular morphology was found to be good under all conditions examined. Probe 
strength and brightness as well as non-specific signals were found to vary as a 
function of the protocol. Although all probes were observed to provide a relatively 
good signal under recommended conditions, there was a distinct difference in signal 
intensities among the probes. The MetaSystems probe set provided the strongest 
and most distinct signals under most protocols examined. In contrast, the Agilent 
probes provided poor signal strength under these conditions. With minimal 
exceptions, all probes generated the correct signal pattern in the normal control 
specimen under each protocol. With the exception of three probes under two specific 
protocols that failed to yield a hybridization signal, all probes were also able to 
identify the 13q14 deletion present in the abnormal control specimen. The 
percentage of abnormal nuclei observed ranged from a low of 10.6% to a high of 
33.3% with most results falling within 5% of the established 22% control value. 
Conclusions: Signal brightness and clarity were found to vary with pretreatment and 
hybridization conditions. Optimal cell processing and probe hybridizations were 
identified for 5 commercially available FISH probes.  
 
TT14. Sensitivity of Pyrosequencing in Detecting the BRAF V600E Mutation 
Compared with the Cobas 4800 BRAF V600 Mutation Test 
C.L. Appin, K.E. Fisher, C.E. Hill 
Emory University School of Medicine, Atlanta, GA. 
Introduction: The BRAF mutation is found in 30% to 70% of melanomas. The 
V600E mutation, which results in the substitution of glutamic acid for valine, 
accounts for over 80% of these mutations. Other BRAF mutations found in 
melanoma include V600K, V600D and V600R. Vemurafenib, a BRAF inhibitor, has 
been shown to improve survival in patients with metastatic melanoma containing the 
V600E mutation. The cobas 4800 BRAF V600 Mutation Test (Roche Diagnostics, 
Indianapolis, IN) is an FDA-approved polymerase chain reaction (PCR)-based test 
that identifies tumors that have the BRAF V600E mutation. The goal of our study 
was to compare the sensitivity of pyrosequencing in detecting the BRAF V600E 
mutation against that of the cobas 4800 BRAF V600 Mutation Test. Methods: 
Nineteen formalin-fixed paraffin embedded melanoma samples with known BRAF 
mutation status were selected. DNA was extracted from these samples using a 
Qiagen DNA Mini Extraction Kit (Qiagen, Germantown, MD) per the manufacturer’s 
protocol. DNA was amplified from each case using the following primers: FW: 5’-
TGAAGACCTCACAGTAAAAATAGG-3’, REV: 5’-
TCCAGACAACTGTTCAAACTGAT-3’. Pyrosequencing with the Qiagen Pyromark 
Q96 was used to analyze the T>A single base pair mutation at amino acid 1799 
(codon 600) in exon 15 of BRAF. Peaks of interest were compared to wild-type 
sequence and melanoma sample with a known positive mutation. These results were 
then compared with those of the cobas 4800 BRAF V600 Mutation Test. Results: 
The cobas 4800 BRAF V600 Mutation Test detected the BRAF V600E mutation in 7 
of the 19 melanoma samples. Pyrosequencing detected the BRAF V600 mutation in 
the same 7 samples. Three of the BRAF mutated samples were found to have a 
mutation other than V600E and were identified as discordant. These discordant 
samples had been interpreted as having the V600E mutation by the cobas 4800 
BRAF V600 Mutation Test. No BRAF mutation was detected in 12 of the 19 samples 
by either the cobas 4800 BRAF V600 Mutation Test or by pyrosequencing. 
Conclusions: Pyrosequencing has comparable sensitivity to the cobas 4800 BRAF 
V600 Mutation Test in detecting the BRAF V600E mutation and greater specificity in 
detecting BRAF mutations other than V600E. 
 
TT15. Significance of the Use of the ViennaLab Cardiovascular Disease Panel 
(CVD) Assay as a Reflex Test for the Factor V/II/MTHFR Assay 
R. Hoteit, F. Abbas, R.A. Mahfouz 
American University of Beirut Medical Center, Beirut. 
Introduction: Trends toward identifying risk factors of thrombotic complications had 
become essential as an attempt to prevent and decrease the incidence of the 
complications. Thrombosis has been associated with predisposing entities like factor 
V Leiden (FVL), prothrombin (PTH) and methylenetetrahydrofolate reductase 
(MTHFR) gene mutations, in addition to Protein C and S de¿ciencies. The aim of this 
study is to evaluate whether the CVD StripAssay has an added value as a reflex test 
in the screening for more thrombophilia risk factors, which may predispose for the 
development of cardiovascular diseases and other thrombotic clinical conditions, 
especially for those patients with a negative initial screening result by the 
conventional factor V/II/MTHFR assay. Methods: We compared the archived results 
for 103 patients who were previously tested for factor V, factor II and MTHFR gene 
mutations using the FV-PTH-MTHFR StripAssay, and for whom additional testing for 
the Cardiovascular Disease panel (CVD StripAssay) was requested. The FV-PTH-
MTHFR StripAssay covers three mutations, whereas the CVD StripAssay covers 
twelve mutations. Results: Using the FV-PTH-MTHFR StripAssay and out of the 103 930patients, 22 were found normal, 17 were normal for FV and PTH and homozygous 
for MTHFR, and 55 were normal for FV and PTH and heterozygous for MTHFR. 
Among these 94 patients, using the CVD StripAssay, 62 (65.96%) were found to 
have additional genes (SNPs or mutations) that are highly associated with a risk of 
thrombosis including, FV (H1299R), MTHFR (A1298C), PAI-1 4G allele, HPA-1 1b 
allele, ACE D allele and ApoE E2 genotype. Conclusions: Rapid screening for the 
most common genes in molecular thrombophilia profiling (factor V, II, and MTHFR) is 
acceptable in most clinical practice, however, the more extended genetic panel 
represented by the Cardiovascular Disease profile offers a broader spectrum of 
genes, polymorphisms or mutations that have been described in the literature as 
predisposing for thrombotic events. According to this study, we observed around 
66% increased positivity rate of detection of an “abnormal” finding in genetic profiling 
of this category of patients. This observation is of extreme importance in clinical 
practice for the introduction of the extended CVD panel into routine molecular 
diagnostic test menus. 
 
TT16. Assessment of Post-Transplant Chimerism Using a Single Short 
Tandem Repeat Locus Versus the Mean of Multiple Loci 
G. Bocsi1, C. Watt2, V. Van Deerlin2 
1Hospital of the University of Pennsylvania, Philadelphia, PA; 2Perelman School of 
Medicine at the University of Pennsylvania, Philadelphia, PA. 
Introduction: Chimerism after hematopoietic stem cell transplantation is commonly 
assessed using PCR of short tandem repeat (STR) loci. Commercially available 
reagents are typically used that amplify multiple STR loci. A single informative locus 
can be selected to assess chimerism post-transplant and this has been the standard 
practice in our center for 15 years. However, potential disadvantages to using a 
single locus compared with an average of multiple loci are the possibility of 
chromosomal abnormalities affecting or masking changes in chimerism and that 
inherent amplification inefficiencies between alleles may make a single locus 
inaccurate. Given this, many laboratories use more than one locus to calculate donor 
chimerism. A disadvantage of using multiple loci for assessment of chimerism is the 
effort involved in calculating results at multiple loci and decreased qualitative 
accuracy at 0% and 100% due to the effect of artifacts such as stutter. We sought to 
compare the chimerism results calculated using a single selected “best” locus to an 
average of all informative loci in a multiplex of 16 loci. Methods: Post-transplant 
DNA samples (n=45) previously assessed for percent recipient (%R; range 0% to 
98%) at an optimal single STR locus selected from a low-order multiplex reaction 
were retested using PowerPlex 16 HS System (Promega Corp). The mean %R was 
recalculated from all informative loci and compared to the single locus %R. A 
Wilcoxon signed-rank test was performed to test for a statistically significant 
difference. Results: There was no statistically significant difference (p < 0.01) 
between the %R calculated at what was considered to be the most optimal single 
informative locus and the mean of multiple loci (mean 9 loci, range 3 to 14). The 
differences in %R ranged from -3% to +4% with a mean of 1.4%. Samples originally 
with 0% R (n=2) appeared to have a small %R when multiple loci were averaged, a 
qualitatively different result. Conclusions: Although there are some potential 
disadvantages to determining chimerism using a single locus we show that on 
average, a single locus selected to avoid stutter and other artifacts performs as well 
as a mean of 3 to 14 loci when recipient DNA is present. At 0 or 100 %R where 
qualitative assessment is more important, a manual evaluation of a single best locus 
is optimal whereas a “blind” average of multiple loci will be less likely to yield an 
accurate result. Both single locus and multiple locus calculations of chimerism are 
acceptable; each having strengths and weaknesses. 
 
TT17. Invivoscribe Primer Mixes in B-cell Immunoglobulin Gene 
Rearrangement Studies: Experience of a Molecular Diagnostics Laboratory in a 
Major Tertiary Care Center 
F. Abbas, R. Abdel Khalek, R.A. Mahfouz 
American University of Beirut Medical Center, Beirut. 
Introduction: Gene rearrangement studies have proved useful as a diagnostic tool 
for leukemias and lymphomas and serve as a molecular marker for tumor cells 
derived from clonal B-lymphocyte expansion. Molecular clonality analysis is based 
on the fact that, in principle, all cells of a malignancy have a common clonal origin 
and show clonally (identically) rearranged immunoglobulin (Ig) genes. It is difficult to 
employ a single set of DNA primer sequences to target all of clonal rearrangements, 
therefore different master mixes are employed in the testing; five master mixes 
targeting IgH clonality, two master mixes for IgK, and one master mix for IgL in the 
Invivoscribe assay. The aim is to evaluate whether the multiple master mixes 
included in the Invivoscribe kit are useful in the detection clonal rearrangements and 
to determine the detection rate of clonal rearrangement by each of the different 
mixes used. Methods: We reviewed the laboratory results of 192 patients who were jmd.amjpathol.org ■ The Journal of Molecular Diagnostics
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by each master mix used. The utilized primers cover for the following targets: IgH: 
VH-FR1+JH, VH-FR2+JH, VH-FR3+JH, DH+JH, DH7+JH. IgK: Vț+Jț, Vț and INTR 
+ Kde IgL: VȜ + JȜ Results: Using the Invivoscribe kit and out of 192 patients, 92.2% 
had Immunoglobulin Heavy chain clonality of which 74% were detected by IgH VH-
FR1+JH primer set, 75.5% by IgH VH-FR2+JH primer set, 65.1% by IgH VH-
FR3+JH primer set, 26% by IgH DH+JH primer set, and 2.1% by IgH DH7+JH primer 
set. Among these 192 patients, 55.7% had clonality in the kappa light chain where 
33.3% were positive by IgK Vț+Jț primer set and 39.6% by IgK Vț and INTR + Kde 
primer sets. Clonality in the lambda light chain of immunoglobulins was detected in 
17.7% of patients tested with Invivoscribe IgL VȜ + JȜ primer set. Conclusions: 
Identifying clonal rearrangement is important in the diagnosis of malignant B-cell 
proliferation. In our experience with the Invivoscribe kit, we were able to detect 
immunoglobulin clonality by the entire provided multiple primer mixes that target 
different regions and rearrangements in the immunoglobulin heavy and light chains 
targeted by this reliable assay. Our practice also includes correlation with 
morphology on aspirates and biopsies as well as other minimal residual disease 
testing panels including flow cytometry or other molecular markers. 
 
TT18. Automated Ultrasensitive Bright Field mRNA in Situ Hybridization 
(BRISH) Assay for Detection of NSCLC ALK Transcription in ThinPrep 
Cytopathology Specimens 
K. Wang1, S. Sanda1, C. Lanigan1, E. Minca1, R. Tubbs1, D. Kim2, S. Bui2, N. Su2, X. 
Ma2, Y. Luo2, Z. Wang1 
1Cleveland Clinic, Cleveland, OH; 2Advanced Cell Diagnostics, Hayward, CA. 
Introduction: The gene fusion between anaplastic lymphoma kinase (ALK) and 
echinoderm microtubule-associated protein-like 4 (EML4) and other partner genes 
and the resulting ALK over-expression are powerful predictive biomarkers for ALK-
targeted therapies (Crizotinib) in patients with non-small cell lung cancer (NSCLC). 
Real-time endobronchial ultrasound guided transbronchial needle aspiration biopsy 
(EBUS-TBNA) has emerged as a cost effective alternative that samples more and 
smaller lymph nodes than conventional mediastinoscopy. Here we determined 
feasibility of detecting ALK mRNA in liquid-based ThinPrep slides using a novel 
automated bright-field mRNA in situ hybridization (BRISH) technique that employs 
pairs of specially designed oligonucleotides probes (ZZ probes). Methods: Controls 
were prepared with equal numbers of SU-DHL-1 (ALK-positive due to NPM-ALK 
fusion) and HL-60 (ALK-negative) cells suspended in PreservCyt Solution (Hologic 
Inc.) and mounted onto ThinPrep slides. Slides emerging from the ThinPrep 
Processor were placed into 95% dehydrates and then air-dried before staining. 
BRISH was performed using a Ventana Discovery XT automated stainer. Briefly, 
ThinPrep slides were baked at 65ºC for 40 min, and then treated with standard cell 
conditioning 1. The slides were then hybridized sequentially with ALK ZZ probes at 
48ºC for 2 hours, preamplifier at 55ºC for 32 min, amplifier at 55ºC for 32 minutes 
and label probes at 40ºC for 20 min. Slides were washed in 0.1x SSC after each 
hybridization step. Hybridization signals were detected by Fast Red staining, 
followed by counter staining with hematoxylin. Results: Overexpression of ALK 
mRNA was readily detectable in SU-DHL-1 cells spiked into a background of HL60 
cells on ThinPrep slides. We identified pre-baking and appropriate cell conditioning 
as the two critical steps for the preservation of morphology and successful 
hybridization.  
Conclusions: Fully automated mRNA in bright field in situ hybridization for the 
detection of NSCLC ALK mRNA in ThinPrep cytopathology specimens is feasible. 
 
TT19. Buccal Swabs as an Alternative Specimen Type for Chromosome 
Microarray (CMA) 
J.A. Lefferts, H.B. Steinmetz, E.I. Reader, M.P. Dinulos, G.J. Tsongalis 
Dartmouth-Hitchcock Medical Center, Lebanon, NH. 
Introduction: Chromosome microarray (CMA) testing is recommended as first-tier 
testing for detection of constitutional copy number variants in patients with 
developmental delay/intellectual disability, autism spectrum disorder and multiple 
congenital abnormalities. CMA testing is normally performed on DNA isolated from 
peripheral blood. Obtaining a sufficient volume of blood can be difficult in some 
situations. Additionally, peripheral blood is not suitable for constitutional genetic 
testing if the patient was recently transfused or has a history of a bone marrow or 
stem cell transplant. Although buccal swabs are a logical alternative to peripheral 
blood or more invasive skin biopsy specimens, several large reference labs that 
were contacted would not accept buccal swabs as a specimen for clinical CMA 
testing due to expected issues with low DNA quantity or quality. Here we evaluate 
the use of buccal swabs as a potential specimen type for clinical CMA testing. 
Methods: Sterile cotton swabs were used to collect buccal cells and were 
subsequently stored for 1 to2 weeks at room temperature and then 1 to2 months at The Journal of Molecular Diagnostics ■ jmd.amjpathol.org4°C. DNA was isolated manually using the Puregene kit according to manufacturer’s 
protocol (QIAGEN). DNA quantity and purity were assessed by spectrophotometry 
(Nanodrop). DNA was then processed according to validated procedures for CMA 
testing using CytoScan HD arrays and reagents (Affymetrix) and the array analysis 
and interpretation was performed using Chromosome Analysis Suite software 
(ChAS, Affymetrix). Results: DNA obtained by buccal swab was acceptable in 
concentration and purity (260/280) according to the specifications in our validated 
CMA protocol for DNA from peripheral blood (greater than 50 ng/L). Buccal swab 
DNA used in the CMA protocol passed all of the QC measures including sizing of 
PCR and fragmentation products by gel electrophoresis, yield of purified PCR 
product as determined by spectrophotometry and all QC measures normally 
evaluated upon analysis of the scanned array in ChAs to ensure acceptable SNP 
calling and uniformity of signal across all probes. Conclusions: DNA isolated from 
buccal swabs is suitable for CMA testing with CytoScan HD arrays. A complete 
validation of this specimen type is required but will allow for improved patient care by 
making CMA testing more readily available to a larger number of patients. 
 
TT20. Quantitation of Mutant BRAF in Peripheral Blood as a Marker of 
Minimal Residual Disease 
A.M. Moyer, K.W. Cradic, D. Milosevic, S.K. Grebe, A. Algeciras-Schimnich 
Mayo Clinic, Rochester, MN. 
Introduction: Somatic BRAF mutations have been identified in various 
malignancies. Detection of mutated BRAF in peripheral blood is an attractive 
minimally invasive method for the detection of residual or recurrent disease and 
monitoring of disease progression. However, current detection and quantitation 
methods lack detection sensitivity, accuracy and precision. We decided to evaluate 
whether the new technology of droplet digital PCR (ddPCR) might be able to address 
these shortcomings of current techniques. Methods: PCR reaction mixtures were 
emulsified into uniform droplets, run in a standard thermocycler, and analyzed on the 
QX100 droplet reader using QuantaSoft software (Bio-Rad). Multiple primer and 
probe combinations and PCR conditions were tested to maximize the specificity of 
the assay. Following optimization, the performance of the ddPCR assay was 
compared with that of two allele-specific real-time PCR assays for mutant BRAF: a 
highly-sensitive in-house developed assay (<1:30,000 copies) and an FDA-approved 
low sensitivity assay (1:100 copies). Results: The droplet generator produced a 
mean of 14918 (+/-1615) droplets per reaction, for a theoretical detection sensitivity 
of ~1:15,000 for singlet reactions. Commercially available probe and primer 
combinations showed significant cross-reactivity between WT and mutant BRAF, 
whereas our laboratory-developed ones did not. The assay was linear with serial 
dilutions from 1:10 to 1:100,000 (r2=0.998). The intra-assay copy number 
imprecision (CV) was 4% for low concentrations of mutant BRAF and 0.9% for high 
concentration WT BRAF. The corresponding inter-assay figures were 24% and 
6.3%, respectively. In eight samples with low level mutant BRAF by ddPCR (all 
below 1% mutant), the FDA-approved assay failed to detect mutant BRAF, as would 
have been predicted, whereas the highly-sensitive in-house assay detected mutant 
BRAF in all 8 samples, but with poorer intra- and interassay imprecision compared to 
ddPCR. Conclusions: Quantitation of low levels of mutant BRAF in the peripheral 
blood with high measurement precision to detect pre-clinical tumor recurrence may 
be possible by ddPCR. ddPCR may be an ideal technique for the quantitation of low 
level mutant DNA in peripheral blood. 
 
TT21. The Development of a Mismatch Repair Gene Sequencing Panel 
Utilizing Semiconductor Sequencing Technology 
J.D. Peterson1, C.D. Tunkey1, L.D. Strausbaugh2, J. Pipas3, E.R. Riggs1, K.J. Bloch1, 
A.A. Suriawinata1, X. Liu1, M. Lisosvsky1, C.I. Amos1, W.A. Wells1, G.J. Tsongalis1, 
L.J. Tafe1 
1Dartmouth Hitchcock Medical Center, Lebanon, NH; 2University of Connecticut, 
Storrs, CT; 3Geisel School of Medicine at Dartmouth, Lebanon, NH. 
Introduction: Up to 5% of colorectal cancers (CRC) are attributed to germline 
mutations in the mismatch repair genes (Lynch Syndrome). It is becoming routine 
practice to screen CRCs for Lynch Syndrome with IHC and/or MSI testing with 
subsequent confirmatory gene sequencing in suspected cases. Here we describe a 
next-generation sequencing assay for direct mutation detection in a panel of MMR 
genes using the Ion Torrent PGM. Methods: The Ion Torrent Ampliseq Designer 
pipeline was used to generate primers to sequence nearly all exons of the MLH1, 
MSH2, MSH6, PMS2 and EPCAM genes. DNA was extracted from 17 FFPE CRCs 
and one FFPE reference standard with a known MLH1 mutation. Barcoded libraries 
were prepared using 10ng of DNA, and Sequencing was performed using the Ion 
Torrent PGM (with 314 and 318 chips). Sequence alignment of the targeted reads 
was done using the Ion Torrent variant caller (version v3.4.51874) and the reference 
genome hg19. The annotation of the variants, as well as a prediction of the 931
AMP Abstractssignificance of the variants was done using Golden Helix’s SVS software version 
7.7.2. Results: The first library containing two samples generated approximately 
547,000 usable sequences (average read length of 111bp and >100x coverage). 
Prior to filtering there were 10 variants detected for the wildtype sample and 16 
detected for the cell line control. The second library, containing the additional 16 
clinical samples, generated approximately 5.4 million usable sequences (average 
read length of 120 bp and 13 of 16 samples with >200x coverage). Approximately 15 
variants were initially called for each of the 18 samples run, with a range between 8 
and 24 variants. A variant filtering pipeline was developed to reduce the total number 
of called variants and identify those that are most clinically significant. Using this 
pipeline, the 276 initially called variants were filtered down to 9 variants resulting in 
nonsynonymous mutations.  Of these 9 variants the Golden Helix SIFT predictor 
annotated 4 as tolerated, 4 as potentially damaging, and 1 as having an unknown 
effect. All of these variants received sufficient coverage and were of high enough 
variant frequency to be annotated as true variants. Conclusions: As the cost of 
next-generation sequencing continually decreases, and functionality increases, it is 
plausible that direct mutation detection by sequencing will become routine in the 
assessment of Lynch Syndrome.  
 
TT22. Quantification of Cross-Contamination among Indexed Samples in 
Multiplexed Next-Generation Sequencing Data 
D. Spencer, E.J. Duncavage 
Washington University, St. Louis, MO. 
Introduction: Next-generation sequencing (NGS) assays are frequently performed 
in multiplex where numerous indexed samples are mixed and sequenced 
simultaneously, creating potential for cross-contamination that could affect the 
sequencing results and clinical interpretation. We analyzed clinical NGS data 
multiplexed with spiked-in controls to quantify the level of cross-contamination that 
occurs during library preparation and multiplex sequencing. Methods: Targeted 
sequence data from clinical lung adenocarcinoma specimens and Hapmap samples 
were generated using indexed library preparation with 7 bp indices and targeted 
enrichment performed on each library individually. Control libraries were prepared 
from a M13 vector sequence and indexed separately prior to pooling with human 
samples and sequencing on a HiSeq 2000. Reads were demultiplexed by requiring a 
perfect match to an expected index sequence and then mapped to a combined 
human/M13 reference sequence. Reads from a human sample that mapped to M13 
with a mapping quality >5, <5 mismatches, and with >33 bp properly aligned were 
considered contaminants. Results: We analyzed data from 228 human samples 
multiplexed with a separately indexed M13 library and sequenced across 12 lanes of 
a HiSeq instrument. The frequency of reads from a human sample that mapped to 
M13 was 0% to 0.077% of all mapped reads per sample (mean: 0.0045%, SD: 
0.011). There was no significant difference in the frequency of contaminating reads 
across different index sequences (ANOVA: P=0.853). Contamination was similar 
within a run, but was highly variable across sequencing runs (ANOVA: P<10-16) with 
some lanes having no contamination and others with almost one contaminating read 
per 1,000. Contaminating reads were either paired, with a mate that also mapped to 
M13, or chimeric and had a mate that mapped to a human chromosome, suggesting 
both reagent or library contamination and on-instrument chimerism contribute to 
cross-contamination. Chimeric reads comprised 57% of the contaminants on 
average and showed a significant association with the proportion of the total reads in 
the lane assigned to the M13 index (linear regression R2: 0.33; P<10 to10), although 
one lane had almost exclusively paired contaminating reads at a high frequency 
indicative of low-level reagent contamination during library preparation. 
Conclusions: Contamination in multiplex NGS was rare using samples prepared 
individually and pooled for multiplex sequencing, occurring in <5 reads per 100,000 
on average, but demonstrated considerable variability across sequencing runs. We 
observed evidence that reagent and/or library contamination and on-instrument 
chimerism contribute to cross-contamination, and that the composition of the 
multiplex pool can influence contamination frequency. 
 
TT23. Functional DNA Quantification Guides Accurate Next-Generation 
Sequencing Mutation Detection in Formalin-Fixed, Paraffin-Embedded Tumor 
Biopsies  
G.J. Latham, L. Chen, J.F. Houghton, J. Kemppainen, A.C. Marko, R. Zeigler, S. Sah 
Asuragen, Inc., Austin, TX. 
Introduction: Formalin-fixed, paraffin-embedded (FFPE) biopsies are indispensable 
samples for cancer diagnostics. These samples, however, are fraught with chemical 
modifications and degradation that can compromise molecular assays, such as 
targeted enrichment upstream of next-generation sequencing (NGS). A rigorous and 
quantitative understanding of FFPE DNA quality is needed to ensure accurate 
mutation calls from NGS-based assays. Methods: Three methods for FFPE DNA 932quantification were compared, including a novel quantitative PCR assay (QFI-PCR) 
that measures the absolute copy number of amplifiable DNA. QFI-PCR was 
validated across 43 FFPE samples, and then applied to a broader set of 165 residual 
clinical FFPE samples. The impact of FFPE DNA copy number and library 
complexity on variant quantification and detection was evaluated by NGS using two 
different platforms. 
Results: Both QFI-PCR and a fluorescent dye-binding assay illuminated “functional” 
DNA concentrations that were approximately 15 times lower on average than 
spectrophotometric measurements. FFPE DNA with known mutations produced 
unreliable quantification and false negatives when titrated below the minimum 
template complexity consistent with theoretical calculations. Analysis of a subset of 
44 FFPE samples using a commercial targeted NGS cancer panel (AmpliSeq) 
demonstrated a false positive rate of up to 89% with the poorest quality samples. A 
direct correlation was observed between the number of confirmed variants and the 
DNA quality determined by QFI-PCR. Conclusions: The implementation of targeted 
NGS assays for clinical use requires stringent pre-analytical sample assessments to 
ensure reliable results. Reliance on DNA quantification assays that underestimate or 
ignore FFPE sample quality can produce spurious sequencing data. The approach 
that we describe, including QFI-PCR, can guide corrections in sample input to help 
“rescue” low quality samples, improve the accuracy of variant detection, and 
minimize the burden of confirmation in heterogeneous cancer samples. 
 
TT24. Spontaneous and FFPE-Induced Noise in Next-Generation Sequencing 
Is Consistent with Cytosine Deamination 
G. Chen, M. Lin, S. Mosier, K. Beierl, C.D. Gocke, J.R. Eshleman 
Johns Hopkins University School of Medicine, Baltimore, MD. 
Introduction: Next-generation sequencing will revolutionize molecular diagnostic 
laboratories. Consequently, it is important to correctly identify and interpret non-
reproducible sequence artifacts that interfere with detection of true gene mutations 
and constitute baseline noise of sequencing data. In this study, we examine baseline 
noise in normal peripheral blood and non-neoplastic FFPE samples. Methods: We 
recently validated KRAS, BRAF and EGFR mutations within the Ion AmpliSeq 
Cancer Hotspot Panel using the Ion Torrent Personal Genome Machine. We first 
quantified the baseline noise level in negative control samples including 16 cancer-
free lymph node FFPE samples and 4 peripheral blood specimens from normal 
donors. The NGS was performed and data were analyzed with Torrent Suite (version 
3.2.0). Mutations were identified and annotated through Torrent Variant Caller 
(Version 3.2.45211), Ion Reporter (Version 1.2) and the Broad Institute’s Integrative 
Genomics Viewer (IGV). Results: The means plus three standard deviations for all 
the common KRAS (codons 12 and 13), BRAF (V600E) and EGFR (T790M and 
L858R) gene point mutations were calculated and graphed. We noted that five 
positions had significantly higher background "noise" than others (p=0.0026). To our 
surprise, the noisy positions in FFPE were the same as those in peripheral blood, 
although the FFPE noise level was about twice as high (mean 0.072% vs. 0.038%). 
Likewise other base positions appeared consistently quiet. To test whether the noisy 
positions were consistently noisy, we generated a second independent FFPE library 
preparation and sequenced the same samples, which was qualitatively identical. 
Because Williams and colleagues (American Journal of Pathology, 155:1467, 1999) 
previously demonstrated high rates of C:G to T:A mutations in FFPE samples, we 
realized that all 5 of our high noise mutations were consistent with this, manifesting 
as either C to T (T790M) or G to A (all 4 KRAS) mutations on the sense strand. 
Conclusions: Baseline noise and FFPE induced mutations in DNA are consistent 
with cytosine deamination.  Because the mutation frequency in peripheral blood 
(0.1% to 0.3%) is too high to be biologic, we hypothesize that it is due to heat 
induced spontaneous deamination associated with thermocycling. 
 
TT25. Routine Clinical Mutation Profiling of Non-Small Cell Lung Cancer 
(NSCLC) Using 454 Next-Generation Sequencing Technology 
P. Starostik, K.K. Deeb, C.M. Hohman, N.F. Risch, D.J. Metzger 
Roswell Park Cancer Institute, Buffalo, NY. 
Introduction: Key driver mutations that provide tumor cells with selective growth 
advantage were identified through genomic, expression, and proteomic profiling of 
lung cancer. Some of the mutations are targeted by existing therapies and their 
detection is the current standard of care, others are potentially druggable. With the 
advent of massive parallel sequencing technologies, simultaneous mutation 
detection became possible. We developed an amplicon-based NGS assay using the 
454 GS Junior platform to detect driver mutations in NSCLC. Methods: DNA 
extracted from 23 primary or metastatic lung FFPE cancer specimens positive for 
mutations in KRAS and EGFR by pyrosequencing was used. Primers (incorporating 
the target sequence, 454 adaptors and MIDs), were designed to generate 35 
amplicons (median length 246 bp) covering 8.9 kb of mutational hotspots in AKT1, jmd.amjpathol.org ■ The Journal of Molecular Diagnostics
 AMP AbstractsBRAF, EGFR, ERBB2, HRAS, KRAS, NRAS, PIK3CA, and MAP2K1 genes and all 
exons of the PTEN gene. Junior Titanium chemistry (Roche) was employed for 
sequencing the amplicons on the GS Junior platform. NGS data were analyzed with 
the GS Amplicon Variant Analyzer (AVA) and annotated by Lasergene 
SeqMan/NGen (DNAStar). Results: An overall median read depth of 529x per 
amplicon was achieved. The minimum number of reads (200x) was consistently 
reached. In total, 29 point mutations were detected. The mutant allele burden varied 
between 5.5% to 82.5%. Four samples showed indels ranging from 15 to 19 bp in 
EGFR exon 19. All KRAS and EGFR mutations as detected by NGS were confirmed 
by pyrosequencing with the exception of one point mutation. A sample with a 5.5% 
mutant allele ratio in KRAS c.34G>T (p.Gly12Cys) from NGS analysis was not 
detected by pyrosequencing, as it fell below the pyrosequencing limit of detection. 
NGS also revealed 3 specimens harboring additional simultaneous mutations: two 
samples showing KRAS and PIK3CA and one positive for KRAS, PTEN and ERBB2 
mutations. Conclusions: We established a clinical robust mutation profiling panel for 
NSCLC. This GS Junior-based targeted resequencing assay for a focused set of 
NSCLC driver genes allows for a quick and sensitive detection of point mutations 
and deletions for the most relevant therapeutic genes in this type of cancer. It shows 
better sensitivity of mutation detection than pyrosequencing and its massively 
parallel nature enables for dramatically enlarged scope of sequence interrogation. 
The ability to detect multiple mutations in lung adenocarcinoma at once provides for 
better therapeutic choices in management of NSCLC. 
 
TT26. NGS Variant Manager - The Ultimate Tool for Analysis of High 
Throughput Next-Generation Sequencing Data 
A. Oultache, A.E. Chenni, C.V. Hedvat, K. Nafa 
Memorial Sloan-Kettering Cancer Center, New York, NY. 
Introduction: Next-Generation Sequencing (NGS) rapid development allows deeper 
insight into the genome and generates a tremendous amount of data. However, 
manageable tools translating platform output into analyzable data are lagging. We 
present a powerful, intelligent yet User-friendly Interface (UI) software enabling 
molecular laboratories with limited bioinformatics resources to analyze NGS output 
data. Methods: NGS Variant Manager (NGSVM) software followed Object Oriented 
Design (OOD) patterns, using multitier architecture and was written in C# (.NET 
framework 4.5). It comprises 4 DLLs (UI, model, utility, and test), 15 classes and 
more than 2500 lines of code. NGSVM is easy to install and compatible with 
Windows 64-bit XP, 7, 8 Operating Systems (OS). The software validation and 
optimization was performed using VCFs generated by Illumina MiSeq Reporter. 
Results: The goal of the NGSVM software is to help in the validation and 
implementation of NGS in the clinical laboratory. Some of the capabilities of the 
NGSVM are that it i) reads different type of VCF file formats generated by different 
callers, ii) enables the identification and sorting of useful information within the VCF, 
iii) compiles a list of criteria available to apply user-defined filters based on the 
loaded VCF files, iv) annotates VCFs using open source tools such as Oncotator, v) 
saves the VCF files with the user’s applied settings, in a binary format for faster 
retrieval of the information generated, vi) allows for tailoring of the documentation for 
sign-out purposes such as variant list with patient and sample information, run 
summary, vii) creates tools for use with IGV (Broad Institute) such as BED files with 
filtered variants based on the settings used on the NGSVM and IGV sessions viii) 
constructs batch scripts that can be loaded in IGV for automatic snapshot 
production, and ix) serves as a “hotspot finder” facilitating the identification of a 
specific list of variants within a set of samples. The software proved to be useful for 
both research and clinical validation purposes. Conclusions: NGS Variant Manager 
is an automated, accessible software solution adapted for research and clinical use 
of NGS data, enabling for fast, accurate analysis of NGS variant data, reducing 
review time thereby improving laboratory resource utilization. 
 
TT27. A Multiplex PCR Assay for the Detection of Chlamydia, Gonorrhea, and 
Trichomonas Using Melt Curve Analysis 
P.R. Burchard1, A.N. Abou Tayoun2, A. Scherer3, G.J. Tsongalis1 
1Dartmouth Hitchcock Medical Center, Lebanon, NH; 2Geisel School of Medicine at 
Dartmouth, Lebanon, NH; 3Kavli Nanoscience Institute, California Institute of 
Technology, Pasadena, CA. 
Introduction: An estimated 448 million new cases of curable sexually transmitted 
infections (STIs) occur every year. Some of these STIs exist without symptoms and, 
if untreated, can have devastating consequences on reproduction, maternal and 
newborn health, as well as increase the likelihood of acquisition and transmission of 
HIV. Traditional methods for diagnosing STIs are laborious, often not very sensitive, 
and have a long turnaround time. Here, we describe the development of a novel, 
rapid and affordable diagnostic assay for the simultaneous detection of Trichomonas 
vaginalis (TV), Neisseria gonorrhea (NG), and Chlamydia trachomatis (CT). The Journal of Molecular Diagnostics ■ jmd.amjpathol.orgMethods: We designed a multiplex PCR assay for the detection of 4 targets (CT, 
TV, NG, and process/PCR control) using melt curve analysis. To establish the limit of 
detection (LOD) for each pathogen, we used previously extracted and quantified TV, 
NG, and CT genomic DNA (Vircell, Spain). For each target, the LOD was determined 
by lowering its copy number while increasing the other two STI loads in a stepwise 
fashion. The process/PCR control remained constant in the optimized assay. For a 
concordance study, we tested vaginal swabs and urine samples from 10 patients 
positive for one or more of the tested STIs. Results: The multiplex assay resolved all 
4 targets, detecting as low as 7 to 15 copies of each STI in the presence of high 
loads of the other 2 targets in the reaction mixture. TV, NG, CT, and our 
process/PCR control were consistently identified at 78 ºC, 82.3 ºC, 85.7 ºC, and ~92 
ºC, respectively. The 10 known clinical samples were 100% concordant with 
expected results. Conclusions: We have developed a rapid, highly sensitive, and 
affordable multiplex assay for the detection of CT, NG, and TV. Such an assay can 
be performed in most medical laboratories with standard molecular equipment.  
 
TT28. False-Positive Mutations from Mispriming Events in Next-Generation 
Sequencing Have Unique Signatures 
C.M. McCall, K. Beierl, S. Mosier, M. Lin, C.D. Gocke, J.R. Eshleman 
Johns Hopkins University School of Medicine, Baltimore, MD. 
Introduction: Next-generation sequencing platforms show great promise by allowing 
rapid mutational analysis of multiple genes in human cancers. Recently, we began 
using the Ion AmpliSeq Cancer Hotspot Panel (over 200 amplicons in 50 genes) in 
our laboratory to evaluate EGFR, KRAS, and BRAF mutations in lung and colorectal 
adenocarcinomas. In several patient specimens, automated sequence analysis 
software identified a novel EGFR exon 21 mutation: a missense mutation resulting in 
a G873R substitution.  But we found similar events in multiple panel amplicons, 
where short reads with a consistent pattern of 5’ end base substitutions produced 
false-positive mutation results. Methods: Formalin-fixed, paraffin-embedded tissue 
specimens from 51 consecutive colon and lung adenocarcinoma specimens were 
submitted for mutational analysis using the Ion AmpliSeq Cancer Hotspot Panel. 
After DNA extraction, library amplification and sequencing, data were analyzed both 
in an automated fashion (Ion Torrent Variant Caller) and by examination of individual 
reads (Integrative Genomics Viewer (Broad Institute, Cambridge, MA) and Geneious 
(Biomatters, Auckland, NZ)). Results: We identified the EGFR G873R mutation in 
>5% of reads in 12 of 51 samples. The G873R mutation only occurred in short reads, 
with 5’ ends located 49 bases from the 5’ end of the exon 21 amplicon and 3’ ends at 
the expected end of the amplicon. By examining each panel amplicon in a 
representative sample, we discovered 20 additional amplicons having similar short 
reads, with 14 of 20 resulting in missense or nonsense mutations. The 5’ ends of the 
short reads were homologous to the expected 5’ ends of other amplicons in the 
panel, which likely correspond to panel primers. There is also a significant inverse 
correlation between input DNA amount and EGFR exon 21 mutation percentage 
(p<0.01), with 1 of 22 samples with 30 ng of DNA having >5% short reads versus 11 
of 29 with <30 ng. The number of total reads similarly inversely correlated with 
number of short reads (p<0.01). Conclusions: Especially in cases of low DNA 
quantity or poor run quality, short reads producing false-positive mutations may 
occur in the Ion AmpliSeq Cancer Hotspot Panel and other multiplex amplicon 
panels. These short reads are consistent from sample to sample and have 5’ ends 
that BLAST to ends of other panel amplicons, making promiscuous primer binding to 
homologous sequences the likely mechanism. Recognition of this phenomenon is 
critical to prevent the release of false-positive mutation results that could impact the 
prognosis and treatment of patients. 
 
TT29. Comparison of Commercial DNA Extraction Kits for Recovery of 
Bacterial, Protozoan, and Viral Organisms Spiked in Human Fecal Samples 
S. Brzezinski, S. Skipworth, E. Grigorenko 
Diatherix Laboratories, Inc, Huntsville, AL. 
Introduction: There is an increasing interest to monitor the gastrointestinal 
microbiome as it plays an important role in defining human health. The molecular 
PCR-based approaches are being widely used for detection of normal and 
pathogenic organisms in human fecal samples. However, there are many “hard to 
lyse” organisms present in stool that may go undetected if traditional methods of 
DNA extraction are applied. Efficient extraction of high purity, inhibitor-free DNA or 
RNA is the main requirement for comprehensive analysis of the gastrointestinal 
microbiome. In this study we evaluated eight DNA extraction kits for efficiency and 
throughput using organisms (Cryptosporidium parvum, Clostridium difficile, 
adenovirus 41) that could cause diarrhea and be present in clinical fecal samples. 
Methods: C. parvum (103 to 106 oocysts/mL), C. difficile (103 to 106 cfu/mL), and 
adenovirus 41 (10 to 104 pfu/mL) were spiked into stool samples. Eight DNA 
extraction kits were evaluated: Thermofisher Plant DNA; MPBio’s FastDNA Soil and 933
AMP AbstractsFastDNA; Mobio’s PowerMag, PowerLyzer, PowerFecal, and PowerPlant; and a 
modified Omega Biotek MagBind Stool kit. Bead bashing on MPBio’s FastPrep 24 
was used for all methods. DNA samples were processed using target enrichment 
multiplex PCR, followed by detection on the Luminex platform. Extraction efficiency 
was evaluated based on detection of lowest number of organisms/mL. A 
phenol/chloroform extraction (Tri-Reagent) was used as an extraction baseline 
control. 
Results: We confirmed that bead-bashing is essential for detection of C. parvum 
and has no or minimal effect on DNA extraction from C.difficile and adenovirus 41. 
Bead matrix (glass, garnet, zirconium, etc.) and bead size have a significant effect 
on releasing DNA from C.parvum. High temperatures or proteinase K digestion 
demonstrated no benefit to lysis of oocysts. The method using Omega Biotek 
reagents produced the lowest limit of detection, detecting C. parvum at 105 
oocyst/mL, C. difficile at 105 cfu/mL and adenovirus 41 at 10 pfu/mL. Optimal bead 
bashing occurred with 3 cycles of 40 seconds at speed 6.5m/s on the MPBio 
FastPrep24 using matrix Y plus matrix Z bead tubes. Tri-Reagent extraction detected 
C. parvum down to 100 oocyst/mL. Conclusions: Evaluation of eight DNA extraction 
methods indicated that a modification of MagBind Stool kit was the most efficient for 
recovery of bacterial, protozoan and viral DNA spiked in human stool samples. No 
kits amendable to automation were able to lyse the oocysts as effectively as Tri-
Reagent. The results of this study can assist diagnostic laboratories with selecting 
the best extraction method for processing fecal specimens for subsequent detection 
using molecular tests. 
 
TT30. A Low-Cost High-Throughput Multiple SNPs Simultaneous Genotyping 
(MSSG) Assay for Thrombophilia Risk Factors 
P. Nham, F. Moatamed, R.T. Phan 
VA Greater Los Angeles Healthcare System, Los Angeles, CA. 
Introduction: Thrombosis is one of the most common blood coagulation disorders. 
Risk factors associated with inherited thrombophilia include SNPs in the factor V 
(FV), prothrombin/factor II (FII), and Methylenetetrahydrofolate Reductase (MTHFR) 
genes. Here we report the development and validation of a low-cost, high-throughput 
multiplex PCR-based assay, termed MSSG (Multiple SNPs Simultaneous 
Genotyping), to concurrently detect the FV 1691G>A, FII 20210G>A, MTHFR 
677C>T and 1298A>C polymorphisms. Methods: A total of 127 blood samples from 
de-identified patients with potential hypercoagulable states were analyzed by MSSG 
and the eSensor Thrombophilia Risk Test (GenMark). The MSSG test employs the 
Eppendorf EpMotion 5075 system with 96-well plates to automatically extract DNA 
from whole blood and to set-up multiplex PCR assays amplifying genomic DNA 
regions spanning the polymorphisms. This is then followed by single nucleotide 
primer extension reactions utilizing a cocktail of primers specific for tested 
polymorphisms. The genotype at each polymorphic site is determined by the 
expected corresponding fragment sizes and fluorochrome signals. DNA sequencing 
was performed to validate the genotyping results. Results: The MSSG assay had 
100% concordance of results with the GenMark assay for all four test 
polymorphisms: FV 1691G>A (GG: 110/127, GA: 17/127, AA: 0/127), FII 20210G>A 
(GG: 114/127, GA: 12/127, AA: 1/127), MTHFR 677C>T (CC: 80/127, CT: 40/127, 
TT: 7/127), and MTHFR 1298A>C ( AA: 80/127, AC: 42/127, CC: 5/127). Direct DNA 
sequencing demonstrated that the MSSG assay has 100% sensitivity and specificity. 
Serial dilution analysis revealed that the detection limit for the MSSG assay is one 
log below the detection limit for the GenMark test (1ng). The MSSG assay resulted in 
reagent cost savings of 90.7% and FTE savings of 82.6% compared to the 
commercial kit. The total cost-saving is greater than 87% per test. Notably, although 
the turn-around time of the MSSG assay is comparable to that of the commercial kit 
(~4 to 5 hours), it reduced hands-on technician time by ~82.6%, which significantly 
decreases the potential for human errors. Conclusions: We have developed and 
validated a highly sensitive and specific MSSG assay that simultaneously genotypes 
the FV 1691G>A, FII 20210G>A, MTHFR 677C>T and 1298A>C polymorphisms. 
This low cost, high-throughput MSSG assay is easy to interpret and significantly 
reduces the potential for human errors. This work presents a platform for other 
applications requiring multiplex, high-throughput rapid genotyping of multiple SNPs 
at a relatively low cost, especially with large sample sizes. 
 
TT31. FFPE DNA Quality: Impact on Downstream Performance in Molecular 
Diagnostic Assays 
J.M. Eibl, J.A. Toplin, C.D. Galderisi, C.S. Spittle 
MolecularMD Corp., Portland, OR. 
Introduction: Personalized medicine for oncology patients is driven by mutation 
profiling of tumors. Improved robust DNA extraction methods that produce high 
quality FFPE DNA template that is suitable for complex molecular diagnostic testing 
are needed. In addition to DNA fragmentation and protein-DNA cross linking, some 934FFPE tissues contain inhibitors and/or quenching substances (e.g., melanin) that 
adversely affect downstream performance in PCR and sequencing assays. In this 
study, we provide a side-by-side evaluation of the Maxwell CSC automated platform 
and a manual, column-based method for isolating DNA from FFPE tissues of various 
tumor types. Methods: The Maxwell CSC platform and Promega Maxwell CSC DNA 
FFPE Custom Kit were used for automated extractions. Manual extractions were 
performed using the MOBIO BiOstic FFPE Tissue DNA Isolation Kit. Equivalent 
FFPE sections from 34 FFPE samples (12 melanoma, 8 GIST, 6 NSCLC, 8 
endometrial tumor) were extracted via both methods. Yields and OD were assessed 
via UV spectroscopy. Equivalent input template amounts from the melanoma 
samples were assayed for both NRAS allele-specific qPCR and NRAS Sanger 
sequencing using the Applied Biosystems 7500 Fast and Applied Biosystems 3730 
DNA Analyzer, respectively. Pairwise Ct values were compared to determine qPCR 
differences and a Phred-score analysis was conducted for a 51-base pair window 
surrounding the NRAS codon 61 hotspot to quantitatively determine sequence-trace 
quality. Other sequence quality metrics from software packages (e.g., Sequence 
Scanner and CodonCode Aligner) were also considered.  A subset of the samples 
was also assayed via PIK3CA Sanger sequencing with qualitative observations and 
comparisons recorded. Results: Overall, yields were greater for samples processed 
on the Maxwell CSC (30 of 34 total samples, 88%; 1.9-fold increase overall). In 
qPCR, 11 of 12 (92%) of the Maxwell-extracted melanoma samples crossed the 
threshold sooner than the paired manual samples (average 1.3 Ct sooner overall). 
Two samples crossed the cycle threshold markedly sooner (~2.5 Ct) than the 
manually-extracted paired samples. Similarly, all Maxwell-extracted melanoma 
isolates produced robust bidirectional sequence, whereas several manually-
extracted isolates failed to produce sequence despite a post-extraction inhibitor-
removal step.  Phred scores and other sequence-quality metrics were higher across 
all tissue types prepared on the Maxwell CSC. Conclusions: Yields, quality and 
functional performance of FFPE DNA extracted via the Maxwell CSC were greater 
than DNA obtained via the manual method. This system provides efficient, 
reproducible extraction of high-yield, high-purity DNA for mutation analysis. Future 
work will compare DNA performance differences on an NGS platform. 
 
TT32. A High-Resolution Melting Assay for Copy Number Variation 
L. Zhou, R. Palais, C. Wittwer 
University of Utah, Salt Lake City, UT. 
Introduction: DNA copy number variation (CNV) is associated with genetic 
disorders, chromosomal rearrangements, and cancer.  We present a simple closed-
tube method based on high-resolution melting that is accurate enough to reliably 
determine all common CNV ratios. Methods: Target and reference regions of 
genomic DNA were amplified together using a variety of reagent and cycling 
protocols. Ratios of reference and copy number variants were maintained either by 
limiting PCR cycle number, or by limiting quantities of dNTPs or Taq polymerase and 
allowing PCR to plateau. Software uMelt was used to predict and design suitable 
fragments having single melting domains, well-separated Tms, and no common 
homologs.  High-resolution melting analysis with double strand DNA dye LCGreen 
Plus was used to determine CNV ratios from relative heights of target melting peak, 
after reference melting peaks were equalized using MeltWizard 5.1 software. After 
the protocols were optimized on samples with known ratios, blinded studies involving 
50 clinical samples that had been previously typed for trisomy 13, 18 and 21, and 50 
samples that had been typed for chromosome X and Y copy number were 
performed. Results: Our experiments demonstrate that all common CNV ratios may 
be detected by detection by comparing equalizing reference peaks and comparing 
CNV target melting peaks if any of the PCR limiting protocols (cycle number, dNTPs, 
Taq polymerase) are employed. The most robust, simplest, and highest resolution 
method uses dNTPs limitation. CNV ratios as small as 10:9 were detectable when 
dNTPs were limited at 3.25 uM. There is no requirement that the Tm of the reference 
peak be lower or higher than that of the CNV target. The method clearly 
distinguishes CNV in chromosome X samples having 1, 2, 3 and 4 copies. Trisomy 
was easily and accurately typed using duplex PCR, and chromosome X and Y copy 
number variants were identified using triplex PCR. The analyses of both sets of 50 
blinded clinical samples using the high-resolution melting method were 100% 
concordant with prior copy number determination. The method also identified large 
CFTR exon 2 and exon 3 heterozygous deletions that are difficult to detect using 
other approaches. Conclusions: This method is simple closed-tube, fast, 
economical, and is more accurate and less susceptible to contamination than other 
methods. Assays are easy to design, limiting dNTPs is simple, and the results are 
stable and reliable. After PCR, only 5 to 10 minutes of melting and analysis are 
required to obtain results. 
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Generation Sequencing Data for Clinical Diagnosis 
S. Shen, D. Qin 
Moffitt Cancer Center, Tampa, FL. 
Introduction: Introduction: Application of next-generation sequencing (NGS) in 
clinical diagnosis is growing rapidly. There are some study indicates that minimum of 
500 X depth is need to have 99% opportunity to detect 5% allele frequency with 0% 
FP. Deeper read depth means higher the cost of test. Here, we explain how to use 
some statistical tools to estimate the required coverage depth and make variant calls 
with desired confident level. Methods: i) Area under normal distribution curve is 
used to calculate desired average coverage: z = (minimum depth – average depth)/ 
std of depth std of depth = CV x average depth when z = -1.68 or -2.33, the 
sequencing will have 95% or 99% reads, respectively, deeper than minimum 
required depth. Based on normal distribution we have. Average Depth (AD) = 
Minimum Required Depth (MRD)/(z*CV+1) (1) ii) Poisson probability model is sued 
to determine positive variant call. System error (Q score) is a synthetic result of any 
causes of error. Guidelines provided by some authorities require system error better 
than (Q20). The null hypothesis is that sample is 100% pure at the target position 
gene; e.g., adenosine. System error rate is 1%. For certain read depth (n): lambda = 
error rate * n kappa is the actually number of read of non-A. By Poisson probability: 
P (lambda, kappa) = e^-lambda*lambda^kappa/kappa! (2). Sum of P(lambda, Kappa 
>=x) sets confident levels. x is the number of variance need to make a positive call. 
Results: i) Average depth was determined by required minimum depth:  
Table 1. 95% of Reads greater than minimum depth 
Minimum  
Depth cv z Average depth 
1000 0.1 -1.68 1201.923 
1000 0.2 -1.68 1506.024 
1000 0.3 -1.68 2016.129 
1000 0.4 -1.68 3048.78 
1000 0.5 -1.68 6250 
Table2. 99% of Reads greater than minimum depth 
Average  
Depth cv z Minimum depth 
1000 0.1 -2.33 1303.781 
1000 0.2 -2.33 1872.659 
1000 0.3 -2.33 3322.259 
ii) Variant call decisions were made based on Poisson model: 
Table 3. Probability of variance p(>=X) set a confident level  
Depth #of A #of 'non- A (x)  p(x)      p(<x)     p(>=x) 
100 100    0      0.367879        0.632121 
100 99    1      0.367879   0.367879  0.264241 
100 98    2      0.18394  0.735759  0.080301 
100 97    3    0.061313 0.919699  0.018988 
100 96    4     0.015328   0.981012  0.00366 
100 95    5     0.003066   0.99634   
Conclusions: The average depth can be estimated by formula (1), when depth of 
the sequencing system is close to normal distribution, and standard deviation is 
smaller than 50% or 40% of the average depth (have 95% or 99% reads greater than 
minimum required depth). Formula (2) can be used to examine each position of a 
target to determine whether to make a positive variant call based on the confident 
level of 95% or 99%. An Excel worksheet has been developed to help calculate 
average depth and determine variant calls at desirable confident level.  
 
TT34. A Comparison Study of the Cobas DNA Sample Preparation Kit and the 
Automated Qiagen EZ-1 XL for DNA Extraction from Formalin Fixed, Paraffin 
Embedded Tissue for Diagnostic Molecular Testing 
S.A. Marconi, K.A. Lebel, J.A. Fienman, F.R. Moore 
Baystate Health Systems, Springfield, MA. 
Introduction: Sensitive molecular diagnostic assays require high quality DNA. This 
DNA often needs to be obtained from a small, area of formalin fixed, paraffin 
embedded tissue sections. The tissue fixation process can make DNA difficult to 
extract and may inhibit PCR reactions. There are many commercially available 
extraction kits and pretreatment options to optimize DNA extraction from FFPE 
tissue that can be used alone or in conjunction with an automated DNA extraction 
system. In this study, we attempt to compare DNA yield and quality obtained from 
two commercially available kits. Methods: The Cobas DNA Sample Preparation Kit 
(Roche Molecular Systems, Pleasanton, CA) was compared to the Qiagen EZ-1 XL 
automated DNA extraction system (Germantown, MD 19300) using the EZ-1 DNA 
Tissue kit. BiOstic Paraffin Removal Reagent (Mo Bio Laboratories, Inc, Carlsbad, 
CA), was also used with the Qiagen EZ-1 XL to observe any improvement to DNA The Journal of Molecular Diagnostics ■ jmd.amjpathol.orgyield or quality. All samples using the Qiagen EZ-1 XL were incubated on the 
Themomixer R (Eppendorf, Hauppauge, NY) for 5 minutes at 72°C followed by 16 to 
18 hours at 56°C with Proteinase K. The Cobas DNA Sample Preparation Kit was 
performed per the protocol. All DNA samples were measured for concentration and 
260/280 values on the NanoDrop 2000 (Thermo Scientific, Wilmington, DE). 
Results: Serial sections of both tumor and normal tissue on slides were alternated to 
ensure each group had equal tissue representation and extracted in triplicate. Using 
4 slides each, Cobas averaged 5.2 μg of total DNA with mean 260/280 readings of 
2.4 whereas EZ-1 XL averaged 0.85 μg per extraction with 260/280 readings of 11.8. 
Using a different set of slides, 1 section was used per extraction with Cobas whereas 
10 slides each were extracted with the EZ-1 XL. The Cobas extraction yielded an 
average of 3.98 μg with 260/280 of 2.5, whereas the EZ-1 XL produced 1.02 μg also 
with a 260/280 of 2.5. BiOstic Paraffin Removal Reagent with the Ez-1 improved 
260/280 values slightly, however, DNA concentrations decreased. Conclusions: 
The Cobas DNA Sample Preparation Kit consistently produced cleaner DNA 
samples with much higher yields while using significantly less tissue. The procedure 
includes two, 1 hour incubations and requires more hands-on, technologist time. The 
Qiagen EZ-1 XL using the EZ-1 DNA Tissue Kit utilizes an overnight incubation but 
involves much less tech time; however, it required considerably more tissue and had 
a consistently much lower DNA yield and quality.  
 
TT35. Stabilizing RNA Samples for Transport to the Clinical Laboratory 
M.V. Dinkelmann, A.T. Vasquez, P.D. Jackson, J. Stoerker 
Progenity, Ann Arbor, MI. 
Introduction: Gene expression changes in blood are often strongly correlated with 
disease and can open valuable diagnostic windows. However, development of 
expression diagnostics is complicated by the variables of cell type composition, and 
choice of cell preparation/purification and RNA stabilization/purification methods. We 
report on combined protocols that minimize perturbation of the innate expression 
profile to improve fidelity and reproducibility of patient samples delivered to a central 
clinical laboratory.  Rapid cell separation and transcriptome stabilization are 
preferred. Methods: For this study, we compared yield, quality (RIN values) and 
RNA-seq profiles of RNA extracted at different timepoints from various cell subsets 
of whole blood starting with collection in Streck Cell-Free RNA BCT tubes, Qiagen 
PAXgene tubes or standard EDTA tubes followed by cell capture using Life 
Technologies LeukoLOCK system. All stabilization systems were used according to 
manufacturer’s instruction. Monocytes were isolated using positive or negative 
selection (magnetic beads or RosetteSEP, Stem Cell Technologies) and stored on a 
LeukoLOCK filter for stability measurement. RNA was extracted using Qiagen 
RNeasy extraction system. RNA yields were determined using the Qubit RNA Assay, 
and the RINs were determined using a Bioanalyzer. Paired-end RNAseq with 
riboreduction was performed to compare transcript profiles. Results: RNA extracted 
from cells stored in Streck tubes produced consistent yields, but decreased RIN 
values over time, whereas RNA yields decreased but RIN values remained 
consistent over time from blood stored in EDTA tubes. Leukocytes stored in 
RNAlater on LeukoLOCK filters produced stable RNA yields and RIN values over 
time, as did RNA from PAXGene tubes. Specific changes in RNA transcript profiles 
are presented to emphasize changes in RNA profile that depend on cell stabilization 
method. Conclusions: Of the methods we tested that resulted in consistent RNA 
yields and RINs over time, the PAXgene system is the simplest to implement in that 
it requires no sample processing at the site of draw. However, RNA isolated using 
this system includes erythrocyte RNAs, which may overwhelm signal from more 
informative cell types. Isolating leukocytes proved promising using the LeukoLOCK 
system, and required only minimal onsite processing as blood is simply passed 
through a syringe filter. To isolate RNA from specific cell types such as monocytes, 
combinations of positive and negative selection with the LeukoLOCK filter proved 
most promising, but required more extensive processing prior to stabilization. 
Therefore, the ideal method for stabilizing RNA for transport to the clinical testing site 
ultimately depends on the cell population of interest. 
 
TT36. The Clinical Advantage of Noncontiguous Loop-out Primers in the 
Avoidance of Problematic DNA Sequences 
K.L. Sumner, J.J. Swensen, T. Lewis, W.L. Wooderchak-Donahue, M. Fong, B.L. 
Brulotte, G. Pont-Kingdon, P. Bayrak-Toydemir, D. Best 
ARUP Laboratories, Salt Lake City, UT. 
Introduction: Noncontinuously binding hybridization, or loop-out probes have been 
described for use in the simultaneous analysis of several loci. The omitted 
sequences ranged from 1 to 73 nucleotides and the probes ranged from 20 to 35 
nucleotides. Reportedly, flanking regions of 11 nucleotides on either side of the 
omitted sequence is sufficient for loop-out probes to reliably bind to the region of 
interest. In the current study, we investigated whether loop-out PCR primers could 935
AMP Abstractsbe used to exclude regions of problematic DNA sequence, e.g., CpG islands or 
mononucleotide repeats from PCR amplicons. Excluding these problematic 
sequences is especially desirable when they are located too close to the sequence 
of interest to simply place a primer inside of the problem area. Methods: Loop-out 
primers were designed for the MEN1, ASS1, and PTEN genes. The MEN1 primer 
was designed to exclude a G-quadruplex and i-motif like sequence in exon 2 of the 
gene that results in allele drop-out when a common polymorphism is present. The 
ASS1 primers were designed to exclude semi-repetitive high GC content regions in 
exons 9 and 11 that are difficult to sequence using traditional methods. The PTEN 
primer was designed to exclude a mononucleotide poly-T repeat region of 10 
nucleotides near exon 9 of the gene. Each of the primers described also included a 
M13 tail and conditions were kept consistent for all amplicons within each assay. In 
addition, 2 genes (TGFȕR1 exon 9 and MECP2 exon 2) were included in this study 
where loop-out primers without M13 tails were designed to exclude a 
mononucleotide poly-T repeat region. Results: Each of the loop-out primers 
consistently excluded the problematic regions and resulted in superior sequencing 
quality when compared to traditional primers. Allele drop-out in exon 2 of MEN1 was 
avoided and the sequencing signal was consistent through-out the entire read for 
exons 9 and 11 of ASS1. The mononucleotide poly-T regions in exon 9 of PTEN, 
exon 9 of TGFȕR1, and exon 2 of MECP2 were excluded so that a single amplicon 
was able to produce clean forward and reverse sequence reads, thereby also 
decreasing the total number of amplicons required for each of these assays. 
Conclusions: Loop-out primers provide a significant advantage over traditional PCR 
primers in regions difficult and sequence. They allow a standardized PCR protocol to 
be used and, therefore, do not interrupt the workflow of the clinical laboratory. 
 
TT37. Detection of Human Papilomavirus Nucleic Acids in Formalin-Fixed, 
Paraffin-Embedded Tissue Specimens by RNAscope in Situ Hybridization 
Technique 
A. Yemelyanova, R. Jiang, A. Ogurtsova, R.B. Roden, B.M. Ronnett 
Johns Hopkins University, Baltimore, MD. 
Introduction: Analysis of gene expression in formalin-fixed, paraffin-embedded 
tissue (FFPE) via RNA in situ hybridization assessing a variety of transcriptionally 
active targets has recently become available. It provides an alternative to RT-PCR 
based assessment of gene expression with the benefit of preservation of 
cellular/tissue context. In particular, the RNAscope (Advanced Cell Diagnostics) 
technique has been used increasingly in clinical settings for human papillomavirus 
(HPV) analysis in FFPE tissue specimens, allowing for detection of transcriptionally 
active virus, primarily in cancer specimens but also in cervical squamous 
intraepithelial lesions (SILs) for potential grading and risk assessment. It also has 
been suggested that specific hybridization patterns differentially indicate the 
presence of different nucleic acids, with diffuse nuclear signals in the superficial 
layers of low-grade SILs [LSIL] representing viral DNA in assembling virions, rather 
than RNA, and fine punctate cytoplasmic and/or nuclear signals representing RNA 
transcripts. The current study further investigates the correlation of hybridization 
patterns with specific HPV nucleic acid detection by RNAscope in FFPE specimens 
containing HPV-related SILs. Methods: Chromogenic patterns were generated using 
a high-risk HPV (18) probe that allows for detection of E6/E7 transcripts of 18 
oncogenic/high-risk HPV types in FFPE cervical specimens containing LSILs that 
were previously shown to contain high-risk HPV by a PCR-based method. In addition 
to a standard RNAscope protocol, modified staining protocols to include RNAse and 
DNAse treatments prior to incubation with the probe were performed on consecutive 
sections from the same block. Results: Marked reduction to complete 
disappearance of the diffuse nuclear signal in the superficial layers of LSILs was 
observed in the sections treated with DNAse, whereas fine punctate cytoplasmic 
signals remained. Sections treated with RNAse demonstrated preservation of the 
diffuse nuclear pattern and complete disappearance of the fine punctate cytoplasmic 
signals. Conclusions: Our findings indicate that the RNAscope assay allows for 
detection of both HPV RNA and DNA in SILs. Testing of invasive cancers is in 
progress. This knowledge is important when using this assay to study viral gene 
expression patterns in SILs where abundant DNA signals due to high viral load can 
interfere with detection of RNA. 
 
TT38. Quality Improvements for Performing Engraftment Analysis after 
Hematopoietic Cell Transplantation 
T. Kemmer1, A. Karge12, D. Zimmerman2, S. Young1, M. Schomaker1, L. Nguyen1, 
M. Spears1, S. Yohe1, B. Thyarajagan1 
1University of Minnesota, Minneapolis, MN; 2Genetic Information Management 
Systems, Inc, Portland, OR. 
Introduction: Hematopoietic cell transplantation (HCT) is routinely used to treat 
patients with a wide variety of diseases, including various malignancies and inherited 936genetic disorders. Engraftment analysis is an important tool used to monitor the 
success of the HCT procedure and provides information on the degree of 
engraftment of donor cells in the recipient. The Molecular Diagnostics Laboratory 
(MDL) at the University of Minnesota Medical Center, Fairview, not only processes a 
large number of engraftment analyses annually (~3200 samples) but also supports 
engraftment testing for increasingly complex transplant protocols that involve 
transplant from 1 to 9 donors. We outline the process improvements implemented at 
the MDL to improve the efficiency and accuracy and also reduce the costs of 
engraftment analyses. Methods: Changes to improve accuracy include utilizing 
simulated control mixtures (5%, 20% and 50%) with each analytical run, automation 
of analyses of controls to determine the markers acceptable to use for analysis of 
patient samples in an analytical run and automation of calculations required to report 
engraftment analyses. Changes to reduce costs and improve efficiency include 
reduction of reaction volume used for PCR, use of electronic files to streamline 
workflow and automated report generation. Results: These process improvements 
resulted in a reduction of turnaround time from an average of 4.4 days to 3.4 days. 
The average time spent doing data analysis of an individual sample reduced from 
approximately 17 minutes/sample to 10.5 minutes/sample. These improvements 
ultimately resulted in reducing the average cost of performing the engraftment 
analysis from approximately $52/sample to $36/sample. Conclusions: Process 
improvements in engraftment testing can result in reduced turnaround time, analysis 
time, and cost of testing. 
 
TT39. A Statistical Model for Next-Generation Sequencing to Determine 
Required Read Depth 
G. Chen, M. Lin, L. Cope, S. Mosier, M. Thiess, K. Beierl, M. Debeljak, S. 
Yegnasubramanian, H. Ho, C.D. Gocke, J.R. Eshleman, S. Wheelan 
Johns Hopkins University School of Medicine, Baltimore, MD. 
Introduction: Next-generation sequencing (NGS) is a promising and powerful tool 
for detecting significant gene mutations in clinical practice. One critical step of 
employing it for clinical diagnosis is determining appropriate read depth, given the 
number of genomes and desired sensitivity. In clinical situations, FFPE and other 
practical considerations likely reduce the number of input functional genomes in the 
reaction due to crosslinking. Methods: In a recent study to validate clinical use of 
NGS for detection of KRAS, BRAF and EGFR mutations within the Ion AmpliSeq 
Cancer Hotspot Panel using the Ion Torrent Personal Genome Machine, we have 
created a two-step statistical model to determine the required read depth of 
coverage for a given number of functional input genomes and desired sensitivity. 
The first step accounts for the number of effective genomes drawn from the formalin-
fixed, paraffin-embedded (FFPE) sample, whereas the second captures the 
contribution of sequencing read depth. The two stages were combined in an easily 
evaluated, normally-distributed model that agrees very well with much more 
computationally intensive Monte-Carlo simulations based on permutations of the 
data. Results: With the model, we graphed the read depth required as a function of 
the percent of malignant cells within the tumor and the number of genomes for a 
desired level of confidence. As an example, at 99% sensitivity, it requires ~400x 
depth of coverage with 1000 genomes analyzed for a sample with 10% malignant 
cells (5% mutant alleles), whereas only ~100x if 20% mutant cells are present. To 
push the sensitivity to 99.9% for 10% cancer cells, 10, 000 genomes (~60 ng) must 
be used for library preparation and sequenced to ~500x depth of coverage. On the 
other end, if we require only 90% or 95% sensitivity with the same sample (10% 
mutant cells) we need only 300x or 140x coverage, respectively, for 300 genomes. 
Conclusions: For employing NGS to detect clinically significant gene mutations, we 
can use the two-step statistical model to estimate an appropriate depth of coverage, 
as well as the minimal number of functional genomes needed to secure a high 
sensitivity at a given depth of coverage. 
 
TT40. Sequential Dual-Color IHC Assay Development and Applications Using 
Laica Bond-Max Autostainer 
Y. Ren, M. Wang, M. Breider 
Celgene Corporation, San Diego, CA. 
Introduction: Over the past decades, immunohistochemistry (IHC) has become a 
crucial and powerful tool in both research and clinical diagnosis. The need for 
multiple-antigen visualization on the same tissue at the same time has grown 
tremendously. However, the current dual-color IHC detection kit available from Leica 
limits the user to using a different host species for each primary antibody; the 
possibility of cross-reactivity is the biggest challenge for preventing antibodies from 
the same species being used. In addition, combination of the two chromogens is also 
limited for visualization of protein colocalization. Although manual assays were 
developed, this approach provides low throughput, inter-assay variability, and less 
than optimal results. Methods: In this study, a sequential double alkaline jmd.amjpathol.org ■ The Journal of Molecular Diagnostics
T AMP Abstractsphosphatase IHC method was developed using antibodies of the same host species 
and a combination of two AP chromogens with Bond Polymer Refine Red Detection 
on the Bond-Max Autostainer. A Heat Step was introduced between the first and 
second detection to eliminate the cross-reactivity and allowed for improved 
specificity of the staining quality. Vector Blue (Vector Laboratories) was used for the 
first chromogen, Fast Red was the second detection substrate, and Methyl Green 
(Vector Laboratories) replaced the Hematoxylin as the counter stain. Results: This 
newly developed sequential dual-color IHC method not only granted flexible 
combinations of antibodies from either different or the same species, but also 
provided optimal visual assessment for colocalization of two proteins in one cell. 
Successful implementation of these assays allowed for visualization of two antigens 
co-localizing in one cell, such as Protein X (a B cell marker) and Ki67 double positive 
cells in a lymphoid tissue, and a direct overview of two different cell populations in 
the same tissue sample, for example, CD34 positive endothelial cells and Ki67 
expressing proliferating cancer cells. Conclusions: The Dual-Color IHC technology 
provided exclusive observation of colocalization of two proteins by utilizing different 
color chromogens. It also granted flexibility of combinations of antibodies from either 
different or the same species.  
 
TT41. Validation of the AvanSci Bio Meso-1 Dissection System and Novel 
xScisor Technology for Slide Mounted Tissue Dissection 
A.M. Decewicz, D.T. Croft, L.M. Voeghtly, S.A. Goldblatt 
Molecular Dx, LLC, Windber, PA. 
Introduction: Diagnostic genetic testing on solid tumor samples is typically 
performed on tissue dissected from formalin-fixed, paraffin embedded (FFPE) 
sections. Various methods for tissue extraction from slides exist including laser 
capture microdissection (LCM), manual (by hand), and a recently developed semi-
automated platform, the Meso-1. For each method of dissection, an area of interest 
(AOI) is marked by a pathologist on a hematoxylin and eosin (H&E) stained slide. An 
unstained slide is matched to the stained slide and the AOI is dissected by laser, 
scalpel, or other cutting tool and transferred to a microcentrifuge tube for DNA 
extraction. The purpose of this study was to validate the Meso-1 Dissection System 
by comparing the xScisor technology to manual dissection in a clinical laboratory 
setting. Methods: A total of eight paraffin slides from one single diagnosed high-risk 
colon cancer patient were used for the study. Four of the slides were dissected using 
the Meso-1 Dissection System and four of the slides were dissected by hand using a 
stainless steel #11 surgical blade. Samples were digested with either Proteinase K 
or xS-A Buffer (AvanSci Bio) and resulting concentrations of DNA were quantified 
using a Qubit Fluorometer. Results: Results from this study demonstrated that the 
Meso-1 Dissection System is comparable to manual dissection methods currently 
used in clinical laboratories. In addition to preserving images for documentation, the 
Meso-1 is also capable of precision alignment of the marked H&E slide to the 
unstained slide for accurate extraction of the AOI. Conclusions: Tissue extraction 
using the Meso-1 platform achieves similar results when compared to manual 
dissection. Increased yields of total DNA appears dependent on the lysis buffer used 
and the length of time the lysis occurs, rather than the method of extraction. In 
addition, the Meso-1 allows archiving of slide images and precise alignment of 
reference slides containing AOIs to the matched unstained dissection slides. 
 
TT42. Evaluation of a Calibrator Panel for Aligning to the International Scale 
for BCR-ABL1  
C. Gentile, V.M. Van Deerlin, C.D. Watt 
Hospital of the University of Pennsylvania, Philadelphia, PA. 
Introduction: A variety of methods are employed by clinical laboratories to quantify 
the b2a2 and b3a2 fusion transcripts associated with t(9;22)(q34;q11) in chronic 
myelogenous leukemia (CML).  Consequently, the primary results from one 
laboratory are not directly comparable to another. In 2005 the International Scale (IS) 
was established to address this issue by creating a mechanism to standardize 
measurement and reporting of BCR-ABL1 transcript levels. To facilitate the adoption 
of the IS by clinical laboratories, calibrators aligned to the IS became commercially 
available in 2011. The goals of this study were to assess the performance of the 
commercially available IS calibrators overtime and to evaluate the impact that IS 
conversion would have on clinically significant log reductions from diagnostic set 
points. 
Methods: Three separate lots of IS calibrators (ARQ IS calibrator panel, Asuragen) 
that span a 3-log range of fusion transcript (i.e., both b2a2 and b3a2) were evaluated 
over a 15 month period by multiple technologists and two separate real-time PCR 
instruments using a laboratory developed quantitative assay for the major 
breakpoints in t(9;22). Analytical performance of the assay and the calibrators were 
evaluated over this time interval using conventional statistical approaches. Once an 
IS conversion parameter was established, retrospective analysis of the log reduction he Journal of Molecular Diagnostics ■ jmd.amjpathol.orgfrom the laboratory diagnostic median as compared to the log reduction from 100% 
IS was performed on 1159 clinical data points. Discordant results near 3-log 
reduction were evaluated for trends. Results: Commercially available IS calibrators 
were easy to use and performed consistently and robustly during the 15 month 
evaluation irrespective of commonly encountered clinical variables including the 
performing technologist, the instrument and the reagent lot. Assuming assay 
precision is approximately 2 fold, the concordance rate for at least a 3-log reduction 
from the two relevant diagnostic set points (i.e., the locally established diagnostic 
median value and 100% IS baseline) was 92%. Based on data trends, the majority of 
the samples with discordant log reductions occurred in the context of increasing or 
decreasing transcript levels; however a subset (~11%) appeared to have reached a 
plateau. Conclusions: Both ease of use and stability of the ARQ IS calibrator panel 
makes it an appealing option for aligning laboratory developed tests to the IS. Based 
on this data, verification of the IS conversion parameter will be performed on a semi-
annual basis. Clinically significant log reductions from diagnostic set points in CML 
should be carefully evaluated when transitioning to the IS. 
 
TT43. Withdrawn 
 
TT44. Validation of Highly-Parallel Targeted Amplicon-Based Sequencing 
Using the MiSeq Personal Genome Sequencer in Cancer Diagnostics 
T. Zhang, M.A. Sukhai, J. De Souza, C. Wei, K. Craddock, B.G. Neel, P. Bedard, L. 
Siu, S. Kamel-Reid 
Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario. 
Introduction: Recent evidence suggests that mutation profiling can be used in the 
prediction of patient outcome and/or efficacy of targeted anticancer therapy. In this 
study, we tested the application of next-generation sequencing (NGS) technology to 
the diagnostic setting, using the Illumina TruSeq Amplicon Cancer Panel (TSACP) 
on the MiSeq personal genome sequencing platform. Methods: The TSACP allows 
for detection of point mutations, frameshift mutations and small indels in 212 
amplicons covering mutation hotspots of 48 cancer-associated genes. Data analysis 
is performed using AmpliconViewer and NextGENe v 2.3.1 (SoftGenetics). Initial 
validation of the platform was conducted using 4 normal blood samples, 7 formalin-
fixed paraffin-embedded (FFPE) normal tissues, and 103 FFPE archived tumor 
specimens in the University Health Network CLIA-certified molecular diagnostics lab. 
Genotyping results were verified using our previously-developed PMH Solid Tumor 
Panel (STP) v1 on the Sequenom MassARRAY platform, or by Sanger sequencing. 
Results: In our validation set, 112/114 samples had been tested using the PMH STP 
v1.0. 11/11 normal samples tested negative for mutations by both platforms, 
indicating an analytical specificity of 100%. 57/103 tumor-derived samples tested 
negative by PMH STP v1.0 analysis (55.3%); 2/103 were not tested (1.9%); and, 
44/103 (42.7%) tested positive for at least one mutation. Using the TSACP, 9/103 
samples had no detectable mutations (8.7%). 4/103 samples failed (3.9%) and, 
6/103 (5.8%) had average read depth < 500x, insufficient to call variants accurately. 
At least one mutation was detected in ~90% (84/93) of samples. Only 1 sample 
(1.1%) showed a discordant result among platforms: a KRAS G12A mutation was 
detected on the MiSeq and verified by Sanger sequencing, but was not detectable by 
Sequenom testing. Next, we selected a variety of mutations (indels, point mutations, 
frameshifts), detected only on the MiSeq, for Sanger sequence verification. In 66 
cases a concordance rate of 94.1% was observed (95 of 101 mutations). All false 
positives were attributable to low allele frequencies (< 10%), and were thus at or 
below the detection threshold for Sanger sequencing. Finally, we determined that we 
are currently able to accurately and reproducibly detect point mutations, frameshifts, 
and small indels, up to 18 bp in size. Conclusions: Application of highly parallel 
targeted sequencing through next-generation sequencing technology allows 
comprehensive mutation analysis in paraffin embedded solid tumours with excellent 
sensitivity and specificity. The enhanced ability to generate potentially relevant 
molecular profiling data using NGS platforms enables greater opportunity to inform 
rational choices for targeted therapy and patient management.  
 
TT45. Tumor Cell Enrichment Using a Pneumatic Cell Collector 
Q. Ren, D.L. Aisner, W.A. Franklin 
University of Colorado Anschutz Medical Campus, Aurora, CO. 
Introduction: Human tumors are complex and contain both malignant cells and 
variable quantities of contaminating stromal cells that complicate molecular analysis. 
In many cases it is necessary to enrich for tumor cells to obtain representative 
molecular analytes for testing.  Current methodology presents limited alternatives for 
accomplishing this efficiently for clinical applications. In collaboration with the 
Mechanical Engineering Department (Team 18) at the University of Colorado, 
Boulder, we have developed a manual tumor cell enrichment protocol utilizing a 
dissecting microscope and a new, user-friendly devise, the pneumatic cell collector 937
AMP Abstracts(PCC), to obtain a highly concentrated tumor cell component from paraffin sections. 
Methods: To enrich for tumor cells, tissue sections are cut from formalin fixed, 
paraffin blocks, mounted on glass slides and stained with hematoxylin. The stained 
slides are rinsed in saline without drying. Sections are then covered with glycerol to 
stabilize cells dislodged from the glass slide. A glass 9-inch Pasteur pipette drawn to 
a fine point using a Sutter pipette puller is connected to the PCC and used for 
microdissection. Under a microdissection scope, selected cells are manually 
dislodged from the stained section using the pipette tip. Dislodged cells are then 
aspirated from the section under PCC-controlled vacuum and discharged into an 
appropriate tube for extraction. The PCC is equipped with hand or foot controls to 
direct the aspiration and discharge of cells. Results: Several hundred cases have 
been processed using a PCC prototype.  Validation of this approach was performed 
using repeat testing of previously evaluated cases. Tumor cell enrichment has been 
documented in mixed cell tumors by comparing quality of DNA and frequency of 
mutant copy in PCC dissected and undissected or alternatively enriched tumor 
samples. The pneumatic cell collector allows for high precision in selectively 
retrieving tumor cells from a variety of tumor types, and examples of microdissection 
will be shown. Microdissection under liquid phase allows for improved optical 
resolution of target cells, and reduced tissue loss related to static charge. The device 
allows for precise adjustments in vacuum pressure to accommodate tissues in which 
tissue fragment require greater or less pressure or where alternative fluid media 
such as saline are used during dissection. Conclusions: Enrichment of tumor cells 
from a mixed cell population in tissue sections is a challenge in many somatic 
mutation analyses. The PCC economically facilitates tumor cell enrichment.  
 
TT46. Development of the EXO50 Kit: Isolation of Microvesicles Including 
Exosomes from Serum and Plasma without Ultracentrifugation for mRNA and 
microRNA Profiling  
C.A. Romain, E.A. Berghoff, D. Enderle, A. Spiel, R. Mueller, M. Noerholm, J. Skog, 
S. Bentink, S.A. Belzer 
Exosome Diagnostics, St Paul, MN. 
Introduction: Biomarker discovery and development in oncology has traditionally 
required the use of tissue, either FFPE or fresh frozen tumor samples. The use of 
microvesicles (exosomes) has allowed biomarker research in biofluids to evolve. 
Exosomes are typically 30 nm to200 nm microvesicles shed into all biofluids, 
including blood, urine, and CSF. They contain a highly rich source of intact protein 
and RNA cargo in a protected, highly stable vesicle. Ultracentrifugation, the gold 
standard for isolation of exosomes, is time consuming and requires special 
equipment not always available in a clinical laboratory. We have developed an 
isolation method that does not require ultracentrifugation and compared that method 
to ultracentrifugation, as well as to three commercially available exosome isolation 
kits. Methods: Serum and plasma samples were collected from four donors. The 
blood tubes were centrifuged at 1300 x g for 10 minutes, then serum and plasma 
were filtered using a 0.8 m syringe filter to ensure no cell carryover, split into 200 L 
and 4 mL aliquots, and stored at -80°Cuntil isolation was performed.We isolated the 
microvesicle fraction from high (4 mL) and low volume (200 L) serum and plasma 
samples using 5 different methods, i.e. three commercially available kits, the EXO50 
kit and ultracentrifugation.  RNA from low volume samples was extracted according 
to manufactures recommendations. Protocols were modified to enable extractions 
from large volume samples.  All samples were reverse transcribed to cDNA and 
assayed using three different platforms: Taqman Gene Expression Assays (18s, 
ALB, GAPDH, HPRT, KRAS, and BRAF), Taqman MicroRNA assays (hsa-let-7a, 
hsa-mir-16, hsa-miR-92a), and the TaqMan OpenArray platform profiling 754 human 
micro RNAs). Results: Commercial kits using precipitation for microvesicle isolation 
were not easily scalable to larger volume samples and one of them only supported 
extraction from serum samples. The EXO50 kit mRNA and miRNA recovery was 
comparable to an optimized ultracentrifugation method for both low volume and high 
volume samples. The EXO50 kit had a better isolation and recovery of both mRNA 
and miRNA than the three commercially available kits and was easily scalable to 
accommodate small and large plasma volumes. Conclusions: The Exosome 
EXO50 kit can be used to isolate exosomes and extract mRNA and miRNA from 
both serum and plasma samples with varying sample volumes. The EXO50 kit 
mRNA and miRNA recovery was comparable to ultracentrifugation. The EXO50 kit 
appears to have better isolation and recovery of both mRNA and miRNA than three 
commercially available kits. 
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 TT47. An Analysis of the Performance Characteristics of the LIFECODES 
RBC Genotyping Assay 
L. Millecker1, T. Ton1, C. Webb1, R. Shafi2, B. Sapinsky1, K. Hartman2, K. Eldin2, S. 
Hui2, J. Teruya2, A. Roy2 
1Texas Children's Hospital, Houston, TX; 2Baylor College of Medicine, Houston, TX. 
Introduction: Traditionally, hemagglutination has been the standard for determining 
a patient’s red blood cell (RBC) phenotype. However, under several clinical 
scenarios, e.g. in multiply-transfused or direct antiglobulin test-positive patients, 
serological typing of RBC antigens can be complex, time-consuming and, difficult to 
interpret. RBC genotyping is recently emerging as an acceptable indirect alternative 
method for RBC type determination. The LIFECODES RBC typing kit (Immucor, 
previously Gen-Probe) is a multiplexed, liquid bead array assay that targets well-
characterized single nucleotide polymorphisms (SNP) to genotype 15 antigens of the 
Kell, Kidd, Duffy, MNS, Rh and Dombrock blood groups. Here the LIFECODES RBC 
typing kit was evaluated by comparing genotypes of samples from the University of 
Illinois at Chicago (UIC) and the Detroit Medical Center (DMC), as well as, by 
comparing genotype-predicted phenotypes to phenotypes obtained at the Texas 
Children's Hospital’s Blood Bank Laboratory (TCH-BBL). Methods: A total of 71 
samples were obtained, of which 39 were nucleic acids previously isolated and 
genotyped with the LIFECODES RBC typing kit at UIC and DMC. The remaining 32 
samples were archived whole blood specimens that had previously undergone 
serological testing for 13 blood antigens at TCH-BBL. Nucleic acids were isolated 
from the whole blood specimens on a MagNA Pure LC (Roche) using a TNAi kit. All 
samples were amplified with the LIFECODES RBC typing master mix, and 
hybridized to beads read on a Luminex 200 instrument. Luminex data were analyzed 
with LIFECODES MATCH-IT!-RBC software for the presence or absence of RBC 
antigens based on adjusted mean fluorescence intensity values for alleles targeted 
within each blood group. Results: The genotypes of the 39 nucleic acid specimens 
yielded a total of 585 blood antigen targets and correlated 100% to the genotypes 
obtained at UIC and DMC. The genotype predicted phenotypes of the 32 whole 
blood specimens yielded a total of 672 antigen targets, of which 393 were used for 
phenotype comparison as serological data were not available for all genotype 
targets. Of these 393 antigen targets, 383 (97.5%) were concordant with previous 
serological testing. For all discrepancies, the antigen was positive by serology at 
TCH-BBL and negative by genotyping. Conclusions: The LIFECODES RBC typing 
kit provided quick, reliable and reproducible genotyping of five clinically significant 
blood antigen groups. Molecular genotyping techniques can complement the 
traditional serology methods currently offered by allowing for the determination of a 
patient’s blood groups on a routine basis. 
 
TT48.  Validation of the AdnaTest Prostate Assay Sensitivity in Detecting 
Prostate-Associated Transcripts Compared to the Veridex Cellsearch 
Enumeration Assay in Patients with Prostate Cancer 
A.Samoila, D.A. Bastos, A. Anand, A. Herkal, C. Patel, K.R. Curtis, N. Schreiber, M. 
Fleisher, H.I. Scher, D.C. Danila 
Memorial Sloan-Kettering Cancer Center, New York, NY. 
Introduction: Enumeration of circulating tumor cells (CTC) in blood is prognostic for 
survival in Castration Resistant Prostate Cancer (CRPC). Veridex CellSearch is the 
only FDA approved assay for CTC enumeration and is based on strict morphologic 
and immunohistochemical criteria. An unmet clinical need is to develop highly 
sensitive biomarker assay to monitor patients with favorable CTC count (<5 cells/7.5 
ml blood). Methods: Whole blood was collected under an IRB approved protocol 
from 58 patients with CRPC for the AdnaTest and CellSearch assays. CellSearch 
platform was used for CTC detection. The AdnaTest included immunomagnetic cell 
enrichment using EpCAM and Her2 antibodies, followed by mRNA isolation and 
multiplex PCR amplification of prostate associated transcripts (PSMA, PSA, and 
EGFR) and ALDH1. Forty of 58 patients were tested using the AdnaTest assay, 
including 8 patients processed in parallel with PBS and wash buffer. The remaining 
18 patients were tested exclusively for ALDH1. Results: AdnaTest detected CTC in 
26/40 patients (65%, 95% CI 50% to 80%) including 6 of the 18 (33%, 95% CI 11% 
to 55%) with no CTC detected by CellSearch. AdnaTest positivity was based on 
detection of PSA, alone or in combination with the other two transcripts. Of 23 
patients with < 5 CTC by CellSearch, 10 (45%, 95% CI 30% to 61%) were positive 
by AdnaTest. In contrast, 17 patients with 5 CTC by CellSearch, 16(94%, 95% CI 
87% to 100%) were positive by AdnaTest. Overall, 70% (28) of the 40 patients had 
detectable CTC by either AdnaTest or CellSearch, with positive agreement in 71%. 
Only 1 patient (4%) was positive based on EGFR alone, and none by PSMA or 
ALDH1 alone. Of the remaining 18 patients tested exclusively for ALDH1 expression, 
only one was AdnaTest positive. The pattern of prostate transcripts expression with 
wash buffer was suboptimal when compared with the standard assay.  jmd.amjpathol.org ■ The Journal of Molecular Diagnostics
 AMP AbstractsConclusions: The AdnaTest demonstrated incremental sensitivity by detecting 
Prostate Specific Transcripts in patients with no CTC identified by CellSearch. This is 
consistent with the difference between PCR detection versus the strict definition of 
CTC based on morphologic and immunohistochemical criteria. Further studies to 
assess the utility of the AdnaTest assay as a biomarker for clinical outcome in 
patients with CPRP and other cancers are warranted. 
 
TT49. Stability Testing of a Noninvasive Prenatal Test (NIPT) in a Clinical 
Setting - The MaterniT21 PLUS Laboratory-Developed Test 
R.C. Tim, J.A. Tynan, T.J. Jensen, L. Cagasan, V. Lu, L. Liu, S. Sovath, M. Riviere, 
P. Oeth, M. Ehrich 
Sequenom Center for Molecular Medicine, San Diego, CA. 
Introduction: Excellent clinical performance of a noninvasive test for fetal 
aneuploidies using next-generation sequencing has been demonstrated by several 
laboratories. This study demonstrates the robustness of the processes involved in 
one such assay, the MaterniT21 PLUS laboratory-developed test, focusing on 
reproducibility and stability of the results. Methods: The study was divided into two 
portions to determine the robustness of the MaterniT21 PLUS test. The first was 
designed to measure reproducibility of chromosomal representation in a pool of 
circulating cell-free (ccf) plasma DNA isolated from women at increased risk for fetal 
aneuploidy with a known euploid fetus as determined by fetal karyotyping. For these 
experiments, ccf DNA obtained from 976 women was combined and used to prepare 
over 1000 libraries. These libraries were sequenced and analyzed for variability of 
chromosomal representation. The second portion of the study was designed to 
investigate the stability of the post-PCR workflow processes. For this part of the 
study, a set of libraries was generated for use throughout the entire series of 
experiments, comprised of 44 known euploid and 44 known trisomy 21 samples. For 
each experimental subset, all factors were kept constant, including operator, reagent 
lots, and instruments, except for the particular variable of interest. All flow cells from 
both portions of the study were clustered on the Illumina cBot in 12-plex and 
sequenced on the HiSeq 2000 (Illumina, San Diego, California). Sequencing reads 
were de-multiplexed, aligned to the human genome with Bowtie2 and chromosomal 
representations were determined. Results: Results demonstrate that although 
library concentrations and raw aligned counts may be variable from plate to plate, 
chromosomal representation is remarkably stable for the pooled maternal ccf DNA 
samples processed by multiple operators, across library batches, and measured on 
multiple sequencing instruments. From the second part of this study, no significant 
differences in classification z-score values were found across flow cells as a function 
of library storage time, flow cell storage time, reagent lot, or sequencing instrument. 
Both sensitivity and specificity for each of these experimental subsets were 
determined to be nearly 100%. Conclusions: This study demonstrates the stability 
for use of the MaterniT21 PLUS test across operators and instruments and reveals 
the low variability for discrete process steps of the assay. 
 
TT50. Molecular Indexing for Improved RNA-Seq Analysis 
M. Toloue, J. Risinger, P. Nakashe 
Bioo Scientific, Austin, TX. 
Introduction: Most current Next-Generation Sequencing (NGS) library prep 
methods introduce significant sequence bias. The use of enzyme processing and 
fragmentation steps can introduce errors in the form of incorrect sequence and 
misrepresented copy number. Conventional RNA sequencing library construction 
involves the ligation of a population of cDNA molecules with adapters prior to 
amplification and sequencing. An inherent weakness of conventional RNA-Seq 
analysis is that cDNA fragments that amplify more efficiently will unavoidably result 
in a higher number of reads than cDNAs that do not amplify as well during the library 
construction PCR step. Therefore, when multiple reads mapping to the same 
transcript are encountered, it is not possible to determine whether sequenced reads 
originate from the same or different cDNA molecules. Methods: With molecular 
indexed libraries, each molecule is tagged with a molecular index randomly chosen 
from ~10,000 combinations so that any two identical molecules become 
distinguishable (with odds of 10,000:1), and can be independently evaluated in later 
data analysis. Analysis using molecular indexing information provides an absolute, 
digital measurement of gene expression levels, irrespective of common amplification 
distortions observed in many RNA-Seq experiments. This type of indexing requires 
no additional steps in RNA-Seq workflow and increases the precision of downstream 
analysis. Results: At low sequencing depths, analysis use of molecular indices is 
identical to conventional analysis and generates equivalent RPKM values in all 
applications. As sequencing depth increases, individual molecular resolution also 
increases. In quantitative RNA-Seq experiments, the molecular indices distinguish 
re-sampling of the same molecule from sampling of a different molecule. At high 
sequencing depths, each molecule can be distinguished and the entire library can be The Journal of Molecular Diagnostics ■ jmd.amjpathol.organalyzed to provide absolute numbers of each molecule. Conclusions: Resolving 
individual clones of molecules is critical for increasing sequencing accuracy, 
measuring bias, PCR duplication rates and identifying mutations in complex sample 
types. Although it is well known that library prep methods introduce bias, tools for 
measuring it are needed if we are to start using NGS for accurate and quantitative 
gene expression measurements. Toward achieving that goal, we propose the use of 
molecular indices for all RNA-Seq experiments.  
  
TT51. Multiplex Ultrasensitive Detection of Somatic Mutations Using MALDI-
TOF Mass Spectrometry 
A. Nygren, M. Mosko, A. Nakorchevsky, E. Flores, A. Nakorchevsky, M. Ehrich, C. 
Honisch, D. van den Boom 
Sequenom, Inc., San Diego, CA. 
Introduction: Systematic characterization of somatic mutations in cancer genomes 
has improved our understanding of this multifaceted disease and has provided 
opportunities for targeted therapeutic development. Despite much progress several 
analytical challenges remain to be resolved such as the detection of low abundance 
somatic mutations, particularly in low percentage tumor cell specimens. These 
genetic events are hard to identify due to the heterogeneous nature of most tumor 
tissue samples and often the mutations may differ from the highly abundant wild type 
sequence by only a single nucleotide. A method capable of accurate detection of 
these rare variants would allow identification of low level genetic determinants for the 
initiation and proliferation in primary tumors or as an early detection or monitoring 
biomarker in circulating cell-free tumor DNA. Methods: We have developed a novel 
approach for ultrasensitive high-throughput multiplex mutation detection and used 
this technique to accurately detect as low as 0.125% of mutant sequences in a 
model system. The process consists of multiplex PCR followed by a mutation-
specific single base extension reaction coupled with mutation-specific chain 
terminators labeled with a moiety for solid phase capture. Captured, washed, and 
eluted products are interrogated for molecular mass and genotypes are identified 
and characterized using MALDI-TOF mass spectrometry. For verification of this 
novel approach we have developed four multiplex reactions comprising 25 assays 
for the simultaneous detection of somatic mutations in 14 genes frequently mutated 
in tumors. Results: For methodology validation, we successfully verified rare 
mutations in a set of characterized cell-lines with ultra-low fractions of defined 
somatic mutations. These cell lines are derived from different tissues and have been 
well characterized in numerous studies using a variety of molecular methods. Each 
cell line was diluted with wild type DNA to 1%, 0.5% and 0% and an analytical 
sensitivity of 96% and 91% for the 1% mutants and 0.5% mutant samples, 
respectively, was obtained. Conclusions: The results show that this approach is a 
powerful method for the detection of rare somatic mutations. The process is readily 
amenable to scaling and automation making it a perfect application to detect low-
level mutations in both tumor samples as well as liquid biopsies. Additional 
verification and validation studies using formalin fixed paraffin embedded DNA 
samples and circulating cell-free DNA isolated from plasma are currently underway. 
Compared to next-generation sequencing platforms, our method offers a rapid and 
simple workflow and minimal sample input requirements.  
 
TT52. Automated ERG and PTEN Quantum Dots FISH Assay in Prostate 
Biopsy: Determination of Optimum Formalin Fixation Conditions for 
Appropriate Quantum Dots FISH Staining 
L. Tang, U. Sathyanarayana, C. Birch, P. Brunhoeber, Y. Wang 
Ventana Medical Systems, Inc., Oro Valley, AZ. 
Introduction: ERG rearrangement and PTEN deletion are the two most common 
genomic events in prostate cancer. Recent studies suggest PTEN loss and ERG 
genetic rearrangements are concomitant events in human prostate cancer (Han B, et 
al. Mod Pathol 2009, 22:1083-1093; Carver BS, et al. Nat Genet 2009, 41:619-624). 
Han  et al.have demonstrated the importance of localization of PTEN and ERG 
genes that make up their signatures in cancer foci, high grade prostatic intraepithelial 
neoplasia (HGPIN) adjacent to cancer, HGPIN away from cancer, and metastatic 
sites. We developed an automated Quantum Dots (QDs) multiplexing fluorescent in 
situ hybridization (FISH) assay for simultaneous detection of ERG and PTEN gene 
status in prostate needle biopsy specimens. Fixation conditions are critical factors for 
successful FISH staining of FFPE tissues. No study has been published regarding 
prostate needle biopsy fixation conditions appropriate for FISH. In this work we 
studied the optimum fixation duration for prostate biopsies in 10% NBF for 
appropriate QDs FISH staining. Methods: From two surgically removed fresh 
prostates, biopsy cores were produced using the Easy Core Biopsy System (Boston 
Scientific #43-454) and fixed for 1, 2, 4, 8, 24, 48, 72, or 120hours in 10% NBF at 
room temp, and paraffin embedded. Test samples were collected, grossed, fixed and 
processed at the Arizona Cancer Center TACMASS laboratory. A total of 32 blocks 939
9AMP Abstractsfor two biopsy cores were used in this study. The slides were stained with 4 probes 
viz., 5p ERG:DIG, 3pERG:DNP, PTEN:TS and CEN10:NP simultaneously, detected 
by 4 color Quantum dot FISH assay - QD565, QD655, QD605 and QD525, 
respectively, on the VENTANA BenchMark ULTRA instrument. The slides were 
stained in duplicates for each time point from both cases (total of 64 slides). The 
slides were evaluated for adequate QDs ISH staining by a board certified 
pathologist. Results: The biopsy samples fixed for 4 to 120 hours gave acceptable 
staining for all the four probe targets. However, the biopsy samples fixed for 8 to 72 
hours gave the best staining performance. The biopsy samples fixed for 1hr to 2 
hours did not result in adequate staining. Conclusions: We developed an 
automated QDs multiplexing FISH assay that detects ERG and PTEN gene status 
simultaneously in prostate biopsy specimens. We demonstrated for the first time the 
optimum prostate biopsy formalin fixation condition for appropriate QDs FISH 
staining.  
 
TT53. Rapid Cycle In-Line PCR with DNA High Resolution Melt (HRM) 
Analysis 
J. Huuskonen1, S. Sundberg1, R. Pryor2, J. Farrar2, C. Wittwer2, H. Stiles1, L. Xu1, R. 
Howell1 
1Canon US Life Sciences, Inc, Rockville, MD; 2University of Utah, Salt Lake City, UT. 
Introduction: Currently PCR and HRM are performed in batch mode using 
thermocyclers, or in instruments that run single-use individual cartridge systems. 
These systems are not well-suited for heritable genetic testing that requires the 
ability to perform many tests under different PCR conditions. Although multiplexing 
can alleviate some restrictions of these formats it often means further optimization of 
tests or omission of a test. Here we present data using the first prototype instruments 
designed by Canon US Life Sciences, Inc. (CLS) that are capable of rapid in-line 
PCR/HRM enabling multiple genetic targets to be tested sequentially on a patient. 
Current prototype design allows eight DNA samples to be loaded onto a single 
cartridge. After each PCR test is complete, an onboard liquid handling system 
delivers reagents for the next PCR test, allowing multiple sequential amplifications 
within a single microfluidic channel.  The design enables rapid heat transfer allowing 
15seconds amplification cycles and completion of PCR in less than 10 minutes. 
Methods: DNA from 100 de-identified clinical blood samples, obtained from ARUP 
Laboratories, was extracted at the University of Utah using the Gentra Puregene 
Blood Kit (Qiagen). A portion of DNA from each sample was genotyped for FII 
(20210G>A), FV (1691G>A), and MTHFR (677C>T and 1298A>C) on an LS32 
(Biofire) using HRM assays designed by the University of Utah. These samples were 
then blinded and tested for the same targets using assays designed by CLS and 
performed in the prototype instruments at both CLS and at the University of Utah. 
HRM data generated by both instruments was interpreted using custom HRM 
software (Melting Wizard: High-Resolution Melting Analysis version MW4.2 
University of Utah). Results: One hundred blinded DNA samples were tested for 
four mutations related to thrombophilia. Each site was able to accurately genotype all 
100 samples for all four targets for a total of 400 accurate test results. Conclusions: 
We have demonstrated the first instrument prototype capable of rapid cycle in-line 
PCR with HRM. Unique design of the microfluidic chip allows for fast PCR and the in-
line execution facilitates performing multiple individually optimized PCR reactions on 
a single patient sample. Furthermore, an on-board liquid handling system could 
facilitate reflex testing, e.g., exon scanning followed by a reflexive genotyping assay, 
or a second reflexive genotyping assay following the presence or absence of a 
relevant mutation in a previous test. 
 
TT54. Identifying a General Reaction Chemistry for Rapid PCR and High 
Resolution Melt (HRM) Analysis Performed In a Microfluidic Environment 
J. Moll, H. Shandilya, N. Eisenach, J. Huuskonen, R. Howell 
Canon US Life Sciences, Inc., Rockville, MD. 
Introduction: Canon US Life Sciences, Inc. is developing an instrument for rapid in-
line DNA amplification coupled with HRM to enable automated genetic analysis. 
PCR chemistry must support rapid PCR (15 second cycling time) and HRM in a 
microfluidic environment to be compatible with this platform. Methods: A fractional 
factorial design of experiments (DOE) was employed to screen the effects of 7 
components (pH, KCl, MgCl2, betaine, DMSO, Tween20, Tris) on amplification 
efficiency and genotyping ability using a LightScanner32 (LS32) instrument (Biofire) 
under fast PCR cycling conditions. Two assays were utilized: FV Leiden 
(20210G>A), a small amplicon genotyping assay (43 bp); and a larger amplicon 
assay covering exon 11 of the ACADM gene (261 bp). A second central composite 
DOE study was then performed to optimize PCR conditions using FV Leiden, 
ACADM exon 11, and an additional large target assay (CFTR exon 6a, 226 bp). The 
central composite design was selected to re-evaluate the effects of varying KCl, 
betaine, DMSO, MgCl2 as well as BSA on LS32. Results from this study were used 40to optimize PCR chemistry on our prototype. Results: Fractional factorial design: 
ACADM exon 11 amplification signal-to-noise ratio (SNR) was significantly affected 
by pH, KCl, betaine, and MgCl2. KCl and MgCl2 similarly affected both ACADM exon 
11 and FV Leiden crossing point (Cp) values. PCR efficiency was enhanced by low 
KCl concentration (20 mM to 50 mM) and high MgCl2 concentration (4.5 to 6 mM). 
The new chemistry formulation derived from this study was compatible with the 
prototype microfluidic platform and significantly reduced total PCR cycling time. The 
new formulation had a reduced Titanium (Clontech) polymerase concentration. 
Central composite design:  PCR efficiency and/or genotyping were enhanced at high 
MgCl2 (6 mM), 0% BSA, and high betaine (0.5 to 1.0 M) for all three assays. Several 
two-factor interactions were observed: betaine:KCl, betaine:MgCl2 and BSA:MgCl2. 
The data suggested that a single PCR chemistry could support strong 
PCR/genotyping performance for large and small target assays of varying GC 
content. Follow-up experiments on our prototype showed that further modifications of 
betaine, DMSO and BSA concentrations were required to support adequate 
performance in a microfluidic environment. The final chemistry selection supported 
rapid PCR cycling (8 to 15 second cycle times) and accurate genotyping. 
Conclusions: Our DOE approach allowed PCR chemistry optimization with minimal 
time and labor. The selected chemistry supported improved performance in our 
microfluidic device with reduced cycling time, while maintaining genotyping accuracy. 
 
TT55. Detection of Somatic Alterations in Plasma from Lung Cancer Patients: 
A Pilot Study 
J. Costa1, A. Justino1, A. Barroso2, B. Parente2, J.C. Machado1 
1IPATIMUP, Porto, Portugal; 2Hospital Center of Vila Nova de Gaia-Espinho, Vila 
Nova de Gaia, Porto. 
Introduction: The identification of tumor-specific (somatic) mutations in plasma can 
serve as biomarkers for tumor detection, monitor tumor response to specific 
therapies, detect residual disease after surgery, and long-term follow-up. The 
intrinsic low abundance of circulating cell-free tumor DNA (cfDNA) makes the 
detection and quantification of such mutations in plasma a challenging task. This 
pilot study aims to evaluate different established methodologies with different levels 
of sensitivity to be used in the detection of somatic alterations in plasma from lung 
cancer patients. Methods: A group of 10 lung cancer patients that typified different 
stages of disease and treatment were selected for this study. Plasma samples were 
obtained and circulating cfDNA isolated. Different genetic alterations in the EGFR 
gene were used as biomarkers: p.E746_A750del and p.L858R, which render the 
patient eligible for tyrosine kinase inhibitors (TKI) target therapy, and p.T790M, 
known to be involved in the development of resistance to TKI treatment. Capillary 
electrophoresis sequencing, quantitative real-time PCR and massive parallel 
sequencing (MPS) with the Ion PGM were used to determine the patient mutational 
status. The alterations identified were compared to the mutational status of the tumor 
biopsy. Results: Tumor derived DNA could be obtained from the plasma of the 
different patients. The three mutations were identified using all the different 
methodologies. However, as anticipated, different methodologies presented different 
levels of sensitivity. Mutations with allelic fractions as low as 10% could be identified 
using the three different methodologies. Mutations with allelic fractions below 10% 
could only be identified using real-time PCR and MPS. The strategy is now being 
extended to a larger cohort of patients to push forward the concept of liquid biopsy in 
the clinical management of cancer patients. Conclusions: In this pilot study, we 
demonstrate the capacity to identify in plasma clinically relevant somatic EGFR 
mutations using methodologies that are or will be in the near future implemented in 
most molecular pathology laboratories. 
 
TT56. Bioinformatics Decision Support for Interpretation of Clinical NGS 
Variants 
E.W. Klee, E. Winter, M.J. Ferber 
Mayo Clinic, Rochester, MN. 
Introduction: Next-generation sequencing has enabled the interrogation of DNA 
sequence at a rapidly decreasing cost per base, facilitating an explosion in research 
and clinical applications of this technology. The simultaneous interrogation of 
multiple disease-associated genes using target-enrichment chemistry followed by 
next-generation sequencing is enabling more rapid and comprehensive testing 
strategies, while simultaneously increasing the complexity of results interpretation. 
We developed a bioinformatics system for NGS variant data review and clinical 
interpretation to support clinical next-generation sequencing assays. Methods: Our 
program is built utilizing current web application standards and practices on the 
server (Java/Spring) and the web browser (jQuery). Data accessed by the web 
application is stored and isolated to a relational database with no reliance on a file 
system. Data processing takes place during sample import on a grid-based system 
keeping user experience responsive once loaded. Results: The system is built to jmd.amjpathol.org ■ The Journal of Molecular Diagnostics
T AMP Abstractssupport the review and interpretation of individual patient results. Information is 
presented in multiple contexts designed to enable a user to quickly assess the 
overall performance of the assay and then focus in on identification and reporting of 
potential actionable variants. A quality control view provides information on the assay 
performance, including summary statistics on the sequencing reaction and read 
alignment, automated flagging of assay target regions failing user-specified minimum 
coverage metrics, as well as, per-base sequence quality scores, sequence quality 
score distributions, and GC content. A summary of sample-specific molecular 
variants is presented in a separate page. Each variant is annotated with genetic 
position, nucleotide and amino substitutions, variant frequency, positional coverage, 
and expert curated clinical classification using the ACMG 5-point classification. For 
each variant, there is sample agnostic variant page with functional predictions, 
splice-site predictions, and curated annotations stored from occurrences noted in 
previous samples. User comments can be captured and are stored along with variant 
records in the underlying relational database. A reporting feature allows users to 
select variants and will generated a PDF report that includes variant-specific 
summary information, basic patient demographics, and user provided comments. 
Conclusions: Next-generation sequencing offers the opportunity to significantly 
change clinical molecular genetic testing, improving patient care. However, the 
complexity of this technology requires the development of a new set of analytical 
requirements and data review systems to support the rapid review and interpretation 
of this information.  
 
TT57. Introducing a Robust and Simplified Personal Genome Machine (PGM) 
Sequencing Workflow  
A.V. Roth, M. Callahan, M. Laptewicz, B. Bharadwaj, V. Sheth, D. Topacio, S. 
Roman, M. Andersen, D. Deng, Y. Korlann, J. Shaw 
Life Technologies, Carlsbad, CA. 
Introduction: A new Ion PGM workflow has been developed that encompasses 
several innovations for a simplified and tightly controlled process from sample 
preparation to sequencing. Here, we describe a simplification in the Ion AmpliSeq 
library preparation protocol, called the Ion AmpliSeq Library Equalizer protocol, 
which allows the user to bypass the need for tedious and variable library quantitative 
assays, such as qPCR or Bioanalyzer, prior to template preparation on the 
OneTouch instruments, all in a single well. Addition of the correct amount of 
amplicon is critical to ensuring that the templating reaction results in the maximum 
amount of clonal DNA template bound to particles for optimal signal in sequencing. 
Methods: To confirm the Ion AmpliSeq Library Equalizer utility, a comprehensive 
study was performed in a direct head-to-head comparison between normalized/non-
equalized libraries vs. equalized libraries.  This study was performed with barcoded 
libraries prepared from genomic DNA extracted from two human cell lines, and a test 
amplicon panel consisting of 621 amplicons, ranging in size from 80 to 200 base 
pairs, 20% to 80% GC content, and containing ~300 SNPs and ~90 InDels. The 
libraries were prepared using the Ion PGM 200bp OneTouch2 Template workflow 
and the resulting samples were sequenced using the Ion PGM 200bpv2 Sequencing 
kit and 318 chips, for a total of 65 library sequencing runs on the PGM. Results: 
Results showed that the equalized libraries matched the performance of non-
equalized libraries in terms of total mapped reads, mean read-length, amplicon 
representation, amplicon coverage uniformity, and SNP and InDel sensitivity.   
Conclusions: This modified approach to Ion AmpliSeq library preparation simplified 
the sample prep process and allowed both library cleanup and equalization of the 
individual library preparation in a single well, with no transfers required.  
 
TT58. Quality Control Measures for Next-Generation Sequencing-Based 
Targeted Gene Panels in a Clinical Diagnostics Laboratory 
K.P. Patel, B.A. Barkoh, N. Reddy, R. Singh, K. Aldape, M. Routbort, R. Luthra 
The University of Texas MD Anderson Cancer Center, Houston, TX. 
Introduction: Next-generation sequencing-based platforms offer powerful tools to 
simultaneously interrogate aberrations in multiple genes using nanograms amounts 
of genetic material. Although, these highly complex tools are increasingly being 
adopted in clinical diagnostics laboratories, no universally acceptable quality control 
measures are available to ensure diagnostic accuracy and optimization of workflow. 
In addition, the workflow and sequencing chemistries differ significantly between the 
two popular NGS platforms namely Ion Torrent and Illumina. We describe quality 
control (QC) matrices established for these two platforms in our high volume clinical 
molecular diagnostics laboratory.  
Methods: We optimized laboratory workflows for a 46-gene Ampliseq cancer panel 
on Ion Torrent PGM platform (Life Technologies, Carlsbad, CA) and a 48-gene 
TruSeq cancer panel on MiSeq platform (Illumina Inc, San Diego, CA). QC indicators 
for each step of the PGM and MiSeq workflows, starting from assessment of 
specimen quality to pathologist sign-out, were established. Reflex workflow actions he Journal of Molecular Diagnostics ■ jmd.amjpathol.orgbased on quality indicators at each step were implemented. Risk assessment 
analysis was performed to identify steps prone to manual errors and specific 
preventive measures were implemented. Additional indicators were established to 
monitor the efficiency of workflow in the form of sample acceptance rate, percentage 
pass rate at each QC step, repeat rate, on-time completion ratio and turn around 
time to name a few. All QC indicators are being continually optimized based on 
tracking data. Results: Proactive establishment of QC and performance indicators 
coupled with active monitoring and continuous optimization allowed seamless 
integration of both Ion PGM and MiSeq NGS platforms in the clinical diagnostics 
workflow. Important benefits include consolidation of multiple different test platforms 
into a single streamlined test platform. Both Ion PGM and MiSeq workflows are 
highly complex and involve several manual steps that are error-prone. The 
preventive measures integrated in the workflow allowed timely identification and 
correction of manual errors. QC parameters allow smooth functioning of the workflow 
as well as high rate of successful NGS analysis on multiple sample types ranging 
from peripheral blood, bone marrow, FFPE tissue, and fine needle aspirate smears. 
Conclusions: We have identified platform-specific QC and performance indicators 
for Ion PGM and Illumina MiSeq for clinical diagnostic workflow that could serve as a 
template for further optimization by the diagnostic community.   
 
TT59. Development of a Novel TPMT Genotyping Assay 
P.R. Burchard, A.N. Abou Tayoun, M.C. Schwab, L.D. Lewis, G.J. Tsongalis, M.A. 
Cervinski 
Dartmouth-Hitchcock Medical Center, Lebanon, NH. 
Introduction: Thiopurine compounds are commonly used in the treatment of 
childhood acute lymphoblastic leukemia, and as immunosuppressants following 
organ transplantation or for treatment of various autoimmune disorders. Thiopurine 
S-methyltransferase (TPMT) is required for detoxification, through S-methylation of 
6-thioguanine nucleotides (TGNs), a byproduct of thiopurine metabolism. Single 
nucleotide polymorphisms (SNPs) in the TPMT gene have been shown to affect its 
function, with some variants associated with serious clinical manifestations including 
severe to fatal myelosuppression and organ transplant rejection following treatment 
with standard thiopurine doses. In this study, we describe a sensitive, fast, and 
precise TaqMan real-time PCR assay for TPMT genotyping. Methods: Five DNA 
samples with known genotypes were obtained from the Coriell Institute and 
American Type Culture Collection to assess the performance of this new Taqman 
assay. DNA samples were run in triplicate daily over five days to generate a total of 
15 data points for each sample. The samples were genotyped for the TPMT*2, *3B, 
*3C, and *3A polymorphisms by TaqMan genotyping assays using previously 
designed primers and probes on the AB 7500 FAST Real-Time PCR instrument 
(Applied Biosystems, Foster City, CA). Allelic discrimination plots in addition to ¨Cq 
analysis were used to identifyeach polymorphism. Results: The TaqMan assay 
correctly genotyped all 5 cell line control samples. Assay controls for blank and no 
template gave the expected results. Comparison of the ¨Cq values for wild type and 
mutant alleles confirmed the allelic discrimination results. The coefficient of variation 
(CV), across all Cq values, averaged 2.19% (0% to 7.18%), reflecting minimal inter-
run variability. Conclusions: The clinical implications of TPMT genotyping, along 
with the simplicity and specificity of the TaqMan genotyping assays make this test 
highly suitable for use in a clinical laboratory. 
 
TT60. A Paired-Sample Analysis Pipeline for Removing Artifacts In Point 
Mutation Calls Made from the Illumina TruSeq Amplicon Cancer Panel (TSACP) 
Assay 
A. Zehir1, T. Mitchell1, W.J. Cheng2, A. Oultache1, K. Nafa1, M.E. Arcila1, M.F. 
Berger1, D.T. Cheng1, C.V. Hedvat1 
1Memorial Sloan-Kettering Cancer Center, New York, NY; 2BioReference Laboratory, 
Inc., Elmwood Park, NJ. 
Introduction: The Illumina TruSeq Amplicon Cancer Panel (TSACP) is a PCR-
based assay for targeted sequencing of 212 mutation hotspots across 48 cancer 
genes. The PCR product is usually sequenced on an Illumina MiSeq, and Illumina 
has developed packaged analysis workflows in MiSeqReporter (MSR) for aligning 
reads and calling variants from the sequencing output. Because MSR assumes all 
samples to be unpaired without normal controls, it reports all variants regardless of 
their status as germline, somatic or assay artifact. In this study, we developed a 
paired-sample analysis pipeline (PSP) for TSACP data and compared it against 
MSR on a dataset of patient samples with known mutations. Methods: DNA 
extracted from FFPE tumor samples was subjected to PCR amplification per TSACP 
protocol, and prepared libraries were sequenced on an Illumina MiSeq. Since 
patient-matched normal samples were unavailable, DNA from a Hapmap cell line 
was included as an unmatched control for the paired-sample pipeline. MSR2.2 used 
a Smith-Waterman aligner for read alignment and Illumina’s Somatic Variant Caller 941
AMP Abstractsalgorithm for variant calling. The PSP consisted of BWA and GATK for read 
alignment and post-processing, and MuTect for calling point mutations. Results: 153 
samples (corresponding to 78 unique patients) with previously identified point 
mutations in BRAF, KRAS, IDH1, NRAS and KIT were profiled using TSACP. The 
PSP reported fewer variants overall (n=6231) relative to MSR2.2 (n=38,777), where 
84% of these calls (n=5240) were in common. After filtering calls for coverage depth, 
variant allele depth and frequency, the PSP reported 472 variants compared to 987 
for MSR2.2, in which 455 calls were in common (96.3%). This amounted to 3 to 4 
variant calls per sample on average for the PSP, or 6 to 7 calls for MSR2.2. Both 
pipelines had similar recall rates of known variants: MSR2.2 recalled 152 out of 153 
(99.3%) variants, whereas the PSP recalled 151 variants (98.7%). The holdout 
known variant call undetected by the PSP was missed because the recalibrated 
base quality score was lower than a requisite Q20 cutoff. Nine samples were 
repeated in triplicate or greater to assess reproducibility of variant calls. 
Reproducibility rates were similar for both pipelines. Conclusions: The PSP 
produced fewer overall calls compared to MSR2.2 while preserving similar recall and 
reproducibility rates of known variants. Confirmation by independent assays will be 
needed to determine if variants uniquely called by MSR2.2 are indeed assay artifacts 
(false positives), or bona fide variants undetected by the paired-sample pipeline 
(false negatives).  
 
TT61. Design and Validation of a SNaPshot Assay for Melanoma and 
Glioblastoma Patients 
F. de Abreu1, M.C. Schwab2, T.M. Smith1, C.H. Rhodes1, W.F. Hickey1, C.E. Fadul1, 
C.A. Storm1, G.D. Seidel1, S. Yan1, J.B. Brennick1, M.S. Ernstoff1, G.J. Tsongalis1 
1Dartmouth Hitchcock Medical Center, Lebanon, NH; 2Geisel School of Medicine at 
Dartmouth, Lebanon, NH. 
Introduction: SNaPshot is a genotyping method that simultaneously detects 
multiple mutations. This technique involves multiplexed amplification of DNA targets 
by PCR with unlabeled oligonucleotide primers, multiplexed single-base primer 
extension with fluorescently labeled dideoxynucleotide triphosphate (ddNTP), and 
analysis of labeled primer-extension products by capillary electrophoresis. We 
designed this assay to detect mutations in cancer-related genes that activate 
signaling pathways that are targeted by novel therapeutic strategies in melanoma 
and glioblastoma patients. Methods: We designed two different cancer panels for 
glioblastoma and melanoma. The glioblastoma panel interrogates five genes with a 
total of 13 mutations and the melanoma panel six genes with a total of 43 mutations. 
Each cancer panel was divided into different sub-panels according to the size of their 
extension products, which were identified by the SNaPshot Primer Focus Kit (Life 
Technologies). The concentration of PCR and extension primers in each sub-panel 
was optimized so each mutation would have similar peak height after capillary 
electrophoresis. The limit of detection (LOD) was assessed by varying the amount of 
genomic DNA input (100, 50, 25, 10, and 5 ng) used in the PCR. Genomic DNA was 
derived from 14 glioblastoma and three melanoma formalin-fixed paraffin-embedded 
tissues (FFPE) using Gentra PureGene Blood Kit Plus (Qiagen). DNA tumor samples 
and human control DNA were amplified using PCR and subjected to multiplex 
extension primers reactions using a SNaPshot Ready Reaction Mix (Life 
Technologies). PCR products were then analyzed using the ABI 3500 Genetic 
Analyzer with POP-7 polymer and 50-cm capillary. The results were analyzed using 
Applied Biosystems GeneMapper 4.1 software and compared to laboratory 
developed tests. Results: Correct genotype calls for samples previously tested were 
made using as little as 5 ng of DNA input. The human DNA control showed complete 
profiling of all 56 alleles. The FFPE melanoma samples were positive for BRAF or 
NRAS and the FFPE glioblastoma samples did not show any mutations. This assay 
was shown to have 100% accuracy and precision. Conclusions: This SNaPshot 
assay is a highly sensitive and specific genotyping assay that allows us to identify a 
prognostic and predictive tumor profile. These panels will allow for appropriate 
workup and management of patients based on mutation status. 
 
TT62. Validation of and Initial Experience with a Next-Generation 
Sequencing-Based 98-Gene Expanded Carrier Screening Assay 
H.P. Kang, J. Maguire, J. Tritt, C. Foo, A.S. Patterson, E.A. Evans 
Counsyl, South San Francisco, CA. 
Introduction: Validation of multi-gene next-generation sequencing (NGS) assays is 
problematic because of the lack of high-quality reference material and the 
impracticality of Sanger sequencing all validation samples. We propose a model for 
validating NGS assays using a combination of different methods. We then use this 
model to validate and demonstrate the sensitivity and specificity of a NGS-based 
carrier screening assay. Methods: The validation study included two classes of 
samples: genomic DNA reference materials obtained from Coriell (N=86), and 
anonymized residual patient samples (N=245), selected to be enriched for positive 942mutations. Data from the NGS assay was compared to 2 different reference data 
sets: a previously validated genotyping assay (N=353) and 1000 Genomes (1KG) 
project data (N=86). In addition, we used Sanger sequencing to resolve conflicts 
between the NGS assay and 1KG data. For the 1KG comparison, a ‘positive’ was 
defined as a position with a non-reference call. Results: Using the genotyping assay 
as a reference, we demonstrated sensitivity of >0.996 and the specificity of 
>0.99997. Comparison to 1KG data revealed 10425 true positive (TP), 28 false 
positive (FP), and 452 false negative (FN) calls. All of the FP and 31 of the FN calls 
were retested by Sanger sequencing, with the results that 28/28 FP calls confirmed 
as true positive, and 22/28 FN calls confirmed as true negative. The remaining 6 FN 
calls were caused by QC failures (‘no-calls’) where no results were provided. 
Extrapolating these results to the entire set of 453 FN calls yields an estimated 96 
total FN calls. Therefore the analytical sensitivity and specificity for this comparison 
are 0.991 and 1.0, respectively. Conclusions: Using a combination of a previously 
validated genotyping assay, low-depth genomic reference sequence, and Sanger 
sequencing, we validated a NGS-based expanded carrier screening assay. We 
demonstrated that the assay has excellent sensitivity and specificity. In addition, we 
have shown that there is very little value in Sanger confirmation of NGS results.  
 
TT63. Development of QȖ Bacteriophage as an Internal Process Control for 
Isolation and Extraction of Microvesicles (Including Exosomes) from Urine 
S. Belzer1, C. Romain1, M. Noerholm2, J. Skog1, I. Sinclair1, J. Fishbeck1, A. Scott1, 
R. Mueller2, D. Enderle2, A. Spiel2 
1Exosome Diagnostics, Inc, St Paul, MN; 2Exosome Diagnostics, GmbH, Martinsried, 
Germany. 
Introduction: Internal controls (IC) added to samples provide a simple and accurate 
method to assess the integrity of all the steps of an isolation and nucleic acid 
amplification procedure. The goal of this study was to have a process control that 
was stable, abundant and could be used for all microvesicle (MVs) (including 
exosomes) isolation procedures including but not limited to ultracentrifugation and 
centrifugation concentration. An appropriate IC concentration should be in a range 
that results in a sensitive method for detection of an extraction failure or the 
presence of RT-PCR inhibitors in the reaction. Neither the IC nor its associated 
primers and probes should interfere with the desired target amplification. We have 
selected and tested Qȕ bacteriophage as an IC for MV isolation and RT-qPCR. The 
bacteriophage is approximately 25 nm in diameter and contains a ssRNA genome 
with 3 genes encoding 4 proteins. We have shown that the Qȕ bacteriophage allows 
co-purification with MVs and the low complexity of the viral ssRNA gene reduces the 
potential of false priming with target human genes. 
Methods: Qȕ Bacteriophage was obtained from AttoStar, (Edina, MN) at a 
concentration of approximately 5 x 108/mL. Serial dilutions were prepared and spiked 
into 20 mL urine at concentrations ranging from 105 to 10 copies per sample. Urine 
MVs were isolated by ultrafiltration concentration and RNA was extracted using the 
Exosome Diagnostics EXO70 kit. RNA was analyzed for integrity and quantity. RNA 
was reverse transcribed and qPCR was performed using primers and probes specific 
to mRNA for prostate, kidney, bladder, and house-keeping genes and Qȕ. In addition 
to validation testing, more than 800 urine samples from our prostate cancer 
biomarker study have been tested using Qȕ as an internal control. Results: The Qȕ 
bacteriophage co-isolates with MVs and Qȕ RNA is extracted along with the MV 
RNA. Qȕ does not interfere with MV RNA quality and quantity determinations, or with 
detection of genes isolated from MVs by RT-qPCR. Qȕ dilutions in urine are linear 
and dilutions of urine do not affect Qȕ recovery until the urine is very dilute. 
Conclusions: Over 800 urine samples from our prostate cancer biomarker study 
have been tested with Qȕ as an internal process control. Qȕ as an IC clearly 
detected samples with inefficient MV extraction or PCR inhibitors as indicated by 
repeat testing with second sample. This demonstrates that Qȕ is suitable as an IC 
for analysis of urine cancer biomarkers from exosomes. 
 
TT64. Low Cost Electrophoresis Systems Detect and Resolve All Categories 
of Fragile X Gene Expansions Amplified Using AmplideX FMR1 PCR Reagents 
G.J. Latham, S. Filipovic-Sadic, R. Cao, A. Hadd 
Asuragen, Inc., Austin, TX. 
Introduction: The fragile X gene, FMR1, codes for an RNA-binding protein that 
regulates the translation of hundreds of genes. Expansion of CGG repeats in the 5’ 
untranslated region of FMR1 modulates RNA and protein levels and results in clinical 
phenotypes in both premutation carriers and full mutation individuals. These 
phenotypes include intellectual disability, autism, anxiety, seizures, ADHD, infertility, 
ataxia, and parkinsonism. As a result, broad access to FMR1 genetic technologies is 
needed to support routine screening and molecular diagnostics. Methods: The 
sizing resolution and analytical sensitivity of PCR products produced using AmplideX 
FMR1 PCR reagents were compared across four different electrophoresis platforms. jmd.amjpathol.org ■ The Journal of Molecular Diagnostics
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cell lines that spanned all categories of normal and expanded alleles. FMR1 
amplicons were resolved on electrophoresis instruments from Life Technologies 
(3500xl Genetic Analyzer), Agilent Technologies (2100 BioAnalyzer and 
TapeStation), and Lonza (FlashGel DNA System). Results: All four platforms 
differentiated normal alleles from premutation and full mutation alleles, classified all 
categories of expansions, and illuminated complex size mosaicism across the 
clinically informative range of CGG repeats. Samples that differed by a single CGG 
repeat could be distinguished on the 3500xl, whereas as few as 3 CGG repeats 
could be resolved on the BioAnalyzer. In addition, the Lonza platform resolved full 
mutation amplicon sizes up to ~1000 CGG. Analytical sensitivity for the detection of 
full mutation expansions was 1% on the 3500xl, and 10% to 20% on the other 
systems. PCR products could be analyzed without purification, supporting a 
streamlined workflow. Conclusions: The capital cost and maintenance expense of 
genetic analyzer instruments can limit the access of molecular assays in some 
laboratories. We demonstrate that alternative, low cost electrophoresis platforms can 
successfully detect and resolve PCR products representing all categories of FMR1 
mutations and generated using standardized, commercially available reagents. 
These findings expand options for US and international laboratories interested in 
FMR1-based screening and diagnostic testing.  
 
TT65. Evaluation of Pyrosequencing for the Detection of BRCA1 Promoter 
Hypermethylation in Ovarian Cancers 
L. Zhang, R. Bacares, M. Bisogna, D.A. Levine 
Memorial Sloan-Kettering Cancer Center, New York, NY. 
Introduction: BRCA1 and BRCA2BRCA2 genes are important for double-strand 
break repair by homologous recombination. Cells with inactivating mutations of the 
BRCA1 or BRCA2BRCA2 show increased sensitivity to Poly-ADP ribose polymerase 
inhibitors (PARPi). Sporadic ovarian tumors with functional inactivation of BRCA1 by 
hypermethylation will also have the BRCA-deficiency phenocopy and may sensitize 
tumors to BRCA-directed therapies. Thus, the determination of methylation status of 
BRCA1 may be important for prediction of benefit in clinical trials of PARPi. Here, we 
describe the validation of Pyrosequencing approach for assaying the promoter 
methylation status of BRCA1 gene. Methods: Tumor DNA from 15 cases of high-
grade serous ovarian carcinoma was bisulfite converted and then run on the Qiagen 
PyroMark Q24 pyrosequencer using in-house developed primers targeting 11 CpG 
sites adjacent to BRCA1 transcription start site. All samples had previously been 
tested through The Cancer Genome Atlas (TCGA) project for methylation and 
mutation events. To determine the sensitivity of this assay, we performed a dilution 
series experiment using 7 mixtures of methylated DNA and unmethylated genomic 
DNA (100%, 50%, 25%, 12.5%, 6.25%, 3.125%, and 1.56%). Intra- and interassay 
reproducibilities were established by performing 6 cases in triplicate in the same run 
and in three different runs. Results: Upon evaluation, we found BRCA1 
hypermethylation in 6/15 cases. The remaining 9 cases were negative. We did not 
have any failures indicating the smaller-sized PCR products are well amplified from 
fragmented FFPE DNA. The average level of methylation across all 11 CpG sites are 
lower than 10 for all our negative cases although CpG sites #2, #6 and #11 give 
slightly higher levels of methylation. For positive results, we observed significantly 
less variation of methylation level among these 11 CpG sites. These data indicate 
that the Pyrosequencing assay gives concordant calls for the methylation status at a 
10% threshold for the average of all eleven (11) CpG sites to detect methylation. 
Using these criteria, all 15 cases had concordant results with TCGA methylation 
data. For the sensitivity analysis, we observed a high degree of correlation (R2 = 
0.9945) between predicted and observed results. The sensitivity of this assay is 6%. 
Conclusions: The PyroMark Q24 pyrosequencer assay had 100% concordance for 
all the ovarian cancer cases included in this validation. This assay has been 
conditionally approved by the New York State Department of Health as a laboratory 
specific assay that can now been put into clinical use. 
 
TT66. Analysis of Circulating miRNA from Dried Blood Spots 
J. Hill1, J. Wright1, J. Hill1, J. Repass2 
1Spot On Sciences, Austin, TX; 2ARQ Genetics, Bastrop, TX. 
Introduction: Circulating microRNA (miRNA) molecules have been implicated in 
many disease states including cancer, diabetes and cardiovascular disease. 
Collection of blood samples by finger stick and preservation by drying on filter paper 
(dried blood spot) is a simple and convenient method for sample collection.  We 
demonstrate that circulating miRNA levels can be accurately measured from dried 
blood spots. Methods: Blood samples from donors were collected by both 
venipuncture (venous) and finger stick (capillary). Portions of the blood sample was 
spotted onto filter paper and dried for 2 hours. miRNA was extracted from wet and 
dry blood samples and analyzed by RT-PCR.Results: Equivalent levels of miRNA The Journal of Molecular Diagnostics ■ jmd.amjpathol.orgwere detected from dried and wet whole blood samples. Minimal variance between 
venous and capillary blood miRNA levels was observed. Use of heparin as an anti-
coagulant for venous blood was discontinued due to 10-fold reduction in detected 
miRNA, likely due to heparin inhibition of RT-PCR.  Conclusions: This data 
demonstrates that levels of circulating miRNA can be accurately determined from 
finger stick dried blood spot samples.  
 
TT67. Use of Digital Droplet PCR to Generate Copy Number Standards for a 
Laboratory-Developed BCR-ABL Assay 
R. Udani, J. Demal, D. Bellissimo 
BloodCenter of Wisconsin, Milwaukee, WI. 
Introduction: Minimal residual disease monitoring for the BCR-ABL transcripts plays 
a crucial role in the treatment of patients with chronic myeloid leukemia and 
Philadelphia chromosome-positive ALL patients treated with tyrosine kinase 
inhibitors. The prognostic value of the BCR-ABL levels and the variability in how 
laboratories report the results insinuated the need for harmonization and the 
institution of the international standard (IS) for BCR-ABL measurement. Several 
studies have shown that patients with major molecular response (MMR) have better 
disease free survival. MMR corresponds to 3-log reduction (defined as 0.1% IS) in 
the BCR-ABL transcript levels from the baseline levels (defined as 100% IS). 
Significant variability among different laboratories is observed due to the differences 
in assay platform, reference gene (ABL, G6PDH, and GUS), and method of 
quantification. Recently, reference materials for % IS reporting have becoming 
available but the availability of quantified standards is still limiting. Digital droplet 
PCR (ddPCR) enables the absolute quantification of nucleic acid targets. We utilized 
ddPCR technology to develop quantitative standards for BCR-ABL and ABL 
transcripts. Four standards were used as the standard curve for our laboratory 
developed (LD) RT-qPCR BCR-ABL assay. The BCR-ABL/ABL ratio was calculated 
and the Asuragen IS calibrators were used to determine the conversion factor 
required to report the results as % IS. Methods: Total RNA from K562 cell line was 
isolated using Promega’s Maxwell instrument with the SimplyRNA Blood kit. The 
RNA was diluted to achieve four concentrations (copy number) for BCR-ABL and 
ABL standard curve independently. The diluted samples were reverse transcribed 
and ddPCR was performed following Quantalife (Bio-Rad) manufacturers guidelines. 
Our LD RT-qPCR BCR-ABL is a singleplex assay, based on Taqman technology, 
designed to detect both the major (b2a2 and b3a2) and minor (e1a2) break-points for 
BCR-ABL message using ABL as the reference gene. Results: Four standards, 
including the prognostically significant range of 100% IS to 0.1% IS, for quantification 
of BCR-ABL and ABL messages have been created. The ratio of BCR-ABL with 
respect to ABL was reproducible and linear over 4 logs on IS (100% to 0.01%IS). A 
total of 17 samples from two different laboratories were tested. The difference in % 
IS for all samples, except one, was < 2 fold. Conclusions: The use of the ddPCR for 
absolute quantification will aid in generating standards and calibrators for other 
biomarkers used for diagnosis, prognosis and residual disease monitoring.  
 
TT68. Method Comparison for Detection of JAK2 Exon 12 Mutations  
N.M. Gomes1, M.C. Aakre2, M.L. Bauman1, D. Xu1 
1Providence Sacred Heart Medical Center & Children's Hospital, Spokane, WA; 
2Pathology Associates Medical Laboratories, Spokane, WA. 
Introduction: Polycythemia vera (PV) is a myeloproliferative disorder characterized 
by erythrocytosis and low serum erythropoietin. The JAK2 V617F mutation in exon 
14 as a diagnostic marker is detected in approximately 95% of patients with PV. 
Among clinically diagnosed PV patients with a JAK2 V617F-negative test result, 
exon12 mutations are detected in about 80% of the cases. To date, 19 different 
small indels and point mutations, clustering within a 33-bp region of exon 12 have 
been reported. In this study, Sanger sequencing, fragment analysis, and high 
resolution melting (HRM) analysis, were compared for detection of exon 12 
mutations in a clinical laboratory setting. Methods: Two plasmid controls, each 
carrying the tandem point mutations of c.1615 A>C and c.1616A>T (p.Lys539Leu), 
or the common 6bp deletion (del/N542-E543), were diluted into whole blood of a 
control individual to achieve different levels of mutant allelic burden. DNA was 
extracted from diluted samples to evaluate the sensitivity of each method. Primers 
designed across the mutation cluster produced PCR amplicons of 453bp, 160bp, 
and 118bp, respectively. Sanger sequencing and fragment analysis were performed 
on a Genetic Analyzer 3130XL and HRM was performed on the LightCycler 480. 
Results: Mutations in plasmid controls were detected at an allelic burden of 100%, 
50%, and 25% by all three methods. Sanger sequencing detected the tandem point 
mutations at approximately 10% and detected the 6bp deletion at 20%. However, the 
deletion control could be detected by fragment analysis at 10%. HRM detected all 
three mutations at an allelic burden of 5% to 10%. Conclusions: Sanger sequencing 
can detect and define the full range of JAK2 exon 12 mutations, but may miss allelic 943
AMP Abstractsburdens of less than 20%. Fragment analysis may be more sensitive than 
sequencing, but is limited to detection of deletions or insertions. HRM achieved an 
analytical sensitivity approaching 5% for all mutations in the plasmid constructs. This 
study shows HRM may offer a rapid and sensitive method for detection of JAK2 exon 
12 mutations. Analysis of additional patient samples and control material will further 
define wild-type allele baseline and differentiate true signal of low positive patients 
from background noise in the assay. 
 
TT69. Microfluidic mRNA Integrity Assay 
R. Dettloff, J. Farinas 
Caerus Molecular, Mountain View, CA. 
Introduction: Monitoring gene expression levels is increasingly used to make 
clinical decisions. To prevent errors due to poor data quality, many users test the 
integrity of RNA samples via the Agilent RIN before using samples in downstream 
assays. Published data show reasonable correlations between microarray results 
and RIN, but even optimal RIN thresholds lead to ~10% of good samples being 
rejected and ~5% of poor samples being run in downstream assays. Additionally, 
samples with equivalent RIN can vary 10-fold in measured mRNA levels. To lower 
failure rates and achieve better correlations with downstream assay results, an 
assay was developed that labels a specific mRNA with fluorescent oligos, uses gel-
microelectrophoresis to size-separate mRNA degradation fragments and analyzes 
the electropherogram to monitor mRNA degradation. By analyzing mRNA rather than 
total RNA, an improved indication of RNA degradation is expected. Methods: 
Differentially degraded rat total RNA was labeled with two 20-nucleotide, Cy5-
labeled oligos targeting a single RNA species. Samples were placed in a microfluidic 
DNA-separation chip containing 1% PDMA gel and run on an Agilent Bioanalyzer 
using voltage scripts that yielded 45 second separations. Detection sensitivity was 
enhanced by the use of Field Amplified Sample Stacking by diluting samples in low 
conductivity buffer (10 mM TAPS) and using a high conductivity separation gel (200 
mM TAPS). The fraction of full-length RNA was calculated by dividing the integrated 
peak height of the full length RNA by the total integrated peak height between the 
lower and upper markers and compared to the Agilent RIN. Results: Maintaining the 
labeled oligos bound to the target RNA during separation is critical to obtaining 
accurate results. The probe oligos and separation buffer used showed that peak 
heights were insensitive to the total separation time (in the range 40 to 120 seconds) 
indicating that oligos stay bound to the target during the 45 second separation times. 
The use of Field Amplified Sample Stacking yielded a detection limit of 1 pM. The 
measured fraction of full-length RNA for the differentially degraded samples was well 
correlated with the results obtained on the Agilent RNA Nano assay. Taken together, 
these results demonstrate the ability of the proposed assay to specifically label an 
RNA species and to obtain fragment length distributions of the specific RNA using 
gel-microelectrophoresis. Conclusions: By monitoring degradation of mRNA rather 
than total RNA, the assay is expected to be a better predictor of the suitability of an 
RNA sample for analysis particularly for FFPE samples. 
 
TT70. Withdrawn 
 
TT71. Sensitivity and Specificity of Methods for the Detection of 
Translocation Breakpoints by Targeted Next-Generation Sequencing 
H. Abel, E. Duncavage 
Washington University School of Medicine, St Louis, MO. 
Introduction: The detection of balanced translocations is critical to both the 
diagnosis and prognosis of many cancers including leukemias, lymphomas, and 
solid tumors.  To date most translocations are detected by fluorescence in situ 
hybridization (FISH) or conventional cytogenetics, adding additional cost and 
complexity to sequencing-based oncology testing. Here, we compare the sensitivity 
and specificity of several bioinformatic tools for the detection of recurrent 
translocations from targeted multiplex NGS data.  
Methods: A set of 6 leukemias with MLL rearrangements and seven cancers (six 
lung cancers and one T-cell lymphoma) with ALK rearrangements were identified as 
positive controls. A total of 136 cases that were negative by FISH for ALK and MLL 
rearrangements were used as negative controls. DNA was first extracted from 
formalin-fixed blocks or bone marrow, prepared for indexed sequencing, and 
captured using probes spanning selected exons/introns of ALK and MLL. Captured 
DNA was then sequenced on a HiSeq 2000 using 2x101bp paired end reads. 
Sequence data were aligned to build 37.2 of the human genome using Novoalign 
and translocations called by Breakdancer, ClusterFASTQ, CREST, and Hydra. 
Computationally identified breakpoints were validated by PCR. Results: The 3 
bioinformatic tools Breakdancer (BD), ClusterFASTQ (CF), and Hydra all detected 
the ALK and MLL rearrangements with 100% sensitivity (13/13), where the mean 
unique read depth for the targeted capture panel ranged from 309x to 1507x 944(mean=1095x); CREST detected only 8/13 (62%) breakpoints. We used random 
downsampling to compare the sensitivities of BD, CF, and Hydra at lower coverage 
depths. Sensitivity was similar among the 3 tools and decreased with depth of 
coverage: at a 50% downsampling rate, sensitivity ranged from 77%(CF) to 
88%(Hydra) for the 3 tools, compared to 38%(BD) to 44%(CF) sensitivity at a 10% 
downsampling rate.  Specificity of the 3 tools was more variable, CF detected only 6 
cases with a structural variant (SV) involving ALK or MLL among the 136 FISH-
negative cases (96% specificity), compared to 52% specificity for BD, and 49% for 
Hydra. Filtering out results not involving a known ALK or MLL translocation partner 
greatly improved specificity to 99% for CF, 94% for BD, and 95% for Hydra. 
Conclusions: Here we demonstrate that translocations can be reliably detected at 
the DNA level using targeted next-generation sequencing.  Our data show that 
software such ClusterFASTQ, Breakdancer, and Hydra can detect recurrent 
translocations with high sensitivity and specificity from NGS data, and that high 
sensitivity requires a high depth of coverage.   
 
TT72. High Resolution CNV Detection by the BlueFuse Multi Software Using 
the Illumina Infinium CytoSNṔ850K BeadChip, an Array Intended for Studies 
Associated with Both Congenital Disorders and Cancer 
M.A. Porter1, M. Eberle1, A. Craig2, M. Harris1 
1Illumina, Inc, San Diego, CA; 2BlueGnome, Cambridge, United Kingdom. 
Introduction: The Infinium CytoSNP-850K BeadChip contains 850,000 empirically 
selected SNPs spanning the entire genome with enriched coverage, from an exon-
centric gene-level design, for 3262 genes of known cytogenetics relevance in both 
constitutional and cancer studies. This gene list was defined based on content from 
the International Collaboration for Clinical Genomics (ICCG) consortium and Cancer 
Cytogenetics Microarray Consortium (CCMC) to provide the most comprehensive 
view of relevant chromosomal aberrations. For optimal detection sensitivity, the 
CytoSNP-850K BeadChip utilizes long 50-mer SNP probes with at least 15x 
redundancies to generate higher signal-to-noise ratios than any other commercially 
available SNP array. The data analysis and interpretation for the CytoSNP-850K 
BeadChip occurs seamlessly within the BlueFuse Multi Software package. To 
demonstrate the high resolution performance of the CytoSNP-850K BeadChip with 
BlueFuse Multi software for CNV detection, the median size for duplications and 
deletions was determined at a targeted detection rate exceeding 90% using an in 
silico approach in which simulated regions were generated from larger karyotyped 
chromosomal abnormalities. Methods: An in silico approach was used create 
duplications and deletions containing a fixed number of probes. In brief, the in silico 
approach was conducted by transferring the log R and B-allele frequency values for 
fixed sized regions from larger chromosomal abnormality previously detected by 
karyotyping into the homologous region of a normal sample. This process was done 
repeatedly to create simulated regions at the limit of resolution all being derived from 
actual deletions or duplications. The detection rate was calculated as the percent of 
regions detected by the BlueFuse Multi software divided by the total expected 
simulated regions. The median size for duplications and deletions at a 90% detection 
rate was determined. Results: The median size for duplications and deletions, 
achieving the 90% detection rate, corresponded to a resolution of 153 kb and 39 kb, 
respectively. Of the regions detected at this level, the smallest duplications and 
deletions were approximately 20 kb and 2 kb, respectively. Conclusions: Our study 
demonstrates the ability of the BlueFuse Multi software to detect duplications and 
deletions at a high resolution when using the Infinium CytoSNṔ850K BeadChip. 
This high resolution CNV detection software package combined with the high density 
of SNPs on the CytoSNP-850K and intelligent design based on the latest updates 
from peer-reviewed literature enables the detection of more relevant chromosomal 
aberrations relative to any other array technologies. 
 
TT73. Comparison of Analysis Pipelines for Next-Generation Sequencing 
Output from MiSeq  
N.G. Reddy, V. Haghshenas, K.P. Patel, M.J. Routbort, R. Luthra, R.R. Singh 
The University of Texas MD Anderson Cancer Center, Houston, TX. 
Introduction: Next-Generation Sequencing (NGS) is rapidly gaining popularity as a 
preferred mutation screening application. However, analysis of the NGS output to 
facilitate accurate variant detection is challenging due to the availability of multiple 
pipelines applying disparate alignment and variant calling algorithms warranting 
validation before clinical applicability. Here, using sequencing output from MiSeq, we 
have compared two analysis pipelines namely MiSeq Reporter Software (Illumina 
Inc, CA) and NextGENe (Softgenetics, PA) Methods: DNA from bone marrows of 15 
AML patients with known mutations ascertained by conventional techniques were 
sequenced using TruSeq Custom Amplicon Library preparation method and MiSeq 
table-top sequencer. The library was designed to enrich for the exonic areas of 28 
genes of clinical significance in leukemia (ABL1, ASXL1, BRAF, CEBPA, DNMT3A, jmd.amjpathol.org ■ The Journal of Molecular Diagnostics
 AMP AbstractsEFGR, EZH2, FLT3, GATA1, GATA2, HRAS, IDH1, IDH2, IKZF2, JAK2, KIT, KRAS 
MDM2, MLL, MPL, MYD88, NOTCH1, NPM1, NRAS, PTPN11, RUNX1, TET2, 
TP53, WT1). The FASTQ files generated were analyzed by both MiSeq Reporter 
Software v.2.0.26 and NextGENe. To generate binary sequencing alignment files 
(.bam) and variant call files (.vcf), MiSeq Reporter aligns the sequencing output to 
hg19 human reference genome (UCSC), whereas NextGENe v2.3.3 aligns to the 
Human Genome 37.2. Results: The 15 patient sample set was positive for 36 
mutations (22 single nucleotide variants and 14 insertions). MiSeq reporter called 
each of the expected 22 SNVs. NextGENe called 21 out of 22 SNVs and missed one 
in the gene MPL due to stringency settings and was called when relaxed. Out of 14 
insertions, 8 were called by Miseq reporter and 9 by NextGENe. The insertions 
missed were internal tandem duplications (ITDs) in FLT3. The size if the ITDs in 
these samples ranged from 43-118 bp. This exceeded the size limit for efficient 
amplification during cluster generation on the flowcell leading to lack of sequencing 
coverage. One ITD (18bp) was missed by Miseq reporter but called by NextGENe. 
Conclusions: Both the analysis pipelines were comparable with regards to detection 
of SNVs and insertions. Miseq reporter is an on-board software and is ideal for a 
clinical lab looking for seamless sequencing analysis setup but does not have the 
flexibility for customizing the settings and can analyze sequencing outputs only from 
MiSeq. However, NextGENe offers settings flexibility and is capable of analyzing 
outputs from multiple NGS platforms.  
 
TT74. Development of a BRAF V600E Assay Capable of Detecting mRNA 
Mutations in Formalin Fixed Tissue 
M. Rounesville1, D. Hoon2, B. Seligmann1, V. Modur1 
1HTG Molecular Diagnostics, Tucson, AZ; 2John Wayne Cancer Institute, Santa 
Monica, CA. 
Introduction: The detection of mutations in oncogenic drivers of cancer allows 
important treatment decisions to be made for targeted therapy. Although most of the 
current mutation assessment methods are focused on DNA, we have devised a 
novel and facile assay for the detection of RNA mutations in clinical specimens. The 
basis of the assay is quantitative nuclease protection (qNPA) that can be used 
directly on fixed tissue sections without prior RNA extraction. Methods: HTG’s qNPA 
(quantitative nuclease protection assay) was modified to use overlapping but offset 
DNA probes to enable a competitive hybridization between wild type and mutant 
BRAF V600E instead of the use of a single probe for gene expression. The 
competitive probe design based qNPA was tested for its ability to detect mutations in 
mRNA by using in vitro transcripts and cell lines with known mutations in the BRAF 
gene. Fifty-two melanoma samples were also tested for the presence of transcribed 
BRAF mutations. Results: Offset probes enabled the detection of wild type vs. 
BRAF V600E in vitro transcripts with a sensitivity of up to 10 fmol of mutant transcript 
in a background of 190 fmol of wild type transcript leading to an ability to detect a 5% 
mutant signal in a background of 95% wild type transcript. Application of the assay to 
known cell lines with wild type (RPMI 2650) and mutant BRAF (HT-29 and COLO-
205) allowed the confirmation of presence of expressed BRAF wild type or mutant 
mRNA respectively. Interestingly COLO-205, a heterozygous cell line at the DNA 
level is a homozygous mutant at the mRNA level. Preliminary clinical testing of 52 
formalin-fixed melanoma patient samples showed a 50% incidence of BRAF 
mutation with an 8% incidence of homozygosity at the mRNA level. Conclusions: 
We have successfully developed a BRAF mutation assay that can detect 5% 
mutation in a background of wild-type mRNA. The detection of the mutation can be 
performed directly without prior RNA extraction from formalin-fixed, paraffin-
embedded tissue. The assay is ready for further clinical validation. 
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